<!DOCTYPE html><html lang="en-us" >

<head>

  <meta charset="utf-8">
  <meta name="viewport" content="width=device-width, initial-scale=1">
  <meta http-equiv="X-UA-Compatible" content="IE=edge">
  <meta name="generator" content="Source Themes Academic 4.8.0">

  

  
  
  
  
  
  

  

  
  
  
    
  
  <meta name="description" content="Web platform to analyze, discuss, cluster, classify COVID-19 scientific literature.">

  
  <link rel="alternate" hreflang="en-us" href="/mesothelioma/tables/">

  


  
  
  
  <meta name="theme-color" content="#2962ff">
  

  
  

  
  
  
  
    
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/academicons/1.8.6/css/academicons.min.css" integrity="sha256-uFVgMKfistnJAfoCUQigIl+JfUaP47GrRKjf6CTPVmw=" crossorigin="anonymous">
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.12.0-1/css/all.min.css" integrity="sha256-4w9DunooKSr3MFXHXWyFER38WmPdm361bQS/2KUWZbU=" crossorigin="anonymous">
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/fancybox/3.5.7/jquery.fancybox.min.css" integrity="sha256-Vzbj7sDDS/woiFS3uNKo8eIuni59rjyNGtXfstRzStA=" crossorigin="anonymous">

    
    
    
      
    
    
      
      
        
          <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/highlight.js/9.18.1/styles/github.min.css" crossorigin="anonymous" title="hl-light">
          <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/highlight.js/9.18.1/styles/dracula.min.css" crossorigin="anonymous" title="hl-dark" disabled>
        
      
    

    

    

    
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
        <script src="https://cdnjs.cloudflare.com/ajax/libs/lazysizes/5.1.2/lazysizes.min.js" integrity="sha256-Md1qLToewPeKjfAHU1zyPwOutccPAm5tahnaw7Osw0A=" crossorigin="anonymous" async></script>
      
    
      

      
      

      
    
      

      
      

      
    
      

      
      
        
      

      
    
      

      
      

      
    

  

  
  
  
  <link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Montserrat:400,700%7CRoboto:400,400italic,700%7CRoboto+Mono&display=swap">
  

  
  
  
  
  <link rel="stylesheet" href="/mesothelioma/css/academic.css">

  





<script async src="https://www.googletagmanager.com/gtag/js?id=google_analytics_ID"></script>
<script>
  window.dataLayer = window.dataLayer || [];

  function gtag() {
      dataLayer.push(arguments);
  }

  function trackOutboundLink(url, target) {
    gtag('event', 'click', {
         'event_category': 'outbound',
         'event_label': url,
         'transport_type': 'beacon',
         'event_callback': function () {
           if (target !== '_blank') {
             document.location = url;
           }
         }
    });
    console.debug("Outbound link clicked: " + url);
  }

  function onClickCallback(event) {
    if ((event.target.tagName !== 'A') || (event.target.host === window.location.host)) {
      return;
    }
    trackOutboundLink(event.target, event.target.getAttribute('target'));  
  }

  gtag('js', new Date());
  gtag('config', 'google_analytics_ID', {});

  
  document.addEventListener('click', onClickCallback, false);
</script>


  


  
  

  
  <link rel="alternate" href="/mesothelioma/tables/index.xml" type="application/rss+xml" title="mesothelioma">
  

  <link rel="manifest" href="/mesothelioma/index.webmanifest">
  <link rel="icon" type="image/png" href="/mesothelioma/images/icon_hu7e12209333f22d741aca7d462871821f_9877_32x32_fill_lanczos_center_2.png">
  <link rel="apple-touch-icon" type="image/png" href="/mesothelioma/images/icon_hu7e12209333f22d741aca7d462871821f_9877_192x192_fill_lanczos_center_2.png">

  <link rel="canonical" href="/mesothelioma/tables/">

  
  
  
  
  
  
  
    
    
  
  
  <meta property="twitter:card" content="summary">
  
  <meta property="og:site_name" content="mesothelioma">
  <meta property="og:url" content="/mesothelioma/tables/">
  <meta property="og:title" content="Articles with Abstract | mesothelioma">
  <meta property="og:description" content="Web platform to analyze, discuss, cluster, classify COVID-19 scientific literature."><meta property="og:image" content="/mesothelioma/images/icon_hu7e12209333f22d741aca7d462871821f_9877_512x512_fill_lanczos_center_2.png">
  <meta property="twitter:image" content="/mesothelioma/images/icon_hu7e12209333f22d741aca7d462871821f_9877_512x512_fill_lanczos_center_2.png"><meta property="og:locale" content="en-us">
  
    <meta property="og:updated_time" content="2018-09-09T00:00:00&#43;00:00">
  

  




  


  





  <title>Articles with Abstract | mesothelioma</title>

</head>

<body id="top" data-spy="scroll" data-offset="70" data-target="#TableOfContents" >

  <aside class="search-results" id="search">
  <div class="container">
    <section class="search-header">

      <div class="row no-gutters justify-content-between mb-3">
        <div class="col-6">
          <h1>Search</h1>
        </div>
        <div class="col-6 col-search-close">
          <a class="js-search" href="#"><i class="fas fa-times-circle text-muted" aria-hidden="true"></i></a>
        </div>
      </div>

      <div id="search-box">
        
        <input name="q" id="search-query" placeholder="Search..." autocapitalize="off"
        autocomplete="off" autocorrect="off" spellcheck="false" type="search">
        
      </div>

    </section>
    <section class="section-search-results">

      <div id="search-hits">
        
      </div>

    </section>
  </div>
</aside>


  







<nav class="navbar navbar-expand-lg navbar-light compensate-for-scrollbar" id="navbar-main">
  <div class="container">

    
    <div class="d-none d-lg-inline-flex">
      <a class="navbar-brand" href="/mesothelioma/">mesothelioma</a>
    </div>
    

    
    <button type="button" class="navbar-toggler" data-toggle="collapse"
            data-target="#navbar-content" aria-controls="navbar" aria-expanded="false" aria-label="Toggle navigation">
    <span><i class="fas fa-bars"></i></span>
    </button>
    

    
    <div class="navbar-brand-mobile-wrapper d-inline-flex d-lg-none">
      <a class="navbar-brand" href="/mesothelioma/">mesothelioma</a>
    </div>
    

    
    
    <div class="navbar-collapse main-menu-item collapse justify-content-start" id="navbar-content">

      
      <ul class="navbar-nav d-md-inline-flex">
        

        

        
        
        
          
        

        
        
        
        
        
        

        <li class="nav-item">
          <a class="nav-link " href="/mesothelioma/syntax/"><span>Syntax</span></a>
        </li>

        
        

        

        
        
        
          
        

        
        
        
        
        
        

        <li class="nav-item">
          <a class="nav-link " href="/mesothelioma/genepanel/"><span>Gene Panel</span></a>
        </li>

        
        

        

        
        
        
          
        

        
        
        
        
        
        

        <li class="nav-item">
          <a class="nav-link " href="/mesothelioma/drugpanel/"><span>Drug Panel</span></a>
        </li>

        
        

        

        
        
        
          
        

        
        
        
        
        
        

        <li class="nav-item">
          <a class="nav-link " href="/mesothelioma/tissuepanel/"><span>Tissue Panel</span></a>
        </li>

        
        

        

        
        
        
          
        

        
        
        
        
        
        

        <li class="nav-item">
          <a class="nav-link " href="/mesothelioma/syntax_summary/"><span>Literature Consensus</span></a>
        </li>

        
        

        

        
        
        
          
        

        
        
        
        
        
        
          
          
          
            
          
          
        

        <li class="nav-item">
          <a class="nav-link " href="/mesothelioma/#about"><span>Contact</span></a>
        </li>

        
        

      

        
      </ul>
    </div>

    <ul class="nav-icons navbar-nav flex-row ml-auto d-flex pl-md-2">
      
      <li class="nav-item">
        <a class="nav-link js-search" href="#"><i class="fas fa-search" aria-hidden="true"></i></a>
      </li>
      

      

      

    </ul>

  </div>
</nav>


  












  

  
  
  
    
  
<div class="universal-wrapper pt-3">
  <p style="font-size:25px" align="justify">Articles with Abstract</p>

  

  
</div>



<div class="universal-wrapper">
  
  <div class="article-style">
<script src="/mesotheliomarmarkdown-libs/kePrint/kePrint.js"></script>


<br>
<p style="font-size:12px" align="center">
<strong>Table 1.</strong> List of all 6102 articles with abstract used in PlatOMICs for mesothelioma. <br>*Curation represents the number of person that analyzed the information
</p>
<hr />
<table class="table table-striped" style="width: auto !important; margin-left: auto; margin-right: auto;">
<thead>
<tr>
<th style="text-align:left;position: sticky; top:0; background-color: #FFFFFF;">
Title
</th>
<th style="text-align:left;position: sticky; top:0; background-color: #FFFFFF;">
Journal
</th>
<th style="text-align:left;position: sticky; top:0; background-color: #FFFFFF;">
Cateogry
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Weekly systemic combination of cisplatin and interferon alpha 2a in diffuse malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
P53-immunoreactive cells in benign and malignant effusions: diagnostic value using a panel of monoclonal antibodies and comparison with CEA-staining.
</td>
<td style="text-align:left;">
Oncol. Rep.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
SWORD ’97: surveillance of work-related and occupational respiratory disease in the UK.
</td>
<td style="text-align:left;">
Occup Med (Lond)
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Diagnostic examination for causes of exudative pleurisy].
</td>
<td style="text-align:left;">
Ned Tijdschr Geneeskd
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
[Primary malignant tumors of the pleura. Pleural Mesothelioma (P.M.)].
</td>
<td style="text-align:left;">
Minerva Chir
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
The clinical importance of magnetic resonance imaging versus computed tomography in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Factors influencing the outcome of radiotherapy in malignant mesothelioma of the pleura–a single-institution experience with 189 patients.
</td>
<td style="text-align:left;">
Int. J. Radiat. Oncol. Biol. Phys.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
E-cadherin, N-cadherin, and calretinin in pleural effusions: the good, the bad, the worthless.
</td>
<td style="text-align:left;">
Diagn. Cytopathol.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleural space perfusion with cisplatin in the multimodality treatment of malignant mesothelioma: a feasibility and pharmacokinetic study.
</td>
<td style="text-align:left;">
J. Thorac. Cardiovasc. Surg.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Thoracic solitary fibrous tumor: clinical and pathological diversity.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Pelvic and lumbar metastasis detected by bone scintigraphy in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Nuklearmedizin
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
[Primary pericardial mesothelioma: report of a case (author’s transl)].
</td>
<td style="text-align:left;">
G Ital Cardiol
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Telomerase activity in human pleural mesothelioma.
</td>
<td style="text-align:left;">
Thorax
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Impressive remission in a patient with locally advanced malignant pleural mesothelioma treated with gemcitabine.
</td>
<td style="text-align:left;">
Anticancer Drugs
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Ga-67 tumor scan in malignant diffuse mesothelioma–comparison with CT and pathological findings.
</td>
<td style="text-align:left;">
Ann Nucl Med
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Magnetic resonance appearance of asbestos-related benign and malignant pleural diseases.
</td>
<td style="text-align:left;">
Scand J Work Environ Health
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Syndecan-1 expression in malignant mesothelioma: correlation with cell differentiation, WT1 expression, and clinical outcome.
</td>
<td style="text-align:left;">
J. Pathol.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Health effects of asbestos exposure in humans: a quantitative assessment.
</td>
<td style="text-align:left;">
Med Lav
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Results of a phase II trial of combined chemotherapy for patients with diffuse malignant mesothelioma of the pleura.
</td>
<td style="text-align:left;">
Cancer
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
[Video thoracoscopy in the diagnosis of pleural effusions].
</td>
<td style="text-align:left;">
Minerva Chir
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
High pleural fluid hyaluronan concentrations in rheumatoid arthritis.
</td>
<td style="text-align:left;">
Eur. Respir. J.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma due to environmental exposure to erionite: follow-up of a Turkish emigrant cohort.
</td>
<td style="text-align:left;">
Eur. Respir. J.
</td>
<td style="text-align:left;">
diagnosis | epidemiology
</td>
</tr>
<tr>
<td style="text-align:left;">
Establishment of four new mesothelioma cell lines: characterization by ultrastructural and immunophenotypic analysis.
</td>
<td style="text-align:left;">
Eur. Respir. J.
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
[Case series of mesotheliomas from hospital archives as contribution to preventive intervention].
</td>
<td style="text-align:left;">
Ann. Ist. Super. Sanita
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Pleural mesotheliomas. Current knowledge].
</td>
<td style="text-align:left;">
Ann Chir
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[MRT, CT and sonography in the preoperative assessment of the primary tumor spread in malignant pleural mesothelioma].
</td>
<td style="text-align:left;">
Rofo
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Simian virus 40 and human pleural mesothelioma.
</td>
<td style="text-align:left;">
Thorax
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant pleural mesotheliomas].
</td>
<td style="text-align:left;">
Medicina (B Aires)
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Occupational cancer in Germany.
</td>
<td style="text-align:left;">
Environ. Health Perspect.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma: US-guided histologic core-needle biopsy.
</td>
<td style="text-align:left;">
Radiology
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Cisplatin in combination with irinotecan in the treatment of patients with malignant pleural mesothelioma: a pilot phase II clinical trial and pharmacokinetic profile.
</td>
<td style="text-align:left;">
Cancer
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[CA 125 in the department of internal medicine–a marker of ovarian tumor, thoracic fluid or ascites?].
</td>
<td style="text-align:left;">
Vnitr Lek
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Pseudomesotheliomatous carcinoma involving pleura and peritoneum: A clinicopathologic and immunohistochemical study of three cases.
</td>
<td style="text-align:left;">
Ann Diagn Pathol
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Indications for pneumonectomy. Extrapleural pneumonectomy.
</td>
<td style="text-align:left;">
Chest Surg. Clin. N. Am.
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Migration of mesothelioma cells correlates with histotype-specific synthesis of extracellular matrix.
</td>
<td style="text-align:left;">
Int. J. Mol. Med.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Diagnosis of malignant pleural mesothelioma by supraclavicular lymph node biopsy.
</td>
<td style="text-align:left;">
Oncol. Rep.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Thrombospondin-1 expression and clinical implications in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Cancer
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
A Phase II study of gemcitabine in patients with malignant pleural mesothelioma. European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group.
</td>
<td style="text-align:left;">
Cancer
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Horner’s syndrome in a patient with diffuse malignant pleural mesothelioma].
</td>
<td style="text-align:left;">
Nihon Kokyuki Gakkai Zasshi
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[A case of diffuse pleural mesothelioma disclosed by a 7 mm tumor shadow on chest X-ray film during a regular physical checkup].
</td>
<td style="text-align:left;">
Nihon Kokyuki Gakkai Zasshi
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Asbestos, chromosomal deletions, and tumor suppressor gene alterations in human malignant mesothelioma.
</td>
<td style="text-align:left;">
J. Cell. Physiol.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
New molecular and epidemiological issues in mesothelioma: role of SV40.
</td>
<td style="text-align:left;">
J. Cell. Physiol.
</td>
<td style="text-align:left;">
epidemiology
</td>
</tr>
<tr>
<td style="text-align:left;">
Thallium-201 scintigraphy in malignant mesothelioma.
</td>
<td style="text-align:left;">
Br J Radiol
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Pleural mesothelioma. A case report].
</td>
<td style="text-align:left;">
Recenti Prog Med
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
[Chronic pleuropathy due to asbestos and malignant mesothelioma of the pleura: a differential diagnosis not always easy. A case report].
</td>
<td style="text-align:left;">
Recenti Prog Med
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Ifosfamide in malignant mesothelioma: a phase II study.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleural mesothelioma.
</td>
<td style="text-align:left;">
Curr Opin Pulm Med
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Peritoneal mesothelioma–incidence and etiology].
</td>
<td style="text-align:left;">
Pathologe
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
[Therapy of malignant pleural mesothelioma–a permanent dilemma].
</td>
<td style="text-align:left;">
Pneumologie
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma: a problematic review.
</td>
<td style="text-align:left;">
Surg Oncol
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Modulation of integrin expression on mesotheliomas: the role of different histotypes in invasiveness.
</td>
<td style="text-align:left;">
Int. J. Oncol.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
SV40 large T-antigen and human pleural mesothelioma. Screening by polymerase chain reaction and tyramine-amplified immunohistochemistry.
</td>
<td style="text-align:left;">
Virchows Arch.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Expression of vascular endothelial growth factor in diffuse malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Virchows Arch.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Pleural malignant mesothelioma complicated by multiple myeloma].
</td>
<td style="text-align:left;">
Nihon Kokyuki Gakkai Zasshi
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma: the spectrum of manifestations on CT in 70 cases.
</td>
<td style="text-align:left;">
Clin Radiol
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
How should we treat malignant pleural mesothelioma (MPM)?
</td>
<td style="text-align:left;">
Acta Chir Hung
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Granulocyte colony stimulating factor-producing diffuse malignant mesothelioma of pleura.
</td>
<td style="text-align:left;">
Intern. Med.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
The hazards of chrysotile asbestos: a critical review.
</td>
<td style="text-align:left;">
Ind Health
</td>
<td style="text-align:left;">
epidemiology | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Preoperative work-up of a solitary diaphragmatic mass in a patient with right shoulder pain: a case for diagnosis.
</td>
<td style="text-align:left;">
Monaldi Arch Chest Dis
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma of the pleural space.
</td>
<td style="text-align:left;">
Oncology (Williston Park, N.Y.)
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Prognostic value of FDG PET imaging in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J. Nucl. Med.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Angiogenic cytokines in mesothelioma: a study of VEGF, FGF-1 and -2, and TGF beta expression.
</td>
<td style="text-align:left;">
J. Pathol.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Cisplatin, mitomycin, and interferon-alpha2a combination chemoimmunotherapy in the treatment of diffuse malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Chest
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Advances in the treatment of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Chest
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Cisplatin and gemcitabine treatment for malignant mesothelioma: a phase II study.
</td>
<td style="text-align:left;">
J. Clin. Oncol.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Late results.
</td>
<td style="text-align:left;">
Chest Surg. Clin. N. Am.
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
[Solitary fibrous tumors of the pleura].
</td>
<td style="text-align:left;">
Chirurg
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Environmental asbestos exposure and malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Respir Med
</td>
<td style="text-align:left;">
epidemiology | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Prognostic value of the serum tumour markers Cyfra 21-1 and tissue polypeptide antigen in malignant mesothelioma.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
High-dose methotrexate in combination with interferons in the treatment of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Br. J. Cancer
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
p53 protein, EGF receptor, and anti-p53 antibodies in serum from patients with occupationally derived lung cancer.
</td>
<td style="text-align:left;">
Br. J. Cancer
</td>
<td style="text-align:left;">
diagnosis | epidemiology
</td>
</tr>
<tr>
<td style="text-align:left;">
Intraglomerular metastasis: a necropsy study.
</td>
<td style="text-align:left;">
J. Clin. Pathol.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Cerebral metastases in malignant mesothelioma: a case report.
</td>
<td style="text-align:left;">
Eur J Cancer Care (Engl)
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
[Clinical comparison of diffuse malignant mesothelioma of the pleura and pseudomesotheliomatous carcinoma of the lung for each case].
</td>
<td style="text-align:left;">
Kyobu Geka
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant pleural mesothelioma with an unusual radiologic manifestation].
</td>
<td style="text-align:left;">
An Med Interna
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Subcutaneous seeding after ultrasound-guided placement of intrapleural catheter. An unusual complication of the intracavitary palliative treatment of pleural mesothelioma.
</td>
<td style="text-align:left;">
Support Care Cancer
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
VEGF and VEGF type C play an important role in angiogenesis and lymphangiogenesis in human malignant mesothelioma tumours.
</td>
<td style="text-align:left;">
Br. J. Cancer
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Increased but low incidence and poor survival of malignant mesothelioma in the southeastern part of The Netherlands since 1970: a population-based study.
</td>
<td style="text-align:left;">
Eur. J. Cancer Prev.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Cytopathology of malignant mesothelioma of the pleura in fine-needle aspiration biopsy.
</td>
<td style="text-align:left;">
Diagn. Cytopathol.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Ultrastructure of pleural mesothelioma and pulmonary adenocarcinoma in malignant effusions as compared with reactive mesothelial cells.
</td>
<td style="text-align:left;">
Acta Cytol.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Posttranscriptional regulation of urokinase receptor gene expression in human lung carcinoma and mesothelioma cells in vitro.
</td>
<td style="text-align:left;">
Mol. Cell. Biochem.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Localized benign fibrous mesothelioma mimicking a malignant tumor of the pleura.
</td>
<td style="text-align:left;">
JBR-BTR
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
The use of histological and immunohistochemical markers to distinguish pleural malignant mesothelioma and in situ mesothelioma from reactive mesothelial hyperplasia and reactive pleural fibrosis.
</td>
<td style="text-align:left;">
J. Pathol.
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Expression of genes coding for proteoglycans and Wilms’ tumour susceptibility gene 1 (WT1) by variously differentiated benign human mesothelial cells.
</td>
<td style="text-align:left;">
Differentiation
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
[Anesthetic management of a patient with tracheal bronchus with one lung ventilation].
</td>
<td style="text-align:left;">
Masui
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
The german thorotrast study: recent results and assessment of risks.
</td>
<td style="text-align:left;">
Radiat. Res.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Inhibition of interleukin-8 reduces human malignant pleural mesothelioma propagation in nude mouse model.
</td>
<td style="text-align:left;">
Oncol. Res.
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Edatrexate (10-ethyl-deaza-aminopterin) (NSC #626715) with or without leucovorin rescue for malignant mesothelioma. Sequential phase II trials by the cancer and leukemia group B.
</td>
<td style="text-align:left;">
Cancer
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Hyaluronan in serum as an indicator of progressive disease in hyaluronan-producing malignant mesothelioma.
</td>
<td style="text-align:left;">
Cancer
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Important prognostic factors in patients with malignant pleural mesothelioma, managed surgically.
</td>
<td style="text-align:left;">
Ann. Thorac. Surg.
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant pleural mesothelioma].
</td>
<td style="text-align:left;">
Bull Cancer
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Staging of malignant pleural mesothelioma: comparison of CT and MR imaging.
</td>
<td style="text-align:left;">
AJR Am J Roentgenol
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Vascular endothelial growth factor levels and induction of permeability in malignant pleural effusions.
</td>
<td style="text-align:left;">
Clin. Cancer Res.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Apoptosis and expression of apoptosis regulating proteins bcl-2, mcl-1, bcl-X, and bax in malignant mesothelioma.
</td>
<td style="text-align:left;">
Clin. Cancer Res.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
[Diagnosis of malignant pleural mesothelioma and asbestosis].
</td>
<td style="text-align:left;">
Ned Tijdschr Geneeskd
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Palliative treatment of malignant pleural effusions by video-assisted thoracoscopic surgery.
</td>
<td style="text-align:left;">
Acta Chir Hung
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Video-assisted thoracoscopic pleurodesis for malignant pleural effusions.
</td>
<td style="text-align:left;">
Acta Chir Hung
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
[A report of 3 cases of pleural mesothelioma with unusual asbestos exposure].
</td>
<td style="text-align:left;">
Med Lav
</td>
<td style="text-align:left;">
epidemiology
</td>
</tr>
<tr>
<td style="text-align:left;">
Pharmacokinetics of intrapleural cisplatin for the treatment of malignant pleural effusions.
</td>
<td style="text-align:left;">
Oncol. Rep.
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
MOC-31 aids in the differentiation between adenocarcinoma and reactive mesothelial cells.
</td>
<td style="text-align:left;">
Cancer
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleuro-pulmonary tumours detected by clinical and chest X-ray analyses in rats transplanted with mesothelioma cells.
</td>
<td style="text-align:left;">
Br. J. Cancer
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma eight years after a diagnosis of atypical mesothelial hyperplasia.
</td>
<td style="text-align:left;">
J. Clin. Pathol.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Occupation and risk of malignant pleural mesothelioma: A case-control study in Spain.
</td>
<td style="text-align:left;">
Am. J. Ind. Med.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
[F-18-FDG PET for primary diagnosis differential diagnosis of pleural processes].
</td>
<td style="text-align:left;">
Nuklearmedizin
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Presence of simian virus 40 sequences in malignant mesotheliomas and mesothelial cell proliferations.
</td>
<td style="text-align:left;">
J. Cell. Biochem.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Simian virus 40 and human tumors: It is time to study mechanisms.
</td>
<td style="text-align:left;">
J. Cell. Biochem.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Surgical treatment of mesothelioma: pleurectomy.
</td>
<td style="text-align:left;">
Chest
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleuropneumonectomy in the treatment of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Chest
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Emerging translational therapies for mesothelioma.
</td>
<td style="text-align:left;">
Chest
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Detection of SV40 like viral DNA and viral antigens in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Eur. Respir. J.
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Glycogen-rich mesothelioma.
</td>
<td style="text-align:left;">
Ultrastruct Pathol
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Antisense to SV40 early gene region induces growth arrest and apoptosis in T-antigen-positive human pleural mesothelioma cells.
</td>
<td style="text-align:left;">
Cancer Res.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Kaposi’s sarcoma following malignant mesothelioma.
</td>
<td style="text-align:left;">
Virchows Arch.
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Value of morphometry, texture analysis, densitometry, and histometry in the differential diagnosis and prognosis of malignant mesothelioma.
</td>
<td style="text-align:left;">
J. Pathol.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Contemporary management of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Oncologist
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
MIB-1 proliferation index correlates with survival in pleural malignant mesothelioma.
</td>
<td style="text-align:left;">
Histopathology
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Diaphragm reconstruction with autologous fascia lata: report of a case.
</td>
<td style="text-align:left;">
Surg. Today
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma without asbestos exposure.
</td>
<td style="text-align:left;">
Indian J Chest Dis Allied Sci
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Expression profile of telomerase subunits in human pleural mesothelioma.
</td>
<td style="text-align:left;">
J. Pathol.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
The prevalence of pleural plaques and/or pulmonary changes among construction workers in Okayama, Japan.
</td>
<td style="text-align:left;">
Am. J. Ind. Med.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Application of the cell block method, utilizing mount quick mounting medium.
</td>
<td style="text-align:left;">
Diagn. Cytopathol.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Immunocytochemistry and DNA-image cytometry in diagnostic effusion cytology I. Prevalence of markers in tumour cell positive and negative smears.
</td>
<td style="text-align:left;">
Anal Cell Pathol
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant epithelioid vascular tumors of the pleura: report of a series and literature review.
</td>
<td style="text-align:left;">
Hum. Pathol.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Diagnosis of malignant mesothelioma by fine needle aspiration of a cervical lymph node. A case report.
</td>
<td style="text-align:left;">
Acta Cytol.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Environmental exposure to tremolite and respiratory cancer in New Caledonia: a case-control study.
</td>
<td style="text-align:left;">
Am. J. Epidemiol.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Talc induces apoptosis in human malignant mesothelioma cells in vitro.
</td>
<td style="text-align:left;">
Am. J. Respir. Crit. Care Med.
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Use of cytokeratin fragments 19.1 and 19.21 (Cyfra 21-1) in the differentiation of malignant and benign pleural effusions.
</td>
<td style="text-align:left;">
Aust N Z J Med
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
[VATS in malignant pleural effusions].
</td>
<td style="text-align:left;">
Zhonghua Wai Ke Za Zhi
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Endoscopic approach to pulmonary diseases: Clinical utility of medical thoracoscopy in diagnosis of pleural diseases].
</td>
<td style="text-align:left;">
Kekkaku
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Cytologic differential diagnosis among reactive mesothelial cells, malignant mesothelioma, and adenocarcinoma: utility of combined E-cadherin and calretinin immunostaining.
</td>
<td style="text-align:left;">
Cancer
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Long term survival of a patient with malignant pleural mesothelioma as a late complication of radiotherapy for Hodgkin’s disease treated with 90yttrium-silicate.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[The incidence of malignant mesothelioma (1977-1996) and asbestos exposure in the population of an area neighboring Lake Iseo, northern Italy].
</td>
<td style="text-align:left;">
Med Lav
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Co-expression of vascular endothelial growth factor and its receptor flt-1 in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Respiration
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Sister chromatid exchange rate from pleural fluid cells in patients with malignant mesothelioma.
</td>
<td style="text-align:left;">
Mutat. Res.
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Reactivity of six antibodies in effusions of mesothelioma, adenocarcinoma and mesotheliosis: stepwise logistic regression analysis.
</td>
<td style="text-align:left;">
Cytopathology
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant Mesothelioma Registry from Piedmont. Incidence in 1990-1995].
</td>
<td style="text-align:left;">
Epidemiol Prev
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Monitoring of impending myocardial damage after pleuropneumonectomy and intraoperative photodynamic therapy for malignant pleural mesothelioma using biochemical markers.
</td>
<td style="text-align:left;">
Photochem. Photobiol.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Manganese superoxide dismutase as a diagnostic marker for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Br. J. Cancer
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Mesothelioma: new concepts in diagnosis and management.
</td>
<td style="text-align:left;">
Curr Opin Pulm Med
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Value of thyroid transcription factor-1, E-cadherin, BG8, WT1, and CD44S immunostaining in distinguishing epithelial pleural mesothelioma from pulmonary and nonpulmonary adenocarcinoma.
</td>
<td style="text-align:left;">
Am. J. Surg. Pathol.
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Intrapleural administration of tumour necrosis factor-alpha (TNFalpha) in patients with mesothelioma: cytokine patterns and acute-phase protein response.
</td>
<td style="text-align:left;">
Eur. J. Clin. Invest.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Chemotherapy in combination with whole-body hyperthermia in advanced malignant pleural mesothelioma].
</td>
<td style="text-align:left;">
Dtsch. Med. Wochenschr.
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Current Therapy for Mesothelioma.
</td>
<td style="text-align:left;">
Cancer Control
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
18-FDG positron emission tomography in the evaluation of malignant pleural diseases - a pilot study.
</td>
<td style="text-align:left;">
Eur J Cardiothorac Surg
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma in subjects with Marfan’s syndrome and Ehlers-Danlos syndrome: only an apparent association?
</td>
<td style="text-align:left;">
Respiration
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Cell-block immunocytochemical characterization of effusions. Use of antibody panel: calretinin, Ber-EP4, keratin and CD68].
</td>
<td style="text-align:left;">
Pathologica
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
The diagnostic yield of pleural fluid cytology in malignant pleural effusions.
</td>
<td style="text-align:left;">
Singapore Med J
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural diseases.
</td>
<td style="text-align:left;">
Monaldi Arch Chest Dis
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Lymphohistiocytoid mesothelioma. An often misdiagnosed variant of sarcomatoid malignant mesothelioma.
</td>
<td style="text-align:left;">
Am. J. Clin. Pathol.
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Simian virus 40: the link with human malignant mesothelioma is well established.
</td>
<td style="text-align:left;">
Anticancer Res.
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
SV40, JC and BK expression in tissue, urine and blood samples from patients with malignant and nonmalignant pleural disease.
</td>
<td style="text-align:left;">
Anticancer Res.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Simian virus 40 is not a cofactor in the pathogenesis of environmentally induced malignant pleural mesothelioma in Turkey.
</td>
<td style="text-align:left;">
Anticancer Res.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Adenovirus-mediated wild-type p53 overexpression reverts tumourigenicity of human mesothelioma cells.
</td>
<td style="text-align:left;">
Int. J. Mol. Med.
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Cancer incidence among male pulp and paper workers in Norway.
</td>
<td style="text-align:left;">
Scand J Work Environ Health
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant fibrous mesothelioma. Metastatic to brain and liver.
</td>
<td style="text-align:left;">
Acta Neuropathol.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Relation between natural killer cells and neoplastic cells in serous fluids.
</td>
<td style="text-align:left;">
Diagn. Cytopathol.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant peritoneal mesothelioma presenting with respiratory symptoms.
</td>
<td style="text-align:left;">
Eur Radiol
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Reconstruction of the diaphragm with a pericardial flap after radical pleuropneumonectomy for malignant pleural mesothelioma (author’s transl)].
</td>
<td style="text-align:left;">
Thoraxchir Vask Chir
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Computed tomography-guided fine needle aspiration of peripheral lung opacities. An initial diagnostic procedure?
</td>
<td style="text-align:left;">
Acta Cytol.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Immunoreactivity for cadherins, HGF/SF, met, and erbB-2 in pleural malignant mesotheliomas.
</td>
<td style="text-align:left;">
Histopathology
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Primary biphasic synovial sarcoma of the pleura].
</td>
<td style="text-align:left;">
Rev Mal Respir
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Loss of heterozygosity analysis of 13q and 14q in human malignant mesothelioma.
</td>
<td style="text-align:left;">
Genes Chromosomes Cancer
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural disease.
</td>
<td style="text-align:left;">
Eur J Radiol
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Multicentric study on malignant pleural mesothelioma and non-occupational exposure to asbestos.
</td>
<td style="text-align:left;">
Br. J. Cancer
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Positron emission tomography with f18-fluorodeoxyglucose in the staging and preoperative evaluation of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J. Thorac. Cardiovasc. Surg.
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Tissue factor pathway inhibitor expression by human pleural mesothelial and mesothelioma cells.
</td>
<td style="text-align:left;">
Eur. Respir. J.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma with CD30-positivity. A case report and review of the literature.
</td>
<td style="text-align:left;">
Arch. Pathol. Lab. Med.
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma presenting as spontaneous pneumothorax: a case series and review.
</td>
<td style="text-align:left;">
Am. J. Ind. Med.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Calretinin staining pattern aids in the differentiation of mesothelioma from adenocarcinoma in serous effusions.
</td>
<td style="text-align:left;">
Cancer
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Docetaxel and irinotecan (CPT-11) in the treatment of malignant pleural mesothelioma–a feasibility study.
</td>
<td style="text-align:left;">
Anticancer Drugs
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Management of malignant pleural mesothelioma: a critical review.
</td>
<td style="text-align:left;">
Curr Opin Pulm Med
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Clinical analysis of 19 patients with pleural mesothelioma].
</td>
<td style="text-align:left;">
Zhonghua Zhong Liu Za Zhi
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Lipid-rich diffuse malignant mesothelioma: a case report.
</td>
<td style="text-align:left;">
Hum. Pathol.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
The long-term morbidity of pleuroperitoneal shunts in the management of recurrent malignant effusions.
</td>
<td style="text-align:left;">
Eur J Cardiothorac Surg
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Primary malignant gonadal mesotheliomas and asbestos.
</td>
<td style="text-align:left;">
Histopathology
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
An optimized battery of eight antibodies that can distinguish most cases of epithelial mesothelioma from adenocarcinoma.
</td>
<td style="text-align:left;">
Am. J. Clin. Pathol.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Caelyx in malignant mesothelioma: a phase II EORTC study.
</td>
<td style="text-align:left;">
Ann. Oncol.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
HHV-8 is not a cofactor in the pathogenesis of environmentally induced malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Monaldi Arch Chest Dis
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Phase II study of intravenous Doxil in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Invest New Drugs
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Diagnostic usefulness of tumour marker levels in pleural effusions of malignant and benign origin.
</td>
<td style="text-align:left;">
Clin. Chim. Acta
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Simian virus-40 sequences are a negative prognostic cofactor in patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Genes Chromosomes Cancer
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Proliferation, apoptosis, and manganese superoxide dismutase in malignant mesothelioma.
</td>
<td style="text-align:left;">
Int. J. Cancer
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[High risk of pleural mesothelioma among the state railroad carriage repair workers].
</td>
<td style="text-align:left;">
Epidemiol Prev
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant solitary fibrous tumor of the pleura: two cases and review of the literature].
</td>
<td style="text-align:left;">
Nihon Igaku Hoshasen Gakkai Zasshi
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Mortality of workers at two asbestos-cement plants in Poland.
</td>
<td style="text-align:left;">
Int J Occup Med Environ Health
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Gene-modified PA1-STK cells home to tumor sites in patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Ann. Thorac. Surg.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Expression of inducible nitric oxide synthase in healthy pleura and in malignant mesothelioma.
</td>
<td style="text-align:left;">
Br. J. Cancer
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
The separation of benign and malignant mesothelial proliferations.
</td>
<td style="text-align:left;">
Am. J. Surg. Pathol.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Simian virus (SV) 40 like sequences in cell lines and tumour biopsies from Australian malignant mesotheliomas.
</td>
<td style="text-align:left;">
Aust N Z J Med
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant vascular tumours of the pleura in “asbestos” workers and endothelial differentiation in malignant mesothelioma.
</td>
<td style="text-align:left;">
Thorax
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant mesothelioma of the pleura, pericardium and peritoneum. 1: Etiology, pathogenesis, pathology].
</td>
<td style="text-align:left;">
Chirurg
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Mesothelioma of the pleura and peritoneum. Diagnostic and therapeutic sequelae].
</td>
<td style="text-align:left;">
Chirurg
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Carbohydrate antigen expression in primary tumors, metastatic lesions, and serous effusions from patients diagnosed with epithelial ovarian carcinoma: evidence of up-regulated Tn and Sialyl Tn antigen expression in effusions.
</td>
<td style="text-align:left;">
Hum. Pathol.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Adenomatoid tumor of the pleura. Case report].
</td>
<td style="text-align:left;">
Ann Pathol
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Use of tumor markers for differential diagnosis of mesothelioma and secondary pleural malignancies.
</td>
<td style="text-align:left;">
Clin. Biochem.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Metastasis of pleural malignant mesothelioma to the brain and upper maxilla: description of 2 cases].
</td>
<td style="text-align:left;">
Pathologica
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Differential gene expression in mesothelioma.
</td>
<td style="text-align:left;">
FEBS Lett.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Patterns of chromosomal imbalances in benign solitary fibrous tumours of the pleura.
</td>
<td style="text-align:left;">
Virchows Arch.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant peritoneal mesothelioma associated with deep vein thrombosis following radiotherapy for seminoma of the testis.
</td>
<td style="text-align:left;">
Intern. Med.
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Phase II study of vinorelbine in patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J. Clin. Oncol.
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
The difficult diagnostic approach of the intraperitoneal mesothelioma.
</td>
<td style="text-align:left;">
Neth J Med
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma in a 13-year-old girl.
</td>
<td style="text-align:left;">
Pediatr Radiol
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Role of occupational asbestos exposure in Hungarian lung cancer patients.
</td>
<td style="text-align:left;">
Int Arch Occup Environ Health
</td>
<td style="text-align:left;">
diagnosis | transmission | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Environmental malignant mesothelioma in southern Anatolia: a study of fifty cases.
</td>
<td style="text-align:left;">
Environ. Health Perspect.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Prognostic significance of presence and reduplication of basal lamina in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Hum. Pathol.
</td>
<td style="text-align:left;">
transmission
</td>
</tr>
<tr>
<td style="text-align:left;">
Indications for pleurectomy in malignant effusion.
</td>
<td style="text-align:left;">
Cancer
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Incidence of malignant pleural mesothelioma due to environmental asbestos fiber exposure in the southeast of Turkey.
</td>
<td style="text-align:left;">
Respiration
</td>
<td style="text-align:left;">
epidemiology
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma caused by environmental exposure to asbestos in the Southeast of Turkey: CT findings in 117 patients.
</td>
<td style="text-align:left;">
Respiration
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Comparison of the effectiveness of some pleural sclerosing agents used for control of effusions in malignant pleural mesothelioma: a review of 117 cases.
</td>
<td style="text-align:left;">
Respiration
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Surgical treatment for malignant pleural mesothelioma in eight cases].
</td>
<td style="text-align:left;">
Kyobu Geka
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
[A case of panpleuropneumonectomy for diffuse pleural mesothelioma].
</td>
<td style="text-align:left;">
Kyobu Geka
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Unusually high incidence of malignant pleural mesothelioma in a town of eastern Sicily: an epidemiological and environmental study.
</td>
<td style="text-align:left;">
Arch. Environ. Health
</td>
<td style="text-align:left;">
epidemiology
</td>
</tr>
<tr>
<td style="text-align:left;">
Well-differentiated papillary mesothelioma involving the peritoneal and pleural cavities: successful treatment by local and systemic administration of carboplatin.
</td>
<td style="text-align:left;">
Tumori
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Extrapleural pneumonectomy for sarcomas report of two cases.
</td>
<td style="text-align:left;">
Tumori
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
p53 autoantibodies in patients with malignant mesothelioma: stability through disease progression.
</td>
<td style="text-align:left;">
Br. J. Cancer
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Immunohistochemical panels for differentiating epithelial malignant mesothelioma from lung adenocarcinoma: a study with logistic regression analysis.
</td>
<td style="text-align:left;">
Am. J. Surg. Pathol.
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Huge malignant localized fibrous tumor of the pleura.
</td>
<td style="text-align:left;">
J Cardiovasc Surg (Torino)
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
<ol start="11" style="list-style-type: decimal">
<li>Evaluation of Patients with Known Mesothelioma with 18F-Fluorodeoxyglucose and PET. Comparison with Computed Tomography.
</td>
<td style="text-align:left;">
Clin. Positron Imaging
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Efficacy of repeated adenoviral suicide gene therapy in a localized murine tumor model.
</td>
<td style="text-align:left;">
Ann. Thorac. Surg.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Diagnostic value of CEA, CA 15-3, CA 19-9, CYFRA 21-1, NSE and TSA assay in pleural effusions.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
A phase II study of combined intravenous and subcutaneous interleukin-2 in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Palliative and therapeutic activity of IL-2 immunotherapy in unresectable malignant pleural mesothelioma with pleural effusion: Results of a phase II study on 31 consecutive patients.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Solitary fibrous tumour of the pleura: surgical treatment.
</td>
<td style="text-align:left;">
Eur J Cardiothorac Surg
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
The alpha folate receptor is highly activated in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J. Thorac. Cardiovasc. Surg.
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
[Treatment of malignant pleural effusion by pleurodesis with talc].
</td>
<td style="text-align:left;">
Chir Ital
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Echocardiographic findings of pericardial involvement in patients with malignant pleural mesothelioma with a history of environmental exposure to asbestos and erionite.
</td>
<td style="text-align:left;">
Respirology
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Membranous glomerulonephritis associated with diffuse malignant pleural mesothelioma: report of a case.
</td>
<td style="text-align:left;">
Surg. Today
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Increased mesothelioma incidence in New Zealand: the asbestos-cancer epidemic has started.
</td>
<td style="text-align:left;">
N. Z. Med. J.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant mesothelioma: clinical and radiological description of 45 cases with and without asbestos exposure].
</td>
<td style="text-align:left;">
Salud Publica Mex
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Clinical behavior of solitary fibrous tumors of the pleura. An immunohistochemical study.
</td>
<td style="text-align:left;">
Anticancer Res.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Recent advances in the molecular analysis of human malignant mesothelioma.
</td>
<td style="text-align:left;">
Clin Ter
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
[Pleural and parenchymal lung diseases from asbestos exposure. CT diagnosis].
</td>
<td style="text-align:left;">
Radiol Med
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleural mesothelioma associated with indoor pollution of asbestos.
</td>
<td style="text-align:left;">
J. Cancer Res. Clin. Oncol.
</td>
<td style="text-align:left;">
transmission
</td>
</tr>
<tr>
<td style="text-align:left;">
Radicular involvement and medullary invasion from a malignant mesothelioma.
</td>
<td style="text-align:left;">
Respiration
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Cancer Treat. Res.
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
A pilot study of systemic corticosteroid administration in conjunction with intrapleural adenoviral vector administration in patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Cancer Gene Ther.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Severe chromosomal aberrations in pleural mesotheliomas with unusual mesodermal features. Comparative genomic hybridization evidence for a mesothelioma subgroup.
</td>
<td style="text-align:left;">
J Mol Diagn
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant mesothelioma in the industrial area of Colleferro].
</td>
<td style="text-align:left;">
Med Lav
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma in pregnancy.
</td>
<td style="text-align:left;">
J Matern Fetal Med
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
SV40 and the pathogenesis of mesothelioma.
</td>
<td style="text-align:left;">
Semin. Cancer Biol.
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Strategies to circumvent SV40 oncoprotein expression in malignant pleural mesotheliomas.
</td>
<td style="text-align:left;">
Semin. Cancer Biol.
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma produces functional granulocyte-colony stimulating factor.
</td>
<td style="text-align:left;">
Chest
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Thoracoscopic pleural biopsy under local anesthesia using a 2 mm laparoscope].
</td>
<td style="text-align:left;">
Nihon Kokyuki Gakkai Zasshi
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Erionite bodies and fibres in bronchoalveolar lavage fluid (BALF) of residents from Tuzköy, Cappadocia, Turkey.
</td>
<td style="text-align:left;">
Occup Environ Med
</td>
<td style="text-align:left;">
transmission
</td>
</tr>
<tr>
<td style="text-align:left;">
Immunotherapy-based treatment strategies for malignant mesothelioma.
</td>
<td style="text-align:left;">
Curr. Opin. Mol. Ther.
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Trimodality management of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Eur J Cardiothorac Surg
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Gene expression profiling of malignant mesothelioma cell lines: cDNA array study.
</td>
<td style="text-align:left;">
Int. J. Cancer
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma in Japan: analysis of registered autopsy cases.
</td>
<td style="text-align:left;">
Arch. Environ. Health
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Extrapleural pneumonectomy for diffuse malignant pleural mesothelioma. A treatment option in selected cases?
</td>
<td style="text-align:left;">
Jpn. J. Thorac. Cardiovasc. Surg.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Genetic-susceptibility factor and malignant mesothelioma in the Cappadocian region of Turkey.
</td>
<td style="text-align:left;">
Lancet
</td>
<td style="text-align:left;">
epidemiology
</td>
</tr>
<tr>
<td style="text-align:left;">
Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma.
</td>
<td style="text-align:left;">
J. Pathol.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleuroperitoneal shunts and tumor seeding.
</td>
<td style="text-align:left;">
J. Thorac. Cardiovasc. Surg.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Expression and prognostic significance of catalase in malignant mesothelioma.
</td>
<td style="text-align:left;">
Cancer
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Basic fibroblast growth factor in mesothelioma pleural effusions: correlation with patient survival and angiogenesis.
</td>
<td style="text-align:left;">
Int. J. Oncol.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Diagnostic value of CYFRA 21-1 tumor marker and CEA in pleural effusion due to mesothelioma.
</td>
<td style="text-align:left;">
Chest
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Asbestos-induced malignant mesothelioma of the tunica vaginalis testis].
</td>
<td style="text-align:left;">
Zentralbl Chir
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Nodular thickening of interlobar fissures: an early manifestation of malignant mesothelioma: a case report.
</td>
<td style="text-align:left;">
Jpn. J. Clin. Oncol.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Superior vena cava obstruction: is stenting necessary?
</td>
<td style="text-align:left;">
Support Care Cancer
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Up-regulation of thioredoxin and thioredoxin reductase in human malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Int. J. Cancer
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
[Gene expression profiling in human mesothelioma cells using DNA microarray and high-density filter array technologies].
</td>
<td style="text-align:left;">
Bull Cancer
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Control of cell cycle progression in human mesothelioma cells treated with gamma interferon.
</td>
<td style="text-align:left;">
Oncogene
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Combination chemotherapy with mitoxantrone, methotrexate, and mitomycin (MMM regimen) in malignant pleural mesothelioma: a phase II study.
</td>
<td style="text-align:left;">
Am. J. Clin. Oncol.
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Nephrotic syndrome and mesenteric infarction secondary to metastatic mesothelioma.
</td>
<td style="text-align:left;">
Postgrad Med J
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Percutaneous image-guided cutting-needle biopsy of the pleura in the presence of a suspected malignant effusion.
</td>
<td style="text-align:left;">
Radiology
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Localised spontaneous regression in mesothelioma – possible immunological mechanism.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
A left pleural effusion with a calcified tumoral mass and left hemithoracic uptake on bone scan.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Lipomatous change in a brain metastasis from malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Neuroradiology
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Early diagnosis of mesothelioma in serous effusions using AgNOR analysis.
</td>
<td style="text-align:left;">
Anal. Quant. Cytol. Histol.
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Treatment of malignant mesothelioma.
</td>
<td style="text-align:left;">
World J Surg
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Asbestos exposure in malignant mesothelioma of the pleura: a survey of 557 cases.
</td>
<td style="text-align:left;">
Ind Health
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Pathology of human malignant mesothelioma–preliminary analysis of 1,517 mesothelioma cases.
</td>
<td style="text-align:left;">
Ind Health
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Asbestos-related lung cancer and mesothelioma in Japan.
</td>
<td style="text-align:left;">
Ind Health
</td>
<td style="text-align:left;">
epidemiology | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Epidemiology of occupational asbestos-related diseases in China.
</td>
<td style="text-align:left;">
Ind Health
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Calretinin and other mesothelioma markers in synovial sarcoma: analysis of antigenic similarities and differences with malignant mesothelioma.
</td>
<td style="text-align:left;">
Am. J. Surg. Pathol.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Immunohistochemical MIB-1 and p27kip1 as prognostic factors in pleural mesothelioma.
</td>
<td style="text-align:left;">
Pathol. Res. Pract.
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Synovial sarcoma and malignant mesothelioma of the pleura: review, differential diagnosis and possible role of apoptosis.
</td>
<td style="text-align:left;">
Pathology
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant solitary fibrous tumor of pleura with focal expression of cytokeratin].
</td>
<td style="text-align:left;">
Ann Pathol
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma in central and Eastern Europe.
</td>
<td style="text-align:left;">
Acta Med Croatica
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Percutaneous balloon pericardiotomy for patients with malignant pericardial effusion including three malignant pleural mesotheliomas.
</td>
<td style="text-align:left;">
Angiology
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Phase II trial of liposomal daunorubicin in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Ann. Oncol.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Use of an implantable pleural catheter for trapped lung syndrome in patients with malignant pleural effusion.
</td>
<td style="text-align:left;">
Chest
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
DNA copy number changes in familial malignant mesothelioma.
</td>
<td style="text-align:left;">
Cancer Genet. Cytogenet.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
[Occupational exposure to asbestos and recognition of pleural mesothelioma as occupational disease in the province of Genoa].
</td>
<td style="text-align:left;">
Epidemiol Prev
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Combined use of novel epithelial (MOC-31) and mesothelial (HBME-1) immunohistochemical markers for optimal first line diagnostic distinction between mesothelioma and metastatic carcinoma in pleura.
</td>
<td style="text-align:left;">
Histopathology
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
p27 immunostaining is related to prognosis in malignant mesothelioma.
</td>
<td style="text-align:left;">
Histopathology
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
[Treatment of malignant pleural mesothelioma].
</td>
<td style="text-align:left;">
Minerva Chir
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
p53, p21 and metallothionein immunoreactivities in patients with malignant pleural mesothelioma: correlations with the epidemiological features and prognosis of mesotheliomas with environmental asbestos exposure.
</td>
<td style="text-align:left;">
Respir Med
</td>
<td style="text-align:left;">
epidemiology
</td>
</tr>
<tr>
<td style="text-align:left;">
[Incidence of malignant mesothelioma in Denmark and expected number of future cases among men].
</td>
<td style="text-align:left;">
Ugeskr. Laeg.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Immunohistochemical differential diagnosis of pleural effusions, with emphasis on malignant mesothelioma.
</td>
<td style="text-align:left;">
Curr Opin Pulm Med
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Wedge-shaped applicator for additional light delivery and dosimetry in the diaphragmal sinus during photodynamic therapy for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Phys Med Biol
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Immunohistochemical analysis still has a limited role in the diagnosis of malignant mesothelioma. A study of thirteen antibodies.
</td>
<td style="text-align:left;">
Am. J. Clin. Pathol.
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma from neighborhood exposure to anthophyllite asbestos.
</td>
<td style="text-align:left;">
Am. J. Ind. Med.
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Glucose transporter Glut-1 is of limited value for detecting breast carcinoma in serous effusions.
</td>
<td style="text-align:left;">
Mod. Pathol.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
A case of repetitive intrapleural cancer chemotherapy using INFUSE-A-PORT for malignant mesothelioma.
</td>
<td style="text-align:left;">
Thorac Cardiovasc Surg
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Combined regimen of cisplatin, doxorubicin, and alpha-2b interferon in the treatment of advanced malignant pleural mesothelioma: a Phase II multicenter trial of the Italian Group on Rare Tumors (GITR) and the Italian Lung Cancer Task Force (FONICAP).
</td>
<td style="text-align:left;">
Cancer
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Hyaluronan production increases the malignant properties of mesothelioma cells.
</td>
<td style="text-align:left;">
Br. J. Cancer
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
p14(ARF) modulates the cytolytic effect of ONYX-015 in mesothelioma cells with wild-type p53.
</td>
<td style="text-align:left;">
Cancer Res.
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleural amyloidosis mimicking mesothelioma: a clinicopathologic study of two cases.
</td>
<td style="text-align:left;">
Ann Diagn Pathol
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[A case of desmoplastic malignant pleural mesothelioma].
</td>
<td style="text-align:left;">
Nihon Kokyuki Gakkai Zasshi
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Unusual case of mesothelioma of the tunica vaginalis associated with prostatic adenocarcinoma].
</td>
<td style="text-align:left;">
Minerva Urol Nefrol
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Information about occupational exposure to asbestos given to cases in an etiological study: ethical aspects.
</td>
<td style="text-align:left;">
Eur. J. Epidemiol.
</td>
<td style="text-align:left;">
diagnosis | epidemiology | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Comparison of antibodies to HBME-1 and calretinin for the detection of mesothelial cells in effusion cytology.
</td>
<td style="text-align:left;">
Diagn. Cytopathol.
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Cancer mortality among workers exposed to amphibole-free chrysotile asbestos.
</td>
<td style="text-align:left;">
Am. J. Epidemiol.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Prognostic significance of flow cytometric DNA analysis in patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Evaluation of pleural disease using MR and CT. With special reference to malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Acta Radiol
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Historical cohort study of US man-made vitreous fiber production workers: II. Mortality from mesothelioma.
</td>
<td style="text-align:left;">
J. Occup. Environ. Med.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma–German mesothelioma register 1987-1999.
</td>
<td style="text-align:left;">
Int Arch Occup Environ Health
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Localized malignant mesothelioma of the pleura.
</td>
<td style="text-align:left;">
Pathol. Int.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Hyaluronan content in pleural fluid as a prognostic factor in patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Cancer
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
p27(kip1) immunoreactivity correlates with long-term survival in pleural malignant mesothelioma.
</td>
<td style="text-align:left;">
Cancer
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma: a comparison of biopsy and postmortem material by light microscopy and immunohistochemistry.
</td>
<td style="text-align:left;">
J. Clin. Pathol.
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
A phase II trial of surgical resection and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J. Thorac. Cardiovasc. Surg.
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Intraoperative photodynamic therapy after pleuropneumonectomy in patients with malignant pleural mesothelioma: dose finding and toxicity results.
</td>
<td style="text-align:left;">
Chest
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma in bakers and pastry cooks.
</td>
<td style="text-align:left;">
Am. J. Ind. Med.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Absence of SV-40 large T antigen (Tag) in malignant mesothelioma effusions: an immunocytochemical study.
</td>
<td style="text-align:left;">
Diagn. Cytopathol.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Prognostic factors in diffuse malignant pleural mesothelioma: effects of pretreatment clinical and laboratory characteristics.
</td>
<td style="text-align:left;">
Respir Med
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
K-ras and rho A mutations in malignant pleural effusion.
</td>
<td style="text-align:left;">
Int. J. Oncol.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Immunocytochemistry in effusion cytology: a contemporary review.
</td>
<td style="text-align:left;">
Cancer
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Increased risk of malignant mesothelioma of the pleura after residential or domestic exposure to asbestos: a case-control study in Casale Monferrato, Italy.
</td>
<td style="text-align:left;">
Environ. Health Perspect.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Incidence of malignant mesothelioma (1980-1999) and asbestos exposure in 190 cases diagnosed among residents of the province of Brescia].
</td>
<td style="text-align:left;">
Med Lav
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Therapeutic outcome according to histologic subtype in 121 patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Well-differentiated papillary mesothelioma.
</td>
<td style="text-align:left;">
Am. J. Surg. Pathol.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
5-lipoxygenase regulates malignant mesothelial cell survival: involvement of vascular endothelial growth factor.
</td>
<td style="text-align:left;">
FASEB J.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma following chemotherapy for breast cancer.
</td>
<td style="text-align:left;">
Anticancer Res.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Technology evaluation: gene therapy (mesothelioma), NCI.
</td>
<td style="text-align:left;">
Curr. Opin. Mol. Ther.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Palliative surgical debulking in malignant mesothelioma. Predictors of survival and symptom control.
</td>
<td style="text-align:left;">
Eur J Cardiothorac Surg
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant pleural mesothelioma].
</td>
<td style="text-align:left;">
Minerva Chir
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Etiology of pleural effusion based on material from the Hospital of Lung Diseases and Tuberculosis].
</td>
<td style="text-align:left;">
Pneumonol Alergol Pol
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Unusual clear cell variant of epithelioid mesothelioma.
</td>
<td style="text-align:left;">
Arch. Pathol. Lab. Med.
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Pulmonary adenocarcinoma simulating malignant mesothelioma.
</td>
<td style="text-align:left;">
Arch. Pathol. Lab. Med.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Percutaneous image-guided cutting needle biopsy of the pleura in the diagnosis of malignant mesothelioma.
</td>
<td style="text-align:left;">
Chest
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
The value of cytokeratins 20 and 7 in discriminating metastatic adenocarcinomas from pleural mesotheliomas.
</td>
<td style="text-align:left;">
Cancer
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Survival after conservative (palliative) management of pleural malignant mesothelioma.
</td>
<td style="text-align:left;">
J Surg Oncol
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Computed tomography features in malignant pleural mesothelioma and other commonly seen pleural diseases.
</td>
<td style="text-align:left;">
Eur J Radiol
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
[Two cases of malignant mesothelioma of the pleura within one family].
</td>
<td style="text-align:left;">
Pol. Merkur. Lekarski
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Numerical alteration of chromosome 8 in pleural effusions].
</td>
<td style="text-align:left;">
Zhonghua Zhong Liu Za Zhi
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Pseudomesotheliomatous adenocarcinoma of the lung with rhabdoid features.
</td>
<td style="text-align:left;">
Pathol. Res. Pract.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Additional proteins in BAL fluid of Metsovites environmentally exposed to asbestos: more evidence of “protection” against neoplasia?
</td>
<td style="text-align:left;">
Chest
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Expression of cytokeratin 5/6 in epithelial neoplasms: an immunohistochemical study of 509 cases.
</td>
<td style="text-align:left;">
Mod. Pathol.
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
The presence of simian-virus 40 sequences in mesothelioma and mesothelial cells is associated with high levels of vascular endothelial growth factor.
</td>
<td style="text-align:left;">
Am. J. Respir. Cell Mol. Biol.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Diseases caused by asbestos: mechanisms of injury and disease development.
</td>
<td style="text-align:left;">
Int. Immunopharmacol.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
[Value of thoracoscopy in undiagnosed pleural effusion].
</td>
<td style="text-align:left;">
Zhonghua Jie He He Hu Xi Za Zhi
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Results of phase II clinical trial of cycloplatam in refractory solid tumors].
</td>
<td style="text-align:left;">
Vopr Onkol
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Induction of apoptosis in malignant pleural mesothelioma cells by activation of the Fas (Apo-1/CD95) death-signal pathway.
</td>
<td style="text-align:left;">
J. Thorac. Cardiovasc. Surg.
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Chylothorax as the initial manifestation of malignant pleural mesothelioma–a case report].
</td>
<td style="text-align:left;">
Nihon Kokyuki Gakkai Zasshi
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Amylase levels in pleural effusions: a consecutive unselected series of 841 patients.
</td>
<td style="text-align:left;">
Chest
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Cytoreductive surgery and intraoperative hyperthermic intrathoracic chemotherapy in patients with malignant pleural mesothelioma or pleural metastases of thymoma.
</td>
<td style="text-align:left;">
Chest
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
The pathogenesis of mesothelioma.
</td>
<td style="text-align:left;">
Semin. Oncol.
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
The epidemiology of mesothelioma.
</td>
<td style="text-align:left;">
Semin. Oncol.
</td>
<td style="text-align:left;">
epidemiology | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
The role of imaging in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Semin. Oncol.
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Prognostic factors in mesothelioma.
</td>
<td style="text-align:left;">
Semin. Oncol.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Multimodality treatment of diffuse malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Semin. Oncol.
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
The emerging role of antifolates in the treatment of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Semin. Oncol.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Multicenter randomized controlled trial of the management of unresectable malignant mesothelioma proposed by the British Thoracic Society and the British Medical Research Council.
</td>
<td style="text-align:left;">
Semin. Oncol.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Thyroid transcription factor-1 is highly sensitive and specific in differentiating metastatic pulmonary from extrapulmonary adenocarcinoma in effusion fluid cytology specimens.
</td>
<td style="text-align:left;">
Cancer
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant mesothelioma in Basse-Normandie, a French population study. Descriptive analysis, prognostic factors and survival].
</td>
<td style="text-align:left;">
Rev Epidemiol Sante Publique
</td>
<td style="text-align:left;">
diagnosis | epidemiology
</td>
</tr>
<tr>
<td style="text-align:left;">
[Current insights in malignant pleural mesothelioma].
</td>
<td style="text-align:left;">
Bull Cancer
</td>
<td style="text-align:left;">
diagnosis | treatment | epidemiology | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Manganese superoxide dismutase genotypes and asbestos-associated pulmonary disorders.
</td>
<td style="text-align:left;">
Cancer Lett.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant mesothelioma with osteoblastic heterologous elements].
</td>
<td style="text-align:left;">
Ann Pathol
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
SV40 infection induces telomerase activity in human mesothelial cells.
</td>
<td style="text-align:left;">
Oncogene
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Overexpression of peroxiredoxins I, II, III, V, and VI in malignant mesothelioma.
</td>
<td style="text-align:left;">
J. Pathol.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
SV40 Tag-specific cytotoxic T lymphocytes generated from the peripheral blood of malignant pleural mesothelioma patients.
</td>
<td style="text-align:left;">
Cancer Immunol. Immunother.
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Hyperthermia and mafosfamide in a human-derived malignant pleural mesothelioma cell line.
</td>
<td style="text-align:left;">
J. Cancer Res. Clin. Oncol.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Clinical and immunological assessment of Mycobacterium vaccae (SRL172) with chemotherapy in patients with malignant mesothelioma.
</td>
<td style="text-align:left;">
Br. J. Cancer
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Multicentre phase II study of gemcitabine and cisplatin in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Br. J. Cancer
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Clinical utility and safety of diagnostic thoracoscopy].
</td>
<td style="text-align:left;">
Nihon Kokyuki Gakkai Zasshi
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Localized pleural malignant mesothelioma.
</td>
<td style="text-align:left;">
Pathol. Int.
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Treatment of postoperative chylothorax through laparoscopic thoracic duct ligation.
</td>
<td style="text-align:left;">
Eur J Cardiothorac Surg
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Phase II study of repeated intrapleural chemotherapy using implantable access system for management of malignant pleural effusion.
</td>
<td style="text-align:left;">
Chest
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant epithelioid mesothelioma: anti-mesothelial marker expression correlates with histological pattern.
</td>
<td style="text-align:left;">
Histopathology
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Diffuse malignant epithelial mesotheliomas of the peritoneum in women: a clinicopathologic study of 25 patients.
</td>
<td style="text-align:left;">
Cancer
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma in Australia, 1945-2000.
</td>
<td style="text-align:left;">
Am. J. Ind. Med.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Phosphatase and tensin analog gene overexpression engenders cellular death in human malignant mesothelioma cells via inhibition of AKT phosphorylation.
</td>
<td style="text-align:left;">
Ann. Surg. Oncol.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Expression of p21 in SV40 large T antigen positive human pleural mesothelioma: relationship with survival.
</td>
<td style="text-align:left;">
Thorax
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Meningeal metastasis of pleural mesothelioma].
</td>
<td style="text-align:left;">
Rev Mal Respir
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant pleural mesothelioma. From diagnosis to prognosis].
</td>
<td style="text-align:left;">
Presse Med
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant pleural mesothelioma. Present data and perspectives for treatment].
</td>
<td style="text-align:left;">
Presse Med
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Asbestos-related disease.
</td>
<td style="text-align:left;">
Hosp Med
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Reappraisal of the strong association between simian virus 40 and human malignant mesothelioma of the pleura (Belgium).
</td>
<td style="text-align:left;">
Cancer Causes Control
</td>
<td style="text-align:left;">
transmission
</td>
</tr>
<tr>
<td style="text-align:left;">
A phase II EORTC study of temozolomide in patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Eur. J. Cancer
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant deciduoid mesothelioma of the pleura: report of two cases with long survival.
</td>
<td style="text-align:left;">
Histopathology
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
The value of Wilms tumor susceptibility gene 1 in cytologic preparations as a marker for malignant mesothelioma.
</td>
<td style="text-align:left;">
Cancer
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Detection and quantification of SV40 large T-antigen DNA in mesothelioma tissues and cell lines.
</td>
<td style="text-align:left;">
Oncol. Rep.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
A case of malignant pleural mesothelioma with unexpectedly long survival without active treatment.
</td>
<td style="text-align:left;">
Respiration
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
[Solitary fibrous thoracic tumor: a rare tumor with unpredictable course].
</td>
<td style="text-align:left;">
Rev Pneumol Clin
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Oxaliplatin and raltitrexed in the treatment of inoperable malignant pleural mesothelioma: results of a pilot study.
</td>
<td style="text-align:left;">
Tumori
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[A case of primary malignant retroperitoneal mesothelioma needed to differentiate adrenal tumor].
</td>
<td style="text-align:left;">
Hinyokika Kiyo
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Cytopathology of pleural mesotheliomas.
</td>
<td style="text-align:left;">
Am. J. Clin. Pathol.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Flow cytometric analysis of a localized malignant mesothelioma.
</td>
<td style="text-align:left;">
Ann. Thorac. Surg.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma: a phase II trial with docetaxel.
</td>
<td style="text-align:left;">
Ann. Oncol.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Non-asbestos related diffuse malignant mesothelioma.
</td>
<td style="text-align:left;">
Tumori
</td>
<td style="text-align:left;">
epidemiology | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Diagnostic value of medical thoracoscopy in pleural disease: a 6-year retrospective study.
</td>
<td style="text-align:left;">
Chest
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Primary thoracic sarcomas.
</td>
<td style="text-align:left;">
Radiographics
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Expression of glycoprotein 90K in human malignant pleural mesothelioma: correlation with patient survival.
</td>
<td style="text-align:left;">
J. Pathol.
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
[Surgery and hyperthermic pleural perfusion–a new approach for malignancies with pleural involvement].
</td>
<td style="text-align:left;">
Harefuah
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
The pathogenesis of pseudoachalasia: a clinicopathologic study of 13 cases of a rare entity.
</td>
<td style="text-align:left;">
Am. J. Surg. Pathol.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Pemetrexed for diffuse malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Semin. Oncol.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma and occupational exposure to asbestos: a clinicopathological correlation of 1445 cases.
</td>
<td style="text-align:left;">
Ultrastruct Pathol
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Current therapy for malignant mesothelioma.
</td>
<td style="text-align:left;">
Curr Oncol Rep
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Current surgical management of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Curr Oncol Rep
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma: immunohistochemistry and DNA ploidy analysis as methods to differentiate mesothelioma from benign reactive mesothelial cell proliferation and adenocarcinoma in pleural and peritoneal effusions.
</td>
<td style="text-align:left;">
Arch. Pathol. Lab. Med.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Lung diseases due to environmental exposures to erionite and asbestos in Turkey.
</td>
<td style="text-align:left;">
Toxicol. Lett.
</td>
<td style="text-align:left;">
epidemiology
</td>
</tr>
<tr>
<td style="text-align:left;">
Photodynamic therapy for mesothelioma.
</td>
<td style="text-align:left;">
Curr Treat Options Oncol
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant peritoneal mesothelioma.
</td>
<td style="text-align:left;">
Curr Treat Options Oncol
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Pericardial mesothelioma.
</td>
<td style="text-align:left;">
Curr Treat Options Oncol
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Curr Treat Options Oncol
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Cyclooxygenase-2 expression is a novel prognostic factor in malignant mesothelioma.
</td>
<td style="text-align:left;">
Clin. Cancer Res.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Antisense therapy for malignant mesothelioma with oligonucleotides targeting the bcl-xl gene product.
</td>
<td style="text-align:left;">
J. Thorac. Cardiovasc. Surg.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
[Diagnosis and staging of malignant pleural mesothelioma].
</td>
<td style="text-align:left;">
Pneumologie
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Intrapleural infusion of activated macrophages and gamma-interferon in malignant pleural mesothelioma: a phase II study.
</td>
<td style="text-align:left;">
Chest
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Inhibitor of apoptosis protein-1 promotes tumor cell survival in mesothelioma.
</td>
<td style="text-align:left;">
Carcinogenesis
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[A case of desmoplastic malignant mesothelioma with elevated serum CYFRA 21-1].
</td>
<td style="text-align:left;">
Nihon Kokyuki Gakkai Zasshi
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Black spots of the parietal pleura: morphology and formal pathogenesis.
</td>
<td style="text-align:left;">
Respiration
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Microcystic variant of localized malignant mesothelioma accompanying an adenomatoid tumor-like lesion.
</td>
<td style="text-align:left;">
Pathol. Int.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Expression of matrix metalloproteinases, tissue inhibitors of metalloproteinase, collagens, and Ki67 antigen in pleural malignant mesothelioma: an immunohistochemical and electron microscopic study.
</td>
<td style="text-align:left;">
Med Electron Microsc
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
CT-guided percutaneous selective cordotomy for treatment of intractable pain in patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Acta Neurochir (Wien)
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Molecular cytogenetic differences between histological subtypes of malignant mesotheliomas: DNA cytometry and comparative genomic hybridization of 90 cases.
</td>
<td style="text-align:left;">
J. Pathol.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Primary thymic epithelial tumours of the pleura mimicking malignant mesothelioma.
</td>
<td style="text-align:left;">
Histopathology
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Diagnostic DNA-flow- vs. -image-cytometry in effusion cytology.
</td>
<td style="text-align:left;">
Anal Cell Pathol
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Tumorigenicity of cellulose fibers injected into the rat peritoneal cavity.
</td>
<td style="text-align:left;">
Inhal Toxicol
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Pitfalls in diagnosis of early stage malignant peritoneal mesothelioma: a case report.
</td>
<td style="text-align:left;">
Clin Imaging
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
The management of malignant pleural mesothelioma; single centre experience in 10 years.
</td>
<td style="text-align:left;">
Eur J Cardiothorac Surg
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Diagnostic utility of thyroid transcription factor-1 expression in adenocarcinomas presenting in serous fluids.
</td>
<td style="text-align:left;">
Acta Cytol.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Accelerated progression of asbestos-induced mesotheliomas in heterozygous p53+/- mice.
</td>
<td style="text-align:left;">
Toxicol. Sci.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Diffuse malignant mesothelioma of the pleural space and its management.
</td>
<td style="text-align:left;">
Oncology (Williston Park, N.Y.)
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Concurrent LOH at multiple loci in human malignant mesothelioma with preferential loss of NF2 gene region.
</td>
<td style="text-align:left;">
Oncol. Rep.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Presence of simian virus 40 (SV40) is not frequent in Swedish malignant mesotheliomas.
</td>
<td style="text-align:left;">
Anticancer Res.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Phase I clinical and pharmacokinetic study of pemetrexed and carboplatin in patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J. Clin. Oncol.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
The potential value of comparative genomic hybridization analysis in effusion-and fine needle aspiration cytology.
</td>
<td style="text-align:left;">
Mod. Pathol.
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Incidence of malignant pleural mesothelioma in coastal and continental Croatia: epidemiological study.
</td>
<td style="text-align:left;">
Croat. Med. J.
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
A multicentre phase II study of cisplatin and gemcitabine for malignant mesothelioma.
</td>
<td style="text-align:left;">
Br. J. Cancer
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant gonadal mesothelioma.
</td>
<td style="text-align:left;">
Curr Treat Options Oncol
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Overexpression of gamma-glutamylcysteine synthetase in human malignant mesothelioma.
</td>
<td style="text-align:left;">
Hum. Pathol.
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant mesothelioma in Emilia-Romagna: incidence and asbestos exposure].
</td>
<td style="text-align:left;">
Epidemiol Prev
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma: PAS-diastase positivity and inversion of polarity in intravascular tumour.
</td>
<td style="text-align:left;">
Histopathology
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Translation of microarray data into clinically relevant cancer diagnostic tests using gene expression ratios in lung cancer and mesothelioma.
</td>
<td style="text-align:left;">
Cancer Res.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Synergistic effect of the anti-HER-2/neu antibody and cisplatin in immortalized and primary mesothelioma cell lines.
</td>
<td style="text-align:left;">
J. Cell. Physiol.
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Assessment of malignant pleural mesothelioma with (18)F-FDG dual-head gamma-camera coincidence imaging: comparison with histopathology.
</td>
<td style="text-align:left;">
J. Nucl. Med.
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Additional techniques in serous effusions.
</td>
<td style="text-align:left;">
Anal Cell Pathol
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
[Report on the study of hyaluronic acid in the diagnosis of pleural mesotheliomas: study of 100 hyaluronic acid rich effusions].
</td>
<td style="text-align:left;">
Biomedicine
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Prognosis, staging and therapy of malignant pleural mesothelioma].
</td>
<td style="text-align:left;">
Med. Klin. (Munich)
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Inhibition of epidermal growth factor receptor signaling in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Cancer Res.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Note on the complications of pleural needle biopsy: neoplastic seeding of the wall (apropos of 300 effusions and 440 puncture biopsies)].
</td>
<td style="text-align:left;">
Poumon Coeur
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
[Etiology and clinical diagnosis of diffuse pleural mesothelioma (author’s transl)].
</td>
<td style="text-align:left;">
Z Erkr Atmungsorgane
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
The epidermiologic relationship between pleural mesothelioma and asbestos exposure.
</td>
<td style="text-align:left;">
Scand J Work Environ Health
</td>
<td style="text-align:left;">
epidemiology
</td>
</tr>
<tr>
<td style="text-align:left;">
[Asbestos as an envoronmental carcinogen (author’s transl)].
</td>
<td style="text-align:left;">
Z Erkr Atmungsorgane
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Synovial sarcoma of the pleura: a clinical and pathologic study of three cases.
</td>
<td style="text-align:left;">
J. Thorac. Cardiovasc. Surg.
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
High frequency of micronuclei in peripheral blood lymphocytes as index of susceptibility to pleural malignant mesothelioma.
</td>
<td style="text-align:left;">
Cancer Res.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Hyaluronan synthesis by anaplastic large cell lymphoma with massive lymphomatous effusion. A case report.
</td>
<td style="text-align:left;">
Acta Cytol.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Asbestos: when the dust settles an imaging review of asbestos-related disease.
</td>
<td style="text-align:left;">
Radiographics
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Low molecular weight hyaluronan induces malignant mesothelioma cell (MMC) proliferation and haptotaxis: role of CD44 receptor in MMC proliferation and haptotaxis.
</td>
<td style="text-align:left;">
Oncol. Res.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Intrapleural interleukin-2 induces nitric oxide production in pleural effusions from malignant mesothelioma: a possible mechanism of interleukin-2-mediated cytotoxicity?
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Survival after pleural malignant mesothelioma: a population-based study in Italy.
</td>
<td style="text-align:left;">
Tumori
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma in a child: long-term survival with ICE-WAC chemotherapy regimen.
</td>
<td style="text-align:left;">
Turk. J. Pediatr.
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Potential of interferon-alpha in solid tumours: part 2.
</td>
<td style="text-align:left;">
BioDrugs
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Small-cell mesothelioma of the pleura: description of a case].
</td>
<td style="text-align:left;">
Pathologica
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Closed pleural needle biopsy: predicting diagnostic yield by examining pleural fluid parameters.
</td>
<td style="text-align:left;">
Respir Med
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
A cluster of familial malignant mesothelioma with del(9p) as the sole chromosomal anomaly.
</td>
<td style="text-align:left;">
Cancer Genet. Cytogenet.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[An autopsy case of desmoplastic malignant mesothelioma].
</td>
<td style="text-align:left;">
Nihon Kokyuki Gakkai Zasshi
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma of the pericardium: case reports and immunohistochemical studies including Ki-67 expression.
</td>
<td style="text-align:left;">
Pathol. Int.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Radical pleurectomy/decortication and intraoperative radiotherapy followed by conformal radiation with or without chemotherapy for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J. Thorac. Cardiovasc. Surg.
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Mortality study of workers compensated for asbestosis in Poland, 1970-1997.
</td>
<td style="text-align:left;">
Int J Occup Med Environ Health
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Simian virus 40 and malignant mesothelioma (Review).
</td>
<td style="text-align:left;">
Int. J. Oncol.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma: options for management.
</td>
<td style="text-align:left;">
Surg. Clin. North Am.
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma due to environmental exposure to asbestos: follow-up of a Turkish cohort living in a rural area.
</td>
<td style="text-align:left;">
Chest
</td>
<td style="text-align:left;">
diagnosis | epidemiology
</td>
</tr>
<tr>
<td style="text-align:left;">
Induction of apoptosis in mesothelioma cells by antisurvivin oligonucleotides.
</td>
<td style="text-align:left;">
Mol. Cancer Ther.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Leptomeningeal infiltration of malignant mesothelioma.
</td>
<td style="text-align:left;">
Med. Oncol.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Concurrent malignant mesothelioma of the pleura and hepatocellular carcinoma in the same patient: a report of five cases.
</td>
<td style="text-align:left;">
Ind Health
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Experimental photodynamic therapy for malignant pleural mesothelioma with pegylated mTHPC.
</td>
<td style="text-align:left;">
Lasers Surg Med
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Combination of raltitrexed and oxaliplatin is an active regimen in malignant mesothelioma: results of a phase II study.
</td>
<td style="text-align:left;">
J. Clin. Oncol.
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Interferons and their application in the diseases of the lung.
</td>
<td style="text-align:left;">
Chest
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Epidemiology of malignant pleural mesotheliomas in Croatia in the period from 1989 to 1998.
</td>
<td style="text-align:left;">
Coll Antropol
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Ultrastructurally “invasive” microvilli in an aggressively metastasizing biphasic malignant mesothelioma.
</td>
<td style="text-align:left;">
Ultrastruct Pathol
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Pharmacokinetics of doxorubicin and cisplatin used in intraoperative hyperthermic intrathoracic chemotherapy after cytoreductive surgery for malignant pleural mesothelioma and pleural thymoma.
</td>
<td style="text-align:left;">
Anticancer Drugs
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Molecular analyses, morphology and immunohistochemistry together differentiate pleural synovial sarcomas from mesotheliomas: clinical implications.
</td>
<td style="text-align:left;">
Anticancer Res.
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Unusual intraparenchymal growth patterns of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Histopathology
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Diagnosis and treatment of pleural mesothelioma].
</td>
<td style="text-align:left;">
Medicina (Kaunas)
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Asbestos fibers contributing to the induction of human malignant mesothelioma.
</td>
<td style="text-align:left;">
Ann. N. Y. Acad. Sci.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
The activity of raltitrexed (Tomudex) in malignant pleural mesothelioma: an EORTC phase II study (08992).
</td>
<td style="text-align:left;">
Eur. J. Cancer
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Emerging insights into the biology and therapy of malignant mesothelioma.
</td>
<td style="text-align:left;">
Semin. Oncol.
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Intensity-modulated radiotherapy following extrapleural pneumonectomy for the treatment of malignant mesothelioma: clinical implementation.
</td>
<td style="text-align:left;">
Int. J. Radiat. Oncol. Biol. Phys.
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Intensity-modulated radiation therapy: a novel approach to the management of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Int. J. Radiat. Oncol. Biol. Phys.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Surgical treatment of malignant pleural mesothelioma: a review.
</td>
<td style="text-align:left;">
Chest
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
The usefulness of 99mTc-tetrofosmin SPECT in the detection of intrathoracic malignant lesions.
</td>
<td style="text-align:left;">
Int. J. Oncol.
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleuropneumonectomy in the management of diffuse malignant mesothelioma of the pleura. Experience with 29 patients.
</td>
<td style="text-align:left;">
Thorax
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Serum anti-p53 autoantibodies in pleural malignant mesothelioma, lung cancer and non-neoplastic lung diseases.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
epidemiology
</td>
</tr>
<tr>
<td style="text-align:left;">
Long microvilli of mesothelioma are conspicuous in pleural effusions processed by Ultrafast Papanicolaou stain.
</td>
<td style="text-align:left;">
Cancer
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
The use of CDKN2A deletion as a diagnostic marker for malignant mesothelioma in body cavity effusions.
</td>
<td style="text-align:left;">
Cancer
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Localized malignant mesethelioma of the peritoneum revealed by a parietal mass].
</td>
<td style="text-align:left;">
Schweiz Med Wochenschr
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma growth inhibition by agents that target the VEGF and VEGF-C autocrine loops.
</td>
<td style="text-align:left;">
Int. J. Cancer
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
[SV40: a possible co-carcinogen of asbestos in the pathogenesis of mesothelioma?].
</td>
<td style="text-align:left;">
Med Lav
</td>
<td style="text-align:left;">
epidemiology | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Tuscany mesothelioma registry (1988-2000): evaluation of asbestos exposure].
</td>
<td style="text-align:left;">
Med Lav
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Predictive and prognostic factors in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Curr Opin Oncol
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
The role of new imaging techniques in diagnosis and staging of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Curr Opin Oncol
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
The role of surgery in diagnosis and treatment of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Curr Opin Oncol
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Indications and limitations of radiotherapy in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Curr Opin Oncol
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Chemotherapy for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Curr Opin Oncol
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Over-expression of tenascin-C in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Histopathology
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Chemotherapy of malignant diffuse mesothelioma.
</td>
<td style="text-align:left;">
Cancer
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Adenoviral transfer of mda-7 leads to BAX up-regulation and apoptosis in mesothelioma cells, and is abrogated by over-expression of BCL-XL.
</td>
<td style="text-align:left;">
Mol. Med.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Ifosfamide, carboplatin and etoposide combined with 41.8 degrees C whole body hyperthermia for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Chemotherapy for malignant pleural mesothelioma: past results and recent developments.
</td>
<td style="text-align:left;">
Br. J. Cancer
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Cytoreductive surgery combined with intraoperative hyperthermic intrathoracic chemotherapy for stage I malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Ann. Surg. Oncol.
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
[Pleuro-pneumonectomy, RT and CT for pleural mesothelioma. Prospective study].
</td>
<td style="text-align:left;">
Chir Ital
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma. Report of 19 cases.
</td>
<td style="text-align:left;">
J. Thorac. Cardiovasc. Surg.
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[A case of diffuse malignant mesothelioma of the pleura with bilateral chylothorax].
</td>
<td style="text-align:left;">
Nihon Kokyuki Gakkai Zasshi
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
A phase I study of Foscan-mediated photodynamic therapy and surgery in patients with mesothelioma.
</td>
<td style="text-align:left;">
Ann. Thorac. Surg.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Cardiac tamponade due to pericardial mesothelioma in an 11-year-old dog: diagnosis, medical and interventional treatments].
</td>
<td style="text-align:left;">
Schweiz. Arch. Tierheilkd.
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Transfer into a mesothelioma cell line of tumor suppressor gene p16 by cholesterol-based cationic lipids.
</td>
<td style="text-align:left;">
Biochim. Biophys. Acta
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Immunological mechanisms in pleural disease.
</td>
<td style="text-align:left;">
Eur. Respir. J.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant pleural mesothelioma incidence and mortality in Tuscany in 1988-1999].
</td>
<td style="text-align:left;">
Epidemiol Prev
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J. Clin. Oncol.
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Assessment of cell-mediated immunity to malignant mesothelioma by microcytotoxicity tests.
</td>
<td style="text-align:left;">
Int. J. Cancer
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
[VEGF (vascular endothelial growth factor) concentration in serum and pleural fluid of patients with pleural malignancy and pleural tuberculosis].
</td>
<td style="text-align:left;">
Pneumonol Alergol Pol
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Standard pleural biopsy versus CT-guided cutting-needle biopsy for diagnosis of malignant disease in pleural effusions: a randomised controlled trial.
</td>
<td style="text-align:left;">
Lancet
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Assessment of cell cycle state may facilitate the histopathological diagnosis of malignant mesothelioma.
</td>
<td style="text-align:left;">
Histopathology
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Pemetrexed and its emerging role in the treatment of thoracic malignancies.
</td>
<td style="text-align:left;">
Expert Opin Investig Drugs
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Gemcitabine improved QOL and survival in a case of diffuse malignant pleural mesothelioma].
</td>
<td style="text-align:left;">
Gan To Kagaku Ryoho
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
The rise and fall in incidence of malignant mesothelioma from a British Naval Dockyard, 1979-1999.
</td>
<td style="text-align:left;">
Occup Med (Lond)
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
A one-generation cluster of malignant mesothelioma within a family reveals exposure to asbestos-contaminated jute bags in Naples, Italy.
</td>
<td style="text-align:left;">
Eur. J. Epidemiol.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
[Mesothelioma–asbestos in Lebanon: a problem to be considered].
</td>
<td style="text-align:left;">
J Med Liban
</td>
<td style="text-align:left;">
diagnosis | epidemiology
</td>
</tr>
<tr>
<td style="text-align:left;">
Analysis of survival of mesothelioma cases in the Italian register (ReNaM).
</td>
<td style="text-align:left;">
Eur. J. Cancer
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Exposure to brake dust and malignant mesothelioma: a study of 10 cases with mineral fiber analyses.
</td>
<td style="text-align:left;">
Ann Occup Hyg
</td>
<td style="text-align:left;">
epidemiology | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Gemcitabine combined with carboplatin in patients with malignant pleural mesothelioma: a multicentric phase II study.
</td>
<td style="text-align:left;">
Cancer
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Matrix metalloproteinases 2 and 9 (gelatinases A and B) expression in malignant mesothelioma and benign pleura.
</td>
<td style="text-align:left;">
Br. J. Cancer
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Radiological manifestations of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Australas Radiol
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Advances in the management of malignant mesothelioma.
</td>
<td style="text-align:left;">
Curr Oncol Rep
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Diagnostic value of CA 549 in pleural fluid. Comparison with CEA, CA 15.3 and CA 72.4.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Desmoplastic malignant mesothelioma of the pleura: autopsy reveals asbestos exposure.
</td>
<td style="text-align:left;">
Pathol. Int.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Menstruation in an unusual place: a case of thoracic endometriosis in Kampala, Uganda.
</td>
<td style="text-align:left;">
Afr Health Sci
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant pleural mesothelioma].
</td>
<td style="text-align:left;">
Gan To Kagaku Ryoho
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[A case of triple malignancies (gastric cancer, lung cancer and malignant pleural mesothelioma) after asbestos exposure].
</td>
<td style="text-align:left;">
Nihon Kokyuki Gakkai Zasshi
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Induction of apoptosis and chemosensitization of mesothelioma cells by Bcl-2 and Bcl-xL antisense treatment.
</td>
<td style="text-align:left;">
Int. J. Cancer
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Diagnostic criteria for human diffuse malignant mesothelioma.
</td>
<td style="text-align:left;">
Acta Pathol. Jpn.
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
The value of chest computer tomography and cervical mediastinoscopy in the preoperative assessment of patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Ann. Thorac. Surg.
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[A case of benign asbestos pleural effusion suspected on thoracoscopic examination under local anesthesia].
</td>
<td style="text-align:left;">
Nihon Kokyuki Gakkai Zasshi
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
[Conservative, palliative therapy of malignant pleural mesothelioma].
</td>
<td style="text-align:left;">
Langenbecks Arch Chir Suppl Kongressbd
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Microarray analysis and RNA silencing link fra-1 to cd44 and c-met expression in mesothelioma.
</td>
<td style="text-align:left;">
Cancer Res.
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Cutaneous metastasis of pleural mesothelioma: two cases].
</td>
<td style="text-align:left;">
Ann Dermatol Venereol
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Second-line treatment of advanced gastric cancer with oxaliplatin plus raltitrexed.
</td>
<td style="text-align:left;">
Onkologie
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Non-melanoma and non-renal cell carcinoma malignancies treated with interleukin-2.
</td>
<td style="text-align:left;">
Hepatogastroenterology
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Mesothelioma: Drug treatment and other interventions.
</td>
<td style="text-align:left;">
Drugs Today
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Mortality from malignant pleural neoplasms in Broni (Pavia), 1980-1997].
</td>
<td style="text-align:left;">
Epidemiol Prev
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
[The in vitro release of hydroxyl radicals from dust containing fluoro-edenite fibers identified in the volcanic rocks of Biancavilla (eastern Sicily)].
</td>
<td style="text-align:left;">
Med Lav
</td>
<td style="text-align:left;">
treatment | epidemiology | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Surgical experience of 15 solitary benign fibrous tumor of the pleura.
</td>
<td style="text-align:left;">
Crit. Rev. Oncol. Hematol.
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma: experience at the Singapore General Hospital.
</td>
<td style="text-align:left;">
Ann. Acad. Med. Singap.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J. Clin. Oncol.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
High-dose ifosfamide with mesna and granulocyte-colony-stimulating factor (recombinant human G-CSF) in patients with unresectable malignant mesothelioma.
</td>
<td style="text-align:left;">
Cancer
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Hemithoracic radiation after extrapleural pneumonectomy for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Int. J. Radiat. Oncol. Biol. Phys.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Positron emission tomography defines metastatic disease but not locoregional disease in patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J. Thorac. Cardiovasc. Surg.
</td>
<td style="text-align:left;">
transmission | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
The immunohistochemical diagnosis of mesothelioma: a comparative study of epithelioid mesothelioma and lung adenocarcinoma.
</td>
<td style="text-align:left;">
Am. J. Surg. Pathol.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Identification of malignant cells in serous effusions using a panel of monoclonal antibodies Ber-EP4, MCA-b-12 and EMA.
</td>
<td style="text-align:left;">
Cytopathology
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Interferon-alpha and -gamma in combination with chemotherapeutic drugs: in vitro sensitivity studies in four human mesothelioma cell lines.
</td>
<td style="text-align:left;">
Anticancer Drugs
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Enhanced effectiveness of last generation antiblastic compounds vs. cisplatin on malignant pleural mesothelioma cell lines.
</td>
<td style="text-align:left;">
Eur. J. Pharmacol.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Growth factors regulate the expression profile of their syndecan co-receptors and the differentiation of mesothelioma cells.
</td>
<td style="text-align:left;">
Anticancer Res.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Wnt pathway activation in mesothelioma: evidence of Dishevelled overexpression and transcriptional activity of beta-catenin.
</td>
<td style="text-align:left;">
Cancer Res.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
[Isolated pleural metastases from an atypical meningioma].
</td>
<td style="text-align:left;">
Rev Mal Respir
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Gene expression profiling of malignant mesothelioma.
</td>
<td style="text-align:left;">
Clin. Cancer Res.
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Miliary pulmonary metastases from a clinically occult pleural mesothelioma.
</td>
<td style="text-align:left;">
Ann Diagn Pathol
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Pemetrexed (Alimta, MTA, multitargeted antifolate, LY231514) for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Semin. Oncol.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
c-Kit is not expressed in malignant mesothelioma.
</td>
<td style="text-align:left;">
Mod. Pathol.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Incidence trends of mesothelioma in Norway, 1965-1999.
</td>
<td style="text-align:left;">
Int. J. Cancer
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Detection of numerical aberrations of chromosomes 7 and 9 in cytologic specimens of pleural malignant mesothelioma.
</td>
<td style="text-align:left;">
Cancer
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Diffuse malignant pleural mesothelioma: Part I. An overview of diagnosis, staging, and treatment options.
</td>
<td style="text-align:left;">
Clin J Oncol Nurs
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Elevated serum cytokine levels in mesothelioma patients who have undergone pleurectomy or extrapleural pneumonectomy and adjuvant intraoperative photodynamic therapy.
</td>
<td style="text-align:left;">
Photochem. Photobiol.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
The use of immunohistochemistry in distinguishing reactive from neoplastic mesothelium. A novel use for desmin and comparative evaluation with epithelial membrane antigen, p53, platelet-derived growth factor-receptor, P-glycoprotein and Bcl-2.
</td>
<td style="text-align:left;">
Histopathology
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
[Surveillance of malignant mesothelioma cases and definition of asbestos exposure: 1997 ReNaM data].
</td>
<td style="text-align:left;">
Epidemiol Prev
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Treatment of mesothelioma in Bloemfontein, South Africa.
</td>
<td style="text-align:left;">
Eur J Cardiothorac Surg
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Globalization and the transfer of hazardous industry: asbestos in Mexico, 1979-2000.
</td>
<td style="text-align:left;">
Int J Occup Environ Health
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Mitomycin C and vindesine: an ineffective combination chemotherapy in the treatment of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Tumori
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Treatment of intervention sites of malignant pleural mesothelioma with radiotherapy: a Dutch-Belgian survey.
</td>
<td style="text-align:left;">
Radiother Oncol
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Issues in the management of chest malignancies.
</td>
<td style="text-align:left;">
Clin. Chest Med.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Immunoreactivity for the beta chain of the platelet-derived growth factor receptor in malignant mesothelioma and non-neoplastic mesothelium.
</td>
<td style="text-align:left;">
J. Pathol.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Spontaneous pneumothorax. Graduated concept of surgical therapy].
</td>
<td style="text-align:left;">
Zentralbl Chir
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma: clinical characteristics, asbestos mineralogy and chromosomal abnormalities of 41 patients.
</td>
<td style="text-align:left;">
Eur. J. Cancer
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma due to environmental mineral fiber exposure in Turkey. Analysis of 135 cases.
</td>
<td style="text-align:left;">
Chest
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Work-related mesothelioma in Québec, 1967-1990.
</td>
<td style="text-align:left;">
Am. J. Ind. Med.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant peritoneal mesothelioma: its evolution and outlook].
</td>
<td style="text-align:left;">
Chir Ital
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Immunoreactivity for P-170 glycoprotein in malignant mesothelioma and in non-neoplastic mesothelium of the pleura using the murine monoclonal antibody JSB-1.
</td>
<td style="text-align:left;">
J. Pathol.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Thrombomodulin expression in malignant pleural mesothelioma and pulmonary adenocarcinoma.
</td>
<td style="text-align:left;">
Am. J. Pathol.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
DNA ploidy analysis of pleural mesotheliomas: its usefulness for their distinction from lung adenocarcinomas.
</td>
<td style="text-align:left;">
Mod. Pathol.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Abnormalities of chromosomes 7 and 22 in human malignant pleural mesothelioma: correlation between Southern blot and cytogenetic analyses.
</td>
<td style="text-align:left;">
Genes Chromosomes Cancer
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
The differential diagnosis of primary peritoneal papillary tumors.
</td>
<td style="text-align:left;">
Arch. Gynecol. Obstet.
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Mechanism for the recruitment of macrophages to cancer site. In vivo concentration gradient of monocyte chemotactic activity.
</td>
<td style="text-align:left;">
Cancer
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
CD7 expression in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Jpn. J. Cancer Res.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Mesothelial and related neoplasms in children and adolescents: a clinicopathologic and immunohistochemical analysis of eight cases.
</td>
<td style="text-align:left;">
Pediatr Pathol
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma producing human chorionic gonadotropin. Report of two cases.
</td>
<td style="text-align:left;">
Am. J. Surg. Pathol.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Photodynamic therapy for thoracic malignancies.
</td>
<td style="text-align:left;">
Semin Surg Oncol
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Interphase cytogenetics on paraffin sections of malignant pleural mesothelioma. A comparison to conventional karyotyping and flow cytometric studies.
</td>
<td style="text-align:left;">
Cancer Genet. Cytogenet.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
The role of closed pleural needle biopsy in the diagnosis of malignant mesothelioma of the pleura.
</td>
<td style="text-align:left;">
Chest
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
p53 expression is common in malignant mesothelioma.
</td>
<td style="text-align:left;">
Histopathology
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[An operated case of malignant localized mesothelioma of the pleura].
</td>
<td style="text-align:left;">
Nihon Kyobu Geka Gakkai Zasshi
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
A dual-isotope method for studying protein kinetics in pleural effusions in humans.
</td>
<td style="text-align:left;">
Nucl Med Commun
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Evaluation of AgNOR count in distinguishing benign from malignant mesothelial cells in pleural fluids.
</td>
<td style="text-align:left;">
Pathol. Res. Pract.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma: value of CT and MR imaging in predicting resectability.
</td>
<td style="text-align:left;">
AJR Am J Roentgenol
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Asbestos fiber analysis in 27 malignant mesothelioma cases.
</td>
<td style="text-align:left;">
Am. J. Ind. Med.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Extrapleural pneumonectomy in the treatment of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Ann. Thorac. Surg.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Prognostic importance of the DNA ploidy pattern in malignant mesothelioma of the pleura.
</td>
<td style="text-align:left;">
Anal. Quant. Cytol. Histol.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
DNA analysis of malignant effusions. Comparison with cytologic diagnosis and carcinoembryonic antigen content.
</td>
<td style="text-align:left;">
Anal. Quant. Cytol. Histol.
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Survival of asbestos insulation workers with mesothelioma.
</td>
<td style="text-align:left;">
Br J Ind Med
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
A phase II evaluation of ifosfamide and mesna in unresectable diffuse malignant mesothelioma. A Southwest Oncology Group study.
</td>
<td style="text-align:left;">
Cancer
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Multimodality treatment programs for malignant pleural mesothelioma using high-dose hemithorax irradiation.
</td>
<td style="text-align:left;">
Int. J. Radiat. Oncol. Biol. Phys.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[A case of malignant localized visceral pleural mesothelioma].
</td>
<td style="text-align:left;">
Kyobu Geka
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Imaging manifestations of pleural tumors.
</td>
<td style="text-align:left;">
Radiographics
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Diagnosis and prognostic factors in malignant pleural mesothelioma: a retrospective analysis of sixty-five patients.
</td>
<td style="text-align:left;">
Respiration
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma of the pleura in Trieste, Italy.
</td>
<td style="text-align:left;">
Am. J. Ind. Med.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant mesothelioma of the vulva. About one case].
</td>
<td style="text-align:left;">
Gynecol Obstet Fertil
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Desmoplastic malignant mesothelioma: two cases and a literature review.
</td>
<td style="text-align:left;">
Med Electron Microsc
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Localized pleural malignant mesothelioma.
</td>
<td style="text-align:left;">
Pathol. Int.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Widespread cutaneous and perioral metastases of mesothelioma.
</td>
<td style="text-align:left;">
J. Cutan. Pathol.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Stereotactic intensity-modulated radiation therapy (IMRT) and inverse treatment planning for advanced pleural mesothelioma. Feasibility and initial results.
</td>
<td style="text-align:left;">
Strahlenther Onkol
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
New strategies are needed in diffuse malignant mesothelioma.
</td>
<td style="text-align:left;">
Cancer
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Synchronous diffuse malignant mesothelioma and carcinomas in asbestos-exposed individuals.
</td>
<td style="text-align:left;">
Histopathology
</td>
<td style="text-align:left;">
transmission | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant and non-malignant asbestos-related pleural and lung disease: 10-year follow-up study.
</td>
<td style="text-align:left;">
Croat. Med. J.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Evaluation of Rare Tumors with [F-18]Fluorodeoxyglucose Positron Emission Tomography.
</td>
<td style="text-align:left;">
Clin. Positron Imaging
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Observation of the morphological genesis of pleural mesothelioma induced by asbestos in rats].
</td>
<td style="text-align:left;">
Hua Xi Yi Ke Da Xue Xue Bao
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Lymphocytic alveolitis and pleural calcifications in nonoccupational asbestos exposure. Protection against neoplasia?
</td>
<td style="text-align:left;">
Am. Rev. Respir. Dis.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Benign pleural lesion and malignant mesothelioma.
</td>
<td style="text-align:left;">
Virchows Arch A Pathol Anat Histol
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Autocrine inhibitory influences of alpha-melanocyte-stimulating hormone in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J. Leukoc. Biol.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Interaction between occupational and environmental exposure to asbestos. Epidemiologic survey].
</td>
<td style="text-align:left;">
G Ital Med Lav Ergon
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
The mesothelial cell.
</td>
<td style="text-align:left;">
Int. J. Biochem. Cell Biol.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Cadherins, catenins and APC in pleural malignant mesothelioma.
</td>
<td style="text-align:left;">
J. Pathol.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Cold abscess due to malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Indian J Chest Dis Allied Sci
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Chemotherapy for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Clin Lung Cancer
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Diffuse malignant pleural mesothelioma: Part II. Symptom management.
</td>
<td style="text-align:left;">
Clin J Oncol Nurs
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Tumor necrosis correlates with angiogenesis and is a predictor of poor prognosis in malignant mesothelioma.
</td>
<td style="text-align:left;">
Chest
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
A multicenter phase II study of gemcitabine and oxaliplatin for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Clin Lung Cancer
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Activation of p38 MAP kinase by asbestos in rat mesothelial cells is mediated by oxidative stress.
</td>
<td style="text-align:left;">
Am. J. Physiol. Lung Cell Mol. Physiol.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleural effusions: is thoracoscopy a reliable investigation? A retrospective review.
</td>
<td style="text-align:left;">
Respir Med
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
The role of smoking and exposure to asbestos and man-made vitreous fibers in a questionable case of mesothelioma.
</td>
<td style="text-align:left;">
Ind Health
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Primary malignant pleural neoplasms. Diagnostic code 163.09].
</td>
<td style="text-align:left;">
Ugeskr. Laeg.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Diagnostic difficulties in pleural mesothelioma].
</td>
<td style="text-align:left;">
Wiad. Lek.
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Mesothelin-family proteins and diagnosis of mesothelioma.
</td>
<td style="text-align:left;">
Lancet
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
CT findings and serum ca 125 levels in malignant peritoneal mesothelioma: report of 11 new cases and review of the literature.
</td>
<td style="text-align:left;">
Eur Radiol
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Localized benign pleural mesothelioma: a case report.
</td>
<td style="text-align:left;">
Monaldi Arch Chest Dis
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
‘Pseudomesotheliomatous’ carcinomas of the pleura: a 10-year analysis of cases from the Environmental Lung Disease Research Group, Cardiff.
</td>
<td style="text-align:left;">
Histopathology
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Is there a role for pre-operative contrast-enhanced magnetic resonance imaging for radical surgery in malignant pleural mesothelioma?
</td>
<td style="text-align:left;">
Eur J Cardiothorac Surg
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Implementation of a molecular epidemiology approach to human pleural malignant mesothelioma.
</td>
<td style="text-align:left;">
Mutat. Res.
</td>
<td style="text-align:left;">
diagnosis | treatment | epidemiology
</td>
</tr>
<tr>
<td style="text-align:left;">
Metabolic significance of the pattern, intensity and kinetics of 18F-FDG uptake in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Thorax
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Expression of calretinin and other mesothelioma-related markers in thymic carcinoma and thymoma.
</td>
<td style="text-align:left;">
Hum. Pathol.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Diagnostic value of MUC4 immunostaining in distinguishing epithelial mesothelioma and lung adenocarcinoma.
</td>
<td style="text-align:left;">
Mod. Pathol.
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
[“Disappearance” of retroperitoneal vessels - a case report].
</td>
<td style="text-align:left;">
Ultraschall Med
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma: surgical roles and novel therapies.
</td>
<td style="text-align:left;">
Clin Lung Cancer
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Molecular pathogenesis of malignant mesothelioma and its relationship to simian virus 40.
</td>
<td style="text-align:left;">
Clin Lung Cancer
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Bronchial cytology in pleural mesothelioma. A report of 3 positive cases, including 1 diagnosed initially on bronchial brushings.
</td>
<td style="text-align:left;">
Acta Cytol.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma in Italy, 1997.
</td>
<td style="text-align:left;">
Am. J. Ind. Med.
</td>
<td style="text-align:left;">
diagnosis | epidemiology | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Risk factors for malignant pleural mesothelioma in crocidolite contaminated area].
</td>
<td style="text-align:left;">
Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi
</td>
<td style="text-align:left;">
epidemiology
</td>
</tr>
<tr>
<td style="text-align:left;">
Inadequacy of the RECIST criteria for response evaluation in patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Inadequacy of the new Response Evaluation Criteria in Solid Tumors (RECIST) in patients with malignant pleural mesothelioma: report of four cases.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Metsovo-tremolite asbestos fibres: in vitro effects on mutation, chromosome aberration, cell transformation and intercellular communication.
</td>
<td style="text-align:left;">
Mutagenesis
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[[18F]-FDG imaging in apparently isolated pleural lesions].
</td>
<td style="text-align:left;">
Rev Pneumol Clin
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Mutation analysis of the BRAF codon 599 in malignant pleural mesothelioma by enriched PCR-RFLP.
</td>
<td style="text-align:left;">
Oncol. Rep.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Disseminated malignant solitary fibrous tumor of the pleura.
</td>
<td style="text-align:left;">
Pathol. Int.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Peritoneal mesothelioma after environmental asbestos exposure.
</td>
<td style="text-align:left;">
Swiss Surg
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Carboplatin and gemcitabine chemotherapy for malignant pleural mesothelioma: a phase II study of the GSTPV.
</td>
<td style="text-align:left;">
Clin Lung Cancer
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma: evaluation with CT, MR imaging, and PET.
</td>
<td style="text-align:left;">
Radiographics
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Cell protection, resistance and invasiveness of two malignant mesotheliomas as assessed by 10K-microarray.
</td>
<td style="text-align:left;">
Biochim. Biophys. Acta
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Promising early local control of malignant pleural mesothelioma following postoperative intensity modulated radiotherapy (IMRT) to the chest.
</td>
<td style="text-align:left;">
Cancer J
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Solitary cerebellar metastasis of malignant pleural mesothelioma: case report.
</td>
<td style="text-align:left;">
Surg Neurol
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Pulmonary neoplasms in rats that inhaled cerium-144 dioxide.
</td>
<td style="text-align:left;">
Toxicol Pathol
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Modified RECIST criteria for assessment of response in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Ann. Oncol.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
BTS randomised feasibility study of active symptom control with or without chemotherapy in malignant pleural mesothelioma: ISRCTN 54469112.
</td>
<td style="text-align:left;">
Thorax
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Subcutaneous tumor growth complicating the positioning of Denver shunt and intrapleural port-à-cath in mesothelioma patients.
</td>
<td style="text-align:left;">
Eur J Surg Oncol
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
[Localized pleural mesotheliomas. Clinicopathological considerations on a case report].
</td>
<td style="text-align:left;">
Minerva Chir
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Immunoreactivity for p53 protein in malignant mesothelioma and non-neoplastic mesothelium.
</td>
<td style="text-align:left;">
J. Pathol.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
p53 immunostaining in the distinction between benign and malignant mesothelial proliferations using formalin-fixed paraffin sections.
</td>
<td style="text-align:left;">
J. Pathol.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Two cases of malignant mesothelioma controlled by pleurectomy].
</td>
<td style="text-align:left;">
Nihon Kyobu Shikkan Gakkai Zasshi
</td>
<td style="text-align:left;">
transmission
</td>
</tr>
<tr>
<td style="text-align:left;">
Gene expression profiles predict survival and progression of pleural mesothelioma.
</td>
<td style="text-align:left;">
Clin. Cancer Res.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
An extended phase II trial of ifosfamide plus mesna in malignant mesothelioma.
</td>
<td style="text-align:left;">
Invest New Drugs
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
[Follow- up of a pleural malignant mesothelioma].
</td>
<td style="text-align:left;">
J Belge Radiol
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Distant cutaneous metastasis of pleural malignant mesothelioma.
</td>
<td style="text-align:left;">
J. Cutan. Pathol.
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
[Mesothelioma of the pleura–pathological anatomy].
</td>
<td style="text-align:left;">
Langenbecks Arch Chir Suppl Kongressbd
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Mesothelioma of the pleura–diagnosis with imaging procedures].
</td>
<td style="text-align:left;">
Langenbecks Arch Chir Suppl Kongressbd
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Preclinical evaluation of the nonsteroidal anti-inflammatory agent celecoxib on malignant mesothelioma chemoprevention.
</td>
<td style="text-align:left;">
Int. J. Cancer
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Proteomic analysis of exosomes isolated from human malignant pleural effusions.
</td>
<td style="text-align:left;">
Am. J. Respir. Cell Mol. Biol.
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Diffuse malignant mesothelioma of the peritoneum and pleura, analysis of markers.
</td>
<td style="text-align:left;">
Mod. Pathol.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Localized fibrous mesothelioma with bloody pleural effusion; report of a case].
</td>
<td style="text-align:left;">
Kyobu Geka
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Microdissection, mRNA amplification and microarray: a study of pleural mesothelial and malignant mesothelioma cells.
</td>
<td style="text-align:left;">
Biochimie
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Factors influencing long-term survival in mesothelioma patients–results of the German mesothelioma register.
</td>
<td style="text-align:left;">
Int Arch Occup Environ Health
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
A vitamin E analogue suppresses malignant mesothelioma in a preclinical model: a future drug against a fatal neoplastic disease?
</td>
<td style="text-align:left;">
Int. J. Cancer
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Squamous cell carcinoma of the lung producing granulocyte colony-stimulating factor and resembling a malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Intern. Med.
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Behaviour of the new asbestos amphibole fluor-edenite in different lung cell systems.
</td>
<td style="text-align:left;">
Int. J. Biochem. Cell Biol.
</td>
<td style="text-align:left;">
treatment | epidemiology | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma in a seven-week-old puppy.
</td>
<td style="text-align:left;">
J S Afr Vet Assoc
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Abrogation of p21 expression by flavopiridol enhances depsipeptide-mediated apoptosis in malignant pleural mesothelioma cells.
</td>
<td style="text-align:left;">
Clin. Cancer Res.
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
[The locoregional treatment of neoplastic ascites with interferon-beta].
</td>
<td style="text-align:left;">
Recenti Prog Med
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Patterns of lymphadenopathy in thoracic malignancies.
</td>
<td style="text-align:left;">
Radiographics
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural and peritoneal mesotheliomas in former miners and millers of crocidolite at Wittenoom, Western Australia.
</td>
<td style="text-align:left;">
Occup Environ Med
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
The case for routine cervical mediastinoscopy prior to radical surgery for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Eur J Cardiothorac Surg
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Ultrastructural and chromosomal studies on manganese superoxide dismutase in malignant mesothelioma.
</td>
<td style="text-align:left;">
Am. J. Respir. Cell Mol. Biol.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Recurrent solitary fibrous tumor of the pleura with malignant transformation.
</td>
<td style="text-align:left;">
Arch. Pathol. Lab. Med.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[A case of splenic hemorrhage in the course of malignant mesothelioma].
</td>
<td style="text-align:left;">
Nihon Kokyuki Gakkai Zasshi
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma–an update.
</td>
<td style="text-align:left;">
Int J Occup Environ Health
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Cytotoxic T cell responses against mesothelioma by apoptotic cell-pulsed dendritic cells.
</td>
<td style="text-align:left;">
Am. J. Respir. Crit. Care Med.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Possibilities of diagnosis and treatment of malignant pleural mesothelioma].
</td>
<td style="text-align:left;">
Medicina (Kaunas)
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Expression of the nerve growth factor receptors TrkA and p75 in malignant mesothelioma.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Capecitabine in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (39807).
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
High-grade neuroendocrine carcinoma of the lung presenting an unusual spread mimicking pleural mesothelioma associated with dermatomyositis.
</td>
<td style="text-align:left;">
Am. J. Med. Sci.
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
The spectrum of Kit (CD117) immunoreactivity in lung and pleural tumors: a study of 96 cases using a single-source antibody with a review of the literature.
</td>
<td style="text-align:left;">
Arch. Pathol. Lab. Med.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Integration of multimodality approaches in the management of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Clin Lung Cancer
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Well-differentiated papillary mesothelioma of the pleura: a series of 24 cases.
</td>
<td style="text-align:left;">
Am. J. Surg. Pathol.
</td>
<td style="text-align:left;">
epidemiology | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[The computed tomographic diagnosis of malignant pleural mesothelioma. A multicenter study].
</td>
<td style="text-align:left;">
Radiol Med
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma: diagnostic and management strategies for 1992.
</td>
<td style="text-align:left;">
Semin. Oncol.
</td>
<td style="text-align:left;">
diagnosis | treatment | epidemiology | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Evaluation of the therapeutic benefit of 41.8 degrees C whole body hyperthermia plus ifosfamide, carboplatin and etoposide (ICE) for patients with malignant pleural mesothelioma using the Modified Brunner-Score (MBS)].
</td>
<td style="text-align:left;">
Pneumologie
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Significance of psammoma bodies in serous cavity fluid: a cytopathologic analysis.
</td>
<td style="text-align:left;">
Cancer
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Estimates of pleural mesothelioma incidence in the Lazio region (Italy), 1997-2000].
</td>
<td style="text-align:left;">
Med Lav
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Prognostic significance of cyclooxygenase-2 (COX-2) and expression of cell cycle inhibitors p21 and p27 in human pleural malignant mesothelioma.
</td>
<td style="text-align:left;">
Thorax
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Pathogenesis of malignant mesothelioma.
</td>
<td style="text-align:left;">
Clin Lung Cancer
</td>
<td style="text-align:left;">
diagnosis | epidemiology
</td>
</tr>
<tr>
<td style="text-align:left;">
Pemetrexed alone and in combination with platinum compounds in the management of malignant mesothelioma.
</td>
<td style="text-align:left;">
Clin Lung Cancer
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Novel combinations using pemetrexed in malignant mesothelioma.
</td>
<td style="text-align:left;">
Clin Lung Cancer
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Metastatic mesothelioma presenting with proptosis.
</td>
<td style="text-align:left;">
Am. J. Ophthalmol.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Multimodal treatment for resectable epithelial type malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
World J Surg Oncol
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma: risk factors and current management.
</td>
<td style="text-align:left;">
Nurs Times
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Surgery for malignant pleural mesothelioma].
</td>
<td style="text-align:left;">
Rev Pneumol Clin
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Gene expression profiling identifies matriptase overexpression in malignant mesothelioma.
</td>
<td style="text-align:left;">
Chest
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Antisense oligonucleotides directed at the bcl-xl gene product augment chemotherapy response in mesothelioma.
</td>
<td style="text-align:left;">
Mol. Cancer Ther.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Gene therapy in malignant mesothelioma].
</td>
<td style="text-align:left;">
Tuberk Toraks
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Pulmonary fibre burden in sheep living in the Biancavilla area (Sicily): preliminary results.
</td>
<td style="text-align:left;">
Sci. Total Environ.
</td>
<td style="text-align:left;">
epidemiology | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Establishment and characterization of a human malignant mesothelioma cell line (HMMME).
</td>
<td style="text-align:left;">
Hum. Cell
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Use of immunohistochemical marker calretinin in the diagnosis of a diffuse malignant metastatic mesothelioma in an equine.
</td>
<td style="text-align:left;">
J. Vet. Diagn. Invest.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Natural history of multifocal solitary fibrous tumors of the pleura: a 25-year follow-up report.
</td>
<td style="text-align:left;">
J Natl Med Assoc
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Expression of hyaluronan synthases and hyaluronan in malignant mesothelioma cells.
</td>
<td style="text-align:left;">
Anticancer Res.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Pemetrexed (Alimta): improving outcomes in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Expert Rev Anticancer Ther
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Defective core-apoptosis signalling in diffuse malignant pleural mesothelioma: opportunities for effective drug development.
</td>
<td style="text-align:left;">
Lancet Oncol.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Role of 18F-FDG PET for evaluating malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Cancer Biother. Radiopharm.
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant mesothelioma–a diagnostic challenge].
</td>
<td style="text-align:left;">
Rev Port Pneumol
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Measurement of mesothelioma on thoracic CT scans: a comparison of manual and computer-assisted techniques.
</td>
<td style="text-align:left;">
Med Phys
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
A randomised trial of single-dose radiotherapy to prevent procedure tract metastasis by malignant mesothelioma.
</td>
<td style="text-align:left;">
Br. J. Cancer
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Mesotheliomas with leucocytic infiltration].
</td>
<td style="text-align:left;">
Pathologe
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Nursing considerations for administering pemetrexed (Alimta) in combination with cisplatin for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Clin J Oncol Nurs
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Chromosome number correlates with survival in patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Cancer Genet. Cytogenet.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Expression of the secreted frizzled-related protein gene family is downregulated in human mesothelioma.
</td>
<td style="text-align:left;">
Oncogene
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
The effect of extent of local resection on patterns of disease progression in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Ann. Thorac. Surg.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Recurrent malignant pleural mesothelioma: case report.
</td>
<td style="text-align:left;">
Tex Heart Inst J
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
[Lymphocyte and lymphocyte subsets in pleural fluid–comparison of malignant and non-malignant disorders].
</td>
<td style="text-align:left;">
Pol. Arch. Med. Wewn.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Localised pleural malignant mesothelioma. Report of two cases simulating pulmonary carcinoma and review of the literature.
</td>
<td style="text-align:left;">
Virchows Arch.
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Intracavitary administration of interleukin-2 as palliative therapy for neoplastic effusions.
</td>
<td style="text-align:left;">
Tumori
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Mortality from chronic obstructive pulmonary disease and pleural mesothelioma in an area contaminated by natural fiber (fluoro-edenite).
</td>
<td style="text-align:left;">
Scand J Work Environ Health
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Evaluation of malignant mesothelioma in central Anatolia: a study of 67 cases.
</td>
<td style="text-align:left;">
Can. Respir. J.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Phase II study of OK-432 intrapleural administration followed by systemic cisplatin and gemcitabine for non-small cell lung cancer with pleuritis carcinomatosa.
</td>
<td style="text-align:left;">
J. Exp. Ther. Oncol.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant pleural mesothelioma: radiotherapy for the prevention of seeding nodules].
</td>
<td style="text-align:left;">
Rev Mal Respir
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma in Turkey, 2000-2002.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Epidemiology of malignant mesothelioma in Australia.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Epidemiology of pleural mesothelioma in Italy.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Pathology of malignant mesothelioma.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Clinico-pathological and biological prognostic factors in pleural malignant mesothelioma.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Staging and response to therapy of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
The use of magnetic resonance imaging in malignant mesothelioma.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Positron emission tomography in the diagnosis of mesothelioma.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma–British surgical strategies.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Considerations for post-operative radiotherapy to the hemithorax following extrapleural pneumonectomy in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Chemotherapy for malignant pleural mesothelioma: past results and recent developments.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
The role of Alimta in the treatment of malignant pleural mesothelioma: an overview of preclinical and clinical trials.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma. Medical oncology: standards, new trends, trials–the French experience.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Pemetrexed: a novel antifolate agent enters clinical practice.
</td>
<td style="text-align:left;">
Expert Rev Anticancer Ther
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Adapting the Lung Cancer Symptom Scale (LCSS) to mesothelioma: using the LCSS-Meso conceptual model for validation.
</td>
<td style="text-align:left;">
Cancer
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Interleukin-4 receptor cytotoxin as therapy for human malignant pleural mesothelioma xenografts.
</td>
<td style="text-align:left;">
Ann. Thorac. Surg.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Respiratory tract cancers: lung and mesothelioma.
</td>
<td style="text-align:left;">
Epidemiol Prev
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleural plaques in a rural population in central Macedonia, Greece.
</td>
<td style="text-align:left;">
Med Lav
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Thoracic actinomycosis with mainly pleural involvement.
</td>
<td style="text-align:left;">
J. Infect. Chemother.
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Survival analysis of malignant mesothelioma treated in Brescia, northern Italy, 1982-2000].
</td>
<td style="text-align:left;">
Epidemiol Prev
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Decreasing prevalence of pleural calcifications among Metsovites with nonoccupational asbestos exposure.
</td>
<td style="text-align:left;">
Chest
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant pleural mesothelioma in housewives in the province of Catania].
</td>
<td style="text-align:left;">
Recenti Prog Med
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Leptomeningeal metastasis from malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
AJNR Am J Neuroradiol
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
The palliative benefits of MVP (mitomycin C, vinblastine and cisplatin) chemotherapy in patients with malignant mesothelioma.
</td>
<td style="text-align:left;">
Ann. Oncol.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Neoadjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J. Clin. Oncol.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Pleuromesothelioma – psychology and pathogenesis].
</td>
<td style="text-align:left;">
Pneumologie
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Soluble type II transforming growth factor-beta receptor inhibits established murine malignant mesothelioma tumor growth by augmenting host antitumor immunity.
</td>
<td style="text-align:left;">
Clin. Cancer Res.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Diagnostic and prognostic value of Ki67 proliferation fraction in serous effusions.
</td>
<td style="text-align:left;">
Cell. Oncol.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Establishment of permanent cell lines purified from human mesothelioma: morphological aspects, new marker expression and karyotypic analysis.
</td>
<td style="text-align:left;">
Histochem. Cell Biol.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Utility of D2-40, a novel mesothelial marker, in the diagnosis of malignant mesothelioma.
</td>
<td style="text-align:left;">
Mod. Pathol.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
L1CAM, INP10, P-cadherin, tPA and ITGB4 over-expression in malignant pleural mesotheliomas revealed by combined use of cDNA and tissue microarray.
</td>
<td style="text-align:left;">
Carcinogenesis
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleural mesothelioma: little evidence, still time to do trials.
</td>
<td style="text-align:left;">
Lancet
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant effusions: from diagnosis to biology.
</td>
<td style="text-align:left;">
Diagn. Cytopathol.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Localized fibrous tumors of the pleura: clinical and surgical evaluation].
</td>
<td style="text-align:left;">
Arch. Bronconeumol.
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Safety and yield of ultrasound-assisted transthoracic biopsy performed by pulmonologists.
</td>
<td style="text-align:left;">
Respiration
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
The pathology associated with therapeutic procedures in malignant mesothelioma.
</td>
<td style="text-align:left;">
Histopathology
</td>
<td style="text-align:left;">
treatment | transmission
</td>
</tr>
<tr>
<td style="text-align:left;">
Methodology for lognormal modelling of malignant pleural mesothelioma survival time distributions: a study of 5580 case histories from Europe and USA.
</td>
<td style="text-align:left;">
Phys Med Biol
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Significance of combining detection of E-cadherin, carcinoembryonic antigen, and calretinin in cytological differential diagnosis of serous effusion].
</td>
<td style="text-align:left;">
Ai Zheng
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Susceptibility of mesothelioma cell lines to adeno-associated virus 2 vector-based suicide gene therapy.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
FDA drug approval summaries: pemetrexed (Alimta).
</td>
<td style="text-align:left;">
Oncologist
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Investigation of simian virus 40 large T antigen in 18 autopsied malignant mesothelioma patients in Japan.
</td>
<td style="text-align:left;">
J. Med. Virol.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma: update, current management, and newer therapeutic strategies.
</td>
<td style="text-align:left;">
Chest
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Selective activation of insulin receptor substrate-1 and -2 in pleural mesothelioma cells: association with distinct malignant phenotypes.
</td>
<td style="text-align:left;">
Cancer Res.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
[Solitary fibrous tumor of the pleura–description of two cases with features of malignancy].
</td>
<td style="text-align:left;">
Cesk Patol
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignancy in a massive localized fibrous tumour of pleura.
</td>
<td style="text-align:left;">
Aust N Z J Surg
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
A cytokeratin- and calretinin-negative staining sarcomatoid malignant mesothelioma.
</td>
<td style="text-align:left;">
Anticancer Res.
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Extrapleural pneumonectomy for thoracic malignancies].
</td>
<td style="text-align:left;">
Kyobu Geka
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
[Extrapleural pneumonectomy for malignant pleural mesothelioma and primary lung cancer].
</td>
<td style="text-align:left;">
Kyobu Geka
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
[Extrapleural pneumonectomy of malignant pleural mesothelioma].
</td>
<td style="text-align:left;">
Kyobu Geka
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
[Extrapleural pneumonectomy for malignant pleural mesothelioma].
</td>
<td style="text-align:left;">
Kyobu Geka
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
[Multimodality therapy for diffuse malignant pleural mesothelioma].
</td>
<td style="text-align:left;">
Kyobu Geka
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Diaphragm reconstruction after extrapleural pneumonectomy].
</td>
<td style="text-align:left;">
Kyobu Geka
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Presentation of malignant pleural mesothelioma with symptomatic brain metastasis: report of a case.
</td>
<td style="text-align:left;">
Tumori
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleural biopsy: a reliable method for determining the diagnosis but not subtype in mesothelioma.
</td>
<td style="text-align:left;">
Ann. Thorac. Surg.
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Assessment of 18F-fluorodeoxyglucose dual-head gamma camera in asbestos lung diseases.
</td>
<td style="text-align:left;">
Eur. Respir. J.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Cerebral metastases in malignant mesothelioma: case report and literature review.
</td>
<td style="text-align:left;">
J Clin Neurosci
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Geographical distribution of mortality from malignant pleural neoplasms and of former asbestos-exposed workers in the Campania Region].
</td>
<td style="text-align:left;">
Epidemiol Prev
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant mesothelioma of the pleura in a worker with brief atypical exposure to chrysotile asbestos].
</td>
<td style="text-align:left;">
Med Lav
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Extraskeletal myxoid chondrosarcoma of the pleura. Report of a case clinically simulating mesothelioma.
</td>
<td style="text-align:left;">
Am. J. Clin. Pathol.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma in parts of Japan in relationship to asbestos exposure.
</td>
<td style="text-align:left;">
Ind Health
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
HMBA induces cell death and potentiates doxorubicin toxicity in malignant mesothelioma cells.
</td>
<td style="text-align:left;">
Cancer Chemother. Pharmacol.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[An unusual diagnosis of post-traumatic hemothorax].
</td>
<td style="text-align:left;">
Rev Pneumol Clin
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
[Spontaneous pneumothorax revealing malignant pleural mesothelioma. Three case reports].
</td>
<td style="text-align:left;">
Rev Pneumol Clin
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
del(6q) as a possible primary change in malignant mesothelioma.
</td>
<td style="text-align:left;">
Cancer Genet. Cytogenet.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Small bowel metastases from lung cancer].
</td>
<td style="text-align:left;">
Chir Ital
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma metastasis to the mandible.
</td>
<td style="text-align:left;">
Int J Oral Maxillofac Surg
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma: overview of the North American and European experience.
</td>
<td style="text-align:left;">
Thorac Surg Clin
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Genetics of malignant pleural mesothelioma: molecular markers and biologic targets.
</td>
<td style="text-align:left;">
Thorac Surg Clin
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Epidemiology, biologic behavior, and natural history of mesothelioma.
</td>
<td style="text-align:left;">
Thorac Surg Clin
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Role of asbestos in etiology of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Thorac Surg Clin
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Preoperative assessment and therapeutic options for patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Thorac Surg Clin
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleurectomy and decortication for malignant mesothelioma.
</td>
<td style="text-align:left;">
Thorac Surg Clin
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Extrapleural pneumonectomy for diffuse malignant pleural mesothelioma: techniques and complications.
</td>
<td style="text-align:left;">
Thorac Surg Clin
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Patterns of failure following surgical resection for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Thorac Surg Clin
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Fibrinolysis of loculated pleural effusion in malignant mesothelioma.
</td>
<td style="text-align:left;">
Singapore Med J
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Current chemotherapeutic treatment of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Expert Opin Pharmacother
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Role of the non-neuronal human cholinergic system in lung cancer and mesothelioma: possibility of new therapeutic strategies.
</td>
<td style="text-align:left;">
Curr Med Chem Anticancer Agents
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Primary synovial sarcoma of the pleura: beware of misdiagnosis.
</td>
<td style="text-align:left;">
Eur. J. Intern. Med.
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant mesothelioma of the pleura among women].
</td>
<td style="text-align:left;">
Med Lav
</td>
<td style="text-align:left;">
diagnosis | epidemiology | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma of the tunica vaginalis testis: a case with a predominant sarcomatous component.
</td>
<td style="text-align:left;">
Pathol. Int.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Role of biochemical tests in the diagnosis of exudative pleural effusions.
</td>
<td style="text-align:left;">
Clin. Biochem.
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
[Carcinoembryonic antigen in pleural effusion. Adenocarcinoma versus mesothelioma].
</td>
<td style="text-align:left;">
Rev Clin Esp
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
TTF-1 and surfactant-B as co-adjuvants in the diagnosis of lung adenocarcinoma and pleural mesothelioma.
</td>
<td style="text-align:left;">
Ann Diagn Pathol
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Rapid pleurodesis in symptomatic malignant pleural effusion.
</td>
<td style="text-align:left;">
Eur J Cardiothorac Surg
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Statistical validation of the EORTC prognostic model for malignant pleural mesothelioma based on three consecutive phase II trials.
</td>
<td style="text-align:left;">
J. Clin. Oncol.
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[A case report of disseminated malignant mesothelioma of peritoneum responding remarkably to thalidomide, celecoxib, vinorelbine and CDDP].
</td>
<td style="text-align:left;">
Gan To Kagaku Ryoho
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Distinct DNA methylation profiles in malignant mesothelioma, lung adenocarcinoma, and non-tumor lung.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Phase II trial of vinorelbine and oxaliplatin as first-line therapy in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Long-term prognostic analysis of patients with malignant pleural mesothelioma].
</td>
<td style="text-align:left;">
Ai Zheng
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma in a woodchuck (Marmota monax).
</td>
<td style="text-align:left;">
J. Vet. Med. Sci.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Am. J. Med. Sci.
</td>
<td style="text-align:left;">
treatment | epidemiology
</td>
</tr>
<tr>
<td style="text-align:left;">
Pemetrexed in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Oncology (Williston Park, N.Y.)
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Asbestosis accompanied by primary peritoneal mesothelioma].
</td>
<td style="text-align:left;">
Radiologe
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Heparanase and basic fibroblast growth factor are co-expressed in malignant mesothelioma.
</td>
<td style="text-align:left;">
Clin. Exp. Metastasis
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Chemotherapy options and new advances in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Ann. Oncol.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
p53 and Kirsten-ras mutations in human mesothelioma cell lines.
</td>
<td style="text-align:left;">
Cancer Res.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
The combination of CEA, EMA, and BerEp4 and hyaluronan analysis specifically identifies 79% of all histologically verified mesotheliomas causing an effusion.
</td>
<td style="text-align:left;">
Diagn. Cytopathol.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
The value of ThinPrep and cytospin preparation in pleural effusion cytological diagnosis of mesothelioma and adenocarcinoma.
</td>
<td style="text-align:left;">
Diagn. Cytopathol.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
The value of epithelial membrane antigen expression in separating benign mesothelial proliferation from malignant mesothelioma: a comparative study.
</td>
<td style="text-align:left;">
Diagn. Cytopathol.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Image cytometry: an aid for cytological diagnosis of pleural effusions.
</td>
<td style="text-align:left;">
Diagn. Cytopathol.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Differentiation of mesothelioma from adenocarcinoma in serous effusions: the role of hyaluronic acid and CD44 localization.
</td>
<td style="text-align:left;">
Diagn. Cytopathol.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Immunocytochemical panel for distinguishing between carcinoma and reactive mesothelial cells in body cavity fluids.
</td>
<td style="text-align:left;">
Diagn. Cytopathol.
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant mesothelioma of the pleura–diagnostic difficulties].
</td>
<td style="text-align:left;">
Pol. Merkur. Lekarski
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Pathogenesis of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Respirology
</td>
<td style="text-align:left;">
diagnosis | epidemiology | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Metastatic renal cell carcinoma presenting as multiple pleural tumours.
</td>
<td style="text-align:left;">
Respirology
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Podoplanin as a marker for mesothelioma.
</td>
<td style="text-align:left;">
Pathol. Int.
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Iodized talc pleurodesis for the treatment of pleural effusions.
</td>
<td style="text-align:left;">
J. Thorac. Cardiovasc. Surg.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[A study on risk of malignant neoplasm and environmental exposure to crocidolite].
</td>
<td style="text-align:left;">
Sichuan Da Xue Xue Bao Yi Xue Ban
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Pemetrexed in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Clin. Cancer Res.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
The effects of intrapleural injections of alumina and aluminosilicate (ceramic) fibres.
</td>
<td style="text-align:left;">
Int J Exp Pathol
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Comparison of monoclonal versus polyclonal calretinin antibodies for immunohistochemical diagnosis of malignant mesothelioma.
</td>
<td style="text-align:left;">
Appl. Immunohistochem. Mol. Morphol.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Second-line treatment of malignant pleural mesothelioma with Pemetrexed (Alimta) – a case report].
</td>
<td style="text-align:left;">
Pneumologie
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Management of malignant pleural effusions].
</td>
<td style="text-align:left;">
Pneumologie
</td>
<td style="text-align:left;">
diagnosis | treatment | epidemiology | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Granulocyte colony-stimulating factor-producing malignant pleural mesothelioma with the expression of other cytokines.
</td>
<td style="text-align:left;">
Int. J. Clin. Oncol.
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Hyaluronan synthase expression in pleural malignant mesotheliomas.
</td>
<td style="text-align:left;">
Virchows Arch.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant deciduoid mesothelioma: a diagnostic challenge.
</td>
<td style="text-align:left;">
Arch. Pathol. Lab. Med.
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
A pilot trial of high-dose-rate intraoperative radiation therapy for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Brachytherapy
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Extra-pleural pneumonectomy for malignant pleural mesothelioma: the risks of induction chemotherapy, right-sided procedures and prolonged operations.
</td>
<td style="text-align:left;">
Eur J Cardiothorac Surg
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Analysis of chromosomes 9 and 11 aneuploidy frequency in pleural effusion of patients with and without malignancy: interphase FISH technique.
</td>
<td style="text-align:left;">
Cancer Biol. Ther.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Pleural mesothelioma–case with effusion in both pleural cavities].
</td>
<td style="text-align:left;">
Pol. Merkur. Lekarski
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Assessment of immunological competence and SV40 specific recall immunity in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Vaccine
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Pemetrexed therapy for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Ann Pharmacother
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Farnesyltransferase inhibitors and human malignant pleural mesothelioma: a first-step comparative translational study.
</td>
<td style="text-align:left;">
Clin. Cancer Res.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Predictors of pleural malignancy in patients with pleural effusion undergoing thoracoscopy.
</td>
<td style="text-align:left;">
Chest
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleurectomy/decortication plus chemotherapy: outcomes of 40 cases of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Chir Ital
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
[Lung cancer and peritoneal mesothelioma: two complications of asbestos exposure in the same patient].
</td>
<td style="text-align:left;">
Rev Pneumol Clin
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Identification of intelectin overexpression in malignant pleural mesothelioma by serial analysis of gene expression (SAGE).
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Cancer risks in a historical UK cohort of benzene exposed workers.
</td>
<td style="text-align:left;">
Occup Environ Med
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Desmoplastic malignant mesothelioma: a review of 17 cases.
</td>
<td style="text-align:left;">
J. Clin. Pathol.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Improved survival with VATS pleurectomy-decortication in advanced malignant mesothelioma.
</td>
<td style="text-align:left;">
Eur J Surg Oncol
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Gefitinib in patients with malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B.
</td>
<td style="text-align:left;">
Clin. Cancer Res.
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
The positive pleural effusion. A retrospective study of cytopathologic diagnoses with autopsy confirmation.
</td>
<td style="text-align:left;">
Acta Cytol.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleural malignant mesothelioma in Tuscany, Italy (1970-1988): I. Anatomo-pathologic aspects.
</td>
<td style="text-align:left;">
Am. J. Ind. Med.
</td>
<td style="text-align:left;">
diagnosis | epidemiology | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleural malignant mesothelioma in Tuscany, Italy (1970-1988): II. Identification of occupational exposure to asbestos.
</td>
<td style="text-align:left;">
Am. J. Ind. Med.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Characterization of a tumor necrosis factor-alpha inhibitor activity in cancer patients.
</td>
<td style="text-align:left;">
Am. J. Respir. Cell Mol. Biol.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Development of malignant mesothelioma during treatment for prolymphocytic leukemia: is asbestos or simian virus 40 a link?
</td>
<td style="text-align:left;">
Anticancer Res.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Pemetrexed (Alimta) in small cell lung cancer.
</td>
<td style="text-align:left;">
Semin. Oncol.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Second-line (post-study) chemotherapy received by patients treated in the phase III trial of pemetrexed plus cisplatin versus cisplatin alone in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Ann. Oncol.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Surgical management of malignant pleural mesothelioma: a systematic review and evidence summary.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Quantitative evaluation of the apoptosis regulating genes Survivin, Bcl-2 and Bax in inflammatory and malignant pleural lesions.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Thalidomide in patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Development in the treatment of malignant mesothelioma].
</td>
<td style="text-align:left;">
Ned Tijdschr Geneeskd
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
[Problematic cases of mesothelioma reported to the Dutch Institute for Asbestos Victims: evaluation by the Mesothelioma Working Group of the Netherlands Association of Pulmonologists and Specialists in Tuberculosis].
</td>
<td style="text-align:left;">
Ned Tijdschr Geneeskd
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Regulatory T cells and cytokines in malignant pleural effusions secondary to mesothelioma and carcinoma.
</td>
<td style="text-align:left;">
Cancer Biol. Ther.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Epirubicin and gemcitabine as first-line treatment in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Tumori
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
The selective epidermal growth factor receptor tyrosine kinase inhibitor PD153035 suppresses expression of prometastasis phenotypes in malignant pleural mesothelioma cells in vitro.
</td>
<td style="text-align:left;">
J. Thorac. Cardiovasc. Surg.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Pemetrexed-cisplatin combination in mesothelioma.
</td>
<td style="text-align:left;">
Expert Rev Anticancer Ther
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Intrapleural cisplatin and mitomycin for malignant mesothelioma following pleurectomy: pharmacokinetic studies.
</td>
<td style="text-align:left;">
J. Clin. Oncol.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Irinotecan for malignant mesothelioma A phase II trial by the Cancer and Leukemia Group B.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Raltitrexed-Oxaliplatin combination chemotherapy is inactive as second-line treatment for malignant pleural mesothelioma patients.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Human mesothelioma cells exhibit tumor cell-specific differences in phosphatidylinositol 3-kinase/AKT activity that predict the efficacy of Onconase.
</td>
<td style="text-align:left;">
Mol. Cancer Ther.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Wnt2 as a new therapeutic target in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Int. J. Cancer
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Survival of malignant pleural mesothelioma cases in the Tuscan Mesothelioma Register, 1988-2000: a population-based study.
</td>
<td style="text-align:left;">
Eur. J. Cancer Prev.
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
[Therapeutic options in malignant pleural mesothelioma].
</td>
<td style="text-align:left;">
Pneumologie
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Phase II study of a liposome-entrapped cisplatin analog (L-NDDP) administered intrapleurally and pathologic response rates in patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J. Clin. Oncol.
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleural mesothelioma.
</td>
<td style="text-align:left;">
Curr Opin Oncol
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Palliative intracavitary carboplatin therapy in a cat with suspected pleural mesothelioma.
</td>
<td style="text-align:left;">
J. Feline Med. Surg.
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Photodynamic therapy as an adjunct to surgery for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Identification of novel candidate oncogenes and tumor suppressors in malignant pleural mesothelioma using large-scale transcriptional profiling.
</td>
<td style="text-align:left;">
Am. J. Pathol.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Cisplatin and gemcitabine in malignant pleural mesothelioma: a phase II study.
</td>
<td style="text-align:left;">
Am. J. Clin. Oncol.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Management of malignant pleural effusions.
</td>
<td style="text-align:left;">
Curr Opin Pulm Med
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma in Hong Kong.
</td>
<td style="text-align:left;">
Respir Med
</td>
<td style="text-align:left;">
diagnosis | epidemiology | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Integrated computed tomography-positron emission tomography in patients with potentially resectable malignant pleural mesothelioma: Staging implications.
</td>
<td style="text-align:left;">
J. Thorac. Cardiovasc. Surg.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
New therapeutic options for mesothelioma.
</td>
<td style="text-align:left;">
Curr Oncol Rep
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Clinical trials in malignant pleural mesothelioma in Australasia.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Overview on ongoing or planned clinical trials in Europe.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Epidemic of mesothelioma in Egypt.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
treatment | epidemiology | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
The role of PET in the surgical management of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
CT, RECIST, and malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma: staging systems.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Molecular prognostic markers in malignant mesothelioma.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Induction chemotherapy, extrapleural pneumonectomy, and radiotherapy in the treatment of malignant pleural mesothelioma: the Memorial Sloan-Kettering experience.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Treatment planning system evaluation for mesothelioma IMRT.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Inverse planned stereotactic intensity modulated radiotherapy (IMRT) in the palliative treatment of malignant mesothelioma of the pleura: the Heidelberg experience.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Implications of P16/CDKN2A deletion in pleural mesotheliomas.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Limited efficacy of imatinib mesylate in malignant mesothelioma: a phase II trial.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Advances in the diagnosis, evaluation, and management of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Respirology
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Validation of genomics-based prognostic tests in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Clin. Cancer Res.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Localized malignant mesothelioma.
</td>
<td style="text-align:left;">
Am. J. Surg. Pathol.
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Pemetrexed disodium.
</td>
<td style="text-align:left;">
Nat Rev Drug Discov
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Cyclooxygenase-2 expression predicts survival in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Eur. J. Cancer
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Short, thin asbestos fibers contribute to the development of human malignant mesothelioma: pathological evidence.
</td>
<td style="text-align:left;">
Int J Hyg Environ Health
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Residential proximity to naturally occurring asbestos and mesothelioma risk in California.
</td>
<td style="text-align:left;">
Am. J. Respir. Crit. Care Med.
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
New agents in the management of advanced mesothelioma.
</td>
<td style="text-align:left;">
Semin. Oncol.
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Monoclonal antibody K1 reacts with epithelial mesothelioma but not with lung adenocarcinoma.
</td>
<td style="text-align:left;">
Am. J. Surg. Pathol.
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleural malignant mesothelioma, genetic susceptibility and asbestos exposure.
</td>
<td style="text-align:left;">
Mutat. Res.
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Measuring quality of life in patients with pleural mesothelioma using a modified version of the Lung Cancer Symptom Scale (LCSS): psychometric properties of the LCSS-Meso.
</td>
<td style="text-align:left;">
Support Care Cancer
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
A phase II study evaluating the cisplatin and epirubicin combination in patients with unresectable malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Triplet chemotherapy with cisplatin, gemcitabine and vinorelbine for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Jpn. J. Clin. Oncol.
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Primary diagnosis of malignant mesothelioma by fine-needle aspiration of a supraclavicular lymph node.
</td>
<td style="text-align:left;">
Diagn. Cytopathol.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Spinal cord compression from a malignant pleural mesothelioma].
</td>
<td style="text-align:left;">
Rev Pneumol Clin
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Clinical significance of the expression of tumor-associated antigen, RCAS1, and its soluble protein in pleural fluid in malignant mesothelioma.
</td>
<td style="text-align:left;">
Oncol. Rep.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Chromosomal alterations in early stages of malignant mesotheliomas.
</td>
<td style="text-align:left;">
Virchows Arch.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Therapeutic targeting of multiple signaling pathways in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Oncology
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma with a pronounced myxoid stroma: a clinical and pathological evaluation of 19 cases.
</td>
<td style="text-align:left;">
Virchows Arch.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[A case of malignant pleural mesothelioma with osseous and cartilaginous formation].
</td>
<td style="text-align:left;">
Nihon Kyobu Shikkan Gakkai Zasshi
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Intensity-modulated radiation therapy for mesothelioma: impact of multileaf collimator leaf width and pencil beam size on planning quality and delivery efficiency.
</td>
<td style="text-align:left;">
Int. J. Radiat. Oncol. Biol. Phys.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
A molecular epidemiology case control study on pleural malignant mesothelioma.
</td>
<td style="text-align:left;">
Cancer Epidemiol. Biomarkers Prev.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Occupational asbestos exposure and predictable asbestos-related diseases in India.
</td>
<td style="text-align:left;">
Am. J. Ind. Med.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
CT in differential diagnosis of benign and malignant pleural disease.
</td>
<td style="text-align:left;">
Monaldi Arch Chest Dis
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Prognostic significance of Bax and Fas ligand in erionite and asbestos induced Turkish malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
[A case of malignant mesothelioma showing rapid progression during one month].
</td>
<td style="text-align:left;">
Nihon Kokyuki Gakkai Zasshi
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Hemithoracic radiation therapy after pleurectomy/decortication for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Int. J. Radiat. Oncol. Biol. Phys.
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma.
</td>
<td style="text-align:left;">
Lancet
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[The role of surgery in the treatment of malignant pleural mesothelioma].
</td>
<td style="text-align:left;">
Chir Ital
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant mesothelioma: prognostic factors in a series of 125 patients studied from 1973 to 1987].
</td>
<td style="text-align:left;">
Bull. Acad. Natl. Med.
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
PET in lung cancer.
</td>
<td style="text-align:left;">
Chang Gung Med J
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Differential diagnosis between mesothelioma and adenocarcinoma: a multimodal approach based on ultrastructure and immunocytochemistry.
</td>
<td style="text-align:left;">
Semin Diagn Pathol
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma: cytologic diagnosis with histologic, immunohistochemical, and ultrastructural correlation.
</td>
<td style="text-align:left;">
Semin Diagn Pathol
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
The concept of mesothelioma in situ: implications for diagnosis and histogenesis.
</td>
<td style="text-align:left;">
Semin Diagn Pathol
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Quantitative and analytical studies in the diagnosis of mesothelioma.
</td>
<td style="text-align:left;">
Semin Diagn Pathol
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
The spectrum of histologic growth patterns in benign and malignant fibrous tumors of the pleura.
</td>
<td style="text-align:left;">
Semin Diagn Pathol
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Open-label study of pemetrexed alone or in combination with cisplatin for the treatment of patients with peritoneal mesothelioma: outcomes of an expanded access program.
</td>
<td style="text-align:left;">
Clin Lung Cancer
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Mesothelioma: treatment and survival of a patient population and review of the literature.
</td>
<td style="text-align:left;">
Anticancer Res.
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Serum PDGF-AB in pleural mesothelioma.
</td>
<td style="text-align:left;">
Tumour Biol.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[The problems of early diagnosis of diffuse malignant mesothelioma from the pathologo-anatomic view].
</td>
<td style="text-align:left;">
Zentralbl. Pathol.
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Radiation recall dermatitis with pemetrexed.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Immunocytochemical detection of XIAP in body cavity effusions and washes.
</td>
<td style="text-align:left;">
Mod. Pathol.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
A median sternotomy approach to right extrapleural pneumonectomy for mesothelioma.
</td>
<td style="text-align:left;">
Ann. Thorac. Surg.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Pseudomesothelioma resulting from metastatic malignant melanoma.
</td>
<td style="text-align:left;">
Eur J Cardiothorac Surg
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
The effects of thermochemotherapy using cyclophosphamide plus hyperthermia on the malignant pleural mesothelioma in vivo.
</td>
<td style="text-align:left;">
Ann. Anat.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Cox and mesothelioma: an overview.
</td>
<td style="text-align:left;">
Histol. Histopathol.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
The evolution of cancer research and drug discovery at Lilly Research Laboratories.
</td>
<td style="text-align:left;">
Adv. Enzyme Regul.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
A case of diffuse pleural mesothelioma in which contralateral exploratory thoracoscopy assisted the selection of therapy.
</td>
<td style="text-align:left;">
Ann Thorac Cardiovasc Surg
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma: current status of histopathologic diagnosis and molecular profile.
</td>
<td style="text-align:left;">
Expert Rev. Mol. Diagn.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Clinical efficacy and safety of thoracoscopic talc pleurodesis in malignant pleural effusions.
</td>
<td style="text-align:left;">
Chest
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma with heterologous osteoblastic elements: computed tomography, magnetic resonance, and positron emission tomography imaging characteristics of a rare tumor.
</td>
<td style="text-align:left;">
J Comput Assist Tomogr
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
High-dose methotrexate in the treatment of malignant mesothelioma of the pleura. A phase II study.
</td>
<td style="text-align:left;">
Br. J. Cancer
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Expression and prognostic significance of hypoxia-inducible factor 1alpha (HIF-1alpha) in malignant pleural mesothelioma (MPM).
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
The additional risk of malignant mesothelioma in former workers and residents of Wittenoom with benign pleural disease or asbestosis.
</td>
<td style="text-align:left;">
Occup Environ Med
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Spindle cell tumours of the pleura: a clinical, histological and comparative genomic hybridization analysis of 14 cases.
</td>
<td style="text-align:left;">
Virchows Arch.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Immunocytochemical staining of serous effusions with the monoclonal antibody Ber-EP4.
</td>
<td style="text-align:left;">
Cytopathology
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
A cancer incidence and mortality study of Dow Chemical Canada Inc. manufacturing sites.
</td>
<td style="text-align:left;">
Occup Med (Lond)
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Second cancers among 40,576 testicular cancer patients: focus on long-term survivors.
</td>
<td style="text-align:left;">
J. Natl. Cancer Inst.
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Determination and distribution of N-acetyl- and N-glycolylneuraminic acids in culture media and cell-associated glycoconjugates from human malignant mesothelioma and adenocarcinoma cells.
</td>
<td style="text-align:left;">
Biomed. Chromatogr.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada.
</td>
<td style="text-align:left;">
J. Clin. Oncol.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Molecular pathways in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Cancer Lett.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
[Recent progress in treatment of malignant pleural mesothelioma].
</td>
<td style="text-align:left;">
Cancer Radiother
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Physical and chemical stability of pemetrexed solutions in plastic syringes.
</td>
<td style="text-align:left;">
Ann Pharmacother
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
The expression pattern of beta-catenin in mesothelial proliferative lesions and its diagnostic utilities.
</td>
<td style="text-align:left;">
Diagn. Cytopathol.
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Differential expression of the 67 kilodalton laminin receptor in epithelioid malignant mesothelioma and carcinomas that spread to serosal cavities.
</td>
<td style="text-align:left;">
Diagn. Cytopathol.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Quantitative analysis of integrin expression in effusions using flow cytometric immunophenotyping.
</td>
<td style="text-align:left;">
Diagn. Cytopathol.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Incidence of pleural mesothelioma in Liguria Region, Italy (1996-2002).
</td>
<td style="text-align:left;">
Eur. J. Cancer
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Long-term follow-up of patients with malignant pleural mesothelioma receiving high-dose adenovirus herpes simplex thymidine kinase/ganciclovir suicide gene therapy.
</td>
<td style="text-align:left;">
Clin. Cancer Res.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Intraoperative photodynamic therapy of the chest cavity in malignant pleural mesothelioma bearing rats.
</td>
<td style="text-align:left;">
Lasers Surg Med
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Mortality of UK electricity generation and transmission workers, 1973-2002.
</td>
<td style="text-align:left;">
Occup Med (Lond)
</td>
<td style="text-align:left;">
transmission
</td>
</tr>
<tr>
<td style="text-align:left;">
Recognition of histopathologic patterns of diffuse malignant mesothelioma in differential diagnosis of pleural biopsies.
</td>
<td style="text-align:left;">
Arch. Pathol. Lab. Med.
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Differential diagnosis of benign and malignant mesothelial proliferations on pleural biopsies.
</td>
<td style="text-align:left;">
Arch. Pathol. Lab. Med.
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Review and update of uncommon primary pleural tumors: a practical approach to diagnosis.
</td>
<td style="text-align:left;">
Arch. Pathol. Lab. Med.
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Needle-track metastases and prophylactic radiotherapy for mesothelioma.
</td>
<td style="text-align:left;">
Respir Med
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Prolonged survival after talc poudrage for malignant pleural mesothelioma: case series.
</td>
<td style="text-align:left;">
Respirology
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Clinicopathological analysis of lung cancer resembling malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Respirology
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Assessment of asbestos exposure, mortality study, and health intervention in workers formerly exposed to asbestos in a small factory making drying machines for textile finishing and the paper mill industry in Pistoia, Italy].
</td>
<td style="text-align:left;">
Med Lav
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Update on malignant mesothelioma.
</td>
<td style="text-align:left;">
Oncology (Williston Park, N.Y.)
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Asbestos-related pleuropulmonary diseases: pictorial essay].
</td>
<td style="text-align:left;">
Rev Port Pneumol
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Use of imaging in the management of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Clin Radiol
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Pemetrexed: a multitargeted antifolate.
</td>
<td style="text-align:left;">
Clin Ther
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Pemetrexed: a new cytotoxic agent in the development for first-line non-small-cell lung cancer.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Standard therapy for the treatment of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Seeking new options for the treatment of small-cell lung cancer.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Perspective on the development of new agents in thoracic cancers.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Cisplatin-induced GADD34 upregulation potentiates oncolytic viral therapy in the treatment of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Cancer Biol. Ther.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Inhibition of the met receptor in mesothelioma.
</td>
<td style="text-align:left;">
Clin. Cancer Res.
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
[Distribution of ferruginous bodies in the lung in cases of malignant pleural mesothelioma with definite occupational history of asbestos exposure].
</td>
<td style="text-align:left;">
Nihon Kyobu Shikkan Gakkai Zasshi
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Prognostic significance of vascular endothelial growth factor, tumor necrosis, and mitotic activity index in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Chest
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Extended surgical staging for potentially resectable malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Ann. Thorac. Surg.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Asbestos and malignant pleural mesothelioma: molecular, cellular and physiopathological aspects].
</td>
<td style="text-align:left;">
Bull Cancer
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
A randomised trial in malignant mesothelioma (M) of early (E) versus delayed (D) chemotherapy in symptomatically stable patients: the MED trial.
</td>
<td style="text-align:left;">
Ann. Oncol.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Autofluorescence videothoracoscopy in exudative pleural effusions: preliminary results.
</td>
<td style="text-align:left;">
Eur. Respir. J.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Molecular biology of malignant mesothelioma: a review.
</td>
<td style="text-align:left;">
Hematol. Oncol. Clin. North Am.
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Multimodality treatments in the management of malignant pleural mesothelioma: an update.
</td>
<td style="text-align:left;">
Hematol. Oncol. Clin. North Am.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Radiotherapy for mesothelioma.
</td>
<td style="text-align:left;">
Hematol. Oncol. Clin. North Am.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Gene therapy for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Hematol. Oncol. Clin. North Am.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma: a case report.
</td>
<td style="text-align:left;">
J Manipulative Physiol Ther
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
The immunohistochemical profile of malignant mesotheliomas of the tunica vaginalis: a study of 20 cases.
</td>
<td style="text-align:left;">
Am. J. Surg. Pathol.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant pleural mesothelioma: early diagnosis and multimodality management].
</td>
<td style="text-align:left;">
G Chir
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Neurofibromatosis 2 (NF2) and malignant mesothelioma in a man with a constitutional NF2 missense mutation.
</td>
<td style="text-align:left;">
Fam. Cancer
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Multimodality approach in management of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Eur J Cardiothorac Surg
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Patterns of recurrence and long-term survival after curative resection of localized fibrous tumors of the pleura.
</td>
<td style="text-align:left;">
Clin Lung Cancer
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant biphasic pleural mesothelioma metastatic to the liver diagnosed by fine-needle aspiration.
</td>
<td style="text-align:left;">
Diagn. Cytopathol.
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Pemetrexed-associated urticarial vasculitis.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Estimation of future mortality from pleural malignant mesothelioma in Japan based on an age-cohort model.
</td>
<td style="text-align:left;">
Am. J. Ind. Med.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Subcutaneous metastases of sarcomatoid mesothelioma with its differential diagnosis on fine needle aspiration–a case report.
</td>
<td style="text-align:left;">
Indian J Pathol Microbiol
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
EGFR overexpression in malignant pleural mesothelioma. An immunohistochemical and molecular study with clinico-pathological correlations.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Cytopathology of malignant mesothelioma: a stepwise logistic regression analysis.
</td>
<td style="text-align:left;">
Diagn. Cytopathol.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Cytologic diagnosis of malignant mesothelioma in serous effusions using an antimesothelial-cell antibody.
</td>
<td style="text-align:left;">
Diagn. Cytopathol.
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
[Magnetic resonance imaging in the evaluation of pneumonia].
</td>
<td style="text-align:left;">
Radiologe
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Functional analysis of c-Met/hepatocyte growth factor pathway in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Cancer Res.
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Lung Cancer Highlights from ASCO 2005.
</td>
<td style="text-align:left;">
Oncologist
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Paradoxic technetium-99 methylene diphosphonate localization in malignant mesothelioma.
</td>
<td style="text-align:left;">
Clin Nucl Med
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Chemotherapy for intrathoracic cancer in dogs and cats.
</td>
<td style="text-align:left;">
Probl Vet Med
</td>
<td style="text-align:left;">
diagnosis | treatment | epidemiology | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Depletion of DNA methyltransferase 1 and/or DNA methyltransferase 3b mediates growth arrest and apoptosis in lung and esophageal cancer and malignant pleural mesothelioma cells.
</td>
<td style="text-align:left;">
J. Thorac. Cardiovasc. Surg.
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Differential diagnosis of preneoplastic lesions of the pleura and of early mesothelioma: immunohistochemical and morphological findings].
</td>
<td style="text-align:left;">
Pathologe
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Additional value of hybrid PET/CT fusion imaging vs. conventional CT scan alone in the staging and management of patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Nucl Med Rev Cent East Eur
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Intrapleural hypotonic cisplatin treatment for malignant pleural mesothelioma: in vitro experiments and clinical application.
</td>
<td style="text-align:left;">
Surg. Today
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Short-term treatment-related symptoms and quality of life: results from an international randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an EORTC Lung-Cancer Group and National Cancer Institute, Canada, Intergroup Study.
</td>
<td style="text-align:left;">
J. Clin. Oncol.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
ERK1/2 and p38 MAP kinase control MMP-2, MT1-MMP, and TIMP action and affect cell migration: a comparison between mesothelioma and mesothelial cells.
</td>
<td style="text-align:left;">
J. Cell. Physiol.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
[Adenosine deaminase 2 in the diagnosis of tuberculous pleuritis].
</td>
<td style="text-align:left;">
Kekkaku
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant cystosarcoma phyllodes].
</td>
<td style="text-align:left;">
Strahlenther Onkol
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Soluble mesothelin-related peptides in the diagnosis of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Am. J. Respir. Crit. Care Med.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Descriptive epidemiology of malignant mesothelioma.
</td>
<td style="text-align:left;">
Med Lav
</td>
<td style="text-align:left;">
epidemiology | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Nordic experience: expected decline in the incidence of mesotheliomas resulting from ceased exposure?
</td>
<td style="text-align:left;">
Med Lav
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma and the working environment: the viewpoint of the occupational physician.
</td>
<td style="text-align:left;">
Med Lav
</td>
<td style="text-align:left;">
diagnosis | epidemiology | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Epidemiologic surveillance for primary prevention of malignant mesothelioma: the Italian experience.
</td>
<td style="text-align:left;">
Med Lav
</td>
<td style="text-align:left;">
epidemiology | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
SV40, genetic polymorphism and mesothelioma. pathological and epidemiological evidence.
</td>
<td style="text-align:left;">
Med Lav
</td>
<td style="text-align:left;">
epidemiology
</td>
</tr>
<tr>
<td style="text-align:left;">
Peculiar features of mesothelioma occurrence as related to exposure patterns and circumstances in the Lombard Region, Italy.
</td>
<td style="text-align:left;">
Med Lav
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma in 2004: How advanced technology and new drugs are changing the perspectives of mesothelioma patients. Highlights from the VIIth Meeting of the International Mesothelioma Interest Group.
</td>
<td style="text-align:left;">
Med Lav
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Computed tomographic characterization of malignant peritoneal mesothelioma.
</td>
<td style="text-align:left;">
Tumori
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Lung asbestos fiber content and mesothelioma cell type, site, and survival.
</td>
<td style="text-align:left;">
Cancer
</td>
<td style="text-align:left;">
diagnosis | transmission | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
The French National Mesothelioma Surveillance Program.
</td>
<td style="text-align:left;">
Occup Environ Med
</td>
<td style="text-align:left;">
diagnosis | epidemiology | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Clinical experience with pemetrexed in breast cancer.
</td>
<td style="text-align:left;">
Semin. Oncol.
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Imaging and therapy of malignant pleural mesothelioma using replication-competent herpes simplex viruses.
</td>
<td style="text-align:left;">
J Gene Med
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Incidence and management of complications after neoadjuvant chemotherapy followed by extrapleural pneumonectomy for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Eur J Cardiothorac Surg
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Occupational asbestos exposure: how to deal with suspected mesothelioma cases–the Dutch approach.
</td>
<td style="text-align:left;">
Ann. Oncol.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Claudins in differential diagnosis between mesothelioma and metastatic adenocarcinoma of the pleura.
</td>
<td style="text-align:left;">
J. Clin. Pathol.
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Establishment and characterization of 20 human non-small cell lung cancer cell lines in a serum-free defined medium (ACL-4).
</td>
<td style="text-align:left;">
Chest
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
BCG therapy of pleural and peritoneal growth of transplanted rat tumours.
</td>
<td style="text-align:left;">
Int. J. Cancer
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Confronting cisternae and ciliated cells in malignant pleural mesothelioma: an ultrastructural study.
</td>
<td style="text-align:left;">
Ultrastruct Pathol
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Intrapleural topical application of cisplatin with the surgical carrier Vivostat increases the local drug concentration in an immune-competent rat model with malignant pleuromesothelioma.
</td>
<td style="text-align:left;">
J. Thorac. Cardiovasc. Surg.
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Wnt inhibitory factor-1, a Wnt antagonist, is silenced by promoter hypermethylation in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Biochem. Biophys. Res. Commun.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
The role of analytical SEM in the determination of causation in malignant mesothelioma.
</td>
<td style="text-align:left;">
Ultrastruct Pathol
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Diffuse malignant mesothelioma.
</td>
<td style="text-align:left;">
Am. J. Clin. Pathol.
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Fluorescence detection of pleural malignancies using 5-aminolaevulinic acid.
</td>
<td style="text-align:left;">
Chest
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Mesothelioma environment comprises cytokines and T-regulatory cells that suppress immune responses.
</td>
<td style="text-align:left;">
Eur. Respir. J.
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Expression of HLA-G in malignant mesothelioma and clinically aggressive breast carcinoma.
</td>
<td style="text-align:left;">
Virchows Arch.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Novel orthotopic implantation model of human malignant pleural mesothelioma (EHMES-10 cells) highly expressing vascular endothelial growth factor and its receptor.
</td>
<td style="text-align:left;">
Cancer Sci.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Sequential chemotherapy with cisplatin/gemcitabine (CG) followed by mitoxantrone/methotrexate/mitomycin (MMM) in patients with malignant pleural mesothelioma. A multicenter Italian Phase II Study (SITMP1).
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J. Clin. Oncol.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Clinical activity of pemetrexed: a multitargeted antifolate anticancer agent.
</td>
<td style="text-align:left;">
Future Oncol
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Recombinant GM-CSF plus autologous tumor cells as a vaccine for patients with mesothelioma.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Polymorphisms in DNA repair genes as risk factors for asbestos-related malignant mesothelioma in a general population study.
</td>
<td style="text-align:left;">
Mutat. Res.
</td>
<td style="text-align:left;">
epidemiology | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Comparative genomic hybridisation in malignant deciduoid mesothelioma.
</td>
<td style="text-align:left;">
J. Clin. Pathol.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Phase I to II study of pleurectomy/decortication and intraoperative intracavitary hyperthermic cisplatin lavage for mesothelioma.
</td>
<td style="text-align:left;">
J. Clin. Oncol.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Intracavitary cisplatin chemotherapy experience with six dogs.
</td>
<td style="text-align:left;">
J. Vet. Intern. Med.
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
[Thoracoscopic pleurodesis in malignant pleural effusions].
</td>
<td style="text-align:left;">
Rev Med Chir Soc Med Nat Iasi
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Systemic chemotherapy in the management of malignant peritoneal mesothelioma.
</td>
<td style="text-align:left;">
Eur J Surg Oncol
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Mortality from malignant neoplasms among workers of an asbestos processing plant in Poland: results of prolonged observation.
</td>
<td style="text-align:left;">
Int J Occup Med Environ Health
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Suppression of pro-metastasis phenotypes expression in malignant pleural mesothelioma by the PI3K inhibitor LY294002 or the MEK inhibitor UO126.
</td>
<td style="text-align:left;">
Anticancer Res.
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
h-Caldesmon, a useful positive marker in the diagnosis of pleural malignant mesothelioma, epithelioid type.
</td>
<td style="text-align:left;">
Am. J. Surg. Pathol.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Monitoring of lung motion in patients with malignant pleural mesothelioma using two-dimensional and three-dimensional dynamic magnetic resonance imaging: comparison with spirometry.
</td>
<td style="text-align:left;">
Invest Radiol
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Infrequent existence of simian virus 40 large T antigen DNA in malignant mesothelioma in Japan.
</td>
<td style="text-align:left;">
Cancer Sci.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Establishment and characterization of four malignant pleural mesothelioma cell lines from Japanese patients.
</td>
<td style="text-align:left;">
Cancer Sci.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Computed tomography findings in 66 patients with malignant pleural mesothelioma due to environmental exposure to asbestos.
</td>
<td style="text-align:left;">
Clin Imaging
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Pemetrexed, a novel antifolate therapeutic alternative for cancer chemotherapy.
</td>
<td style="text-align:left;">
Pharmacotherapy
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Pleural cancer mortality and compensated cases of asbestosis in Sardinia Region municipalities (1980-2000)].
</td>
<td style="text-align:left;">
Epidemiol Prev
</td>
<td style="text-align:left;">
epidemiology
</td>
</tr>
<tr>
<td style="text-align:left;">
[Mortality among workers in a cigarette factory in Lucca (Tuscany)].
</td>
<td style="text-align:left;">
Epidemiol Prev
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
[18-Fluoro-deoxy-glucose (15FDG) positon emission tomography (PET) for the evaluation of malignant pleural disease].
</td>
<td style="text-align:left;">
Rev Pneumol Clin
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
The pattern of lymph node involvement influences outcome after extrapleural pneumonectomy for malignant mesothelioma.
</td>
<td style="text-align:left;">
J. Thorac. Cardiovasc. Surg.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Prognostic value of pleural fluid pH in malignant epithelial mesothelioma after talc poudrage.
</td>
<td style="text-align:left;">
Respiration
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Imaging before and after multimodal treatment for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Radiol Med
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Synchronous pulmonary carcinoma and pleural diffuse malignant mesothelioma.
</td>
<td style="text-align:left;">
Arch. Pathol. Lab. Med.
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Incidence and survival of mesothelioma in Osaka, Japan.
</td>
<td style="text-align:left;">
Jpn. J. Clin. Oncol.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Metabolic genotypes as modulators of asbestos-related pleural malignant mesothelioma risk: a comparison of Finnish and Italian populations.
</td>
<td style="text-align:left;">
Int J Hyg Environ Health
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
A novel radiation therapy technique for malignant pleural mesothelioma combining electrons with intensity-modulated photons.
</td>
<td style="text-align:left;">
Radiother Oncol
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Comparison of patterns of metastasis between malignant pleural mesotheliomas and pulmonary carcinomas].
</td>
<td style="text-align:left;">
Pneumologie
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Characterization of human malignant mesothelioma cell lines orthotopically implanted in the pleural cavity of immunodeficient mice for their ability to grow and form metastasis.
</td>
<td style="text-align:left;">
BMC Cancer
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Two cases of pleural mesothelioma following unusual and unrecognized exposure to asbestos. The role of Occupational Health and Safety Service in identifying past occupational exposure].
</td>
<td style="text-align:left;">
Med Lav
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Cluster cases of malignant pleural mesothelioma in an oil factory].
</td>
<td style="text-align:left;">
Med Lav
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Management of malignant mesothelioma by decortication and adjunct phototherapy.
</td>
<td style="text-align:left;">
Asian Cardiovasc Thorac Ann
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Imaging of pleural disease.
</td>
<td style="text-align:left;">
Clin. Chest Med.
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Management of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Clin. Chest Med.
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Physical and chemical stability of pemetrexed in infusion solutions.
</td>
<td style="text-align:left;">
Ann Pharmacother
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Activity of intrapleural recombinant gamma-interferon in malignant mesothelioma.
</td>
<td style="text-align:left;">
Cancer
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
My approach to the diagnosis of mesothelial lesions.
</td>
<td style="text-align:left;">
J. Clin. Pathol.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Diachronic study of pleural plaques in rural population with environmental exposure to asbestos.
</td>
<td style="text-align:left;">
Am. J. Ind. Med.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Nodular glomeruloid pleuroblastoma: a biphasic pleural-based malignant tumor with immature elements.
</td>
<td style="text-align:left;">
Virchows Arch.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Expression of renal cell carcinoma-associated markers erythropoietin, CD10, and renal cell carcinoma marker in diffuse malignant mesothelioma and metastatic renal cell carcinoma.
</td>
<td style="text-align:left;">
Arch. Pathol. Lab. Med.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Expression of bcl-2 family members in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Acta Oncol
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Systemic sclerosis and pseudomesotheliomatous adenocarcinoma of the lung.
</td>
<td style="text-align:left;">
Mod Rheumatol
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Preoperative evaluation of patients with malignant pleural mesothelioma: role of integrated CT-PET imaging.
</td>
<td style="text-align:left;">
J Thorac Imaging
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Subarachnoid-pleural fistula as a complication of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Respirology
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
The role of Abrams percutaneous pleural biopsy in the investigation of exudative pleural effusions.
</td>
<td style="text-align:left;">
Chest
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Dynamic contrast-enhanced MRI of malignant pleural mesothelioma: a feasibility study of noninvasive assessment, therapeutic follow-up, and possible predictor of improved outcome.
</td>
<td style="text-align:left;">
Chest
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Fluoro-edenitic fibres in the sputum of subjects from Biancavilla (Sicily): a pilot study.
</td>
<td style="text-align:left;">
Environ Health
</td>
<td style="text-align:left;">
epidemiology | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Preclinical comparison of mTHPC and verteporfin for intracavitary photodynamic therapy of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Eur Surg Res
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
D2-40: a reliable marker in the diagnosis of pleural mesothelioma.
</td>
<td style="text-align:left;">
Pathobiology
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Cellular and molecular parameters of mesothelioma.
</td>
<td style="text-align:left;">
J. Cell. Biochem.
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Healing of bronchopleural fistula using a modified Dumon stent: a case report.
</td>
<td style="text-align:left;">
J Cardiothorac Surg
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Nature and extent of the exposure to fibrous amphiboles in Biancavilla.
</td>
<td style="text-align:left;">
Sci. Total Environ.
</td>
<td style="text-align:left;">
epidemiology | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Pemetrexed and malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Ann. Oncol.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Epithelioid and sarcomatoid malignant pleural mesothelioma in endoscopic gastric biopsies: a diagnostic pitfall.
</td>
<td style="text-align:left;">
Pathol. Res. Pract.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
D2-40 is not a specific marker for cells of mesothelial origin in serous effusions.
</td>
<td style="text-align:left;">
Am. J. Surg. Pathol.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
The role of radiation therapy in malignant pleural mesothelioma: a systematic review.
</td>
<td style="text-align:left;">
Radiother Oncol
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Physical instability of frozen pemetrexed solutions in PVC bags.
</td>
<td style="text-align:left;">
Ann Pharmacother
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Divided dose of cisplatin combined with gemcitabine in malignant mesothelioma.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Mesothelioma in patients with nonoccupational asbestos exposure. An evidence-based approach to causation assessment.
</td>
<td style="text-align:left;">
Ann Diagn Pathol
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Mesothelioma of the tunica vaginalis testis: a rare malignancy mimicking more common inguino-scrotal masses.
</td>
<td style="text-align:left;">
J Surg Oncol
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Perineural spread of malignant mesothelioma resulting in an intradural spinal cord mass: case report.
</td>
<td style="text-align:left;">
J. Neurooncol.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
The high post-test probability of a cytological examination renders further investigations to establish a diagnosis of epithelial malignant pleural mesothelioma redundant.
</td>
<td style="text-align:left;">
Diagn. Cytopathol.
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Plasma and cerebrospinal fluid pharmacokinetics of pemetrexed after intravenous administration in non-human primates.
</td>
<td style="text-align:left;">
Cancer Chemother. Pharmacol.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Radiotherapy for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Cochrane Database Syst Rev
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
The diagnosis of malignancy in effusion cytology: a pattern recognition approach.
</td>
<td style="text-align:left;">
Adv Anat Pathol
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
p53-induced apoptosis occurs in the absence of p14(ARF) in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Neoplasia
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Promoter methylation of RASSF1A, RARbeta and DAPK predict poor prognosis of patients with malignant mesothelioma.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
The treatment of malignant mesothelioma of the pleura: review of a 5-year experience, with special reference to radiotherapy.
</td>
<td style="text-align:left;">
Am. J. Clin. Oncol.
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma: some aspects of epidemiology, differential diagnosis and prognosis. Histological and immunohistochemical evaluation and follow-up of mesotheliomas diagnosed from 1964 to January 1985.
</td>
<td style="text-align:left;">
Pathol. Res. Pract.
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant pleural mesothelioma: diagnosis, therapy and prognosis].
</td>
<td style="text-align:left;">
Schweiz. Rundsch. Med. Prax.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Factors affecting the mesothelioma detection rate within national and international epidemiological studies: insights from Scottish linked cancer registry-mortality data.
</td>
<td style="text-align:left;">
Br. J. Cancer
</td>
<td style="text-align:left;">
epidemiology
</td>
</tr>
<tr>
<td style="text-align:left;">
Diagnostic value of thoracoscopic pleural biopsy for pleurisy under local anaesthesia.
</td>
<td style="text-align:left;">
ANZ J Surg
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Animal models of malignant mesothelioma.
</td>
<td style="text-align:left;">
Inhal Toxicol
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Tumor suppressor gene alterations in patients with malignant mesothelioma due to environmental asbestos exposure in Turkey.
</td>
<td style="text-align:left;">
J Carcinog
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Effects of insulin-like growth factor-1 receptor inhibition in mesothelioma. Thoracic Surgery Directors Association Resident Research Award.
</td>
<td style="text-align:left;">
Ann. Thorac. Surg.
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Heterogeneous nuclear ribonucleoprotein B1 expression in malignant mesothelioma.
</td>
<td style="text-align:left;">
Cancer Sci.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Expression of “myelomonocytic” antigens in mesotheliomas and adenocarcinomas involving the serosal surfaces.
</td>
<td style="text-align:left;">
Am. J. Clin. Pathol.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
A molecular diagnostic test for distinguishing lung adenocarcinoma from malignant mesothelioma using cells collected from pleural effusions.
</td>
<td style="text-align:left;">
Clin. Cancer Res.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Asbestos-related disease from recycled hessian superphosphate bags in rural Western Australia.
</td>
<td style="text-align:left;">
Aust N Z J Public Health
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma masquerading as a multinodular bronchioloalveolar cell adenocarcinoma with widespread pulmonary nodules.
</td>
<td style="text-align:left;">
Int. J. Surg. Pathol.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Exclusive intrapulmonary lepidic growth of a malignant pleural mesothelioma presenting with pneumothorax and involving the peritoneum.
</td>
<td style="text-align:left;">
Int. J. Surg. Pathol.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma: a survival study.
</td>
<td style="text-align:left;">
J Surg Oncol
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleuroperitoneal shunt for recurrent malignant pleural effusions.
</td>
<td style="text-align:left;">
Thorax
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant mesothelioma–diagnosis and treatment strategies].
</td>
<td style="text-align:left;">
Gan To Kagaku Ryoho
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Portal site metastasis of invasive mesothelioma after diagnostic thoracoscopy in a dog.
</td>
<td style="text-align:left;">
J. Am. Vet. Med. Assoc.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
An atypical presentation of thymoma with diffuse pleural dissemination mimicking mesothelioma.
</td>
<td style="text-align:left;">
Cancer Invest.
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma of the pleura among seafarers.
</td>
<td style="text-align:left;">
Med Lav
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
[Recurrent pneumothorax as alone manifestation of mesothelioma pleurae].
</td>
<td style="text-align:left;">
Pneumonol Alergol Pol
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Biology and management of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Eur. J. Cancer
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Pemetrexed-induced edema of the eyelid.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Expression of Snail, Slug and Sip1 in malignant mesothelioma effusions is associated with matrix metalloproteinase, but not with cadherin expression.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Positron emission tomography predicts survival in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J. Thorac. Cardiovasc. Surg.
</td>
<td style="text-align:left;">
treatment | transmission | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[New challenges in thoracic surgery as exemplified in asbestos exposure and mesothelioma treatment].
</td>
<td style="text-align:left;">
Offentl Gesundheitswes
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleural mesothelioma: sensitivity and incidence of needle track seeding after image-guided biopsy versus surgical biopsy.
</td>
<td style="text-align:left;">
Radiology
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Mesothelioma after lung transplantation.
</td>
<td style="text-align:left;">
Thorax
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Early response evaluation in malignant pleural mesothelioma by positron emission tomography with [18F]fluorodeoxyglucose.
</td>
<td style="text-align:left;">
J. Clin. Oncol.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Pleural mesothelioma in cotton spinning workers].
</td>
<td style="text-align:left;">
Med Lav
</td>
<td style="text-align:left;">
epidemiology
</td>
</tr>
<tr>
<td style="text-align:left;">
Diagnosis of asbestos-related pleuropolmonary diseases.
</td>
<td style="text-align:left;">
Med Lav
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Extrapleural pneumonectomy in children.
</td>
<td style="text-align:left;">
J. Pediatr. Surg.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Phase I study of decitabine-mediated gene expression in patients with cancers involving the lungs, esophagus, or pleura.
</td>
<td style="text-align:left;">
Clin. Cancer Res.
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Sarcomatous pleural mesothelioma metastatic to left ventricular endocardium.
</td>
<td style="text-align:left;">
Angiology
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Establishment and characterization of five human malignant mesothelioma cell lines derived from pleural effusions.
</td>
<td style="text-align:left;">
Int. J. Cancer
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
5-year prospective results of trimodality treatment for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J Cardiovasc Surg (Torino)
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Unique uptake of acid-prepared mesoporous spheres by lung epithelial and mesothelioma cells.
</td>
<td style="text-align:left;">
Am. J. Respir. Cell Mol. Biol.
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Silencing the receptor EphA2 suppresses the growth and haptotaxis of malignant mesothelioma cells.
</td>
<td style="text-align:left;">
Cancer
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Distinguishing benign mesothelial hyperplasia from neoplasia: a practical approach.
</td>
<td style="text-align:left;">
Semin Diagn Pathol
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
The role of immunohistochemistry in distinguishing squamous cell carcinoma from mesothelioma and adenocarcinoma in pleural effusion.
</td>
<td style="text-align:left;">
Semin Diagn Pathol
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Use of mesothelin as a marker for mesothelial cells in cytologic specimens.
</td>
<td style="text-align:left;">
Semin Diagn Pathol
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Pathological recognition of diffuse malignant mesothelioma of the pleura: the significance of the historical perspective as regards this signal tumor.
</td>
<td style="text-align:left;">
Semin Diagn Pathol
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Spindle cell tumors of the pleura: differential diagnosis.
</td>
<td style="text-align:left;">
Semin Diagn Pathol
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
The pathogenesis of mesothelioma.
</td>
<td style="text-align:left;">
Semin Diagn Pathol
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
EGFR expression: associations with outcome and clinicopathological variables in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
The use of monoclonal antibody 44-3A6 in cell blocks in the diagnosis of lung carcinoma, carcinomas metastatic to lung and pleura, and pleural malignant mesothelioma.
</td>
<td style="text-align:left;">
Am. J. Clin. Pathol.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Feasibility of boron neutron capture therapy (BNCT) for malignant pleural mesothelioma from a viewpoint of dose distribution analysis.
</td>
<td style="text-align:left;">
Int. J. Radiat. Oncol. Biol. Phys.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma: a new standard of care.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Autocrine growth by granulocyte colony-stimulating factor in malignant mesothelioma.
</td>
<td style="text-align:left;">
Ann. Thorac. Surg.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Can pemetrexed help in malignant mesothelioma?
</td>
<td style="text-align:left;">
Drug Ther Bull
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Extrapleural pneumonectomy via a lower door open thoracotomy with reconstruction of the diaphragm and pericardium using autologous materials for mesothelioma.
</td>
<td style="text-align:left;">
Surg. Today
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Applications and limitations of immunohistochemistry in the diagnosis of malignant mesothelioma.
</td>
<td style="text-align:left;">
Adv Anat Pathol
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma: a comprehensive review.
</td>
<td style="text-align:left;">
Cancer Control
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Solitary fibrous tumor of the pleura.
</td>
<td style="text-align:left;">
Cancer Control
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Video-assisted diagnostic thoracoscopy].
</td>
<td style="text-align:left;">
Chirurg
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Mesothelioma with non-pleural malignancy: a red herring or just an uncommon pairing?
</td>
<td style="text-align:left;">
J Cardiothorac Surg
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Hyperthermia combined with intra-thoracic chemotherapy and radiotherapy for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Int J Hyperthermia
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Radiation-induced cellular DNA damage repair response enhances viral gene therapy efficacy in the treatment of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Ann. Surg. Oncol.
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma in a 14-year-old boy with right aortic arch.
</td>
<td style="text-align:left;">
Jpn. J. Thorac. Cardiovasc. Surg.
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
[Autopsy case of sarcomatoid malignant pleural mesothelioma].
</td>
<td style="text-align:left;">
Nihon Kokyuki Gakkai Zasshi
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
The Portsmouth thoracoscopy experience, an evaluation of service by retrospective case note analysis.
</td>
<td style="text-align:left;">
Respir Med
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Single-arm, open label study of pemetrexed plus cisplatin in chemotherapy naïve patients with malignant pleural mesothelioma: outcomes of an expanded access program.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Extension of liver tissue into the thorax following a right extrapleural pneumonectomy for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Ann Thorac Cardiovasc Surg
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Intracranial metastases from malignant pleural mesothelioma. Report of three autopsy cases and review of the literature.
</td>
<td style="text-align:left;">
Arch. Pathol. Lab. Med.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Immunocytochemical panel for the identification of malignant cells in serous effusions.
</td>
<td style="text-align:left;">
Am. J. Clin. Pathol.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
PET: other thoracic malignancies.
</td>
<td style="text-align:left;">
Cancer Imaging
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
The diagnostic utility of D2-40 for malignant mesothelioma versus pulmonary carcinoma with pleural involvement.
</td>
<td style="text-align:left;">
Diagn. Cytopathol.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
CT-guided percutaneous transthoracic biopsy in the evaluation of undetermined pulmonary lesions.
</td>
<td style="text-align:left;">
Rev Port Pneumol
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Immunocytochemical differential diagnosis of diffuse malignant pleural mesotheliomas–a clinicomorphological study of 158 cases.
</td>
<td style="text-align:left;">
Anticancer Res.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Atypical mesothelial hyperplasia associated with bronchogenic carcinoma.
</td>
<td style="text-align:left;">
Hum. Pathol.
</td>
<td style="text-align:left;">
epidemiology | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Guidelines of the French Speaking Society for Chest Medicine for management of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Respir Med
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[A case of malignant mesothelioma presenting with recurrent pneumothorax].
</td>
<td style="text-align:left;">
Nihon Kokyuki Gakkai Zasshi
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
In vivo loss of expression of argininosuccinate synthetase in malignant pleural mesothelioma is a biomarker for susceptibility to arginine depletion.
</td>
<td style="text-align:left;">
Clin. Cancer Res.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Efficacy and safety of first- or second-line irinotecan, cisplatin, and mitomycin in mesothelioma.
</td>
<td style="text-align:left;">
Cancer
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Sensitivity and specificity of immunohistochemical antibodies used to distinguish between benign and malignant pleural disease: a systematic review of published reports.
</td>
<td style="text-align:left;">
Histopathology
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Development of novel therapeutic strategies for lung cancer: targeting the cholinergic system.
</td>
<td style="text-align:left;">
Curr. Med. Chem.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
A retrospective analysis of malignant pleural mesothelioma patients treated either with chemotherapy or best supportive care between 1990 and 2005 A single institution experience.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
[Mortality and hospital discharges in the population of Biancavilla (Sicily) contaminated by natural fibres].
</td>
<td style="text-align:left;">
Epidemiol Prev
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Pemetrexed disodium for the treatment of malignant pleural mesothelioma: a systematic review and economic evaluation.
</td>
<td style="text-align:left;">
Health Technol Assess
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Prolonged survival due to spontaneous regression and surgical excision of malignant mesothelioma.
</td>
<td style="text-align:left;">
Ann. Thorac. Surg.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
A phase II study of intrapleural immuno-chemotherapy, pleurectomy/decortication, radiotherapy, systemic chemotherapy and long-term sub-cutaneous IL-2 in stage II-III malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Eur J Cardiothorac Surg
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Immunohistochemical detection of GLUT-1 can discriminate between reactive mesothelium and malignant mesothelioma.
</td>
<td style="text-align:left;">
Mod. Pathol.
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Impact of lymph node metastasis on outcome after extrapleural pneumonectomy for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J. Thorac. Cardiovasc. Surg.
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Thoracic stop-flow perfusion in the treatment of refractory malignant pleural mesothelioma: a phase I-II evaluation/trial.
</td>
<td style="text-align:left;">
In Vivo
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
The role of palliative radiotherapy in malignant mesothelioma.
</td>
<td style="text-align:left;">
Clin Oncol (R Coll Radiol)
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Expression of vascular endothelial growth factor in malignant mesothelioma.
</td>
<td style="text-align:left;">
Anticancer Res.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Cluster of malignant mesothelioma cases in a thermostat manufacturing industry].
</td>
<td style="text-align:left;">
Med Lav
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Kallikrein 4 is expressed in malignant mesothelioma–further evidence for the histogenetic link between mesothelial and epithelial cells.
</td>
<td style="text-align:left;">
Diagn. Cytopathol.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Metastatic malignant pleural mesothelioma to the breast.
</td>
<td style="text-align:left;">
South. Med. J.
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
[Immunotherapy and malignant mesothelioma: clinical perspectives].
</td>
<td style="text-align:left;">
Bull Cancer
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant pleural cancers mortality and compensated cases for asbestos related diseases in Lazio municipalities (1980-2001)].
</td>
<td style="text-align:left;">
Med Lav
</td>
<td style="text-align:left;">
epidemiology
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma: a case presentation and review.
</td>
<td style="text-align:left;">
J Am Osteopath Assoc
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Histopathologic diagnosis of malignant pleural mesothelioma].
</td>
<td style="text-align:left;">
Kyobu Geka
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Clinical diagnosis of malignant pleural mesothelioma].
</td>
<td style="text-align:left;">
Kyobu Geka
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
[Current problems in the diagnosis of malignant pleural mesothelioma].
</td>
<td style="text-align:left;">
Kyobu Geka
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Survey of surgical treatment of malignant pleural mesothelioma in Japan].
</td>
<td style="text-align:left;">
Kyobu Geka
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
[Preoperative assessment and surgical indication for malignant pleural mesothelioma].
</td>
<td style="text-align:left;">
Kyobu Geka
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant pleural mesothelioma].
</td>
<td style="text-align:left;">
Kyobu Geka
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Diffuse malignant pleural mesothelioma].
</td>
<td style="text-align:left;">
Kyobu Geka
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Extrapleural pneumonectomy for malignant pleural mesothelioma].
</td>
<td style="text-align:left;">
Kyobu Geka
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
[Extrapleural pneumonectomy with wide resection of the chest wall, diaphragm, and pericardium for malignant pleural mesothelioma].
</td>
<td style="text-align:left;">
Kyobu Geka
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Talc mediates angiostasis in malignant pleural effusions via endostatin induction.
</td>
<td style="text-align:left;">
Eur. Respir. J.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Pemetrexed disodium in combination with cisplatin versus other cytotoxic agents or supportive care for the treatment of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Cochrane Database Syst Rev
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Expression patterns of inhibitor of apoptosis proteins in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J. Pathol.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Inhibitor of apoptosis proteins are regulated by tumour necrosis factor-alpha in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J. Pathol.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
[Clinical types of thoracic cancer. Pleural mesothelioma].
</td>
<td style="text-align:left;">
Rev Mal Respir
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Morphological aspects as prognostic factors in malignant mesothelioma: a study of 58 cases.
</td>
<td style="text-align:left;">
J Bras Pneumol
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma with scalp, cerebellar, and finger metastases: a rare case.
</td>
<td style="text-align:left;">
South. Med. J.
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Genomic profiling of malignant pleural mesothelioma with array-based comparative genomic hybridization shows frequent non-random chromosomal alteration regions including JUN amplification on 1p32.
</td>
<td style="text-align:left;">
Cancer Sci.
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Clinico-pathological features and somatic gene alterations in refractory ceramic fibre-induced murine mesothelioma reveal mineral fibre-induced mesothelioma identities.
</td>
<td style="text-align:left;">
Carcinogenesis
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Novel marker D2-40, combined with calretinin, CEA, and TTF-1: an optimal set of immunodiagnostic markers for pleural mesothelioma.
</td>
<td style="text-align:left;">
Cancer
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant peritoneal mesothelioma].
</td>
<td style="text-align:left;">
Chirurgia (Bucur)
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
MESOMARK: a potential test for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Clin. Chem.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Polymorphisms of glutathione-S-transferase M1 and manganese superoxide dismutase are associated with the risk of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Int. J. Cancer
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Restored expression of the MYO18B gene suppresses orthotopic growth and the production of bloody pleural effusion by human malignant pleural mesothelioma cells in SCID mice.
</td>
<td style="text-align:left;">
Oncol. Res.
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
[Expanded access program in the United States and Alimta program for malignant mesothelioma patients].
</td>
<td style="text-align:left;">
Gan To Kagaku Ryoho
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Preliminary data suggestive of a novel translational approach to mesothelioma treatment: imatinib mesylate with gemcitabine or pemetrexed.
</td>
<td style="text-align:left;">
Thorax
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
A novel small-molecule inhibitor of transforming growth factor beta type I receptor kinase (SM16) inhibits murine mesothelioma tumor growth in vivo and prevents tumor recurrence after surgical resection.
</td>
<td style="text-align:left;">
Cancer Res.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Molecular basis of antifolate resistance.
</td>
<td style="text-align:left;">
Cancer Metastasis Rev.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Detection of SS18-SSX fusion transcripts in formalin-fixed paraffin-embedded neoplasms: analysis of conventional RT-PCR, qRT-PCR and dual color FISH as diagnostic tools for synovial sarcoma.
</td>
<td style="text-align:left;">
Mod. Pathol.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Case-control study between extrapleural pneumonectomy and radical pleurectomy/decortication for pathological N2 malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Eur J Cardiothorac Surg
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Palliative intravenous cisplatin treatment for concurrent peritoneal and pleural mesothelioma in a dog.
</td>
<td style="text-align:left;">
J. Vet. Med. Sci.
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Clonal chromosome abnormalities in a case of pleural mesothelioma].
</td>
<td style="text-align:left;">
Arch Sci Med (Torino)
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
[Immunohistochemistry and surgical approaches in solitary fibrous tumor of the pleura].
</td>
<td style="text-align:left;">
Cir Esp
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Expression of inhibitor-of-apoptosis protein family members in malignant mesothelioma.
</td>
<td style="text-align:left;">
Hum. Pathol.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Right extrapleural pneumonectomy for malignant mesothelioma via median sternotomy or thoracotomy? Short- and long-term results.
</td>
<td style="text-align:left;">
Eur J Cardiothorac Surg
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Local recurrence model of malignant pleural mesothelioma for investigation of intrapleural treatment.
</td>
<td style="text-align:left;">
Eur J Cardiothorac Surg
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Primary pleural epithelioid hemangioendothelioma with rhabdoid phenotype: report and review of the literature.
</td>
<td style="text-align:left;">
Diagn. Cytopathol.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Clinico-pathological prognostic factors in malignant pleural mesothelioma].
</td>
<td style="text-align:left;">
Nihon Kokyuki Gakkai Zasshi
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Stathmin is overexpressed in malignant mesothelioma.
</td>
<td style="text-align:left;">
Anticancer Res.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Emerging drugs for mesothelioma.
</td>
<td style="text-align:left;">
Expert Opin Emerg Drugs
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Soluble mesothelin in effusions: a useful tool for the diagnosis of malignant mesothelioma.
</td>
<td style="text-align:left;">
Thorax
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Expression of the proliferation-associated Ki-67 antigen of transferrin receptors and of DNA polymerase alpha in human tumour lines: implications for in vitro chemoresistance.
</td>
<td style="text-align:left;">
J. Cancer Res. Clin. Oncol.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
The role of radiotherapy in the treatment of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Clin Oncol (R Coll Radiol)
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
D2-40 and calretinin - a tissue microarray analysis of 341 malignant mesotheliomas with emphasis on sarcomatoid differentiation.
</td>
<td style="text-align:left;">
Mod. Pathol.
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Biphasic malignant mesothelioma cases with osseous differentiation and long survival: a review of the literature.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Myasthenia gravis in ectopic thymoma presenting as pleural masses.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Computed tomographic assessment of patients following radical surgery for malignant mesothelioma.
</td>
<td style="text-align:left;">
Clin Radiol
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Asbestos-related lung disease.
</td>
<td style="text-align:left;">
Am Fam Physician
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Cytological diagnosis of malignant mesothelioma–improvement by additional analysis of hyaluronic acid in pleural effusions.
</td>
<td style="text-align:left;">
Virchows Arch.
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Assessment of asbestos in drinking water in alexandria, egypt.
</td>
<td style="text-align:left;">
J Egypt Public Health Assoc
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Taurolidine and povidone-iodine induce different types of cell death in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Retroperitoneal malignant schwannoma and peritoneal malignant mesothelioma: a case report.
</td>
<td style="text-align:left;">
J BUON
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
A case of malignant mesothelioma in a rice-starch factory.
</td>
<td style="text-align:left;">
Int Arch Occup Environ Health
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Can serum inflammatory parameters estimate outcome of pleurodesis in mesothelioma?
</td>
<td style="text-align:left;">
ANZ J Surg
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Medical thoracoscopy in an Australian regional hospital.
</td>
<td style="text-align:left;">
Intern Med J
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Value of antimesothelioma HBME-1 in the diagnosis of inflammatory and malignant pleural effusions.
</td>
<td style="text-align:left;">
Rom J Morphol Embryol
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Non-occupational malignant pleural mesothelioma due to asbestos and non-asbestos fibres.
</td>
<td style="text-align:left;">
Monaldi Arch Chest Dis
</td>
<td style="text-align:left;">
epidemiology
</td>
</tr>
<tr>
<td style="text-align:left;">
Asbestos-related diseases of the lungs and pleura: uses, trends and management over the last century.
</td>
<td style="text-align:left;">
Int. J. Tuberc. Lung Dis.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Inhibition of survivin and aurora B kinase sensitizes mesothelioma cells by enhancing mitotic arrests.
</td>
<td style="text-align:left;">
Int. J. Radiat. Oncol. Biol. Phys.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma: two cases in first degree relatives.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Induction chemotherapy, extrapleural pneumonectomy (EPP) and adjuvant hemi-thoracic radiation in malignant pleural mesothelioma (MPM): Feasibility and results.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Mesothelioma in blood related subjects: report of 11 clusters among 1954 Italy cases and review of the literature.
</td>
<td style="text-align:left;">
Am. J. Ind. Med.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Phase II trial of pralatrexate (10-propargyl-10-deazaaminopterin, PDX) in patients with unresectable malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Pemetrexed maintenance therapy in patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Induction chemotherapy, extrapleural pneumonectomy, and postoperative high-dose radiotherapy for locally advanced malignant pleural mesothelioma: a phase II trial.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Pemetrexed alone or in combination with cisplatin in previously treated malignant pleural mesothelioma: outcomes from a phase IIIB expanded access program.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
The use of chemotherapy in patients with advanced malignant pleural mesothelioma: a systematic review and practice guideline.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Targeting mesothelioma using an infectivity enhanced survivin-conditionally replicative adenoviruses.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Pemetrexed as second-line treatment in malignant pleural mesothelioma after platinum-based first-line treatment.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Four-modality therapy in malignant pleural mesothelioma: a phase II study.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Diagnostic procedures of pleural malignant mesothelioma: our experience.
</td>
<td style="text-align:left;">
J BUON
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Fine-needle aspiration of malignant mesothelioma with unusual morphologic features: a case report.
</td>
<td style="text-align:left;">
Diagn. Cytopathol.
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
[A case of malignant pleural mesothelioma with elevation of G-CSF and CYFRA in the serum and pleural fluid].
</td>
<td style="text-align:left;">
Nihon Kokyuki Gakkai Zasshi
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Catheter-tract metastases associated with chronic indwelling pleural catheters.
</td>
<td style="text-align:left;">
Chest
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Multicenter trial of neo-adjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Ann. Oncol.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Treatment of malignant pleural mesothelioma].
</td>
<td style="text-align:left;">
Gan To Kagaku Ryoho
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Potential role of ferritin heavy chain in oxidative stress and apoptosis in human mesothelial and mesothelioma cells: implications for asbestos-induced oncogenesis.
</td>
<td style="text-align:left;">
Carcinogenesis
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
A large abdominal wall mass as an initial manifestation of malignant mesothelioma.
</td>
<td style="text-align:left;">
Am. J. Med. Sci.
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Chemokine receptors are infrequently expressed in malignant and benign mesothelial cells.
</td>
<td style="text-align:left;">
Am. J. Clin. Pathol.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Late-onset chylothorax following extrapleural pneumonectomy for mesothelioma.
</td>
<td style="text-align:left;">
Gen Thorac Cardiovasc Surg
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Superior vena cava syndrome associated with malignant mesothelioma.
</td>
<td style="text-align:left;">
J La State Med Soc
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Immunocytochemistry of malignant mesothelioma: OV632 as a marker of malignant mesothelioma.
</td>
<td style="text-align:left;">
J. Pathol.
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma with intracytoplasmic crystalline inclusions.
</td>
<td style="text-align:left;">
Ultrastruct Pathol
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma of the pleura and other malignancies in the same patient.
</td>
<td style="text-align:left;">
Tumori
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Lymphohistiocytoid variant of malignant mesothelioma of the pleura: a series of 22 cases.
</td>
<td style="text-align:left;">
Am. J. Surg. Pathol.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Sequence-dependent administration of raloxifene and 5-fluorouracil/pemetrexed protects against pemetrexed cytotoxicity in human bone marrow.
</td>
<td style="text-align:left;">
Anticancer Res.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Dose-dependent pulmonary toxicity after postoperative intensity-modulated radiotherapy for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Int. J. Radiat. Oncol. Biol. Phys.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma following thoracic radiotherapy for lung cancer.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Mesothelin family proteins and diagnosis of mesothelioma: analytical evaluation of an automated immunoassay and preliminary clinical results.
</td>
<td style="text-align:left;">
Clin. Chem. Lab. Med.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Computer-assisted diagnosis for early stage pleural mesothelioma: towards automated detection and quantitative assessment of pleural thickening from thoracic CT images.
</td>
<td style="text-align:left;">
Methods Inf Med
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Osteopontin is linked to p65 and MMP-9 expression in pulmonary adenocarcinoma but not in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Histopathology
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Diagnostic utility of D2-40 and podoplanin in effusion cell blocks.
</td>
<td style="text-align:left;">
Diagn. Cytopathol.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Sudden death of an elderly man with multiple malignant neoplasms.
</td>
<td style="text-align:left;">
Am J Forensic Med Pathol
</td>
<td style="text-align:left;">
epidemiology | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Utility of osteopontin and serum mesothelin in malignant pleural mesothelioma diagnosis and prognosis assessment.
</td>
<td style="text-align:left;">
Clin. Cancer Res.
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
The diagnostic role of claudins in serous effusions.
</td>
<td style="text-align:left;">
Am. J. Clin. Pathol.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Low prevalence of SV40 in Swiss mesothelioma patients after elimination of false-positive PCR results.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
A preliminary experimental study of boron neutron capture therapy for malignant tumors spreading in thoracic cavity.
</td>
<td style="text-align:left;">
Jpn. J. Clin. Oncol.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Severe cutaneous toxicity after Pemetrexed as second line treatment for a refractory non small cell lung cancer].
</td>
<td style="text-align:left;">
Rev Mal Respir
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Management options for malignant pleural mesothelioma: clinical and cost considerations.
</td>
<td style="text-align:left;">
Drugs
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Preclinical studies of the proteasome inhibitor bortezomib in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Cancer Chemother. Pharmacol.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Evidence-based guidelines for the utilization of immunostains in diagnostic pathology: pulmonary adenocarcinoma versus mesothelioma.
</td>
<td style="text-align:left;">
Appl. Immunohistochem. Mol. Morphol.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
The risk of mesothelioma from exposure to chrysotile asbestos.
</td>
<td style="text-align:left;">
Curr Opin Pulm Med
</td>
<td style="text-align:left;">
epidemiology | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Local adoptive immunotherapy using lymphokine-activated killer cells and interleukin-2 against malignant pleural mesothelioma: report of two cases.
</td>
<td style="text-align:left;">
Jpn. J. Clin. Oncol.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma: current concepts in treatment.
</td>
<td style="text-align:left;">
Nat Clin Pract Oncol
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
MN/CA9: a potential gene marker for detection of malignant cells in effusions.
</td>
<td style="text-align:left;">
Biomarkers
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Recent discovery of an old disease: malignant pleural mesothelioma in a village in south-east Turkey.
</td>
<td style="text-align:left;">
Respirology
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[A comparative evaluation of immunohistochemical markers for the differential diagnosis between malignant mesothelioma, non-small cell carcinoma involving the pleura, and benign reactive mesothelial cell proliferation].
</td>
<td style="text-align:left;">
Pneumonol Alergol Pol
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Solitary fibrous tumor of the mediastinum.
</td>
<td style="text-align:left;">
Ultrastruct Pathol
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Phase II study of erlotinib in patients with malignant pleural mesothelioma: a Southwest Oncology Group Study.
</td>
<td style="text-align:left;">
J. Clin. Oncol.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Effect of the TAT-RasGAP(317-326) peptide on apoptosis of human malignant mesothelioma cells and fibroblasts exposed to meso-tetra-hydroxyphenyl-chlorin and light.
</td>
<td style="text-align:left;">
J. Photochem. Photobiol. B, Biol.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Pseudomesotheliomatous carcinoma of the lung. A variant of peripheral lung cancer.
</td>
<td style="text-align:left;">
Am. J. Clin. Pathol.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
The essential role of the mitochondria and reactive oxygen species in Cisplatin-mediated enhancement of fas ligand-induced apoptosis in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J. Surg. Res.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Establishment and characterization of two distinct malignant mesothelioma cell lines with common clonal origin.
</td>
<td style="text-align:left;">
Cancer Genet. Cytogenet.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Management of malignant pleural effusion].
</td>
<td style="text-align:left;">
Rev Prat
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
A randomised controlled trial of intervention site radiotherapy in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Radiother Oncol
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma: King Faisal Specialist Hospital and Research Centre experience.
</td>
<td style="text-align:left;">
Ann Saudi Med
</td>
<td style="text-align:left;">
epidemiology
</td>
</tr>
<tr>
<td style="text-align:left;">
[Peritoneal mesothelioma: an inusual clinical presentation in a patient without exposure to asbestos].
</td>
<td style="text-align:left;">
An Med Interna
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant mesothelioma of the pleura in a truck driver].
</td>
<td style="text-align:left;">
Med Lav
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Constrictive pericarditis after left extrapleural pneumonectomy and radiotherapy for malignant mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Evaluation of simian virus-40 as a biological prognostic factor in Egyptian patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Pathol. Int.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Inhibition of c-Src expression and activation in malignant pleural mesothelioma tissues leads to apoptosis, cell cycle arrest, and decreased migration and invasion.
</td>
<td style="text-align:left;">
Mol. Cancer Ther.
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Trousseau syndrome due to pleural mesothelioma.
</td>
<td style="text-align:left;">
Neurologist
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
[Pseudomesotheliomatous carcinoma of the lung].
</td>
<td style="text-align:left;">
Kyobu Geka
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Combined CA125 and mesothelin levels for the diagnosis of malignant mesothelioma.
</td>
<td style="text-align:left;">
Chest
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
DNA methylation profile of 28 potential marker loci in malignant mesothelioma.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Intradural pleural malignant mesothelioma.
</td>
<td style="text-align:left;">
Acta Neurochir (Wien)
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
[Case of asbestosis with massive benign pleural involvement].
</td>
<td style="text-align:left;">
Med Tr Prom Ekol
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma presenting as a lip tumor: report of two cases with one unrecognized by 166 pathologists.
</td>
<td style="text-align:left;">
Am J Dermatopathol
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma: outcome of limited surgical management.
</td>
<td style="text-align:left;">
Interact Cardiovasc Thorac Surg
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Polyhematoporphyrin-mediated photodynamic therapy and decortication in palliation of malignant pleural mesothelioma: a clinical pilot study.
</td>
<td style="text-align:left;">
Interact Cardiovasc Thorac Surg
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Extended posterolateral-subcostal thoracotomy for extrapleural pneumonectomy: a surgical approach for radical operation of pleural mesothelioma.
</td>
<td style="text-align:left;">
Interact Cardiovasc Thorac Surg
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
The MARS trial: mesothelioma and radical surgery.
</td>
<td style="text-align:left;">
Interact Cardiovasc Thorac Surg
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
A phase I clinical trial of single-dose intrapleural IFN-beta gene transfer for malignant pleural mesothelioma and metastatic pleural effusions: high rate of antitumor immune responses.
</td>
<td style="text-align:left;">
Clin. Cancer Res.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Multidisciplinary treatment of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Oncologist
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Influence of radiotherapy technique and dose on patterns of failure for mesothelioma patients after extrapleural pneumonectomy.
</td>
<td style="text-align:left;">
Int. J. Radiat. Oncol. Biol. Phys.
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
D2-40-positive solitary fibrous tumors of the pleura: diagnostic pitfall of biopsy specimen.
</td>
<td style="text-align:left;">
Pathol. Int.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Optimising survival in malignant mesothelioma.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Accuracy and reproducibility of pleural effusion cytology.
</td>
<td style="text-align:left;">
Leg Med (Tokyo)
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Early prediction of response to chemotherapy and survival in malignant pleural mesothelioma using a novel semiautomated 3-dimensional volume-based analysis of serial 18F-FDG PET scans.
</td>
<td style="text-align:left;">
J. Nucl. Med.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[The prospects for the appearance of pleural mesothelioma in Italy].
</td>
<td style="text-align:left;">
Med Lav
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Phase II testing of sunitinib: the National Cancer Institute of Canada Clinical Trials Group IND Program Trials IND.182-185.
</td>
<td style="text-align:left;">
Curr Oncol
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Localized malignant mesothelioma of the pleura.
</td>
<td style="text-align:left;">
Ann Thorac Cardiovasc Surg
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Incidence trends and gender differences in malignant mesothelioma in New South Wales, Australia.
</td>
<td style="text-align:left;">
Scand J Work Environ Health
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Use of aprotinin in extrapleural pneumonectomy: effect on hemostasis and incidence of complications.
</td>
<td style="text-align:left;">
Ann. Thorac. Surg.
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
[Family mesotheliomas: genetic interaction with environmental carcinogenic exposure?].
</td>
<td style="text-align:left;">
Bull Cancer
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
[Clinical utility of thoracoscopy under local anesthesia].
</td>
<td style="text-align:left;">
Kyobu Geka
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Assessment of tumor response in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Cancer Treat. Rev.
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Mitoxantrone in malignant pleural mesothelioma: a study by the EORTC Lung Cancer Cooperative Group.
</td>
<td style="text-align:left;">
Eur. J. Cancer
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Correlations between findings at computed tomography (CT) and at thoracoscopy/thoracotomy/autopsy in pleural mesothelioma.
</td>
<td style="text-align:left;">
Eur. Respir. J.
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Update of pemetrexed in thoracic oncology].
</td>
<td style="text-align:left;">
Bull Cancer
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
[Pemetrexed development in oncology].
</td>
<td style="text-align:left;">
Bull Cancer
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
SV40 multiple tissue infection and asbestos exposure in a hyperendemic area for malignant mesothelioma.
</td>
<td style="text-align:left;">
Cancer Res.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
[Differential diagnosis of pleurisy of tuberculous etiology].
</td>
<td style="text-align:left;">
Probl Tuberk
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Accuracy of pleural biopsy using thoracoscopy for the diagnosis of histologic subtype in patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Cancer
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Apparent spontaneous complete regression of a multifocal malignant mesothelioma of the pleura.
</td>
<td style="text-align:left;">
Med. J. Aust.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
The therapeutic efficacy of anti vascular endothelial growth factor antibody, bevacizumab, and pemetrexed against orthotopically implanted human pleural mesothelioma cells in severe combined immunodeficient mice.
</td>
<td style="text-align:left;">
Clin. Cancer Res.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Prognostic factors in the treatment of malignant pleural mesothelioma at a large tertiary referral center.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mediastinal tumor with bone formation–mesothelioma or sarcoma?
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Primary pleural thymoma with coexistent incidental small hepatocellular carcinoma - an autopsy case report with brief review of literature.
</td>
<td style="text-align:left;">
Pathol. Res. Pract.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
The value of calretinin and cytokeratin 5/6 as markers for mesothelioma in cell block preparations of serous effusions.
</td>
<td style="text-align:left;">
Cytopathology
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma of the tunica vaginalis testis: a case report and review of the literature.
</td>
<td style="text-align:left;">
Med. Oncol.
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Retreatment with pemetrexed-based chemotherapy in malignant pleural mesothelioma (MPM): a second line treatment option.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Gene methylation in pleural mesothelioma: correlations with clinico-pathological features and patient’s follow-up.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Role of DNA microarrays in the diagnosis of pleural exudates: a feasibility study].
</td>
<td style="text-align:left;">
Rev Mal Respir
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
The incidence of malignant mesothelioma in Australia 1982-1988.
</td>
<td style="text-align:left;">
Am. J. Ind. Med.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Combined photon and electron three-dimensional conformal versus intensity-modulated radiotherapy with integrated boost for adjuvant treatment of malignant pleural mesothelioma after pleuropneumonectomy.
</td>
<td style="text-align:left;">
Int. J. Radiat. Oncol. Biol. Phys.
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Non-invasive diagnosis of pleural malignancies: the role of tumour markers.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Cancer mortality and incidence of mesothelioma in a cohort of wives of asbestos workers in Casale Monferrato, Italy.
</td>
<td style="text-align:left;">
Environ. Health Perspect.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Mesothelin targeted cancer immunotherapy.
</td>
<td style="text-align:left;">
Eur. J. Cancer
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Phase II study of vinflunine in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J. Clin. Oncol.
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Immunohistochemical detection of XIAP in mesothelium and mesothelial lesions.
</td>
<td style="text-align:left;">
Am. J. Clin. Pathol.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Increased pleural fluid adenosine deaminase levels in patients with malignant pleural effusions: a potential predictor of talc pleurodesis outcome.
</td>
<td style="text-align:left;">
Lung
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Human agonistic TRAIL receptor antibodies Mapatumumab and Lexatumumab induce apoptosis in malignant mesothelioma and act synergistically with cisplatin.
</td>
<td style="text-align:left;">
Mol. Cancer
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Morphologic and functional imaging of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Eur J Radiol
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Outcomes after extrapleural pneumonectomy and intensity-modulated radiation therapy for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Ann. Thorac. Surg.
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Localized malignant pleural mesothelioma treated by a curative intent lobectomy: a case report.
</td>
<td style="text-align:left;">
Ann Thorac Cardiovasc Surg
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Peritoneal mesothelioma: a review.
</td>
<td style="text-align:left;">
MedGenMed
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Low-dose computed tomography screening for lung cancer and pleural mesothelioma in an asbestos-exposed population: baseline results of a prospective, nonrandomized feasibility trial–an Alpe-adria Thoracic Oncology Multidisciplinary Group Study (ATOM 002).
</td>
<td style="text-align:left;">
Oncologist
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Peritoneal mesothelioma presenting as an acute surgical abdomen due to jejunal perforation.
</td>
<td style="text-align:left;">
J Dig Dis
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Flowcytometric immunophenotyping of peripheral-blood leukocytes in relation to immunopathology and cellular proliferation of pleural mesothelioma.
</td>
<td style="text-align:left;">
Egypt J Immunol
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Novel expression of kallikreins, kallikrein-related peptidases and kinin receptors in human pleural mesothelioma.
</td>
<td style="text-align:left;">
Biol. Chem.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Analysis of latency time and its determinants in asbestos related malignant mesothelioma cases of the Italian register.
</td>
<td style="text-align:left;">
Eur. J. Cancer
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Pseudomesotheliomatous adenocarcinoma of the lung with synchronous gastric and esophageal cancer.
</td>
<td style="text-align:left;">
Australas Radiol
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Gemcitabine and cisplatin in unresectable malignant mesothelioma of the pleura: a phase II study of the Southwest Oncology Group (SWOG 9810).
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
MUC4 is upregulated in ovarian carcinoma effusions and differentiates carcinoma cells from mesothelial cells.
</td>
<td style="text-align:left;">
Diagn. Cytopathol.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Immunohistochemical expression and distribution of VEGFR-3 in malignant mesothelioma.
</td>
<td style="text-align:left;">
Diagn. Cytopathol.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Asbestos content in bronchoalveolar lavage fluid].
</td>
<td style="text-align:left;">
Zentralbl Hyg Umweltmed
</td>
<td style="text-align:left;">
transmission
</td>
</tr>
<tr>
<td style="text-align:left;">
Dedifferentiated liposarcoma of the pleura mimicking a malignant solitary fibrous tumor and associated with dedifferentiated liposarcoma of the mediastinum: usefulness of cytogenetic and molecular genetic analyses.
</td>
<td style="text-align:left;">
Cancer Genet. Cytogenet.
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Role of fragile histidine triad protein expression in pathogenesis of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Pathology
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Solitary fibrous tumor of the anterior mediastinum: a rare extrapleural neoplasm.
</td>
<td style="text-align:left;">
Tumori
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Mortality of former crocidolite (blue asbestos) miners and millers at Wittenoom.
</td>
<td style="text-align:left;">
Occup Environ Med
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Reactivity of integrin-linked kinase in human mesothelial cell proliferation.
</td>
<td style="text-align:left;">
Interact Cardiovasc Thorac Surg
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Radical surgery for malignant pleural mesothelioma: results and prognosis.
</td>
<td style="text-align:left;">
Interact Cardiovasc Thorac Surg
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
[The epidemiologic surveillance of malignant mesothelioma in the Lower Iseo Lake area].
</td>
<td style="text-align:left;">
Epidemiol Prev
</td>
<td style="text-align:left;">
epidemiology
</td>
</tr>
<tr>
<td style="text-align:left;">
[Epidemiological surveillance of malignant mesothelioma cases in Italy: incidence and asbestos exposure figures by the Italian mesothelioma registry (ReNaM)].
</td>
<td style="text-align:left;">
Epidemiol Prev
</td>
<td style="text-align:left;">
epidemiology | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Asbestos exposure in the non-asbestos textile industry: the experience of the Lombardy Mesothelioma Registry].
</td>
<td style="text-align:left;">
Epidemiol Prev
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Renal cell carcinoma with malignant pleural mesothelioma after asbestos exposure: a case report].
</td>
<td style="text-align:left;">
Hinyokika Kiyo
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
The role of video assisted thoracoscopic pleurectomy/decortication in the therapeutic management of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Eur J Cardiothorac Surg
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
The potential role of pemetrexed in gastrointestinal cancer.
</td>
<td style="text-align:left;">
Chemotherapy
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Proaggregating and procoagulant activities of human mesothelioma tumor cells at different stages of “in vitro” culture.
</td>
<td style="text-align:left;">
Haematologica
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Endoscopic ultrasound-guided fine needle aspiration is useful for nodal staging in patients with pleural mesothelioma.
</td>
<td style="text-align:left;">
Diagn. Cytopathol.
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Utility of WT-1, p63, MOC31, mesothelin, and cytokeratin (K903 and CK5/6) immunostains in differentiating adenocarcinoma, squamous cell carcinoma, and malignant mesothelioma in effusions.
</td>
<td style="text-align:left;">
Diagn. Cytopathol.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Fine needle aspiration of follicular variant of papillary thyroid carcinoma presenting with pleural effusion: a case report.
</td>
<td style="text-align:left;">
Acta Cytol.
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Integrated FDG PET-CT imaging improves staging in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Nuklearmedizin
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
EGFR and PDGFR differentially promote growth in malignant epithelioid mesothelioma of short and long term survivors.
</td>
<td style="text-align:left;">
Thorax
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Symptoms and patient-reported well-being: do they predict survival in malignant pleural mesothelioma? A prognostic factor analysis of EORTC-NCIC 08983: randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J. Clin. Oncol.
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Absence of evidence for a significant background incidence of diffuse malignant mesothelioma apart from asbestos exposure.
</td>
<td style="text-align:left;">
Ann. N. Y. Acad. Sci.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Analysis of asbestos fibers in lung parenchyma, pleural plaques, and mesothelioma tissues of North American insulation workers.
</td>
<td style="text-align:left;">
Ann. N. Y. Acad. Sci.
</td>
<td style="text-align:left;">
transmission | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Asbestos-associated pleural mesothelioma in school teachers: a discussion of four cases.
</td>
<td style="text-align:left;">
Ann. N. Y. Acad. Sci.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Asbestos related diseases in Italy: an integrated approach to identify unexpected professional or environmental exposure risks at municipal level.
</td>
<td style="text-align:left;">
Int Arch Occup Environ Health
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Utility of anti-L523S antibody in the diagnosis of benign and malignant serous effusions.
</td>
<td style="text-align:left;">
Cancer
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma: surgical management in 285 patients.
</td>
<td style="text-align:left;">
Ann. Thorac. Surg.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Soluble mesothelin-related peptide level elevation in mesothelioma serum and pleural effusions.
</td>
<td style="text-align:left;">
Ann. Thorac. Surg.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Localised malignant pleural mesothelioma: a separate clinical entity requiring aggressive local surgery.
</td>
<td style="text-align:left;">
Eur J Cardiothorac Surg
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Phase II study of pemetrexed in combination with carboplatin in patients with malignant pleural mesothelioma (MPM).
</td>
<td style="text-align:left;">
Ann. Oncol.
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Gene copy number analysis in malignant pleural mesothelioma using oligonucleotide array CGH.
</td>
<td style="text-align:left;">
Cytogenet. Genome Res.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma: clinicopathologic and survival characteristics in a consecutive series of 394 patients.
</td>
<td style="text-align:left;">
Eur J Cardiothorac Surg
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant pleural mesothelioma: interrogations and hopes concerning the expected epidemic].
</td>
<td style="text-align:left;">
Rev Pneumol Clin
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Aberrant splicing and protease involvement in mesothelin release from epithelioid mesothelioma cells.
</td>
<td style="text-align:left;">
Cancer Sci.
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Environmental mesothelioma associated with tremolite asbestos: lessons from the experiences of Turkey, Greece, Corsica, New Caledonia and Cyprus.
</td>
<td style="text-align:left;">
Regul. Toxicol. Pharmacol.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Presence of malignant mesothelial cells in the sputum.
</td>
<td style="text-align:left;">
Intern. Med.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Cytologic malignancy versus benignancy: how useful are the “newer” markers in body fluid cytology?
</td>
<td style="text-align:left;">
Arch. Pathol. Lab. Med.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Twenty-five years of fiber analysis: what have we learned?
</td>
<td style="text-align:left;">
Hum. Pathol.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Helical tomotherapy. Experiences of the first 150 patients in Heidelberg.
</td>
<td style="text-align:left;">
Strahlenther Onkol
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Anesthetic management of patients undergoing extrapleural pneumonectomy for mesothelioma.
</td>
<td style="text-align:left;">
Curr Opin Anaesthesiol
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Epidemiology of pleural mesothelioma in a population with non-occupational asbestos exposure.
</td>
<td style="text-align:left;">
Respirology
</td>
<td style="text-align:left;">
epidemiology
</td>
</tr>
<tr>
<td style="text-align:left;">
Population based epidemiology and prognosis of mesothelioma in Leeds, UK.
</td>
<td style="text-align:left;">
Thorax
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Tissue inhibitor of metalloproteinase 2 (TIMP-2) expression in adenocarcinoma pleural effusions.
</td>
<td style="text-align:left;">
Oncol. Rep.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Recurrent hydropneumothorax as a presenting feature of malignant mesothelioma.
</td>
<td style="text-align:left;">
Eur. J. Intern. Med.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Evaluating target coverage and normal tissue sparing in the adjuvant radiotherapy of malignant pleural mesothelioma: helical tomotherapy compared with step-and-shoot IMRT.
</td>
<td style="text-align:left;">
Radiother Oncol
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Coincident manifestation of mesotheliomas of the tunica vaginalis and pleura. Case report and literature overview].
</td>
<td style="text-align:left;">
Urologe A
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Xanthomatous pleuritis mimicking mesothelioma.
</td>
<td style="text-align:left;">
Respiration
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Advances in the systemic therapy of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Nat Clin Pract Oncol
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Environmental cancer: malignant pleural mesothelioma].
</td>
<td style="text-align:left;">
Bull Cancer
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
[Pleural mesothelioma: impact of the staging for the therapeutic strategy].
</td>
<td style="text-align:left;">
Rev Mal Respir
</td>
<td style="text-align:left;">
diagnosis | treatment | epidemiology
</td>
</tr>
<tr>
<td style="text-align:left;">
[Epidemiology, molecular biology, diagnostic and therapeutic strategy of malignant pleural mesothelioma in 2007 - an update].
</td>
<td style="text-align:left;">
Rev Mal Respir
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Cost-effectiveness of pemetrexed plus cisplatin: malignant pleural mesothelioma treatment in UK clinical practice.
</td>
<td style="text-align:left;">
Value Health
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
PTEN expression is a strong predictor of survival in mesothelioma patients.
</td>
<td style="text-align:left;">
Eur J Cardiothorac Surg
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Intensity-modulated radiotherapy for resected mesothelioma: the Duke experience.
</td>
<td style="text-align:left;">
Int. J. Radiat. Oncol. Biol. Phys.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Phase-contrast microscopy studies of early cisplatin-induced morphological changes of malignant mesothelioma cells and the correspondence to induced apoptosis.
</td>
<td style="text-align:left;">
Exp. Lung Res.
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Diploid predominance and prognostic significance of S-phase cells in malignant mesothelioma.
</td>
<td style="text-align:left;">
Eur. J. Cancer
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[The Lombardy Mesothelioma Register, Regional Operating Centre (ROC) of National Mesothelioma Register: organizational aspects].
</td>
<td style="text-align:left;">
Epidemiol Prev
</td>
<td style="text-align:left;">
diagnosis | epidemiology | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant pleural mesothelioma: multidisciplinary experience in a public tertiary hospital].
</td>
<td style="text-align:left;">
J Bras Pneumol
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Current concepts in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Expert Rev Anticancer Ther
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Pericardial malignant mesothelioma: a latent complication of radiotherapy?
</td>
<td style="text-align:left;">
Eur J Cardiothorac Surg
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Mesothelin-related predictive and prognostic factors in malignant mesothelioma: a nested case-control study.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Gemcitabine and vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Cancer
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Establishment of a novel specific ELISA system for rat N- and C-ERC/mesothelin. Rat ERC/mesothelin in the body fluids of mice bearing mesothelioma.
</td>
<td style="text-align:left;">
Cancer Sci.
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Intracavitary radioimmunotherapy to treat solid tumors.
</td>
<td style="text-align:left;">
Cancer Biother. Radiopharm.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Biological characteristics of cancers involving the serosal cavities.
</td>
<td style="text-align:left;">
Crit Rev Oncog
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Unusual features of malignant pleural mesothelioma metastatic to the mediastinal lymph nodes.
</td>
<td style="text-align:left;">
Appl. Immunohistochem. Mol. Morphol.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleural mesothelioma: diagnostic problems and evaluation of prognostic factors.
</td>
<td style="text-align:left;">
J Egypt Natl Canc Inst
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Transcriptome sequencing of malignant pleural mesothelioma tumors.
</td>
<td style="text-align:left;">
Proc. Natl. Acad. Sci. U.S.A.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Local recurrence of tumor at sites of intervention in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
[New diagnostic markers for malignant pleural mesothelioma].
</td>
<td style="text-align:left;">
Bull Cancer
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
9p21 Deletion in the diagnosis of malignant mesothelioma in serous effusions additional to immunocytochemistry, DNA-ICM, and AgNOR analysis.
</td>
<td style="text-align:left;">
Cancer
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Asbestos exposure predicts cell cycle control gene promoter methylation in pleural mesothelioma.
</td>
<td style="text-align:left;">
Carcinogenesis
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Characterization of human mesothelioma cell lines as tumor models for suicide gene therapy.
</td>
<td style="text-align:left;">
Onkologie
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Improved identification of malignant cells in serous effusions using a small, robust panel of antibodies on paraffin-embedded cell suspensions.
</td>
<td style="text-align:left;">
Acta Cytol.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Advances in the molecular biology of malignant mesothelioma.
</td>
<td style="text-align:left;">
Acta Med. Okayama
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Localized malignant mesenteric mesothelioma causing small bowel obstruction.
</td>
<td style="text-align:left;">
Pathol. Int.
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant mesothelioma in the Veneto Region (north-east of Italy), 1988-2002: incidence, geographical analysis, trends and comparison with mortality].
</td>
<td style="text-align:left;">
Epidemiol Prev
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Diagnostic importance of 9p21 homozygous deletion in malignant mesotheliomas.
</td>
<td style="text-align:left;">
Mod. Pathol.
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
A conditional mouse model for malignant mesothelioma.
</td>
<td style="text-align:left;">
Cancer Cell
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients.
</td>
<td style="text-align:left;">
J. Thorac. Cardiovasc. Surg.
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Expression of cell adhesion molecule 1 in malignant pleural mesothelioma as a cause of efficient adhesion and growth on mesothelium.
</td>
<td style="text-align:left;">
Lab. Invest.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma resistance to apoptosis: recent discoveries and their implication for effective therapeutic strategies.
</td>
<td style="text-align:left;">
Curr. Med. Chem.
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant pleural effusion].
</td>
<td style="text-align:left;">
Ann Ital Chir
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma: utility of 18 F-FDG PET.
</td>
<td style="text-align:left;">
Ann Ital Chir
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Evaluation of the rehabilitation program in a patient submitted to pleuropneumonectomy for malignant pleural mesothelioma].
</td>
<td style="text-align:left;">
Ann Ital Chir
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Regional pharmacokinetic selectivity of intrapleural cisplatin.
</td>
<td style="text-align:left;">
Eur. J. Cancer
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Erionite series minerals: mineralogical and carcinogenic properties.
</td>
<td style="text-align:left;">
Environ Geochem Health
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Phase II trial of pemetrexed and gemcitabine in chemotherapy-naive malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J. Clin. Oncol.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Risk factors for major complications after extrapleural pneumonectomy for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Ann. Thorac. Surg.
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Efficacy and safety of pemetrexed in elderly cancer patients: results of an integrated analysis.
</td>
<td style="text-align:left;">
Crit. Rev. Oncol. Hematol.
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma: computed tomography and correlation with histology.
</td>
<td style="text-align:left;">
Eur J Radiol
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Bcl-xL antisense oligonucleotide and cisplatin combination therapy extends survival in SCID mice with established mesothelioma xenografts.
</td>
<td style="text-align:left;">
Int. J. Cancer
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
alpha-Toxin of Staphylococcus aureus overcomes acquired cisplatin-resistance in malignant mesothelioma cells.
</td>
<td style="text-align:left;">
Cancer Lett.
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Novel dual targeting strategy with vandetanib induces tumor cell apoptosis and inhibits angiogenesis in malignant pleural mesothelioma cells expressing RET oncogenic rearrangement.
</td>
<td style="text-align:left;">
Cancer Lett.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Therapy response in malignant pleural mesothelioma-role of MRI using RECIST, modified RECIST and volumetric approaches in comparison with CT.
</td>
<td style="text-align:left;">
Eur Radiol
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Impact of tumor-infiltrating T cells on survival in patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J. Thorac. Cardiovasc. Surg.
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J. Clin. Oncol.
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
The role of muscle flap in preventing bronchus stump insufficiency after pneumonectomy for malignant pleural mesothelioma in high-risk patients.
</td>
<td style="text-align:left;">
Interact Cardiovasc Thorac Surg
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Management of malignant pleural effusion associated with trapped lung syndrome.
</td>
<td style="text-align:left;">
Asian Cardiovasc Thorac Ann
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Establishment of three novel human malignant pleural mesothelioma cell lines: morphological and cytogenetical studies and EGFR mutation status.
</td>
<td style="text-align:left;">
Anticancer Res.
</td>
<td style="text-align:left;">
transmission | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
The diagnostic value of Ki-67 and repp86 in distinguishing between benign and malignant mesothelial proliferations.
</td>
<td style="text-align:left;">
Arch. Pathol. Lab. Med.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Epidermal growth factor receptor gene mutation, amplification and protein expression in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J. Cancer Res. Clin. Oncol.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Megakaryocyte potentiating factor as a tumor marker of malignant pleural mesothelioma: evaluation in comparison with mesothelin.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Frequent p16 inactivation by homozygous deletion or methylation is associated with a poor prognosis in Japanese patients with pleural mesothelioma.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Surgical treatment in the management of malignant pleural mesothelioma: a single institution’s experience.
</td>
<td style="text-align:left;">
Ann. Surg. Oncol.
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Outcome after extrapleural pneumonectomy for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Eur J Cardiothorac Surg
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Work related mesothelioma: analysis of cases discovered at the Section for Occupational Medicine and Toxicology of Siena University during the years 2000-2007].
</td>
<td style="text-align:left;">
G Ital Med Lav Ergon
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant mesothelioma (MM) in women: findings of the Mesothelioma Register of the Friuli Venezia Giulia Region].
</td>
<td style="text-align:left;">
G Ital Med Lav Ergon
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
[Biomarkers for prevention and early diagnosis of malignant pleural mesothelioma].
</td>
<td style="text-align:left;">
G Ital Med Lav Ergon
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
[Evaluation of a series of serum mesothelin in patients with pleural malignant mesothelioma].
</td>
<td style="text-align:left;">
G Ital Med Lav Ergon
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Serum mesothelin dosages in follow-up of previously exposed workers].
</td>
<td style="text-align:left;">
G Ital Med Lav Ergon
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant pleuric mesothelioma in Sicily. Epidemiologic observations during the time 1998-2005].
</td>
<td style="text-align:left;">
G Ital Med Lav Ergon
</td>
<td style="text-align:left;">
epidemiology
</td>
</tr>
<tr>
<td style="text-align:left;">
[Pleural mesothelioma in barman with probable occupational exposure to asbestos].
</td>
<td style="text-align:left;">
G Ital Med Lav Ergon
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
[Activity of the Campania Register of Mesothelioma from July 2003 to October 2007].
</td>
<td style="text-align:left;">
G Ital Med Lav Ergon
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Measurement of trends in incidence of work-related skin and respiratory diseases, UK 1996-2005.
</td>
<td style="text-align:left;">
Occup Environ Med
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Genetic susceptibility to malignant pleural mesothelioma and other asbestos-associated diseases.
</td>
<td style="text-align:left;">
Mutat. Res.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Diagnostic value of carcinoembryonic antigen in malignant pleural effusion: a meta-analysis.
</td>
<td style="text-align:left;">
Respirology
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Pharmacokinetic analysis of malignant pleural mesothelioma-initial results of tumor microcirculation and its correlation to microvessel density (CD-34).
</td>
<td style="text-align:left;">
Acad Radiol
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Individual versus standard quality of life assessment in a phase II clinical trial in mesothelioma patients: feasibility and responsiveness to clinical changes.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Efficacy and safety of pemetrexed in combination with cisplatin for malignant pleural mesothelioma: a phase I/II study in Japanese patients.
</td>
<td style="text-align:left;">
Jpn. J. Clin. Oncol.
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Incidence of pleural mesotheliomas in Poland (preliminary report)].
</td>
<td style="text-align:left;">
Pneumonol Alergol Pol
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant peritoneal mesothelioma as a rare cause of ascites: a case report.
</td>
<td style="text-align:left;">
J Med Case Rep
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma with unexpected contralateral mediastinal shift: a case report.
</td>
<td style="text-align:left;">
J Med Case Rep
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
The value of occult disease in resection margin and lymph node after extrapleural pneumonectomy for malignant mesothelioma.
</td>
<td style="text-align:left;">
Ann. Thorac. Surg.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
[Video-assisted thoracoscopic surgery in diagnostic and treatment of non-operable malignant pleural mesothelioma].
</td>
<td style="text-align:left;">
Khirurgiia (Sofiia)
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Trimodality treatment of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[The contribution of positron emission tomography in pleural disease].
</td>
<td style="text-align:left;">
Rev Mal Respir
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Video-assisted cervical thoracoscopy: a novel approach for diagnosis, staging and pleurodesis of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Eur J Cardiothorac Surg
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Overexpression and altered glycosylation of MUC1 in malignant mesothelioma.
</td>
<td style="text-align:left;">
Br. J. Cancer
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Chrysotile asbestos and health in Zimbabwe: I. Analysis of miners and millers compensated for asbestos-related diseases since independence (1980).
</td>
<td style="text-align:left;">
Am. J. Ind. Med.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Molecular targets and targeted therapies for malignant mesothelioma.
</td>
<td style="text-align:left;">
Curr. Med. Chem.
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
MR imaging of benign and malignant pleural disease.
</td>
<td style="text-align:left;">
Magn Reson Imaging Clin N Am
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Neoplastic and nonneoplastic conditions of serosal membrane origin: CT findings.
</td>
<td style="text-align:left;">
Radiographics
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
CT findings in malignant pleural mesothelioma related to nonoccupational exposure to asbestos and fibrous zeolite (erionite).
</td>
<td style="text-align:left;">
J Comput Assist Tomogr
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
The efficacy and safety of weekly vinorelbine in relapsed malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial.
</td>
<td style="text-align:left;">
Lancet
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Thoracoscopy in pleural malignant mesothelioma diagnosis.
</td>
<td style="text-align:left;">
Diagn Ther Endosc
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Erionite-induced pleural plaques. Exposition to urban pollution in a female Turkish migrant in Germany].
</td>
<td style="text-align:left;">
Chirurg
</td>
<td style="text-align:left;">
diagnosis | epidemiology | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Two cases of asbestosis and one case of rounded atelectasis due to non-occupational asbestos exposure.
</td>
<td style="text-align:left;">
Monaldi Arch Chest Dis
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Metastases in malignant pleural mesothelioma: a new radiological appearance.
</td>
<td style="text-align:left;">
Respirology
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
[Autopsy case of diffuse pleural thickening presenting respiratory impairment and benign asbestos pleurisy].
</td>
<td style="text-align:left;">
Nihon Kokyuki Gakkai Zasshi
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Pulmonary paragonimiasis with coincidental malignant mesothelioma.
</td>
<td style="text-align:left;">
Intern. Med.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma 2008.
</td>
<td style="text-align:left;">
Curr Opin Pulm Med
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
The relationship between simian virus 40 and mesothelioma.
</td>
<td style="text-align:left;">
Curr Opin Pulm Med
</td>
<td style="text-align:left;">
epidemiology | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Mesothelioma due to environmental exposure to erionite in Turkey.
</td>
<td style="text-align:left;">
Curr Opin Pulm Med
</td>
<td style="text-align:left;">
epidemiology
</td>
</tr>
<tr>
<td style="text-align:left;">
Prophylactic radiotherapy for pleural puncture sites in mesothelioma: the controversy continues.
</td>
<td style="text-align:left;">
Curr Opin Pulm Med
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Image-guided pleural biopsy.
</td>
<td style="text-align:left;">
Curr Opin Pulm Med
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Response of a patient with pleural and peritoneal mesothelioma after second-line chemotherapy with lipoplatin and gemcitabine.
</td>
<td style="text-align:left;">
Oncology
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Excess of mesotheliomas after exposure to chrysotile in Balangero, Italy.
</td>
<td style="text-align:left;">
Occup Environ Med
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Uroplakin is not a reliable immunohistochemical marker for malignant mesothelioma of the pleura.
</td>
<td style="text-align:left;">
Appl. Immunohistochem. Mol. Morphol.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Trends in mesothelioma incidence in Norway 1960-1988.
</td>
<td style="text-align:left;">
Toxicol Ind Health
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Clinical activity of vinflunine in transitional cell carcinoma of the urothelium and other solid tumors.
</td>
<td style="text-align:left;">
Semin. Oncol.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Pemetrexed plus carboplatin in elderly patients with malignant pleural mesothelioma: combined analysis of two phase II trials.
</td>
<td style="text-align:left;">
Br. J. Cancer
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Cisplatin and vinorelbine first-line chemotherapy in non-resectable malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Br. J. Cancer
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Cancer
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Prognostic significance of pleural fluid data in patients with malignant effusion.
</td>
<td style="text-align:left;">
Eur. J. Intern. Med.
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Prognostic role of osteopontin expression in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Am. J. Clin. Pathol.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
SV40 large T antigen-specific human T cell memory responses.
</td>
<td style="text-align:left;">
J. Med. Virol.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Trisomy of rat chromosome 1 associated with mesothelial cell transformation.
</td>
<td style="text-align:left;">
Cancer Res.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Measles virus induces oncolysis of mesothelioma cells and allows dendritic cells to cross-prime tumor-specific CD8 response.
</td>
<td style="text-align:left;">
Cancer Res.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Schedule-dependent synergistic effect of pemetrexed combined with gemcitabine against malignant pleural mesothelioma and non-small cell lung cancer cell lines.
</td>
<td style="text-align:left;">
Chemotherapy
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Asbestos burden predicts survival in pleural mesothelioma.
</td>
<td style="text-align:left;">
Environ. Health Perspect.
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Pathology of primary tumours of the pleura].
</td>
<td style="text-align:left;">
Zentralbl Chir
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Multimodal therapy for malignant pleural mesothelioma including extrapleural pneumonectomy].
</td>
<td style="text-align:left;">
Zentralbl Chir
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
[Chemotherapy of malignant pleural mesothelioma: have we made any progress?].
</td>
<td style="text-align:left;">
Zentralbl Chir
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Coalescent pleural malignant mesothelioma and adenocarcinoma of the lung, involving only minor asbestos exposure.
</td>
<td style="text-align:left;">
Pathol. Int.
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Piroxicam and intracavitary platinum-based chemotherapy for the treatment of advanced mesothelioma in pets: preliminary observations.
</td>
<td style="text-align:left;">
J. Exp. Clin. Cancer Res.
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Induction of apoptosis by intrapleural perfusion hyperthermo-chemotherapy for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Ann Thorac Cardiovasc Surg
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Paget disease of the humerus mimicking metastatic disease in a patient with metastatic malignant mesothelioma on whole body F-18 FDG PET/CT.
</td>
<td style="text-align:left;">
Clin Nucl Med
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma with osseous metastases and pathologic fracture of femoral neck.
</td>
<td style="text-align:left;">
Appl. Immunohistochem. Mol. Morphol.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Radiation associated malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Thorax
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Soluble mesothelin-related protein in an asbestos-exposed population: the dust diseases board cohort study.
</td>
<td style="text-align:left;">
Am. J. Respir. Crit. Care Med.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Mesothelioma and asbestos-related pleural diseases.
</td>
<td style="text-align:left;">
Respiration
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Morbidity, mortality, mean survival, and the impact of histology on survival after pleurectomy in 64 patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Int J Surg
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Solitary fibrous pleural tumor.
</td>
<td style="text-align:left;">
J Am Osteopath Assoc
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma with heterologous elements: clinicopathological correlation of 27 cases and literature review.
</td>
<td style="text-align:left;">
Mod. Pathol.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Multiple mechanisms of telomere maintenance exist and differentially affect clinical outcome in diffuse malignant peritoneal mesothelioma.
</td>
<td style="text-align:left;">
Clin. Cancer Res.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemonaïve patients with malignant pleural mesothelioma: results of the International Expanded Access Program.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Single-agent pemetrexed for chemonaïve and pretreated patients with malignant pleural mesothelioma: results of an International Expanded Access Program.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Primary pleural neoplasia: entities other than diffuse malignant mesothelioma.
</td>
<td style="text-align:left;">
Arch. Pathol. Lab. Med.
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma: current status and perspective in Japan and the world.
</td>
<td style="text-align:left;">
Gen Thorac Cardiovasc Surg
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Incidence of atrial fibrillation after extrapleural pneumonectomy vs. pleurectomy in patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Interact Cardiovasc Thorac Surg
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
[Involvement of zinc in taste disturbance occurring during treatment for malignant tumor in the chest and the effects of polaprezinc oral disintegrating tablets (a retrospective study)].
</td>
<td style="text-align:left;">
Gan To Kagaku Ryoho
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
[Pemetrexed].
</td>
<td style="text-align:left;">
Gan To Kagaku Ryoho
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Assessment of biomarkers in asbestos-exposed workers as indicators of cancer risk.
</td>
<td style="text-align:left;">
Mutat. Res.
</td>
<td style="text-align:left;">
epidemiology | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
A phase II trial of tetrathiomolybdate after surgery for malignant mesothelioma: final results.
</td>
<td style="text-align:left;">
Ann. Thorac. Surg.
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Prevalence and pattern of lymph node metastasis in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Ann. Thorac. Surg.
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Pemetrexed plus gemcitabine as first-line chemotherapy for patients with peritoneal mesothelioma: final report of a phase II trial.
</td>
<td style="text-align:left;">
J. Clin. Oncol.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Long-term indwelling pleural catheter (PleurX) for malignant pleural effusion unsuitable for talc pleurodesis.
</td>
<td style="text-align:left;">
Eur J Surg Oncol
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
The comparative accuracy of different pleural biopsy techniques in the diagnosis of malignant mesothelioma.
</td>
<td style="text-align:left;">
Histopathology
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
A novel concept of treatment of diffuse or multiple pleural tumors by boron neutron capture therapy (BNCT).
</td>
<td style="text-align:left;">
Radiother Oncol
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
[A case of malignant pleural mesothelioma presenting as pneumothorax].
</td>
<td style="text-align:left;">
Nihon Kyobu Shikkan Gakkai Zasshi
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Open lung-sparing surgery for malignant pleural mesothelioma: the benefits of a radical approach within multimodality therapy.
</td>
<td style="text-align:left;">
Eur J Cardiothorac Surg
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
[Utility of morphometry and nucleolar organizer regions count in the differentiation of reactive and malignant mesothelial cells in pleural effusions].
</td>
<td style="text-align:left;">
Pathologica
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Use of monoclonal antibody B72.3 as a marker of metastatic carcinoma cells in neoplastic effusions.
</td>
<td style="text-align:left;">
Pathologica
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Pathogenesis of malignant pleural mesothelioma and the role of environmental and genetic factors.
</td>
<td style="text-align:left;">
J Carcinog
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Establishment of a human malignant fibrous mesothelioma cell line and the biological characteristics compared with malignant epithelial mesothelioma cell line.
</td>
<td style="text-align:left;">
Hum. Cell
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Comparison of osteopontin, megakaryocyte potentiating factor, and mesothelin proteins as markers in the serum of patients with malignant mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
MET as a target for treatment of chest tumors.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Use of hospital discharge records to estimate the incidence of malignant mesotheliomas].
</td>
<td style="text-align:left;">
Epidemiol Prev
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Incidence of malignant mesothelioma in Piedmont, 1990-2001].
</td>
<td style="text-align:left;">
Epidemiol Prev
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Sensitivity analysis of the relationship between disease occurrence and distance from a putative source of pollution.
</td>
<td style="text-align:left;">
Geospat Health
</td>
<td style="text-align:left;">
epidemiology | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant mesothelioma in garment sewing-machine workers].
</td>
<td style="text-align:left;">
Med Lav
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Full-thickness pleural biopsy using an Insulation-tipped Diathermic Knife in a patient with malignant pleural mesothelioma].
</td>
<td style="text-align:left;">
Kyobu Geka
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Enhanced antitumor therapy by inhibition of p21waf1 in human malignant mesothelioma.
</td>
<td style="text-align:left;">
Clin. Cancer Res.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Acute generalized exanthematous pustulosis after pemetrexed, and recurrence after re-introduction.
</td>
<td style="text-align:left;">
Clin. Exp. Dermatol.
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Soft tissue sarcoma metastatic to pleura.
</td>
<td style="text-align:left;">
Tuberk Toraks
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Mesothelioma epidemiology, carcinogenesis, and pathogenesis.
</td>
<td style="text-align:left;">
Curr Treat Options Oncol
</td>
<td style="text-align:left;">
epidemiology | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Successful palliation of malignant ascites from peritoneal mesothelioma by laparoscopic intraperitoneal hyperthermic chemotherapy.
</td>
<td style="text-align:left;">
Surg Laparosc Endosc Percutan Tech
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Targeting alpha7-nicotinic receptor for the treatment of pleural mesothelioma.
</td>
<td style="text-align:left;">
Eur. J. Cancer
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
YAP1 is involved in mesothelioma development and negatively regulated by Merlin through phosphorylation.
</td>
<td style="text-align:left;">
Carcinogenesis
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Review of pemetrexed in combination with cisplatin for the treatment of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Ther Clin Risk Manag
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Effusion cytology.
</td>
<td style="text-align:left;">
Clin. Lab. Med.
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Novel oncolytic agent GLV-1h68 is effective against malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Hum. Gene Ther.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Lysophosphatidic acid stimulates the proliferation and motility of malignant pleural mesothelioma cells through lysophosphatidic acid receptors, LPA1 and LPA2.
</td>
<td style="text-align:left;">
Cancer Sci.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
The role of polio-vaccine in pleural mesothelioma–an epidemiological observation.
</td>
<td style="text-align:left;">
Coll Antropol
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma-targeted CREBBP/EP300 inhibitory protein 1 promoter system for gene therapy and virotherapy.
</td>
<td style="text-align:left;">
Cancer Res.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Recent advances in the treatment of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Diagnosis, staging, and surgical treatment of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Curr Treat Options Oncol
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Distinction of mesothelioma from carcinoma in pleural effusions. An immunocytochemical study on routinely processed cytoblock preparations.
</td>
<td style="text-align:left;">
Pathol. Res. Pract.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
[Diagnosis of diffuse pleural mesotheliomas].
</td>
<td style="text-align:left;">
Pneumologie
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Therapy of malignant pleural mesothelioma].
</td>
<td style="text-align:left;">
Pneumologie
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Protein kinase C beta in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Anticancer Drugs
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Acquisition of cisplatin-resistance in malignant mesothelioma cells abrogates Na+,K+,2Cl(-)-cotransport activity and cisplatin-induced early membrane blebbing.
</td>
<td style="text-align:left;">
Cell. Physiol. Biochem.
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Prevention of malignant seeding at drain sites after invasive procedures (surgery and/or thoracoscopy) by hypofractionated radiotherapy in patients with pleural mesothelioma.
</td>
<td style="text-align:left;">
Acta Oncol
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Clinical consequences of asbestos-related diffuse pleural thickening: A review.
</td>
<td style="text-align:left;">
J Occup Med Toxicol
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Pathogenesis of malignant pleural mesothelioma and the role of environmental and genetic factors.
</td>
<td style="text-align:left;">
J. Cancer Res. Clin. Oncol.
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Computed tomography, positron emission tomography, positron emission tomography/computed tomography, and magnetic resonance imaging for staging of limited pleural mesothelioma: initial results.
</td>
<td style="text-align:left;">
Invest Radiol
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Survival of pleural malignant mesothelioma in Italy: a population-based study.
</td>
<td style="text-align:left;">
Int. J. Cancer
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Survival of peritoneal malignant mesothelioma in Italy: a population-based study.
</td>
<td style="text-align:left;">
Int. J. Cancer
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Proteasome Inhibitor MG132 Induces Apoptosis and Inhibits Invasion of Human Malignant Pleural Mesothelioma Cells.
</td>
<td style="text-align:left;">
Transl Oncol
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleural fluid findings as prognostic factors for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J. Clin. Lab. Anal.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
The impact of lymph node station on survival in 348 patients with surgically resected malignant pleural mesothelioma: implications for revision of the American Joint Committee on Cancer staging system.
</td>
<td style="text-align:left;">
J. Thorac. Cardiovasc. Surg.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Predicted mortality from malignant mesothelioma among women exposed to blue asbestos at Wittenoom, Western Australia.
</td>
<td style="text-align:left;">
Occup Environ Med
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Inhibition of Hsp90 leads to cell cycle arrest and apoptosis in human malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Transesophageal endoscopic ultrasound with fine needle aspiration in the preoperative staging of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Clin. Cancer Res.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
CK5/6 in effusions: no difference between mesothelioma and pulmonary and nonpulmonary adenocarcinoma.
</td>
<td style="text-align:left;">
Acta Cytol.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Pooled analysis of NAT2 genotypes as risk factors for asbestos-related malignant mesothelioma.
</td>
<td style="text-align:left;">
Int J Hyg Environ Health
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Assessment of Survival and Clinical Benefit in Malignant Pleural Mesothelioma (MPM) Patients Treated with Gemcitabine and Carboplatin.
</td>
<td style="text-align:left;">
J Egypt Natl Canc Inst
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Peritoneal mesothelioma.
</td>
<td style="text-align:left;">
Curr Treat Options Oncol
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Pulmonary epithelioid hemangioendothelioma mimicking mesothelioma.
</td>
<td style="text-align:left;">
Pathol. Int.
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Histologic assessment and prognostic factors of malignant pleural mesothelioma treated with extrapleural pneumonectomy.
</td>
<td style="text-align:left;">
Am. J. Clin. Pathol.
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
A useful antibody panel for differential diagnosis between peritoneal mesothelioma and ovarian serous carcinoma in Japanese cases.
</td>
<td style="text-align:left;">
Am. J. Clin. Pathol.
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Cardiac tamponade as primary manifestation of angioimmunoblastic T-cell lymphoma (AILT). Coexistence with malignant mesothelioma.
</td>
<td style="text-align:left;">
Onkologie
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Tranexamic acid treatment of hemothorax in two patients with malignant mesothelioma.
</td>
<td style="text-align:left;">
Chest
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Down-regulation of inhibition of differentiation-1 via activation of activating transcription factor 3 and Smad regulates REIC/Dickkopf-3-induced apoptosis.
</td>
<td style="text-align:left;">
Cancer Res.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Carboplatin and pemetrexed in the management of malignant pleural mesothelioma: a realistic treatment option?
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
A case of solid pseudopapillary tumour of the pancreas and malignant mesothelioma.
</td>
<td style="text-align:left;">
J Gastrointest Cancer
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
The aberrant promoter methylation of BMP3b and BMP6 in malignant pleural mesotheliomas.
</td>
<td style="text-align:left;">
Oncol. Rep.
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Prognostic significance of p16/cdkn2a loss in pleural malignant mesotheliomas.
</td>
<td style="text-align:left;">
Virchows Arch.
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Diffuse malignant pleural mesothelioma: a multi-institutional clinicopathological study.
</td>
<td style="text-align:left;">
Surg. Today
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Pleural mesothelioma in data from the Surgical Clinic in Hradec Králové 1971-1987].
</td>
<td style="text-align:left;">
Rozhl Chir
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
[Other thoracic cancers. Malignant pleural mesothelioma: biology and diagnosis].
</td>
<td style="text-align:left;">
Rev Mal Respir
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Other thoracic cancers. Mesothelioma: treatment].
</td>
<td style="text-align:left;">
Rev Mal Respir
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Cytopathologic differential diagnosis of malignant mesothelioma, adenocarcinoma and reactive mesothelial cells: A logistic regression analysis.
</td>
<td style="text-align:left;">
Diagn. Cytopathol.
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Genomic events associated with progression of pleural malignant mesothelioma.
</td>
<td style="text-align:left;">
Int. J. Cancer
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Diagnostic and prognostic value of soluble mesothelin-related proteins in patients with malignant pleural mesothelioma in comparison with benign asbestosis and lung cancer.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Treatment of malignant pleural mesothelioma with carboplatin, liposomized doxorubicin, and gemcitabine: a phase II study.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Polyneuropathy in a patient with malignant pleural mesothelioma: a paraneoplastic syndrome.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
A case report of malignant pleural mesothelioma with long-term disease control after chemotherapy.
</td>
<td style="text-align:left;">
Cancer
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Effective chemotherapy based on a chemosensitivity test for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Ann Thorac Cardiovasc Surg
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Transudates in malignancy: still a role for pleural fluid.
</td>
<td style="text-align:left;">
Ann. Acad. Med. Singap.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
The CREST biorepository: a tool for molecular epidemiology and translational studies on malignant mesothelioma, lung cancer, and other respiratory tract diseases.
</td>
<td style="text-align:left;">
Cancer Epidemiol. Biomarkers Prev.
</td>
<td style="text-align:left;">
epidemiology | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Role of viral induced vascular endothelial growth factor (VEGF) production in pleural effusion and malignant mesothelioma.
</td>
<td style="text-align:left;">
Cell Biol. Int.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Outcomes with first-line platinum-based combination chemotherapy for malignant pleural mesothelioma: a review of practice in British Columbia.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma of the tunica vaginalis of the testis without exposure to asbestos.
</td>
<td style="text-align:left;">
Cases J
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Compensator-based intensity-modulated radiation therapy for malignant pleural mesothelioma post extrapleural pneumonectomy.
</td>
<td style="text-align:left;">
J Appl Clin Med Phys
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Biomarkers for malignant pleural mesothelioma: current status.
</td>
<td style="text-align:left;">
Mol Diagn Ther
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Monitoring of chemotherapy response in malignant pleural mesothelioma using fluorodeoxyglucose positron emission tomography.
</td>
<td style="text-align:left;">
Intern. Med.
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Problems in mesothelioma diagnosis.
</td>
<td style="text-align:left;">
Histopathology
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Expression of GATA-6 transcription factor in pleural malignant mesothelioma and metastatic pulmonary adenocarcinoma.
</td>
<td style="text-align:left;">
J. Clin. Pathol.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Telomerase activity in effusions: a comparison between telomere repeat amplification protocol in situ and conventional telomere repeat amplification protocol assay.
</td>
<td style="text-align:left;">
Arch. Pathol. Lab. Med.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[An autopsy case of sarcomatoid malignant mesothelioma mimicking adenocarcinoma with sarcomatoid elements of lung].
</td>
<td style="text-align:left;">
Nihon Kokyuki Gakkai Zasshi
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Simian virus 40 sequences in blood specimens from healthy individuals of Casale Monferrato, an industrial town with a history of asbestos pollution.
</td>
<td style="text-align:left;">
J. Infect.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Diffuse malignant peritoneal mesothelioma: Failure analysis following cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC).
</td>
<td style="text-align:left;">
Ann. Surg. Oncol.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
JBIR-23 and -24, novel anticancer agents from Streptomyces sp. AK-AB27.
</td>
<td style="text-align:left;">
Org. Lett.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Asbestos-related occupational lung diseases in NSW, Australia and potential exposure of the general population.
</td>
<td style="text-align:left;">
Ind Health
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Medical thoracoscopic talc pleurodesis for malignant pleural effusion: an analysis of 27 cases].
</td>
<td style="text-align:left;">
Beijing Da Xue Xue Bao
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Gemcitabine combined with oxaliplatin in pretreated patients with malignant pleural mesothelioma: an observational study.
</td>
<td style="text-align:left;">
J Occup Med Toxicol
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Vitamin D-mediated hypercalcemia and Cushing syndrome as manifestations of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Endocr Pract
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Phase II study of belinostat (PXD101), a histone deacetylase inhibitor, for second line therapy of advanced malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma.
</td>
<td style="text-align:left;">
Orphanet J Rare Dis
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Proteome analysis of bronchoalveolar lavage in individuals from Metsovo, nonoccupationally exposed to asbestos.
</td>
<td style="text-align:left;">
J. Proteome Res.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant pleural effusion as the presenting site of cancer: comparison with metastatic pleural effusions from known cancers].
</td>
<td style="text-align:left;">
Rev Mal Respir
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Phase I and pharmacokinetic study of pemetrexed plus cisplatin in chemonaive patients with locally advanced or metastatic malignant pleural mesothelioma or non-small cell lung cancer.
</td>
<td style="text-align:left;">
Clin. Cancer Res.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
A new electrocautery pleural biopsy technique using an insulated-tip diathermic knife during semirigid pleuroscopy.
</td>
<td style="text-align:left;">
Surg Endosc
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma treated in Clinic for Pulmonary Diseases and Tuberculosis “Podhrastovi” in ten-year period (from 1998 to 2007).
</td>
<td style="text-align:left;">
Bosn J Basic Med Sci
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Duodenal metastasis of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J. Formos. Med. Assoc.
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
A feasibility study of induction pemetrexed plus cisplatin followed by extrapleural pneumonectomy and postoperative hemithoracic radiation for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Jpn. J. Clin. Oncol.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
In vitro-chemosensitivity test using the collagen gel droplet embedded culture drug test (CD-DST) for malignant pleural mesothelioma: possibility of clinical application.
</td>
<td style="text-align:left;">
Ann Thorac Cardiovasc Surg
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Does video-assisted thoracoscopic decortication in advanced malignant mesothelioma improve prognosis?
</td>
<td style="text-align:left;">
Interact Cardiovasc Thorac Surg
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Pemetrexed disodium for the treatment of NSCLC: an update.
</td>
<td style="text-align:left;">
Drugs Today
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant pleural diseases: diagnosis and treatment].
</td>
<td style="text-align:left;">
Medicina (Kaunas)
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleural fluid analysis in malignant mesothelioma. Prognostic implications.
</td>
<td style="text-align:left;">
Chest
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesenterial mesothelioma in stroke patients.
</td>
<td style="text-align:left;">
Acta Med Indones
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Diagnosis of epithelial mesothelioma using tree-based regression analysis and a minimal panel of antibodies.
</td>
<td style="text-align:left;">
Pathology
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Tryptase mast cells in malignant pleural mesothelioma as an independent favorable prognostic factor.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Texture- and object-related automated information analysis in histological still images of various organs.
</td>
<td style="text-align:left;">
Anal. Quant. Cytol. Histol.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Immuno-chemotherapy reduces recurrence of malignant pleural mesothelioma: an experimental setting.
</td>
<td style="text-align:left;">
Eur J Cardiothorac Surg
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Induction of multiple-drug resistance during anti-neoplastic chemotherapy in vitro.
</td>
<td style="text-align:left;">
Int. J. Cancer
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Osteopontin levels in an asbestos-exposed population.
</td>
<td style="text-align:left;">
Clin. Cancer Res.
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
The plexin-A1 receptor activates vascular endothelial growth factor-receptor 2 and nuclear factor-kappaB to mediate survival and anchorage-independent growth of malignant mesothelioma cells.
</td>
<td style="text-align:left;">
Cancer Res.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Inhibition of the insulin-like growth factor 1 receptor pathway enhances the antitumor effect of cisplatin in human malignant mesothelioma cell lines.
</td>
<td style="text-align:left;">
Cancer Lett.
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
A phase I study of extrapleural pneumonectomy and intracavitary intraoperative hyperthermic cisplatin with amifostine cytoprotection for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J. Thorac. Cardiovasc. Surg.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Serum levels of soluble mesothelin-related peptides in malignant and nonmalignant asbestos-related pleural disease: relation with past asbestos exposure.
</td>
<td style="text-align:left;">
Cancer Epidemiol. Biomarkers Prev.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Gene therapy for malignant pleural mesothelioma: present and future.
</td>
<td style="text-align:left;">
Oncol. Res.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Kinetics of soluble mesothelin in patients with malignant pleural mesothelioma during treatment.
</td>
<td style="text-align:left;">
Am. J. Respir. Crit. Care Med.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Early detection of malignant pleural mesothelioma through measurement of soluble mesothelin-related protein and positron emission tomography.
</td>
<td style="text-align:left;">
Med. J. Aust.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Death certificate categorization of malignant pleural and peritoneal mesothelioma in a cohort of asbestos insulation workers.
</td>
<td style="text-align:left;">
J Soc Occup Med
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Thoracoscopy in the diagnosis of pleural effusion of ambiguous etiology.
</td>
<td style="text-align:left;">
J Surg Oncol
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Identification of potential therapeutic targets in malignant mesothelioma using cell-cycle gene expression analysis.
</td>
<td style="text-align:left;">
Am. J. Pathol.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Trimodality therapy with induction chemotherapy followed by extrapleural pneumonectomy and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J. Clin. Oncol.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Decitabine, differently from DNMT1 silencing, exerts its antiproliferative activity through p21 upregulation in malignant pleural mesothelioma (MPM) cells.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Chemotherapy of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Expert Opin Pharmacother
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant sarcomatoid mesothelioma of the pleura: a histological and immunohistological study of a case.
</td>
<td style="text-align:left;">
Pathologica
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Intrapleural administration of pemetrexed: a pharmacokinetic study in an animal model.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
[Remission of malignant pleural mesothelioma using high-dose cisplatin in monochemotherapy].
</td>
<td style="text-align:left;">
Rev Mal Respir
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Hyperthermic chemoperfusion for the treatment of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Semin. Thorac. Cardiovasc. Surg.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Mortality among British asbestos workers undergoing regular medical examinations (1971-2005).
</td>
<td style="text-align:left;">
Occup Environ Med
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J. Clin. Oncol.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Pneumothorax and malignant mesothelioma in patients over the age of 40.
</td>
<td style="text-align:left;">
Thorax
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
[A case of malignant pleural mesothelioma with gastrointestinal metastases which were diagnosed by endoscopic biopsy].
</td>
<td style="text-align:left;">
Nihon Kokyuki Gakkai Zasshi
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Establishment of novel mAb to human ERC/mesothelin useful for study and diagnosis of ERC/mesothelin-expressing cancers.
</td>
<td style="text-align:left;">
Pathol. Int.
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Is FDG-PET/CT useful for managing malignant pleural mesothelioma?
</td>
<td style="text-align:left;">
J. Med. Invest.
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
[Size distribution of amphibole fibres from lung and pleural tissues sampled from mesothelioma cases due to environmental exposure].
</td>
<td style="text-align:left;">
Med Lav
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
[Asbestos fibre lung burden and exposure indices in asbestos-cement workers].
</td>
<td style="text-align:left;">
Med Lav
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Chrysotile biopersistence: the misuse of biased studies.
</td>
<td style="text-align:left;">
Int J Occup Environ Health
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Immunohistochemical distribution patterns of epidermal growth factor receptor in malignant mesothelioma and non-neoplastic mesothelium.
</td>
<td style="text-align:left;">
Virchows Arch A Pathol Anat Histopathol
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Three-dimensional evaluation of chemotherapy response in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Eur J Radiol
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Pemetrexed in first-line treatment of non-small cell lung cancer.
</td>
<td style="text-align:left;">
Cancer Treat. Rev.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Ultrastructural and immunohistochemical analysis of fibrous long-spacing collagen fibrils in malignant mesothelioma.
</td>
<td style="text-align:left;">
Ultrastruct Pathol
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Symptomatic and quality of life changes after extrapleural pneumonectomy for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J Surg Oncol
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Tumorigenic properties of alternative osteopontin isoforms in mesothelioma.
</td>
<td style="text-align:left;">
Biochem. Biophys. Res. Commun.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Neoadjuvant and intrapleural therapies for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Clin Lung Cancer
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Usefulness of EMA, GLUT-1, and XIAP for the cytologic diagnosis of malignant mesothelioma in body cavity fluids.
</td>
<td style="text-align:left;">
Am. J. Clin. Pathol.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Clinical impact and reliability of pleural fluid mesothelin in undiagnosed pleural effusions.
</td>
<td style="text-align:left;">
Am. J. Respir. Crit. Care Med.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleural mesothelioma: an unusual case diagnosed on pleural fluid cytology and immunocytochemistry.
</td>
<td style="text-align:left;">
Diagn. Cytopathol.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Serum mesothelin has a higher diagnostic utility than hyaluronic acid in malignant mesothelioma.
</td>
<td style="text-align:left;">
Clin. Biochem.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Update in respiratory disease and environmental exposure: an invisible relationship].
</td>
<td style="text-align:left;">
Arch. Bronconeumol.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Dual time point FDG PET for evaluation of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Nucl Med Commun
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
CXCR4+FOXP3+CD25+ lymphocytes accumulate in CXCL12-expressing malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Int J Immunopathol Pharmacol
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Diagnostic and therapeutic strategy in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Eur J Cardiothorac Surg
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Growth inhibition by tyrosine kinase inhibitors in mesothelioma cell lines.
</td>
<td style="text-align:left;">
Eur. J. Cancer
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Recurrent malignant peritoneal mesothelioma: radiological manifestations.
</td>
<td style="text-align:left;">
Abdom Imaging
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Impact of accelerator-based boron neutron capture therapy (AB-BNCT) on the treatment of multiple liver tumors and malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Radiother Oncol
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Prognostic value of 18F-FDG PET/CT in patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Mol Imaging Biol
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Chemosensitivity and cytokine sensitivity of malignant mesothelioma.
</td>
<td style="text-align:left;">
Cancer Chemother. Pharmacol.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma cells resist anoikis as quiescent pluricellular aggregates.
</td>
<td style="text-align:left;">
Cell Death Differ.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Recycle of jute bags; asbestos in agriculture, exposure and pathology ].
</td>
<td style="text-align:left;">
G Ital Med Lav Ergon
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Chromosomal deletion in patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Interact Cardiovasc Thorac Surg
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Association of transforming growth factor beta1 gene polymorphisms and asbestos-induced fibrosis and tumors.
</td>
<td style="text-align:left;">
J. Investig. Med.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Protumorigenic role of HAPLN1 and its IgV domain in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Clin. Cancer Res.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Screening for malignant pleural mesothelioma and lung cancer in individuals with a history of asbestos exposure.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Updated clinical information on multitargeted antifolates in lung cancer.
</td>
<td style="text-align:left;">
Clin Lung Cancer
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma: medical treatment update.
</td>
<td style="text-align:left;">
Clin Lung Cancer
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Pulmonary toxicity following IMRT after extrapleural pneumonectomy for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Radiother Oncol
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J. Clin. Oncol.
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma with brain metastasis.
</td>
<td style="text-align:left;">
J BUON
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Fine-needle aspiration of a well-differentiated papillary mesothelioma in the inguinal hernia sac: A case report and review of literature.
</td>
<td style="text-align:left;">
Diagn. Cytopathol.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Fine-needle aspiration biopsy of pleural metastases from a carcinosarcoma or true malignant mixed tumor of the parotid gland mimicking a mesothelioma.
</td>
<td style="text-align:left;">
Diagn. Cytopathol.
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Future Oncol
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Future developments in the management of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Expert Rev Anticancer Ther
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[First-line treatment with pemetrexed in association with cisplatin in patients with non-operable malignant pleural mesothelioma].
</td>
<td style="text-align:left;">
Rev Pneumol Clin
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Prognostic features of long-term survivors after surgical management of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Ann. Thorac. Surg.
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Extrapleural pneumonectomy with reconstruction of diaphragm and pericardium using autologous materials.
</td>
<td style="text-align:left;">
Ann. Thorac. Surg.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma: genome-wide expression patterns reflecting general resistance mechanisms and a proposal of novel targets.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Combined inhibition of MET and EGFR suppresses proliferation of malignant mesothelioma cells.
</td>
<td style="text-align:left;">
Carcinogenesis
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Observations on environmental asbestos exposure in a high risk area.
</td>
<td style="text-align:left;">
Respirology
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Animal models of malignant pleural effusion.
</td>
<td style="text-align:left;">
Curr Opin Pulm Med
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleural malignant mesothelioma causing cord infiltration through the nerve root. Case report.
</td>
<td style="text-align:left;">
Neurol. Med. Chir. (Tokyo)
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Four-gene expression ratio test for survival in patients undergoing surgery for mesothelioma.
</td>
<td style="text-align:left;">
J. Natl. Cancer Inst.
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Patterns of local and nodal failure in malignant pleural mesothelioma after extrapleural pneumonectomy and photon-electron radiotherapy.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Effect of citrate on malignant pleural mesothelioma cells: a synergistic effect with cisplatin.
</td>
<td style="text-align:left;">
Anticancer Res.
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Novel therapy for malignant pleural mesothelioma based on anti-energetic effect: an experimental study using 3-Bromopyruvate on nude mice.
</td>
<td style="text-align:left;">
Anticancer Res.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Can “steroid switching” improve steroid-induced psychosis in a patient with advanced cancer?
</td>
<td style="text-align:left;">
J Palliat Med
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Serum and pleural fluid biomarkers for mesothelioma.
</td>
<td style="text-align:left;">
Curr Opin Pulm Med
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Comparison of conventional and novel PET tracers for imaging mesothelioma in nude mice with subcutaneous and intrapleural xenografts.
</td>
<td style="text-align:left;">
Nucl. Med. Biol.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Asbestos–a legacy and a persistent problem.
</td>
<td style="text-align:left;">
J R Nav Med Serv
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Expanded applications of diagnostic and therapeutic thoracoscopy.
</td>
<td style="text-align:left;">
J. Thorac. Cardiovasc. Surg.
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma-associated antigens recognized by tumor-infiltrating B cells and the clinical significance of the antibody titers.
</td>
<td style="text-align:left;">
Cancer Sci.
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Benign cystic mesothelioma in a child.
</td>
<td style="text-align:left;">
J. Pediatr. Surg.
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Stage Ia malignant pleural mesothelioma: clinical course and appropriate diagnostic process.
</td>
<td style="text-align:left;">
Gen Thorac Cardiovasc Surg
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
All-trans-retinoic acid inhibits tumour growth of malignant pleural mesothelioma in mice.
</td>
<td style="text-align:left;">
Eur. Respir. J.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
COX-2 specific inhibitors enhance the cytotoxic effects of pemetrexed in mesothelioma cell lines.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Expression of the folate receptor genes FOLR1 and FOLR3 differentiates ovarian carcinoma from breast carcinoma and malignant mesothelioma in serous effusions.
</td>
<td style="text-align:left;">
Hum. Pathol.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Spontaneous pneumothorax and lung carcinoma: should one consider synchronous malignant pleural mesothelioma?
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
A biphasic malignant mesothelioma of the peritoneum and pleura in a horse.
</td>
<td style="text-align:left;">
DTW. Dtsch. Tierarztl. Wochenschr.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Environmental exposure to asbestos and the exposure-response relationship with mesothelioma.
</td>
<td style="text-align:left;">
East. Mediterr. Health J.
</td>
<td style="text-align:left;">
epidemiology
</td>
</tr>
<tr>
<td style="text-align:left;">
Imaging a Genetically Engineered Oncolytic Vaccinia Virus (GLV-1h99) Using a Human Norepinephrine Transporter Reporter Gene.
</td>
<td style="text-align:left;">
Clin. Cancer Res.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Potential of dual time point FDG-PET imaging in differentiating malignant from benign pleural disease.
</td>
<td style="text-align:left;">
Mol Imaging Biol
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Combined FDG-PET/CT in response evaluation of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Estrogen receptor-beta affects the prognosis of human malignant mesothelioma.
</td>
<td style="text-align:left;">
Cancer Res.
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant peritoneal mesothelioma].
</td>
<td style="text-align:left;">
Chirurgia (Bucur)
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Metastatic tumors in fine needle aspiration biopsy of the thyroid.
</td>
<td style="text-align:left;">
Acta Cytol.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Placenta growth factor is a survival factor for human malignant mesothelioma cells.
</td>
<td style="text-align:left;">
Int J Immunopathol Pharmacol
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
[Laparoscopic intraperitoneal hyperthermic perfusion in palliation of malignant ascites. Case report].
</td>
<td style="text-align:left;">
G Chir
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Twenty-one patients of malignant pleural mesothelioma in the Senshu district].
</td>
<td style="text-align:left;">
Nihon Kokyuki Gakkai Zasshi
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
[Case of malignant pleural mesothelioma with long-term disease control after 4 different lines of systemic chemotherapy and pleurodesis].
</td>
<td style="text-align:left;">
Nihon Kokyuki Gakkai Zasshi
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Case of pemetrexed-induced acute lung injury].
</td>
<td style="text-align:left;">
Nihon Kokyuki Gakkai Zasshi
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Comparison of different clones (WT49 versus 6F-H2) of WT-1 antibodies for immunohistochemical diagnosis of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Appl. Immunohistochem. Mol. Morphol.
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Clinical utility of diagnostic markers for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Monaldi Arch Chest Dis
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Adaptation of a commercial fluorescent in situ hybridization test to the diagnosis of malignant cells in effusions.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Is malignant pleural mesothelioma a surgical disease? A review of 83 consecutive extra-pleural pneumonectomies.
</td>
<td style="text-align:left;">
Eur J Cardiothorac Surg
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Closed pleural biopsy to diagnose mesothelioma: dead or alive?
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
18F-fluoro-2-deoxy-D-glucose positron emission tomography and positron emission tomography/computed tomography imaging of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J Med Imaging Radiat Oncol
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Osteopontin modulates malignant pleural mesothelioma cell functions in vitro.
</td>
<td style="text-align:left;">
Anticancer Res.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Improving the outcome in malignant pleural mesothelioma: nonaggressive or aggressive approach?
</td>
<td style="text-align:left;">
Curr Opin Oncol
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleurodesis in follow-up and treatment of malignant pleural mesothelioma patients.
</td>
<td style="text-align:left;">
Tuberk Toraks
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Impact of malignant mesothelioma in Taiwan: a 27-year review of population-based cancer registry data.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
diagnosis | epidemiology | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Miliary spread of malignant pleural mesothelioma without a clinically identifiable pleural tumour.
</td>
<td style="text-align:left;">
Aust N Z J Med
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Cytogenetics and fluorescence in situ hybridization as adjuncts to cytology in the diagnosis of malignant mesothelioma.
</td>
<td style="text-align:left;">
Cancer
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Outcome for patients with malignant pleural mesothelioma referred for Trimodality therapy in Western Australia.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleural well-differentiated papillary mesothelioma: a case report.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Mesothelioma cells escape heat stress by upregulating Hsp40/Hsp70 expression via mitogen-activated protein kinases.
</td>
<td style="text-align:left;">
J. Biomed. Biotechnol.
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma: current treatments and emerging drugs.
</td>
<td style="text-align:left;">
Expert Opin Emerg Drugs
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Cytokine alteration and speculated immunological pathophysiology in silicosis and asbestos-related diseases.
</td>
<td style="text-align:left;">
Environ Health Prev Med
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Current therapies for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Environ Health Prev Med
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Evolution of pleural cancers and malignant pleural mesothelioma incidence in France between 1980 and 2005.
</td>
<td style="text-align:left;">
Int. J. Cancer
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Scoring system for differential diagnosis of malignant mesothelioma and reactive mesothelial cells on cytology specimens.
</td>
<td style="text-align:left;">
Diagn. Cytopathol.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Is D2-40 a useful marker for distinguishing malignant mesothelioma from pulmonary adenocarcinoma and benign mesothelial proliferations?
</td>
<td style="text-align:left;">
Pathol. Res. Pract.
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Pemetrexed in the treatment of advanced non-squamous lung cancer.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Interobserver variations in diagnosing asbestosis according to the ILO classification.
</td>
<td style="text-align:left;">
Arh Hig Rada Toksikol
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[A retrospective cohort study of workers in small asbestos industries in south Osaka].
</td>
<td style="text-align:left;">
Nihon Koshu Eisei Zasshi
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant pleural mesothelioma in which many asbestos bodies were counted in its specimen].
</td>
<td style="text-align:left;">
Kyobu Geka
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
[Early malignant pleural mesothelioma; report of a case].
</td>
<td style="text-align:left;">
Kyobu Geka
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Use of totally implantable central venous access port via the basilic vein in patients with thoracic malignancies.
</td>
<td style="text-align:left;">
Int. J. Clin. Oncol.
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Isolated pancreatic metastasis of a malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Kaohsiung J. Med. Sci.
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Lung cancer gene expression database analysis incorporating prior knowledge with support vector machine-based classification method.
</td>
<td style="text-align:left;">
J. Exp. Clin. Cancer Res.
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
alpha7-Nicotinic receptor antagonists at the beginning of a clinical era for NSCLC and Mesothelioma?
</td>
<td style="text-align:left;">
Drug Discov. Today
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Lymphangiomatoid pattern in diffuse malignant mesothelioma of the pleura: a report of six cases.
</td>
<td style="text-align:left;">
Virchows Arch.
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Extrapleural pneumonectomy followed by intracavitary intraoperative hyperthermic cisplatin with pharmacologic cytoprotection for treatment of malignant pleural mesothelioma: a phase II prospective study.
</td>
<td style="text-align:left;">
J. Thorac. Cardiovasc. Surg.
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
[Asbestos as a risk factor for pulmonary diseases].
</td>
<td style="text-align:left;">
Prz. Lek.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Evidence-based guidelines to optimize the selection of antibody panels in cytopathology: pleural effusions with malignant epithelioid cells.
</td>
<td style="text-align:left;">
Diagn. Cytopathol.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma: clinicopathology of 16 extrapleural pneumonectomy patients with special reference to early stage features.
</td>
<td style="text-align:left;">
Pathol. Int.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma initially diagnosed on cervical lymph node biopsy.
</td>
<td style="text-align:left;">
Pathol. Int.
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Prophylactic radiotherapy to intervention sites in mesothelioma: a systematic review and survey of UK practice.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Placenta growth factor expression has prognostic value in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Ann. Thorac. Surg.
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Utility of integrated computed tomography-positron emission tomography for selection of operable malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Clin Lung Cancer
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Localized malignant pleural mesothelioma: report of two cases.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Osteopontin is not a specific marker in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Int. J. Biol. Markers
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
The urokinase receptor supports tumorigenesis of human malignant pleural mesothelioma cells.
</td>
<td style="text-align:left;">
Am. J. Respir. Cell Mol. Biol.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant mesothelioma].
</td>
<td style="text-align:left;">
Rev Prat
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
The role of surgery in the management of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J BUON
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Guidelines for pathologic diagnosis of malignant mesothelioma: a consensus statement from the International Mesothelioma Interest Group.
</td>
<td style="text-align:left;">
Arch. Pathol. Lab. Med.
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Venous thromboembolism in patients receiving multimodality therapy for thoracic malignancies.
</td>
<td style="text-align:left;">
J. Thorac. Cardiovasc. Surg.
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Docetaxel plus gemcitabine as first-line treatment in malignant pleural mesothelioma: a single institution phase II study.
</td>
<td style="text-align:left;">
Anticancer Res.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
The Mesothelioma and Radical surgery randomized controlled trial: the Mars feasibility study.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Genome-wide profile of pleural mesothelioma versus parietal and visceral pleura: the emerging gene portrait of the mesothelioma phenotype.
</td>
<td style="text-align:left;">
PLoS ONE
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Expression of cancer-associated molecules in malignant mesothelioma.
</td>
<td style="text-align:left;">
Biomark Insights
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
CT appearances of pleural tumours.
</td>
<td style="text-align:left;">
Clin Radiol
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
The role of positron emission tomography/computed tomography in the diagnosis of pleural diseases.
</td>
<td style="text-align:left;">
Thorac Cardiovasc Surg
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
A 74-year-old man with an enlarging pleural-based mass that was not a mesothelioma.
</td>
<td style="text-align:left;">
Thorac Cardiovasc Surg
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
A patient’s journey. Mesothelioma.
</td>
<td style="text-align:left;">
BMJ
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Extrapleural pneumonectomy for malignant pleural mesothelioma: outcomes of treatment and prognostic factors.
</td>
<td style="text-align:left;">
J. Thorac. Cardiovasc. Surg.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Endoscopic ultrasound-guided fine needle aspiration for staging of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Ann. Thorac. Surg.
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Trimodality therapy for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Ann. Thorac. Surg.
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
[C-arm computed tomography for transarterial chemoperfusion and chemo-embolization of thoracic lesions].
</td>
<td style="text-align:left;">
Radiologe
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Epidermal growth factor receptor aberrations in malignant mesotheliomas].
</td>
<td style="text-align:left;">
Rinsho Byori
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Solitary fibrous tumor of the pleura: surgery and clinical course in 18 cases.
</td>
<td style="text-align:left;">
Asian Cardiovasc Thorac Ann
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Evaluation of an attenuated vesicular stomatitis virus vector expressing interferon-beta for use in malignant pleural mesothelioma: heterogeneity in interferon responsiveness defines potential efficacy.
</td>
<td style="text-align:left;">
Hum. Gene Ther.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Three decades of experience in the surgical multi-modality management of pleural mesothelioma.
</td>
<td style="text-align:left;">
Eur J Cardiothorac Surg
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Eur. Respir. J.
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Update on pleural diseases–2007.
</td>
<td style="text-align:left;">
Ann Thorac Med
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma: an update on biomarkers and treatment.
</td>
<td style="text-align:left;">
Chest
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Tenascin-X is a novel diagnostic marker of malignant mesothelioma.
</td>
<td style="text-align:left;">
Am. J. Surg. Pathol.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Hemithoracic radiotherapy after extrapleural pneumonectomy for malignant pleural mesothelioma: a dosimetric comparison of two well-described techniques.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Risk of malignant pleural mesothelioma and polymorphisms in genes involved in the genome stability and xenobiotics metabolism.
</td>
<td style="text-align:left;">
Mutat. Res.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Prognostic factors according to the treatment schedule in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Protein profiling of pleural effusions to identify malignant pleural mesothelioma using SELDI-TOF MS.
</td>
<td style="text-align:left;">
Technol. Cancer Res. Treat.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Immunocytochemical identification of carcinomas of unknown primaries on fine-needle-aspiration-biopsies].
</td>
<td style="text-align:left;">
Pathologe
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Comparison of CT and integrated PET-CT based radiation therapy planning in patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Radiat Oncol
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Pemetrexed for the treatment of non-small-cell lung cancer.
</td>
<td style="text-align:left;">
Expert Rev Anticancer Ther
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Survival after trimodality therapy for malignant pleural mesothelioma: Radical Pleurectomy, chemotherapy with Cisplatin/Pemetrexed and radiotherapy.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Intrapleural polymeric films containing cisplatin for malignant pleural mesothelioma in a rat tumour model: a preliminary study.
</td>
<td style="text-align:left;">
Eur J Cardiothorac Surg
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Proteomic differential display analysis identified upregulated astrocytic phosphoprotein PEA-15 in human malignant pleural mesothelioma cell lines.
</td>
<td style="text-align:left;">
Proteomics
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Ambulatory intercostal drainage for the management of malignant pleural effusion: a single center experience.
</td>
<td style="text-align:left;">
Ann. Surg. Oncol.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Prognostic significance of epithelial-mesenchymal transition in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Eur J Cardiothorac Surg
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleural fluid mesothelin for the differential diagnosis of exudative pleural effusions.
</td>
<td style="text-align:left;">
Med Clin (Barc)
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Pemetrexed-induced pneumonitis: a case report.
</td>
<td style="text-align:left;">
Clin Lung Cancer
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Activated cAMP response element binding protein is overexpressed in human mesotheliomas and inhibits apoptosis.
</td>
<td style="text-align:left;">
Am. J. Pathol.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Pemetrexed in the treatment of malignant mesothelioma: results from an expanded access program in Germany.
</td>
<td style="text-align:left;">
Respir Med
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Significance of cell proliferation markers (Minichromosome maintenance protein 7, topoisomerase IIalpha and Ki-67) in cavital fluid cytology: can we differentiate reactive mesothelial cells from malignant cells?
</td>
<td style="text-align:left;">
Diagn. Cytopathol.
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Current status of screening for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Semin. Thorac. Cardiovasc. Surg.
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Recent advances in mesothelioma staging.
</td>
<td style="text-align:left;">
Semin. Thorac. Cardiovasc. Surg.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Current trends in radiologic management of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Semin. Thorac. Cardiovasc. Surg.
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Pathologic evaluation of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Semin. Thorac. Cardiovasc. Surg.
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Mesothelioma: path to multimodality treatment.
</td>
<td style="text-align:left;">
Semin. Thorac. Cardiovasc. Surg.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Surgical techniques for multimodality treatment of malignant pleural mesothelioma: extrapleural pneumonectomy and pleurectomy/decortication.
</td>
<td style="text-align:left;">
Semin. Thorac. Cardiovasc. Surg.
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Surgical options in malignant pleural mesothelioma: extrapleural pneumonectomy or pleurectomy/decortication.
</td>
<td style="text-align:left;">
Semin. Thorac. Cardiovasc. Surg.
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Radiation therapy options for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Semin. Thorac. Cardiovasc. Surg.
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Palliative care for the patient with mesothelioma.
</td>
<td style="text-align:left;">
Semin. Thorac. Cardiovasc. Surg.
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Multimodality strategies in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Semin. Thorac. Cardiovasc. Surg.
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Photodynamic therapy as an innovative treatment for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Semin. Thorac. Cardiovasc. Surg.
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Making the case for molecular staging of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Semin. Thorac. Cardiovasc. Surg.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma of the greater omentum mimicking omental infarction: a case report.
</td>
<td style="text-align:left;">
World J. Gastroenterol.
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Asbestos exposure and malignant mesothelioma in Korea.
</td>
<td style="text-align:left;">
Asian Pac. J. Cancer Prev.
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Tract metastasis from previously unknown malignant pleural mesothelioma: a case report.
</td>
<td style="text-align:left;">
Cases J
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma with long-term tumor disappearance of a local relapse after surgery: a case report.
</td>
<td style="text-align:left;">
J Med Case Rep
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Treatment of pleural metastases in an interdisciplinary concept].
</td>
<td style="text-align:left;">
Langenbecks Arch Chir Suppl II Verh Dtsch Ges Chir
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Staging algorithm for diffuse malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Interact Cardiovasc Thorac Surg
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
High-dose-rate surface brachytherapy to boost elongated, curvilinear incisional scars after extrapleural pneumonectomy for malignant pleural mesothelioma treated with adjuvant intensity-modulated radiation therapy.
</td>
<td style="text-align:left;">
Brachytherapy
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Mechanisms of FUS1/TUSC2 deficiency in mesothelioma and its tumorigenic transcriptional effects.
</td>
<td style="text-align:left;">
Mol. Cancer
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Combined treatment with cisplatin and sirolimus to enhance cell death in human mesothelioma.
</td>
<td style="text-align:left;">
J. Thorac. Cardiovasc. Surg.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Post-transcriptional regulation of plasminogen activator inhibitor type-1 expression in human pleural mesothelial cells.
</td>
<td style="text-align:left;">
Am. J. Respir. Cell Mol. Biol.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
[Medical insurance aspects of peritoneal tumors with particular attention to peritoneal mesotheliomas].
</td>
<td style="text-align:left;">
Med. Klin. (Munich)
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Polymorphisms in the putative micro-RNA-binding sites of mesothelin gene are associated with serum levels of mesothelin-related protein.
</td>
<td style="text-align:left;">
Occup Environ Med
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Primary small cell carcinoma of the pleura: a case report with immunohistochemical and molecular genetic analyses of KIT and PDGFRA genes.
</td>
<td style="text-align:left;">
Med. Oncol.
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Porcelain factory worker with asbestos-related mesothelioma.
</td>
<td style="text-align:left;">
J. Formos. Med. Assoc.
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Clinical value of fluorodeoxyglucose-positron emission tomography/computed tomography in differentiation of malignant mesothelioma from asbestos-related benign pleural disease: an observational pilot study.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
An orthotopic implantation mouse model of human malignant pleural mesothelioma for in vivo photon counting analysis and evaluation of the effect of S-1 therapy.
</td>
<td style="text-align:left;">
Int. J. Cancer
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Second-line treatment for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Cancer Treat. Rev.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Well-differentiated papillary mesothelioma with invasion to the chest wall.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant peritoneal mesothelioma: quantitative analysis of asbestos burden.
</td>
<td style="text-align:left;">
Pathol. Int.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Estimation of pulmonary motion in healthy subjects and patients with intrathoracic tumors using 3D-dynamic MRI: initial results.
</td>
<td style="text-align:left;">
Korean J Radiol
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Intrapleural cisplatin and cytarabine in the management of malignant pleural effusions: a Lung Cancer Study Group trial.
</td>
<td style="text-align:left;">
J. Clin. Oncol.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Epigenetic profiles distinguish malignant pleural mesothelioma from lung adenocarcinoma.
</td>
<td style="text-align:left;">
Cancer Res.
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Late cutaneous metastases to the face from malignant pleural mesothelioma: a case report and review of the literature.
</td>
<td style="text-align:left;">
World J Surg Oncol
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Survival and relapse pattern after trimodality therapy for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Gen Thorac Cardiovasc Surg
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Molecular targets in malignant pleural mesothelioma treatment.
</td>
<td style="text-align:left;">
Curr Drug Targets
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Cellular and molecular basis of the asbestos-related diseases.
</td>
<td style="text-align:left;">
Am. Rev. Respir. Dis.
</td>
<td style="text-align:left;">
epidemiology | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Asbestos-related cancers among 28,300 military servicemen in the Royal Norwegian Navy.
</td>
<td style="text-align:left;">
Am. J. Ind. Med.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Cul4A is an oncogene in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J. Cell. Mol. Med.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Neurotensin expression and outcome of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Biochimie
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
E7080, a multi-tyrosine kinase inhibitor, suppresses the progression of malignant pleural mesothelioma with different proangiogenic cytokine production profiles.
</td>
<td style="text-align:left;">
Clin. Cancer Res.
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
[Carcinoembryonic antigen in serum and pleural fluid to distinguish between bronchial carcinoma and pleural mesothelioma].
</td>
<td style="text-align:left;">
Dtsch. Med. Wochenschr.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma presenting as low back pain: diagnosed by bone scan coordinating with F-18 FDG PET/CT.
</td>
<td style="text-align:left;">
Spine
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
A novel translational approach for human malignant pleural mesothelioma: heparanase-assisted dual virotherapy.
</td>
<td style="text-align:left;">
Oncogene
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Treatment with interleukin-2 in malignant pleural mesothelioma: immunological and angiogenetic assessment and prognostic impact.
</td>
<td style="text-align:left;">
Br. J. Cancer
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Diagnostic value of soluble mesothelin-related peptides for malignant mesothelioma: a meta-analysis.
</td>
<td style="text-align:left;">
Respir Med
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Targeted proteasome inhibition by Velcade induces apoptosis in human mesothelioma and breast cancer cell lines.
</td>
<td style="text-align:left;">
Cancer Chemother. Pharmacol.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant peritoneal mesothelioma: contribution and limitation of imaging for its diagnosis.
</td>
<td style="text-align:left;">
JBR-BTR
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
[Diagnosis of malignant pleural mesothelioma–thoracoscopic biopsy and tumor marker].
</td>
<td style="text-align:left;">
Nihon Geka Gakkai Zasshi
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
[Therapeutic strategies for resectable malignant pleural mesothelioma].
</td>
<td style="text-align:left;">
Nihon Geka Gakkai Zasshi
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[What is the role of pleuropneumonectomy in malignant pleural mesothelioma?].
</td>
<td style="text-align:left;">
Nihon Geka Gakkai Zasshi
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
[Intrapleural perfusion hyperthermo-chemotherapy with cisplatin in patients with malignant pleural mesothelioma].
</td>
<td style="text-align:left;">
Nihon Geka Gakkai Zasshi
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Cisplatin-induced expression of Gb3 enables verotoxin-1 treatment of cisplatin resistance in malignant pleural mesothelioma cells.
</td>
<td style="text-align:left;">
Br. J. Cancer
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Case-control study of pleural mesothelioma in workers with social security in Mexico.
</td>
<td style="text-align:left;">
Am. J. Ind. Med.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Expression of blood group-related antigens and Helix pomatia agglutinin in malignant pleural mesothelioma and pulmonary adenocarcinoma.
</td>
<td style="text-align:left;">
Hum. Pathol.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma: biology, diagnosis and therapeutic approaches.
</td>
<td style="text-align:left;">
Curr Mol Pharmacol
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleural malignant mesothelioma with invasive micropapillary component and its association with pulmonary metastasis.
</td>
<td style="text-align:left;">
Pathol. Int.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Comparison of diagnostic quality and accuracy in color-coded versus gray-scale DCE-MR imaging display.
</td>
<td style="text-align:left;">
Int J Comput Assist Radiol Surg
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Chest CT combined with artificial pneumothorax: value in determining origin and extent of tumor.
</td>
<td style="text-align:left;">
AJR Am J Roentgenol
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Histone deacetylase inhibitors in malignant pleural mesothelioma: preclinical rationale and clinical trials.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Sorafenib inhibits ERK1/2 and MCL-1(L) phosphorylation levels resulting in caspase-independent cell death in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Cancer Biol. Ther.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Differentially expressed alternatively spliced genes in malignant pleural mesothelioma identified using massively parallel transcriptome sequencing.
</td>
<td style="text-align:left;">
BMC Med. Genet.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma.
</td>
<td style="text-align:left;">
Br. Med. Bull.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Biopersistence and potential adverse health impacts of fibrous nanomaterials: what have we learned from asbestos?
</td>
<td style="text-align:left;">
Wiley Interdiscip Rev Nanomed Nanobiotechnol
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
The sensitivity of cytologic evaluation of pleural fluid in the diagnosis of malignant mesothelioma.
</td>
<td style="text-align:left;">
Diagn. Cytopathol.
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
The role of folate receptor alpha (FRalpha) in the response of malignant pleural mesothelioma to pemetrexed-containing chemotherapy.
</td>
<td style="text-align:left;">
Br. J. Cancer
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Multimodality treatment of malignant pleural mesothelioma with or without immunotherapy: does it change anything?
</td>
<td style="text-align:left;">
Interact Cardiovasc Thorac Surg
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
IMP3/L523S, a novel immunocytochemical marker that distinguishes benign and malignant cells: the expression profiles of IMP3/L523S in effusion cytology.
</td>
<td style="text-align:left;">
Hum. Pathol.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Occupational cancers in Poland, 1995-2003].
</td>
<td style="text-align:left;">
Med Pr
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Asbestos, lung cancers, and mesotheliomas: from molecular approaches to targeting tumor survival pathways.
</td>
<td style="text-align:left;">
Am. J. Respir. Cell Mol. Biol.
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
A phase I trial of repeated intrapleural adenoviral-mediated interferon-beta gene transfer for mesothelioma and metastatic pleural effusions.
</td>
<td style="text-align:left;">
Mol. Ther.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Cold-plasma coagulation in the treatment of malignant pleural mesothelioma: results of a combined approach.
</td>
<td style="text-align:left;">
Interact Cardiovasc Thorac Surg
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Diagnostic performance of soluble mesothelin and megakaryocyte potentiating factor in mesothelioma.
</td>
<td style="text-align:left;">
Am. J. Respir. Crit. Care Med.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Sarcomatoid mesothelioma: a clinical-pathologic correlation of 326 cases.
</td>
<td style="text-align:left;">
Mod. Pathol.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Carboplatin plus pemetrexed as first-line treatment of patients with malignant pleural mesothelioma: a phase II study.
</td>
<td style="text-align:left;">
Clin Lung Cancer
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Role of integrated 18-fluorodeoxyglucose position emission tomography-computed tomography in patients surveillance after multimodality therapy of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Gefitinib targets EGFR dimerization and ERK1/2 phosphorylation to inhibit pleural mesothelioma cell proliferation.
</td>
<td style="text-align:left;">
Curr Cancer Drug Targets
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Biological agents involved in malignant mesothelioma: relevance as biomarkers or therapeutic targets.
</td>
<td style="text-align:left;">
Curr Cancer Drug Targets
</td>
<td style="text-align:left;">
epidemiology | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Primary pleural epithelioid angiosarcoma. A case report and review of the literature.
</td>
<td style="text-align:left;">
Pathol. Res. Pract.
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Computed tomography of asbestos-related pulmonary parenchymal and pleural diseases.
</td>
<td style="text-align:left;">
Clin. Chest Med.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Osteopontin-mediated enhanced hyaluronan binding induces multidrug resistance in mesothelioma cells.
</td>
<td style="text-align:left;">
Oncogene
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Increasing of malignant pleural mesothelioma: burning issue in Split-Dalmatian County, Croatia.
</td>
<td style="text-align:left;">
Coll Antropol
</td>
<td style="text-align:left;">
epidemiology | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Second surgery for recurrence of malignant pleural mesothelioma after extrapleural pneumonectomy.
</td>
<td style="text-align:left;">
Ann. Thorac. Surg.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Inhibition of Met/HGF receptor and angiogenesis by NK4 leads to suppression of tumor growth and migration in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Int. J. Cancer
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Arginine deprivation and argininosuccinate synthetase expression in the treatment of cancer.
</td>
<td style="text-align:left;">
Int. J. Cancer
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Proposed adjustments to pathologic staging of epithelial malignant pleural mesothelioma based on analysis of 354 cases.
</td>
<td style="text-align:left;">
Cancer
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
[Management of pleural disease].
</td>
<td style="text-align:left;">
Arch. Bronconeumol.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Primary malignant mesothelioma of the pericardium.
</td>
<td style="text-align:left;">
Cardiovasc. Pathol.
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Predictors of mortality within three months in the patients with malignant pleural effusion.
</td>
<td style="text-align:left;">
Eur. J. Intern. Med.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Kindlin-2 is expressed in malignant mesothelioma and is required for tumor cell adhesion and migration.
</td>
<td style="text-align:left;">
Int. J. Cancer
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Hyaluronan in pleural effusions and in serum.
</td>
<td style="text-align:left;">
Cancer
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Surgical assessment of malignant pleural mesothelioma: have we reached a critical stage?
</td>
<td style="text-align:left;">
Eur J Cardiothorac Surg
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Fluorescence in situ hybridization in the definitive diagnosis of malignant mesothelioma in effusion cytology.
</td>
<td style="text-align:left;">
Chest
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Downregulation of Bcl-xL and Mcl-1 is sufficient to induce cell death in mesothelioma cells highly refractory to conventional chemotherapy.
</td>
<td style="text-align:left;">
Carcinogenesis
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Phase II study of gemcitabine plus docetaxel as second-line treatment in malignant pleural mesothelioma: a single institution study.
</td>
<td style="text-align:left;">
Am. J. Clin. Oncol.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Podoplanin is a useful marker for identifying mesothelioma in malignant effusions.
</td>
<td style="text-align:left;">
Diagn. Cytopathol.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Localized intrapancreatic malignant mesothelioma: a rare entity that may be confused with other pancreatic neoplasms.
</td>
<td style="text-align:left;">
Virchows Arch.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Knockdown of COPA, identified by loss-of-function screen, induces apoptosis and suppresses tumor growth in mesothelioma mouse model.
</td>
<td style="text-align:left;">
Genomics
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Effect of induction chemotherapy on lung function and exercise capacity in patients affected by malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Eur J Cardiothorac Surg
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Medical thoracoscopy vs CT scan-guided Abrams pleural needle biopsy for diagnosis of patients with pleural effusions: a randomized, controlled trial.
</td>
<td style="text-align:left;">
Chest
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Minute localized malignant pleural mesothelioma coexisting with multiple adenocarcinomas.
</td>
<td style="text-align:left;">
Gen Thorac Cardiovasc Surg
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Cigarette smoking, asbestos exposure, and malignant mesothelioma.
</td>
<td style="text-align:left;">
Cancer Res.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
hsa-miR-29c* is linked to the prognosis of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Cancer Res.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Gene therapy for mesothelioma and lung cancer.
</td>
<td style="text-align:left;">
Am. J. Respir. Cell Mol. Biol.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Two cases of pulmonary sarcomatoid carcinoma mimicking malignant mesothelioma].
</td>
<td style="text-align:left;">
Nihon Kokyuki Gakkai Zasshi
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
25-year old male with pleural thickening.
</td>
<td style="text-align:left;">
Lung India
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Consolidative dendritic cell-based immunotherapy elicits cytotoxicity against malignant mesothelioma.
</td>
<td style="text-align:left;">
Am. J. Respir. Crit. Care Med.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Therapeutic surgery for nonepithelioid malignant pleural mesothelioma: is it really worthwhile?
</td>
<td style="text-align:left;">
Ann. Thorac. Surg.
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
In vitro and in vivo characterization of highly purified human mesothelioma derived cells.
</td>
<td style="text-align:left;">
BMC Cancer
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Thymidylate synthase but not excision repair cross-complementation group 1 tumor expression predicts outcome in patients with malignant pleural mesothelioma treated with pemetrexed-based chemotherapy.
</td>
<td style="text-align:left;">
J. Clin. Oncol.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
What’s the place of immunotherapy in malignant mesothelioma treatments?
</td>
<td style="text-align:left;">
Cell Adh Migr
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
A novel clinical role for angiopoietin-1 in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Eur. Respir. J.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Diagnostic usefulness of endobronchial ultrasound-guided transbronchial needle aspiration in a case with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Intern. Med.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Metsovo lung outside Metsovo. Endemic pleural calcifications in the ophiolite belts of Greece.
</td>
<td style="text-align:left;">
Chest
</td>
<td style="text-align:left;">
epidemiology
</td>
</tr>
<tr>
<td style="text-align:left;">
Deciduoid mesothelioma of the pleura in an adolescent boy.
</td>
<td style="text-align:left;">
Pediatr Hematol Oncol
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
The use of immunohistochemistry to distinguish reactive mesothelial cells from malignant mesothelioma in cytologic effusions.
</td>
<td style="text-align:left;">
Cancer Cytopathol
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Benign multicystic peritoneal mesothelioma associated with hydronephrosis and colovesical fistula formation: report of a case.
</td>
<td style="text-align:left;">
Tumori
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Clinical investigation of malignant mesothelioma in Japan.
</td>
<td style="text-align:left;">
J. Cancer Res. Clin. Oncol.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Outcome of patients with nonspecific pleuritis/fibrosis on thoracoscopic pleural biopsies.
</td>
<td style="text-align:left;">
Eur J Cardiothorac Surg
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Retreatment of recurrent malignant pleural mesothelioma with cisplatin and pemetrexed.
</td>
<td style="text-align:left;">
Int. J. Clin. Oncol.
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma presenting as an acute surgical abdomen due to metastatic jejunal perforation.
</td>
<td style="text-align:left;">
Intern. Med.
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
The influence of the diagnostic technique on the histopathological diagnosis in malignant mesothelioma.
</td>
<td style="text-align:left;">
Virchows Arch A Pathol Anat Histopathol
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Mesothelioma presenting with pneumothorax and interlobar tumour.
</td>
<td style="text-align:left;">
Eur. Respir. J.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Current concepts in chemotherapy for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Clin Respir J
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Treatment of malignant pleural mesothelioma with liposomized doxorubicine: prolonged time to progression and good survival. A Nordic study.
</td>
<td style="text-align:left;">
Clin Respir J
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma.
</td>
<td style="text-align:left;">
Intern Med J
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Palliative treatment of malignant pleural effusions.
</td>
<td style="text-align:left;">
Acta Chir. Belg.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
[A case of malignant pleural mesothelioma that responded to cisplatin plus pemetrexed rechallenge].
</td>
<td style="text-align:left;">
Gan To Kagaku Ryoho
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
The differential diagnosis of epithelial-type mesothelioma from adenocarcinoma and reactive mesothelial proliferation.
</td>
<td style="text-align:left;">
J. Pathol.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
May cyclooxygenase-2 (COX-2), p21 and p27 expression affect prognosis and therapeutic strategy of patients with malignant pleural mesothelioma?
</td>
<td style="text-align:left;">
Eur J Cardiothorac Surg
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Mesothelioma risk associated with asbestos production in Slovenia.
</td>
<td style="text-align:left;">
Arh Hig Rada Toksikol
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Factors affecting soluble mesothelin related protein levels in an asbestos-exposed population.
</td>
<td style="text-align:left;">
Clin. Chem. Lab. Med.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Life after first-line chemotherapy in malignant pleural mesothelioma: a North-East England experience.
</td>
<td style="text-align:left;">
Clin Oncol (R Coll Radiol)
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Tissue and serum EGFR as prognostic factors in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Obtaining an upper estimate of the survival benefit associated with surgery for mesothelioma.
</td>
<td style="text-align:left;">
Eur J Cardiothorac Surg
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Clinical significance of serum vascular endothelial growth factor in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
In vitro anti-mesothelioma activity of cisplatin-gemcitabine combinations: evidence for sequence-dependent effects.
</td>
<td style="text-align:left;">
Cancer Chemother. Pharmacol.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
A novel prognostic model for malignant mesothelioma incorporating quantitative FDG-PET imaging with clinical parameters.
</td>
<td style="text-align:left;">
Clin. Cancer Res.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Localized malignant pleural mesothelioma showing a thoracic mass and metastasizing to the stomach.
</td>
<td style="text-align:left;">
Intern. Med.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Volumetric modulation arc radiotherapy compared with static gantry intensity-modulated radiotherapy for malignant pleural mesothelioma tumor: a feasibility study.
</td>
<td style="text-align:left;">
Int. J. Radiat. Oncol. Biol. Phys.
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Proton therapy for malignant pleural mesothelioma after extrapleural pleuropneumonectomy.
</td>
<td style="text-align:left;">
Int. J. Radiat. Oncol. Biol. Phys.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma in Italy.
</td>
<td style="text-align:left;">
Indian J Occup Environ Med
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma without asbestos exposure with distant metastasis in a peripheral lymph node: a case report.
</td>
<td style="text-align:left;">
Lung India
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
[Surgical treatment of primary pleural tumours in our department].
</td>
<td style="text-align:left;">
Magy Seb
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleural malignant mesothelioma with osteoclast-like giant cells.
</td>
<td style="text-align:left;">
Pathol. Int.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Early and late morbidity and mortality and life expectancy following thoracoscopic talc insufflation for control of malignant pleural effusions: a review of 400 cases.
</td>
<td style="text-align:left;">
J Cardiothorac Surg
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Translational therapies for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Expert Rev Respir Med
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Phase II study of asparagine-glycine-arginine-human tumor necrosis factor alpha, a selective vascular targeting agent, in previously treated patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J. Clin. Oncol.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Expert opinions of the first italian consensus conference on the management of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Am. J. Clin. Oncol.
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
PAX8 reliably distinguishes ovarian serous tumors from malignant mesothelioma.
</td>
<td style="text-align:left;">
Am. J. Surg. Pathol.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Radiologic manifestation of primary pleural tumors].
</td>
<td style="text-align:left;">
Acta Chir Iugosl
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Assessment of therapy responses and prediction of survival in malignant pleural mesothelioma through computer-aided volumetric measurement on computed tomography scans.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Soluble mesothelin-related protein in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J Egypt Natl Canc Inst
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma in a patient with anthophyllite asbestos fibres in the lungs.
</td>
<td style="text-align:left;">
Ann Occup Hyg
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Chemotherapy induced pathologic complete response in malignant pleural mesothelioma: a review and case report.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Value of D2-40 in the differential diagnosis of pleural neoplasms with emphasis on its positivity in solitary fibrous tumor.
</td>
<td style="text-align:left;">
Appl. Immunohistochem. Mol. Morphol.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Prognostic factors for 100 patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Arch Environ Occup Health
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Lung India
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Activity of doxorubicin and cisplatin combination chemotherapy in patients with diffuse malignant pleural mesothelioma. An Italian Lung Cancer Task Force (FONICAP) Phase II study.
</td>
<td style="text-align:left;">
Cancer
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant peritoneal mesothelioma].
</td>
<td style="text-align:left;">
Rev Gastroenterol Peru
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Pemetrexed safety and pharmacokinetics in patients with third-space fluid.
</td>
<td style="text-align:left;">
Clin. Cancer Res.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Volume-based parameter of 18)F-FDG PET/CT in malignant pleural mesothelioma: prediction of therapeutic response and prognostic implications.
</td>
<td style="text-align:left;">
Ann. Surg. Oncol.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[A case of malignant pericardial mesothelioma detected by gallium-67 scintigraphy].
</td>
<td style="text-align:left;">
Kaku Igaku
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Pro-tumorigenic effects of miR-31 loss in mesothelioma.
</td>
<td style="text-align:left;">
J. Biol. Chem.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Monitoring the effectiveness of surgical treatment of malignant pleural effusions].
</td>
<td style="text-align:left;">
Klin Onkol
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma: the standard of care and challenges for future management.
</td>
<td style="text-align:left;">
Crit. Rev. Oncol. Hematol.
</td>
<td style="text-align:left;">
diagnosis | treatment | epidemiology | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
A new technique of diaphragmatic patch fixation in extrapleural pneumonectomy.
</td>
<td style="text-align:left;">
Eur J Cardiothorac Surg
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
[Thoracic pain, dyspnea].
</td>
<td style="text-align:left;">
Schweiz. Rundsch. Med. Prax.
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Second generation sequencing of the mesothelioma tumor genome.
</td>
<td style="text-align:left;">
PLoS ONE
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Soluble mesothelin-related Peptide and osteopontin as markers of response in malignant mesothelioma.
</td>
<td style="text-align:left;">
J. Clin. Oncol.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Diagnosis and origin determination of malignant pleural effusions through the use of the breast cancer marker human mammaglobin.
</td>
<td style="text-align:left;">
Diagn. Mol. Pathol.
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
[Reconstruction of anterior chest wall defect with ceramic bone grafts–a case of localized malignant mesothelioma].
</td>
<td style="text-align:left;">
Nihon Kyobu Geka Gakkai Zasshi
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Integrated positron emission tomography-computed tomography does not accurately stage intrathoracic disease of patients undergoing trimodality therapy for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Thorac Cardiovasc Surg
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
9p21 deletion in the diagnosis of malignant mesothelioma, using fluorescence in situ hybridization analysis.
</td>
<td style="text-align:left;">
Pathol. Int.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Treatment of cases of cardiac surgery complicated with malignant neoplasms].
</td>
<td style="text-align:left;">
Nihon Geka Gakkai Zasshi
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
[Asbestos-related diseases of the thorax].
</td>
<td style="text-align:left;">
Radiologe
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Surgery for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Expert Rev Respir Med
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Trimodality therapy for malignant pleural mesothelioma: results from an EORTC phase II multicentre trial.
</td>
<td style="text-align:left;">
Eur. Respir. J.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Valproate-doxorubicin: promising therapy for progressing mesothelioma. A phase II study.
</td>
<td style="text-align:left;">
Eur. Respir. J.
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
WT1 peptide vaccinations induce CD4 and CD8 T cell immune responses in patients with mesothelioma and non-small cell lung cancer.
</td>
<td style="text-align:left;">
Cancer Immunol. Immunother.
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
The efficacy of the frontline platinum-based combination chemotherapy in malignant peritoneal mesothelioma.
</td>
<td style="text-align:left;">
Jpn. J. Clin. Oncol.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Imaging in pleural mesothelioma: a review of imaging research presented at the 9th International Meeting of the International Mesothelioma Interest Group.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Synergistic antitumor effects of regulatory T cell blockade combined with pemetrexed in murine malignant mesothelioma.
</td>
<td style="text-align:left;">
J. Immunol.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[A case of pulmonary epithelioid hemangioendothelioma that required differentiation from malignant mesothelioma].
</td>
<td style="text-align:left;">
Nihon Kokyuki Gakkai Zasshi
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
[Osteoarthropathy].
</td>
<td style="text-align:left;">
Gan To Kagaku Ryoho
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
CD8+ tumor-infiltrating lymphocytes predict favorable prognosis in malignant pleural mesothelioma after resection.
</td>
<td style="text-align:left;">
Cancer Immunol. Immunother.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Pearls and myths in pleural fluid analysis.
</td>
<td style="text-align:left;">
Respirology
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Mesothelin (MSLN) promoter is hypomethylated in malignant mesothelioma, but its expression is not associated with methylation status of the promoter.
</td>
<td style="text-align:left;">
Hum. Pathol.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Integrin-linked kinase, phosphorylated AKT and the prognosis of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Eur J Cardiothorac Surg
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Vinflunine: review of a new vinca alkaloid and its potential role in oncology.
</td>
<td style="text-align:left;">
J Oncol Pharm Pract
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
FISH assay development for the detection of p16/CDKN2A deletion in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J. Clin. Pathol.
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Multimodality approach to malignant pleural mesothelioma. A case report.
</td>
<td style="text-align:left;">
Ann Ital Chir
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Establishment of in vivo fluorescence imaging in mouse models of malignant mesothelioma.
</td>
<td style="text-align:left;">
Int. J. Oncol.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Putative cancer stem cells in malignant pleural mesothelioma show resistance to cisplatin and pemetrexed.
</td>
<td style="text-align:left;">
Int. J. Oncol.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Successful salvage chemotherapy with gemcitabine and vinorelbine in a malignant pleural mesothelioma patient previously treated with pemetrexed.
</td>
<td style="text-align:left;">
Jpn. J. Clin. Oncol.
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
In vitro and in vivo therapeutic efficacy of the PPAR-γ agonist troglitazone in combination with cisplatin against malignant pleural mesothelioma cell growth.
</td>
<td style="text-align:left;">
Cancer Sci.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Predominantly fibrous malignant mesothelioma in a cat.
</td>
<td style="text-align:left;">
Vet Med Int
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Programmed necrosis induced by asbestos in human mesothelial cells causes high-mobility group box 1 protein release and resultant inflammation.
</td>
<td style="text-align:left;">
Proc. Natl. Acad. Sci. U.S.A.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Molecular imaging of mesothelioma by detection of manganese-superoxide dismutase activity using manganese-enhanced magnetic resonance imaging.
</td>
<td style="text-align:left;">
Int. J. Cancer
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Methylation of MGMT in malignant pleural mesothelioma occurs in a subset of patients and is associated with the T allele of the rs16906252 MGMT promoter SNP.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Secretion of intelectin-1 from malignant pleural mesothelioma into pleural effusion.
</td>
<td style="text-align:left;">
Br. J. Cancer
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
The incidence of medically reported work-related ill health in the UK construction industry.
</td>
<td style="text-align:left;">
Occup Environ Med
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Diffusion-weighted MRI of malignant pleural mesothelioma: preliminary assessment of apparent diffusion coefficient in histologic subtypes.
</td>
<td style="text-align:left;">
AJR Am J Roentgenol
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Usefulness of the nude mouse model in mesothelioma based on a direct patient-xenograft comparison.
</td>
<td style="text-align:left;">
Cancer
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Prevalence of in vitro chemotherapeutic drug resistance in primary malignant pleural mesothelioma: result in a cohort of 203 resection specimens.
</td>
<td style="text-align:left;">
J. Thorac. Cardiovasc. Surg.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Immunocytochemistry of CD146 is useful to discriminate between malignant pleural mesothelioma and reactive mesothelium.
</td>
<td style="text-align:left;">
Mod. Pathol.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Preliminary study of positron emission tomography/computed tomography and plasma osteopontin levels in patients with asbestos-related pleural disease.
</td>
<td style="text-align:left;">
Jpn J Radiol
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
[Effect of cigarette smoking and/or N-bis(2-hydroxypropyl)nitrosamine (DHPN) on the development of lung and pleural tumors in rats induced by administration of asbestos].
</td>
<td style="text-align:left;">
Sangyo Igaku
</td>
<td style="text-align:left;">
treatment | epidemiology
</td>
</tr>
<tr>
<td style="text-align:left;">
Analysis of the effect of radiotherapy on malignant pleural mesothelioma when given on adjuvant or palliative basis.
</td>
<td style="text-align:left;">
Zhongguo Fei Ai Za Zhi
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Diagnosis of diffuse malignant mesothelioma: experience of a US/Canadian Mesothelioma Panel.
</td>
<td style="text-align:left;">
Mod. Pathol.
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
[A case of localized malignant pleural mesothelioma].
</td>
<td style="text-align:left;">
Nihon Kokyuki Gakkai Zasshi
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
[Pulmonary concentration of asbestos fibers in steel workers with pleural mesothelioma].
</td>
<td style="text-align:left;">
G Ital Med Lav Ergon
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Receptor tyrosine kinase and downstream signalling analysis in diffuse malignant peritoneal mesothelioma.
</td>
<td style="text-align:left;">
Eur. J. Cancer
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
How successful is lung-preserving radical surgery in the mesothelioma and radical surgery-trial environment? A case-controlled analysis.
</td>
<td style="text-align:left;">
Eur J Cardiothorac Surg
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Extrapleural pneumonectomy, photodynamic therapy and intensity modulated radiation therapy for the treatment of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Cancer Biol. Ther.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleural mesothelioma.
</td>
<td style="text-align:left;">
Curr Opin Oncol
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Multiple bowel intussusceptions from metastatic localized malignant pleural mesothelioma: a case report.
</td>
<td style="text-align:left;">
World J. Gastroenterol.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
[Technical pitfalls of pleural dissection in extrapleural pneumonectomy].
</td>
<td style="text-align:left;">
Kyobu Geka
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleural liposarcoma mimicking carcinoma in pleural effusion cytology: a case report.
</td>
<td style="text-align:left;">
Acta Cytol.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Inflammation precedes the development of human malignant mesotheliomas in a SCID mouse xenograft model.
</td>
<td style="text-align:left;">
Ann. N. Y. Acad. Sci.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
SV40 associated miRNAs are not detectable in mesotheliomas.
</td>
<td style="text-align:left;">
Br. J. Cancer
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma with associated minimal change disease and acute renal failure.
</td>
<td style="text-align:left;">
Ren Fail
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
The role of extrapleural pneumonectomy in malignant pleural mesothelioma. A Lung Cancer Study Group trial.
</td>
<td style="text-align:left;">
J. Thorac. Cardiovasc. Surg.
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Extrapleural pneumonectomy, chemotherapy, and radiotherapy in the treatment of diffuse malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J. Thorac. Cardiovasc. Surg.
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Characteristics of malignant pleural mesothelioma in women.
</td>
<td style="text-align:left;">
Ann. Thorac. Surg.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
A phase II study of sorafenib in malignant mesothelioma: results of Cancer and Leukemia Group B 30307.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Performance of biomarkers SMRP, CA125, and CYFRA 21-1 as potential tumor markers for malignant mesothelioma and lung cancer in a cohort of workers formerly exposed to asbestos.
</td>
<td style="text-align:left;">
Arch. Toxicol.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
A case of cardiac herniation after extrapleural pneumonectomy for malignant thymoma.
</td>
<td style="text-align:left;">
J Anesth
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Primary Pericardial Mesothelioma: Report of a Patient and Literature Review.
</td>
<td style="text-align:left;">
Case Rep Oncol
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Analysis of pleural plaque found at lung cancer screening examination].
</td>
<td style="text-align:left;">
Nihon Kyobu Shikkan Gakkai Zasshi
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Incidence of extrapleural malignant mesothelioma and asbestos exposure, from the Italian national register.
</td>
<td style="text-align:left;">
Occup Environ Med
</td>
<td style="text-align:left;">
diagnosis | epidemiology | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Survival and prognostic factors in malignant pleural mesothelioma: a retrospective study of 314 patients in the west part of Japan.
</td>
<td style="text-align:left;">
Jpn. J. Clin. Oncol.
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma detected by spontaneous pneumothorax.
</td>
<td style="text-align:left;">
Jpn J Radiol
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
A systematic review of extrapleural pneumonectomy for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Prognostic factors for survival after surgical palliation of malignant pleural effusion.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
[Lung asbestos fibre burden in textile workers with malignant mesothelioma].
</td>
<td style="text-align:left;">
Med Lav
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Sensitivity of urinary mesothelin in patients with malignant mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
The diagnostic utility of maspin in the distinction between malignant mesothelioma and pulmonary adenocarcinoma.
</td>
<td style="text-align:left;">
J. Int. Med. Res.
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Mechanisms of oxidative stress and alterations in gene expression by Libby six-mix in human mesothelial cells.
</td>
<td style="text-align:left;">
Part Fibre Toxicol
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Cytological differential diagnosis among adenocarcinoma, epithelial mesothelioma, and reactive mesothelial cells in serous effusions by immunocytochemistry.
</td>
<td style="text-align:left;">
Diagn. Cytopathol.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma in a female lion (Panthera leo).
</td>
<td style="text-align:left;">
Res. Vet. Sci.
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Expression of thyroid transcription factor-1 in malignant pleural effusions.
</td>
<td style="text-align:left;">
Pathol. Oncol. Res.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Expectations after ban on asbestos].
</td>
<td style="text-align:left;">
Arh Hig Rada Toksikol
</td>
<td style="text-align:left;">
diagnosis | treatment | epidemiology | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Incidence of malignant pleural mesothelioma in Split-Dalmatia County].
</td>
<td style="text-align:left;">
Arh Hig Rada Toksikol
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant pleural mesothelioma in patients hospitalised at the Clinical Hospital Centre Rijeka between 1989 and 2008].
</td>
<td style="text-align:left;">
Arh Hig Rada Toksikol
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Immunological aspects of asbestos-related diseases].
</td>
<td style="text-align:left;">
Arh Hig Rada Toksikol
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Croatian and international regulations on the protection and rights of workers exposed to asbestos at work].
</td>
<td style="text-align:left;">
Arh Hig Rada Toksikol
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
[Experience in treating patients with malignant pleural mesothelioma].
</td>
<td style="text-align:left;">
J. UOEH
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
[Diagnosis of pleural metastatic carcinoma with fibrous bronchoscope in thoracoscopy].
</td>
<td style="text-align:left;">
Zhonghua Jie He He Hu Xi Za Zhi
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Genetically engineered oncolytic Newcastle disease virus effectively induces sustained remission of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Mol. Cancer Ther.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
A diagnostic assay based on microRNA expression accurately identifies malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J Mol Diagn
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
A rare cause of dysphagia: malignant pleural mesothelioma in the posterior mediastinum.
</td>
<td style="text-align:left;">
Ann. Thorac. Surg.
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
A₃ receptors are overexpressed in pleura from patients with mesothelioma and reduce cell growth via Akt/nuclear factor-κB pathway.
</td>
<td style="text-align:left;">
Am. J. Respir. Crit. Care Med.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Frequency of use and predictors of cancer-directed surgery in the management of malignant pleural mesothelioma in a community-based (Surveillance, Epidemiology, and End Results [SEER]) population.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
<td style="text-align:left;">
diagnosis | epidemiology | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Comparison between plasma and serum osteopontin levels: usefulness in diagnosis of epithelial malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Int. J. Biol. Markers
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
A clinical, radiographic and laboratory evaluation of prognostic factors in 363 patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Respiration
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Prevention of malignant seeding at drain sites by hypofractionated radiotherapy in patients with pleural mesothelioma.
</td>
<td style="text-align:left;">
Asia Pac J Clin Oncol
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
[Sarcomatoid mesothelioma–a diagnostic challenge].
</td>
<td style="text-align:left;">
Ugeskr. Laeg.
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Chemical characterization of exhaled breath to differentiate between patients with malignant plueral mesothelioma from subjects with similar professional asbestos exposure.
</td>
<td style="text-align:left;">
Anal Bioanal Chem
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Second-line therapy in patients with malignant pleural mesothelioma. A French retrospective study (2005-2006)].
</td>
<td style="text-align:left;">
Rev Pneumol Clin
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Acute postoperative cardiac herniation.
</td>
<td style="text-align:left;">
Interact Cardiovasc Thorac Surg
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
[A case of diffuse peritoneal malignant mesothelioma–intraabdominal administration of cisplatin is useful for diminishing ascites].
</td>
<td style="text-align:left;">
Gan To Kagaku Ryoho
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Overexpression of SOCS3 exhibits preclinical antitumor activity against malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Int. J. Cancer
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Treatment of malignant pleural mesothelioma: current status and future directions.
</td>
<td style="text-align:left;">
Monaldi Arch Chest Dis
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
High blood neutrophil-to-lymphocyte ratio is an indicator of poor prognosis in malignant mesothelioma patients undergoing systemic therapy.
</td>
<td style="text-align:left;">
Clin. Cancer Res.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Evaluation of ovarian cancer biomarkers in subjects with benign asbestos-related pleural diseases.
</td>
<td style="text-align:left;">
Clin. Chem. Lab. Med.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Contribution of positron emission tomography in pleural disease.
</td>
<td style="text-align:left;">
Rev Mal Respir
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Intensity-modulated radiation therapy with simultaneous integrated boost in unresected left-sided pleural mesothelioma: a case report.
</td>
<td style="text-align:left;">
Tumori
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
MT1-MMP plays an important role in an invasive activity of malignant pleural mesothelioma cell.
</td>
<td style="text-align:left;">
Exp. Mol. Pathol.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
The use of insulin like-growth factor II messenger RNA binding protein-3 in diagnostic pathology.
</td>
<td style="text-align:left;">
Hum. Pathol.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma: a population-based study of survival.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
<td style="text-align:left;">
treatment | epidemiology | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
An unusual pleural effusion.
</td>
<td style="text-align:left;">
Br J Clin Pract
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Cytopathology of malignant mesothelioma. Reappraisal of the diagnostic value of collagen cores.
</td>
<td style="text-align:left;">
Cytopathology
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Induction of senescence markers after neo-adjuvant chemotherapy of malignant pleural mesothelioma and association with clinical outcome: an exploratory analysis.
</td>
<td style="text-align:left;">
Eur. J. Cancer
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
TS, DHFR and GARFT expression in non-squamous cell carcinoma of NSCLC and malignant pleural mesothelioma patients treated with pemetrexed.
</td>
<td style="text-align:left;">
Anticancer Res.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Cytokeratin 19 fragment/carcinoembryonic antigen ratio in pleural effusion is a useful marker for detecting malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Anticancer Res.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pericardial mesothelioma following thoracal radiotherapy; dissemination from pericardium to pleura.
</td>
<td style="text-align:left;">
Tuberk Toraks
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleural effusion VEGF levels as a prognostic factor of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Respir Med
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Inhibition of activated phosphatidylinositol 3-kinase/AKT pathway in malignant pleural mesothelioma leads to G1 cell cycle arrest.
</td>
<td style="text-align:left;">
Oncol. Rep.
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Sarcomatoid neoplasms of the lung and pleura.
</td>
<td style="text-align:left;">
Arch. Pathol. Lab. Med.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Translational advances in pleural malignancies.
</td>
<td style="text-align:left;">
Respirology
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
What is the best way to diagnose and stage malignant pleural mesothelioma?
</td>
<td style="text-align:left;">
Interact Cardiovasc Thorac Surg
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Cutaneous needle track seeding of mesothelioma diagnosed by fine needle aspiration cytology: a case report.
</td>
<td style="text-align:left;">
Acta Cytol.
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Induction of tubulin polymerization and apoptosis in malignant mesothelioma cells by a new compound JBIR-23.
</td>
<td style="text-align:left;">
Cancer Lett.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Epidemiology of malignant mesothelioma–an outline.
</td>
<td style="text-align:left;">
Ann Occup Hyg
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
CT in differential diagnosis of diffuse pleural disease.
</td>
<td style="text-align:left;">
AJR Am J Roentgenol
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[The postoperative management of patients after pluropneumonectomy–influence of the mode of the operation].
</td>
<td style="text-align:left;">
Masui
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
A case of malignant pleural mesothelioma with osseous and cartilaginous differentiation.
</td>
<td style="text-align:left;">
J Thorac Imaging
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
The use of pleural fluid sCD44v6/std ratio for distinguishing mesothelioma from other pleural malignancies.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
The therapeutic efficacy of S-1 against orthotopically implanted human pleural mesothelioma cells in severe combined immunodeficient mice.
</td>
<td style="text-align:left;">
Cancer Chemother. Pharmacol.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant peritoneal mesothelioma: a case report].
</td>
<td style="text-align:left;">
Rev Med Liege
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Fine-needle aspiration biopsies for gene expression ratio-based diagnostic and prognostic tests in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Clin. Cancer Res.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Premature senescence induced by DNA demethylating agent (Decitabine) as therapeutic option for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Latent TGF-β binding proteins (LTBPs) 1 and 3 differentially regulate transforming growth factor-β activity in malignant mesothelioma.
</td>
<td style="text-align:left;">
Hum. Pathol.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma with prominent adenomatoid features: a clinicopathologic and immunohistochemical study of 10 cases.
</td>
<td style="text-align:left;">
Ann Diagn Pathol
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
An analysis of the utility of handheld PET probes for the intraoperative localization of malignant tissue.
</td>
<td style="text-align:left;">
J. Gastrointest. Surg.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Audit of patients with mesothelioma treated with pemetrexed in a single institution in Western Australia.
</td>
<td style="text-align:left;">
Asia Pac J Clin Oncol
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Proteomic differential display analysis shows up-regulation of 14-3-3 sigma protein in human scirrhous-type gastric carcinoma cells.
</td>
<td style="text-align:left;">
Anticancer Res.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Value of immunohistochemistry in distinguishing malignant epithelial tumors in the pleura].
</td>
<td style="text-align:left;">
Zhongguo Fei Ai Za Zhi
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Brain metastasis in malignant pleural mesothelioma presenting as intratumoral hemorrhage.
</td>
<td style="text-align:left;">
Neurol. Med. Chir. (Tokyo)
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Estrogen receptor β exerts tumor repressive functions in human malignant pleural mesothelioma via EGFR inactivation and affects response to gefitinib.
</td>
<td style="text-align:left;">
PLoS ONE
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Continued pemetrexed and platin-based chemotherapy in patients with malignant pleural mesothelioma (MPM): value of 18F-FDG-PET/CT.
</td>
<td style="text-align:left;">
Eur J Radiol
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Delayed bronchial stump dehiscence following trimodality treatment for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J Egypt Natl Canc Inst
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Current evidence base of FDG-PET/CT imaging in the clinical management of malignant pleural mesothelioma: emerging significance of image segmentation and global disease assessment.
</td>
<td style="text-align:left;">
Mol Imaging Biol
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Case of benign asbestos pleurisy with diffuse pleural thickening confirmed on autopsy].
</td>
<td style="text-align:left;">
Nihon Kokyuki Gakkai Zasshi
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Mesothelioma and asbestos, fifty years of evidence: Chris Wagner and the contribution of the Italian occupational medicine community.
</td>
<td style="text-align:left;">
Med Lav
</td>
<td style="text-align:left;">
epidemiology | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Asbestos-related diseases in entertainment workers.
</td>
<td style="text-align:left;">
Med Lav
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Quantitative measurement of lung reexpansion in malignant pleural mesothelioma patients undergoing pleurectomy/decortication.
</td>
<td style="text-align:left;">
Acad Radiol
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Physical aspects of external beam radiotherapy for the treatment of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Int. J. Radiat. Oncol. Biol. Phys.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Can “steroid switching” improve steroid-induced musical hallucinations in a patient with terminal cancer?
</td>
<td style="text-align:left;">
J Palliat Med
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Pericardial mesothelioma and asbestos exposure.
</td>
<td style="text-align:left;">
Int J Hyg Environ Health
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Identification of cancer stem cell markers in human malignant mesothelioma cells.
</td>
<td style="text-align:left;">
Biochem. Biophys. Res. Commun.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Vascular endothelial growth factor in pleural fluid for differential diagnosis of benign and malignant origin and its clinical applications.
</td>
<td style="text-align:left;">
Interact Cardiovasc Thorac Surg
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma: a clinical study of 238 cases.
</td>
<td style="text-align:left;">
Ind Health
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[A case of peritoneal mesothelioma with direct invasion to gastric mucosa].
</td>
<td style="text-align:left;">
Korean J Gastroenterol
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Treatment of malignant mesothelioma using intrapleural gamma interferon].
</td>
<td style="text-align:left;">
Bull. Acad. Natl. Med.
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Serum soluble mesothelin concentrations in malignant pleural mesothelioma: relationship to tumor volume, clinical stage and changes in tumor burden.
</td>
<td style="text-align:left;">
Clin. Cancer Res.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
European guidelines for the management of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Pol. Arch. Med. Wewn.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Cervical endometriosis associated with malignant pleural mesothelioma mimicking cervical cancer–Occam’s razor or the “third man”.
</td>
<td style="text-align:left;">
Fertil. Steril.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Targeted epidermal growth factor receptor therapy in malignant pleural mesothelioma: where do we stand?
</td>
<td style="text-align:left;">
Cancer Treat. Rev.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleural mesothelioma in New Caledonia: associations with environmental risk factors.
</td>
<td style="text-align:left;">
Environ. Health Perspect.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleural mesothelioma in paraoccupational, environmental and occupational patients exposed to asbestos.
</td>
<td style="text-align:left;">
Rev Med Inst Mex Seguro Soc
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Antiangiogenic therapies for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Front Biosci (Landmark Ed)
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Establishment of a cell line from a Japanese patient useful for generating an in vivo model of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Cancer Sci.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma: CT manifestations in 50 cases.
</td>
<td style="text-align:left;">
AJR Am J Roentgenol
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
FDG PET/CT patterns of treatment failure of malignant pleural mesothelioma: relationship to histologic type, treatment algorithm, and survival.
</td>
<td style="text-align:left;">
Eur. J. Nucl. Med. Mol. Imaging
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
The pleura in health and disease.
</td>
<td style="text-align:left;">
Semin Respir Crit Care Med
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Retreatment with pemetrexed-based chemotherapy in patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Dasatinib: an anti-tumour agent via Src inhibition.
</td>
<td style="text-align:left;">
Curr Drug Targets
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Rat mesothelioma cell proliferation requires p38δ mitogen activated protein kinase and C/EBP-α.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Validation of tissue microarray technology in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Pathology
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Exposure to asbestos: correlation between blood levels of mesothelin and frequency of micronuclei in peripheral blood lymphocytes.
</td>
<td style="text-align:left;">
Mutat. Res.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Clinical-therapeutic management of thoracoscopy in pleural effusion: a groundbreaking technique in the twenty-first century.
</td>
<td style="text-align:left;">
Clin Transl Oncol
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Computed tomography-guided interstitial high-dose-rate brachytherapy in the local treatment of primary and secondary intrathoracic malignancies.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Thymidylate synthase and excision repair cross-complementing group-1 as predictors of responsiveness in mesothelioma patients treated with pemetrexed/carboplatin.
</td>
<td style="text-align:left;">
Clin. Cancer Res.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Targeted therapies in malignant pleural mesothelioma: a review of clinical studies.
</td>
<td style="text-align:left;">
Anticancer Drugs
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Does positron emission tomography offer prognostic information in malignant pleural mesothelioma?
</td>
<td style="text-align:left;">
Interact Cardiovasc Thorac Surg
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Accuracy of diagnostic biopsy for the histological subtype of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
A practical guide of the Southwest Oncology Group to measure malignant pleural mesothelioma tumors by RECIST and modified RECIST criteria.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Volumetry: an alternative to assess therapy response for malignant pleural mesothelioma?
</td>
<td style="text-align:left;">
Eur. Respir. J.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Telomerase activity in pleural malignant mesotheliomas.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
XRCC1 and ERCC1 variants modify malignant mesothelioma risk: a case-control study.
</td>
<td style="text-align:left;">
Mutat. Res.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Syntenic relationships between genomic profiles of fiber-induced murine and human malignant mesothelioma.
</td>
<td style="text-align:left;">
Am. J. Pathol.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
A systematic review of lung-sparing extirpative surgery for pleural mesothelioma.
</td>
<td style="text-align:left;">
J R Soc Med
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Targeted drug delivery and penetration into solid tumors.
</td>
<td style="text-align:left;">
Med Res Rev
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Advances in the biology of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Cancer Treat. Rev.
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
The expression of CXCR4, CXCL12 and CXCR7 in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J. Pathol.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Platinum-based doublet chemotherapy in pre-treated malignant pleural mesothelioma (MPM) patients: a mono-institutional experience.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Epithelial-to-mesenchymal transition, cell polarity and stemness-associated features in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Cancer Lett.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
No implication of Simian virus 40 in pathogenesis of malignant pleural mesothelioma in Slovenia.
</td>
<td style="text-align:left;">
Tumori
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Staging of patients after extrapleural pneumonectomy for malignant pleural mesothelioma–institutional review and current update.
</td>
<td style="text-align:left;">
Interact Cardiovasc Thorac Surg
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Asbestos-related disease.
</td>
<td style="text-align:left;">
Intern Med J
</td>
<td style="text-align:left;">
diagnosis | epidemiology | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Clinical and pathological features of three-year survivors of malignant pleural mesothelioma following extrapleural pneumonectomy.
</td>
<td style="text-align:left;">
Eur J Cardiothorac Surg
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Onconase mediated NFKβ downregulation in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Oncogene
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
New angucycline C-glycosides from Streptomyces sp. RI33.
</td>
<td style="text-align:left;">
J. Antibiot.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Peritoneal mesothelioma: description of a case and review of literature.
</td>
<td style="text-align:left;">
Int J Immunopathol Pharmacol
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Tumor type influences the effectiveness of pleurodesis in malignant effusions.
</td>
<td style="text-align:left;">
Lung
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Platinum-bisphosphonate complexes have proven to be inactive chemotherapeutics targeted for malignant mesothelioma because of inappropriate hydrolysis.
</td>
<td style="text-align:left;">
J. Inorg. Biochem.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Is pleurectomy and decortication superior to palliative care in the treatment of malignant pleural mesothelioma?
</td>
<td style="text-align:left;">
Interact Cardiovasc Thorac Surg
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
What is the role of radiotherapy in malignant pleural mesothelioma?
</td>
<td style="text-align:left;">
Oncologist
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma risk among nuclear workers: a review.
</td>
<td style="text-align:left;">
J Radiol Prot
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Photodynamic therapy for malignant pleural mesothelioma: the future of treatment?
</td>
<td style="text-align:left;">
Expert Rev Respir Med
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Downregulated microRNAs in the differential diagnosis of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Int. J. Cancer
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
5-Aminolevulinic acid-induced fluorescence diagnosis of pleural malignant tumor.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Identification of novel markers for the diagnosis of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Am. J. Pathol.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Decreased CXCR3 expression in CD4+ T cells exposed to asbestos or derived from asbestos-exposed patients.
</td>
<td style="text-align:left;">
Am. J. Respir. Cell Mol. Biol.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleomorphic epithelioid diffuse malignant pleural mesothelioma: a clinicopathological review and conceptual proposal to reclassify as biphasic or sarcomatoid mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Serial measurements of mesothelioma serum biomarkers in asbestos-exposed individuals: a prospective longitudinal cohort study.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
MicroRNAs dysregulation in human malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Temsirolimus inhibits malignant pleural mesothelioma growth in vitro and in vivo: synergism with chemotherapy.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Computerized segmentation and measurement of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Med Phys
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Pathology of the pleura: what the pulmonologists need to know.
</td>
<td style="text-align:left;">
Respirology
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Tumor extension along chest wall tract after diagnostic intervention in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Interact Cardiovasc Thorac Surg
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Resistance to caspase-8 and -9 fragments in a malignant pleural mesothelioma cell line with acquired cisplatin-resistance.
</td>
<td style="text-align:left;">
Cell Death Dis
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[A case of coexisting malignant mesothelioma and squamous cell carcinoma of the lung].
</td>
<td style="text-align:left;">
Gan To Kagaku Ryoho
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Is serum thioredoxin-1 a useful clinical marker for malignant pleural mesothelioma?
</td>
<td style="text-align:left;">
Antioxid. Redox Signal.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Breath analysis in asbestos-related disorders: a review of the literature and potential future applications.
</td>
<td style="text-align:left;">
J Breath Res
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Role of protein kinase C β and vascular endothelial growth factor receptor in malignant pleural mesothelioma: Therapeutic implications and the usefulness of Caenorhabditis elegans model organism.
</td>
<td style="text-align:left;">
J Carcinog
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
An unusually large pleural mesothelioma with an outstanding clinical response and long lasting survival: a case report and literature review.
</td>
<td style="text-align:left;">
Tumori
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Extrapleural pneumonectomy or supportive care: treatment of malignant pleural mesothelioma?
</td>
<td style="text-align:left;">
Interact Cardiovasc Thorac Surg
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Occupational morbidity and mortality in malignant neoplasms among persons professionally exposed to asbestos dust].
</td>
<td style="text-align:left;">
Gig Tr Prof Zabol
</td>
<td style="text-align:left;">
epidemiology | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Plasma versus serum levels of osteopontin and mesothelin in patients with malignant mesothelioma–which is best?
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
The evolution of multimodality therapy for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Curr Treat Options Oncol
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
The diagnostic utility of p16 FISH and GLUT-1 immunohistochemical analysis in mesothelial proliferations.
</td>
<td style="text-align:left;">
Am. J. Clin. Pathol.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma: facts, myths, and hypotheses.
</td>
<td style="text-align:left;">
J. Cell. Physiol.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Synergistic effect of non-transmissible Sendai virus vector encoding the c-myc suppressor FUSE-binding protein-interacting repressor plus cisplatin in the treatment of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Cancer Sci.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Molecular biomarkers in malignant mesothelioma: state of the art.
</td>
<td style="text-align:left;">
Pathology
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Epidermal growth factor receptor overexpression in malignant pleural mesothelioma: prognostic correlations.
</td>
<td style="text-align:left;">
J Surg Oncol
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Markers for the non-invasive diagnosis of mesothelioma: a systematic review.
</td>
<td style="text-align:left;">
Br. J. Cancer
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Pemetrexed in the treatment of thoracic malignancies: a single centre experience in Singapore.
</td>
<td style="text-align:left;">
Singapore Med J
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Rarity of malignant mesothelioma prior to the widespread commercial introduction of asbestos: the Mount Sinai autopsy experience 1883-1910.
</td>
<td style="text-align:left;">
Am. J. Ind. Med.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
An extracellular signal-regulated kinase 2 survival pathway mediates resistance of human mesothelioma cells to asbestos-induced injury.
</td>
<td style="text-align:left;">
Am. J. Respir. Cell Mol. Biol.
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
[Cytologic diagnosis of pleural mesothelioma].
</td>
<td style="text-align:left;">
Grud Serdechnososudistaia Khir
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma of the spermatic cord.
</td>
<td style="text-align:left;">
Korean J Urol
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Surgical treatment of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Curr Treat Options Oncol
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Chemotherapy for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Curr Treat Options Oncol
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Cytopathologic diagnosis in pleural effusion and cyto-histopathologic correlation.
</td>
<td style="text-align:left;">
Turk Patoloji Derg
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Antiproliferative effects of novel aliphatic acetogenin analogs against aggressive solid tumor cell lines.
</td>
<td style="text-align:left;">
In Vivo
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Diagnostic significance of carcinoembryonic antigen in the differential diagnosis of malignant mesothelioma.
</td>
<td style="text-align:left;">
J. Thorac. Cardiovasc. Surg.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Soluble markers for diagnosis of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Biomark Med
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Imaging of mesothelioma.
</td>
<td style="text-align:left;">
Recent Results Cancer Res.
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Pathohistological diagnosis and differential diagnosis.
</td>
<td style="text-align:left;">
Recent Results Cancer Res.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Mesothelioma and analysis of tissue fiber content.
</td>
<td style="text-align:left;">
Recent Results Cancer Res.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Surgical therapy of mesothelioma.
</td>
<td style="text-align:left;">
Recent Results Cancer Res.
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Chemotherapy and radiotherapy for mesothelioma.
</td>
<td style="text-align:left;">
Recent Results Cancer Res.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Association of MiR-126 with soluble mesothelin-related peptides, a marker for malignant mesothelioma.
</td>
<td style="text-align:left;">
PLoS ONE
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Usefulness of Claudin 4 in the cytological diagnosis of serosal effusions.
</td>
<td style="text-align:left;">
Diagn. Cytopathol.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Update on malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Semin Respir Crit Care Med
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Multicystic mesothelioma of the pericardium.
</td>
<td style="text-align:left;">
Pathol. Int.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Medical treatment of mesothelioma: anything new?
</td>
<td style="text-align:left;">
Curr Oncol Rep
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma: when is radiation therapy indicated?
</td>
<td style="text-align:left;">
Expert Rev Anticancer Ther
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Summary of prognostic factors and patient selection for extrapleural pneumonectomy in the treatment of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Ann. Surg. Oncol.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
A case report of metastasis of malignant mesothelioma to the oral gingiva.
</td>
<td style="text-align:left;">
Head Neck Oncol
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Asbestos-related benign disease and cancer: symptoms and treatment.
</td>
<td style="text-align:left;">
Anticancer Drugs
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Outcome of patients with nonspecific pleuritis at thoracoscopy.
</td>
<td style="text-align:left;">
Curr Opin Pulm Med
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Localized malignant lymphohistiocytoid pleural mesothelioma.
</td>
<td style="text-align:left;">
Acta Chir. Belg.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Circulating and tumor-infiltrating myeloid cells predict survival in human pleural mesothelioma.
</td>
<td style="text-align:left;">
Cancer
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Intensity-modulated radiotherapy after extrapleural pneumonectomy in the combined-modality treatment of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Validation of a minimal panel of antibodies for the diagnosis of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Pathology
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Non-neoplastic and neoplastic pleural endpoints following fiber exposure.
</td>
<td style="text-align:left;">
J Toxicol Environ Health B Crit Rev
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Factors that impact susceptibility to fiber-induced health effects.
</td>
<td style="text-align:left;">
J Toxicol Environ Health B Crit Rev
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
The diminishing role of surgery in pleural disease.
</td>
<td style="text-align:left;">
Curr Opin Pulm Med
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Recognition of pleural mesothelioma by mucin-1(950-958)/human leukocyte antigen A*0201-specific CD8+ T-cells.
</td>
<td style="text-align:left;">
Eur. Respir. J.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
A 5-aza-2’-deoxycytidine/valproate combination induces cytotoxic T-cell response against mesothelioma.
</td>
<td style="text-align:left;">
Eur. Respir. J.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Asbestos exposure affects poly(ADP-ribose) polymerase-1 activity: role in asbestos-induced carcinogenesis.
</td>
<td style="text-align:left;">
Mutagenesis
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Review on clinical trials of targeted treatments in malignant mesothelioma.
</td>
<td style="text-align:left;">
Cancer Chemother. Pharmacol.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma: clustering in a family producing asbestos cement in their home.
</td>
<td style="text-align:left;">
Br J Ind Med
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Natural-killer cell-mediated cytotoxicity of blood-lymphocytes from patients with malignant mesothelioma treated by intrapleural interleukin-2.
</td>
<td style="text-align:left;">
Int. J. Oncol.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Prognostic evaluation of patients submitted to surgery for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Int. J. Oncol.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Oncofetal protein IMP3, a new diagnostic biomarker to distinguish malignant mesothelioma from reactive mesothelial proliferation.
</td>
<td style="text-align:left;">
Am. J. Surg. Pathol.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Genes associated with prognosis after surgery for malignant pleural mesothelioma promote tumor cell survival in vitro.
</td>
<td style="text-align:left;">
BMC Cancer
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Curr Oncol Rep
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Two novel polymorphisms in 5’ flanking region of the mesothelin gene are associated with soluble mesothelin-related peptide (SMRP) levels.
</td>
<td style="text-align:left;">
Int. J. Biol. Markers
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Diagnostic usefulness of EMA, IMP3, and GLUT-1 for the immunocytochemical distinction of malignant cells from reactive mesothelial cells in effusion cytology using cytospin preparations.
</td>
<td style="text-align:left;">
Diagn. Cytopathol.
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
A patient-like human malignant pleural mesothelioma nude-mouse model.
</td>
<td style="text-align:left;">
Oncol. Rep.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleurectomy, intrapleural cisplatin and interferon followed by systemic carboplatin plus interferon in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Oncol. Rep.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Curcumin suppresses growth of mesothelioma cells in vitro and in vivo, in part, by stimulating apoptosis.
</td>
<td style="text-align:left;">
Mol. Cell. Biochem.
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Expression of a functional CCR2 receptor enhances tumor localization and tumor eradication by retargeted human T cells expressing a mesothelin-specific chimeric antibody receptor.
</td>
<td style="text-align:left;">
Clin. Cancer Res.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Inactivation of Merlin in malignant mesothelioma cells and the Hippo signaling cascade dysregulation.
</td>
<td style="text-align:left;">
Pathol. Int.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma of the pleura in nonagenarian patients.
</td>
<td style="text-align:left;">
Tumori
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Photodynamic therapy and the evolution of a lung-sparing surgical treatment for mesothelioma.
</td>
<td style="text-align:left;">
Ann. Thorac. Surg.
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Detection of integrin-linked kinase in the serum of patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J. Thorac. Cardiovasc. Surg.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Combined chemotherapy with cytotoxic and targeted compounds for the management of human malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Trends Pharmacol. Sci.
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
The use of the PleurX catheter in the management of non-malignant pleural effusions.
</td>
<td style="text-align:left;">
Chron Respir Dis
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
[Usefulness of 18F-FDG PET-CT in the presurgical assessment of malignant pleural mesothelioma treated with neoadjuvant chemotherapy].
</td>
<td style="text-align:left;">
Rev Esp Med Nucl
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
A trial of intrapleural adenoviral-mediated Interferon-α2b gene transfer for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Am. J. Respir. Crit. Care Med.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Tumor cell repopulation between cycles of chemotherapy is inhibited by regulatory T-cell depletion in a murine mesothelioma model.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Combined serum mesothelin and plasma osteopontin measurements in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Nat. Genet.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
[Value of tomotherapy in malignant pleural mesothelioma: first clinical results].
</td>
<td style="text-align:left;">
Rev Mal Respir
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleural malignant mesothelioma epidemic: incidence, modalities of asbestos exposure and occupations involved from the Italian National Register.
</td>
<td style="text-align:left;">
Int. J. Cancer
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Pemetrexed in malignant pleural mesothelioma and the clinical outcome.
</td>
<td style="text-align:left;">
Clin Respir J
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Outcomes and complications following medical thoracoscopy.
</td>
<td style="text-align:left;">
Clin Respir J
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Cell-growth and migration inhibition of human mesothelioma cells induced by 3-O-methylfunicone from Penicillium pinophilum and cisplatin.
</td>
<td style="text-align:left;">
Invest New Drugs
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Re-evaluating the role of palliative radiotherapy in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Eur. J. Cancer
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Mesothelioma at era of helical tomotherapy: results of two institutions in combining chemotherapy, surgery and radiotherapy.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Lovastatin and valproic acid additively attenuate cell invasion in ACC-MESO-1 cells.
</td>
<td style="text-align:left;">
Biochem. Biophys. Res. Commun.
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Epigenetic silencing of microRNA-34b/c plays an important role in the pathogenesis of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Clin. Cancer Res.
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Intrathoracic chemo-thermotherapy with radiofrequency waves after extrapleural pneumonectomy for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Interact Cardiovasc Thorac Surg
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleural effusion: what lies underneath?
</td>
<td style="text-align:left;">
BMJ Case Rep
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Clinical significance of pleural effusion mesothelin in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Clin. Chem. Lab. Med.
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Establishing locoregional control of malignant pleural mesothelioma using high-dose radiotherapy and (18) F-FDG PET/CT scan correlation.
</td>
<td style="text-align:left;">
J Med Imaging Radiat Oncol
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Improving survival results after surgical management of malignant pleural mesothelioma: an Australian institution experience.
</td>
<td style="text-align:left;">
Ann Thorac Cardiovasc Surg
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
A case of diffused malignant pleural mesothelioma forming small multiple disseminations with intraoperatively suspicious carcinoid tumors.
</td>
<td style="text-align:left;">
Ann Thorac Cardiovasc Surg
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Exploratory study on the detection of markers for diagnosing early-stage malignant mesothelioma].
</td>
<td style="text-align:left;">
Nihon Eiseigaku Zasshi
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Current status and future direction of Japan’s clinical trial for malignant pleural mesothelioma].
</td>
<td style="text-align:left;">
Nihon Eiseigaku Zasshi
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Mechanisms of asbestos-induced carcinogenesis].
</td>
<td style="text-align:left;">
Nihon Eiseigaku Zasshi
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Aberrant methylation of p21 gene in lung cancer and malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Acta Med. Okayama
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
ERK2 is essential for the growth of human epithelioid malignant mesotheliomas.
</td>
<td style="text-align:left;">
Int. J. Cancer
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study.
</td>
<td style="text-align:left;">
Lancet Oncol.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Death receptor 5 and cellular FLICE-inhibitory protein regulate pemetrexed-induced apoptosis in human lung cancer cells.
</td>
<td style="text-align:left;">
Eur. J. Cancer
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleural mesothelioma side populations have a precursor phenotype.
</td>
<td style="text-align:left;">
Carcinogenesis
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Massive exposure to asbestos and malignant mesothelioma, familial accumulation].
</td>
<td style="text-align:left;">
Ugeskr. Laeg.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Predicting survival in malignant mesothelioma.
</td>
<td style="text-align:left;">
Eur. Respir. J.
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma: clinicopathologic and survival characteristic in a consecutive series of 40 patients.
</td>
<td style="text-align:left;">
Ann Thorac Cardiovasc Surg
</td>
<td style="text-align:left;">
diagnosis | treatment | epidemiology | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Occupation and work-related ill-health in UK construction workers.
</td>
<td style="text-align:left;">
Occup Med (Lond)
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Validity of procalcitonin and C-reactive protein measurement when differentiating between benign and malignant pleural effusion.
</td>
<td style="text-align:left;">
Clin. Lab.
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleural mesothelioma instigates tumor-associated fibroblasts to promote progression via a malignant cytokine network.
</td>
<td style="text-align:left;">
Am. J. Pathol.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Chronic inflammation in tumor stroma is an independent predictor of prolonged survival in epithelioid malignant pleural mesothelioma patients.
</td>
<td style="text-align:left;">
Cancer Immunol. Immunother.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Coactivation of receptor tyrosine kinases in malignant mesothelioma as a rationale for combination targeted therapy.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
The relationship between tumor MSLN methylation and serum mesothelin (SMRP) in mesothelioma.
</td>
<td style="text-align:left;">
Epigenetics
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Prospective clinical and radiologic study of zeolite-exposed Turkish immigrants in Sweden.
</td>
<td style="text-align:left;">
Respiration
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Thrombocytosis in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Tumori
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Receptor tyrosine kinase inhibitors and cytotoxic drugs affect pleural mesothelioma cell proliferation: insight into EGFR and ERK1/2 as antitumor targets.
</td>
<td style="text-align:left;">
Biochem. Pharmacol.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Expression and regulation of B7-H3 immunoregulatory receptor, in human mesothelial and mesothelioma cells: immunotherapeutic implications.
</td>
<td style="text-align:left;">
J. Cell. Physiol.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
The cytostatic effects of lovastatin on ACC-MESO-1 cells.
</td>
<td style="text-align:left;">
J. Surg. Res.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Missed opportunities to counsel patients with malignant pleural mesothelioma about causation and potential compensation.
</td>
<td style="text-align:left;">
Am. J. Med. Sci.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
SEOM guidelines for the treatment of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Clin Transl Oncol
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Achalasia secondary to malignant mesothelioma of the pleura.
</td>
<td style="text-align:left;">
J. Clin. Gastroenterol.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
CBP501-calmodulin binding contributes to sensitizing tumor cells to cisplatin and bleomycin.
</td>
<td style="text-align:left;">
Mol. Cancer Ther.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Proteomic surfaceome analysis of mesothelioma.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Soluble mesothelin, megakaryocyte potentiating factor, and osteopontin as markers of patient response and outcome in mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Frequent deletion of 3p21.1 region carrying semaphorin 3G and aberrant expression of the genes participating in semaphorin signaling in the epithelioid type of malignant mesothelioma cells.
</td>
<td style="text-align:left;">
Int. J. Oncol.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Recommendations for uniform definitions of surgical techniques for malignant pleural mesothelioma: a consensus report of the international association for the study of lung cancer international staging committee and the international mesothelioma interest group.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Tissue factor pathway inhibitor attenuates the progression of malignant pleural mesothelioma in nude mice.
</td>
<td style="text-align:left;">
Am. J. Respir. Cell Mol. Biol.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Expression of the Ets transcription factor EHF in serous ovarian carcinoma effusions is a marker of poor survival.
</td>
<td style="text-align:left;">
Hum. Pathol.
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Is adenosine deaminase in pleural fluid a useful marker for differentiating tuberculosis from lung cancer or mesothelioma in Japan, a country with intermediate incidence of tuberculosis?
</td>
<td style="text-align:left;">
Acta Med. Okayama
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
BIRC5 promoter SNPs do not affect nuclear survivin expression and survival of malignant pleural mesothelioma patients.
</td>
<td style="text-align:left;">
J. Cancer Res. Clin. Oncol.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Helical tomotherapy for resected malignant pleural mesothelioma: dosimetric evaluation and toxicity.
</td>
<td style="text-align:left;">
Radiother Oncol
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
EphrinA1 inhibits malignant mesothelioma tumor growth via let-7 microRNA-mediated repression of the RAS oncogene.
</td>
<td style="text-align:left;">
Cancer Gene Ther.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Germline BAP1 mutations predispose to malignant mesothelioma.
</td>
<td style="text-align:left;">
Nat. Genet.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma in Singapore.
</td>
<td style="text-align:left;">
Asian Pac. J. Cancer Prev.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleurectomy/decortication, hyperthermic pleural lavage with povidone-iodine followed by adjuvant chemotherapy in patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Epithelioid malignant mesothelioma presenting with features of esophageal tumor.
</td>
<td style="text-align:left;">
Asian Cardiovasc Thorac Ann
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Desmoplastic malignant mesothelioma of the pericardium: Description of a case and review of the literature.
</td>
<td style="text-align:left;">
Lung India
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Safety and effectiveness of pemetrexed in patients with malignant pleural mesothelioma based on all-case drug-registry study.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Increasing incidence of malignant mesothelioma after exposure to asbestos during home maintenance and renovation.
</td>
<td style="text-align:left;">
Med. J. Aust.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Pre-clinical mouse models of primary and metastatic pleural cancers of the lung and breast and the use of bioluminescent imaging to monitor pleural tumor burden.
</td>
<td style="text-align:left;">
Curr Protoc Pharmacol
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Effects of the demethylating agent, 5-azacytidine, on expression of the kallikrein-kinin genes in carcinoma cells of the lung and pleura.
</td>
<td style="text-align:left;">
Patholog Res Int
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
G-CSF-producing malignant pleural mesothelioma: an autopsy case report with literature review.
</td>
<td style="text-align:left;">
Int. J. Surg. Pathol.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Immune responses and immunotherapeutic interventions in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Cancer Immunol. Immunother.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Current status of surgical treatment for malignant pleural mesothelioma].
</td>
<td style="text-align:left;">
Kyobu Geka
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Miliary mesothelioma: a new clinical and radiological presentation in mesothelioma patients with prolonged survival after trimodality therapy.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
An electronic nose distinguishes exhaled breath of patients with Malignant Pleural Mesothelioma from controls.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma presenting with a spontaneous hydropneumothorax: a report of 2 cases.
</td>
<td style="text-align:left;">
Rev Port Pneumol
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Biomarkers in malignant mesothelioma: diagnostic and prognostic role of soluble mesothelin-related peptide.
</td>
<td style="text-align:left;">
Int. J. Biol. Markers
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Raltitrexed plus cisplatin is cost-effective compared with pemetrexed plus cisplatin in patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Second-line chemotherapy in malignant pleural mesothelioma: results of a retrospective multicenter survey.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant epithelioid pleural mesothelioma versus peripheral pulmonary adenocarcinoma: a histochemical, ultrastructural, and immunohistologic study of 103 cases.
</td>
<td style="text-align:left;">
Hum. Pathol.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Benign pulmonary lesions that may be misdiagnosed as malignant.
</td>
<td style="text-align:left;">
Semin Diagn Pathol
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Metastatic proximal epithelioid sarcoma in pleural effusion: cytopathologic findings and differential diagnosis.
</td>
<td style="text-align:left;">
Diagn. Cytopathol.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Leu-M1, CEA and intermediate filament proteins in histochemical differential diagnosis of malignant pleural mesothelioma].
</td>
<td style="text-align:left;">
Pneumologie
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
The fake fat phenomenon in organizing pleuritis: a source of confusion with desmoplastic malignant mesotheliomas.
</td>
<td style="text-align:left;">
Am. J. Surg. Pathol.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Automated ERCC1 immunochemistry on hybrid cytology/tissue microarray of malignant effusions: evaluation of antibodies 8F1 and D-10.
</td>
<td style="text-align:left;">
J Clin Bioinforma
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Phase II study of cediranib in patients with malignant pleural mesothelioma: SWOG S0509.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
The immunohistochemical characterization of sarcomatoid malignant mesothelioma of the pleura.
</td>
<td style="text-align:left;">
Am J Cancer Res
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Preclinical emergence of vandetanib as a potent antitumour agent in mesothelioma: molecular mechanisms underlying its synergistic interaction with pemetrexed and carboplatin.
</td>
<td style="text-align:left;">
Br. J. Cancer
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Primary pleural epithelioid mesothelioma of clear cell type: a case report and review of current literature.
</td>
<td style="text-align:left;">
Ultrastruct Pathol
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Prophylactic irradiation of intervention sites in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Radiother Oncol
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
A nuclear grading system is a strong predictor of survival in epitheloid diffuse malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Mod. Pathol.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Strong anti-tumor effect of NVP-AUY922, a novel Hsp90 inhibitor, on non-small cell lung cancer.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Periostin expression and epithelial-mesenchymal transition in cancer: a review and an update.
</td>
<td style="text-align:left;">
Virchows Arch.
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Raltitrexed in mesothelioma.
</td>
<td style="text-align:left;">
Expert Rev Anticancer Ther
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Brief report: a phase II study of sunitinib in malignant pleural mesothelioma. the NCIC Clinical Trials Group.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Low calretinin expression and high neutrophil-to-lymphocyte ratio are poor prognostic factors in patients with malignant mesothelioma undergoing extrapleural pneumonectomy.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Sustained expression of steroid receptor coactivator SRC-2/TIF-2 is associated with better prognosis in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
SASP mediates chemoresistance and tumor-initiating-activity of mesothelioma cells.
</td>
<td style="text-align:left;">
Oncogene
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Aquaporin 1 is an independent prognostic factor in pleural malignant mesothelioma.
</td>
<td style="text-align:left;">
Cancer
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Lymphohistiocytoid mesothelioma of the pleura: a case report with cytological findings.
</td>
<td style="text-align:left;">
Diagn. Cytopathol.
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Clinical implications of 18F-fluorodeoxyglucose positron emission tomography/computed tomography at delayed phase for diagnosis and prognosis of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Oncol. Rep.
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleural mesothelioma mortality and asbestos exposure mapping in Italy.
</td>
<td style="text-align:left;">
Am. J. Ind. Med.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Evaluation of platinum-ethacrynic acid conjugates in the treatment of mesothelioma.
</td>
<td style="text-align:left;">
ChemMedChem
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
A phase II trial of low-dose gemcitabine in a prolonged infusion and cisplatin for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Anticancer Drugs
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Polycomb repressor complex-2 is a novel target for mesothelioma therapy.
</td>
<td style="text-align:left;">
Clin. Cancer Res.
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Low ERCC1 expression in malignant pleural mesotheliomas treated with cisplatin and vinorelbine predicts prolonged progression-free survival.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Flow cytometric measurement of cellular FLICE-inhibitory protein (c-FLIP) in ovarian carcinoma effusions.
</td>
<td style="text-align:left;">
Cytopathology
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
PET-guided dose escalation tomotherapy in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Strahlenther Onkol
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
PET-CT in the diagnosis of localized malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Clin Imaging
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma presenting as a giant chest, abdominal and pelvic wall mass.
</td>
<td style="text-align:left;">
Korean J Radiol
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
An in vivo platform for tumor biomarker assessment.
</td>
<td style="text-align:left;">
PLoS ONE
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Metastasis of pleural mesothelioma presenting as bleeding colonic polyp.
</td>
<td style="text-align:left;">
Ann. Thorac. Surg.
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Proteomic study of malignant pleural mesothelioma by laser microdissection and two-dimensional difference gel electrophoresis identified cathepsin D as a novel candidate for a differential diagnosis biomarker.
</td>
<td style="text-align:left;">
J Proteomics
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Gene therapy for lung neoplasms.
</td>
<td style="text-align:left;">
Clin. Chest Med.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Eosinophil colony-stimulating factor induced by administration of interleukin-2 into the pleural cavity of patients with malignant pleurisy.
</td>
<td style="text-align:left;">
Am. J. Respir. Cell Mol. Biol.
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Mortality and cancer morbidity in cohorts of asbestos cement workers and referents.
</td>
<td style="text-align:left;">
Br J Ind Med
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Causation in the court: the complex case of malignant mesothelioma].
</td>
<td style="text-align:left;">
G Ital Med Lav Ergon
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
New pemetrexed-peptide conjugates: synthesis, characterization and in vitro cytostatic effect on non-small cell lung carcinoma (NCI-H358) and human leukemia (HL-60) cells.
</td>
<td style="text-align:left;">
J. Pept. Sci.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Metastases to the oral region from pleural mesothelioma: Clinicopathologic review.
</td>
<td style="text-align:left;">
Head Neck
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Transient but not stable ZEB1 knockdown dramatically inhibits growth of malignant pleural mesothelioma cells.
</td>
<td style="text-align:left;">
Ann. Surg. Oncol.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Expression of calretinin by breast carcinoma and the potential for misdiagnosis of mesothelioma.
</td>
<td style="text-align:left;">
Histopathology
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Diffuse malignant peritoneal mesothelioma–an update on treatment.
</td>
<td style="text-align:left;">
Cancer Treat. Rev.
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Data-driven information retrieval in heterogeneous collections of transcriptomics data links SIM2s to malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Bioinformatics
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
[Pleuro-pulmonary metastases from a malignant mesothelioma of the tunica vaginalis].
</td>
<td style="text-align:left;">
Rev Mal Respir
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
National survey of malignant mesothelioma and asbestos exposure in Japan.
</td>
<td style="text-align:left;">
Cancer Sci.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Population-based survival for malignant mesothelioma after introduction of novel chemotherapy.
</td>
<td style="text-align:left;">
Eur. Respir. J.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
β-catenin expression in benign and malignant pleural disorders.
</td>
<td style="text-align:left;">
Int J Clin Exp Pathol
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Downregulation of MUC1 expression and its recognition by CD8⁺ T cells on the surface of malignant pleural mesothelioma cells treated with HDACi.
</td>
<td style="text-align:left;">
Eur. J. Immunol.
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Aberrant DNA methylation profile in pleural fluid for differential diagnosis of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Cancer Sci.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Anti-angiogenic factors in thoracic oncology: successes, failures and prospects].
</td>
<td style="text-align:left;">
Rev Mal Respir
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Follow-up of subjects occupationally exposed to asbestos, what are the objectives, the benefits, and the possible risks?].
</td>
<td style="text-align:left;">
Rev Mal Respir
</td>
<td style="text-align:left;">
diagnosis | treatment | epidemiology
</td>
</tr>
<tr>
<td style="text-align:left;">
Vorinostat/SAHA-induced apoptosis in malignant mesothelioma is FLIP/caspase 8-dependent and HR23B-independent.
</td>
<td style="text-align:left;">
Eur. J. Cancer
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Mortality results in SENTIERI Project].
</td>
<td style="text-align:left;">
Epidemiol Prev
</td>
<td style="text-align:left;">
epidemiology
</td>
</tr>
<tr>
<td style="text-align:left;">
Asbestos bodies in pulmonary hilar lymph nodes.
</td>
<td style="text-align:left;">
Mod. Pathol.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
[Tumoral markers and monoclonal antibodies].
</td>
<td style="text-align:left;">
Rev Prat
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Diagnosis and prognosis of malignant mesothelioma].
</td>
<td style="text-align:left;">
Rev Prat
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Treatment of pleural tumors].
</td>
<td style="text-align:left;">
Rev Prat
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Butein impairs the protumorigenic activity of malignant pleural mesothelioma cells.
</td>
<td style="text-align:left;">
Cell Cycle
</td>
<td style="text-align:left;">
treatment | epidemiology | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
BRCA1 is an essential mediator of vinorelbine-induced apoptosis in mesothelioma.
</td>
<td style="text-align:left;">
J. Pathol.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Clinical impact of extrapleural pneumonectomy for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Ann. Surg. Oncol.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
The application of cold-plasma coagulation on the visceral pleura results in a predictable depth of necrosis without fistula generation.
</td>
<td style="text-align:left;">
Interact Cardiovasc Thorac Surg
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
A review of transcriptome studies combined with data mining reveals novel potential markers of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Mutat. Res.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
L-type amino acid transporter 1 (LAT1) expression in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Anticancer Res.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Long-term survival after lung-sparing total pleurectomy for locally advanced (International Mesothelioma Interest Group Stage T3-T4) non-sarcomatoid malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Eur J Cardiothorac Surg
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Novel therapies in phase II and III trials for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J Natl Compr Canc Netw
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Effect of dispersants of multi-walled carbon nanotubes on cellular uptake and biological responses.
</td>
<td style="text-align:left;">
Int J Nanomedicine
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Practical approaches to diagnose and treat for T0 malignant pleural mesothelioma: a proposal for diagnostic total parietal pleurectomy.
</td>
<td style="text-align:left;">
Int. J. Clin. Oncol.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Pathological and molecular biological approaches to early mesothelioma.
</td>
<td style="text-align:left;">
Int. J. Clin. Oncol.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Extrapleural pneumonectomy for early stage malignant pleural mesothelioma: a harmful procedure.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Plasma cell membrane localization of c-MET predicts longer survival in patients with malignant mesothelioma: a series of 157 cases from the MESOPATH Group.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
CD26 overexpression is associated with prolonged survival and enhanced chemosensitivity in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Clin. Cancer Res.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Expression of interleukin-4 receptor alpha in human pleural mesothelioma is associated with poor survival and promotion of tumor inflammation.
</td>
<td style="text-align:left;">
Clin. Cancer Res.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Treatment failure after extrapleural pneumonectomy for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Dis
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Radiological Findings in a case of Advance staged Mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Dis
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
A pathological complete response after preoperative chemotherapy with carboplatin and pemetrexed in malignant pleural mesothelioma: A case report.
</td>
<td style="text-align:left;">
J Thorac Dis
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Elucidation mechanism of different biological responses to multi-walled carbon nanotubes using four cell lines.
</td>
<td style="text-align:left;">
Int J Nanomedicine
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Epithelial malignant pleural mesothelioma after extrapleural pneumonectomy: stratification of survival with CT-derived tumor volume.
</td>
<td style="text-align:left;">
AJR Am J Roentgenol
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Heme oxygenase-1 promoter polymorphism is associated with risk of malignant mesothelioma.
</td>
<td style="text-align:left;">
Lung
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant Mesothelioma in the Thoracic Cavity of a Crj:CD(SD) Rat Characterized by Round Hyalinous Stroma.
</td>
<td style="text-align:left;">
J Toxicol Pathol
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
The incidence of mesothelioma has not decreased for the last twenty years in Southeast region of Anatolia.
</td>
<td style="text-align:left;">
Afr Health Sci
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Synthesis, characterization and antiproliferative activity on mesothelioma cell lines of bis(carboxylato)platinum(IV) complexes based on picoplatin.
</td>
<td style="text-align:left;">
Dalton Trans
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Mechanisms of pleurodesis.
</td>
<td style="text-align:left;">
Respiration
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
A retrospective study of chemotherapy with and without pemetrexed in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Anticancer Res.
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Preclinical studies identify novel targeted pharmacological strategies for treatment of human malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Br. J. Pharmacol.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Photodynamic drug delivery enhancement in tumours does not depend on leukocyte-endothelial interaction in a human mesothelioma xenograft model.
</td>
<td style="text-align:left;">
Eur J Cardiothorac Surg
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Cyberknife radiosurgery for focal paravertebral recurrence after radical pleurectomy/decortication in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Eur J Cardiothorac Surg
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
The new case for cervical mediastinoscopy in selection for radical surgery for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Eur J Cardiothorac Surg
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Is α7-nAChR a possible target for lung cancer and malignant pleural mesothelioma treatment?
</td>
<td style="text-align:left;">
Curr Drug Targets
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Desmoplastic mesothelioma with bony metastases. A case report].
</td>
<td style="text-align:left;">
Rev Pneumol Clin
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleural fluid cytological yield and visceral pleural invasion in patients with epithelioid malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Inflammation-based prognostic indices in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
DNA analysis by flow cytometry in malignant pleural mesothelioma: relationship to histology and survival.
</td>
<td style="text-align:left;">
J. Pathol.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
BioKnife, a uPA activity-dependent oncolytic Sendai virus, eliminates pleural spread of malignant mesothelioma via simultaneous stimulation of uPA expression.
</td>
<td style="text-align:left;">
Mol. Ther.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesotheliomas in former miners and millers of crocidolite at Wittenoom (Western Australia) after more than 50 years follow-up.
</td>
<td style="text-align:left;">
Br. J. Cancer
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Adjuvant intensity-modulated proton therapy in malignant pleural mesothelioma. A comparison with intensity-modulated radiotherapy and a spot size variation assessment.
</td>
<td style="text-align:left;">
Strahlenther Onkol
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
¹⁸F-FDG uptake on PET could be a predictive marker of excision repair cross-complementation group 1 (ERCC1) expression in patients with thoracic neoplasms?
</td>
<td style="text-align:left;">
Neoplasma
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Relationship between 18F-FDG uptake on positron emission tomography and molecular biology in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Eur. J. Cancer
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Prognostic value of 18F-FDG standard uptake value by integrated PET/CT in the staging of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Technol. Cancer Res. Treat.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Clinical analysis of 45 patients with malignant pleural mesothelioma].
</td>
<td style="text-align:left;">
Zhongguo Fei Ai Za Zhi
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Fluorescence thoracoscopy in the detection of pleural malignancy.
</td>
<td style="text-align:left;">
Eur J Cardiothorac Surg
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Am J Health Syst Pharm
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Familial mesothelioma in first degree relatives.
</td>
<td style="text-align:left;">
Diagn. Cytopathol.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
[An autopsied case of primary malignant pericardial mesothelioma diagnosed antemortally].
</td>
<td style="text-align:left;">
Nihon Kokyuki Gakkai Zasshi
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant pleural mesothelioma with multiple nodules].
</td>
<td style="text-align:left;">
Nihon Kokyuki Gakkai Zasshi
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
First-line chemotherapy with liposomal doxorubicin plus cisplatin for patients with advanced malignant pleural mesothelioma: phase II trial.
</td>
<td style="text-align:left;">
Br. J. Cancer
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Diagnosis and treatment of pleural mesothelioma.
</td>
<td style="text-align:left;">
Semin Surg Oncol
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Mesothelin overexpression promotes mesothelioma cell invasion and MMP-9 secretion in an orthotopic mouse model and in epithelioid pleural mesothelioma patients.
</td>
<td style="text-align:left;">
Clin. Cancer Res.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Epithelioid lesions of the serosa.
</td>
<td style="text-align:left;">
Arch. Pathol. Lab. Med.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Immunohistochemistry and molecular diagnostics of pleural malignant mesothelioma.
</td>
<td style="text-align:left;">
Arch. Pathol. Lab. Med.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Mesothelioma not associated with asbestos exposure.
</td>
<td style="text-align:left;">
Arch. Pathol. Lab. Med.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Lymphoproliferative conditions of the serosa.
</td>
<td style="text-align:left;">
Arch. Pathol. Lab. Med.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Molecular changes in mesothelioma with an impact on prognosis and treatment.
</td>
<td style="text-align:left;">
Arch. Pathol. Lab. Med.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Hemithoracic intensity-modulated radiotherapy using helical tomotherapy for patients after extrapleural pneumonectomy for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J. Radiat. Res.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant pleural mesothelioma].
</td>
<td style="text-align:left;">
Dtsch. Med. Wochenschr.
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Soluble mesothelin-related peptides levels in patients with malignant mesothelioma.
</td>
<td style="text-align:left;">
Dis. Markers
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Is there a single spot size and grid for intensity modulated proton therapy? Simulation of head and neck, prostate and mesothelioma cases.
</td>
<td style="text-align:left;">
Med Phys
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Curcumin induces autophagy in ACC-MESO-1 cells.
</td>
<td style="text-align:left;">
Phytother Res
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
The diagnostic value of immunohistochemically detected methylthioadenosine phosphorylase deficiency in malignant pleural mesotheliomas.
</td>
<td style="text-align:left;">
Histopathology
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Immunity and malignant mesothelioma: from mesothelial cell damage to tumor development and immune response-based therapies.
</td>
<td style="text-align:left;">
Cancer Lett.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Chemoprevention of asbestos-linked cancers: a systematic review.
</td>
<td style="text-align:left;">
Anticancer Res.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Systemic treatment of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Future Oncol
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Epidermal growth factor receptor mutations in malignant pleural and peritoneal mesothelioma.
</td>
<td style="text-align:left;">
J. Clin. Pathol.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Serum mesothelin for diagnosing malignant pleural mesothelioma: an individual patient data meta-analysis.
</td>
<td style="text-align:left;">
J. Clin. Oncol.
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleurectomy/decortication is superior to extrapleural pneumonectomy in the multimodality management of patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Phase II study of dasatinib in patients with previously treated malignant mesothelioma (cancer and leukemia group B 30601): a brief report.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Epidemiology of mesothelioma in Egypt. A ten-year (1998-2007) multicentre study.
</td>
<td style="text-align:left;">
Arch Med Sci
</td>
<td style="text-align:left;">
treatment | epidemiology
</td>
</tr>
<tr>
<td style="text-align:left;">
Tunneling nanotubes provide a unique conduit for intercellular transfer of cellular contents in human malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
PLoS ONE
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Advances in malignant pleural mesothelioma therapy: targeting EphA2 a novel approach.
</td>
<td style="text-align:left;">
Am J Cancer Res
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Respiratory malignancies induced by asbestos exposure and evaluation of cases with typical pleural malignant mesothelioma and lung cancer with asbestosis].
</td>
<td style="text-align:left;">
Nihon Kyobu Shikkan Gakkai Zasshi
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Mesothelioma: a review.
</td>
<td style="text-align:left;">
Ochsner J
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
A comparison of epidermal growth factor receptor expression in malignant peritoneal and pleural mesothelioma.
</td>
<td style="text-align:left;">
Pathol. Int.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[A comprehensive review of literature to investigate development of global knowledge and consensus on asbestos carcinogenicity: up to the report and recommendations by UICC Working Group in 1964].
</td>
<td style="text-align:left;">
Nihon Eiseigaku Zasshi
</td>
<td style="text-align:left;">
epidemiology
</td>
</tr>
<tr>
<td style="text-align:left;">
[microRNAs as biological indicators of environmental and occupational exposure to asbestos].
</td>
<td style="text-align:left;">
G Ital Med Lav Ergon
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
The role of cytological evaluation of pleural fluid in diagnosing malignant mesothelioma.
</td>
<td style="text-align:left;">
Med. Pregl.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Induction chemotherapy, extrapleural pneumonectomy, and adjuvant radiotherapy for malignant pleural mesothelioma: experience of Guy’s and St Thomas’ hospitals.
</td>
<td style="text-align:left;">
Gen Thorac Cardiovasc Surg
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Novel intrapleural therapies for malignant diseases.
</td>
<td style="text-align:left;">
Respiration
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
An overview of neoadjuvant chemotherapy in the multimodality treatment of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Cancer Treat. Rev.
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Exploratory analysis of activation of PTEN-PI3K pathway and downstream proteins in malignant pleural mesothelioma (MPM).
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[A case of malignant mesothelioma of the pleura].
</td>
<td style="text-align:left;">
Nihon Kyobu Geka Gakkai Zasshi
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Prognostic factors in malignant pleural mesothelioma: a retrospective study.
</td>
<td style="text-align:left;">
Intern. Med.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
18F-FDG PET/CT in a recurrent diffuse malignant peritoneal mesothelioma.
</td>
<td style="text-align:left;">
Clin Nucl Med
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Incarcerated inguinal hernia from metastatic pleural mesothelioma: PET/CT imaging.
</td>
<td style="text-align:left;">
Clin Nucl Med
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Bilateral pleural mesothelioma–case report].
</td>
<td style="text-align:left;">
Z Gesamte Inn Med
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Complete response and long-term survival in malignant pleural mesothelioma: case report.
</td>
<td style="text-align:left;">
Anticancer Res.
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[‘Malignant peritoneal mesothelioma’: a condition difficult to diagnose].
</td>
<td style="text-align:left;">
Ned Tijdschr Geneeskd
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Overexpression and potential targeting of the oncofoetal antigen 5T4 in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Asbestos-induced cellular and molecular alteration of immunocompetent cells and their relationship with chronic inflammation and carcinogenesis.
</td>
<td style="text-align:left;">
J. Biomed. Biotechnol.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Perineal and colonic metastases in two cases of malignant mesothelioma.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
[A diffuse, pleural, malignant mesothelioma kept in long remission by chemotherapy combining pirarubicin and cisplatin].
</td>
<td style="text-align:left;">
Gan No Rinsho
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Aberrant expression of cell cycle regulatory genes predicts overall and disease free survival in malignant pleural mesothelioma patients.
</td>
<td style="text-align:left;">
Exp. Mol. Pathol.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Estimating treatment effects from a randomized clinical trial in the presence of a secondary treatment.
</td>
<td style="text-align:left;">
Biostatistics
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
The circadian clock gene BMAL1 is a novel therapeutic target for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Int. J. Cancer
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma in a child with ataxia-telangiectasia.
</td>
<td style="text-align:left;">
Pediatr. Pulmonol.
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Effect of increasing experience on dosimetric and clinical outcomes in the management of malignant pleural mesothelioma with intensity-modulated radiation therapy.
</td>
<td style="text-align:left;">
Int. J. Radiat. Oncol. Biol. Phys.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Anti-angiogenic therapies for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Expert Opin Investig Drugs
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
What is the optimum strategy for thromboembolic prophylaxis following extrapleural pneumonectomy in patients with malignant pleural mesothelioma?
</td>
<td style="text-align:left;">
Interact Cardiovasc Thorac Surg
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
SOCS-1 gene delivery cooperates with cisplatin plus pemetrexed to exhibit preclinical antitumor activity against malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Int. J. Cancer
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Radical pleurectomy and intraoperative photodynamic therapy for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Ann. Thorac. Surg.
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Laparoscopic thoracic duct clipping for persistent chylothorax after extrapleural pneumonectomy.
</td>
<td style="text-align:left;">
Ann. Thorac. Surg.
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
[Follow-up of subjects occupationally exposed to asbestos: MRI and PET scans].
</td>
<td style="text-align:left;">
Rev Mal Respir
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
The application of immunocytochemistry to direct smears in the diagnosis of effusions.
</td>
<td style="text-align:left;">
Diagn. Cytopathol.
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Nitric oxide (NO) enhances pemetrexed cytotoxicity via NO‑cGMP signaling in lung adenocarcinoma cells in vitro and in vivo.
</td>
<td style="text-align:left;">
Int. J. Oncol.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
The flavonoid resveratrol suppresses growth of human malignant pleural mesothelioma cells through direct inhibition of specificity protein 1.
</td>
<td style="text-align:left;">
Int. J. Mol. Med.
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Cytologic re-evaluation of negative effusions from patients with malignant mesothelioma.
</td>
<td style="text-align:left;">
Pathologica
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Asbestos-induced lung diseases].
</td>
<td style="text-align:left;">
Ugeskr. Laeg.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Interaction and cross-resistance of cisplatin and pemetrexed in malignant pleural mesothelioma cell lines.
</td>
<td style="text-align:left;">
Oncol. Rep.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Epigallocatechin-3-gallate induces mesothelioma cell death via H2 O2 -dependent T-type Ca2+ channel opening.
</td>
<td style="text-align:left;">
J. Cell. Mol. Med.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Huge malignant solitary fibrous tumor of the pleura.
</td>
<td style="text-align:left;">
Gen Thorac Cardiovasc Surg
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Localized malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Gen Thorac Cardiovasc Surg
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
SU6668, a multiple tyrosine kinase inhibitor, inhibits progression of human malignant pleural mesothelioma in an orthotopic model.
</td>
<td style="text-align:left;">
Respirology
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Radiation-induced malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Can Assoc Radiol J
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Postmortem findings of malignant pleural mesothelioma: a two-center study of 318 patients.
</td>
<td style="text-align:left;">
Chest
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Topotecan and pegylated liposomal doxorubicin combination as palliative treatment in patients with pretreated advanced malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Int J Clin Pharmacol Ther
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Interleukin gene polymorphisms in pneumoconiosis.
</td>
<td style="text-align:left;">
Int. J. Mol. Med.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Antitumor activity of MEK and PI3K inhibitors against malignant pleural mesothelioma cells in vitro and in vivo.
</td>
<td style="text-align:left;">
Int. J. Oncol.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Bilateral dissemination of malignant pleural mesothelioma via iatrogenic buffalo chest: a rare route of disease progression.
</td>
<td style="text-align:left;">
Gen Thorac Cardiovasc Surg
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[The chemotherapy of peritoneal malignant mesothelioma].
</td>
<td style="text-align:left;">
Gan To Kagaku Ryoho
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Perifosine as a potential novel anti-cancer agent inhibits EGFR/MET-AKT axis in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
PLoS ONE
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleural intensity-modulated radiotherapy for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Int. J. Radiat. Oncol. Biol. Phys.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Outcome of patients diagnosed with fibrinous pleuritis after medical thoracoscopy.
</td>
<td style="text-align:left;">
Respir Med
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
High SUVmax on FDG-PET indicates pleomorphic subtype in epithelioid malignant pleural mesothelioma: supportive evidence to reclassify pleomorphic as nonepithelioid histology.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Increased circulating miR-625-3p: a potential biomarker for patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Salvage therapy with topical antifungal for Aspergillus fumigatus empyema complicating extrapleural pneumonectomy.
</td>
<td style="text-align:left;">
Interact Cardiovasc Thorac Surg
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Asbestos-related pleural disease.
</td>
<td style="text-align:left;">
Curr Opin Pulm Med
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Bilateral pleural effusion due to malignant mesothelioma, diagnosed by means of immunostaining.
</td>
<td style="text-align:left;">
Eur. Respir. J.
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Molecular pathogenesis of malignant mesothelioma.
</td>
<td style="text-align:left;">
Expert Rev Mol Med
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Resection of a giant, invasive malignant solitary fibrous tumor of pleura.
</td>
<td style="text-align:left;">
Gen Thorac Cardiovasc Surg
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Prognosis and prognostic factors of patients with mesothelioma: a population-based study.
</td>
<td style="text-align:left;">
Br. J. Cancer
</td>
<td style="text-align:left;">
diagnosis | epidemiology
</td>
</tr>
<tr>
<td style="text-align:left;">
Cancer incidence among Swedish pulp and paper mill workers: a cohort study of sulphate and sulphite mills.
</td>
<td style="text-align:left;">
Int Arch Occup Environ Health
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Validation of prognostic factors in malignant pleural mesothelioma: a retrospective analysis of data from patients seeking compensation from the New South Wales Dust Diseases Board.
</td>
<td style="text-align:left;">
Clin Lung Cancer
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma.
</td>
<td style="text-align:left;">
J. Clin. Oncol.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Investigational approaches for mesothelioma.
</td>
<td style="text-align:left;">
Front Oncol
</td>
<td style="text-align:left;">
treatment | epidemiology | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma in US automotive mechanics: reported vs expected number of cases from 1975 to 2007.
</td>
<td style="text-align:left;">
Regul. Toxicol. Pharmacol.
</td>
<td style="text-align:left;">
epidemiology | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
FDG PET/CT Response Evaluation in Malignant Pleural Mesothelioma Patients Treated with Talc Pleurodesis and Chemotherapy.
</td>
<td style="text-align:left;">
J Cancer
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
PET scan contribution in chest tumor management: a systematic review for thoracic surgeons.
</td>
<td style="text-align:left;">
Tumori
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Asbestos and SV40 in malignant pleural mesothelioma from a hyperendemic area of north-eastern Italy.
</td>
<td style="text-align:left;">
Tumori
</td>
<td style="text-align:left;">
epidemiology | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Effects of combined therapies on the survival of pleural mesothelioma patients treated in Brescia, 1982-2006.
</td>
<td style="text-align:left;">
Tumori
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Radiologic aspect of benign pleural fibrous mesothelioma. Reports of 4 cases].
</td>
<td style="text-align:left;">
Ann Radiol (Paris)
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Increased frequency of circulating invariant natural killer T cells in malignant pleural mesothelioma patients.
</td>
<td style="text-align:left;">
Cancer Biol. Ther.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Mesothelioma and mesothelial hyperplasia].
</td>
<td style="text-align:left;">
Zhonghua Nei Ke Za Zhi
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Asbestos-related pleuropulmonary diseases: benign and malignant.
</td>
<td style="text-align:left;">
Postgrad Med
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Cancer incidence in a chlorochemical plant in Isère, France: an occupational cohort study, 1979-2002.
</td>
<td style="text-align:left;">
Am. J. Ind. Med.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Response to chemotherapy is predictive in relation to longer overall survival in an individual patient combined-analysis with pleural mesothelioma.
</td>
<td style="text-align:left;">
Eur. J. Cancer
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma: from the bench to the bedside.
</td>
<td style="text-align:left;">
Respiration
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Activated leukocyte cell-adhesion molecule (ALCAM) promotes malignant phenotypes of malignant mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Prospective study on functional results after lung-sparing radical pleurectomy in the management of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Multicentric study on malignant pleural mesothelioma in Turkey: clinicopathologic and survival characteristics of 282 patients.
</td>
<td style="text-align:left;">
Med. Oncol.
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Human epidemiology: a review of fiber type and characteristics in the development of malignant and nonmalignant disease.
</td>
<td style="text-align:left;">
Environ. Health Perspect.
</td>
<td style="text-align:left;">
epidemiology | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Elimination of asbestos use and asbestos-related diseases: an unfinished story.
</td>
<td style="text-align:left;">
Cancer Sci.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
CCL2, galectin-3, and SMRP combination improves the diagnosis of mesothelioma in pleural effusions.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Distribution and trends in mesothelioma mortality in Italy from 1974 to 2006.
</td>
<td style="text-align:left;">
Int Arch Occup Environ Health
</td>
<td style="text-align:left;">
diagnosis | epidemiology | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Role of hedgehog signaling in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Clin. Cancer Res.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Natural diterpenes from coffee, cafestol and kahweol induce apoptosis through regulation of specificity protein 1 expression in human malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J. Biomed. Sci.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Gallium-67 scanning in patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Jpn. J. Med.
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
[Eosinophil colony stimulating activity induced by administration of interleukin-2 into the pleural cavity of patients with malignant pleurisy].
</td>
<td style="text-align:left;">
Nihon Kyobu Shikkan Gakkai Zasshi
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Clinical role of pleural effusion MMP-3 levels in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Oncol Lett
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Utility of glucose transporter 1 in the distinction of benign and malignant thoracic and abdominal mesothelial lesions.
</td>
<td style="text-align:left;">
Arch. Pathol. Lab. Med.
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Histopathology of the pleura.
</td>
<td style="text-align:left;">
Respiration
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Pretreatment serum C-reactive protein levels predict benefit from multimodality treatment including radical surgery in malignant pleural mesothelioma: a retrospective multicenter analysis.
</td>
<td style="text-align:left;">
Ann. Surg.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Extracellular protease imaging for cell mass tracking of xenografted human malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Oncol. Rep.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant pleural mesothelioma].
</td>
<td style="text-align:left;">
Ther Umsch
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Chemotherapy for malignant tumors of lung and pleura].
</td>
<td style="text-align:left;">
Ther Umsch
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
AMP converted from intracellularly transported adenosine upregulates p53 expression to induce malignant pleural mesothelioma cell apoptosis.
</td>
<td style="text-align:left;">
Cell. Physiol. Biochem.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Specific expression of human intelectin-1 in malignant pleural mesothelioma and gastrointestinal goblet cells.
</td>
<td style="text-align:left;">
PLoS ONE
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
A multicenter phase II study of cisplatin, pemetrexed, and bevacizumab in patients with advanced malignant mesothelioma.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma in a patient with systemic sclerosis: the first report.
</td>
<td style="text-align:left;">
Respiration
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
An open-label phase I pilot study of continuous intrapleural infusion of escalated doses of methotrexate in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Am. J. Clin. Oncol.
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Two cases of malignant peritoneal mesothelioma without asbestos exposure: cytologic and immunohistochemical features.
</td>
<td style="text-align:left;">
Ann Diagn Pathol
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
A prospective trial evaluating the role of mesothelin in undiagnosed pleural effusions.
</td>
<td style="text-align:left;">
Eur. Respir. J.
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Meningeal and brainstem infiltration by a malignant mesothelioma.
</td>
<td style="text-align:left;">
BMJ Case Rep
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
High risk of malignant mesothelioma and pleural plaques in subjects born close to ophiolites.
</td>
<td style="text-align:left;">
Chest
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
New strategies in pleural mesothelioma: BAP1 and NF2 as novel targets for therapeutic development and risk assessment.
</td>
<td style="text-align:left;">
Clin. Cancer Res.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Circulating endothelial cell (CEC) as a diagnostic and prognostic marker in malignant pleural mesothelioma (MPM).
</td>
<td style="text-align:left;">
Ann. Surg. Oncol.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
A case report of an extremely rare and aggressive tumor: primary malignant pericardial mesothelioma.
</td>
<td style="text-align:left;">
Rare Tumors
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Cytomorphologic features of metastatic urothelial carcinoma in serous effusions.
</td>
<td style="text-align:left;">
Diagn. Cytopathol.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Effectiveness of mesothelin family proteins and osteopontin for malignant mesothelioma.
</td>
<td style="text-align:left;">
Eur. Respir. J.
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Characterization of DNA hypermethylation in two cases of peritoneal mesothelioma.
</td>
<td style="text-align:left;">
Tumour Biol.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Immunoperoxidase staining of malignant cells in pleural effusions.
</td>
<td style="text-align:left;">
Pathologica
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
A somatic TSHR mutation in a patient with lung adenocarcinoma with bronchioloalveolar carcinoma, coronary artery disease and severe chronic obstructive pulmonary disease.
</td>
<td style="text-align:left;">
Oncol. Rep.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Role of transcription factor Sp1 in the quercetin-mediated inhibitory effect on human malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Int. J. Mol. Med.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
[Diffuse malignant mesothelioma. Presentation of 10 cases and review of the literature].
</td>
<td style="text-align:left;">
Rev Med Panama
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Diffuse malignant mesothelioma.
</td>
<td style="text-align:left;">
Arch. Pathol. Lab. Med.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Inhibition of phosphoinositide-3 kinase pathway down regulates ABCG2 function and sensitizes malignant pleural mesothelioma to chemotherapy.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
[Cisplatin and cytosine arabinoside (ARA-C) for the therapy of primary and secondary pleural neoplasms].
</td>
<td style="text-align:left;">
G Ital Oncol
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Revisiting cutaneous adverse reactions to pemetrexed.
</td>
<td style="text-align:left;">
Oncol Lett
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Asbestos-related disease: screening and diagnosis.
</td>
<td style="text-align:left;">
Adv Clin Chem
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Prognostic factors in malignant pleural mesothelioma: role of talc pleurodesis.
</td>
<td style="text-align:left;">
Asian Cardiovasc Thorac Ann
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Cytoreductive surgery and hyperthermic intrathoracic chemotherapy perfusion for malignant pleural tumours: perioperative management and clinical experience.
</td>
<td style="text-align:left;">
Eur J Cardiothorac Surg
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Effects of hyaluronic acid and CD44 interaction on the proliferation and invasiveness of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Tumour Biol.
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Folylpoly-glutamate synthetase expression is associated with tumor response and outcome from pemetrexed-based chemotherapy in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
A phase II study of intermittent sunitinib malate as second-line therapy in progressive malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Phase II clinical trial of first or second-line treatment with bortezomib in patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
‘It’s all bad news’: the first 3 months following a diagnosis of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Psychooncology
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Molecular resistance fingerprint of pemetrexed and platinum in a long-term survivor of mesothelioma.
</td>
<td style="text-align:left;">
PLoS ONE
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Patterns of care for malignant pleural mesothelioma patients compensated by the Dust Diseases Board in New South Wales, Australia.
</td>
<td style="text-align:left;">
Intern Med J
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Withaferin A inhibits the proteasome activity in mesothelioma in vitro and in vivo.
</td>
<td style="text-align:left;">
PLoS ONE
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Convergent signaling in the regulation of connective tissue growth factor in malignant mesothelioma: TGFβ signaling and defects in the Hippo signaling cascade.
</td>
<td style="text-align:left;">
Cell Cycle
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Parakeratotic-like cells in effusions - A clue to diagnosis of malignant mesothelioma.
</td>
<td style="text-align:left;">
Cytojournal
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Paratesticular mesothelioma in young age. Case report.
</td>
<td style="text-align:left;">
Klin Onkol
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Quality of life after radical pleurectomy decortication for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Ann. Thorac. Surg.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Therapeutic antitumor efficacy of anti-epidermal growth factor receptor antibody, cetuximab, against malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Int. J. Oncol.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Guidelines for pathologic diagnosis of malignant mesothelioma: 2012 update of the consensus statement from the International Mesothelioma Interest Group.
</td>
<td style="text-align:left;">
Arch. Pathol. Lab. Med.
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Histone deacetylase inhibitors as potential therapeutic agents for the treatment of malignant mesothelioma.
</td>
<td style="text-align:left;">
Anticancer Agents Med Chem
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
3T MRI in evaluation of asbestos-related thoracic diseases - preliminary results.
</td>
<td style="text-align:left;">
Radiol Oncol
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Health-related quality of life and inflammatory markers in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Support Care Cancer
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Paraneoplastic leukocytoclastic vasculitis as an initial presentation of malignant pleural mesothelioma: a case report.
</td>
<td style="text-align:left;">
J Med Case Rep
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Comprehensive treatment of malignant mesothelioma patients after the failure of systemic chemotherapy.
</td>
<td style="text-align:left;">
Cryobiology
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Association of biomarker levels with severity of asbestos-related diseases.
</td>
<td style="text-align:left;">
Saf Health Work
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
A biomarker profile for predicting efficacy of cisplatin-vinorelbine therapy in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Cancer Chemother. Pharmacol.
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Potassium octatitanate fibers (TISMO) induce pleural mesothelial cell reactions with iron accumulation in female A/J mice.
</td>
<td style="text-align:left;">
Oncol Lett
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
CREST biorepository for translational studies on malignant mesothelioma, lung cancer and other respiratory tract diseases: Informatics infrastructure and standardized annotation.
</td>
<td style="text-align:left;">
Exp Ther Med
</td>
<td style="text-align:left;">
epidemiology | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Intratumoral Wnt2B expression affects tumor proliferation and survival in malignant pleural mesothelioma patients.
</td>
<td style="text-align:left;">
Exp Ther Med
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Diagnostic value of neurotrophin expression in malignant pleural effusions.
</td>
<td style="text-align:left;">
Exp Ther Med
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Development of a guideline on reading CT images of malignant pleural mesothelioma and selection of the reference CT films.
</td>
<td style="text-align:left;">
Eur J Radiol
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
DNA repair polymorphisms and treatment outcomes of patients with malignant mesothelioma treated with gemcitabine-platinum combination chemotherapy.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Role of conservative (palliative) care-only in the management of advanced malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Anticancer Res.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Soluble mesothelin-related protein in pleural effusion from patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Exp Ther Med
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Serum levels of alpha-tocopherol, vitamin C, beta-carotene, and retinol in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Asian Pac. J. Cancer Prev.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Distinguishing benign from malignant mesothelial cells in effusions by Glut-1, EMA, and Desmin expression: an evidence-based approach.
</td>
<td style="text-align:left;">
Diagn. Cytopathol.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Case reports of primary pulmonary adenocarcinoma with pleural spread: so-called pseudomesotheliomatous adenocarcinoma.
</td>
<td style="text-align:left;">
Pathol. Int.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Mesothelioma mortality surveillance and asbestos exposure tracking in Italy.
</td>
<td style="text-align:left;">
Ann. Ist. Super. Sanita
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleural fluid cell-free DNA integrity index to identify cytologically negative malignant pleural effusions including mesotheliomas.
</td>
<td style="text-align:left;">
BMC Cancer
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
NLRP3 promotes inflammation-induced skin cancer but is dispensable for asbestos-induced mesothelioma.
</td>
<td style="text-align:left;">
Immunol. Cell Biol.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Evaluation of the efficacy of the guideline on reading CT images of malignant pleural mesothelioma with reference CT films for improving the proficiency of radiologists.
</td>
<td style="text-align:left;">
Eur J Radiol
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Mitochondrial-targeted nitroxides disrupt mitochondrial architecture and inhibit expression of peroxiredoxin 3 and FOXM1 in malignant mesothelioma cells.
</td>
<td style="text-align:left;">
J. Cell. Physiol.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
The separation of benign and malignant mesothelial proliferations.
</td>
<td style="text-align:left;">
Arch. Pathol. Lab. Med.
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Analysis of “dry” mesothelioma with ultrasound guided biopsies.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Asbestos exposure and survival in malignant mesothelioma: a description of 122 consecutive cases at an occupational clinic.
</td>
<td style="text-align:left;">
Int J Occup Environ Med
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Sphingosine kinase 1 is required for mesothelioma cell proliferation: role of histone acetylation.
</td>
<td style="text-align:left;">
PLoS ONE
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Carbonic anhydrase IX in malignant pleural mesotheliomas: a potential target for anti-cancer therapy.
</td>
<td style="text-align:left;">
Bioorg. Med. Chem.
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Heterozygous loss of NF2 is an early molecular alteration in well-differentiated papillary mesothelioma of the peritoneum.
</td>
<td style="text-align:left;">
Cancer Genet
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Toxic epidermal necrolysis related to Cisplatin and pemetrexed for metastatic non-small cell lung cancer.
</td>
<td style="text-align:left;">
Onkologie
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Recombinant human endostatin (endostar) decreased recurrent ascites, pleural fluid and ascitic VEGF in a case of advanced mesothelioma.
</td>
<td style="text-align:left;">
J Chemother
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Serum concentration of integrin-linked kinase in malignant pleural mesothelioma and after asbestos exposure.
</td>
<td style="text-align:left;">
Eur J Cardiothorac Surg
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Fibulin-3 as a blood and effusion biomarker for pleural mesothelioma.
</td>
<td style="text-align:left;">
N. Engl. J. Med.
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Spinal cord compression: an unusual presentation of malignant pleural mesothelioma. A case report and review of the literature.
</td>
<td style="text-align:left;">
Tumori
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Photodynamic therapy for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J Natl Compr Canc Netw
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Pegylated liposomal doxorubicin in malignant pleural mesothelioma: a possible guardian for long-term survival.
</td>
<td style="text-align:left;">
Onco Targets Ther
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Early detection of malignant pleural mesothelioma in asbestos-exposed individuals with a noninvasive proteomics-based surveillance tool.
</td>
<td style="text-align:left;">
PLoS ONE
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
ME1. A monoclonal antibody that distinguishes epithelial-type malignant mesothelioma from pulmonary adenocarcinoma and extrapulmonary malignancies.
</td>
<td style="text-align:left;">
Am. J. Pathol.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Optimization of response classification criteria for patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Tunneling Nanotubes: A new paradigm for studying intercellular communication and therapeutics in cancer.
</td>
<td style="text-align:left;">
Commun Integr Biol
</td>
<td style="text-align:left;">
treatment | transmission
</td>
</tr>
<tr>
<td style="text-align:left;">
[One case of malignant mesothelioma that developed right pneumothorax after a diagnosis with left pneumothorax].
</td>
<td style="text-align:left;">
Gan To Kagaku Ryoho
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
The role of FDG PET-CT in differential diagnosis of pleural pathologies.
</td>
<td style="text-align:left;">
Rev Esp Med Nucl Imagen Mol
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Initial analysis of the international association for the study of lung cancer mesothelioma database.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
High prevalence of serum antibodies reacting with simian virus 40 capsid protein mimotopes in patients affected by malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Proc. Natl. Acad. Sci. U.S.A.
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Outcome and prognostic factors of pleural mesothelioma after surgical diagnosis and/or pleurodesis.
</td>
<td style="text-align:left;">
J. Thorac. Cardiovasc. Surg.
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
The diagnostic utility of D2-40, calretinin, CK5/6, desmin and MOC-31 in the differentiation of mesothelioma from adenocarcinoma in pleural effusion cytology.
</td>
<td style="text-align:left;">
Acta Cytol.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Improved survival after introduction of chemotherapy for malignant pleural mesothelioma in Slovenia: Population-based survey of 444 patients.
</td>
<td style="text-align:left;">
Radiol Oncol
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Excision repair cross complementation group 1 and thymidylate synthase expression in patients with mesothelioma.
</td>
<td style="text-align:left;">
Clin Lung Cancer
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Cohort study of workers employed in an Italian tire manufacturing plant, 1962-2004.
</td>
<td style="text-align:left;">
Cancer Causes Control
</td>
<td style="text-align:left;">
epidemiology
</td>
</tr>
<tr>
<td style="text-align:left;">
A predictive equation to adjust for clinical variables in soluble mesothelin-related protein (SMRP) levels.
</td>
<td style="text-align:left;">
Clin. Chem. Lab. Med.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Three-dimensional stereoscopic volume rendering of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Int Surg
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Utilisation of a thoracic oncology database to capture radiological and pathological images for evaluation of response to chemotherapy in patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
BMJ Open
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Diffusion magnetic resonance imaging of chest tumors.
</td>
<td style="text-align:left;">
Cancer Imaging
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Glutathione S-transferase P1-1 as a target for mesothelioma treatment.
</td>
<td style="text-align:left;">
Cancer Sci.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
The recurrence of malignant pleural mesothelioma 14 years after extrapleural pneumonectomy: possible histological transformation.
</td>
<td style="text-align:left;">
Pathol. Int.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Pleural mesothelioma–case report].
</td>
<td style="text-align:left;">
Acta Med Croatica
</td>
<td style="text-align:left;">
diagnosis | epidemiology | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
CD9 expression as a favorable prognostic marker for patients with malignant mesothelioma.
</td>
<td style="text-align:left;">
Oncol. Rep.
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Asbestos-related diseases in Thailand and review literature.
</td>
<td style="text-align:left;">
J Med Assoc Thai
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
[PleurX drainage catheter for palliative treatment of malignant pleural effusion].
</td>
<td style="text-align:left;">
Pneumologie
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Long term survival after trimodal therapy in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Swiss Med Wkly
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Prognostic significance of metabolic response by positron emission tomography after neoadjuvant chemotherapy for resectable malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Ann. Oncol.
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Clinical utility of 18-fluorodeoxyglucose positron emission tomography/computed tomography in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Exp Ther Med
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Disease volumes as a marker for patient response in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Ann. Oncol.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Novel genes and pathways modulated by syndecan-1: implications for the proliferation and cell-cycle regulation of malignant mesothelioma cells.
</td>
<td style="text-align:left;">
PLoS ONE
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Nonselective transarterial chemoperfusion: a palliative treatment for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Radiology
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Incidence and survival of malignant pleural mesothelioma in norway: a population-based study of 1686 cases.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Tomotherapy after pleurectomy/decortication or biopsy for malignant pleural mesothelioma allows the delivery of high dose of radiation in patients with intact lung.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
MicroRNA miR-34b/c enhances cellular radiosensitivity of malignant pleural mesothelioma cells.
</td>
<td style="text-align:left;">
Anticancer Res.
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Talc pleurodesis as surgical palliation of patients with malignant pleural effusion. Analysis of factors affecting survival.
</td>
<td style="text-align:left;">
Anticancer Res.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Improved quality of life in patients with malignant pleural effusion following videoassisted thoracoscopic talc pleurodesis. Preliminary results.
</td>
<td style="text-align:left;">
Anticancer Res.
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Adenomatoid mesothelioma with intranuclear inclusion bodies: a case report with cytological and histological findings.
</td>
<td style="text-align:left;">
Diagn. Cytopathol.
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Immunohistochemistry in the diagnosis of malignant pleural mesothelioma: trends in Australia and a literature review.
</td>
<td style="text-align:left;">
Asia Pac J Clin Oncol
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Diagnosis of Mesothelioma Using Flexible Bronchoscopy With Endobronchial Ultrasound-guided Biopsy of Mediastinal Lymph Nodes.
</td>
<td style="text-align:left;">
J Bronchology Interv Pulmonol
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Performance characteristics of semirigid thoracoscopy in pleural effusions of undetermined etiology.
</td>
<td style="text-align:left;">
J Bronchology Interv Pulmonol
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Suppression of activin A signals inhibits growth of malignant pleural mesothelioma cells.
</td>
<td style="text-align:left;">
Br. J. Cancer
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Multimodal therapy of malignant pleural mesothelioma: is the replacement of radical surgery imminent?
</td>
<td style="text-align:left;">
Interact Cardiovasc Thorac Surg
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Intraoperative hyperthermic chemotherapy perfusion for malignant pleural mesothelioma: an in vitro evaluation.
</td>
<td style="text-align:left;">
J. Thorac. Cardiovasc. Surg.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Diagnosis of malignant pericarditis: a single centre experience.
</td>
<td style="text-align:left;">
Kardiol Pol
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Expression and role of GLUT-1, MCT-1, and MCT-4 in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Virchows Arch.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
The role of immunohistochemistry in the diagnosis of neoplastic pleural effusions.
</td>
<td style="text-align:left;">
Rom J Morphol Embryol
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
NK cells from malignant pleural effusions are not anergic but produce cytokines and display strong antitumor activity on short-term IL-2 activation.
</td>
<td style="text-align:left;">
Eur. J. Immunol.
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleurectomy decortication in the treatment of the “trapped lung” in benign and malignant pleural effusions.
</td>
<td style="text-align:left;">
Thorac Surg Clin
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Surgical management of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Thorac Surg Clin
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
18F-fluoro-2-deoxy-d-glucose positron emission tomography/computed tomography fused imaging in malignant mesothelioma patients: looking from outside is not enough.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Mesothelioma: a soon to be forgotten disease in the United States?
</td>
<td style="text-align:left;">
J Bronchology Interv Pulmonol
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
A diagnosis of malignant pleural mesothelioma can be made by effusion cytology: results of a 20 year audit.
</td>
<td style="text-align:left;">
Pathology
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Loss of mesothelin expression by mesothelioma cells grown in vitro determines sensitivity to anti-mesothelin immunotoxin SS1P.
</td>
<td style="text-align:left;">
Anticancer Res.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Pemetrexed plus carboplatin or cisplatin as neoadjuvant treatment of operable malignant pleural mesothelioma (MPM).
</td>
<td style="text-align:left;">
Anticancer Res.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Mechanisms of cisplatin-induced cell death in malignant mesothelioma cells: role of inhibitor of apoptosis proteins (IAPs) and caspases.
</td>
<td style="text-align:left;">
Int. J. Oncol.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Asbestos-related malignant mesothelioma: growth, cytology, tumorigenicity and consistent chromosome findings in cell lines from five patients.
</td>
<td style="text-align:left;">
Carcinogenesis
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Extraskeletal osteosarcoma of the pleura:report of a case.
</td>
<td style="text-align:left;">
Ann Thorac Cardiovasc Surg
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
“Thick” cell membranes revealed by immunocytochemical staining: a clue to the diagnosis of mesothelioma.
</td>
<td style="text-align:left;">
Diagn. Cytopathol.
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
PTEN protein expression in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Tumour Biol.
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Factors predicting poor survival after lung-sparing radical pleurectomy of IMIG stage III malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Eur J Cardiothorac Surg
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma in Eastern Asia.
</td>
<td style="text-align:left;">
Asian Pac. J. Cancer Prev.
</td>
<td style="text-align:left;">
epidemiology | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Second Italian consensus conference on malignant pleural mesothelioma: state of the art and recommendations.
</td>
<td style="text-align:left;">
Cancer Treat. Rev.
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Patterns of failure, toxicity, and survival after extrapleural pneumonectomy and hemithoracic intensity-modulated radiation therapy for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Evaluation of soluble mesothelin-related peptide as a diagnostic marker of malignant pleural mesothelioma effusions: its contribution to cytology.
</td>
<td style="text-align:left;">
Cancer Invest.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Computerized tomography in a case of malignant mesothelioma with atypical clinical manifestations].
</td>
<td style="text-align:left;">
Minerva Med.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Antibody therapy for malignant mesothelioma: humanized anti-cD26 mAb therapy].
</td>
<td style="text-align:left;">
Nippon Rinsho
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Re-directed T cells for the treatment of fibroblast activation protein (FAP)-positive malignant pleural mesothelioma (FAPME-1).
</td>
<td style="text-align:left;">
BMC Cancer
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Diagnostic usefulness of p16/CDKN2A FISH in distinguishing between sarcomatoid mesothelioma and fibrous pleuritis.
</td>
<td style="text-align:left;">
Am. J. Clin. Pathol.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
A seven-year disease-free survivor of malignant pleural mesothelioma treated with hyperthermia and chemotherapy: a case report.
</td>
<td style="text-align:left;">
J Med Case Rep
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma: new insights into a rare disease.
</td>
<td style="text-align:left;">
Cancer Treat. Rev.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Individual predictors of increased serum mesothelin in asbestos-exposed workers.
</td>
<td style="text-align:left;">
Med. Oncol.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant mesothelioma of the pleura. Analysis of its immunohistochemical aspects].
</td>
<td style="text-align:left;">
Ann Pathol
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Podoplanin overexpression in human mesothelioma cell lines enhances the tumorigenic phenotype.
</td>
<td style="text-align:left;">
Oncol. Rep.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Mesothelioma - Update on Diagnostic Strategies.
</td>
<td style="text-align:left;">
Clin Pulm Med
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleurodesis outcome in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Thorax
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
PARP1 inhibition affects pleural mesothelioma cell viability and uncouples AKT/mTOR axis via SIRT1.
</td>
<td style="text-align:left;">
J. Cell. Mol. Med.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Gene expression profile of aquaporin 1 and associated interactors in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Gene
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Asymptomatic primary tuberculous pleurisy with intense 18-fluorodeoxyglucose uptake mimicking malignant mesothelioma.
</td>
<td style="text-align:left;">
BMC Infect. Dis.
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Clinical characteristics, treatment and survival outcomes in malignant mesothelioma: eighteen years’ experience in Turkey.
</td>
<td style="text-align:left;">
Asian Pac. J. Cancer Prev.
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Phase II trial of neoadjuvant pemetrexed plus cisplatin followed by surgery and radiation in the treatment of pleural mesothelioma.
</td>
<td style="text-align:left;">
BMC Cancer
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
What is the survival after surgery for localized malignant pleural mesothelioma?
</td>
<td style="text-align:left;">
Interact Cardiovasc Thorac Surg
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Effects of treatment regimens on survival in patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Eur Rev Med Pharmacol Sci
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Orthotopic pleural mesothelioma in mice: SPECT/CT and MR imaging with HER1- and HER2-targeted radiolabeled antibodies.
</td>
<td style="text-align:left;">
Radiology
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant pleural mesothelioma: diagnosis and treatment].
</td>
<td style="text-align:left;">
Rev Pneumol Clin
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Changes in pulmonary function tests predict radiological response to chemotherapy in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Eur J Cardiothorac Surg
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Metachronous malignant mesothelioma and pulmonary adenocarcinoma.
</td>
<td style="text-align:left;">
Turk Patoloji Derg
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Morphologic and immunocytochemical performances of effusion cell blocks prepared using 3 different methods.
</td>
<td style="text-align:left;">
Am. J. Clin. Pathol.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
The malignancy grading method is not a reliable assessment of malignancy in mesothelioma.
</td>
<td style="text-align:left;">
J. Pathol.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Is survivin expression prognostic or predictive in malignant pleural mesothelioma?
</td>
<td style="text-align:left;">
Virchows Arch.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
The expression of Axl receptor tyrosine kinase influences the tumour phenotype and clinical outcome of patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Br. J. Cancer
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Compensation for environmental asbestos-related diseases in South Africa: a neglected issue.
</td>
<td style="text-align:left;">
Glob Health Action
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
A case of malignant peritoneal mesothelioma revealed with limitation of PET-CT in the diagnosis of thoracic metastasis.
</td>
<td style="text-align:left;">
J Thorac Dis
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
SMO expression level correlates with overall survival in patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J. Exp. Clin. Cancer Res.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Local and systemic exposure of cisplatin during hyperthermic intrathoracic chemotherapy perfusion after pleurectomy and decortication for treatment of pleural malignancies.
</td>
<td style="text-align:left;">
J Surg Oncol
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Gene therapy for malignant mesothelioma: current prospects and challenges.
</td>
<td style="text-align:left;">
Cancer Gene Ther.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Expression of thrombomodulin in malignant pleural mesothelioma].
</td>
<td style="text-align:left;">
G Ital Med Lav Ergon
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
[A case report: an university professor suffering from malignant mesothelioma].
</td>
<td style="text-align:left;">
G Ital Med Lav Ergon
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Identification and characterization of microRNA involving in malignant pleural mesothelioma].
</td>
<td style="text-align:left;">
G Ital Med Lav Ergon
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant mesothelioma: analysis of a hospital case series].
</td>
<td style="text-align:left;">
G Ital Med Lav Ergon
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Preliminary study to evaluate the meaning of GGT fractions analysis in a population of workers previously exposed to asbestos].
</td>
<td style="text-align:left;">
G Ital Med Lav Ergon
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Surgery in mesothelioma–where do we go after MARS?
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Thoracic computed tomography findings in malignant mesothelioma.
</td>
<td style="text-align:left;">
Iran J Radiol
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Use of cancer therapy at the end of life in patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Support Care Cancer
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Chemotherapy management of malignant pleural mesothelioma: a phase II study comparing two popular chemotherapy regimens.
</td>
<td style="text-align:left;">
Clin Transl Oncol
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma: update on treatment options with a focus on novel therapies.
</td>
<td style="text-align:left;">
Clin. Chest Med.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Rare pleural tumors.
</td>
<td style="text-align:left;">
Clin. Chest Med.
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
The endoplasmic reticulum stress marker CHOP predicts survival in malignant mesothelioma.
</td>
<td style="text-align:left;">
Br. J. Cancer
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Therapeutic targeting malignant mesothelioma with a novel 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolate via its selective uptake by the proton-coupled folate transporter.
</td>
<td style="text-align:left;">
Cancer Chemother. Pharmacol.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma: factors influencing the prognosis.
</td>
<td style="text-align:left;">
Oncology (Williston Park, N.Y.)
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Laparoscopic repair of secondary parahiatal hernia with incarceration of the stomach: a case report.
</td>
<td style="text-align:left;">
J Med Case Rep
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
M14K and M38K malignant pleural mesothelioma cell lines preserve the same claudin-based phenotype in vivo.
</td>
<td style="text-align:left;">
In Vivo
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Changes of mesothelin and osteopontin levels over time in formerly asbestos-exposed power industry workers.
</td>
<td style="text-align:left;">
Int Arch Occup Environ Health
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Value of autofluorescence in video-assisted thoracoscopic surgery in pleural diseases.
</td>
<td style="text-align:left;">
Thorac Cardiovasc Surg
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Hypoxia affects in vitro growth of newly established cell lines from patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Biomed. Res.
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Changes in lung function after surgery for mesothelioma.
</td>
<td style="text-align:left;">
Asian Cardiovasc Thorac Ann
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Hyperthermic intraoperative pleural cisplatin chemotherapy extends interval to recurrence and survival among low-risk patients with malignant pleural mesothelioma undergoing surgical macroscopic complete resection.
</td>
<td style="text-align:left;">
J. Thorac. Cardiovasc. Surg.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Differential mutation profiles and similar intronic TP53 polymorphisms in asbestos-related lung cancer and pleural mesothelioma.
</td>
<td style="text-align:left;">
Mutagenesis
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Reduced folate carrier and folylpolyglutamate synthetase, but not thymidylate synthase predict survival in pemetrexed-treated patients suffering from malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Pneumoconiosis and malignant mesothelioma in a family operated metal casting business that used industrial talc from New York state.
</td>
<td style="text-align:left;">
Am. J. Ind. Med.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Morphology of 9p21 homozygous deletion-positive pleural mesothelioma cells analyzed using fluorescence in situ hybridization and virtual microscope system in effusion cytology.
</td>
<td style="text-align:left;">
Cancer Cytopathol
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Multimodality treatment of pleural mesothelioma.
</td>
<td style="text-align:left;">
Surg. Oncol. Clin. N. Am.
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Snail expression is associated with a poor prognosis in malignant pleural mesotheliomas.
</td>
<td style="text-align:left;">
Ann. Thorac. Surg.
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma forming a huge mediastinal mass and causing atrial fibrillation.
</td>
<td style="text-align:left;">
Indian J Pathol Microbiol
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Oestrogen receptors are prognostic factors in malignant peritoneal mesothelioma.
</td>
<td style="text-align:left;">
J. Cancer Res. Clin. Oncol.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Anti-Yo antibody-mediated paraneoplastic cerebellar degeneration in a female patient with pleural malignant mesothelioma.
</td>
<td style="text-align:left;">
Jpn. J. Clin. Oncol.
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Circulating tumor cells as a diagnostic test for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Expert Opin Med Diagn
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma diagnosed by endobronchial ultrasound-guided transbronchial needle aspiration.
</td>
<td style="text-align:left;">
Tuberc Respir Dis (Seoul)
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Gli as a novel therapeutic target in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
PLoS ONE
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Regional differences in incidence of malignant mesothelioma in Denmark.
</td>
<td style="text-align:left;">
Dan Med J
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Thymidylate synthase and folyl-polyglutamate synthase are not clinically useful markers of response to pemetrexed in patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Lung volume measurements as a surrogate marker for patient response in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
ΔNp63 (p40) distribution inside lung cancer: a driver biomarker approach to tumor characterization.
</td>
<td style="text-align:left;">
Int. J. Surg. Pathol.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Thoracic shaping technique to avoid residual space after extended pleurectomy/decortication.
</td>
<td style="text-align:left;">
Eur J Cardiothorac Surg
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Sequential binary gene ratio tests define a novel molecular diagnostic strategy for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Clin. Cancer Res.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
A feasibility study of induction pemetrexed plus cisplatin followed by pleurectomy/decortication aimed at macroscopic complete resection for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Jpn. J. Clin. Oncol.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
PET/CT demonstration and monitoring of thoracic and abdominal wall mesothelioma.
</td>
<td style="text-align:left;">
Clin Nucl Med
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Development of a biosensor for detection of pleural mesothelioma cancer biomarker using surface imprinting.
</td>
<td style="text-align:left;">
PLoS ONE
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Phenotypes and karyotypes of human malignant mesothelioma cell lines.
</td>
<td style="text-align:left;">
PLoS ONE
</td>
<td style="text-align:left;">
transmission | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
TRAIL and proteasome inhibitors combination induces a robust apoptosis in human malignant pleural mesothelioma cells through Mcl-1 and Akt protein cleavages.
</td>
<td style="text-align:left;">
BMC Cancer
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Autopsy findings and pleural plaques in the Malignant Mesothelioma (MM) Regional Register of Friuli-Venezia-Giulia].
</td>
<td style="text-align:left;">
Med Lav
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Pemetrexed-induced neutropenic enteritis and severe cutaneous hyperpigmentation in a patient with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Downregulation of Sp1 is involved in honokiol-induced cell cycle arrest and apoptosis in human malignant pleural mesothelioma cells.
</td>
<td style="text-align:left;">
Oncol. Rep.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Preclinical demonstration of synergistic Active Nutrients/Drug (AND) combination as a potential treatment for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
PLoS ONE
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Diagnostic value of mesothelin in pleural fluids: comparison with CYFRA 21-1 and CEA.
</td>
<td style="text-align:left;">
Med. Oncol.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Is galectin-3 antibody a useful marker in the diagnosis of malignant pleural mesothelioma?
</td>
<td style="text-align:left;">
J Immunoassay Immunochem
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Endothelial cell protein C receptor opposes mesothelioma growth driven by tissue factor.
</td>
<td style="text-align:left;">
Cancer Res.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Current and future options for the diagnosis of malignant pleural effusion.
</td>
<td style="text-align:left;">
Expert Opin Med Diagn
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Mutation analysis of the EGFR gene and downstream signalling pathway in histologic samples of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Br. J. Cancer
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Phase 2 study of sorafenib in malignant mesothelioma previously treated with platinum-containing chemotherapy.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Diagnostic delay in malignant pleural mesothelioma due to physicians fixation on history with non-exposure to asbestos.
</td>
<td style="text-align:left;">
BMJ Case Rep
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Cytogenetic analysis of malignant mesothelioma.
</td>
<td style="text-align:left;">
Cancer Genet. Cytogenet.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
[Epidemiological and occupational medicine aspects of pleural mesothelioma].
</td>
<td style="text-align:left;">
Pneumologie
</td>
<td style="text-align:left;">
epidemiology
</td>
</tr>
<tr>
<td style="text-align:left;">
Is living close to ophiolites related to asbestos related diseases? Cross-sectional study.
</td>
<td style="text-align:left;">
Respir Med
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Thalidomide versus active supportive care for maintenance in patients with malignant mesothelioma after first-line chemotherapy (NVALT 5): an open-label, multicentre, randomised phase 3 study.
</td>
<td style="text-align:left;">
Lancet Oncol.
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
[Epidemiologic surveillance of mesothelioma for the prevention of asbestos exposure also in non-traditional settings].
</td>
<td style="text-align:left;">
Epidemiol Prev
</td>
<td style="text-align:left;">
diagnosis | epidemiology
</td>
</tr>
<tr>
<td style="text-align:left;">
[Considerations about the epidemiologic surveillance system on mesothelioma in Tuscany (Italy) after 25 years of activity].
</td>
<td style="text-align:left;">
Epidemiol Prev
</td>
<td style="text-align:left;">
diagnosis | epidemiology
</td>
</tr>
<tr>
<td style="text-align:left;">
The N-ERC index is a novel monitoring and prognostic marker for advanced malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Dis
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Bone metastases with nerve root compression as a late complication in patient with epithelial pleural mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Dis
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Cytological exam of the pleural fluid in the diagnosis of neoplastic pleuritis. Cases contribution].
</td>
<td style="text-align:left;">
Minerva Med.
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Calretinin is essential for mesothelioma cell growth/survival in vitro: a potential new target for malignant mesothelioma therapy?
</td>
<td style="text-align:left;">
Int. J. Cancer
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant pleural mesothelioma: comparison of radical pleurectomy und extrapleural pneumonectomy].
</td>
<td style="text-align:left;">
Chirurg
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
[Intraoperative chemotherapy after radical pleurectomy or extrapleural pneumonectomy].
</td>
<td style="text-align:left;">
Chirurg
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Desmoplastic malignant mesothelioma.
</td>
<td style="text-align:left;">
J Bronchology Interv Pulmonol
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Serum HMGB1 as a prognostic marker for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
BMC Cancer
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Pseudomesotheliomatous lung cancer mimicking mesothelioma on ¹⁸F-FDG PET/CT images: report of 2 cases.
</td>
<td style="text-align:left;">
Jpn J Radiol
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Survival of mesothelioma in a palliative medical care unit in egypt.
</td>
<td style="text-align:left;">
Asian Pac. J. Cancer Prev.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Overexpression of Numb suppresses tumor cell growth and enhances sensitivity to cisplatin in epithelioid malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Oncol. Rep.
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Genetic variants associated with increased risk of malignant pleural mesothelioma: a genome-wide association study.
</td>
<td style="text-align:left;">
PLoS ONE
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
p16 Deletion in sarcomatoid tumors of the lung and pleura.
</td>
<td style="text-align:left;">
Arch. Pathol. Lab. Med.
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
EZH2, a unique marker of malignancy in effusion cytology.
</td>
<td style="text-align:left;">
Diagn. Cytopathol.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Good response of malignant pleural effusion from carcinoma of unknown primary site to the anti-tuberculosis therapy: a case report.
</td>
<td style="text-align:left;">
Int J Clin Exp Pathol
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Diagnostic surgical pathology in lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.
</td>
<td style="text-align:left;">
Chest
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Proton magnetic resonance metabolomic characterization of ovarian serous carcinoma effusions: chemotherapy-related effects and comparison with malignant mesothelioma and breast carcinoma.
</td>
<td style="text-align:left;">
Hum. Pathol.
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Value of Glut-1 and Koc markers in the differential diagnosis of reactive mesothelial hyperplasia, malignant mesothelioma and pulmonary adenocarcinoma.
</td>
<td style="text-align:left;">
Turk Patoloji Derg
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
No detection of simian virus 40 in malignant mesothelioma in Korea.
</td>
<td style="text-align:left;">
Korean J Pathol
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
PET/CT versus body coil PET/MRI: how low can you go?
</td>
<td style="text-align:left;">
Insights Imaging
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Thymidylate synthase expression determines pemetrexed targets and resistance development in tumour cells.
</td>
<td style="text-align:left;">
PLoS ONE
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Management of malignant pleural mesothelioma: have we made any progress?
</td>
<td style="text-align:left;">
Panminerva Med
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Molecular pathogenesis of malignant mesothelioma.
</td>
<td style="text-align:left;">
Carcinogenesis
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Simultaneous bilateral spontaneous hydropneumothorax: a rare presentation of bilateral malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
BMJ Case Rep
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Germline BAP1 mutations predispose to renal cell carcinomas.
</td>
<td style="text-align:left;">
Am. J. Hum. Genet.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Two malignancies or an unusual presentation of a pleural malignancy?
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Secondary malignant peritoneal mesothelioma of the greater omentum after therapy for primary pleural mesothelioma.
</td>
<td style="text-align:left;">
Case Rep Oncol
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Radical pleurectomy and chemoradiation for malignant pleural mesothelioma: the outcome of incomplete resections.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Relationship between 18 FDG PET-CT findings and the survival of 177 patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Eur Rev Med Pharmacol Sci
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
A novel targeting therapy of malignant mesothelioma using anti-podoplanin antibody.
</td>
<td style="text-align:left;">
J. Immunol.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Asbestos and the lung in the 21st century: an update.
</td>
<td style="text-align:left;">
Clin Respir J
</td>
<td style="text-align:left;">
diagnosis | epidemiology | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Investigation of pleural effusion: comparison between fibreoptic thoracoscopy, needle biopsy and cytology.
</td>
<td style="text-align:left;">
Respir Med
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Peritoneal mesothelioma: the site of origin matters.
</td>
<td style="text-align:left;">
Am Soc Clin Oncol Educ Book
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma: incidence, etiology, diagnosis, treatment, and occupational health.
</td>
<td style="text-align:left;">
Dtsch Arztebl Int
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
EphB4 as a therapeutic target in mesothelioma.
</td>
<td style="text-align:left;">
BMC Cancer
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma and epidermal growth factor receptor (EGF-R). Relationship of EGF-R with histology and survival using fixed paraffin embedded tissue and the F4, monoclonal antibody.
</td>
<td style="text-align:left;">
Br. J. Cancer
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Cyclooxygenase-2, epidermal growth factor receptor, and aromatase signaling in inflammation and mesothelioma.
</td>
<td style="text-align:left;">
Mol. Cancer Ther.
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
[Pulmonary disease due to asbestos in steel industry workers].
</td>
<td style="text-align:left;">
Medicina (B Aires)
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
[Asbestos and harmful health effects: from denial theories to epidemiological evidence].
</td>
<td style="text-align:left;">
Ig Sanita Pubbl
</td>
<td style="text-align:left;">
epidemiology
</td>
</tr>
<tr>
<td style="text-align:left;">
[Regional treatment of malignant pleural mesothelioma: results from the tumor centre Regensburg].
</td>
<td style="text-align:left;">
Chirurg
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Sensitivity to epidermal growth factor receptor tyrosine kinase inhibitor requires E-cadherin in esophageal cancer and malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Anticancer Res.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Up-regulation of DDX39 in human malignant pleural mesothelioma cell lines compared to normal pleural mesothelial cells.
</td>
<td style="text-align:left;">
Anticancer Res.
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Mesothelin is more useful in pleural effusion than in serum in the diagnosis of pleural mesothelioma.
</td>
<td style="text-align:left;">
Anticancer Res.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Effusion cytology in the diagnosis of malignant epithelioid and biphasic pleural mesothelioma.
</td>
<td style="text-align:left;">
Arch. Pathol. Lab. Med.
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
[Surgical aspects of malignant pleural mesothelioma: from the perspective of pathology].
</td>
<td style="text-align:left;">
Chirurg
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Surgery in the treatment of malignant pleural mesothelioma: recruitment into trials should be the default position.
</td>
<td style="text-align:left;">
Thorax
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Unusual presentation and location pleural malignant mesothelioma.
</td>
<td style="text-align:left;">
BMJ Case Rep
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
BAK and NOXA are critical determinants of mitochondrial apoptosis induced by bortezomib in mesothelioma.
</td>
<td style="text-align:left;">
PLoS ONE
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Systematic review of pleurectomy in the treatment of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Combination of mesothelin and CEA significantly improves the differentiation between malignant pleural mesothelioma, benign asbestos disease, and lung cancer.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Primary pleural malignant mesothelioma with delayed metastasis to the piriform sinus: report of a case.
</td>
<td style="text-align:left;">
Ear Nose Throat J
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
A phase II clinical trial of the vascular disrupting agent BNC105P as second line chemotherapy for advanced Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Occupational exposure to asbestos and incidence of malignant mesothelioma in the Lazio region, years 2001-2009: results of the activities of the regional register].
</td>
<td style="text-align:left;">
Med Lav
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
The role of epigenetics in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Hyaluronic acid in the pleural fluid of patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Respir Investig
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Phase II study of first-line bortezomib and cisplatin in malignant pleural mesothelioma and prospective validation of progression free survival rate as a primary end-point for mesothelioma clinical trials (European Organisation for Research and Treatment of Cancer 08052).
</td>
<td style="text-align:left;">
Eur. J. Cancer
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Meta-analysis of microRNA-183 family expression in human cancer studies comparing cancer tissues with noncancerous tissues.
</td>
<td style="text-align:left;">
Gene
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant pleural mesothelioma after radiation treatment for Hodgkin lymphoma].
</td>
<td style="text-align:left;">
Rev Pneumol Clin
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Diffuse intrapulmonary malignant mesothelioma masquerading as interstitial lung disease: a distinctive variant of mesothelioma.
</td>
<td style="text-align:left;">
Am. J. Surg. Pathol.
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
ERCC1, MLH1, MSH2, MSH6, and βIII-tubulin: resistance proteins associated with response and outcome to platinum-based chemotherapy in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Clin Lung Cancer
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Challenges and controversies in the diagnosis of mesothelioma: Part 1. Cytology-only diagnosis, biopsies, immunohistochemistry, discrimination between mesothelioma and reactive mesothelial hyperplasia, and biomarkers.
</td>
<td style="text-align:left;">
J. Clin. Pathol.
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Therapies currently in Phase II trials for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Expert Opin Investig Drugs
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Defect in recruiting effector memory CD8+ T-cells in malignant pleural effusions compared to normal pleural fluid.
</td>
<td style="text-align:left;">
BMC Cancer
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
The challenge of prognostic markers in pleural mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Dis
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
miR-1 induces growth arrest and apoptosis in malignant mesothelioma.
</td>
<td style="text-align:left;">
Chest
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
MUC1 has prognostic significance in malignant peritoneal mesothelioma.
</td>
<td style="text-align:left;">
Int. J. Biol. Markers
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
No association between simian virus 40 and diffuse malignant mesothelioma of the pleura in Iranian patients: a molecular and epidemiologic case-control study of 60 patients.
</td>
<td style="text-align:left;">
Am. J. Ind. Med.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Challenges and controversies in the diagnosis of malignant mesothelioma: Part 2. Malignant mesothelioma subtypes, pleural synovial sarcoma, molecular and prognostic aspects of mesothelioma, BAP1, aquaporin-1 and microRNA.
</td>
<td style="text-align:left;">
J. Clin. Pathol.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Intensity-modulated radiotherapy and volumetric-modulated arc therapy for malignant pleural mesothelioma after extrapleural pleuropneumonectomy.
</td>
<td style="text-align:left;">
J Appl Clin Med Phys
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Primary pericardial mesothelioma: a rare entity.
</td>
<td style="text-align:left;">
Case Rep Oncol Med
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Diffuse mesothelioma of the peritoneum: a pathological study of 64 tumours treated with cytoreductive therapy.
</td>
<td style="text-align:left;">
Pathology
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Further evidence for germline BAP1 mutations predisposing to melanoma and malignant mesothelioma.
</td>
<td style="text-align:left;">
Cancer Genet
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Tsc1-Tp53 loss induces mesothelioma in mice, and evidence for this mechanism in human mesothelioma.
</td>
<td style="text-align:left;">
Oncogene
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Pemetrexed-induced eyelid edema in lung cancer.
</td>
<td style="text-align:left;">
J Craniofac Surg
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
[Prognosis related clinical and molecular factors in malignant pleural mesothelioma].
</td>
<td style="text-align:left;">
Zhonghua Jie He He Hu Xi Za Zhi
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Differential diagnosis of reactive mesothelial cells and malignant mesothelioma cells using the cell proliferation markers minichromosome maintenance protein 7, geminin, topoisomerase II alpha and Ki-67.
</td>
<td style="text-align:left;">
Acta Cytol.
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Phase II study of pemetrexed and carboplatin plus bevacizumab as first-line therapy in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Br. J. Cancer
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
SAHA overcomes FLIP-mediated inhibition of SMAC mimetic-induced apoptosis in mesothelioma.
</td>
<td style="text-align:left;">
Cell Death Dis
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
A phase II study of pirarubicin in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Cancer
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Metastatic carcinoma to the thyroid gland: a single institution 20-year experience and review of the literature.
</td>
<td style="text-align:left;">
Endocr. Pathol.
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Clinical value of mesothelin in pleural effusions versus histology by medical thoracoscopy: brief report.
</td>
<td style="text-align:left;">
Med. Oncol.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleural mesothelioma: epidemiological and public health issues. Report from the Second Italian Consensus Conference on Pleural Mesothelioma.
</td>
<td style="text-align:left;">
Med Lav
</td>
<td style="text-align:left;">
epidemiology
</td>
</tr>
<tr>
<td style="text-align:left;">
Enhancement of in vitro cell motility and invasiveness of human malignant pleural mesothelioma cells through the HIF-1α-MUC1 pathway.
</td>
<td style="text-align:left;">
Cancer Lett.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
FDG PET/CT in the management of primary pleural tumors and pleural metastases.
</td>
<td style="text-align:left;">
AJR Am J Roentgenol
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Secondline chemotherapy versus best supportive care in patient with malignant pleural mesothelioma: a retrospective study.
</td>
<td style="text-align:left;">
Asian Pac. J. Cancer Prev.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
The use of indwelling pleural catheters for the management of malignant pleural effusion–direct costs in a Dutch hospital.
</td>
<td style="text-align:left;">
Respiration
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Overexpression of EPH receptor B2 in malignant mesothelioma correlates with oncogenic behavior.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
An oncolytic vaccinia virus expressing the human sodium iodine symporter prolongs survival and facilitates SPECT/CT imaging in an orthotopic model of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Surgery
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma, airborne asbestos, and the need for accuracy in chrysotile risk assessments.
</td>
<td style="text-align:left;">
New Solut
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Identification of pregnancy-associated plasma protein A as a migration-promoting gene in malignant pleural mesothelioma cells: a potential therapeutic target.
</td>
<td style="text-align:left;">
Oncotarget
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Up-regulation of DDX39 in human pancreatic cancer cells with acquired gemcitabine resistance compared to gemcitabine-sensitive parental cells.
</td>
<td style="text-align:left;">
Anticancer Res.
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Lymph node metastasis as the initial manifestation of malignant mesothelioma. Report of six cases.
</td>
<td style="text-align:left;">
Am. J. Surg. Pathol.
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Epidemiology of malignant pleural mesothelioma in the province of Sassari (Sardinia, Italy). A population-based report.
</td>
<td style="text-align:left;">
Ann Ital Chir
</td>
<td style="text-align:left;">
treatment | epidemiology
</td>
</tr>
<tr>
<td style="text-align:left;">
Pulmonary toxicity of carbon nanotubes and asbestos - similarities and differences.
</td>
<td style="text-align:left;">
Adv. Drug Deliv. Rev.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Use of the posterior pericardium to cover the bronchial stump after right extrapleural pneumonectomy.
</td>
<td style="text-align:left;">
Ann. Thorac. Surg.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Negative modulation of mitochondrial oxidative phosphorylation by epigallocatechin-3 gallate leads to growth arrest and apoptosis in human malignant pleural mesothelioma cells.
</td>
<td style="text-align:left;">
Biochim. Biophys. Acta
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Risk factors associated with asbestos-related diseases: a community-based case-control study.
</td>
<td style="text-align:left;">
BMC Public Health
</td>
<td style="text-align:left;">
treatment | epidemiology | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Chronic exposure to carbon nanotubes induces invasion of human mesothelial cells through matrix metalloproteinase-2.
</td>
<td style="text-align:left;">
ACS Nano
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Variability of tumor area measurements for response assessment in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Med Phys
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
18F-FDG PET/CT in suspected recurrences of epithelial malignant pleural mesothelioma in asbestos-fibers-exposed patients (comparison to standard diagnostic follow-up).
</td>
<td style="text-align:left;">
Clin Imaging
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma in a clerk working in an asbestos factory.
</td>
<td style="text-align:left;">
Ann. Acad. Med. Singap.
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Treatment of malignant pleural mesothelioma by fibroblast activation protein-specific re-directed T cells.
</td>
<td style="text-align:left;">
J Transl Med
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Asbestos and erionite prime and activate the NLRP3 inflammasome that stimulates autocrine cytokine release in human mesothelial cells.
</td>
<td style="text-align:left;">
Part Fibre Toxicol
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Characterization of a French series of female cases of mesothelioma.
</td>
<td style="text-align:left;">
Am. J. Ind. Med.
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Giant malignant mesothelioma in the upper mediastinum: A case report.
</td>
<td style="text-align:left;">
Oncol Lett
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Localized mesothelioma tumour arising synchronously with a primary contralateral lung cancer.
</td>
<td style="text-align:left;">
Interact Cardiovasc Thorac Surg
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Patterns of disease progression on 18F-fluorodeoxyglucose positron emission tomography-computed tomography in patients with malignant pleural mesothelioma undergoing multimodality therapy with pleurectomy/decortication.
</td>
<td style="text-align:left;">
Nucl Med Commun
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
BAP1 protein is a progression factor in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Pathol. Oncol. Res.
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Overexpression and promoter mutation of the TERT gene in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Oncogene
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Long non coding RNAs (lncRNAs) are dysregulated in Malignant Pleural Mesothelioma (MPM).
</td>
<td style="text-align:left;">
PLoS ONE
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Systematic review of trimodality therapy for patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Ann Cardiothorac Surg
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Do we need a revised staging system for malignant pleural mesothelioma? Analysis of the IASLC database.
</td>
<td style="text-align:left;">
Ann Cardiothorac Surg
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma: an epidemiological perspective.
</td>
<td style="text-align:left;">
Ann Cardiothorac Surg
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Video-atlas of extrapleural pneumonectomy.
</td>
<td style="text-align:left;">
Ann Cardiothorac Surg
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Gremlin-1 associates with fibrillin microfibrils in vivo and regulates mesothelioma cell survival through transcription factor slug.
</td>
<td style="text-align:left;">
Oncogenesis
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Existing models, but not neutrophil-to-lymphocyte ratio, are prognostic in malignant mesothelioma.
</td>
<td style="text-align:left;">
Br. J. Cancer
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Small orangiophilic squamous-like cells: an underrecognized and useful morphological feature for the diagnosis of malignant mesothelioma in pleural effusion cytology.
</td>
<td style="text-align:left;">
Cancer Cytopathol
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Quality of life and personality traits in patients with malignant pleural mesothelioma and their first-degree caregivers.
</td>
<td style="text-align:left;">
Neuropsychiatr Dis Treat
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Hyaluronan and N-ERC/mesothelin as key biomarkers in a specific two-step model to predict pleural malignant mesothelioma.
</td>
<td style="text-align:left;">
PLoS ONE
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Which type of surgery should become the preferred procedure for malignant pleural mesothelioma: extrapleural pneumonectomy or extended pleurectomy?
</td>
<td style="text-align:left;">
J Thorac Dis
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Antitumor impact of interferon-γ producing CD1d-restricted NKT cells in murine malignant mesothelioma.
</td>
<td style="text-align:left;">
J. Immunother.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Imaging in pleural mesothelioma: a review of the 11th International Conference of the International Mesothelioma Interest Group.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
The value of pemetrexed for the treatment of malignant pleural mesothelioma: a comprehensive review.
</td>
<td style="text-align:left;">
Anticancer Res.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Cytoreductive surgery and post-operative heated pleural chemotherapy for the management of pleural surface malignancy.
</td>
<td style="text-align:left;">
Int J Hyperthermia
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial.
</td>
<td style="text-align:left;">
Lancet Oncol.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
The diagnosis of malignant mesothelioma in effusion cytology: a reappraisal and results of a multi-institution survey.
</td>
<td style="text-align:left;">
Cancer Cytopathol
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Expression profile and function of Wnt signaling mechanisms in malignant mesothelioma cells.
</td>
<td style="text-align:left;">
Biochem. Biophys. Res. Commun.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
CD90 is a diagnostic marker to differentiate between malignant pleural mesothelioma and lung carcinoma with immunohistochemistry.
</td>
<td style="text-align:left;">
Am. J. Clin. Pathol.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Giant benign solitary fibrous tumour of the pleura (&gt; 15 cm): role of radiological pathological correlations in management. Report of 3 cases and review of the literature.
</td>
<td style="text-align:left;">
Pathologica
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[The diagnostic value of medical thoracoscopy for unexplained pleural effusion].
</td>
<td style="text-align:left;">
Zhonghua Jie He He Hu Xi Za Zhi
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Localized Intrasplenic Mesothelioma: A Case Report.
</td>
<td style="text-align:left;">
Int. J. Surg. Pathol.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Pulmonary mucinous cystadenocarcinoma presenting as a pleural mesothelioma.
</td>
<td style="text-align:left;">
Int J Surg Case Rep
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
The hexacarbonyldicobalt derivative of aspirin acts as a CO-releasing NSAID on malignant mesothelioma cells.
</td>
<td style="text-align:left;">
Metallomics
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
The association of 18F-FDG PET/CT parameters with survival in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Eur. J. Nucl. Med. Mol. Imaging
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Florid mesothelial hyperplasia of the tunica vaginalis mimicking malignant mesothelioma: a clinicopathologic study of 12 cases.
</td>
<td style="text-align:left;">
Am. J. Surg. Pathol.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Estrogen receptor β activation impairs mitochondrial oxidative metabolism and affects malignant mesothelioma cell growth in vitro and in vivo.
</td>
<td style="text-align:left;">
Oncogenesis
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma with bone metastases.
</td>
<td style="text-align:left;">
Med. Pediatr. Oncol.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma presenting with symptomatic brain metastases: report of a case.
</td>
<td style="text-align:left;">
Rom J Morphol Embryol
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Antiproliferative activity of Pt(IV)-bis(carboxylato) conjugates on malignant pleural mesothelioma cells.
</td>
<td style="text-align:left;">
J. Inorg. Biochem.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Pulmonary alveolar microlithiasis with concurrent pleural mesothelioma in a dog.
</td>
<td style="text-align:left;">
J. Vet. Diagn. Invest.
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Differential expression of extracellular matrix constituents and cell adhesion molecules between malignant pleural mesothelioma and mesothelial hyperplasia.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Ca2 and Ca3. New monoclonal antibodies evaluated as tumor markers in serous effusions.
</td>
<td style="text-align:left;">
Cancer
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma presenting as acute empyema with severe leukocytosis.
</td>
<td style="text-align:left;">
Ann Thorac Cardiovasc Surg
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Targeting of the Hedgehog signal transduction pathway suppresses survival of malignant pleural mesothelioma cells in vitro.
</td>
<td style="text-align:left;">
J. Thorac. Cardiovasc. Surg.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma: current and future perspectives.
</td>
<td style="text-align:left;">
J Thorac Dis
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Free fatty acids inhibit protein tyrosine phosphatase 1B and activate Akt.
</td>
<td style="text-align:left;">
Cell. Physiol. Biochem.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Clinical indications and results after chest wall resection for recurrent mesothelioma.
</td>
<td style="text-align:left;">
J. Thorac. Cardiovasc. Surg.
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Treatment of malignant pleural effusion.
</td>
<td style="text-align:left;">
Chest
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant transformation of well-differentiated papillary mesothelioma 13 years after the diagnosis: a case report.
</td>
<td style="text-align:left;">
Clin Respir J
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Intracavitary chemotherapy.
</td>
<td style="text-align:left;">
Crit. Rev. Oncol. Hematol.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Clinical characteristics of patients with malignant pleural mesothelioma harboring somatic BAP1 mutations.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Hesperidin Induces Apoptosis by Inhibiting Sp1 and Its Regulatory Protein in MSTO-211H Cells.
</td>
<td style="text-align:left;">
Biomol Ther (Seoul)
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Stratification of malignant pleural mesothelioma prognosis using recursive partitioning analysis.
</td>
<td style="text-align:left;">
Lung
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Lymph node involvement and metastatic lymph node ratio influence the survival of malignant pleural mesothelioma: a French multicenter retrospective study.
</td>
<td style="text-align:left;">
Oncol. Rep.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Restoring expression of miR-16: a novel approach to therapy for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Ann. Oncol.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Prognostic nutritional index predicts outcomes of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J. Cancer Res. Clin. Oncol.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
The intermediate filament cytoskeleton of malignant mesotheliomas and its diagnostic significance.
</td>
<td style="text-align:left;">
Am. J. Pathol.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Gemcitabine and vinorelbine as second-line or beyond treatment in patients with malignant pleural mesothelioma pretreated with platinum plus pemetrexed chemotherapy.
</td>
<td style="text-align:left;">
Int. J. Clin. Oncol.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Follow-up study of 100 malignant pleural mesotheliomas.
</td>
<td style="text-align:left;">
Thorac Cardiovasc Surg
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleural effusion hyaluronic acid as a prognostic marker in pleural malignant mesothelioma.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleuroscopic punch biopsy using insulated-tip diathermic knife-2 for the diagnosis of desmoplastic malignant mesothelioma.
</td>
<td style="text-align:left;">
J Bronchology Interv Pulmonol
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Comparison of the diagnostic accuracy of the MSLN gene products, mesothelin and megakaryocyte potentiating factor, as biomarkers for mesothelioma in pleural effusions and serum.
</td>
<td style="text-align:left;">
Dis. Markers
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
The degree of microRNA-34b/c methylation in serum-circulating DNA is associated with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
¹⁸F-FDG uptake on PET is a predictive marker of thymidylate synthase expression in patients with thoracic neoplasms.
</td>
<td style="text-align:left;">
Oncol. Rep.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Pathology of pleural mesothelioma.
</td>
<td style="text-align:left;">
Thorac Cardiovasc Surg
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Immunological effects of the TGFβ-blocking antibody GC1008 in malignant pleural mesothelioma patients.
</td>
<td style="text-align:left;">
Oncoimmunology
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Diffuse malignant peritoneal mesothelioma.
</td>
<td style="text-align:left;">
Kaohsiung J. Med. Sci.
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
The diagnostic distinction between malignant mesothelioma of the pleura and adenocarcinoma of the lung as defined by a monoclonal antibody (B72.3).
</td>
<td style="text-align:left;">
Am. J. Pathol.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Immunohistochemical staining for vimentin and keratin in malignant mesothelioma.
</td>
<td style="text-align:left;">
Am. J. Surg. Pathol.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma presenting as a gradually enlarging pneumothorax.
</td>
<td style="text-align:left;">
Case Rep Pulmonol
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Identification of a seven glycopeptide signature for malignant pleural mesothelioma in human serum by selected reaction monitoring.
</td>
<td style="text-align:left;">
Clin Proteomics
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Pleural lymphatics and pleural diseases related to fibres].
</td>
<td style="text-align:left;">
Rev Pneumol Clin
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Radical pleurectomy/decortication followed by high dose of radiation therapy for malignant pleural mesothelioma. Final results with long-term follow-up.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
The state of the art in the technical performance of lung-sparing operations for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Semin. Thorac. Cardiovasc. Surg.
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Keratin and epithelial membrane antigen immunoreactivity in nonneoplastic fibrous pleural lesions: implications for the diagnosis of desmoplastic mesothelioma.
</td>
<td style="text-align:left;">
Hum. Pathol.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant pleural mesothelioma: 2013 state of the art].
</td>
<td style="text-align:left;">
Bull Cancer
</td>
<td style="text-align:left;">
diagnosis | treatment | epidemiology | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Antigenic phenotype of malignant mesotheliomas and pulmonary adenocarcinomas. An immunohistologic analysis demonstrating the value of Leu M1 antigen.
</td>
<td style="text-align:left;">
Am. J. Pathol.
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Leser–Trélat syndrome in malignant mesothelioma and pulmonary adenocarcinoma: is the EGFR pathway part of the syndrome?
</td>
<td style="text-align:left;">
Virchows Arch.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Cytoskeletal proteins as tissue-specific markers in cytopathology.
</td>
<td style="text-align:left;">
Exp. Cell Biol.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Protumorigenic effects of mir-145 loss in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Oncogene
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
[Expression of glucose transporter protein 1 and desmin in reactive mesothelial hyperplasia and epithelioid malignant mesothelioma].
</td>
<td style="text-align:left;">
Zhonghua Bing Li Xue Za Zhi
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Clinicopathologic characteristics of malignant mesotheliomas arising in patients with a history of radiation for Hodgkin and non-Hodgkin lymphoma.
</td>
<td style="text-align:left;">
J. Clin. Oncol.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Extrapleural and cardiophrenic lymph nodes: prevalence, clinical significance and diagnostic value.
</td>
<td style="text-align:left;">
Radiol Med
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
AHNAK is highly expressed and plays a key role in cell migration and invasion in mesothelioma.
</td>
<td style="text-align:left;">
Int. J. Oncol.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Localized fibrous tumour of serosal surfaces. Immunohistochemical and ultrastructural evidence for a type of mesothelioma.
</td>
<td style="text-align:left;">
Virchows Arch A Pathol Anat Histopathol
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Iron overload as a major targetable pathogenesis of asbestos-induced mesothelial carcinogenesis.
</td>
<td style="text-align:left;">
Redox Rep.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Surgical pathology of lung cancer.
</td>
<td style="text-align:left;">
Semin Respir Crit Care Med
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Helical tomotherapy in the treatment of malignant pleural mesothelioma: The impact of low doses on pulmonary and oesophageal toxicity].
</td>
<td style="text-align:left;">
Cancer Radiother
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
FDG PET/CT is useful for detecting infiltration to the port site in patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Gen Thorac Cardiovasc Surg
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant cardiac tamponade.
</td>
<td style="text-align:left;">
Acta Cardiol
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
An enzyme immunoassay for auto-antibodies to keratin in normal human serum and in pleural fluids from patients with various malignant or non-malignant lung diseases.
</td>
<td style="text-align:left;">
J Clin Lab Immunol
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Metastasis of cancer to cancer. A case of breast carcinoma metastasizing to a malignant mesothelioma.
</td>
<td style="text-align:left;">
Thorac Cardiovasc Surg
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Targeted delivery of let-7a microRNA encapsulated ephrin-A1 conjugated liposomal nanoparticles inhibit tumor growth in lung cancer.
</td>
<td style="text-align:left;">
Int J Nanomedicine
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Effects of cisplatin and panobinostat on human mesothelial (Met-5A) and malignant pleural mesothelioma (MSTO-211H) cells.
</td>
<td style="text-align:left;">
Genet. Mol. Res.
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Circulating tumor cells (CTCs) in malignant pleural mesothelioma (MPM).
</td>
<td style="text-align:left;">
Ann. Surg. Oncol.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Radiotherapy for the treatment of pain in malignant pleural mesothelioma: a systematic review.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Immunopathology of diffuse malignant mesothelioma].
</td>
<td style="text-align:left;">
Zentralbl Allg Pathol
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Extrapleural pneumonectomy for diffuse, malignant mesothelioma.
</td>
<td style="text-align:left;">
Ann. Thorac. Surg.
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Expression of Wilms’ tumor gene (WT1) is associated with survival in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Clin Transl Oncol
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Solitary fibrous tumors of the pleura: a case report and review of the literature.
</td>
<td style="text-align:left;">
Tumori
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
An RNAi-based screen reveals PLK1, CDK1 and NDC80 as potential therapeutic targets in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Br. J. Cancer
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Current readings: improvements in intensity-modulated radiation therapy for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Semin. Thorac. Cardiovasc. Surg.
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
The distinction of adenocarcinoma from malignant mesothelioma in cell blocks of effusions: the role of routine mucin histochemistry and immunohistochemical assessment of carcinoembryonic antigen, keratin proteins, epithelial membrane antigen, and milk fat globule-derived antigen.
</td>
<td style="text-align:left;">
Hum. Pathol.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Pharmacological targeting of p53 through RITA is an effective antitumoral strategy for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Cell Cycle
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Tissue polypeptide antigen (TPA) in pleural effusions.
</td>
<td style="text-align:left;">
Tumori
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Simultaneous immunoenzyme staining of vimentin and cytokeratins with monoclonal antibodies as an aid in the differential diagnosis of malignant mesothelioma from pulmonary adenocarcinoma.
</td>
<td style="text-align:left;">
Virchows Arch., B, Cell Pathol.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleural mesothelioma in a young male patient.
</td>
<td style="text-align:left;">
Monaldi Arch Chest Dis
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
A systematic review and meta-analysis of surgical treatments for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Proteome screening of pleural effusions identifies galectin 1 as a diagnostic biomarker and highlights several prognostic biomarkers for malignant mesothelioma.
</td>
<td style="text-align:left;">
Mol. Cell Proteomics
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.
</td>
<td style="text-align:left;">
Cancer Res.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Diagnostic histochemical and immunohistochemical studies in malignant mesothelioma.
</td>
<td style="text-align:left;">
J Surg Oncol
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Antitumor effect and antiangiogenic potential of the mTOR inhibitor temsirolimus against malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Oncol. Rep.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Diagnosis and treatment of malignant pleural effusion.
</td>
<td style="text-align:left;">
Cancer Metastasis Rev.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Antineoplastic activity of povidone-iodine on different mesothelioma cell lines: results of in vitro study.
</td>
<td style="text-align:left;">
Eur J Cardiothorac Surg
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma incidence and survival in the Republic of Ireland 1994-2009.
</td>
<td style="text-align:left;">
Cancer Epidemiol
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
The role of immunohistochemical evaluation in the diagnosis of malignant mesothelioma of the pleura.
</td>
<td style="text-align:left;">
Vojnosanit Pregl
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Is soluble mesothelin-related protein an upfront predictive marker of pleural mesothelioma? A prospective study on Italian workers exposed to asbestos.
</td>
<td style="text-align:left;">
Oncology
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Pemetrexed combined with platinum-based chemotherapy for advanced malignant peritoneal mesothelioma: retrospective analysis of six cases.
</td>
<td style="text-align:left;">
Anticancer Res.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Extrapleural pneumonectomy for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Multimed Man Cardiothorac Surg
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Distinction between cells in serous effusions using a panel of antibodies.
</td>
<td style="text-align:left;">
Virchows Arch A Pathol Anat Histopathol
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Comparative proteomic analysis of malignant pleural mesothelioma evidences an altered expression of nuclear lamin and filament-related proteins.
</td>
<td style="text-align:left;">
Proteomics Clin Appl
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Radiotherapy applications of patients with malignant mesothelioma: A single center experience.
</td>
<td style="text-align:left;">
Rep Pract Oncol Radiother
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
PI3K/mTOR signaling in mesothelioma patients treated with induction chemotherapy followed by extrapleural pneumonectomy.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Claudin-4 immunohistochemistry is highly effective in distinguishing adenocarcinoma from malignant mesothelioma in effusion cytology.
</td>
<td style="text-align:left;">
Cancer Cytopathol
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Immunohistochemistry in the diagnosis of malignant mesothelioma.
</td>
<td style="text-align:left;">
Virchows Arch A Pathol Anat Histopathol
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Circulating fibrinogen is a prognostic and predictive biomarker in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Br. J. Cancer
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
How useful is GLUT-1 in differentiating mesothelial hyperplasia and fibrosing pleuritis from epithelioid and sarcomatoid mesotheliomas? An international collaborative study.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Systemic treatment of malignant pleural mesothelioma: new agents in clinical trials raise hope of relevant improvements.
</td>
<td style="text-align:left;">
Curr Opin Oncol
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Molecular classification of malignant pleural mesothelioma: identification of a poor prognosis subgroup linked to the epithelial-to-mesenchymal transition.
</td>
<td style="text-align:left;">
Clin. Cancer Res.
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
A feasibility study evaluating Surgery for Mesothelioma After Radiation Therapy: the “SMART” approach for resectable malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
The diagnosis of thoracic malignant mesothelioma: practical considerations and recent developments.
</td>
<td style="text-align:left;">
Turk Patoloji Derg
</td>
<td style="text-align:left;">
diagnosis | epidemiology | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Immunotherapy for malignant pleural mesothelioma. Current status and future prospects.
</td>
<td style="text-align:left;">
Am. J. Respir. Cell Mol. Biol.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Clinical outcome of postoperative highly conformal versus 3D conformal radiotherapy in patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Radiat Oncol
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
ZIC1 is silenced and has tumor suppressor function in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Clinical significance of epithelial-mesenchymal transition-associated markers in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Oncology
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Prognostic factors in patients presenting with pleural effusion revealing malignancy.
</td>
<td style="text-align:left;">
Respiration
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
MSLN gene silencing has an anti-malignant effect on cell lines overexpressing mesothelin deriving from malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
PLoS ONE
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Expression of carbonic anhydrase IX (CAIX) in malignant mesothelioma. An immunohistochemical and immunocytochemical study.
</td>
<td style="text-align:left;">
Neoplasma
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
New applications of magnetic resonance imaging for thoracic oncology.
</td>
<td style="text-align:left;">
Semin Respir Crit Care Med
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Predictors of long-term survival following radical surgery for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Eur J Cardiothorac Surg
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Differences in lectin binding of malignant pleural mesothelioma and adenocarcinoma of the lung.
</td>
<td style="text-align:left;">
Am. J. Pathol.
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Phase I trial of cisplatin, pemetrexed, and imatinib mesylate in chemonaive patients with unresectable malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Clin Lung Cancer
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
An autopsy case of malignant pleural mesothelioma associated with nephrotic syndrome.
</td>
<td style="text-align:left;">
Intern. Med.
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
A microfluidic platform for chemoresistive testing of multicellular pleural cancer spheroids.
</td>
<td style="text-align:left;">
Lab Chip
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Diffuse malignant epithelioid mesothelioma in a background of benign multicystic peritoneal mesothelioma: a case report and review of the literature.
</td>
<td style="text-align:left;">
BMJ Case Rep
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Clinicopathological characteristics and prognosis of malignant pleural mesothelioma].
</td>
<td style="text-align:left;">
Zhonghua Jie He He Hu Xi Za Zhi
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Occupational and non-occupational attributable risk of asbestos exposure for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Thorax
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
The journey of mesothelioma: from postmortem to FNA.
</td>
<td style="text-align:left;">
BMJ Case Rep
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Does surgery improve survival of patients with malignant pleural mesothelioma?: a multicenter retrospective analysis of 1365 consecutive patients.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
A Case Report of IgG4-Related Disease Clinically Mimicking Pleural Mesothelioma.
</td>
<td style="text-align:left;">
Tuberc Respir Dis (Seoul)
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Multimodal management of malignant pleural mesothelioma: where are we today?
</td>
<td style="text-align:left;">
Eur. Respir. J.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
CEA, AFP, CA125, CA153 and CA199 in malignant pleural effusions predict the cause.
</td>
<td style="text-align:left;">
Asian Pac. J. Cancer Prev.
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Intrapleural natural beta interferon in the treatment of malignant pleural effusions.
</td>
<td style="text-align:left;">
Oncology
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleural resection and pleural infusion chemotherapy for therapy of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Genet. Mol. Res.
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma.
</td>
<td style="text-align:left;">
Pak J Med Sci
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Preclinical evaluation of microRNA-34b/c delivery for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Acta Med. Okayama
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Role of microRNAs in malignant mesothelioma.
</td>
<td style="text-align:left;">
Cell. Mol. Life Sci.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Diagnostic values of soluble mesothelin-related peptides for malignant pleural mesothelioma: updated meta-analysis.
</td>
<td style="text-align:left;">
BMJ Open
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Systemic but not topical TRAIL-expressing mesenchymal stem cells reduce tumour growth in malignant mesothelioma.
</td>
<td style="text-align:left;">
Thorax
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies.
</td>
<td style="text-align:left;">
Cancer Immunol Res
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Pathologic complete remission of malignant pleural mesothelioma after combined modality treatment: a case report.
</td>
<td style="text-align:left;">
Acta Clin Belg
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
“Dry” pleural mesothelioma successfully diagnosed on endobronchial ultrasound (EBUS)-guided transbronchial needle aspiration (TBNA).
</td>
<td style="text-align:left;">
Intern. Med.
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Pericardiectomy for treatment of neoplastic constrictive pericarditis.
</td>
<td style="text-align:left;">
Asian Cardiovasc Thorac Ann
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Lymphohistiocytoid mesothelioma: a rare lymphomatoid variant of predominantly sarcomatoid mesothelioma.
</td>
<td style="text-align:left;">
Ultrastruct Pathol
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Semirigid thoracoscopy: an effective method for diagnosing pleural malignancies.
</td>
<td style="text-align:left;">
Radiol Oncol
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant intraperitoneal mesothelioma-Başkent University experience.
</td>
<td style="text-align:left;">
J Turk Ger Gynecol Assoc
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
CD74: a new prognostic factor for patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Br. J. Cancer
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Cilengitide inhibits attachment and invasion of malignant pleural mesothelioma cells through antagonism of integrins αvβ3 and αvβ5.
</td>
<td style="text-align:left;">
PLoS ONE
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
CARP-1 functional mimetics are a novel class of small molecule inhibitors of malignant pleural mesothelioma cells.
</td>
<td style="text-align:left;">
PLoS ONE
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Surgery for malignant pleural mesothelioma: why, when and what?
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Radiological review of pleural tumors.
</td>
<td style="text-align:left;">
Indian J Radiol Imaging
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Diagnostic accuracy of osteopontin for malignant pleural mesothelioma: a systematic review and meta-analysis.
</td>
<td style="text-align:left;">
Clin. Chim. Acta
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[The role of systemic therapies of non-small cell lung cancer and malignant pleural mesothelioma: updated expert recommendations].
</td>
<td style="text-align:left;">
Pneumonol Alergol Pol
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Pleural effusion cytology of asbestos-associated malignant mesothelioma and lung carcinoma in the diagnosis of occupational diseases by the statutory accident insurance funds].
</td>
<td style="text-align:left;">
Pneumologie
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant pleural mesothelioma: new aspects of medical therapy].
</td>
<td style="text-align:left;">
Pneumologie
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Differentiation of malignant from normal and reactive mesothelial cells by the argyrophil technique for nucleolar organiser region associated proteins.
</td>
<td style="text-align:left;">
Thorax
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Well-differentiated papillary mesothelioma with invasive foci.
</td>
<td style="text-align:left;">
Am. J. Surg. Pathol.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Biomolecular and clinical practice in malignant pleural mesothelioma and lung cancer: what thoracic surgeons should know.
</td>
<td style="text-align:left;">
Eur J Cardiothorac Surg
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Surgical management of malignant pleural mesothelioma: impact of surgery on survival and quality of life-relation to chemotherapy, radiotherapy, and alternative therapies.
</td>
<td style="text-align:left;">
ISRN Surg
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Peritoneal malignant mesothelioma: review and recent data].
</td>
<td style="text-align:left;">
Ann Pathol
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Impact of a nursing education program about caring for patients in Japan with malignant pleural mesothelioma on nurses’ knowledge, difficulties and attitude: a randomized control trial.
</td>
<td style="text-align:left;">
Nurse Educ Today
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Small cell carcinoma presenting with massive pleural spread mimicking malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Intern. Med.
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Comparison of cisplatin plus pemetrexed and cisplatin plus gemcitabine for the treatment of malignant pleural mesothelioma in Japanese patients.
</td>
<td style="text-align:left;">
Respir Investig
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Extrapleural pneumonectomy or pleurectomy/decortication for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Gen Thorac Cardiovasc Surg
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
A retrospective review of the palliative surgical management of malignant pleural effusions.
</td>
<td style="text-align:left;">
BMJ Support Palliat Care
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Prognostic factors influencing survival in 35 patients with malignant peritoneal mesothelioma.
</td>
<td style="text-align:left;">
Neoplasma
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Methotrexate and gemcitabine combination chemotherapy for the treatment of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Mol Clin Oncol
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Clinical characteristics, treatment and survival outcomes in malignant pleural mesothelioma: an institutional experience in Turkey.
</td>
<td style="text-align:left;">
J BUON
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Expression profiling stratifies mesothelioma tumors and signifies deregulation of spindle checkpoint pathway and microtubule network with therapeutic implications.
</td>
<td style="text-align:left;">
Ann. Oncol.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Cells of squamous cell carcinoma in pleural, peritoneal and pericardial fluids. Origin and morphology.
</td>
<td style="text-align:left;">
Acta Cytol.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Prognostic factors affecting survival in malignant pleural mesothelioma: analysis of 125 subjects.
</td>
<td style="text-align:left;">
Tumori
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Catheter tract metastasis associated with indwelling pleural catheters.
</td>
<td style="text-align:left;">
Chest
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
A phase II trial of prolonged, continuous infusion of low-dose gemcitabine plus cisplatin in patients with advanced malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Cancer Chemother. Pharmacol.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Vinorelbine and gemcitabine as second- or third-line therapy for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Disulfiram suppresses growth of the malignant pleural mesothelioma cells in part by inducing apoptosis.
</td>
<td style="text-align:left;">
PLoS ONE
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Telomerase activity analyzed with TRAP in situ provides additional information in effusions remaining equivocal after immunocytochemistry and hyaluronan analysis.
</td>
<td style="text-align:left;">
Diagn. Cytopathol.
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Dipalmitoleoyl-phosphatidylethanolamine induces apoptosis of NCI-H28 malignant mesothelioma cells.
</td>
<td style="text-align:left;">
Anticancer Res.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Strengths, weaknesses, and opportunities of diagnostic breathomics in pleural mesothelioma-a hypothesis.
</td>
<td style="text-align:left;">
Cancer Epidemiol. Biomarkers Prev.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
A biphasic tumor of the mediastinum with features of synovial sarcoma. A report of four cases.
</td>
<td style="text-align:left;">
Am. J. Surg. Pathol.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Significance of osteopontin in the sensitivity of malignant pleural mesothelioma to pemetrexed.
</td>
<td style="text-align:left;">
Int. J. Oncol.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant peritoneal mesothelioma: clinicopathological characteristics of two cases.
</td>
<td style="text-align:left;">
Case Rep Surg
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Relationship between prognosis and neutrophil: lymphocyte and platelet:lymphocyte ratios in patients with malignant pleural mesotheliomas.
</td>
<td style="text-align:left;">
Asian Pac. J. Cancer Prev.
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Autocrine CSF-1R signaling drives mesothelioma chemoresistance via AKT activation.
</td>
<td style="text-align:left;">
Cell Death Dis
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Extrapleural pneumonectomy for malignant mesothelioma: an Italian multicenter retrospective study.
</td>
<td style="text-align:left;">
Ann. Thorac. Surg.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma and the Society of Thoracic Surgeons Database: an analysis of surgical morbidity and mortality.
</td>
<td style="text-align:left;">
J. Thorac. Cardiovasc. Surg.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Clinical utility of 18F-FDG positron emission tomography in malignant peritoneal mesothelioma.
</td>
<td style="text-align:left;">
Q J Nucl Med Mol Imaging
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Synchronous occurrence of pulmonary adenocarcinoma and pleural diffuse malignant mesothelioma.
</td>
<td style="text-align:left;">
Pathologica
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Distribution of silver-stained interphase nucleolar organizer regions as a parameter to distinguish neoplastic from nonneoplastic reactive cells in human effusions.
</td>
<td style="text-align:left;">
Acta Cytol.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Pseudomesotheliomatous carcinoma due to pleural metastasis from renal pelvic cancer.
</td>
<td style="text-align:left;">
Intern. Med.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Regulation of somatostatin receptor 4-mediated cytostatic effects by CD26 in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Br. J. Cancer
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Elevated PDGFRB gene copy number gain is prognostic for improved survival outcomes in resected malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Ann Diagn Pathol
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
CD26-mediated regulation of periostin expression contributes to migration and invasion of malignant pleural mesothelioma cells.
</td>
<td style="text-align:left;">
Biochem. Biophys. Res. Commun.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Newly synthesized anticancer drug HUHS1015 is effective on malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Cancer Sci.
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Wide complex ventricular tachycardia presenting sign of metastatic pleural mesothelioma.
</td>
<td style="text-align:left;">
BMJ Case Rep
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma metastatic to the submandibular salivary gland, simulating glandular hypertrophy, diagnosed by fine-needle aspiration biopsy: a case report and literature review.
</td>
<td style="text-align:left;">
World J Surg Oncol
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Detection and cultivation of circulating tumor cells in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Anticancer Res.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Significance of serum mesothelin in an asbestos-exposed population in the Czech Republic.
</td>
<td style="text-align:left;">
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Biological responses according to the shape and size of carbon nanotubes in BEAS-2B and MESO-1 cells.
</td>
<td style="text-align:left;">
Int J Nanomedicine
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Immunohistochemical differentiation of sarcomatoid mesotheliomas from other spindle cell neoplasms.
</td>
<td style="text-align:left;">
Am. J. Clin. Pathol.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
A review and critique of U.S. EPA’s risk assessments for asbestos.
</td>
<td style="text-align:left;">
Crit. Rev. Toxicol.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Supplementary prognostic variables for pleural mesothelioma: a report from the IASLC staging committee.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Inhibitory effects of 3-bromopyruvate on human gastric cancer implant tumors in nude mice.
</td>
<td style="text-align:left;">
Asian Pac. J. Cancer Prev.
</td>
<td style="text-align:left;">
transmission
</td>
</tr>
<tr>
<td style="text-align:left;">
Diagnostic utility of immunohistochemistry in distinguishing between epithelioid pleural mesotheliomas and breast carcinomas: a comparative study.
</td>
<td style="text-align:left;">
Hum. Pathol.
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Desmoplastic small round cell tumor with sphere-like clusters mimicking adenocarcinoma.
</td>
<td style="text-align:left;">
Diagn. Cytopathol.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Expression of keratin 5 as a distinctive feature of epithelial and biphasic mesotheliomas. An immunohistochemical study using monoclonal antibody AE14.
</td>
<td style="text-align:left;">
Virchows Arch., B, Cell Pathol.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Analysis of asbestos concentration in 20 cases of pseudomesotheliomatous lung cancer.
</td>
<td style="text-align:left;">
Ultrastruct Pathol
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Physician-based ultrasound-guided biopsy for diagnosing pleural disease.
</td>
<td style="text-align:left;">
Chest
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Immune therapies for malignant mesothelioma.
</td>
<td style="text-align:left;">
Expert Rev Anticancer Ther
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Tumor/stromal caveolin-1 expression patterns in pleural mesothelioma define a subgroup of the epithelial histotype with poorer prognosis.
</td>
<td style="text-align:left;">
Am. J. Clin. Pathol.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Signal transducer and activator of transcription 1 (STAT1) acts like an oncogene in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Virchows Arch.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma: a single-center experience in Turkey.
</td>
<td style="text-align:left;">
Med. Sci. Monit.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Mesothelioma risk after 40 years since first exposure to asbestos: a pooled analysis.
</td>
<td style="text-align:left;">
Thorax
</td>
<td style="text-align:left;">
epidemiology | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Merlin deficiency predicts FAK inhibitor sensitivity: a synthetic lethal relationship.
</td>
<td style="text-align:left;">
Sci Transl Med
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Autofluorescence thoracoscopy in pleural disease: does it have clinical relevance?
</td>
<td style="text-align:left;">
Expert Rev Respir Med
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
EUS-guided fine needle tissue acquisition for the diagnosis of pleural metastases from endometrial cancer.
</td>
<td style="text-align:left;">
Eur Rev Med Pharmacol Sci
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Assessing the function of homologous recombination DNA repair in malignant pleural effusion (MPE) samples.
</td>
<td style="text-align:left;">
Br. J. Cancer
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleural mesothelioma: an institutional experience of 66 cases.
</td>
<td style="text-align:left;">
Korean J Pathol
</td>
<td style="text-align:left;">
diagnosis | epidemiology | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Management of malignant pleural mesothelioma-The European experience.
</td>
<td style="text-align:left;">
J Thorac Dis
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Recurring loss involving chromosomes 1, 3, and 22 in malignant mesothelioma: possible sites of tumor suppressor genes.
</td>
<td style="text-align:left;">
Genes Chromosomes Cancer
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Assessment of cisplatin concentration and depth of penetration in human lung tissue after hyperthermic exposure.
</td>
<td style="text-align:left;">
Eur J Cardiothorac Surg
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleural mesothelioma in a couple of brothers.
</td>
<td style="text-align:left;">
Indian J Occup Environ Med
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Efficacy of phase 1 trials in malignant pleural mesothelioma: description of a series of patients at a single institution.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Cisplatin-resistant cells in malignant pleural mesothelioma cell lines show ALDH(high)CD44(+) phenotype and sphere-forming capacity.
</td>
<td style="text-align:left;">
BMC Cancer
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
GAS5 long non-coding RNA in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Mol. Cancer
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Flex-rigid pleuroscopy under local anesthesia in patients with dry pleural dissemination on radiography.
</td>
<td style="text-align:left;">
Jpn. J. Clin. Oncol.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Diagnostic potential of miR-126, miR-143, miR-145, and miR-652 in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J Mol Diagn
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
[Intrathoracic schwannoma].
</td>
<td style="text-align:left;">
Medicina (B Aires)
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Prognostic factors in elderly patients with malignant pleural mesothelioma: results of a multicenter survey.
</td>
<td style="text-align:left;">
Br. J. Cancer
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Synergistic antitumor activity of recombinant human Apo2L/tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in combination with carboplatin and pemetrexed in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Carbonic anhydrase IX (CAIX) does not differentiate between benign and malignant mesothelium.
</td>
<td style="text-align:left;">
Am. J. Clin. Pathol.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Frequent coamplification and cooperation between C-MYC and PVT1 oncogenes promote malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
B7-H1 expression in malignant pleural mesothelioma is associated with sarcomatoid histology and poor prognosis.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Women with malignant pleural mesothelioma have a threefold better survival rate than men.
</td>
<td style="text-align:left;">
Ann. Thorac. Surg.
</td>
<td style="text-align:left;">
diagnosis | treatment | epidemiology
</td>
</tr>
<tr>
<td style="text-align:left;">
Third-space fluid distribution of pemetrexed in non-small cell lung cancer patients.
</td>
<td style="text-align:left;">
Cancer Chemother. Pharmacol.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
ERCC1 as a biological marker guiding management in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Asian Pac. J. Cancer Prev.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Mdm2 protein expression is strongly associated with survival in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Future Oncol
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Efficacy and cost of video-assisted thoracoscopic partial pleurectomy versus talc pleurodesis in patients with malignant pleural mesothelioma (MesoVATS): an open-label, randomised, controlled trial.
</td>
<td style="text-align:left;">
Lancet
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Interventional therapies for malignant pleural effusions: the present and the future.
</td>
<td style="text-align:left;">
Respirology
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Second-line gemcitabine-based chemotherapy regimens improve overall 3-year survival rate in patients with malignant pleural mesothelioma: a multicenter retrospective study.
</td>
<td style="text-align:left;">
Med. Oncol.
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Cerebral metastasis from malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J Surg Case Rep
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Nonamplified FGFR1 is a growth driver in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Mol. Cancer Res.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Synchronous pleural and peritoneal malignant mesothelioma: a case report and review of literature.
</td>
<td style="text-align:left;">
Int J Clin Exp Pathol
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Epithelioid malignant mesothelioma presenting with features of gastric tumor in a child.
</td>
<td style="text-align:left;">
Int J Clin Exp Pathol
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Incidence of pleural mesothelioma in a community exposed to fibres with fluoro-edenitic composition in Biancavilla (Sicily, Italy).
</td>
<td style="text-align:left;">
Ann. Ist. Super. Sanita
</td>
<td style="text-align:left;">
epidemiology
</td>
</tr>
<tr>
<td style="text-align:left;">
Health impact of the exposure to fibres with fluoro-edenitic composition on the residents in Biancavilla (Sicily, Italy): mortality and hospitalization from current data.
</td>
<td style="text-align:left;">
Ann. Ist. Super. Sanita
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
New histone deacetylase inhibitors improve cisplatin antitumor properties against thoracic cancer cells.
</td>
<td style="text-align:left;">
Oncotarget
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[SENTIERI Project: discussion and conclusions].
</td>
<td style="text-align:left;">
Epidemiol Prev
</td>
<td style="text-align:left;">
epidemiology | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Metastatic mesothelioma to the thyroid.
</td>
<td style="text-align:left;">
Cytojournal
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Phase 1 study of the antimesothelin immunotoxin SS1P in combination with pemetrexed and cisplatin for front-line therapy of pleural mesothelioma and correlation of tumor response with serum mesothelin, megakaryocyte potentiating factor, and cancer antigen 125.
</td>
<td style="text-align:left;">
Cancer
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Polymorphisms in folate pathway and pemetrexed treatment outcome in patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Radiol Oncol
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Usp9x- and Noxa-mediated Mcl-1 downregulation contributes to pemetrexed-induced apoptosis in human non-small-cell lung cancer cells.
</td>
<td style="text-align:left;">
Cell Death Dis
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Imaging findings from a case of pleural low-grade fibromyxoid sarcoma similar to mesothelioma with pleural effusion.
</td>
<td style="text-align:left;">
Clin Respir J
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Performance of osteopontin in the diagnosis of malignant pleural mesothelioma: a meta-analysis.
</td>
<td style="text-align:left;">
Int J Clin Exp Med
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Prognostic coronary surgery in a case of malignant mesothelioma previously managed with trimodality treatment.
</td>
<td style="text-align:left;">
Heart Lung Circ
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Local recurrence of lung adenocarcinoma 10 years after left upper lobectomy resembling pseudomesotheliomatous adenocarcinoma: a case report.
</td>
<td style="text-align:left;">
J Nippon Med Sch
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
The homeobox gene EMX2 is a prognostic and predictive marker in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
p53 Expression in a Malignant Mesothelioma Patient during Seven-Year Follow-up.
</td>
<td style="text-align:left;">
Tuberc Respir Dis (Seoul)
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
CD157 enhances malignant pleural mesothelioma aggressiveness and predicts poor clinical outcome.
</td>
<td style="text-align:left;">
Oncotarget
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
EF24 and RAD001 potentiates the anticancer effect of platinum-based agents in human malignant pleural mesothelioma (MSTO-211H) cells and protects nonmalignant mesothelial (MET-5A) cells.
</td>
<td style="text-align:left;">
Hum Exp Toxicol
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Comparison of fibulin-3 and mesothelin as markers in malignant mesothelioma.
</td>
<td style="text-align:left;">
Thorax
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Wilms tumor 1/cytokeratin dual-color immunostaining reveals distinctive staining patterns in metastatic melanoma, metastatic carcinoma, and mesothelial cells in pleural fluids: an effective first-line test for the workup of malignant effusions.
</td>
<td style="text-align:left;">
Cancer Cytopathol
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Newly established ELISA for N-ERC/mesothelin improves diagnostic accuracy in patients with suspected pleural mesothelioma.
</td>
<td style="text-align:left;">
Cancer Med
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Functional properties of CD8(+) lymphocytes in patients with pleural plaque and malignant mesothelioma.
</td>
<td style="text-align:left;">
J Immunol Res
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Randomized phase II trial of pemetrexed/cisplatin with or without CBP501 in patients with advanced malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Photodynamic therapy enhanced by hyperbaric oxygenation in palliation of malignant pleural mesothelioma: clinical experience.
</td>
<td style="text-align:left;">
Photodiagnosis Photodyn Ther
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
The role of microRNAs in the diagnosis and treatment of malignant pleural mesothelioma–a short review.
</td>
<td style="text-align:left;">
Microrna
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Photodynamic therapy in the management of malignant pleural mesothelioma: A review.
</td>
<td style="text-align:left;">
Photodiagnosis Photodyn Ther
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Serum albumin as a significant prognostic factor in patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Tumour Biol.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Activation of Nrf2 pathways correlates with resistance of NSCLC cell lines to CBP501 in vitro.
</td>
<td style="text-align:left;">
Mol. Cancer Ther.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Sarcomatoid malignant mesothelioma presenting with intramedullary spinal cord metastasis: a case report and literature review.
</td>
<td style="text-align:left;">
Global Spine J
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Predictive value of systemic and local inflammation parameters in talc pleurodesis assessment.
</td>
<td style="text-align:left;">
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Diagnosis and treatment of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Arch. Bronconeumol.
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Current issues in malignant pleural mesothelioma evaluation and management.
</td>
<td style="text-align:left;">
Oncologist
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant mesothelioma risk factors: experience in the General Hospital of Mexico].
</td>
<td style="text-align:left;">
Cir Cir
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
[Epidemiologic situation in Ukraine, concerning malignant mesothelioma prevalence].
</td>
<td style="text-align:left;">
Med Tr Prom Ekol
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
[Pleural mesothelioma. Cytology and molecular diagnostics].
</td>
<td style="text-align:left;">
Pathologe
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Microcystic variant malignant mesothelioma presenting as a localized paraspinal mass.
</td>
<td style="text-align:left;">
Cytojournal
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Failure patterns after hemithoracic pleural intensity modulated radiation therapy for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Int. J. Radiat. Oncol. Biol. Phys.
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Phrenic nerve paralysis as the initial presentation in pleural sarcomatoid mesothelioma.
</td>
<td style="text-align:left;">
Case Rep Oncol
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Role of CT in assessing pleural malignancy prior to thoracoscopy.
</td>
<td style="text-align:left;">
Thorax
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma and central nervous system metastases. Report of two cases, pooled analysis, and systematic review.
</td>
<td style="text-align:left;">
Ann Am Thorac Soc
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Spinal cord ischemia resulting in paraplegia following extrapleural pneumonectomy.
</td>
<td style="text-align:left;">
Chest
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Predicting survival in malignant pleural effusion: development and validation of the LENT prognostic score.
</td>
<td style="text-align:left;">
Thorax
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Extrapleural pneumonectomy after induction chemotherapy: perioperative outcome in 251 mesothelioma patients from three high-volume institutions.
</td>
<td style="text-align:left;">
Ann. Thorac. Surg.
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Metastasis of mesothelioma to the maxillary gingiva.
</td>
<td style="text-align:left;">
Oncol Lett
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
A commercially available preparation of Staphylococcus aureus bio-products potently inhibits tumour growth in a murine model of mesothelioma.
</td>
<td style="text-align:left;">
Respirology
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Gamma knife radiosurgery of brain metastasis from malignant pleural mesothelioma–report of three cases with autopsy study in a case.
</td>
<td style="text-align:left;">
Nagoya J Med Sci
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Silica exposure and altered regulation of autoimmunity.
</td>
<td style="text-align:left;">
Environ Health Prev Med
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Absence of amplification of the FGFR1-gene in human malignant mesothelioma of the pleura: a pilot study.
</td>
<td style="text-align:left;">
BMC Res Notes
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Hyponatraemia is a predictor of clinical outcome for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Support Care Cancer
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Photodynamic diagnoses of malignant pleural diseases using the autofluorescence imaging system.
</td>
<td style="text-align:left;">
Ann Thorac Cardiovasc Surg
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Diagnostic and prognostic value of soluble syndecan-1 in pleural malignancies.
</td>
<td style="text-align:left;">
Biomed Res Int
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Progression free survival rate at 9 and 18 weeks predict overall survival in patients with malignant pleural mesothelioma: an individual patient pooled analysis of 10 European Organisation for Research and Treatment of Cancer Lung Cancer Group studies and an independent study validation.
</td>
<td style="text-align:left;">
Eur. J. Cancer
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Gingival metastasis as first sign of multiorgan dissemination of epithelioid malignant mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural and peritoneal mesothelioma consequential to brief indirect asbestos exposure.
</td>
<td style="text-align:left;">
J Clin Imaging Sci
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Identification of actionable mutations in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Non-asbestos-related malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Intern. Med.
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Effect of NSAIDS and COX-2 inhibitors on the incidence and severity of asbestos-induced malignant mesothelioma: evidence from an animal model and a human cohort.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Almost half of women with malignant mesothelioma were exposed to asbestos at home through their husbands or sons.
</td>
<td style="text-align:left;">
Dan Med J
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Should we continue to offer extrapleural pneumonectomy to selected mesothelioma patients? A single center experience comparing surgical and non-surgical management.
</td>
<td style="text-align:left;">
Jpn. J. Clin. Oncol.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Factors associated with survival in a large series of patients with malignant pleural mesothelioma in New South Wales.
</td>
<td style="text-align:left;">
Br. J. Cancer
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Accuracy of fluorodeoxyglucose-PET imaging for differentiating benign from malignant pleural effusions: a meta-analysis.
</td>
<td style="text-align:left;">
Chest
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Ultrasound-guided medical thoracoscopy in the absence of pleural effusion.
</td>
<td style="text-align:left;">
Chest
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Fibroblast growth factor receptor inhibition is active against mesothelioma and synergizes with radio- and chemotherapy.
</td>
<td style="text-align:left;">
Am. J. Respir. Crit. Care Med.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Ratio of intratumoral macrophage phenotypes is a prognostic factor in epithelioid malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
PLoS ONE
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Past trends and future prediction of mesothelioma incidence in an industrialized area of Italy, the Veneto Region.
</td>
<td style="text-align:left;">
Cancer Epidemiol
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Extrapleural pneumonectomy in the treatment of epithelioid malignant pleural mesothelioma: novel prognostic implications of combined N1 and N2 nodal involvement based on experience in 529 patients.
</td>
<td style="text-align:left;">
Ann. Surg.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
The clinicopathological characteristics with long-term outcomes in malignant mesothelioma.
</td>
<td style="text-align:left;">
Med. Oncol.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Sarcomatoid malignant mesothelioma: a clinicopathologic and immunohistochemical analysis of 22 cases].
</td>
<td style="text-align:left;">
Zhonghua Bing Li Xue Za Zhi
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Tuberculosis and risk of cancer: a Danish nationwide cohort study.
</td>
<td style="text-align:left;">
Int. J. Tuberc. Lung Dis.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Systematic review of response rates of sarcomatoid malignant pleural mesotheliomas in clinical trials.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Comparison of genomic abnormality in malignant mesothelioma by the site of origin.
</td>
<td style="text-align:left;">
J. Clin. Pathol.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
MET and PI3K/mTOR as a potential combinatorial therapeutic target in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
PLoS ONE
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma.
</td>
<td style="text-align:left;">
Clin. Cancer Res.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
MiR-379/411 cluster regulates IL-18 and contributes to drug resistance in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Oncol. Rep.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
High incidence of lung cancer and malignant mesothelioma linked to erionite fibre exposure in a rural community in Central Mexico.
</td>
<td style="text-align:left;">
Occup Environ Med
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Analysis of microRNA expression signatures in malignant pleural mesothelioma, pleural inflammation, and atypical mesothelial hyperplasia reveals common predictive tumorigenesis-related targets.
</td>
<td style="text-align:left;">
Exp. Mol. Pathol.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
A multicentre non-blinded randomised controlled trial to assess the impact of regular early specialist symptom control treatment on quality of life in malignant mesothelioma (RESPECT-MESO): study protocol for a randomised controlled trial.
</td>
<td style="text-align:left;">
Trials
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma: visual assessment by using pleural pointillism at diffusion-weighted MR imaging.
</td>
<td style="text-align:left;">
Radiology
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Correlation between TS, MTHFR, and ERCC1 gene polymorphisms and the efficacy of platinum in combination with pemetrexed first-line chemotherapy in mesothelioma patients.
</td>
<td style="text-align:left;">
Clin Lung Cancer
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
A rare case of primary malignant pericardial mesothelioma.
</td>
<td style="text-align:left;">
J Clin Imaging Sci
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
[Correlation of computed tomography imaging and clinical prognosis of pleural mesothelioma].
</td>
<td style="text-align:left;">
Zhonghua Yi Xue Za Zhi
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Characterization and drug sensitivity profiling of primary malignant mesothelioma cells from pleural effusions.
</td>
<td style="text-align:left;">
BMC Cancer
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Airways microbiota: Hidden Trojan horses in asbestos exposed individuals?
</td>
<td style="text-align:left;">
Med. Hypotheses
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Local and systemic therapies for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Curr Treat Options Oncol
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Electron microscopy remains the gold standard for the diagnosis of epithelial malignant mesothelioma: a case study.
</td>
<td style="text-align:left;">
Ultrastruct Pathol
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Agonist activation of estrogen receptor beta (ERβ) sensitizes malignant pleural mesothelioma cells to cisplatin cytotoxicity.
</td>
<td style="text-align:left;">
Mol. Cancer
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Rechallenge with pemetrexed-based chemotherapy improves the survival of patients with advanced non-squamous non-small-cell lung cancer.
</td>
<td style="text-align:left;">
Mol Clin Oncol
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Reproducibility of histological subtyping of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Virchows Arch.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Naftopidil is useful for the treatment of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Pharmacology
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
[Morphological diagnostics of malignant pleural mesothelioma].
</td>
<td style="text-align:left;">
Pathologe
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Multimodality imaging for characterization, classification, and staging of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Radiographics
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
[The carcinogenic effect of asbestos].
</td>
<td style="text-align:left;">
Offentl Gesundheitswes
</td>
<td style="text-align:left;">
epidemiology
</td>
</tr>
<tr>
<td style="text-align:left;">
Analysis of mortality patterns and workers’ compensation awards among asbestos insulation workers in Ontario.
</td>
<td style="text-align:left;">
Am. J. Ind. Med.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Impact of New Chemotherapeutic agents on the outcome of Egyptian patients with Advanced Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
Gulf J Oncolog
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Long progression-free survival by pemetrexed continuation maintenance therapy following cisplatin-based chemotherapy in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Intern. Med.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Pseudo-tumor mimicking indwelling pleural catheter tract metastasis in mesothelioma.
</td>
<td style="text-align:left;">
J Bronchology Interv Pulmonol
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Advances in malignant peritoneal mesothelioma.
</td>
<td style="text-align:left;">
Int J Colorectal Dis
</td>
<td style="text-align:left;">
diagnosis | treatment | epidemiology | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Downregulation of thymidylate synthase and E2F1 by arsenic trioxide in mesothelioma.
</td>
<td style="text-align:left;">
Int. J. Oncol.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Evaluation of imaging techniques for the assessment of tumour progression in an orthotopic rat model of malignant pleural mesothelioma†.
</td>
<td style="text-align:left;">
Eur J Cardiothorac Surg
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Use of computed tomography and positron emission tomography/computed tomography for staging of local extent in patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J Comput Assist Tomogr
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Upregulation of microRNA-31 associates with a poor prognosis of malignant pleural mesothelioma with sarcomatoid component.
</td>
<td style="text-align:left;">
Med. Oncol.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Cisplatin in combination with Phenethyl Isothiocyanate (PEITC), a potential new therapeutic strategy for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Oncotarget
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Clinicopathological characteristics of pulmonary epithelioid hemangioendothelioma: A report of four cases and review of the literature.
</td>
<td style="text-align:left;">
Oncol Lett
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Altered protease-activated receptor-1 expression and signaling in a malignant pleural mesothelioma cell line, NCI-H28, with homozygous deletion of the β-catenin gene.
</td>
<td style="text-align:left;">
PLoS ONE
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Hyaluronic Acid concentration in pleural fluid: diagnostic aid for tuberculous pleurisy.
</td>
<td style="text-align:left;">
J Clin Med Res
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Oral cyclophosphamide and etoposide in treatment of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Asian Pac. J. Cancer Prev.
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity.
</td>
<td style="text-align:left;">
Sci Transl Med
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Mesothelioma patients with germline BAP1 mutations have 7-fold improved long-term survival.
</td>
<td style="text-align:left;">
Carcinogenesis
</td>
<td style="text-align:left;">
epidemiology | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Estimation of an optimal chemotherapy utilization rate for malignant pleural mesothelioma: an evidence-based benchmark for cancer care.
</td>
<td style="text-align:left;">
Asia Pac J Clin Oncol
</td>
<td style="text-align:left;">
treatment | epidemiology | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Combination effect of photodynamic therapy using NPe6 with pemetrexed for human malignant pleural mesothelioma cells.
</td>
<td style="text-align:left;">
Int. J. Oncol.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Intercellular communication in malignant pleural mesothelioma: properties of tunneling nanotubes.
</td>
<td style="text-align:left;">
Front Physiol
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Quantitative analyses at baseline and interim PET evaluation for response assessment and outcome definition in patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Eur. J. Nucl. Med. Mol. Imaging
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Extrapleural pneumonectomy plus rib resection for malignant pleural mesothelioma: a case report.
</td>
<td style="text-align:left;">
J Cardiothorac Surg
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
An exception that proves the rule: recurrence free survival five years after extrapleural pneumonectomy for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J Cardiothorac Surg
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Therapeutic activity of glycoengineered anti-GM2 antibodies against malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Cancer Sci.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Methylation profile landscape in mesothelioma: possible implications in early detection, disease progression, and therapeutic options.
</td>
<td style="text-align:left;">
Methods Mol. Biol.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
CK2α, over-expressed in human malignant pleural mesothelioma, regulates the Hedgehog signaling pathway in mesothelioma cells.
</td>
<td style="text-align:left;">
J. Exp. Clin. Cancer Res.
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Caring for patients with malignant pleural mesothelioma in Japan: evaluation of a Palliative Care Educational Program.
</td>
<td style="text-align:left;">
Asian Pac. J. Cancer Prev.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
FISH analysis of intrapulmonary malignant mesothelioma without a clinically detectable primary pleural lesion: an autopsy case.
</td>
<td style="text-align:left;">
Jpn. J. Clin. Oncol.
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Survival in Patients With Malignant Pleural Effusions Who Developed Pleural Infection: A Retrospective Case Review From Six UK Centers.
</td>
<td style="text-align:left;">
Chest
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Contribution of pleural fluid analysis to the diagnosis of pleural effusion].
</td>
<td style="text-align:left;">
Med Clin (Barc)
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
A common polymorphism within MSLN affects miR-611 binding site and soluble mesothelin levels in healthy people.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Extrapleural pneumonectomy for pleural malignancies.
</td>
<td style="text-align:left;">
Thorac Surg Clin
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Hemithoracic intensity modulated radiation therapy after pleurectomy/decortication for malignant pleural mesothelioma: toxicity, patterns of failure, and a matched survival analysis.
</td>
<td style="text-align:left;">
Int. J. Radiat. Oncol. Biol. Phys.
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Computed tomography-guided cutting needle pleural biopsy: Accuracy and complications.
</td>
<td style="text-align:left;">
Exp Ther Med
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Cytokeratin 19 expression in primary thoracic tumors and lymph node metastases.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Impact of an asbestos cement factory on mesothelioma incidence: global assessment of effects of occupational, familial, and environmental exposure.
</td>
<td style="text-align:left;">
Environ Int
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Non-occupational malignant mesotheliomas.
</td>
<td style="text-align:left;">
IARC Sci. Publ.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Current controversies in the management of malignant pleural effusions.
</td>
<td style="text-align:left;">
Semin Respir Crit Care Med
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma: new hope in the horizon with novel therapeutic strategies.
</td>
<td style="text-align:left;">
Cancer Treat. Rev.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Prevalence of BRCA-1 associated protein 1 germline mutation in sporadic malignant pleural mesothelioma cases.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Predictors of clinical use of pleurodesis and/or indwelling pleural catheter therapy for malignant pleural effusion.
</td>
<td style="text-align:left;">
Chest
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
The risk of lung cancer after cessation of asbestos exposure in construction workers using pleural malignant mesothelioma as a marker of exposure.
</td>
<td style="text-align:left;">
J. Occup. Environ. Med.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Synergistic activity of the c-Met and tubulin inhibitor tivantinib (ARQ197) with pemetrexed in mesothelioma cells.
</td>
<td style="text-align:left;">
Curr Drug Targets
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Whole-exome sequencing reveals frequent genetic alterations in BAP1, NF2, CDKN2A, and CUL1 in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Cancer Res.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
[A clinical study of six surgically treated patients with malignant tumors arising from chronic pleuritis and pyothorax].
</td>
<td style="text-align:left;">
Nihon Kyobu Geka Gakkai Zasshi
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Amosite mesothelioma in a cohort of asbestos workers.
</td>
<td style="text-align:left;">
Scand J Work Environ Health
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
MiR-score: a novel 6-microRNA signature that predicts survival outcomes in patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Mol Oncol
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Photodynamic therapy for lung cancer and malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Semin. Oncol.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Cancer mortality in relation to measures of occupational exposure to crocidolite at Wittenoom Gorge in Western Australia.
</td>
<td style="text-align:left;">
Br J Ind Med
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Combination of arginine deprivation with TRAIL treatment as a targeted-therapy for mesothelioma.
</td>
<td style="text-align:left;">
Anticancer Res.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Mesothelin in serum and pleural effusion in the diagnosis of malignant pleural mesothelioma with non-positive cytology.
</td>
<td style="text-align:left;">
Anticancer Res.
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleural fluid mesothelin as an adjunct to the diagnosis of pleural malignant mesothelioma.
</td>
<td style="text-align:left;">
Dis. Markers
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Clinicopathologic and survival characteristics of malignant pleural mesothelioma registered in hospital cancer registry.
</td>
<td style="text-align:left;">
Tanaffos
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Targeted next-generation sequencing of cancer genes in advanced stage malignant pleural mesothelioma: a retrospective study.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Detection of circulating tumour cells in peripheral blood of patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Cancer Biomark
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Thromboembolic Events in Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
Clin. Appl. Thromb. Hemost.
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Clinical significance of soluble CD26 in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
PLoS ONE
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Novel induction therapies for pleural mesothelioma.
</td>
<td style="text-align:left;">
Semin. Thorac. Cardiovasc. Surg.
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Henoch-Schonlein purpura in mesothelioma.
</td>
<td style="text-align:left;">
Respirol Case Rep
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
1-[2-(2-Methoxyphenylamino)ethylamino]-3-(naphthalene-1- yloxy)propan-2-ol may be a promising anticancer drug.
</td>
<td style="text-align:left;">
Molecules
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
The distribution of amosite asbestos fibers in the lungs of workers with mesothelioma or carcinoma.
</td>
<td style="text-align:left;">
Exp. Lung Res.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Meta-analysis of survival after pleurectomy decortication versus extrapleural pneumonectomy in mesothelioma.
</td>
<td style="text-align:left;">
Ann. Thorac. Surg.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Adenosine deaminase inhibitor EHNA exhibits a potent anticancer effect against malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Cell. Physiol. Biochem.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Hyperthermic chemoperfusion of the pleural cavity in the combined treatment for malignant pleural mesothelioma].
</td>
<td style="text-align:left;">
Vopr Onkol
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
[Pemetrexed-induced scleroderma-like changes in the lower legs].
</td>
<td style="text-align:left;">
Ann Dermatol Venereol
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Overexpression of activin-A and -B in malignant mesothelioma - attenuated Smad3 signaling responses and ERK activation promote cell migration and invasive growth.
</td>
<td style="text-align:left;">
Exp. Cell Res.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Early experience with intensity modulated proton therapy for lung-intact mesothelioma: A case series.
</td>
<td style="text-align:left;">
Pract Radiat Oncol
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Third-line chemotherapy with carboplatin, gemcitabine and liposomised doxorubicin for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Med. Oncol.
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Protocol for the surgical and large bore procedures in malignant pleural mesothelioma and radiotherapy trial (SMART Trial): an RCT evaluating whether prophylactic radiotherapy reduces the incidence of procedure tract metastases.
</td>
<td style="text-align:left;">
BMJ Open
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Mesothelioma in Mongolia: case report.
</td>
<td style="text-align:left;">
Int J Occup Environ Health
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Licochalcone A induces apoptosis in malignant pleural mesothelioma through downregulation of Sp1 and subsequent activation of mitochondria-related apoptotic pathway.
</td>
<td style="text-align:left;">
Int. J. Oncol.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Acute lower limb ischemia complicating pemetrexed and carboplatin combination chemotherapy for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Ann Ital Chir
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Fluoro deoxyglucose positron emission tomography-computerized tomography in primary staging and response assessment of a rare case of primary pleural synovial sarcoma.
</td>
<td style="text-align:left;">
Indian J Nucl Med
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
[Current surgical therapy for malignant pleural mesothelioma].
</td>
<td style="text-align:left;">
Kyobu Geka
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Detection of malignant mesothelioma using nuclear structure of mesothelial cells in effusion cytology specimens.
</td>
<td style="text-align:left;">
Cytometry A
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Cancer incidence, trends, and survival among immigrants to Sweden: a population-based study.
</td>
<td style="text-align:left;">
Eur. J. Cancer Prev.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Clinical experience of volumetric modulated arc therapy for malignant pleural mesothelioma after extrapleural pneumonectomy.
</td>
<td style="text-align:left;">
J. Radiat. Res.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Tumoral CD10 expression correlates with aggressive histology and prognosis in patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Ann. Surg. Oncol.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
SWOG S0722: phase II study of mTOR inhibitor everolimus (RAD001) in advanced malignant pleural mesothelioma (MPM).
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Non-occupational pleural mesothelioma].
</td>
<td style="text-align:left;">
Ugeskr. Laeg.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Testing mapping algorithms of the cancer-specific EORTC QLQ-C30 onto EQ-5D in malignant mesothelioma.
</td>
<td style="text-align:left;">
Health Qual Life Outcomes
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Fast neutron radiotherapy in the treatment of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Am. J. Clin. Oncol.
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Wnt7A is a putative prognostic and chemosensitivity marker in human malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Oncol. Rep.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Ki67 index is an independent prognostic factor in epithelioid but not in non-epithelioid malignant pleural mesothelioma: a multicenter study.
</td>
<td style="text-align:left;">
Br. J. Cancer
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Oncogenic mutation profiling in new lung cancer and mesothelioma cell lines.
</td>
<td style="text-align:left;">
Onco Targets Ther
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
A case of advanced malignant pleural mesothelioma treatment with chemotherapy and photodynamic therapy.
</td>
<td style="text-align:left;">
Tuberc Respir Dis (Seoul)
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Is Radiotherapy Useful for Treating Pain in Mesothelioma?: A Phase II Trial.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
High Incidence of Somatic BAP1 alterations in sporadic malignant mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Cytoreductive surgery and hyperthermic intrapleural chemotherapy for malignant pleural diseases: preliminary experience.
</td>
<td style="text-align:left;">
Future Oncol
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
MDM2 is an important prognostic and predictive factor for platin-pemetrexed therapy in malignant pleural mesotheliomas and deregulation of P14/ARF (encoded by CDKN2A) seems to contribute to an MDM2-driven inactivation of P53.
</td>
<td style="text-align:left;">
Br. J. Cancer
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Persistent lung expansion after pleural talc poudrage in non-surgically resected malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Ann. Thorac. Surg.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Itraconazole therapy in a pancreatic adenocarcinoma patient: A case report.
</td>
<td style="text-align:left;">
J Oncol Pharm Pract
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
New and emerging therapeutic options for malignant pleural mesothelioma: review of early clinical trials.
</td>
<td style="text-align:left;">
Cancer Manag Res
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Epithelioid angiosarcoma at chest wall which needs to be carefully distinguished from malignant mesothelioma: report of a rare case.
</td>
<td style="text-align:left;">
Int J Clin Exp Pathol
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Feasibility and performance of an adaptive contrast-oriented FDG PET/CT quantification technique for global disease assessment of malignant pleural mesothelioma and a brief review of the literature.
</td>
<td style="text-align:left;">
Hell J Nucl Med
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Clinical and prognostic features of erionite-induced malignant mesothelioma.
</td>
<td style="text-align:left;">
Yonsei Med. J.
</td>
<td style="text-align:left;">
treatment | transmission
</td>
</tr>
<tr>
<td style="text-align:left;">
New biomarkers in the selection of patients for talcage of pleural cavity in the palliative therapy of malign pleural exudate.
</td>
<td style="text-align:left;">
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant Pleural Mesothelioma: Accuracy of CT Against Immunohistochemical Test Among the Mexican Population.
</td>
<td style="text-align:left;">
Arch. Med. Res.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Searching for targets for the systemic therapy of mesothelioma.
</td>
<td style="text-align:left;">
Ann. Oncol.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Shoulder ring complaints as a rare first symptom of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Adv. Exp. Med. Biol.
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma: history, controversy and future of a manmade epidemic.
</td>
<td style="text-align:left;">
Eur Respir Rev
</td>
<td style="text-align:left;">
diagnosis | treatment | epidemiology | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleurectomy/decortication, hyperthermic pleural lavage with povidone-iodine, prophylactic radiotherapy, and systemic chemotherapy in patients with malignant pleural mesothelioma: a 10-year experience.
</td>
<td style="text-align:left;">
J. Thorac. Cardiovasc. Surg.
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Evaluation of androgen receptor and GATA binding protein 3 as immunohistochemical markers in the diagnosis of metastatic breast carcinoma to the lung.
</td>
<td style="text-align:left;">
Pathol. Int.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[A case of malignant peritoneal mesothelioma without deletion of p16].
</td>
<td style="text-align:left;">
Gan To Kagaku Ryoho
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Intrapleural Fibrinolysis for the Treatment of Indwelling Pleural Catheter-Related Symptomatic Loculations: A Multicenter Observational Study.
</td>
<td style="text-align:left;">
Chest
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Pemetrexed induces G1 phase arrest and apoptosis through inhibiting Akt activation in human non small lung cancer cell line A549.
</td>
<td style="text-align:left;">
Asian Pac. J. Cancer Prev.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Changing pattern in malignant mesothelioma survival.
</td>
<td style="text-align:left;">
Transl Oncol
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Interim results of pleurectomy/decortication and intraoperative intrapleural hyperthermic cisplatin perfusion for patients with malignant pleural mesothelioma intolerable to extrapleural pneumonectomy.
</td>
<td style="text-align:left;">
Gen Thorac Cardiovasc Surg
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Hemithoracic radiation therapy after extrapleural pneumonectomy for malignant pleural mesothelioma: Toxicity and outcomes at an Australian institution.
</td>
<td style="text-align:left;">
J Med Imaging Radiat Oncol
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Incidence of malignant mesothelioma of the pleura in Québec and Canada from 1984 to 2007, and projections from 2008 to 2032.
</td>
<td style="text-align:left;">
Am. J. Ind. Med.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
MicroRNA and mRNA features of malignant pleural mesothelioma and benign asbestos-related pleural effusion.
</td>
<td style="text-align:left;">
Biomed Res Int
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
The effect of chemotherapy on health-related quality of life in mesothelioma: results from the SWAMP trial.
</td>
<td style="text-align:left;">
Br. J. Cancer
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
The South West Area Mesothelioma and Pemetrexed trial: a multicentre prospective observational study evaluating novel markers of chemotherapy response and prognostication.
</td>
<td style="text-align:left;">
Br. J. Cancer
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Differential Susceptibility of Human Pleural and Peritoneal Mesothelial Cells to Asbestos Exposure.
</td>
<td style="text-align:left;">
J. Cell. Biochem.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Liposomal pemetrexed: formulation, characterization and in vitro cytotoxicity studies for effective management of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Biol. Pharm. Bull.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Diffuse intrapulmonary malignant mesothelioma presenting with miliary pulmonary nodules: A case report.
</td>
<td style="text-align:left;">
Pathol. Int.
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Expression status of candidate genes in mesothelioma tissues and cell lines.
</td>
<td style="text-align:left;">
Mutat. Res.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Updated patterns of failure after multimodality therapy for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J. Thorac. Cardiovasc. Surg.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Analysis of expression of programmed cell death 1 ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM).
</td>
<td style="text-align:left;">
PLoS ONE
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Impact of mesothelioma histologic subtype on outcomes in the Surveillance, Epidemiology, and End Results database.
</td>
<td style="text-align:left;">
J. Surg. Res.
</td>
<td style="text-align:left;">
treatment | epidemiology | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Unusual appearance of malignant peritoneal mesothelioma.
</td>
<td style="text-align:left;">
J Comput Assist Tomogr
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Role of the Sonic Hedgehog pathway in thoracic cancers].
</td>
<td style="text-align:left;">
Rev Mal Respir
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Diagnostic yield of pleural biopsy in exudative pleural effusion.
</td>
<td style="text-align:left;">
Nepal Med Coll J
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): a phase 3, double-blind, randomised, placebo-controlled trial.
</td>
<td style="text-align:left;">
Lancet Oncol.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma presenting as a spontaneous pneumothorax.
</td>
<td style="text-align:left;">
Respirol Case Rep
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Hippo/YAP pathway for targeted therapy.
</td>
<td style="text-align:left;">
Transl Lung Cancer Res
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
The efficacy of pemetrexed and bevacizumab intrapleural injection for malignant pleural mesothelioma-mediated malignant pleural effusion.
</td>
<td style="text-align:left;">
Indian J Cancer
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: an open-label, single-arm, phase 2 study.
</td>
<td style="text-align:left;">
Lancet Respir Med
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Diagnostic accuracy of calretinin for malignant mesothelioma in serous effusions: a meta-analysis.
</td>
<td style="text-align:left;">
Sci Rep
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Blockade of aquaporin 1 inhibits proliferation, motility, and metastatic potential of mesothelioma in vitro but not in an in vivo model.
</td>
<td style="text-align:left;">
Dis. Markers
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
NF2 blocks Snail-mediated p53 suppression in mesothelioma.
</td>
<td style="text-align:left;">
Oncotarget
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Loss of miR-223 and JNK Signaling Contribute to Elevated Stathmin in Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
Mol. Cancer Res.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Prognostic factors in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Hum. Pathol.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Effects of extended pleurectomy and decortication on quality of life and pulmonary function in patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Ann. Thorac. Surg.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
BAP1 missense mutation c.2054 A&gt;T (p.E685V) completely disrupts normal splicing through creation of a novel 5’ splice site in a human mesothelioma cell line.
</td>
<td style="text-align:left;">
PLoS ONE
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
A new prognostic index for overall survival in malignant pleural mesothelioma: the rPHS (regimen, PS, histology or stage) index.
</td>
<td style="text-align:left;">
Jpn. J. Clin. Oncol.
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Importance of excision repair cross-complementation group 1 and ribonucleotide reductase M1 as prognostic biomarkers in malignant pleural mesothelioma treated with platinum-based induction chemotherapy followed by surgery.
</td>
<td style="text-align:left;">
J. Thorac. Cardiovasc. Surg.
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Intratumoral macrophage phenotype and CD8+ T lymphocytes as potential tools to predict local tumor outgrowth at the intervention site in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Breast cancer or metastasis? An unusual case of metastatic malignant pleural mesothelioma to the breast.
</td>
<td style="text-align:left;">
World J Surg Oncol
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Importance of the cell block technique in diagnosing patients with non-small cell carcinoma accompanied by pleural effusion.
</td>
<td style="text-align:left;">
Asian Pac. J. Cancer Prev.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
An 8-Year-Old Child with Malignant Deciduoid Mesothelioma of the Abdomen: Report of a Case and Review of the Literature.
</td>
<td style="text-align:left;">
Pediatr. Dev. Pathol.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Pathologic diagnosis of malignant mesothelioma: chronological prospect and advent of recommendations and guidelines.
</td>
<td style="text-align:left;">
Ann. Ist. Super. Sanita
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[A case of malignant pleural mesothelioma with infectious bronchogenic cyst].
</td>
<td style="text-align:left;">
Nihon Kyobu Shikkan Gakkai Zasshi
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Demographics, management and survival of patients with malignant pleural mesothelioma in the National Lung Cancer Audit in England and Wales.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
diagnosis | treatment | epidemiology | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
A STAT3-NFkB/DDIT3/CEBPβ axis modulates ALDH1A3 expression in chemoresistant cell subpopulations.
</td>
<td style="text-align:left;">
Oncotarget
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Defining the minimal important difference for the visual analogue scale assessing dyspnea in patients with malignant pleural effusions.
</td>
<td style="text-align:left;">
PLoS ONE
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Comparing the results of pathologic diagnosis of mesothelioma between Chinese and Japanese experts].
</td>
<td style="text-align:left;">
Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Prognostic factors in malignant pleural mesothelioma: a retrospective study of 60 Turkish patients.
</td>
<td style="text-align:left;">
J Cancer Res Ther
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
BAP1 mutation is a frequent somatic event in peritoneal malignant mesothelioma.
</td>
<td style="text-align:left;">
J Transl Med
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Single-dose dexamethasone for the prevention of pemetrexed associated cutaneous adverse reactions.
</td>
<td style="text-align:left;">
J Oncol Pharm Pract
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Intrapleural Photodynamic Therapy for Mesothelioma: What Place and Which Future?
</td>
<td style="text-align:left;">
Ann. Thorac. Surg.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Claudin 3, 4, and 15 expression in solid tumors of lung adenocarcinoma versus malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Ann Diagn Pathol
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Chemokine (C-C motif) ligand 3 detection in the serum of persons exposed to asbestos: A patient-based study.
</td>
<td style="text-align:left;">
Cancer Sci.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Local treatment of a pleural mesothelioma tumor with ONCOS-102 induces a systemic antitumor CD8<sup>+</sup> T-cell response, prominent infiltration of CD8<sup>+</sup> lymphocytes and Th1 type polarization.
</td>
<td style="text-align:left;">
Oncoimmunology
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
First-in-human, phase I study of elisidepsin (PM02734) administered as a 30-min or as a 3-hour intravenous infusion every three weeks in patients with advanced solid tumors.
</td>
<td style="text-align:left;">
Invest New Drugs
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Inhibition of autophagy sensitizes malignant pleural mesothelioma cells to dual PI3K/mTOR inhibitors.
</td>
<td style="text-align:left;">
Cell Death Dis
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Humoral immunity alterations after environmental asbestos exposure.
</td>
<td style="text-align:left;">
Respiration
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Mesothelioma patient derived tumor xenografts with defined BAP1 mutations that mimic the molecular characteristics of human malignant mesothelioma.
</td>
<td style="text-align:left;">
BMC Cancer
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
The combination of sorafenib and everolimus shows antitumor activity in preclinical models of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
BMC Cancer
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Randomized Trials of Systemic Medically-treated Malignant Mesothelioma: A Systematic Review.
</td>
<td style="text-align:left;">
Anticancer Res.
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Positron Emission Tomography/Computed Tomography for the Pleural Staging of Malignant Pleural Mesothelioma: How Accurate Is It?
</td>
<td style="text-align:left;">
Respiration
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Mesothelioma treatment.
</td>
<td style="text-align:left;">
Rev Port Pneumol
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Loss of the deubiquitylase BAP1 alters class I histone deacetylase expression and sensitivity of mesothelioma cells to HDAC inhibitors.
</td>
<td style="text-align:left;">
Oncotarget
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
p16/CDKN2A FISH in Differentiation of Diffuse Malignant Peritoneal Mesothelioma From Mesothelial Hyperplasia and Epithelial Ovarian Cancer.
</td>
<td style="text-align:left;">
Am. J. Clin. Pathol.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Detection of p16 by fluorescence in-situ hybridization and immunohistochemistry in malignant mesothelioma].
</td>
<td style="text-align:left;">
Zhonghua Bing Li Xue Za Zhi
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
The established and future biomarkers of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Cancer Treat. Rev.
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Amplatzer Device in Bronchial Stump Fistula after Extrapleural Pneumonectomy.
</td>
<td style="text-align:left;">
Thorac Cardiovasc Surg
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Localized malignant pleural mesothelioma with renal metastasis.
</td>
<td style="text-align:left;">
Oxf Med Case Reports
</td>
<td style="text-align:left;">
treatment | epidemiology
</td>
</tr>
<tr>
<td style="text-align:left;">
An IR Navigation System for Pleural PDT.
</td>
<td style="text-align:left;">
Front Phys
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Surgical cytoreduction restores the antitumor efficacy of a Listeria monocytogenes vaccine in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Immunol. Lett.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Monte Carlo simulation of light fluence calculation during pleural PDT.
</td>
<td style="text-align:left;">
Proc SPIE Int Soc Opt Eng
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Diarachidonoylphosphoethanolamine induces necrosis/necroptosis of malignant pleural mesothelioma cells.
</td>
<td style="text-align:left;">
Cell. Signal.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Targeting glucosylceramide synthase induction of cell surface globotriaosylceramide (Gb3) in acquired cisplatin-resistance of lung cancer and malignant pleural mesothelioma cells.
</td>
<td style="text-align:left;">
Exp. Cell Res.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Surgical treatment for malignant pleural mesothelioma: extrapleural pneumonectomy, pleurectomy/decortication or extended pleurectomy?
</td>
<td style="text-align:left;">
J BUON
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Epigenetic down-regulation of integrin α7 increases migratory potential and confers poor prognosis in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J. Pathol.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Comparison of mesothelin and fibulin-3 in pleural fluid and serum as markers in malignant mesothelioma.
</td>
<td style="text-align:left;">
Curr Opin Pulm Med
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant Pleural Mesothelioma : Rationale for a New TNM Classification.
</td>
<td style="text-align:left;">
Acta Chir. Belg.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
BAP1 (BRCA1-associated protein 1) is a highly specific marker for differentiating mesothelioma from reactive mesothelial proliferations.
</td>
<td style="text-align:left;">
Mod. Pathol.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Long-Term Chronic Toxicity and Mesothelial Cell Reactions Induced by Potassium Octatitanate Fibers (TISMO) in the Left Thoracic Cavity in A/J Female Mice.
</td>
<td style="text-align:left;">
Int. J. Toxicol.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Asbestos-related lung cancer and malignant mesothelioma of the pleura: selected current issues.
</td>
<td style="text-align:left;">
Semin Respir Crit Care Med
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
[Protein-poor pleurisy and mesothelioma. Apropos of 2 cases].
</td>
<td style="text-align:left;">
Rev Mal Respir
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
An unusual cause of an anterior mediastinal mass.
</td>
<td style="text-align:left;">
Respir Med Case Rep
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Multiple distant metastases in a case of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Respir Med Case Rep
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Effectiveness of medical thoracoscopy and thoracoscopic talc poudrage in patients with exudative pleural effusion.
</td>
<td style="text-align:left;">
Singapore Med J
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Treatment patterns and survival analysis in 9014 patients with malignant pleural mesothelioma from Belgium, the Netherlands and England.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma due to non-occupational asbestos exposure from the Italian national surveillance system (ReNaM): epidemiology and public health issues.
</td>
<td style="text-align:left;">
Occup Environ Med
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Asbestos exposure increases the incidence of histologically confirmed usual interstitial pneumonia.
</td>
<td style="text-align:left;">
Histopathology
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleural neoplastic pathology.
</td>
<td style="text-align:left;">
Respir Med
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[18F]Fluorodeoxyglucose PET in Thoracic Malignancies.
</td>
<td style="text-align:left;">
PET Clin
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Differential diagnosis of pleural mesothelioma using Logic Learning Machine.
</td>
<td style="text-align:left;">
BMC Bioinformatics
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Differential p16/INK4A cyclin-dependent kinase inhibitor expression correlates with chemotherapy efficacy in a cohort of 88 malignant pleural mesothelioma patients.
</td>
<td style="text-align:left;">
Br. J. Cancer
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma in the southwestern part of The Netherlands.
</td>
<td style="text-align:left;">
Eur. Respir. J.
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Frequency of Surgery in Black Patients with Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
Dis. Markers
</td>
<td style="text-align:left;">
diagnosis | treatment | epidemiology
</td>
</tr>
<tr>
<td style="text-align:left;">
[Endobronchial ultrasound in the diagnosis of malignant pleural mesothelioma].
</td>
<td style="text-align:left;">
Rev Mal Respir
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Clinical Evaluation of ErbB-Targeted CAR T-Cells, Following Intracavity Delivery in Patients with ErbB-Expressing Solid Tumors.
</td>
<td style="text-align:left;">
Methods Mol. Biol.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Surgical Management of Malignant Pleural Mesothelioma: An Update of Clinical Evidence.
</td>
<td style="text-align:left;">
Semin. Thorac. Cardiovasc. Surg.
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Are pleural plaques an appropriate endpoint for risk analyses?
</td>
<td style="text-align:left;">
Inhal Toxicol
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Combinatorial anti-angiogenic gene therapy in a human malignant mesothelioma model.
</td>
<td style="text-align:left;">
Oncol. Rep.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Prognostic factors in diffuse malignant mesothelioma of the pleura].
</td>
<td style="text-align:left;">
Pneumologie
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Guidelines for the cytopathologic diagnosis of epithelioid and mixed-type malignant mesothelioma: Complementary Statement from the International Mesothelioma Interest Group, Also Endorsed by the International Academy of Cytology and the Papanicolaou Society of Cytopathology.
</td>
<td style="text-align:left;">
Diagn. Cytopathol.
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Diffuse malignant pleural mesothelioma in an urban hospital: clinical spectrum and trend in incidence over time.
</td>
<td style="text-align:left;">
Am. J. Ind. Med.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Drug fever after cancer chemotherapy is most commonly observed on posttreatment days 3 and 4.
</td>
<td style="text-align:left;">
Support Care Cancer
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Sarcomatoid mesothelioma: future advances in diagnosis, biomolecular assessment, and therapeutic options in a poor-outcome disease.
</td>
<td style="text-align:left;">
Tumori
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Phosphatidylinositol Induces Caspase-Independent Apoptosis of Malignant Pleural Mesothelioma Cells by Accumulating AIF in the Nucleus.
</td>
<td style="text-align:left;">
Cell. Physiol. Biochem.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Research priorities in mesothelioma: A James Lind Alliance Priority Setting Partnership.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Prophylactic Radiotherapy to Intervention Sites in Malignant Pleural Mesothelioma–Single-institution Experience and Literature Review.
</td>
<td style="text-align:left;">
Anticancer Res.
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
miR-193a-3p is a potential tumor suppressor in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Oncotarget
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant peritoneal mesothelioma: a series of 19 cases.
</td>
<td style="text-align:left;">
Digestion
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Cynara scolymus affects malignant pleural mesothelioma by promoting apoptosis and restraining invasion.
</td>
<td style="text-align:left;">
Oncotarget
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Gene-asbestos interaction in malignant pleural mesothelioma susceptibility.
</td>
<td style="text-align:left;">
Carcinogenesis
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Medical and oncological management of malignant mesothelioma.
</td>
<td style="text-align:left;">
Br J Hosp Med (Lond)
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Asbestos textile production linked to malignant peritoneal and pleural mesothelioma in women: Analysis of 28 cases in Southeast China.
</td>
<td style="text-align:left;">
Am. J. Ind. Med.
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleural mesothelial cells in pleural and lung diseases.
</td>
<td style="text-align:left;">
J Thorac Dis
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Epidemiologic surveillance of mesothelioma in Umbria.
</td>
<td style="text-align:left;">
Ann Ig
</td>
<td style="text-align:left;">
epidemiology | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
The tumoral and stromal immune microenvironment in malignant pleural mesothelioma: A comprehensive analysis reveals prognostic immune markers.
</td>
<td style="text-align:left;">
Oncoimmunology
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
The endoplasmic reticulum mitochondrial calcium cross talk is downregulated in malignant pleural mesothelioma cells and plays a critical role in apoptosis inhibition.
</td>
<td style="text-align:left;">
Oncotarget
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
The effectiveness and safety of platinum-based pemetrexed and platinum-based gemcitabine treatment in patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
BMC Cancer
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Functional Alteration of Natural Killer Cells and Cytotoxic T Lymphocytes upon Asbestos Exposure and in Malignant Mesothelioma Patients.
</td>
<td style="text-align:left;">
Biomed Res Int
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Second line therapy in malignant pleural mesothelioma: A systematic review.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Prognostic Score of Long-Term Survival After Surgery for Malignant Pleural Mesothelioma: A Multicenter Analysis.
</td>
<td style="text-align:left;">
Ann. Thorac. Surg.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Mesothelioma cells breaking bad: loss of integrin α7 promotes cell motility and poor clinical outcomes in patients.
</td>
<td style="text-align:left;">
J. Pathol.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant Mesothelioma Diagnosed by Bronchoscopic Biopsy.
</td>
<td style="text-align:left;">
Tuberc Respir Dis (Seoul)
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Cerebral Metastasis of a Malignant Pleural Mesothelioma: A Case Report and Review of the Literature.
</td>
<td style="text-align:left;">
Cureus
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Survival from malignant mesothelioma: where are we now?
</td>
<td style="text-align:left;">
J R Coll Physicians Edinb
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Hedgehog Signaling in Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
Genes (Basel)
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant spindle cell tumor of the pericardium. Evidence of sarcomatous mesothelioma with aberrant antigen expression.
</td>
<td style="text-align:left;">
Acta Pathol. Jpn.
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
A clinical protocol to inhibit the HGF/c-Met pathway for malignant mesothelioma with an intrapleural injection of adenoviruses expressing the NK4 gene.
</td>
<td style="text-align:left;">
Springerplus
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Emerging evidence that the ban on asbestos use is reducing the occurrence of pleural mesothelioma in Sweden.
</td>
<td style="text-align:left;">
Scand J Public Health
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Diagnostic Ability of FDG-PET/CT in the Detection of Malignant Pleural Effusion.
</td>
<td style="text-align:left;">
Medicine (Baltimore)
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesotheliomas in Kure City, Japan: the relationship of asbestos exposure.
</td>
<td style="text-align:left;">
Cancer Invest.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Distinctive clinical characteristics of malignant mesothelioma in young patients.
</td>
<td style="text-align:left;">
Oncotarget
</td>
<td style="text-align:left;">
epidemiology
</td>
</tr>
<tr>
<td style="text-align:left;">
Intracellular lactate-mediated induction of estrogen receptor beta (ERβ) in biphasic malignant pleural mesothelioma cells.
</td>
<td style="text-align:left;">
Oncotarget
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Syndecan-1 alters heparan sulfate composition and signaling pathways in malignant mesothelioma.
</td>
<td style="text-align:left;">
Cell. Signal.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Downregulation of TBXAS1 in an iron-induced malignant mesothelioma model.
</td>
<td style="text-align:left;">
Cancer Sci.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Long-term Outcome of Patients With Undiagnosed Pleural Effusion.
</td>
<td style="text-align:left;">
Arch. Bronconeumol.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Cul4A overexpression associated with Gli1 expression in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J. Cell. Mol. Med.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Primary Peritoneal Mesothelioma Resulting in Small Bowel Obstruction: A Case Report and Review of Literature.
</td>
<td style="text-align:left;">
Am J Case Rep
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Loss of expression of BAP1 is a useful adjunct, which strongly supports the diagnosis of mesothelioma in effusion cytology.
</td>
<td style="text-align:left;">
Mod. Pathol.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant Mesothelioma Diagnosis.
</td>
<td style="text-align:left;">
Arch. Pathol. Lab. Med.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Pleuropulmonary tumors. Presentation of 2 cases with peculiar clinicopathologic traits].
</td>
<td style="text-align:left;">
Rev Clin Esp
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
NLRP1 and NLRP3 polymorphisms in mesothelioma patients and asbestos exposed individuals a population-based autopsy study from North East Italy.
</td>
<td style="text-align:left;">
Infect. Agents Cancer
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Inhibition of NADPH oxidase 4 induces apoptosis in malignant mesothelioma: Role of reactive oxygen species.
</td>
<td style="text-align:left;">
Oncol. Rep.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Molecular Pharmacology of Malignant Pleural Mesothelioma: Challenges and Perspectives From Preclinical and Clinical Studies.
</td>
<td style="text-align:left;">
Curr Drug Targets
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[MULTIMODAL APPROACH IN THE TREATMENT OF PATIENTS WITH MALIGNANT PLEURAL LESIONS].
</td>
<td style="text-align:left;">
Vopr Onkol
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Temsirolimus targets multiple hallmarks of cancer to impede mesothelioma growth in vivo.
</td>
<td style="text-align:left;">
Respirology
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Frequent genomic rearrangements of BRCA1 associated protein-1 (BAP1) gene in Japanese malignant mesothelioma-characterization of deletions at exon level.
</td>
<td style="text-align:left;">
J. Hum. Genet.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Computational genomic analysis of PARK7 interactome reveals high BBS1 gene expression as a prognostic factor favoring survival in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Am. J. Physiol. Lung Cell Mol. Physiol.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Mesothelioma treatment: Are we on target? A review.
</td>
<td style="text-align:left;">
J Adv Res
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Prognostic significance of the lymphocyte-to-monocyte ratio in patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Characterization of hypoxia in malignant pleural mesothelioma with FMISO PET-CT.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Two Different Serum MiRNA Signatures Correlate with the Clinical Outcome and Histological Subtype in Pleural Malignant Mesothelioma Patients.
</td>
<td style="text-align:left;">
PLoS ONE
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Fibulin-3 levels in malignant pleural mesothelioma are associated with prognosis but not diagnosis.
</td>
<td style="text-align:left;">
Br. J. Cancer
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleural mesothelioma and occupational and non-occupational asbestos exposure: a case-control study with quantitative risk assessment.
</td>
<td style="text-align:left;">
Occup Environ Med
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Prognostic significance of morphological growth patterns and mitotic index of epithelioid malignant peritoneal mesothelioma.
</td>
<td style="text-align:left;">
Histopathology
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Granulocyte-colony stimulating factor (G-CSF) producing malignant pleural mesothelioma: Report of a case.
</td>
<td style="text-align:left;">
Thorac Cancer
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
The expression and clinical effects of alpha-methylacyl-CoA racemase (AMACR/ P504S) as an immunohistochemical marker in malign pleural mesothelioma.
</td>
<td style="text-align:left;">
Turk J Med Sci
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Radical Radiation Therapy After Lung-Sparing Surgery for Malignant Pleural Mesothelioma: Survival, Pattern of Failure, and Prognostic Factors.
</td>
<td style="text-align:left;">
Int. J. Radiat. Oncol. Biol. Phys.
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
An immunohistochemical comparison of two TTF-1 monoclonal antibodies in atypical squamous lesions and sarcomatoid carcinoma of the lung, and pleural malignant mesothelioma.
</td>
<td style="text-align:left;">
J. Clin. Pathol.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Autophagy Correlates with the Therapeutic Responsiveness of Malignant Pleural Mesothelioma in 3D Models.
</td>
<td style="text-align:left;">
PLoS ONE
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
New Markers for Separating Benign From Malignant Mesothelial Proliferations: Are We There Yet?
</td>
<td style="text-align:left;">
Arch. Pathol. Lab. Med.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Increased Standardised Incidence Ratio of Malignant Pleural Mesothelioma in Taiwanese Asbestos Workers: A 29-Year Retrospective Cohort Study.
</td>
<td style="text-align:left;">
Biomed Res Int
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Deletion status of p16 in effusion smear preparation correlates with that of underlying malignant pleural mesothelioma tissue.
</td>
<td style="text-align:left;">
Cancer Sci.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Akt Kinase-Interacting Protein 1 Signals through CREB to Drive Diffuse Malignant Mesothelioma.
</td>
<td style="text-align:left;">
Cancer Res.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Imaging in pleural mesothelioma: A review of the 12th International Conference of the International Mesothelioma Interest Group.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Improvement of malignant pleural mesothelioma immunotherapy by epigenetic modulators.
</td>
<td style="text-align:left;">
Curr Top Med Chem
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Latest developments in our understanding of the pathogenesis of mesothelioma and the design of targeted therapies.
</td>
<td style="text-align:left;">
Expert Rev Respir Med
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Environmental carcinogenesis - 100th anniversary of creating cancer.
</td>
<td style="text-align:left;">
Cancer Sci.
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Recurrent pneumothorax: an unusual presentation of malignant mesothelioma.
</td>
<td style="text-align:left;">
Scott Med J
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
The role of endobronchial ultrasound-guided fine needle aspiration in the diagnosis of pleural mesothelioma.
</td>
<td style="text-align:left;">
Cytopathology
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant Pleural Mesothelioma Outcomes in the Era of Combined Platinum and Folate Antimetabolite Chemotherapy.
</td>
<td style="text-align:left;">
Lung Cancer Int
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
A New Prognostic Score Supporting Treatment Allocation for Multimodality Therapy for Malignant Pleural Mesothelioma: A Review of 12 Years’ Experience.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Extended Pleurectomy and Decortication for Malignant Pleural Mesothelioma Is an Effective and Safe Cytoreductive Surgery in the Elderly.
</td>
<td style="text-align:left;">
Ann. Thorac. Surg.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Inhibition of Src family kinases overcomes anoikis resistance induced by spheroid formation and facilitates cisplatin-induced apoptosis in human mesothelioma cells.
</td>
<td style="text-align:left;">
Oncol. Rep.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Localized Malignant Mesothelioma of the Pleura].
</td>
<td style="text-align:left;">
Kyobu Geka
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
[Radiologic diagnosis of pleural mesothelioma].
</td>
<td style="text-align:left;">
Nihon Igaku Hoshasen Gakkai Zasshi
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Trimodality Treatment of Malignant Pleural Mesothelioma: An Institutional Review.
</td>
<td style="text-align:left;">
Am. J. Clin. Oncol.
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Critical review about MDM2 in cancer: Possible role in malignant mesothelioma and implications for treatment.
</td>
<td style="text-align:left;">
Crit. Rev. Oncol. Hematol.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
The diagnosis, therapy and prognosis of diffuse malignant mesothelioma.
</td>
<td style="text-align:left;">
Eur J Cardiothorac Surg
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Prognostic value of several biomarkers for the patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Tumour Biol.
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[The role of pleural effusion cytology in the diagnosis of malignancies].
</td>
<td style="text-align:left;">
Plucne Bolesti
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
An asbestos-exposed family with multiple cases of pleural malignant mesothelioma without inheritance of a predisposing BAP1 mutation.
</td>
<td style="text-align:left;">
Cancer Genet
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma with fungating masses and multiple sites involvement.
</td>
<td style="text-align:left;">
Clin Respir J
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Advances in the diagnosis, treatment and prognosis of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Ann Transl Med
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Systemic therapy options for malignant pleural mesothelioma beyond first-line therapy: a systematic review.
</td>
<td style="text-align:left;">
Expert Rev Respir Med
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Epithelioid pleural mesothelioma concurrently associated with miliary pulmonary metastases and minimal change nephrotic syndrome - A hitherto undescribed case.
</td>
<td style="text-align:left;">
Pathol. Res. Pract.
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Successful palliation for an aged patient with primary pericardial mesothelioma.
</td>
<td style="text-align:left;">
World J Surg Oncol
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
BAP1 facilitates diagnostic objectivity, classification, and prognostication in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Hum. Pathol.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
III Italian Consensus Conference on Malignant Mesothelioma of the Pleura. Epidemiology, Public Health and Occupational Medicine related issues.
</td>
<td style="text-align:left;">
Med Lav
</td>
<td style="text-align:left;">
diagnosis | epidemiology
</td>
</tr>
<tr>
<td style="text-align:left;">
[Health expenditures for cases of pleural mesothelioma].
</td>
<td style="text-align:left;">
Med Lav
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
A phase 1b clinical trial of the CD40-activating antibody CP-870,893 in combination with cisplatin and pemetrexed in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Ann. Oncol.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Expression Profiles of Cytokine mRNAs in the Pleural Fluid Reveal Differences Among Tuberculosis, Malignancies, and Pneumonia-Exudative Pleural Effusions.
</td>
<td style="text-align:left;">
Lung
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Germline BAP1 mutation in a family with high incidence of multiple primary cancers and a potential gene-environment interaction.
</td>
<td style="text-align:left;">
Cancer Lett.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Which is the Role of Pneumonectomy in the Era of Parenchymal-Sparing Procedures? Early/Long-Term Survival and Functional Results of a Single-Center Experience.
</td>
<td style="text-align:left;">
Lung
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Differential protein expression and oncogenic gene network link tyrosine kinase ephrin B4 receptor to aggressive gastric and gastroesophageal junction cancers.
</td>
<td style="text-align:left;">
Int. J. Cancer
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Encapsulation in a rapid-release liposomal formulation enhances the anti-tumor efficacy of pemetrexed in a murine solid mesothelioma-xenograft model.
</td>
<td style="text-align:left;">
Eur J Pharm Sci
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Identification of circulating miRNAs profiles that distinguish malignant pleural mesothelioma from lung adenocarcinoma.
</td>
<td style="text-align:left;">
EXCLI J
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Expression of the Stem Cell Factor Nestin in Malignant Pleural Mesothelioma Is Associated with Poor Prognosis.
</td>
<td style="text-align:left;">
PLoS ONE
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
A novel link between FMR gene and the JNK pathway provides clues to possible role in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
FEBS Open Bio
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Tomotherapy improves local control and changes failure patterns in locally advanced malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Pract Radiat Oncol
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Targeting immune checkpoints: New opportunity for mesothelioma treatment?
</td>
<td style="text-align:left;">
Cancer Treat. Rev.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Computed tomography in the diagnosis of asbestos-related thoracic disease.
</td>
<td style="text-align:left;">
J Thorac Imaging
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
The potential value of volume-based quantitative PET parameters and increased bone marrow uptake for the prediction of survival in patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Nucl Med Commun
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Response evaluation in mesothelioma: Beyond RECIST.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Transcriptional over-expression of chloride intracellular channels 3 and 4 in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Comput Biol Chem
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Utility of BAP1 Immunohistochemistry and p16 (CDKN2A) FISH in the Diagnosis of Malignant Mesothelioma in Effusion Cytology Specimens.
</td>
<td style="text-align:left;">
Am. J. Surg. Pathol.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant Mesothelioma Mimicking Invasive Mammary Carcinoma in a Male Breast.
</td>
<td style="text-align:left;">
Case Rep Oncol Med
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
The diagnosis of pleural effusions.
</td>
<td style="text-align:left;">
Expert Rev Respir Med
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
A Cause of Bilateral Chylothorax: A Case of Mesothelioma without Pleural Involvement during Initial Diagnosis.
</td>
<td style="text-align:left;">
Case Rep Pulmonol
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Tomotherapy PET-guided dose escalation: A dosimetric feasibility study for patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Strahlenther Onkol
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Paraneoplastic nephritic syndrome and concurrent solitary mediastinal lymph node metastasis from mesothelioma of testis diagnosed by endobronchial ultrasound: Unusual manifestations of an extremely rare tumor.
</td>
<td style="text-align:left;">
J Cancer Res Ther
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Mithramycin Depletes Specificity Protein 1 and Activates p53 to Mediate Senescence and Apoptosis of Malignant Pleural Mesothelioma Cells.
</td>
<td style="text-align:left;">
Clin. Cancer Res.
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Verification of the histologic diagnosis of malignant mesothelioma in relation to the binding of an antimesothelial cell antibody.
</td>
<td style="text-align:left;">
Cancer
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Immunocytology in malignant pleural mesothelioma. Expression of tumor markers and distribution of lymphocyte subsets.
</td>
<td style="text-align:left;">
Chest
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Expression and activity of eIF6 trigger malignant pleural mesothelioma growth in vivo.
</td>
<td style="text-align:left;">
Oncotarget
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Driver Gene and Novel Mutations in Asbestos-Exposed Lung Adenocarcinoma and Malignant Mesothelioma Detected by Exome Sequencing.
</td>
<td style="text-align:left;">
Lung
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
MesobanK UK: an international mesothelioma bioresource.
</td>
<td style="text-align:left;">
Thorax
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Imaging characteristics of pleural tumours.
</td>
<td style="text-align:left;">
Insights Imaging
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Advanced therapeutic approach for the treatment of malignant pleural mesothelioma via the intrapleural administration of liposomal pemetrexed.
</td>
<td style="text-align:left;">
J Control Release
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Systemic approach to malignant pleural mesothelioma: what news of chemotherapy, targeted agents and immunotherapy?
</td>
<td style="text-align:left;">
Tumori
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Orthotopic Implantation and Peripheral Immune Cell Monitoring in the II-45 Syngeneic Rat Mesothelioma Model.
</td>
<td style="text-align:left;">
J Vis Exp
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
The immunohistochemical diagnosis of mesothelioma. Differentiation of mesothelioma and lung adenocarcinoma.
</td>
<td style="text-align:left;">
Am. J. Surg. Pathol.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
The prognostic significance of BAP1, NF2, and CDKN2A in malignant peritoneal mesothelioma.
</td>
<td style="text-align:left;">
Mod. Pathol.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Lapatinib enhances trastuzumab-mediated antibody-dependent cellular cytotoxicity via upregulation of HER2 in malignant mesothelioma cells.
</td>
<td style="text-align:left;">
Oncol. Rep.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Methylation-associated Silencing of microRNA-126 and its Host Gene EGFL7 in Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
Anticancer Res.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma in infancy.
</td>
<td style="text-align:left;">
Arch. Pathol. Lab. Med.
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Rapidly progressive sarcomatoid malignant mesothelioma of the pleura mimicking pulmonary empyema.
</td>
<td style="text-align:left;">
Clin Case Rep
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
MMP-7 is a highly specific negative marker for benign and malignant mesothelial cells in serous effusions.
</td>
<td style="text-align:left;">
Hum. Pathol.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Pemetrexed-Induced Rash May Be Prevented by Supplementary Corticosteroids.
</td>
<td style="text-align:left;">
Biol. Pharm. Bull.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Four cases of cell cannibalism in highly malignant feline and canine tumors.
</td>
<td style="text-align:left;">
Diagn Pathol
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Vinca alkaloids in the therapeutic management of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Cancer Treat. Rev.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma with or without hemithoracic radiotherapy (SAKK 17/04): a randomised, international, multicentre phase 2 trial.
</td>
<td style="text-align:left;">
Lancet Oncol.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Sensitivity of human pleural mesothelioma to oncolytic measles virus depends on defects of the type I interferon response.
</td>
<td style="text-align:left;">
Oncotarget
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
MDM2 and HIF1alpha expression levels in different histologic subtypes of malignant pleural mesothelioma: correlation with pathological and clinical data.
</td>
<td style="text-align:left;">
Oncotarget
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Erratum to: Tomotherapy PET-guided dose escalation–A dosimetric feasibility study for patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Strahlenther Onkol
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Management of malignant pleural mesothelioma: a French multicenter retrospective study (GFPC 0802 study).
</td>
<td style="text-align:left;">
BMC Cancer
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Gender-Specific Molecular and Clinical Features Underlie Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
Cancer Res.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Tremelimumab for the treatment of malignant mesothelioma.
</td>
<td style="text-align:left;">
Expert Opin Biol Ther
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
An Autopsy Case Report of Malignant Pleural Mesothelioma with Deciduoid Features.
</td>
<td style="text-align:left;">
Intern. Med.
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Trimodality strategy for treating malignant pleural mesothelioma: results of a feasibility study of induction pemetrexed plus cisplatin followed by extrapleural pneumonectomy and postoperative hemithoracic radiation (Japan Mesothelioma Interest Group 0601 Trial).
</td>
<td style="text-align:left;">
Int. J. Clin. Oncol.
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Brain metastases in malignant pleural mesothelioma. Case report and review of the literature.
</td>
<td style="text-align:left;">
Am. J. Clin. Oncol.
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Diarachidonoylphosphoethanolamine induces apoptosis of malignant pleural mesothelioma cells through a Trx/ASK1/p38 MAPK pathway.
</td>
<td style="text-align:left;">
J. Pharmacol. Sci.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Relapse pattern and second-line treatment following multimodality treatment for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Eur J Cardiothorac Surg
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Current surgical strategies for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Surg. Today
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
An Autopsied Case of Malignant Sarcomatoid Pleural Mesothelioma in Which Chest Pain Developed Several Months Earlier without Abnormality on Imaging.
</td>
<td style="text-align:left;">
Case Rep Oncol
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Biologic therapy and gene therapy in the multimodality treatment of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Ann Transl Med
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[About a case of calcifying fibrous tumor of the pleura].
</td>
<td style="text-align:left;">
Ann Pathol
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Isolation of Chemoresistant Cell Subpopulations.
</td>
<td style="text-align:left;">
Methods Mol. Biol.
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Adoption of pleurectomy and decortication for malignant mesothelioma leads to similar survival as extrapleural pneumonectomy.
</td>
<td style="text-align:left;">
J. Thorac. Cardiovasc. Surg.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Accelerated hemithoracic radiation followed by extrapleural pneumonectomy for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J. Thorac. Cardiovasc. Surg.
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Cytomorphometry of serosal effusion in dogs.
</td>
<td style="text-align:left;">
Pol J Vet Sci
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Brain metastases in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Clin. Exp. Metastasis
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Invasive pleural malignant mesothelioma with rib destruction and concurrent osteosarcoma in a dog.
</td>
<td style="text-align:left;">
Acta Vet. Scand.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Pembrolizumab for the treatment of thoracic malignancies: current landscape and future directions.
</td>
<td style="text-align:left;">
Future Oncol
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Cell aggregates in malignant mesothelioma.
</td>
<td style="text-align:left;">
Acta Cytol.
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Fibrocyte-like cells mediate acquired resistance to anti-angiogenic therapy with bevacizumab.
</td>
<td style="text-align:left;">
Nat Commun
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Effects on health of non-occupational exposure to airborne mineral fibres.
</td>
<td style="text-align:left;">
IARC Sci. Publ.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
High RRM1 Expression Is Associated with Adverse Outcome in Patients with Cisplatin/Vinorelbine-treated Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
Anticancer Res.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Extrapleural pneumonectomy for malignant pleural mesothelioma: is this an operation that should now be consigned to history?
</td>
<td style="text-align:left;">
Future Oncol
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Is the patient with mesothelioma without hope?
</td>
<td style="text-align:left;">
Future Oncol
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
The MesoVATS trial: is there a future for video-assisted thoracoscopic surgery partial pleurectomy?
</td>
<td style="text-align:left;">
Future Oncol
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleurectomy/decortication and hyperthermic intrapleural chemotherapy for malignant pleural mesothelioma: initial experience.
</td>
<td style="text-align:left;">
Future Oncol
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Management of recurrence after initial surgery for malignant pleural mesothelioma: a mini-review.
</td>
<td style="text-align:left;">
Future Oncol
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Biomarkers and prognostic factors for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Future Oncol
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
FBLN-3 as a biomarker of pleural plaques in workers occupationally exposed to carcinogenic fibers: a pilot study.
</td>
<td style="text-align:left;">
Future Oncol
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
CT differentiation of diffuse malignant peritoneal mesothelioma and peritoneal carcinomatosis.
</td>
<td style="text-align:left;">
J. Gastroenterol. Hepatol.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Clinically occult primary fallopian tube carcinoma presenting as a malignant pleural effusion.
</td>
<td style="text-align:left;">
Clin Respir J
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Extended Tumor Control after Dendritic Cell Vaccination with Low-Dose Cyclophosphamide as Adjuvant Treatment in Patients with Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
Am. J. Respir. Crit. Care Med.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Disseminated Pleural Siliconoma Mimicking Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
Ann. Thorac. Surg.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
[Analysis of the clinical diagnosis of asbestosis complicated with malignant mesothelioma].
</td>
<td style="text-align:left;">
Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Localized benign and malignant fibrous tumors of the pleura. A clinicopathologic review of 223 cases.
</td>
<td style="text-align:left;">
Am. J. Surg. Pathol.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Determinants of Survival in Malignant Pleural Mesothelioma: A Surveillance, Epidemiology, and End Results (SEER) Study of 14,228 Patients.
</td>
<td style="text-align:left;">
PLoS ONE
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
CT differentiation of malignant peritoneal mesothelioma and tuberculous peritonitis.
</td>
<td style="text-align:left;">
Radiol Med
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Unusual lesions of the mediastinum.
</td>
<td style="text-align:left;">
Lung India
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleural epitheliod hemangioendothelioma: What started as a liver fluke and ended up being almost mistaken for malignant mesothelioma.
</td>
<td style="text-align:left;">
Ann Thorac Med
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Diffuse malignant mesothelioma of the pleura in Ontario and Quebec: a retrospective study of 332 patients.
</td>
<td style="text-align:left;">
J. Clin. Oncol.
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Closing faucets: the role of anti-angiogenic therapies in malignant pleural diseases.
</td>
<td style="text-align:left;">
Clin Transl Oncol
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
MTA1 promotes metastasis of MPM via suppression of E-cadherin.
</td>
<td style="text-align:left;">
J. Exp. Clin. Cancer Res.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Clinical Investigation of Benign Asbestos Pleural Effusion.
</td>
<td style="text-align:left;">
Pulm Med
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma of tunica vaginalis testis.
</td>
<td style="text-align:left;">
Urology
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
[Analysis of misdiagnosis of 38 cases of solitary fibrous tumor of the pleura].
</td>
<td style="text-align:left;">
Zhonghua Jie He He Hu Xi Za Zhi
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Patterns in the incidence, mortality and survival of malignant pleural and peritoneal mesothelioma, New South Wales, 1972-2009.
</td>
<td style="text-align:left;">
Aust N Z J Public Health
</td>
<td style="text-align:left;">
treatment | epidemiology | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleural mesothelioma and lung cancer risks in relation to occupational history and asbestos lung burden.
</td>
<td style="text-align:left;">
Occup Environ Med
</td>
<td style="text-align:left;">
transmission | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Long-term results in malignant pleural mesothelioma treated with neoadjuvant chemotherapy, extrapleural pneumonectomy and intensity-modulated radiotherapy.
</td>
<td style="text-align:left;">
Radiat Oncol
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Non-islet Cell Tumour Hypoglycaemia (NICTH) in Malignant Mesothelioma: Case Report.
</td>
<td style="text-align:left;">
Malays J Med Sci
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Clinical role of a new prognostic score using platelet-to-lymphocyte ratio in patients with malignant pleural mesothelioma undergoing extrapleural pneumonectomy.
</td>
<td style="text-align:left;">
J Thorac Dis
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial.
</td>
<td style="text-align:left;">
Lancet
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Germline BAP1 Mutational Landscape of Asbestos-Exposed Malignant Mesothelioma Patients with Family History of Cancer.
</td>
<td style="text-align:left;">
Cancer Res.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
DNA copy number gains in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Oncol Lett
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Infant pleuropulmonary blastoma: report of a rare case and review of literature.
</td>
<td style="text-align:left;">
Int J Clin Exp Pathol
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
HMGB1 and Its Hyperacetylated Isoform are Sensitive and Specific Serum Biomarkers to Detect Asbestos Exposure and to Identify Mesothelioma Patients.
</td>
<td style="text-align:left;">
Clin. Cancer Res.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant peritoneal mesothelioma in patients without occupational exposure. Case report].
</td>
<td style="text-align:left;">
Acta Gastroenterol. Latinoam.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Foreign body granuloma mimicking recurrence of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Respir Med Case Rep
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
A rare clinical case - Solitary fibrous tumor of the pleura.
</td>
<td style="text-align:left;">
Respir Med Case Rep
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Functional Analysis of the Adrenomedullin Pathway in Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Young investigator challenge: MicroRNA-21/MicroRNA-126 profiling as a novel tool for the diagnosis of malignant mesothelioma in pleural effusion cytology.
</td>
<td style="text-align:left;">
Cancer Cytopathol
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Massive localized malignant pleural mesothelioma (LMPM): manifestations on computed tomography in 6 cases.
</td>
<td style="text-align:left;">
Int J Clin Exp Med
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Efficacy of medical thoracoscopic talc pleurodesis in malignant pleural effusion caused by different types of tumors and different pathological classifications of lung cancer.
</td>
<td style="text-align:left;">
Int J Clin Exp Med
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Influence of AQP1 on cell adhesion, migration, and tumor sphere formation in malignant pleural mesothelioma is substratum- and histological-type dependent.
</td>
<td style="text-align:left;">
Am. J. Physiol. Lung Cell Mol. Physiol.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
A Novel Clinical Prediction Model for Prognosis in Malignant Pleural Mesothelioma Using Decision Tree Analysis.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
CT Scan-Guided Abrams’ Needle Pleural Biopsy versus Ultrasound-Assisted Cutting Needle Pleural Biopsy for Diagnosis in Patients with Pleural Effusion: A Randomized, Controlled Trial.
</td>
<td style="text-align:left;">
Respiration
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
KAT5 (Tip60) is a potential therapeutic target in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Int. J. Oncol.
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Constitutive expression and anticancer potency of a novel immunotoxin onconase-DV3.
</td>
<td style="text-align:left;">
Oncol. Rep.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Non-coding RNA repertoires in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Incidence and survival trends for malignant pleural and peritoneal mesothelioma, Australia, 1982-2009.
</td>
<td style="text-align:left;">
Occup Environ Med
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Specimen weight and volume: important predictors of survival in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Eur J Cardiothorac Surg
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
ENOX2-based early detection (ONCOblot) of asbestos-induced malignant mesothelioma 4-10 years in advance of clinical symptoms.
</td>
<td style="text-align:left;">
Clin Proteomics
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
The 2015 World Health Organization Classification of Tumors of the Pleura: Advances since the 2004 Classification.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Retrospective analysis of unknown primary cancers with malignant pleural effusion at initial diagnosis.
</td>
<td style="text-align:left;">
Thorac Cancer
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Prognostic and Therapeutic Implications of MicroRNA in Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
Microrna
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Protocol for PIT: a phase III trial of prophylactic irradiation of tracts in patients with malignant pleural mesothelioma following invasive chest wall intervention.
</td>
<td style="text-align:left;">
BMJ Open
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Iron signature in asbestos-induced malignant pleural mesothelioma: A population-based autopsy study.
</td>
<td style="text-align:left;">
J. Toxicol. Environ. Health Part A
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Asbestos and respiratory diseases].
</td>
<td style="text-align:left;">
Presse Med
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant mesotheliomas with unknown exposure to asbestos: a re-examination].
</td>
<td style="text-align:left;">
Med Lav
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Comments on the causation of malignant mesothelioma: rebutting the false concept that recent exposures to asbestos do not contribute to causation of mesothelioma.
</td>
<td style="text-align:left;">
Ind Health
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Whole exome and targeted deep sequencing identify genome-wide allelic loss and frequent SETDB1 mutations in malignant pleural mesotheliomas.
</td>
<td style="text-align:left;">
Oncotarget
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Longitudinal Measurement of Pleural Fluid Biochemistry and Cytokines in Malignant Pleural Effusions.
</td>
<td style="text-align:left;">
Chest
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Benign and Malignant Mesothelial Proliferation.
</td>
<td style="text-align:left;">
Surg Pathol Clin
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Antagonizing the Hedgehog Pathway with Vismodegib Impairs Malignant Pleural Mesothelioma Growth In Vivo by Affecting Stroma.
</td>
<td style="text-align:left;">
Mol. Cancer Ther.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Repetitive responses to nanoparticle albumin-bound paclitaxel and carboplatin in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Respirol Case Rep
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Contemporary Analysis of Prognostic Factors in Patients with Unresectable Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
A Randomized Phase II Study Adding Axitinib to Pemetrexed-Cisplatin in Patients with Malignant Pleural Mesothelioma: A Single-Center Trial Combining Clinical and Translational Outcomes.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Downregulation of thymidylate synthase by RNAi molecules enhances the antitumor effect of pemetrexed in an orthotopic malignant mesothelioma xenograft mouse model.
</td>
<td style="text-align:left;">
Int. J. Oncol.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Identification of cis- and trans-acting elements regulating calretinin expression in mesothelioma cells.
</td>
<td style="text-align:left;">
Oncotarget
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Genome-wide analysis of abdominal and pleural malignant mesothelioma with DNA arrays reveals both common and distinct regions of copy number alteration.
</td>
<td style="text-align:left;">
Cancer Biol. Ther.
</td>
<td style="text-align:left;">
epidemiology | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Human lung-derived mesenchymal stem cell-conditioned medium exerts in vitro antitumor effects in malignant pleural mesothelioma cell lines.
</td>
<td style="text-align:left;">
Stem Cell Res Ther
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
HOX transcription factors are potential targets and markers in malignant mesothelioma.
</td>
<td style="text-align:left;">
BMC Cancer
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Establishment and molecular characterization of cell lines from Japanese patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Oncol Lett
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma: an update on diagnosis and treatment options.
</td>
<td style="text-align:left;">
Ther Adv Respir Dis
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Oncol Nurs Forum
</td>
<td style="text-align:left;">
treatment | epidemiology | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Primary malignant mesothelioma of the pericardium masquerading as malignant pleural mesothelioma: report of an autopsy case and review of the reported cases in Japan as to its invasion to neighboring organs].
</td>
<td style="text-align:left;">
Kokyu To Junkan
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Mesothelioma with superior vena cava obstruction in young female following short latency of asbestos exposure.
</td>
<td style="text-align:left;">
J Cancer Res Ther
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Role of MIF/CD74 signaling pathway in the development of pleural mesothelioma.
</td>
<td style="text-align:left;">
Oncotarget
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
SIRT1 at the crossroads of AKT1 and ERβ in malignant pleural mesothelioma cells.
</td>
<td style="text-align:left;">
Oncotarget
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
A proteomics-based approach identifies secreted protein acidic and rich in cysteine as a prognostic biomarker in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Br. J. Cancer
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Clinical and pathologic predictors of clinical outcome of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Tumori
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Cutaneous Metastases From Malignant Mesothelioma of the Tunica Vaginalis Testis.
</td>
<td style="text-align:left;">
Am J Dermatopathol
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Population pharmacokinetics and exposure-response relationship of amatuximab, an anti-mesothelin monoclonal antibody, in patients with malignant pleural mesothelioma and its application in dose selection.
</td>
<td style="text-align:left;">
Cancer Chemother. Pharmacol.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Peritoneal mesothelioma metastasis to the tongue - Comparison with 8 pleural mesothelioma reports with tongue metastases.
</td>
<td style="text-align:left;">
Ann Med Surg (Lond)
</td>
<td style="text-align:left;">
treatment | epidemiology | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
BAP1 Immunohistochemistry and p16 FISH in the Diagnosis of Sarcomatous and Desmoplastic Mesotheliomas.
</td>
<td style="text-align:left;">
Am. J. Surg. Pathol.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Plasma Biomarker Enrichment of Clinical Prognostic Indices in Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Anaesthetic management of extra-pleural pneumonectomy and hyperthermic intrathoracic chemotherapy procedure.
</td>
<td style="text-align:left;">
Indian J Anaesth
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Asymptomatic localized pleural amyloidosis mimicking malignant pleural mesothelioma: report of a case.
</td>
<td style="text-align:left;">
J Thorac Dis
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Erratum to clinical role of a new prognostic score using platelet-to-lymphocyte ratio in patients with malignant pleural mesothelioma undergoing extrapleural pneumonectomy.
</td>
<td style="text-align:left;">
J Thorac Dis
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Mesotheliomas show higher hyaluronan positivity around tumor cells than metastatic pulmonary adenocarcinomas.
</td>
<td style="text-align:left;">
Histol. Histopathol.
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
microRNAs are differentially regulated between MDM2-positive and negative malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Oncotarget
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Evaluation of Machine Learning Algorithm Utilization for Lung Cancer Classification Based on Gene Expression Levels.
</td>
<td style="text-align:left;">
Asian Pac. J. Cancer Prev.
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations.
</td>
<td style="text-align:left;">
Nat. Genet.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Cytomorphology of ovarian clear cell carcinomas in peritoneal effusions.
</td>
<td style="text-align:left;">
Cytopathology
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Chondrosarcoma of the Rib Mimicking Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
Case Rep Oncol
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Microfluidic gradient device for studying mesothelial cell migration and the effect of chronic carbon nanotube exposure.
</td>
<td style="text-align:left;">
J Micromech Microeng
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Asbestos Induces Oxidative Stress and Activation of Nrf2 Signaling in Murine Macrophages: Chemopreventive Role of the Synthetic Lignan Secoisolariciresinol Diglucoside (LGM2605).
</td>
<td style="text-align:left;">
Int J Mol Sci
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
A catalogue of treatment and technologies for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Expert Rev Anticancer Ther
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
[Increased risk of mesothelioma and lung cancer among workers exposed to asbestos who could require an anticipated retirement].
</td>
<td style="text-align:left;">
Epidemiol Prev
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
[Proposal of an Italian national protocol of health surveillance for former asbestos workers: an ongoing project].
</td>
<td style="text-align:left;">
Epidemiol Prev
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Icmt inhibition exerts anti-angiogenic and anti-hyperpermeability activities impeding malignant pleural effusion.
</td>
<td style="text-align:left;">
Oncotarget
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Identifying Thoracic Malignancies Through Pleural Fluid Biomarkers: A Predictive Multivariate Model.
</td>
<td style="text-align:left;">
Medicine (Baltimore)
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Pilot and Feasibility Trial Evaluating Immuno-Gene Therapy of Malignant Mesothelioma Using Intrapleural Delivery of Adenovirus-IFNα Combined with Chemotherapy.
</td>
<td style="text-align:left;">
Clin. Cancer Res.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Safety of indwelling pleural catheter use in patients undergoing chemotherapy: a five-year retrospective evaluation.
</td>
<td style="text-align:left;">
BMC Pulm Med
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
A simple “expert system” for morphometric evaluation of cells in pleural effusions.
</td>
<td style="text-align:left;">
Pathol. Res. Pract.
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Diagnostic accuracy of sequential co-registered PET+MR in comparison to PET/CT in local thoracic staging of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Chemokines involved in the early inflammatory response and in pro-tumoral activity in asbestos-exposed workers from an Italian coastal area with territorial clusters of pleural malignant mesothelioma.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Novel Hyaluronan Formulation Enhances the Efficacy of Boron Neutron Capture Therapy for Murine Mesothelioma.
</td>
<td style="text-align:left;">
Anticancer Res.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Computed Tomographic Features of Malignant Peritoneal Mesothelioma.
</td>
<td style="text-align:left;">
Anticancer Res.
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Immune biomarkers PD-1/PD-L1 and TLR3 in malignant pleural mesotheliomas.
</td>
<td style="text-align:left;">
Hum. Pathol.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Advanced epithelioid pleural mesothelioma, long lasting disease stabilization and long term survival with cisplatin-pemetrexed chemotherapy re-challenge: a case report.
</td>
<td style="text-align:left;">
Clin Ter
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Analysis of Gene Expression in 3D Spheroids Highlights a Survival Role for ASS1 in Mesothelioma.
</td>
<td style="text-align:left;">
PLoS ONE
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleural mesothelioma: Case-report of uncommon occupational asbestos exposure in a small furniture industry.
</td>
<td style="text-align:left;">
Int J Occup Med Environ Health
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Histopathology of removed indwelling pleural catheters from patients with malignant pleural diseases.
</td>
<td style="text-align:left;">
Respirology
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[BRCA1 associated protein 1 (BAP1) expression in pleural diffuse malignant mesothelioma: A comparative cytological and histological analyses on 50 patients].
</td>
<td style="text-align:left;">
Ann Pathol
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Simian virus 40 may be associated with developing malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Oncol Lett
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
The management of the diaphragm during radical surgery for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Eur J Cardiothorac Surg
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Impact of induction therapy on postoperative outcome after extrapleural pneumonectomy for malignant pleural mesothelioma: does induction-accelerated hemithoracic radiation increase the surgical risk?
</td>
<td style="text-align:left;">
Eur J Cardiothorac Surg
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Immune response profiling of malignant pleural mesothelioma for diagnostic and prognostic biomarkers.
</td>
<td style="text-align:left;">
Biomarkers
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Pleural mesothelioma in a school teacher: asbestos exposure due to DAS paste].
</td>
<td style="text-align:left;">
Med Lav
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
The role of thoracic surgery in the management of mesothelioma: an expert opinion on the limited evidence.
</td>
<td style="text-align:left;">
Expert Rev Respir Med
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Immunocytochemical utility of claudin-4 versus those of Ber-EP4 and MOC-31 in effusion cytology.
</td>
<td style="text-align:left;">
Diagn. Cytopathol.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Fatal pleural mesothelioma in Japan (2003-2008): evaluation of computed tomography findings.
</td>
<td style="text-align:left;">
Jpn J Radiol
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleural metastasis of malignant thymoma. A pitfall in the CT-diagnosis of pleural mesothelioma.
</td>
<td style="text-align:left;">
Comput Med Imaging Graph
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
An intrapleural administration of zoledronic acid for inoperable malignant mesothelioma patients: a phase I clinical study protocol.
</td>
<td style="text-align:left;">
Springerplus
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Dataset for Reporting of Malignant Mesothelioma of the Pleura or Peritoneum: Recommendations From the International Collaboration on Cancer Reporting (ICCR).
</td>
<td style="text-align:left;">
Arch. Pathol. Lab. Med.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Evaluation of New Biomarkers in the Prediction of Malignant Mesothelioma in Subjects with Environmental Asbestos Exposure.
</td>
<td style="text-align:left;">
Lung
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Primary Malignant Neuroendocrine Tumour of Pleura: First Case Report.
</td>
<td style="text-align:left;">
Case Rep Oncol Med
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Diffuse malignant mesothelioma and synchronous lung cancer: A clinicopathological study of 18 cases.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Brain Metastasis of Pleural Mesothelioma after a Subarachnoid Hemorrhage.
</td>
<td style="text-align:left;">
Intern. Med.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
[Pleural mesothelioma–problems in diagnosis and clinical course in 25 patients].
</td>
<td style="text-align:left;">
Langenbecks Arch Chir
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Deformable medical image registration of pleural cavity for photodynamic therapy by using finite-element based method.
</td>
<td style="text-align:left;">
Proc SPIE Int Soc Opt Eng
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Advances in treatment of mesothelioma.
</td>
<td style="text-align:left;">
Expert Opin Pharmacother
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Pemetrexed Maintenance Therapy Following Bevacizumab-Containing First-Line Chemotherapy in Advanced Malignant Pleural Mesothelioma: A Case Report and Literatures Review.
</td>
<td style="text-align:left;">
Medicine (Baltimore)
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Prognostic value of the lymphocyte-to-monocyte ratio and other inflammatory markers in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Environ Health Prev Med
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
The role of the HGF/Met axis in mesothelioma.
</td>
<td style="text-align:left;">
Biochem. Soc. Trans.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma not related to asbestos exposure: Analytical scanning electron microscopic analysis of 83 cases and comparison with 442 asbestos-related cases.
</td>
<td style="text-align:left;">
Ultrastruct Pathol
</td>
<td style="text-align:left;">
epidemiology
</td>
</tr>
<tr>
<td style="text-align:left;">
A pilot study of volumetric-modulated arc therapy for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J Appl Clin Med Phys
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Localized Malignant Mesothelioma of the Pleura with Hemothorax].
</td>
<td style="text-align:left;">
Kyobu Geka
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Primary papillary serous neoplasia of the peritoneum: a clinicopathologic and ultrastructural study of eight cases.
</td>
<td style="text-align:left;">
Hum. Pathol.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Cytologic Differential Diagnosis of Malignant Mesothelioma and Reactive Mesothelial Cells With FISH Analysis of p16.
</td>
<td style="text-align:left;">
Diagn. Cytopathol.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Chronic mesothelial reaction and toxicity of potassium octatitanate fibers in the pleural cavity in mice and F344 rats.
</td>
<td style="text-align:left;">
Cancer Sci.
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Comparative genetic analysis of a rare synchronous collision tumor composed of malignant pleural mesothelioma and primary pulmonary adenocarcinoma.
</td>
<td style="text-align:left;">
Diagn Pathol
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
A phase Ia/Ib clinical trial of metronomic chemotherapy based on a mathematical model of oral vinorelbine in metastatic non-small cell lung cancer and malignant pleural mesothelioma: rationale and study protocol.
</td>
<td style="text-align:left;">
BMC Cancer
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Multiwalled carbon nanotubes intratracheally instilled into the rat lung induce development of pleural malignant mesothelioma and lung tumors.
</td>
<td style="text-align:left;">
Cancer Sci.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Diffuse neoplastic infiltration of leptomeninges by malignant pleural mesothelioma].
</td>
<td style="text-align:left;">
Recenti Prog Med
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant Mesothelioma Versus Metastatic Carcinoma of the Pleura: A CT Challenge.
</td>
<td style="text-align:left;">
Iran J Radiol
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Pain in Malignant Pleural Mesothelioma: A Prospective Characterization Study.
</td>
<td style="text-align:left;">
Pain Med
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Intrathoracic splenosis - lesson learned: a case report.
</td>
<td style="text-align:left;">
J Cardiothorac Surg
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
BAP1 Immunostain and CDKN2A (p16) FISH Analysis: Clinical Applicability for the Diagnosis of Malignant Mesothelioma in Effusions.
</td>
<td style="text-align:left;">
Diagn. Cytopathol.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Genome-based Mutational Analysis by Next Generation Sequencing in Patients with Malignant Pleural and Peritoneal Mesothelioma.
</td>
<td style="text-align:left;">
Anticancer Res.
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Predictive value of BRCA1 expression on the efficacy of chemotherapy based on anti-microtubule agents: a pooled analysis across different malignancies and agents.
</td>
<td style="text-align:left;">
Ann Transl Med
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Analysis of expression of PTEN/PI3K pathway and programmed cell death ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM).
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Massive chest wall resection and reconstruction for malignant disease.
</td>
<td style="text-align:left;">
Onco Targets Ther
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Overexpression of micro ribonucleic acid-591 inhibits cell proliferation and invasion of malignant pleural mesothelioma cells.
</td>
<td style="text-align:left;">
Thorac Cancer
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Multimodality Imaging Review of Malignant Pleural Mesothelioma Diagnosis and Staging.
</td>
<td style="text-align:left;">
PET Clin
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
A Multimodality Imaging Review of Malignant Pleural Mesothelioma Response Assessment.
</td>
<td style="text-align:left;">
PET Clin
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
The incidence of malignant mesothelioma in Australia, 1947-1980.
</td>
<td style="text-align:left;">
Med. J. Aust.
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Geometric dose prediction model for hemithoracic intensity-modulated radiation therapy in mesothelioma patients with two intact lungs.
</td>
<td style="text-align:left;">
J Appl Clin Med Phys
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Precision immunotherapy; dynamics in the cellular profile of pleural effusions in malignant mesothelioma patients.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Surgical therapy of malignant pleural mesothelioma].
</td>
<td style="text-align:left;">
Chirurg
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
The role of “closed abdomen” hyperthermic intraperitoneal chemotherapy (HIPEC) in the palliative treatment of neoplastic ascites from peritoneal carcinomatosis: report of a single-center experience.
</td>
<td style="text-align:left;">
Support Care Cancer
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Incidence and familial risk of pleural mesothelioma in Sweden: a national cohort study.
</td>
<td style="text-align:left;">
Eur. Respir. J.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Conjunctival Metastasis from Pleural Mesothelioma.
</td>
<td style="text-align:left;">
Ocul Oncol Pathol
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Thoracoscopy in malignant mesothelioma.
</td>
<td style="text-align:left;">
Pneumologie
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Manumycin A induces apoptosis in malignant pleural mesothelioma through regulation of Sp1 and activation of the mitochondria-related apoptotic pathway.
</td>
<td style="text-align:left;">
Oncol. Rep.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
North American Multicenter Volumetric CT Study for Clinical Staging of Malignant Pleural Mesothelioma: Feasibility and Logistics of Setting Up a Quantitative Imaging Study.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Genomic copy number alterations in 33 malignant peritoneal mesothelioma analyzed by comparative genomic hybridization array.
</td>
<td style="text-align:left;">
Hum. Pathol.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Clinical development of TargomiRs, a miRNA mimic-based treatment for patients with recurrent thoracic cancer.
</td>
<td style="text-align:left;">
Epigenomics
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Inhibition of PAI-1 Limits Tumor Angiogenesis Regardless of Angiogenic Stimuli in Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
Cancer Res.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
CTLA-4 in mesothelioma patients: tissue expression, body fluid levels and possible relevance as a prognostic factor.
</td>
<td style="text-align:left;">
Cancer Immunol. Immunother.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
[Clinical Pathological Diagnosis, and Treatment for Pleural Mesothelioma].
</td>
<td style="text-align:left;">
Gan To Kagaku Ryoho
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Are neutrophil/lymphocyte ratio and platelet/lymphocyte ratio reliable parameters as prognostic indicators in malignant mesothelioma?
</td>
<td style="text-align:left;">
Ther Clin Risk Manag
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Use of p16 FISH for differential diagnosis of mesothelioma in smear preparations.
</td>
<td style="text-align:left;">
Diagn. Cytopathol.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Present and future roles of FDG-PET/CT imaging in the management of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Jpn J Radiol
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma in a 17-year old boy: A case report and literature review.
</td>
<td style="text-align:left;">
Respir Med Case Rep
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma: initial experience in integrated (18)F-FDG PET/MR imaging.
</td>
<td style="text-align:left;">
Clin Imaging
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Impact of Age on Long-Term Outcomes of Surgery for Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
Clin Lung Cancer
</td>
<td style="text-align:left;">
treatment | epidemiology | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Metastatic malignant pleural mesothelioma masquerading as a case of acute abdomen secondary to small bowel perforation.
</td>
<td style="text-align:left;">
Ann Saudi Med
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
KCa1.1, a calcium-activated potassium channel subunit alpha 1, is targeted by miR-17-5p and modulates cell migration in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Mol. Cancer
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Diagnosis and prognosis of malignant mesothelioma. A description of 8 clinical cases].
</td>
<td style="text-align:left;">
Minerva Med.
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Risk of second primary cancers after malignant mesothelioma and vice versa.
</td>
<td style="text-align:left;">
Cancer Lett.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
[Drug carrier nanosystems in malignant pleural mesothelioma].
</td>
<td style="text-align:left;">
Tuberk Toraks
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Conventional and high resolution computed tomography in the diagnosis of asbestos-related diseases.
</td>
<td style="text-align:left;">
Radiographics
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Orotate phosphoribosyltransferase is overexpressed in malignant pleural mesothelioma: Dramatically responds one case in high OPRT expression.
</td>
<td style="text-align:left;">
Rare Dis
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Kinesin family members KIF11 and KIF23 as potential therapeutic targets in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Int. J. Oncol.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Asbestos content of lung tissue in patients with malignant peritoneal mesothelioma: A study of 42 cases.
</td>
<td style="text-align:left;">
Ultrastruct Pathol
</td>
<td style="text-align:left;">
epidemiology
</td>
</tr>
<tr>
<td style="text-align:left;">
The Genetic Landscape of Malignant Pleural Mesothelioma: Results from Massively Parallel Sequencing.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
The Third Italian Consensus Conference for Malignant Pleural Mesothelioma: State of the art and recommendations.
</td>
<td style="text-align:left;">
Crit. Rev. Oncol. Hematol.
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Effect of renal function on pemetrexed-induced haematotoxicity.
</td>
<td style="text-align:left;">
Cancer Chemother. Pharmacol.
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Synergistic anti-tumor efficacy of immunogenic adenovirus ONCOS-102 (Ad5/3-D24-GM-CSF) and standard of care chemotherapy in preclinical mesothelioma model.
</td>
<td style="text-align:left;">
Int. J. Cancer
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Circulating activin A is a novel prognostic biomarker in malignant pleural mesothelioma - A multi-institutional study.
</td>
<td style="text-align:left;">
Eur. J. Cancer
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Moving Immune Checkpoint Blockade in Thoracic Tumors beyond NSCLC.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Localized malignant pleural sarcomatoid mesothelioma misdiagnosed as benign localized fibrous tumor.
</td>
<td style="text-align:left;">
J Thorac Dis
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Nanoparticle-based targeted gene therapy for lung cancer.
</td>
<td style="text-align:left;">
Am J Cancer Res
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Antitumor effect of novel anti-podoplanin antibody NZ-12 against malignant pleural mesothelioma in an orthotopic xenograft model.
</td>
<td style="text-align:left;">
Cancer Sci.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Applications of Magnetic Resonance Imaging of the Thorax in Pleural Diseases: A State-of-the-Art Review.
</td>
<td style="text-align:left;">
Lung
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Role of respiratory-triggered diffusion-weighted MRI in the assessment of pleural disease.
</td>
<td style="text-align:left;">
Br J Radiol
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Spinal cord ischaemia after radical pleurectomy/decortication operation for mesothelioma.
</td>
<td style="text-align:left;">
Eur J Cardiothorac Surg
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
A longitudinal study of the hyaluronan level in the serum of patients with malignant mesothelioma under treatment. Hyaluronan as an indicator of progressive disease.
</td>
<td style="text-align:left;">
Cancer
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Circulating epigenetic biomarkers in lung malignancies: From early diagnosis to therapy.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleural fluid infection caused by Dietzia cinnamea.
</td>
<td style="text-align:left;">
Diagn. Microbiol. Infect. Dis.
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
A phase II study of vincristine in malignant mesothelioma–a negative report.
</td>
<td style="text-align:left;">
Cancer Chemother. Pharmacol.
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Reduction of estradiol in human malignant pleural mesothelioma tissues may prevent tumour growth, as implied by in in-vivo and in-vitro models.
</td>
<td style="text-align:left;">
Oncotarget
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Comments on the Causation of Malignant Mesothelioma: Rebutting the False Concept That Recent Exposures to Asbestos Do Not Contribute to Causation of Mesothelioma.
</td>
<td style="text-align:left;">
Ann Glob Health
</td>
<td style="text-align:left;">
epidemiology
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant Mesothelioma in a Motor Vehicle Mechanic.
</td>
<td style="text-align:left;">
New Solut
</td>
<td style="text-align:left;">
epidemiology
</td>
</tr>
<tr>
<td style="text-align:left;">
Phase II Study of Hemithoracic Intensity-Modulated Pleural Radiation Therapy (IMPRINT) As Part of Lung-Sparing Multimodality Therapy in Patients With Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
J. Clin. Oncol.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Comorbidity, postoperative morbidity and survival in patients undergoing radical surgery for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Eur J Cardiothorac Surg
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Prophylactic radiotherapy for the prevention of procedure-tract metastases after surgical and large-bore pleural procedures in malignant pleural mesothelioma (SMART): a multicentre, open-label, phase 3, randomised controlled trial.
</td>
<td style="text-align:left;">
Lancet Oncol.
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Positive response of a primary malignant pericardial mesothelioma to pemetrexed plus cisplatin followed by pemetrexed maintenance chemotherapy: A case report.
</td>
<td style="text-align:left;">
Oncol Lett
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Angiogenesis correlates with macrophage and mast cell infiltration in lung tissue of animals exposed to fluoro-edenite fibers.
</td>
<td style="text-align:left;">
Exp. Cell Res.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
[Thoracoscopy using flexible fiberoptic bronchoscopy–a preliminary report of experimental and clinical studies].
</td>
<td style="text-align:left;">
Zhonghua Nei Ke Za Zhi
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
A case of pseudoachalasia hiding a malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Tumori
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Usefulness of Aquaporin 1 as a Prognostic Marker in a Prospective Cohort of Malignant Mesotheliomas.
</td>
<td style="text-align:left;">
Int J Mol Sci
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Low Merlin expression and high Survivin labeling index are indicators for poor prognosis in patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Mol Oncol
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Protocol of the Australasian Malignant Pleural Effusion-2 (AMPLE-2) trial: a multicentre randomised study of aggressive versus symptom-guided drainage via indwelling pleural catheters.
</td>
<td style="text-align:left;">
BMJ Open
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Multidetector CT Findings and Differential Diagnoses of Malignant Pleural Mesothelioma and Metastatic Pleural Diseases in Korea.
</td>
<td style="text-align:left;">
Korean J Radiol
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
P2X7 targeting inhibits growth of human mesothelioma.
</td>
<td style="text-align:left;">
Oncotarget
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
HMGB1 overexpression as a prognostic factor for survival in cancer: a meta-analysis and systematic review.
</td>
<td style="text-align:left;">
Oncotarget
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Dasatinib modulates sensitivity to pemetrexed in malignant pleural mesothelioma cell lines.
</td>
<td style="text-align:left;">
Oncotarget
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
c-Met expression and MET amplification in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Ann Diagn Pathol
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
A Biphasic Pleural Tumor with Features of an Epithelioid and Small Cell Mesothelioma: Morphologic and Molecular Findings.
</td>
<td style="text-align:left;">
Case Rep Pathol
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Diagnostic efficacy of electron microscopy and pleural effusion cytology for the distinction of pleural mesothelioma and lung adenocarcinoma.
</td>
<td style="text-align:left;">
Ultrastruct Pathol
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
NCCN Guidelines Insights: Malignant Pleural Mesothelioma, Version 3.2016.
</td>
<td style="text-align:left;">
J Natl Compr Canc Netw
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
MicroRNA gene expression signatures in long-surviving malignant pleural mesothelioma patients.
</td>
<td style="text-align:left;">
Genom Data
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Safety and Complications of Medical Thoracoscopy.
</td>
<td style="text-align:left;">
Adv Med
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleural Effusions from Patients with Mesothelioma Induce Recruitment of Monocytes and Their Differentiation into M2 Macrophages.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleural Effusion of Patients with Malignant Mesothelioma Induces Macrophage-Mediated T Cell Suppression.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Cochrane corner: interventions for the management of malignant pleural effusions.
</td>
<td style="text-align:left;">
Thorax
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma with lacrimal gland metastasis.
</td>
<td style="text-align:left;">
Acta Ophthalmol
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
BRCA1-Associated Protein 1 (BAP1) Immunohistochemical Expression as a Diagnostic Tool in Malignant Pleural Mesothelioma Classification: A Large Retrospective Study.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Current Treatment of Mesothelioma: Extrapleural Pneumonectomy Versus Pleurectomy/Decortication.
</td>
<td style="text-align:left;">
Thorac Surg Clin
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
New therapeutic strategies for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Biochem. Pharmacol.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Silencing Receptor EphA2 Enhanced Sensitivity to Lipoplatin™ in Lung Tumor and MPM Cells.
</td>
<td style="text-align:left;">
Cancer Invest.
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
A Histomorphologic Grading System That Predicts Overall Survival in Diffuse Malignant Peritoneal Mesothelioma With Epithelioid Subtype.
</td>
<td style="text-align:left;">
Am. J. Surg. Pathol.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
A case report of metastasis of malignant mesothelioma to the retromolar trigone.
</td>
<td style="text-align:left;">
World J Surg Oncol
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Combination of cisplatin and lurbinectedin as palliative chemotherapy in progressive malignant pleural mesothelioma: Report of two cases.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Flow cytometric analysis of malignant pleural mesotheliomas.
</td>
<td style="text-align:left;">
Hum. Pathol.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Positive nuclear BAP1 immunostaining helps differentiate non-small cell lung carcinomas from malignant mesothelioma.
</td>
<td style="text-align:left;">
Oncotarget
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
A Phase II Study of PF-03446962 in Patients with Advanced Malignant Pleural Mesothelioma. CCTG Trial IND.207.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Inhibition of the Polyamine Synthesis Pathway Is Synthetically Lethal with Loss of Argininosuccinate Synthase 1.
</td>
<td style="text-align:left;">
Cell Rep
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Updated mortality study of a cohort of asbestos textile workers.
</td>
<td style="text-align:left;">
Cancer Med
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
MR imaging of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J Comput Assist Tomogr
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Management of malignant pleural mesothelioma-part 2: therapeutic approaches : Consensus of the Austrian Mesothelioma Interest Group (AMIG).
</td>
<td style="text-align:left;">
Wien. Klin. Wochenschr.
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Management of malignant pleural mesothelioma - part 3 : Data from the Austrian Mesothelioma Interest Group (AMIG) database.
</td>
<td style="text-align:left;">
Wien. Klin. Wochenschr.
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma incidence by nation-wide cancer registry: a population-based study.
</td>
<td style="text-align:left;">
J Occup Med Toxicol
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
[Not Available].
</td>
<td style="text-align:left;">
Med Lav
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Pathology reporting of malignant pleural mesothelioma first diagnosis: A population-based approach.
</td>
<td style="text-align:left;">
Pathol. Res. Pract.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Recurrent hydropneumothorax: An unusual presentation for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Respir Med Case Rep
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
[Health damage caused by asbestos and other mineral fibers].
</td>
<td style="text-align:left;">
Tidsskr. Nor. Laegeforen.
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleural irregularities and mediastinal pleural involvement in early stages of malignant pleural mesothelioma and benign asbestos pleural effusion.
</td>
<td style="text-align:left;">
Eur J Radiol
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Early recognition of lung cancer in workers occupationally exposed to asbestos].
</td>
<td style="text-align:left;">
Radiologe
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Genomic Landscape of Malignant Mesotheliomas.
</td>
<td style="text-align:left;">
Mol. Cancer Ther.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Potent efficacy signals from systemically administered oncolytic herpes simplex virus (HSV1716) in hepatocellular carcinoma xenograft models.
</td>
<td style="text-align:left;">
J Hepatocell Carcinoma
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Calpeptin Prevents Malignant Pleural Mesothelioma Cell Proliferation via the Angiopoietin1/Tie2 System.
</td>
<td style="text-align:left;">
Asian Pac. J. Cancer Prev.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Sarcomatous tumor of the chest wall with osteochondroid differentiation. Evidence of mesothelial origin.
</td>
<td style="text-align:left;">
Am. J. Surg. Pathol.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Trabectedin Is Active against Malignant Pleural Mesothelioma Cell and Xenograft Models and Synergizes with Chemotherapy and Bcl-2 Inhibition In Vitro.
</td>
<td style="text-align:left;">
Mol. Cancer Ther.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Medical thoracoscopy: Analysis on diagnostic yield through 30 years of experience.
</td>
<td style="text-align:left;">
Ann Thorac Med
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Quercetin and Cisplatin combined treatment altered cell cycle and mitogen activated protein kinase expressions in malignant mesotelioma cells.
</td>
<td style="text-align:left;">
BMC Complement Altern Med
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Alveolar-filling growth pattern of sarcomatoid malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Respirol Case Rep
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Evaluation of predictive value of pleural CEA in patients with pleural effusions and histological findings: A prospective study and literature review.
</td>
<td style="text-align:left;">
Clin. Biochem.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Treatment offers hope in mesothelioma.
</td>
<td style="text-align:left;">
Nurs Stand
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
KDM6B histone demethylase is an epigenetic regulator of estrogen receptor β expression in human pleural mesothelioma.
</td>
<td style="text-align:left;">
Epigenomics
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Pembrolizumab-associated minimal change disease in a patient with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
BMC Cancer
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Co-existing tuberculosis and malignant mesothelioma with multiple sites venous thrombosis: a case report.
</td>
<td style="text-align:left;">
BMC Res Notes
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Comparison of SKIP expression in malignant pleural mesotheliomas with Ki-67 proliferation index and prognostic parameters.
</td>
<td style="text-align:left;">
Pol J Pathol
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant Mesothelioma Effusions Are Infiltrated by CD3<sup>+</sup> T Cells Highly Expressing PD-L1 and the PD-L1<sup>+</sup> Tumor Cells within These Effusions Are Susceptible to ADCC by the Anti-PD-L1 Antibody Avelumab.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural fluid from mesothelioma has potent biological activities.
</td>
<td style="text-align:left;">
Respirology
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
The Role of 18F-FDG PET/CT Integrated Imaging in Distinguishing Malignant from Benign Pleural Effusion.
</td>
<td style="text-align:left;">
PLoS ONE
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Low homozygous/high heterozygous deletion status by p16 FISH correlates with a better prognostic group than high homozygous deletion status in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Metformin and survival of people with type 2 diabetes and pleural mesothelioma: A population-based retrospective cohort study.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Arginine Deprivation With Pegylated Arginine Deiminase in Patients With Argininosuccinate Synthetase 1-Deficient Malignant Pleural Mesothelioma: A Randomized Clinical Trial.
</td>
<td style="text-align:left;">
JAMA Oncol
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Erratum: Multidetector CT Findings and Differential Diagnoses of Malignant Pleural Mesothelioma and Metastatic Pleural Diseases in Korea.
</td>
<td style="text-align:left;">
Korean J Radiol
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Promising in vivo efficacy of the BET bromodomain inhibitor OTX015/MK-8628 in malignant pleural mesothelioma xenografts.
</td>
<td style="text-align:left;">
Int. J. Cancer
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
A Multicenter Study of Volumetric Computed Tomography for Staging Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
Ann. Thorac. Surg.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
How does the timing of chemotherapy affect outcome following radical surgery for malignant pleural mesothelioma?
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma of the pleura with desmoplastic histology: a case series and literature review.
</td>
<td style="text-align:left;">
BMC Cancer
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant Pleural Mesotheliomas].
</td>
<td style="text-align:left;">
Zentralbl Chir
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
BAP1 immunohistochemistry and p16 FISH results in combination provide higher confidence in malignant pleural mesothelioma diagnosis: ROC analysis of the two tests.
</td>
<td style="text-align:left;">
Pathol. Int.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Management of malignant pleural mesothelioma - part 1: epidemiology, diagnosis, and staging : Consensus of the Austrian Mesothelioma Interest Group (AMIG).
</td>
<td style="text-align:left;">
Wien. Klin. Wochenschr.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Validation of EORTC and CALGB prognostic models in surgical patients submitted to diagnostic, palliative or curative surgery for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Dis
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
PI3 Kinase Pathway and MET Inhibition is Efficacious in Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
Sci Rep
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
The cytology of malignant mesothelioma in Western Australia.
</td>
<td style="text-align:left;">
Acta Cytol.
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma in western Glasgow 1980-6.
</td>
<td style="text-align:left;">
Thorax
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Mesotheliomas in Lebanon: Witnessing a Change in Epidemiology.
</td>
<td style="text-align:left;">
Asian Pac. J. Cancer Prev.
</td>
<td style="text-align:left;">
treatment | epidemiology | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Serum mesothelin, osteopontin and vimentin: useful markers for clinical monitoring of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Int. J. Biol. Markers
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
The NLRP3 inflammasome in pathogenic particle and fibre-associated lung inflammation and diseases.
</td>
<td style="text-align:left;">
Part Fibre Toxicol
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Intensity-modulated radiotherapy for relapsed malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Future Oncol
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Diagnostic value of monoclonal antibody B72.3 in detecting adenocarcinoma cells in serous effusions.
</td>
<td style="text-align:left;">
APMIS
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Biphasic Malignant Pleural Mesothelioma Masquerading as a Primary Skeletal Tumor.
</td>
<td style="text-align:left;">
Case Rep Pulmonol
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Detection of malignant pleural mesothelioma in exhaled breath by multicapillary column/ion mobility spectrometry (MCC/IMS).
</td>
<td style="text-align:left;">
J Breath Res
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
The IASLC Mesothelioma Staging Project: Improving Staging of a Rare Disease Through International Participation.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Mesothelioma in South Africa, 1976-84: incidence and case characteristics.
</td>
<td style="text-align:left;">
Int J Epidemiol
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Geographical patterns of mesothelioma incidence and asbestos exposure in Lombardy, Italy.
</td>
<td style="text-align:left;">
Med Lav
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Patient-Derived Xenograft Establishment from Human Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
Clin. Cancer Res.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
First reported finding of a Malignant Pleural Mesothelioma in a patient post Liver Transplant.
</td>
<td style="text-align:left;">
Ir Med J
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
The IASLC Mesothelioma Staging Project: Proposals for the M Descriptors and for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
The IASLC Mesothelioma Staging Project: Proposals for Revisions of the T Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Pleural Mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
The IASLC Mesothelioma Staging Project: Proposals for Revisions of the N Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Pleural Mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Targeting the vasculature: anti-angiogenic agents for malignant mesothelioma.
</td>
<td style="text-align:left;">
Expert Rev Anticancer Ther
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Screening of Pleural Mesotheliomas for DNA-damage Repair Players by Digital Gene Expression Analysis Can Enhance Clinical Management of Patients Receiving Platin-Based Chemotherapy.
</td>
<td style="text-align:left;">
J Cancer
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Membranous nephropathy associated with malignant pleural mesothelioma in an adult patient: A case report.
</td>
<td style="text-align:left;">
Mol Clin Oncol
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Rare presentation of a localised malignant pleural mesothelioma with cranial metastasis.
</td>
<td style="text-align:left;">
BMJ Case Rep
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Five years update on relationships between malignant pleural mesothelioma and exposure to asbestos and other elongated mineral particles.
</td>
<td style="text-align:left;">
J Toxicol Environ Health B Crit Rev
</td>
<td style="text-align:left;">
treatment | epidemiology | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Tyler asbestos workers: A mortality update in a cohort exposed to amosite.
</td>
<td style="text-align:left;">
J Toxicol Environ Health B Crit Rev
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Epithelioid peritoneal mesothelioma: a hybrid phenotype within a mesenchymal-epithelial/epithelial-mesenchymal transition framework.
</td>
<td style="text-align:left;">
Oncotarget
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Glycodelin is a potential novel follow-up biomarker for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Oncotarget
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Pulmonary tumor diagnosed as an undifferentiated sarcoma with epithelioid features: a case report.
</td>
<td style="text-align:left;">
J Med Case Rep
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Circulating microRNAs found dysregulated in ex-exposed asbestos workers and pleural mesothelioma patients as potential new biomarkers.
</td>
<td style="text-align:left;">
Oncotarget
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
MicroRNA-302b targets Mcl-1 and inhibits cell proliferation and induces apoptosis in malignant pleural mesothelioma cells.
</td>
<td style="text-align:left;">
Am J Cancer Res
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Optimal gross tumor volume definition in lung-sparing intensity modulated radiotherapy for pleural mesothelioma: an in silico study.
</td>
<td style="text-align:left;">
Acta Oncol
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Systemically Administered RNAi Molecule Sensitizes Malignant Pleural Mesotheliomal Cells to Pemetrexed Therapy.
</td>
<td style="text-align:left;">
Mol. Pharm.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Management of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Thorac Cancer
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma: A retrospective analysis of clinicopathological and survival data.
</td>
<td style="text-align:left;">
Thorac Cancer
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
The Role of CD90 in the Differential Diagnosis of Pleural Malignant Mesothelioma, Pulmonary Carcinoma and Comparison with Calretının.
</td>
<td style="text-align:left;">
Pathol. Oncol. Res.
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
[National epidemiological surveillance systems of mesothelioma cases].
</td>
<td style="text-align:left;">
Epidemiol Prev
</td>
<td style="text-align:left;">
epidemiology
</td>
</tr>
<tr>
<td style="text-align:left;">
Amount of Epithelioid Differentiation Is a Predictor of Survival in Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
Ann. Thorac. Surg.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Ultrastructural histochemistry of mesotheliomas and adenocarcinomas in malignant effusions.
</td>
<td style="text-align:left;">
Diagn. Cytopathol.
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Relation between neutrophil/lymphocyte ratio and primary tumor metabolic activity in patients with malign pleural mesothelioma.
</td>
<td style="text-align:left;">
Clin Respir J
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Diagnostic value of fibulin-3 for malignant pleural mesothelioma: A systematic review and meta-analysis.
</td>
<td style="text-align:left;">
Oncotarget
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
BAP1 immunohistochemistry has limited prognostic utility as a complement of CDKN2A (p16) fluorescence in situ hybridization in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Hum. Pathol.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Polyanionic Biopolymers for the Delivery of Pt(II) Cationic Antiproliferative Complexes.
</td>
<td style="text-align:left;">
Bioinorg Chem Appl
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Current best practice in the evaluation and management of malignant pleural effusions.
</td>
<td style="text-align:left;">
Ther Adv Respir Dis
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Calretinin but not caveolin-1 correlates with tumour histology and survival in malignant mesothelioma.
</td>
<td style="text-align:left;">
Pathology
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Vascular endothelial growth factor promoter-based conditionally replicative adenoviruses effectively suppress growth of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Cancer Sci.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Tamoxifen Suppresses the Growth of Malignant Pleural Mesothelioma Cells.
</td>
<td style="text-align:left;">
Anticancer Res.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Imaging in pleural mesothelioma: A review of the 13th International Conference of the International Mesothelioma Interest Group.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Myxoid variant epithelioid pleural mesothelioma defines a favourable prognosis group: an analysis of 191 patients with pleural malignant mesothelioma.
</td>
<td style="text-align:left;">
J. Clin. Pathol.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Sarcomatoid Type Primary Pericardial Mesothelioma with a Long-term Survival after the Onset of Cardiac Tamponade.
</td>
<td style="text-align:left;">
Intern. Med.
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
In Vitro and In Vivo Antitumor Activity of [Pt(O,O’-acac)(γ-acac)(DMS)] in Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
PLoS ONE
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Genomic profiling of malignant peritoneal mesothelioma reveals recurrent alterations in epigenetic regulatory genes BAP1, SETD2, and DDX3X.
</td>
<td style="text-align:left;">
Mod. Pathol.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Update on epidemiology, pathophysiology, diagnosis and treatment of malignant pleural mesothelioma].
</td>
<td style="text-align:left;">
Rev Med Inst Mex Seguro Soc
</td>
<td style="text-align:left;">
diagnosis | treatment | epidemiology | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Residual fibre lung burden among patients with pleural mesothelioma who have been occupationally exposed to asbestos.
</td>
<td style="text-align:left;">
Occup Environ Med
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Mesothelioma in the United States: a Surveillance, Epidemiology, and End Results (SEER)-Medicare investigation of treatment patterns and overall survival.
</td>
<td style="text-align:left;">
Clin Epidemiol
</td>
<td style="text-align:left;">
diagnosis | treatment | epidemiology
</td>
</tr>
<tr>
<td style="text-align:left;">
Mortality among employees of an Ontario factory that manufactured construction materials using chrysotile asbestos and coal tar pitch.
</td>
<td style="text-align:left;">
Am. J. Ind. Med.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
The resistance related to targeted therapy in malignant pleural mesothelioma: Why has not the target been hit yet?
</td>
<td style="text-align:left;">
Crit. Rev. Oncol. Hematol.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Extended Pleurectomy-Decortication-Based Treatment for Advanced Stage Epithelial Mesothelioma Yielding a Median Survival of Nearly Three Years.
</td>
<td style="text-align:left;">
Ann. Thorac. Surg.
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Intrapleural Adenoviral-mediated Endothelial Cell Protein C Receptor Gene Transfer Suppresses the Progression of Malignant Pleural Mesothelioma in a Mouse Model.
</td>
<td style="text-align:left;">
Sci Rep
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma and mesothelial hyperplasia: A new molecular tool for the differential diagnosis.
</td>
<td style="text-align:left;">
Oncotarget
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
SORORIN and PLK1 as potential therapeutic targets in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Int. J. Oncol.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
3D Mass Spectrometry Imaging Reveals a Very Heterogeneous Drug Distribution in Tumors.
</td>
<td style="text-align:left;">
Sci Rep
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
FAS and FASL genetic polymorphisms impact on clinical outcome of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Onco Targets Ther
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Cytotoxic T Cells in PD-L1-Positive Malignant Pleural Mesotheliomas Are Counterbalanced by Distinct Immunosuppressive Factors.
</td>
<td style="text-align:left;">
Cancer Immunol Res
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Lysis of human malignant mesothelioma cells by natural killer (NK) and lymphokine-activated killer (LAK) cells.
</td>
<td style="text-align:left;">
Am. Rev. Respir. Dis.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Trametinib plus 4-Methylumbelliferone Exhibits Antitumor Effects by ERK Blockade and CD44 Downregulation and Affects PD-1 and PD-L1 in Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Accelerated cell cycle progression of human regulatory T cell-like cell line caused by continuous exposure to asbestos fibers.
</td>
<td style="text-align:left;">
Int. J. Oncol.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Diagnostic Utility of Pleural Fluid Cell Block versus Pleural Biopsy Collected by Flex-Rigid Pleuroscopy for Malignant Pleural Disease: A Single Center Retrospective Analysis.
</td>
<td style="text-align:left;">
PLoS ONE
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Elevated aspartate aminotransferase and monocyte counts predict unfavorable prognosis in patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Neoplasma
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Diagnostic and Prognostic Biomarkers in the Rational Assessment of Mesothelioma (DIAPHRAGM) study: protocol of a prospective, multicentre, observational study.
</td>
<td style="text-align:left;">
BMJ Open
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Indomethacin augments lymphokine-activated killer cell generation by patients with malignant mesothelioma.
</td>
<td style="text-align:left;">
Clin. Immunol. Immunopathol.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Fluoro-edenite induces fibulin-3 overexpression in non-malignant human mesothelial cells.
</td>
<td style="text-align:left;">
Oncol Lett
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Primary malignant pericardial mesothelioma with increased serum mesothelin diagnosed by surgical pericardial resection: A case report.
</td>
<td style="text-align:left;">
Mol Clin Oncol
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma: an update on investigation, diagnosis and treatment.
</td>
<td style="text-align:left;">
Eur Respir Rev
</td>
<td style="text-align:left;">
diagnosis | treatment | epidemiology | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
A specific inhibitor of lactate dehydrogenase overcame the resistance toward gemcitabine in hypoxic mesothelioma cells, and modulated the expression of the human equilibrative transporter-1.
</td>
<td style="text-align:left;">
Nucleosides Nucleotides Nucleic Acids
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Characterization of three human malignant mesothelioma cell lines.
</td>
<td style="text-align:left;">
Cancer Genet. Cytogenet.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Giant primary malignant mesothelioma of the liver: A case report.
</td>
<td style="text-align:left;">
Int J Surg Case Rep
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Serum-dependent growth patterns of two, newly established human mesothelioma cell lines.
</td>
<td style="text-align:left;">
Cancer Res.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Disease mapping of zero-excessive mesothelioma data in Flanders.
</td>
<td style="text-align:left;">
Ann Epidemiol
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Lung asbestos burden in shipyard and construction workers with mesothelioma: comparison with burdens in subjects with asbestosis or lung cancer.
</td>
<td style="text-align:left;">
Environ. Res.
</td>
<td style="text-align:left;">
epidemiology
</td>
</tr>
<tr>
<td style="text-align:left;">
Chest wall resection for mesothelioma recurrence after surgery.
</td>
<td style="text-align:left;">
Asian Cardiovasc Thorac Ann
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Extrapleural Pneumonectomy for Malignant Pleural Mesothelioma: A Novel Mini-Invasive Technique.
</td>
<td style="text-align:left;">
Innovations (Phila)
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
A Comparison of Singlet Oxygen Explicit Dosimetry (SOED) and Singlet Oxygen Luminescence Dosimetry (SOLD) for Photofrin-Mediated Photodynamic Therapy.
</td>
<td style="text-align:left;">
Cancers (Basel)
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
The evolution of the diminishing role of extrapleural pneumonectomy in the surgical management of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Onco Targets Ther
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
The role of surgical intervention in lung cancer with carcinomatous pleuritis.
</td>
<td style="text-align:left;">
J Thorac Dis
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[A case of mesothelioma of the pleura with pneumothorax].
</td>
<td style="text-align:left;">
Kyobu Geka
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Open access phone triage for veterans with suspected malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J. Surg. Res.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Percutaneous Cryoablation for the Treatment of Recurrent Malignant Pleural Mesothelioma: Safety, Early-Term Efficacy, and Predictors of Local Recurrence.
</td>
<td style="text-align:left;">
J Vasc Interv Radiol
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Loss of BRCA1-associated protein 1 (BAP1) expression is rare in non-small cell lung cancer.
</td>
<td style="text-align:left;">
Hum. Pathol.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Signal Transducer and Activator of Transcription 1 (STAT1) Knock-down Induces Apoptosis in Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
Pathol. Oncol. Res.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Minimal change disease associated with malignant pleural mesothelioma: case report and review of the literature.
</td>
<td style="text-align:left;">
BMJ Case Rep
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Advances in pleuroscopy.
</td>
<td style="text-align:left;">
Clin Respir J
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Heterogeneity of paclitaxel distribution in different tumor models assessed by MALDI mass spectrometry imaging.
</td>
<td style="text-align:left;">
Sci Rep
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Distinction between mesothelioma and lung adenocarcinoma based on immunohistochemistry in a patient with asbestos bodies in bronchoalveolar fluid - case report.
</td>
<td style="text-align:left;">
Rom J Morphol Embryol
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Co-occurring Mutations of Tumor Suppressor Genes, <i>LATS2</i> and <i>NF2</i>, in Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
Clin. Cancer Res.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Usefulness of Thoracoscopic Debridement for Chronic Empyema after an Extrapleural Pneumonectomy.
</td>
<td style="text-align:left;">
Acta Med. Okayama
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Pericardial Effusion due to Primary Malignant Pericardial Mesothelioma: A Common Finding but an Uncommon Cause.
</td>
<td style="text-align:left;">
Case Rep Med
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant Mesothelioma Biomarkers: From Discovery to Use in Clinical Practice for Diagnosis, Monitoring, Screening, and Treatment.
</td>
<td style="text-align:left;">
Chest
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Improving the Accuracy of Mesothelioma Diagnosis in China.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
The importance of EZH2 and MOC-31 expression in the differential diagnosis of benign and malignant effusions.
</td>
<td style="text-align:left;">
Diagn. Cytopathol.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
The diagnostic performance of routinely acquired and reported computed tomography imaging in patients presenting with suspected pleural malignancy.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Incidence of malignant mesothelioma in Germany 2009-2013.
</td>
<td style="text-align:left;">
Cancer Causes Control
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Deciduoid mesothelioma of the thorax: A comprehensive review of the scientific literature.
</td>
<td style="text-align:left;">
Clin Respir J
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Prognostic value of pretreatment volume-based quantitative <sup>18</sup>F-FDG PET/CT parameters in patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Eur J Radiol
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Metabolic response assessment with 18F-FDG-PET/CT is superior to modified RECIST for the evaluation of response to platinum-based doublet chemotherapy in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Eur J Radiol
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Giant benign mesothelioma.
</td>
<td style="text-align:left;">
Ann. Thorac. Surg.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Computer-aided volumetric assessment of malignant pleural mesothelioma on CT using a random walk-based method.
</td>
<td style="text-align:left;">
Int J Comput Assist Radiol Surg
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Pemetrexed for epithelioid haemangioendothelioma of the pleura.
</td>
<td style="text-align:left;">
Respirol Case Rep
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
BAP1 Is Altered by Copy Number Loss, Mutation, and/or Loss of Protein Expression in More Than 70% of Malignant Peritoneal Mesotheliomas.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
<td style="text-align:left;">
diagnosis | treatment | epidemiology | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Usefulness of p16/CDKN2A fluorescence in situ hybridization and BAP1 immunohistochemistry for the diagnosis of biphasic mesothelioma.
</td>
<td style="text-align:left;">
Ann Diagn Pathol
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Chromosomal abnormalities and their correlations with asbestos exposure and survival in patients with mesothelioma.
</td>
<td style="text-align:left;">
Br. J. Cancer
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Immune Checkpoints Aberrations and Malignant Mesothelioma: Assessment of Prognostic Value and Evaluation of Therapeutic Potentials.
</td>
<td style="text-align:left;">
Anticancer Agents Med Chem
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Role of postoperative radiotherapy in the management of malignant pleural mesothelioma : A propensity score matching of the SEER database.
</td>
<td style="text-align:left;">
Strahlenther Onkol
</td>
<td style="text-align:left;">
treatment | epidemiology | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleural mesothelioma–analysis of 12 cases in Chang-Gung Memorial Hospital.
</td>
<td style="text-align:left;">
Changgeng Yi Xue Za Zhi
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleural Mesothelioma with No Asbestos Exposure: A Case Report.
</td>
<td style="text-align:left;">
J Clin Diagn Res
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Mesothelioma and interferon-γ-dependent chemokine IP-10.
</td>
<td style="text-align:left;">
Clin Ter
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Turning back the Wheel: Inducing Mesenchymal to Epithelial Transition via Wilms Tumor 1 Knockdown in Human Mesothelioma Cell Lines to Influence Proliferation, Invasiveness, and Chemotaxis.
</td>
<td style="text-align:left;">
Pathol. Oncol. Res.
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Flex-rigid pleuroscopic biopsy with the SB knife Jr is a novel technique for diagnosis of malignant or benign fibrothorax.
</td>
<td style="text-align:left;">
J Thorac Dis
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Asbestos fibres detected by scanning electron microscopy in the gallbladder of patients with malignant pleural mesothelioma (MPM).
</td>
<td style="text-align:left;">
J Microsc
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Blockage of epithelial to mesenchymal transition and upregulation of let 7b are critically involved in ursolic acid induced apoptosis in malignant mesothelioma cell.
</td>
<td style="text-align:left;">
Int. J. Biol. Sci.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Problems of diagnosis and surgical treatment in pleural mesothelioma].
</td>
<td style="text-align:left;">
Nihon Kyobu Geka Gakkai Zasshi
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Diagnostic and prognostic utilities of humoral fibulin-3 in malignant pleural mesothelioma: Evidence from a meta-analysis.
</td>
<td style="text-align:left;">
Oncotarget
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Small bowel metastasis from pancreatic cancer in a long-term survival patient with synchronous advanced malignant pleural mesothelioma: A case report and literature review.
</td>
<td style="text-align:left;">
Oncol Lett
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
[Prognostic factors in cases of diffuse malignant pleural mesothelioma].
</td>
<td style="text-align:left;">
Nihon Kyobu Shikkan Gakkai Zasshi
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleural fluid cytology samples in cases of suspected lung cancer: An experience from a tertiary care centre.
</td>
<td style="text-align:left;">
Diagn. Cytopathol.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Long-term outcomes of intensity-modulated radiotherapy following extra-pleural pneumonectomy for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Acta Oncol
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Identification of MiR-21-5p as a Functional Regulator of Mesothelin Expression Using MicroRNA Capture Affinity Coupled with Next Generation Sequencing.
</td>
<td style="text-align:left;">
PLoS ONE
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
MUC4, a novel immunohistochemical marker identified by gene expression profiling, differentiates pleural sarcomatoid mesothelioma from lung sarcomatoid carcinoma.
</td>
<td style="text-align:left;">
Mod. Pathol.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pericardial mesothelioma : A systematic review of current practice.
</td>
<td style="text-align:left;">
Herz
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant Pleural Mesothelioma with Excessive Inflammation and High Level of Interleukin 6 - A Case Report].
</td>
<td style="text-align:left;">
Gan To Kagaku Ryoho
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
A Single-Institution Experience in Percutaneous Image-Guided Biopsy of Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
Cardiovasc Intervent Radiol
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Geographic and socioeconomic factors in patients with malignant pleural mesothelioma in New South Wales and their impact upon clinical outcomes.
</td>
<td style="text-align:left;">
Respirology
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Clinical Experience With Pemetrexed in Breast Cancer.
</td>
<td style="text-align:left;">
Semin. Oncol.
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
[Soft tissue tumors of the lung and pleura].
</td>
<td style="text-align:left;">
Tidsskr. Nor. Laegeforen.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Tissue transglutaminase (TG2) enables survival of human malignant pleural mesothelioma cells in hypoxia.
</td>
<td style="text-align:left;">
Cell Death Dis
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Stent Implantation for Superior Vena Cava Syndrome of Malignant Cause.
</td>
<td style="text-align:left;">
Rofo
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Paclitaxel-releasing mesenchymal stromal cells inhibit in vitro proliferation of human mesothelioma cells.
</td>
<td style="text-align:left;">
Biomed. Pharmacother.
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Pemetrexed-related interstitial lung disease reported from post marketing surveillance (malignant pleural mesothelioma/non-small cell lung cancer).
</td>
<td style="text-align:left;">
Jpn. J. Clin. Oncol.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Two Case Reports of Benign Testicular Mesothelioma and Review of the Literature.
</td>
<td style="text-align:left;">
Case Rep Oncol Med
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Prognostication and monitoring of mesothelioma using biomarkers: a systematic review.
</td>
<td style="text-align:left;">
Br. J. Cancer
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[A case of remission induced in diffuse pleural malignant mesothelioma by the treatment with cisplatin and doxorubicin].
</td>
<td style="text-align:left;">
Gan To Kagaku Ryoho
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
[Further comment on mesotheliomas].
</td>
<td style="text-align:left;">
Arkh. Patol.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Podoplanin promotes progression of malignant pleural mesothelioma by regulating motility and focus formation.
</td>
<td style="text-align:left;">
Cancer Sci.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Monosomy 14, monosomy 22 and 13q–three chromosomal abnormalities observed in cells of two malignant mesotheliomas studied by banding techniques.
</td>
<td style="text-align:left;">
Acta Cytol.
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Switching off malignant mesothelioma: exploiting the hypoxic microenvironment.
</td>
<td style="text-align:left;">
Genes Cancer
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Unusual pleural effusion from vulvar squamous cell carcinoma: report of a case and review of the literature.
</td>
<td style="text-align:left;">
Pathologica
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Comparison of outcomes following a cytological or histological diagnosis of malignant mesothelioma.
</td>
<td style="text-align:left;">
Br. J. Cancer
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Prognostic and predictive aspects of the tumor immune microenvironment and immune checkpoints in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Oncoimmunology
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Kdm6a and Kdm6b: Altered expression in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Int. J. Oncol.
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Does selective pleural irradiation of malignant pleural mesothelioma allow radiation dose escalation? : A planning study.
</td>
<td style="text-align:left;">
Strahlenther Onkol
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Long-term epidemiological observation of asbestos-related diseases in Poland, 1970-2015.
</td>
<td style="text-align:left;">
Occup Med (Lond)
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Large primary pleural synovial sarcoma with severe dyspnea: a case report.
</td>
<td style="text-align:left;">
Surg Case Rep
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Modern management of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Lung Cancer (Auckl)
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Activation of JNK and IRE1 is critically involved in tanshinone I-induced p62 dependent autophagy in malignant pleural mesothelioma cells: implication of p62 UBA domain.
</td>
<td style="text-align:left;">
Oncotarget
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
A phase II trial of dovitinib in previously-treated advanced pleural mesothelioma: The Ontario Clinical Oncology Group.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Pharmacokinetic evaluation of intrapleural perfusion with hyperthermic chemotherapy using cisplatin in patients with malignant pleural effusion.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Immunohistochemical detection of MTAP and BAP1 protein loss for mesothelioma diagnosis: Comparison with 9p21 FISH and BAP1 immunohistochemistry.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleural carcinogenic potency of mineral fibers (asbestos, attapulgite) and their cytotoxicity on cultured cells.
</td>
<td style="text-align:left;">
J. Natl. Cancer Inst.
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Clinical outcomes and prognostic factors of patients with advanced mesothelioma treated in a phase I clinical trials unit.
</td>
<td style="text-align:left;">
Eur. J. Cancer
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Intracavitary ‘T4 immunotherapy’ of malignant mesothelioma using pan-ErbB re-targeted CAR T-cells.
</td>
<td style="text-align:left;">
Cancer Lett.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Radiation therapy for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Cancer Radiother
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleuroperitoneal Mesothelioma: A Rare Entity on 18F-FDG PET/CT.
</td>
<td style="text-align:left;">
Indian J Nucl Med
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma due to asbestos exposure in dental tape.
</td>
<td style="text-align:left;">
Am. J. Ind. Med.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Positive pleural cytology is an indicator for visceral pleural invasion in metastatic pleural effusions.
</td>
<td style="text-align:left;">
Clin Respir J
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Aberrant Cytokeratin 20 Reactivity in Epithelioid Malignant Mesothelioma: A Case Report.
</td>
<td style="text-align:left;">
Appl. Immunohistochem. Mol. Morphol.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Real-time light dosimetry for intra-cavity photodynamic therapy: Application for pleural mesothelioma treatment.
</td>
<td style="text-align:left;">
Photodiagnosis Photodyn Ther
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
The Immune Microenvironment, Genome-wide Copy Number Aberrations, and Survival in Mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Mesothelioid reaction following talc pleurodesis: a case report.
</td>
<td style="text-align:left;">
Gen Thorac Cardiovasc Surg
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Non-Hodgkin Lymphoma and Pleural Mesothelioma in a Person Exposed to Asbestos.
</td>
<td style="text-align:left;">
Turk Patoloji Derg
</td>
<td style="text-align:left;">
diagnosis | treatment | epidemiology
</td>
</tr>
<tr>
<td style="text-align:left;">
Is less also better? A single-institution experience on treatment of early stage Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
Eur J Surg Oncol
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
The Controlling Nutritional Status Score Is a Significant Independent Predictor of Poor Prognosis in Patients With Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
Clin Lung Cancer
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Mesothelin promotes epithelial-to-mesenchymal transition and tumorigenicity of human lung cancer and mesothelioma cells.
</td>
<td style="text-align:left;">
Mol. Cancer
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
The PD-L1/PD-1 pathway promotes dysfunction, but not “exhaustion”, in tumor-responding T cells from pleural effusions in lung cancer patients.
</td>
<td style="text-align:left;">
Cancer Immunol. Immunother.
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial.
</td>
<td style="text-align:left;">
Lancet Oncol.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Pembrolizumab in the treatment of metastatic non-small-cell lung cancer: patient selection and perspectives.
</td>
<td style="text-align:left;">
Lung Cancer (Auckl)
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Physical function and health-related quality of life in patients undergoing surgical treatment for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Support Care Cancer
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Impact of tumour thickness on survival after radical radiation and surgery in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Eur. Respir. J.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Mortality in miners and millers of crocidolite in Western Australia.
</td>
<td style="text-align:left;">
Br J Ind Med
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Comparison of the Diagnostic Performance of Fibulin-3 and Mesothelin in Patients with Pleural Effusions from Malignant Mesothelioma.
</td>
<td style="text-align:left;">
Anticancer Res.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Midkine is a potential novel marker for malignant mesothelioma with different prognostic and diagnostic values from mesothelin.
</td>
<td style="text-align:left;">
BMC Cancer
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Combinational therapy of crizotinib and afatinib for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Am J Cancer Res
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Improved Outcomes with Modern Lung-Sparing Trimodality Therapy in Patients with Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Targeting BAP1: a new paradigm for mesothelioma.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Mesothelin promoter variants are associated with increased soluble mesothelin-related peptide levels in asbestos-exposed individuals.
</td>
<td style="text-align:left;">
Occup Environ Med
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Integrated analysis of somatic mutations and immune microenvironment in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Oncoimmunology
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
A Novel Panel of Serum Biomarkers for MPM Diagnosis.
</td>
<td style="text-align:left;">
Dis. Markers
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Serum HMGB1 as a Potential Biomarker for Patients with Asbestos-Related Diseases.
</td>
<td style="text-align:left;">
Dis. Markers
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Histopathologic features predict survival in diffuse pleural malignant mesothelioma on pleural biopsies.
</td>
<td style="text-align:left;">
Virchows Arch.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
A second case of pericardial mesothelioma mimicking systemic lupus erythematosus in the literature in over 30 years: a case report.
</td>
<td style="text-align:left;">
J Med Case Rep
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Intensity modulated radiation therapy after extra-pleural pneumonectomy for malignant pleural mesothelioma is feasible without fatal pulmonary toxicity and provides good survival.
</td>
<td style="text-align:left;">
Asia Pac J Clin Oncol
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Transcriptomic Analysis of the Claudin Interactome in Malignant Pleural Mesothelioma: Evaluation of the Effect of Disease Phenotype, Asbestos Exposure, and CDKN2A Deletion Status.
</td>
<td style="text-align:left;">
Front Physiol
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
A Proteomic Analysis of the Malignant Mesothelioma Secretome Using iTRAQ.
</td>
<td style="text-align:left;">
Cancer Genomics Proteomics
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Phase 1 Dose-Escalation Study of Pegylated Arginine Deiminase, Cisplatin, and Pemetrexed in Patients With Argininosuccinate Synthetase 1-Deficient Thoracic Cancers.
</td>
<td style="text-align:left;">
J. Clin. Oncol.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
A Novel BRCA1-Associated Protein-1 Isoform Affects Response of Mesothelioma Cells to Drugs Impairing BRCA1-Mediated DNA Repair.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Imaging findings of pseudomesothelioma cases resulting from two different primary tumours.
</td>
<td style="text-align:left;">
Tuberk Toraks
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Analysis of fibulin-3 after exposure to asbestos-like fibers.
</td>
<td style="text-align:left;">
Environ. Res.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Experimental lung tumors following specific intrabronchial application of chrysotile asbestos. Longitudinal light and electron microscopic investigations in rats.
</td>
<td style="text-align:left;">
Respiration
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma: single-institution experience of 101 patients over a 15-year period.
</td>
<td style="text-align:left;">
Acta Chir. Belg.
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
CD44 and its ligand hyaluronan as potential biomarkers in malignant pleural mesothelioma: evidence and perspectives.
</td>
<td style="text-align:left;">
Respir. Res.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleural malignant mesothelioma in dental laboratory technicians: A case series.
</td>
<td style="text-align:left;">
Am. J. Ind. Med.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
The case for performing pleural biopsies for the aetiological diagnosis of exudates. Yes.
</td>
<td style="text-align:left;">
Rev Clin Esp
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Epidemiology of Environmental Exposure and Malignant Mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Folic acid phenotype (FAP) is a superior biomarker predicting response to pemetrexed-based chemotherapy in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Oncotarget
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleurectomy-decortication in malignant pleural mesothelioma: are different surgical techniques associated with different outcomes? Results from a multicentre study.
</td>
<td style="text-align:left;">
Eur J Cardiothorac Surg
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Three-dimensional finite-element based deformable image registration for evaluation of pleural cavity irradiation during photodynamic therapy.
</td>
<td style="text-align:left;">
Med Phys
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Prophylactic radiotherapy for procedure tract metastases in mesothelioma: a review.
</td>
<td style="text-align:left;">
Curr Opin Pulm Med
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Can CT and MR Shape and Textural Features Differentiate Benign Versus Malignant Pleural Lesions?
</td>
<td style="text-align:left;">
Acad Radiol
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Spotlight on bevacizumab and its potential in the treatment of malignant pleural mesothelioma: the evidence to date.
</td>
<td style="text-align:left;">
Onco Targets Ther
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Inhibition of the platelet-derived growth factor receptor beta (PDGFRB) using gene silencing, crenolanib besylate, or imatinib mesylate hampers the malignant phenotype of mesothelioma cell lines.
</td>
<td style="text-align:left;">
Genes Cancer
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Mortality from cancer and other causes among Italian chrysotile asbestos miners.
</td>
<td style="text-align:left;">
Occup Environ Med
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Post-recurrence chemotherapy for mesothelioma patients undergoing extrapleural pneumonectomy.
</td>
<td style="text-align:left;">
Int. J. Clin. Oncol.
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleural mesothelioma in doll manufacture: possible asbestos exposure.
</td>
<td style="text-align:left;">
Med Lav
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
miR-130A as a diagnostic marker to differentiate malignant mesothelioma from lung adenocarcinoma in pleural effusion cytology.
</td>
<td style="text-align:left;">
Cancer Cytopathol
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Comprehensive immunohistochemical study of mesothelin (MSLN) using different monoclonal antibodies 5B2 and MN-1 in 1562 tumors with evaluation of its prognostic value in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Oncotarget
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Intensity-Modulated Radiation Therapy Improves the Target Coverage Over 3-D Planning While Meeting Lung Tolerance Doses for All Patients With Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
Technol. Cancer Res. Treat.
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Growth suppressive effect of pegylated arginase in malignant pleural mesothelioma xenografts.
</td>
<td style="text-align:left;">
Respir. Res.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
miRNA regulation is important for DNA damage repair and recognition in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Virchows Arch.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Combined Inhibition of NEDD8-Activating Enzyme and mTOR Suppresses <i>NF2</i> Loss-Driven Tumorigenesis.
</td>
<td style="text-align:left;">
Mol. Cancer Ther.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Significant Clinical Benefit of Pemetrexed-based Chemotherapy for Advanced Diffuse Malignant Peritoneal Mesothelioma: A Case Presentation.
</td>
<td style="text-align:left;">
Indian J Med Paediatr Oncol
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Targeting YAP in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J. Cell. Mol. Med.
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Plasmatic extracellular vesicle microRNAs in malignant pleural mesothelioma and asbestos-exposed subjects suggest a 2-miRNA signature as potential biomarker of disease.
</td>
<td style="text-align:left;">
PLoS ONE
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Clinical Features and Treatment Outcome of Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
Oncol Res Treat
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Spontaneous massive hemopneumothorax: Double trouble with a twist.
</td>
<td style="text-align:left;">
Lung India
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Fibronectin and Hepatocyte Growth Factor Produced by Lung Fibroblasts Augment Migration and Invasion of Malignant Pleural Mesothelioma Cells.
</td>
<td style="text-align:left;">
Anticancer Res.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleural mesothelioma in household members of asbestos-exposed workers in Friuli Venezia Giulia, Italy.
</td>
<td style="text-align:left;">
Int J Occup Med Environ Health
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
BAP1 mutations in high-grade meningioma: implications for patient care.
</td>
<td style="text-align:left;">
Neuro-oncology
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Induction chemotherapy, extrapleural pneumonectomy and adjuvant radiotherapy for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Eur J Cardiothorac Surg
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Successful lung-sparing resection of synchronous pleural mesothelioma and contralateral lung cancer.
</td>
<td style="text-align:left;">
Surg Case Rep
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Multiple malignant epithelioid mesotheliomas of the liver and greater omentum: a case report and review of the literature.
</td>
<td style="text-align:left;">
Surg Case Rep
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant Pleural Mesothelioma Presenting Refractory Pneumothorax Successfully Treated by Intrapleural Administration of Diluted Fibrin Glue;Report of a Case].
</td>
<td style="text-align:left;">
Kyobu Geka
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Induction of IL-17 production from human peripheral blood CD4+ cells by asbestos exposure.
</td>
<td style="text-align:left;">
Int. J. Oncol.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Dose-time-response association between occupational asbestos exposure and pleural mesothelioma.
</td>
<td style="text-align:left;">
Occup Environ Med
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
CAR T-cell therapy for lung cancer and malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Transl Res
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
A Subset of Malignant Mesotheliomas in Young Adults Are Associated With Recurrent EWSR1/FUS-ATF1 Fusions.
</td>
<td style="text-align:left;">
Am. J. Surg. Pathol.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Prognostic significance of soluble mesothelin in malignant pleural mesothelioma: a meta-analysis.
</td>
<td style="text-align:left;">
Oncotarget
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
SU-E-T-595: Comparison of Volumetric Modulated Arc Therapy (VMAT) and Static Intensity Modulated Radiotherapy (IMRT) for Malignant Pleural Mesothelioma in Patients with Intact Lungs/Post Pleurectomy.
</td>
<td style="text-align:left;">
Med Phys
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Epidemiology of mesothelioma of the pericardium and tunica vaginalis testis.
</td>
<td style="text-align:left;">
Ann Epidemiol
</td>
<td style="text-align:left;">
epidemiology | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Diode-Pumped Laser for Lung-Sparing Surgical Treatment of Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
Ann. Thorac. Surg.
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Immunotherapy and radiation therapy for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Transl Lung Cancer Res
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Viroimmunotherapy of Thoracic Cancers.
</td>
<td style="text-align:left;">
Biomedicines
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
The inhibition of FGF receptor 1 activity mediates sorafenib antiproliferative effects in human malignant pleural mesothelioma tumor-initiating cells.
</td>
<td style="text-align:left;">
Stem Cell Res Ther
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Calretinin as a blood-based biomarker for mesothelioma.
</td>
<td style="text-align:left;">
BMC Cancer
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Unusual Contiguous Soft Tissue Spread of Advanced Malignant Mesothelioma Detected by FDG PET/CT.
</td>
<td style="text-align:left;">
Nucl Med Mol Imaging
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
DCLK1 is correlated with MET and ERK5 expression, and associated with prognosis in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Int. J. Oncol.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Significance of flower pot cells in effusion cytology.
</td>
<td style="text-align:left;">
Diagn. Cytopathol.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Synergistic targeting of malignant pleural mesothelioma cells by MDM2 inhibitors and TRAIL agonists.
</td>
<td style="text-align:left;">
Oncotarget
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Improved diagnosis and prognostication of patients with pleural malignant mesothelioma using biomarkers in pleural effusions and peripheral blood samples - a short report.
</td>
<td style="text-align:left;">
Cell Oncol (Dordr)
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Whole exome sequencing of an asbestos-induced wild-type murine model of malignant mesothelioma.
</td>
<td style="text-align:left;">
BMC Cancer
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Induction chemotherapy vs post-operative adjuvant therapy for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Expert Rev Respir Med
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Surgery as part of radical treatment for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Curr Opin Pulm Med
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
First-line chemotherapy with pemetrexed plus cisplatin for malignant peritoneal mesothelioma.
</td>
<td style="text-align:left;">
Expert Rev Anticancer Ther
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Phase I Trial of Cediranib in Combination with Cisplatin and Pemetrexed in Chemonaive Patients with Unresectable Malignant Pleural Mesothelioma (SWOG S0905).
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Deregulation of miRNAs in malignant pleural mesothelioma is associated with prognosis and suggests an alteration of cell metabolism.
</td>
<td style="text-align:left;">
Sci Rep
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Posttranscriptional Regulation Controls Calretinin Expression in Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
Front Genet
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
GATA3 Immunohistochemistry for Distinguishing Sarcomatoid and Desmoplastic Mesothelioma From Sarcomatoid Carcinoma of the Lung.
</td>
<td style="text-align:left;">
Am. J. Surg. Pathol.
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Tissue-specific significance of BAP1 gene mutation in prognostic prediction and molecular taxonomy among different types of cancer.
</td>
<td style="text-align:left;">
Tumour Biol.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Tumor Suppressor microRNAs Contribute to the Regulation of PD-L1 Expression in Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant Pleural Mesothelioma with Marked Lymphatic Involvement: A Report of Two Autopsy Cases.
</td>
<td style="text-align:left;">
Case Rep Oncol Med
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Chest pain and recurrent chylothorax: an unusual presentation of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Respirol Case Rep
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Correction: MSLN gene silencing has an anti-malignant effect on cell lines overexpressing mesothelin deriving from malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
PLoS ONE
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
A pilot study of zoledronic acid in the treatment of patients with advanced malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Lung Cancer (Auckl)
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Predicting Malignant and Paramalignant Pleural Effusions by Combining Clinical, Radiological and Pleural Fluid Analytical Parameters.
</td>
<td style="text-align:left;">
Lung
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Increase of exposure and event acceleration.
</td>
<td style="text-align:left;">
Med Lav
</td>
<td style="text-align:left;">
epidemiology
</td>
</tr>
<tr>
<td style="text-align:left;">
JQ1, a BET Inhibitor, Synergizes with Cisplatin and Induces Apoptosis in Highly Chemoresistant Malignant Pleural Mesothelioma Cells.
</td>
<td style="text-align:left;">
Curr Cancer Drug Targets
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Association Between Clinicopathological Factors and Genomic Abnormalities Detected by FISH Analysis in Epithelioid Diffuse Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
Int. J. Surg. Pathol.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Cost-effectiveness analysis of additional bevacizumab to pemetrexed plus cisplatin for malignant pleural mesothelioma based on the MAPS trial.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Promising investigational drug candidates in phase I and phase II clinical trials for mesothelioma.
</td>
<td style="text-align:left;">
Expert Opin Investig Drugs
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Risk Factors of Mortality from All Asbestos-Related Diseases: A Competing Risk Analysis.
</td>
<td style="text-align:left;">
Can. Respir. J.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Optimal Therapy of Advanced Stage Mesothelioma.
</td>
<td style="text-align:left;">
Curr Treat Options Oncol
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesotheliomas in a small village in the Anatolian region of Turkey: an epidemiologic study.
</td>
<td style="text-align:left;">
J. Natl. Cancer Inst.
</td>
<td style="text-align:left;">
epidemiology
</td>
</tr>
<tr>
<td style="text-align:left;">
Guidelines for Pathologic Diagnosis of Malignant Mesothelioma 2017 Update of the Consensus Statement From the International Mesothelioma Interest Group.
</td>
<td style="text-align:left;">
Arch. Pathol. Lab. Med.
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Germline mutations in DNA repair genes predispose asbestos-exposed patients to malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Cancer Lett.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
LUME-Meso: Design and Rationale of the Phase III Part of a Placebo-Controlled Study of Nintedanib and Pemetrexed/Cisplatin Followed by Maintenance Nintedanib in Patients With Unresectable Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
Clin Lung Cancer
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Antimetabolites in the treatment of advanced pleural mesothelioma: a network meta-analysis of randomized clinical trials.
</td>
<td style="text-align:left;">
J Chemother
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Apoptosis by [Pt(O,O’-acac)(γ-acac)(DMS)] requires PKC-δ mediated p53 activation in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
PLoS ONE
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Combined Inhibition of CDK4/6 and PI3K/AKT/mTOR Pathways Induces a Synergistic Anti-Tumor Effect in Malignant Pleural Mesothelioma Cells.
</td>
<td style="text-align:left;">
Neoplasia
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
The impact of surgical approach on quality of life for pleural malignant mesothelioma.
</td>
<td style="text-align:left;">
Ann Transl Med
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Intra-abdominal manifestations of pleural mesothelioma.
</td>
<td style="text-align:left;">
Ann Transl Med
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Extrapleural pneumonectomy (EPP) <i>vs.</i> pleurectomy decortication (P/D).
</td>
<td style="text-align:left;">
Ann Transl Med
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Intraoperative intracavitary hyperthermic chemotherapy for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Ann Transl Med
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Overview of treatment related complications in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Ann Transl Med
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant peritoneal mesothelioma: a review.
</td>
<td style="text-align:left;">
Ann Transl Med
</td>
<td style="text-align:left;">
diagnosis | treatment | epidemiology | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
A nuanced view of extrapleural pneumonectomy for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Ann Transl Med
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Randomized controlled trials in malignant pleural mesothelioma surgery-mistakes made and lessons learned.
</td>
<td style="text-align:left;">
Ann Transl Med
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Volumetric assessment in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Ann Transl Med
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma: adjuvant therapy with radiation therapy.
</td>
<td style="text-align:left;">
Ann Transl Med
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma: predictors and staging.
</td>
<td style="text-align:left;">
Ann Transl Med
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Diagnosis and prognosis-review of biomarkers for mesothelioma.
</td>
<td style="text-align:left;">
Ann Transl Med
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Novel immunotherapy clinical trials in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Ann Transl Med
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleurectomy and decortication.
</td>
<td style="text-align:left;">
Ann Transl Med
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Reproducibility for histologic parameters in peritoneal mesothelioma.
</td>
<td style="text-align:left;">
Hum. Pathol.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
<i>In vitro</i> experimental models of mesothelioma revisited.
</td>
<td style="text-align:left;">
Transl Lung Cancer Res
</td>
<td style="text-align:left;">
treatment | epidemiology | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Intraoperative near-infrared imaging of mesothelioma.
</td>
<td style="text-align:left;">
Transl Lung Cancer Res
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Intraoperative adjuncts for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Transl Lung Cancer Res
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Novel systemic therapy against malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Transl Lung Cancer Res
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Immunotherapy for malignant pleural mesothelioma: current status and future directions.
</td>
<td style="text-align:left;">
Transl Lung Cancer Res
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Radio-immunotherapy and chemo-immunotherapy as a novel treatment paradigm in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Transl Lung Cancer Res
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Drug development against the hippo pathway in mesothelioma.
</td>
<td style="text-align:left;">
Transl Lung Cancer Res
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Targeting the epigenome in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Transl Lung Cancer Res
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Can malignant and inflammatory pleural effusions in dogs be distinguished using computed tomography?
</td>
<td style="text-align:left;">
Vet Radiol Ultrasound
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Tumor suppressor candidate 2 (TUSC2, FUS-1) and human cancers.
</td>
<td style="text-align:left;">
Discov Med
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
High-dose palliative radiotherapy for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J Med Imaging Radiat Oncol
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial.
</td>
<td style="text-align:left;">
Lancet Oncol.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Magnetic nanoparticles-based therapy for malignant mesothelioma.
</td>
<td style="text-align:left;">
Rom J Morphol Embryol
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
The Drive For Self-Assertion And The Reality Principle In A Patient With Malignant Pleural Mesothelioma: The History of Giulia.
</td>
<td style="text-align:left;">
Am J Psychoanal
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Functional image guided radiation therapy planning in volumetric modulated arc therapy for patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Adv Radiat Oncol
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Synthetic lethality in malignant pleural mesothelioma with PARP1 inhibition.
</td>
<td style="text-align:left;">
Cancer Chemother. Pharmacol.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
MicroRNA Expression in Malignant Pleural Mesothelioma and Asbestosis: A Pilot Study.
</td>
<td style="text-align:left;">
Dis. Markers
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
TRANSTHORACIC FINE NEEDLE ASPIRATION CYTOLOGY IN DIAGNOSING NON-RESOLVING PNEUMONIAS - A STUDY OF 170 CASES.
</td>
<td style="text-align:left;">
Med J Armed Forces India
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Italian pool of asbestos workers cohorts: mortality trends of asbestos-related neoplasms after long time since first exposure.
</td>
<td style="text-align:left;">
Occup Environ Med
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Diagnostic value of medical thoracoscopy in malignant pleural effusion.
</td>
<td style="text-align:left;">
BMC Pulm Med
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
The differential diagnosis between pleural sarcomatoid mesothelioma and spindle cell/pleomorphic (sarcomatoid) carcinomas of the lung: evidence-based guidelines from the International Mesothelioma Panel and the MESOPATH National Reference Center.
</td>
<td style="text-align:left;">
Hum. Pathol.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma segmentation for photodynamic therapy planning.
</td>
<td style="text-align:left;">
Comput Med Imaging Graph
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Isolated thoracic perfusion with chemofiltration for progressive malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Onco Targets Ther
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Epithelioid malignant mesothelioma metastatic to the skin: A case report and review of the literature.
</td>
<td style="text-align:left;">
J. Cutan. Pathol.
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant Pleural Mesothelioma: State of the art and advanced cell therapy.
</td>
<td style="text-align:left;">
Eur J Med Chem
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Radiographic features of importance in the National Institute for Occupational Safety and Health-administered Coal Workers’ Health Surveillance Program: characterising the use of the ‘other symbols’.
</td>
<td style="text-align:left;">
BMJ Open
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
[Clinical and pathologic features of extrapleural sarcomatoid mesothelioma].
</td>
<td style="text-align:left;">
Zhonghua Bing Li Xue Za Zhi
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Expression of ALCAM (CD166) and PD-L1 (CD274) independently predicts shorter survival in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Hum. Pathol.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Heart Dosimetry is Correlated With Risk of Radiation Pneumonitis After Lung-Sparing Hemithoracic Pleural Intensity Modulated Radiation Therapy for Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
Int. J. Radiat. Oncol. Biol. Phys.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Long-Term Survival Outcomes of Cancer-Directed Surgery for Malignant Pleural Mesothelioma: Propensity Score Matching Analysis.
</td>
<td style="text-align:left;">
J. Clin. Oncol.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Estimated future incidence of malignant mesothelioma in South Korea: Projection from 2014 to 2033.
</td>
<td style="text-align:left;">
PLoS ONE
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Association of Metsovo lung and pleural mesothelioma with exposure to tremolite-containing whitewash.
</td>
<td style="text-align:left;">
Lancet
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant Deciduoid Mesothelioma: case presentation of an exceptional variant and review of the literature.
</td>
<td style="text-align:left;">
BMC Clin Pathol
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Radiological predictors of complete cytoreduction in 59 patients with peritoneal mesothelioma treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy at a UK referral centre.
</td>
<td style="text-align:left;">
Br J Radiol
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma - Pleural cavity irradiation after decortication with helical tomotherapy.
</td>
<td style="text-align:left;">
Rep Pract Oncol Radiother
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Mortality in asbestos cement workers in Pavia, Italy: A cohort study.
</td>
<td style="text-align:left;">
Am. J. Ind. Med.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Chest ultrasonography in health surveillance of asbestos related pleural disease.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Pathological complete response in malignant pleural mesothelioma patients following induction chemotherapy: Predictive factors and outcomes.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Survival in Good Performance Malignant Pleural Mesothelioma Patients; Prognostic Factors and Predictors of Response
</td>
<td style="text-align:left;">
Asian Pac. J. Cancer Prev.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
National Cancer Database Report on Pneumonectomy Versus Lung-Sparing Surgery for Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Diagnostic Imaging and workup of Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
Acta Biomed
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Accumulation of long asbestos fibers in the peripheral upper lobe in cases of malignant mesothelioma.
</td>
<td style="text-align:left;">
Am. J. Ind. Med.
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Differential diagnosis between mesotheliomas and metastatic adenocarcinomas using monoclonal antibodies against gastrointestinal carcinoma antigen and stage-specific embryonic antigen.
</td>
<td style="text-align:left;">
Appl Pathol
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Migrating pleural plaque in a patient with asbestos induced pleural disease: a case report.
</td>
<td style="text-align:left;">
J Occup Med Toxicol
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Near-Infrared Intraoperative Imaging Can Successfully Identify Malignant Pleural Mesothelioma After Neoadjuvant Chemotherapy.
</td>
<td style="text-align:left;">
Mol Imaging
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
The role of radical radiotherapy in the management of malignant pleural mesothelioma: A systematic review.
</td>
<td style="text-align:left;">
Radiother Oncol
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Clinical staging of malignant pleural mesothelioma: current perspectives.
</td>
<td style="text-align:left;">
Lung Cancer (Auckl)
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Chimeric Antigen Receptor (CAR) T Cell Therapy for Malignant Pleural Mesothelioma (MPM).
</td>
<td style="text-align:left;">
Cancers (Basel)
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Ambient Asbestos Fiber Concentrations and Long-Term Trends in Pleural Mesothelioma Incidence between Urban and Rural Areas in the United States (1973-2012).
</td>
<td style="text-align:left;">
Risk Anal.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study.
</td>
<td style="text-align:left;">
Lancet Oncol.
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Biomarkers for early diagnosis of malignant mesothelioma: Do we need another moonshot?
</td>
<td style="text-align:left;">
Oncotarget
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Oncolytic Viral Therapy for Mesothelioma.
</td>
<td style="text-align:left;">
Front Oncol
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Radiotherapy for the treatment of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Lancet Oncol.
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Clinicopathologic and genetic characteristics of young patients with pleural diffuse malignant mesothelioma.
</td>
<td style="text-align:left;">
Mod. Pathol.
</td>
<td style="text-align:left;">
epidemiology | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Secondary hypertrophic osteoarthropathy caused by non-pleural or pulmonary tumors.
</td>
<td style="text-align:left;">
Medicine (Baltimore)
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
The epithelioid BAP1-negative and p16-positive phenotype predicts prolonged survival in pleural mesothelioma.
</td>
<td style="text-align:left;">
Histopathology
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Nintedanib Plus Pemetrexed/Cisplatin in Patients With Malignant Pleural Mesothelioma: Phase II Results From the Randomized, Placebo-Controlled LUME-Meso Trial.
</td>
<td style="text-align:left;">
J. Clin. Oncol.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Prognosis of Cancer with Synchronous or Metachronous Malignant Pleural Effusion.
</td>
<td style="text-align:left;">
Lung
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Identification of ALK Rearrangements in Malignant Peritoneal Mesothelioma.
</td>
<td style="text-align:left;">
JAMA Oncol
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Prognostic significance of neutrophil-to-lymphocyte ratio in patients with malignant pleural mesothelioma: a meta-analysis.
</td>
<td style="text-align:left;">
Oncotarget
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
MicroRNA-31 Regulates Chemosensitivity in Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
Mol Ther Nucleic Acids
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Role of new radiation techniques in the treatment of pleural mesothelioma.
</td>
<td style="text-align:left;">
Thorac Cancer
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Clinical and biologic prognostic factors in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Thorac Cancer
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Treatment for recurrence after extrapleural pneumonectomy for malignant pleural mesothelioma: A single institution experience.
</td>
<td style="text-align:left;">
Thorac Cancer
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Determination of PD-L1 expression in effusions from mesothelioma by immuno-cytochemical staining.
</td>
<td style="text-align:left;">
Cancer Cytopathol
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
The value of delayed phase enhanced imaging in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Dis
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Non-occupational exposure to asbestos and risk of pleural mesothelioma: review and meta-analysis.
</td>
<td style="text-align:left;">
Occup Environ Med
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Prognostic and predictive role of [<sup>18</sup> F]fluorodeoxyglucose positron emission tomography (FDG-PET) in patients with unresectable malignant pleural mesothelioma (MPM) treated with up-front pemetrexed-based chemotherapy.
</td>
<td style="text-align:left;">
Cancer Med
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Role of proton-coupled folate transporter in pemetrexed resistance of mesothelioma: clinical evidence and new pharmacological tools.
</td>
<td style="text-align:left;">
Ann. Oncol.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Influence of Pleurectomy and Decortication in Health-Related Quality of Life Among Patients with Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
World J Surg
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
A Case Report of Primary Pericardial Malignant Mesothelioma Treated with Pemetrexed and Cisplatin.
</td>
<td style="text-align:left;">
J. Korean Med. Sci.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Novel ATP-competitive Akt inhibitor afuresertib suppresses the proliferation of malignant pleural mesothelioma cells.
</td>
<td style="text-align:left;">
Cancer Med
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Soluble Mesothelin-Related Peptides to Monitor Recurrence After Resection of Pleural Mesothelioma.
</td>
<td style="text-align:left;">
Ann. Thorac. Surg.
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleural effusion biomarkers and computed tomography findings in diagnosing malignant pleural mesothelioma: A retrospective study in a single center.
</td>
<td style="text-align:left;">
PLoS ONE
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
A Randomized Phase II Trial of Adjuvant Galinpepimut-S, WT-1 Analogue Peptide Vaccine, After Multimodality Therapy for Patients with Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
Clin. Cancer Res.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Low-dose photon irradiation induces invasiveness through the SDF-1α/CXCR4 pathway in malignant mesothelioma cells.
</td>
<td style="text-align:left;">
Oncotarget
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Downregulation of miR-99a/let-7c/miR-125b miRNA cluster predicts clinical outcome in patients with unresected malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Oncotarget
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
miR-30d is related to asbestos exposure and inhibits migration and invasion in NCI-H2452 cells.
</td>
<td style="text-align:left;">
FEBS Open Bio
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
[Mesothelioma].
</td>
<td style="text-align:left;">
Pathologe
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Loss of BRCA1-associated protein 1 (BAP1) expression is useful in diagnostic cytopathology of malignant mesothelioma in effusions.
</td>
<td style="text-align:left;">
Diagn. Cytopathol.
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Evidence Suggesting the End of Universal Domestic Asbestos Exposure in Metsovo, NW Greece.
</td>
<td style="text-align:left;">
Respiration
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Application of 3D Mass Spectrometry Imaging to TKIs.
</td>
<td style="text-align:left;">
Clin. Pharmacol. Ther.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
New Concepts in the Treatment of Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
Annu. Rev. Med.
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Estimating past inhalation exposure to asbestos: A tool for risk attribution and disease screening.
</td>
<td style="text-align:left;">
Int J Hyg Environ Health
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
A panel of markers for identification of malignant and non-malignant cells in culture from effusions.
</td>
<td style="text-align:left;">
Oncol. Rep.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Unilateral pulmonary artery pre-operative occlusion test: technical feasibility and safety prior to pneumonectomy or pleuropneumonectomy for malignancy.
</td>
<td style="text-align:left;">
Br J Radiol
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Carcinogenicity of multi-walled carbon nanotubes: challenging issue on hazard assessment.
</td>
<td style="text-align:left;">
J Occup Health
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Immunohistochemistry in Peritoneal Mesothelioma: A Single-Center Experience of 244 Cases.
</td>
<td style="text-align:left;">
Arch. Pathol. Lab. Med.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Extended pleurectomy decortication for malignant pleural mesothelioma in the elderly: the need for an inclusive yet selective approach.
</td>
<td style="text-align:left;">
Interact Cardiovasc Thorac Surg
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Loss of BRCA associated protein 1 expression in malignant mesothelioma and its diagnostic application].
</td>
<td style="text-align:left;">
Zhonghua Bing Li Xue Za Zhi
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
The revised staging system for malignant pleural mesothelioma based on surveillance, epidemiology, and end results database.
</td>
<td style="text-align:left;">
Int J Surg
</td>
<td style="text-align:left;">
epidemiology | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
A combination of MTAP and BAP1 immunohistochemistry in pleural effusion cytology for the diagnosis of mesothelioma.
</td>
<td style="text-align:left;">
Cancer Cytopathol
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Cutaneous Presentation of Mesothelioma With a Sarcomatoid Transformation.
</td>
<td style="text-align:left;">
Am J Dermatopathol
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Comprehensive Pharmacogenomic Profiling of Malignant Pleural Mesothelioma Identifies a Subgroup Sensitive to FGFR Inhibition.
</td>
<td style="text-align:left;">
Clin. Cancer Res.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Chemical Profiling of Primary Mesothelioma Cultures Defines Subtypes with Different Expression Profiles and Clinical Responses.
</td>
<td style="text-align:left;">
Clin. Cancer Res.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Turkey National Mesothelioma Surveillance and Environmental Asbestos Exposure Control Program.
</td>
<td style="text-align:left;">
Int J Environ Res Public Health
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
An Overview of Asbestos and Malignant Pleural Mesothelioma: An Iranian Perspective
</td>
<td style="text-align:left;">
Asian Pac. J. Cancer Prev.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Loss of BAP1 Expression in Atypical Mesothelial Proliferations Helps to Predict Malignant Mesothelioma.
</td>
<td style="text-align:left;">
Am. J. Surg. Pathol.
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Role of thoracoscopy, mediastinoscopy and laparoscopy in the diagnosis and staging of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J Vis Surg
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Video assisted thoracoscopic and open chest surgery in diagnosis and treatment of malignant pleural diseases.
</td>
<td style="text-align:left;">
J Vis Surg
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Molecular and Histopathological Characterization of the Tumor Immune Microenvironment in Advanced Stage of Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant Mesothelioma, BAP1 Immunohistochemistry, and VEGFA: Does BAP1 Have Potential for Early Diagnosis and Assessment of Prognosis?
</td>
<td style="text-align:left;">
Dis. Markers
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
A review of bevacizumab in the treatment of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Future Oncol
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Retrospective study of hypersensitivity reactions to chemotherapeutic agents in a thoracic oncology service.
</td>
<td style="text-align:left;">
J Clin Pharm Ther
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
A link between the fibroblast growth factor axis and the miR-16 family reveals potential new treatment combinations in mesothelioma.
</td>
<td style="text-align:left;">
Mol Oncol
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Cancer antigen profiling for malignant pleural mesothelioma immunotherapy: expression and coexpression of mesothelin, cancer antigen 125, and Wilms tumor 1.
</td>
<td style="text-align:left;">
Oncotarget
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Targeting microRNA to improve diagnostic and therapeutic approaches for malignant mesothelioma.
</td>
<td style="text-align:left;">
Oncotarget
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
PD-L1 expression associated with worse survival outcome in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Asia Pac J Clin Oncol
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Chimeric Antigen Receptor (CAR) T-Cell Therapy for Thoracic Malignancies.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Challenging a dogma; AJCC 8th staging system is not sufficient to predict outcomes of patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
epidemiology
</td>
</tr>
<tr>
<td style="text-align:left;">
External validation of prognostic indices for overall survival of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Surgical and non-surgical management of malignant pleural effusions.
</td>
<td style="text-align:left;">
Expert Rev Respir Med
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Long-Fiber Carbon Nanotubes Replicate Asbestos-Induced Mesothelioma with Disruption of the Tumor Suppressor Gene Cdkn2a (Ink4a/Arf).
</td>
<td style="text-align:left;">
Curr. Biol.
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Dysregulated Expression of the MicroRNA miR-137 and Its Target YBX1 Contribute to the Invasive Characteristics of Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
4EGI-1 represses cap-dependent translation and regulates genome-wide translation in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Invest New Drugs
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Cytological Profile of a Case of Malignant Mesothelioma of Pleura with Supraclavicular Lymph Node Metastasis.
</td>
<td style="text-align:left;">
J Cytol
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Effects of human bone marrow stroma on the growth of human tumor cells.
</td>
<td style="text-align:left;">
Cancer Res.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
The promise and challenges of exploiting the proton-coupled folate transporter for selective therapeutic targeting of cancer.
</td>
<td style="text-align:left;">
Cancer Chemother. Pharmacol.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Immunohistochemical distinction of malignant mesothelioma from pulmonary adenocarcinoma with anti-surfactant apoprotein, anti-Lewisa, and anti-Tn antibodies.
</td>
<td style="text-align:left;">
Hum. Pathol.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Mesothelioma in Australia: a review.
</td>
<td style="text-align:left;">
Med. J. Aust.
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
[Prophylactic radiotherapy in a single fraction of 10Gy at intervention pleural site in patient with malignant pleural mesothelioma: A retrospective monocentric cohort study].
</td>
<td style="text-align:left;">
Cancer Radiother
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
High dose irradiation after pleurectomy/decortication or biopsy for pleural mesothelioma treatment.
</td>
<td style="text-align:left;">
Cancer Radiother
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
<i>Ex vivo</i> evaluation of tumor cell specific drug responses in malignant pleural effusions.
</td>
<td style="text-align:left;">
Oncotarget
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Matrix Metalloproteinases Polymorphisms as Prognostic Biomarkers in Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
Dis. Markers
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Efficacy of Cell-Free and Concentrated Ascites Reinfusion Therapy for Palliative Care in a Patient with Malignant Pleural Mesothelioma: A Case Report.
</td>
<td style="text-align:left;">
J Nippon Med Sch
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Evaluation of the pleural malignant mesothelioma patients with the relation of asbestos exposure.
</td>
<td style="text-align:left;">
Environ. Res.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Temporal and spatial heterogeneity of programmed cell death 1-Ligand 1 expression in malignant mesothelioma.
</td>
<td style="text-align:left;">
Oncoimmunology
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
The analysis of novel microRNA mimic sequences in cancer cells reveals lack of specificity in stem-loop RT-qPCR-based microRNA detection.
</td>
<td style="text-align:left;">
BMC Res Notes
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Proton Therapy for Malignant Pleural Mesothelioma: A Three Case Series Describing the Clinical and Dosimetric Advantages of Proton-Based Therapy.
</td>
<td style="text-align:left;">
Cureus
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Abundant expression of TIM-3, LAG-3, PD-1 and PD-L1 as immunotherapy checkpoint targets in effusions of mesothelioma patients.
</td>
<td style="text-align:left;">
Oncotarget
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Effect of an Indwelling Pleural Catheter vs Talc Pleurodesis on Hospitalization Days in Patients With Malignant Pleural Effusion: The AMPLE Randomized Clinical Trial.
</td>
<td style="text-align:left;">
JAMA
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Activity of pirarubicin (4’-0-tetrahydropyranyladriamycin) in malignant mesothelioma.
</td>
<td style="text-align:left;">
Cancer
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant Pleural Mesothelioma: Diagnosis, Staging, Pitfalls and Follow-up.
</td>
<td style="text-align:left;">
Semin. Ultrasound CT MR
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
The importance of serum and pleural fluid level of vascular endothelial growth factor (VEGF) and VEGF fluid/serum ratio in the differential diagnosis of malignant mesothelioma-related pleural effusion.
</td>
<td style="text-align:left;">
Contemp Oncol (Pozn)
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Metastatic malignant mesothelioma in a dog.
</td>
<td style="text-align:left;">
J. Comp. Pathol.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Circulating complement component 4d (C4d) correlates with tumor volume, chemotherapeutic response and survival in patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Sci Rep
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
A Case of the Resected Lymphohistiocytoid Mesothelioma: BAP1 Is a Key of Accurate Diagnosis.
</td>
<td style="text-align:left;">
Anticancer Res.
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Patterns of care and survival among patients with malignant mesothelioma in the United States.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
treatment | epidemiology
</td>
</tr>
<tr>
<td style="text-align:left;">
Diaphragm and lung-preserving surgery with hyperthermic chemotherapy for malignant pleural mesothelioma: A 10-year experience.
</td>
<td style="text-align:left;">
J. Thorac. Cardiovasc. Surg.
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Plasma Fibulin-3 as a Potential Biomarker for Patients with Asbestos-Related Diseases in the Han Population.
</td>
<td style="text-align:left;">
Dis. Markers
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Sudden death as the initial manifestation of diffuse pleural mesothelioma.
</td>
<td style="text-align:left;">
Chest
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Validation of the diagnosis of mesothelioma and BAP1 protein expression in a cohort of asbestos textile workers from Northern Italy.
</td>
<td style="text-align:left;">
Ann. Oncol.
</td>
<td style="text-align:left;">
diagnosis | epidemiology
</td>
</tr>
<tr>
<td style="text-align:left;">
Breath analysis by gas chromatography-mass spectrometry and electronic nose to screen for pleural mesothelioma: a cross-sectional case-control study.
</td>
<td style="text-align:left;">
Oncotarget
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Complement Protein C1q Binds to Hyaluronic Acid in the Malignant Pleural Mesothelioma Microenvironment and Promotes Tumor Growth.
</td>
<td style="text-align:left;">
Front Immunol
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
CAR T-cell immunotherapy of MET-expressing malignant mesothelioma.
</td>
<td style="text-align:left;">
Oncoimmunology
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Predictors of trimodality therapy and trends in therapy for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Eur J Cardiothorac Surg
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Hyaluronic acid enhances cell migration and invasion via the YAP1/TAZ-RHAMM axis in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Oncotarget
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
National Trends in the Epidemiology of Malignant Pleural Mesothelioma: A National Cancer Data Base Study.
</td>
<td style="text-align:left;">
Ann. Thorac. Surg.
</td>
<td style="text-align:left;">
treatment | epidemiology | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Mortality of auto mechanics. A ten-year follow-up.
</td>
<td style="text-align:left;">
Scand J Work Environ Health
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Efficacy of sonographic and biological pleurodesis indicators of malignant pleural effusion (SIMPLE): protocol of a randomised controlled trial.
</td>
<td style="text-align:left;">
BMJ Open Respir Res
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Recent Advances in the Diagnosis of Malignant Mesothelioma: Focus on Approach in Challenging Cases and in Limited Tissue and Cytologic Samples.
</td>
<td style="text-align:left;">
Adv Anat Pathol
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Targeting CXCR4 with [<sup>68</sup>Ga]Pentixafor: a suitable theranostic approach in pleural mesothelioma?
</td>
<td style="text-align:left;">
Oncotarget
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Pseudomesotheliomatous carcinoma of the pleura: an autopsy case of metastasis from a G-CSF-producing anaplastic carcinoma of the pancreas.
</td>
<td style="text-align:left;">
APMIS
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Aberrant Pax-8 expression in well-differentiated papillary mesothelioma and malignant mesothelioma of the peritoneum: a clinicopathologic study.
</td>
<td style="text-align:left;">
Hum. Pathol.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Effect of hyperthermic intrathoracic chemotherapy on the malignant pleural mesothelioma: a systematic review and meta-analysis.
</td>
<td style="text-align:left;">
Oncotarget
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Proteasome stress sensitizes malignant pleural mesothelioma cells to bortezomib-induced apoptosis.
</td>
<td style="text-align:left;">
Sci Rep
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Asbestos fibre burden in gallbladder: A case study.
</td>
<td style="text-align:left;">
Micron
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
The Association Between the FTO rs9939609 Variant and Malignant Pleural Mesothelioma Risk: A Case-Control Study.
</td>
<td style="text-align:left;">
Genet Test Mol Biomarkers
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
A genetic variant of NLRP1 gene is associated with asbestos body burden in patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J. Toxicol. Environ. Health Part A
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Prognostic and Clinicopathological Significance of BAP1 Protein Expression in Different Types of Cancer-A Meta-Analysis.
</td>
<td style="text-align:left;">
Genet Test Mol Biomarkers
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
The epidemiology of malignant mesothelioma in women: gender differences and modalities of asbestos exposure.
</td>
<td style="text-align:left;">
Occup Environ Med
</td>
<td style="text-align:left;">
diagnosis | epidemiology | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Exhaled breath to screen for malignant pleural mesothelioma: a validation study.
</td>
<td style="text-align:left;">
Eur. Respir. J.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
[Is malignant mesothelioma of the pleura only an occupational disease?].
</td>
<td style="text-align:left;">
Minerva Med.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Molecular heterogeneity of malignant pleural mesotheliomas].
</td>
<td style="text-align:left;">
Bull Cancer
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
A Nomogram to Predict Prognosis in Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
World J Surg
</td>
<td style="text-align:left;">
diagnosis | treatment | epidemiology | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Omentin-A Novel Adipokine in Respiratory Diseases.
</td>
<td style="text-align:left;">
Int J Mol Sci
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
18F-Fluorodeoxyglucose PET/CT and dynamic contrast-enhanced MRI as imaging biomarkers in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Nucl Med Commun
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malign pleural mesothelioma - so far an undefeated tumor].
</td>
<td style="text-align:left;">
Vnitr Lek
</td>
<td style="text-align:left;">
diagnosis | treatment | epidemiology | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Focal adhesion kinase a potential therapeutic target for pancreatic cancer and malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Cancer Biol. Ther.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Biological responses to asbestos inhalation and pathogenesis of asbestos-related benign and malignant disease.
</td>
<td style="text-align:left;">
J. Investig. Med.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Radical multimodality therapy for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Cochrane Database Syst Rev
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Cisplatin-induced sudden cardiac death with hemodynamic collapse: a severe adverse drug reaction: Case report.
</td>
<td style="text-align:left;">
Medicine (Baltimore)
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
HSP90 inhibition alters the chemotherapy-driven rearrangement of the oncogenic secretome.
</td>
<td style="text-align:left;">
Oncogene
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Review of malignant pleural mesothelioma survival after talc pleurodesis or surgery.
</td>
<td style="text-align:left;">
J Thorac Dis
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Minor regression and long-time survival (56 months) in a patient with malignant pleural mesothelioma under Viscum album and Helleborus niger extracts-a case report.
</td>
<td style="text-align:left;">
J Thorac Dis
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Biomarker-Integrated Neoadjuvant Dasatinib Trial in Resectable Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
SMARCB1/INI1/BAF47- deficient pleural malignant mesothelioma with rhabdoid features.
</td>
<td style="text-align:left;">
Pathol. Int.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Germline and somatic variant identification using BGISEQ-500 and HiSeq X Ten whole genome sequencing.
</td>
<td style="text-align:left;">
PLoS ONE
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Success rate of medical thoracoscopy and talc pleurodesis in malignant pleurisy: A single-centre experience.
</td>
<td style="text-align:left;">
Respirology
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Nuclear grade and necrosis predict prognosis in malignant epithelioid pleural mesothelioma: a multi-institutional study.
</td>
<td style="text-align:left;">
Mod. Pathol.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Induction of protein citrullination and auto-antibodies production in murine exposed to nickel nanomaterials.
</td>
<td style="text-align:left;">
Sci Rep
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Clinical evaluation of circulating miR-548a-3p and -20a expression in malignant pleural mesothelioma patients.
</td>
<td style="text-align:left;">
Biomark Med
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Pseudomesotheliomatous carcinoma of the lung.
</td>
<td style="text-align:left;">
Vojnosanit Pregl
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Heterogeneous Contributing Factors in MPM Disease Development and Progression: Biological Advances and Clinical Implications.
</td>
<td style="text-align:left;">
Int J Mol Sci
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Treatment of Malignant Pleural Mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline.
</td>
<td style="text-align:left;">
J. Clin. Oncol.
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma in situ.
</td>
<td style="text-align:left;">
Histopathology
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma as a difficult interdisciplinary problem.
</td>
<td style="text-align:left;">
Kardiochir Torakochirurgia Pol
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Mesothelioma With a Large Prevascular Lymph Node: N1 Involvement or Something Different?
</td>
<td style="text-align:left;">
Ann. Thorac. Surg.
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Expression analysis of HMGB1 in histological samples of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Histopathology
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Survivin is a negative prognostic factor in malignant pleural effusion.
</td>
<td style="text-align:left;">
Eur. J. Clin. Invest.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Systemic Treatment of Malignant Pleural Mesothelioma].
</td>
<td style="text-align:left;">
Gan To Kagaku Ryoho
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Therapeutic potential of targeting S100A11 in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Oncogenesis
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Is Pleurectomy/Decortication Superior to Extrapleural Pneumonectomy for Patients with Malignant Pleural Mesothelioma? A Single-Institutional Experience.
</td>
<td style="text-align:left;">
Ann Thorac Cardiovasc Surg
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Large-scale copy number analysis reveals variations in genes not previously associated with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Oncotarget
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
<i>SFRP</i> Tumour Suppressor Genes Are Potential Plasma-Based Epigenetic Biomarkers for Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
Dis. Markers
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Multiple intracranial metastases from postoperative giant sarcomatoid malignant pleural mesothelioma: A case report and literature review.
</td>
<td style="text-align:left;">
Mol Clin Oncol
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Content validity and electronic PRO (ePRO) usability of the Lung Cancer Symptom Scale-Mesothelioma (LCSS-Meso) in mesothelioma patients.
</td>
<td style="text-align:left;">
Support Care Cancer
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Bromodomain inhibition exerts its therapeutic potential in malignant pleural mesothelioma by promoting immunogenic cell death and changing the tumor immune-environment.
</td>
<td style="text-align:left;">
Oncoimmunology
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Single-institution experience of intensity-modulated radiotherapy for malignant pleural mesothelioma at University of Catania.
</td>
<td style="text-align:left;">
Future Oncol
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Evaluating quality of life and cost implications of prophylactic radiotherapy in mesothelioma: Health economic analysis of the SMART trial.
</td>
<td style="text-align:left;">
PLoS ONE
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Radiofrequency Ablation Effectively Treated Focal Recurrence of Mesothelioma.
</td>
<td style="text-align:left;">
Ann. Thorac. Surg.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Vascular endothelial growth factor in pleural effusions and correlation with radiologic and biochemical parameters.
</td>
<td style="text-align:left;">
Niger J Clin Pract
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Computed tomography in the evaluation of malignant pleural mesothelioma-Association of tumor size to a sarcomatoid histology, a more advanced TNM stage and poor survival.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Progress and challenges in Mesothelioma: From bench to bedside.
</td>
<td style="text-align:left;">
Respir Med
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Anti-tumor immunotherapy in malignant pleural mesothelioma].
</td>
<td style="text-align:left;">
Rev Mal Respir
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Inflammatory Alteration of Human T Cells Exposed Continuously to Asbestos.
</td>
<td style="text-align:left;">
Int J Mol Sci
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Outcomes of the Multimodal Treatment of Malignant Pleural Mesiothelioma: The Role of Surgery.
</td>
<td style="text-align:left;">
Korean J Thorac Cardiovasc Surg
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma with squamous differentiation.
</td>
<td style="text-align:left;">
Histopathology
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Correction: Apoptosis by [Pt(O,O’-acac)(γ-acac)(DMS)] requires PKC-δ mediated p53 activation in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
PLoS ONE
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Real-life feasibility of home-based pulmonary rehabilitation in chemotherapy-treated patients with thoracic cancers: a pilot study.
</td>
<td style="text-align:left;">
BMC Cancer
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
An RNAi-based screen reveals PLK1, CDK1 and NDC80 as potential therapeutic targets in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Br. J. Cancer
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
A prospective study to investigate the role of serial serum mesothelin in monitoring mesothelioma.
</td>
<td style="text-align:left;">
BMC Cancer
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Secreted and Tissue miRNAs as Diagnosis Biomarkers of Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
Int J Mol Sci
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Survival prediction in mesothelioma using a scalable Lasso regression model: instructions for use and initial performance using clinical predictors.
</td>
<td style="text-align:left;">
BMJ Open Respir Res
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Prognostic Impact of Inflammation-related Biomarkers on Overall Survival of Patients with Inoperable Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
In Vivo
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Determinants of malignant pleural mesothelioma survival and burden of disease in France: a national cohort analysis.
</td>
<td style="text-align:left;">
Cancer Med
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant Mesothelioma and Its Non-Asbestos Causes.
</td>
<td style="text-align:left;">
Arch. Pathol. Lab. Med.
</td>
<td style="text-align:left;">
epidemiology | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma presenting with remitting-relapsing pleural effusions: report of two cases.
</td>
<td style="text-align:left;">
Respirol Case Rep
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Non-incisional pleurectomy-decortication for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Surg. Today
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Stem Cells Application in Thoracic Surgery: Current Perspective and Future Directions.
</td>
<td style="text-align:left;">
Adv. Exp. Med. Biol.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Immunohistochemical Expression of Aquaporin-1 in Fluoro-Edenite-Induced Malignant Mesothelioma: A Preliminary Report.
</td>
<td style="text-align:left;">
Int J Mol Sci
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
<sup>18</sup>F-FDG PET/CT in the management of patients with malignant pleural mesothelioma being considered for multimodality therapy: experience of a tertiary referral center.
</td>
<td style="text-align:left;">
Br J Radiol
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
The C-Reactive Protein/Albumin Ratio is a Novel Significant Prognostic Factor in Patients with Malignant Pleural Mesothelioma: A Retrospective Multi-institutional Study.
</td>
<td style="text-align:left;">
Ann. Surg. Oncol.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Mesothelin and osteopontin as circulating markers of diffuse malignant peritoneal mesothelioma: A preliminary study.
</td>
<td style="text-align:left;">
Eur J Surg Oncol
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Rapid diffuse pleural thickening due to metastatic meningioma.
</td>
<td style="text-align:left;">
Respirol Case Rep
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Physicochemical and pharmacokinetic properties of polymeric films loaded with cisplatin for the treatment of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Dis
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Polymeric films loaded with cisplatin for malignant pleural mesothelioma: a pharmacokinetic study in an ovine model.
</td>
<td style="text-align:left;">
J Thorac Dis
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Hyperthermic intrathoracic chemotherapy after extended pleurectomy and decortication for malignant pleura mesothelioma: an observational study on outcome and microcirculatory changes.
</td>
<td style="text-align:left;">
J Thorac Dis
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
The genetic susceptibility in the development of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Dis
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Clinical diagnosis of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Dis
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Imaging of malignant pleural mesothelioma: it is possible a screening or early diagnosis program?-a systematic review about the use of screening programs in a population of asbestos exposed workers.
</td>
<td style="text-align:left;">
J Thorac Dis
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Endoscopic diagnosis and management of pleural effusion in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Dis
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
The pathological and molecular diagnosis of malignant pleural mesothelioma: a literature review.
</td>
<td style="text-align:left;">
J Thorac Dis
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Surgery for malignant pleural mesothelioma: an international guidelines review.
</td>
<td style="text-align:left;">
J Thorac Dis
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
The role of intracavitary therapies in the treatment of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Dis
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Diaphragmatic and pericardial reconstruction after surgery for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Dis
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Chemotherapy treatment in malignant pleural mesothelioma: a difficult history.
</td>
<td style="text-align:left;">
J Thorac Dis
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Target therapy: new drugs or new combinations of drugs in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Dis
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
New horizons from immunotherapy in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Dis
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Medical treatment of malignant pleural mesothelioma relapses.
</td>
<td style="text-align:left;">
J Thorac Dis
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Molecular markers and new diagnostic methods to differentiate malignant from benign mesothelial pleural proliferations: a literature review.
</td>
<td style="text-align:left;">
J Thorac Dis
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Serum mesothelin and other biomarkers: what have we learned in the last decade?
</td>
<td style="text-align:left;">
J Thorac Dis
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Overexpressed genes in malignant pleural mesothelioma: implications in clinical management.
</td>
<td style="text-align:left;">
J Thorac Dis
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Novel therapies for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Lancet Oncol.
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Reproducibility of Malignant Pleural Mesothelioma Histopathologic Subtyping.
</td>
<td style="text-align:left;">
Arch. Pathol. Lab. Med.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Macroscopic complete resection is not associated with improved survival in patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J. Thorac. Cardiovasc. Surg.
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Influence of inter-observer delineation variability on radiomics stability in different tumor sites.
</td>
<td style="text-align:left;">
Acta Oncol
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma immune microenvironment and checkpoint expression: correlation with clinical-pathological features and intratumor heterogeneity over time.
</td>
<td style="text-align:left;">
Ann. Oncol.
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Aminopeptidase N/CD13 as a potential therapeutic target in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Eur. Respir. J.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
DNA methylation profiling of asbestos-treated MeT5A cell line reveals novel pathways implicated in asbestos response.
</td>
<td style="text-align:left;">
Arch. Toxicol.
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Progress in the Management of Malignant Pleural Mesothelioma in 2017.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
<td style="text-align:left;">
diagnosis | treatment | epidemiology | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Live-Cell Mesothelioma Biobank to Explore Mechanisms of Tumor Progression.
</td>
<td style="text-align:left;">
Front Oncol
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Implementation of Hyperthermic Intrathoracic Chemotherapy (HITHOC) in Germany].
</td>
<td style="text-align:left;">
Zentralbl Chir
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Drug repurposing in malignant pleural mesothelioma: a breath of fresh air?
</td>
<td style="text-align:left;">
Eur Respir Rev
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Post-irradiation pericardial malignant mesothelioma with deletion of p16: a case report.
</td>
<td style="text-align:left;">
Cancer Biol Med
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Phase I Study of Intrapleural Gene-Mediated Cytotoxic Immunotherapy in Patients with Malignant Pleural Effusion.
</td>
<td style="text-align:left;">
Mol. Ther.
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Updates in the diagnosis and treatment of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Curr Opin Pulm Med
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Targeting the Hippo Pathway Is a New Potential Therapeutic Modality for Malignant Mesothelioma.
</td>
<td style="text-align:left;">
Cancers (Basel)
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Low-dose chest computed tomography screening of subjects exposed to asbestos.
</td>
<td style="text-align:left;">
Eur J Radiol
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Early Contrast Enhancement: A novel magnetic resonance imaging biomarker of pleural malignancy.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Environmental asbestos exposure and mesothelioma cases in Bari, Apulia region, southern Italy: a national interest site for land reclamation.
</td>
<td style="text-align:left;">
Environ Sci Pollut Res Int
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Inhibition of yes-associated protein down-regulates PD-L1 (CD274) expression in human malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J. Cell. Mol. Med.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant Peritoneal Mesothelioma Presenting as Mucinous Ascites.
</td>
<td style="text-align:left;">
ACG Case Rep J
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Involvement of Heparanase in the Pathogenesis of Mesothelioma: Basic Aspects and Clinical Applications.
</td>
<td style="text-align:left;">
J. Natl. Cancer Inst.
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Quality of life of survivors of malignant pleural mesothelioma in Japan: a cross sectional study.
</td>
<td style="text-align:left;">
BMC Cancer
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Primary Spinal Malignant Mesothelioma: A Case Report and Literature Review.
</td>
<td style="text-align:left;">
World Neurosurg
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
SYSTEMS-2: A randomised phase II study of radiotherapy dose escalation for pain control in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Clin Transl Radiat Oncol
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Heterogeneity in Immune Cell Content in Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
Int J Mol Sci
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Utility of Site-Specific Biopsy for Diagnosis of Desmoplastic Malignant Mesothelioma.
</td>
<td style="text-align:left;">
Ann. Thorac. Surg.
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant Pleural Mesothelioma with Bone Marrow Metastases.
</td>
<td style="text-align:left;">
Intern. Med.
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
MR Imaging of Pleural Neoplasms.
</td>
<td style="text-align:left;">
Top Magn Reson Imaging
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant Pleural Mesothelioma: Are There Imaging Characteristics Associated With Different Histologic Subtypes on Computed Tomography?
</td>
<td style="text-align:left;">
J Comput Assist Tomogr
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma: diagnostic value of medical thoracoscopy and long-term prognostic analysis.
</td>
<td style="text-align:left;">
BMC Pulm Med
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Randomised controlled trial to compare the diagnostic yield of positron emission tomography CT (PET-CT) TARGETed pleural biopsy versus CT-guided pleural biopsy in suspected pleural malignancy (TARGET trial).
</td>
<td style="text-align:left;">
BMJ Open Respir Res
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Poor Prognostic Factors in Patients with Malignant Pleural Mesothelioma Classified as Pathological Stage IB According to the Eighth Edition TNM Classification.
</td>
<td style="text-align:left;">
Ann. Surg. Oncol.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Comprehensive immunoproteogenomic analyses of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
JCI Insight
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
The current aetiology of malignant pleural effusion in the Western Cape Province, South Africa.
</td>
<td style="text-align:left;">
S. Afr. Med. J.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
FGF2 and EGF induce epithelial-mesenchymal transition in malignant pleural mesothelioma cells via a MAPKinase/MMP1 signal.
</td>
<td style="text-align:left;">
Carcinogenesis
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Carbon Nanotubes and Other Engineered Nanoparticles Induced Pathophysiology on Mesothelial Cells and Mesothelial Membranes.
</td>
<td style="text-align:left;">
Front Physiol
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
CA125 suppresses amatuximab immune-effector function and elevated serum levels are associated with reduced clinical response in first line mesothelioma patients.
</td>
<td style="text-align:left;">
Cancer Biol. Ther.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant cells from pleural fluids in malignant mesothelioma patients reveal novel mutations.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
New Perspectives on Diagnosis and Therapy of Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
Front Oncol
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) for the treatment of malignant mesothelioma.
</td>
<td style="text-align:left;">
BMC Cancer
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
A review of the cohorts with environmental and occupational mineral fiber exposure.
</td>
<td style="text-align:left;">
Arch Environ Occup Health
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Video-assisted thoracoscopic PlasmaJet ablation for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J Vis Surg
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant pleural mesothelioma].
</td>
<td style="text-align:left;">
Ugeskr. Laeg.
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
In Silico and In Vitro Analyses of LncRNAs as Potential Regulators in the Transition from the Epithelioid to Sarcomatoid Histotype of Malignant Pleural Mesothelioma (MPM).
</td>
<td style="text-align:left;">
Int J Mol Sci
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
MiR-21 over-expression and Programmed Cell Death 4 down-regulation features malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Oncotarget
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Prospective registry database of patients with malignant mesothelioma: directions for a future Japanese registry-based lung cancer study.
</td>
<td style="text-align:left;">
J Thorac Dis
</td>
<td style="text-align:left;">
treatment | epidemiology | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Prognostic factors and treatment outcomes of malignant pleural mesothelioma in Eastern Asian patients - A Taiwanese study.
</td>
<td style="text-align:left;">
J. Formos. Med. Assoc.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Increased micronucleus count predicts malignant behavior in pleural effusion fluid
</td>
<td style="text-align:left;">
Turk J Med Sci
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
On the diagnosis of malignant pleural mesothelioma: A necropsy-based study of 171 cases (1997-2016).
</td>
<td style="text-align:left;">
Tumori
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma presenting as recurrent hydro-pneumothorax: An atypical case presentation and literature review.
</td>
<td style="text-align:left;">
Respir Med Case Rep
</td>
<td style="text-align:left;">
diagnosis | epidemiology | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Expression of plakophilin 3 in diffuse malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Histol. Histopathol.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Nintedanib Is Active in Malignant Pleural Mesothelioma Cell Models and Inhibits Angiogenesis and Tumor Growth <i>In Vivo</i>.
</td>
<td style="text-align:left;">
Clin. Cancer Res.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Ipilimumab/Nivolumab-related Opsoclonus-Myoclonus-Ataxia Syndrome Variant in a Patient with Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
J. Immunother.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Loss of C/EBP-β LIP drives cisplatin resistance in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Facility volume and postoperative outcomes for malignant pleural mesothelioma: A National Cancer Data Base analysis.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Aberrant Lck Signal via CD28 Costimulation Augments Antigen-Specific Functionality and Tumor Control by Redirected T Cells with PD-1 Blockade in Humanized Mice.
</td>
<td style="text-align:left;">
Clin. Cancer Res.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
A Phase I Trial of Surgical Resection and Intraoperative Hyperthermic Cisplatin and Gemcitabine for Pleural Mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Revised Modified Response Evaluation Criteria in Solid Tumors for Assessment of Response in Malignant Pleural Mesothelioma (Version 1.1).
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
NGR-hTNF in combination with best investigator choice in previously treated malignant pleural mesothelioma (NGR015): a randomised, double-blind, placebo-controlled phase 3 trial.
</td>
<td style="text-align:left;">
Lancet Oncol.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Four immunohistochemical assays to measure the PD-L1 expression in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Oncotarget
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
A subgroup of pleural mesothelioma expresses ALK protein and may be targetable by combined rapamycin and crizotinib therapy.
</td>
<td style="text-align:left;">
Oncotarget
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
How to assess the best immunohistochemical panel in the diagnosis of malignant pleural mesothelioma in a pathology lab.
</td>
<td style="text-align:left;">
J Immunoassay Immunochem
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Correction: Diagnostic and prognostic utilities of humoral fibulin-3 in malignant pleural mesothelioma: Evidence from a meta-analysis.
</td>
<td style="text-align:left;">
Oncotarget
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, phase 2 study.
</td>
<td style="text-align:left;">
Lancet Respir Med
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Targeting Tie-2/angiopoietin axis in experimental mesothelioma confers differential responses and raises predictive implications.
</td>
<td style="text-align:left;">
Oncotarget
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Health impact of asbestos fibres naturally occurring in Mount Pollino area (Basilicata Region, Southern Italy)].
</td>
<td style="text-align:left;">
Epidemiol Prev
</td>
<td style="text-align:left;">
epidemiology
</td>
</tr>
<tr>
<td style="text-align:left;">
Longevity and pleural mesothelioma: age-period-cohort analysis of incidence data from the Surveillance, Epidemiology, and End Results (SEER) Program, 1973-2013.
</td>
<td style="text-align:left;">
BMC Res Notes
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
A preclinical model to investigate the role of surgically-induced inflammation in tumor responses to intraoperative photodynamic therapy.
</td>
<td style="text-align:left;">
Lasers Surg Med
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
The diagnostic role of BAP1 in serous effusions.
</td>
<td style="text-align:left;">
Hum. Pathol.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Utilization of Intensity-Modulated Radiation Therapy for Malignant Pleural Mesothelioma in the United States.
</td>
<td style="text-align:left;">
Clin Lung Cancer
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Effects of Reduction in Tumor Burden on Survival in Epithelioid Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
Mayo Clin. Proc.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
<sup>18</sup>F-fluorodeoxyglucose imaging of primary malignant pericardial mesothelioma with concurrent pericardial and pleural effusions and bone metastasis: A case report.
</td>
<td style="text-align:left;">
Mol Clin Oncol
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Is there a role for immunotherapy in malignant pleural mesothelioma?
</td>
<td style="text-align:left;">
Med. Oncol.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Critical role of the Ror-family of receptor tyrosine kinases in invasion and proliferation of malignant pleural mesothelioma cells.
</td>
<td style="text-align:left;">
Genes Cells
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Heterogeneity in Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
Int J Mol Sci
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
A case of malignant mesothelioma detected hydropneumothorax.
</td>
<td style="text-align:left;">
J Thorac Dis
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
A Phase II Trial of First-Line Combination Chemotherapy With Cisplatin, Pemetrexed, and Nivolumab for Unresectable Malignant Pleural Mesothelioma: A Study Protocol.
</td>
<td style="text-align:left;">
Clin Lung Cancer
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Immunohistochemically detectable metallothionein expression in malignant pleural mesotheliomas is strongly associated with early failure to platin-based chemotherapy.
</td>
<td style="text-align:left;">
Oncotarget
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Soluble CD157 in pleural effusions: a complementary tool for the diagnosis of malignant mesothelioma.
</td>
<td style="text-align:left;">
Oncotarget
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Surgical Options for Malignant Mesothelioma: A Single-Center Experience.
</td>
<td style="text-align:left;">
Korean J Thorac Cardiovasc Surg
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Diagnostic yield of pleural fluid cytology in malignant effusions: an Australian tertiary centre experience.
</td>
<td style="text-align:left;">
Intern Med J
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Aquaporin-1 expression in fluoro-edenite-induced mesothelioma effusions: An approach by cell-block procedure.
</td>
<td style="text-align:left;">
Cytopathology
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Proton beam therapy for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Transl Lung Cancer Res
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
FDG PET-derived parameters as prognostic tool in progressive malignant pleural mesothelioma treated patients.
</td>
<td style="text-align:left;">
Eur. J. Nucl. Med. Mol. Imaging
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Air in the Pleural Cavity Enhances Detection of Pleural Abnormalities by CT Scan.
</td>
<td style="text-align:left;">
Chest
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma following radiotherapy in a 16-year-old boy.
</td>
<td style="text-align:left;">
Cancer
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural effusions.
</td>
<td style="text-align:left;">
Clin. Chest Med.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Integrated Histogenetic Analysis Reveals <i>BAP1</i>-Mutated Epithelioid Mesothelioma in a Patient With Cancer of Unknown Primary.
</td>
<td style="text-align:left;">
J Natl Compr Canc Netw
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
The cisplatin-based Pt(iv)-diclorofibrato multi-action anticancer prodrug exhibits excellent performances also under hypoxic conditions.
</td>
<td style="text-align:left;">
Dalton Trans
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Comparative proteomic analysis of malignant pleural mesothelioma: Focusing on the biphasic subtype.
</td>
<td style="text-align:left;">
EuPA Open Proteom
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
[A case-control study on the relationship between food preference and lung cancer and mesothelioma in a rural area with naturally occurring asbestos].
</td>
<td style="text-align:left;">
Wei Sheng Yan Jiu
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Inactivation of Tp53 and Pten drives rapid development of pleural and peritoneal malignant mesotheliomas.
</td>
<td style="text-align:left;">
J. Cell. Physiol.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Compensation, radiographic changes, and survival in applicants for asbestosis compensation.
</td>
<td style="text-align:left;">
Br J Ind Med
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleural mesothelioma: is the surgeon still there?
</td>
<td style="text-align:left;">
Ann. Oncol.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Programmed Death 1 Blockade With Nivolumab in Patients With Recurrent Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Biomarkers for Early Diagnosis and Prognosis of Malignant Pleural Mesothelioma: The Quest Goes on.
</td>
<td style="text-align:left;">
Cancers (Basel)
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Mesothelioma in Italy: the Casale Monferrato model to a national epidemiological surveillance system.
</td>
<td style="text-align:left;">
Ann. Ist. Super. Sanita
</td>
<td style="text-align:left;">
epidemiology
</td>
</tr>
<tr>
<td style="text-align:left;">
Increased sensitivity to apoptosis upon endoplasmic reticulum stress-induced activation of the unfolded protein response in chemotherapy-resistant malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Br. J. Cancer
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Quantitative Clinical Staging for Patients With Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
J. Natl. Cancer Inst.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Biological mechanisms of non-linear dose-response for respirable mineral fibers.
</td>
<td style="text-align:left;">
Toxicol. Appl. Pharmacol.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Immune checkpoint blockade therapy of mesothelioma: a clinical and radiological challenge.
</td>
<td style="text-align:left;">
Cancer Immunol. Immunother.
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Assessment of new HDAC inhibitors for immunotherapy of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Clin Epigenetics
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Experimental Model of Human Malignant Mesothelioma in Athymic Mice.
</td>
<td style="text-align:left;">
Int J Mol Sci
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Trophoblast Glycoprotein is Associated With a Favorable Outcome for Mesothelioma and a Target for Antibody Drug Conjugates.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Computed tomographic findings in diffuse malignant pleural mesothelioma].
</td>
<td style="text-align:left;">
Rofo
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Multisensor Imaging-From Sample Preparation to Integrated Multimodal Interpretation of LA-ICPMS and MALDI MS Imaging Data.
</td>
<td style="text-align:left;">
Anal. Chem.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Scientific Advances and New Frontiers in Mesothelioma Therapeutics.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Dynamic contrast-enhanced CT for the assessment of tumour response in malignant pleural mesothelioma: a pilot study.
</td>
<td style="text-align:left;">
Eur Radiol
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Nivolumab Immunotherapy in Malignant Mesothelioma: A Case Report Highlighting a New Opportunity for Exceptional Outcomes.
</td>
<td style="text-align:left;">
Am J Case Rep
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Chemo-manipulation of tumor blood vessels by a metal-based anticancer complex enhances antitumor therapy.
</td>
<td style="text-align:left;">
Sci Rep
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
The role of pemetrexed in recurrent epithelial ovarian cancer: A scoping review.
</td>
<td style="text-align:left;">
Oncol Rev
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Epidemiological surveillance of mesothelioma mortality in Italy.
</td>
<td style="text-align:left;">
Cancer Epidemiol
</td>
<td style="text-align:left;">
epidemiology | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Asbestos exposure, smoking habits, and cancer incidence among production and maintenance workers in an electrochemical plant.
</td>
<td style="text-align:left;">
Am. J. Ind. Med.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
What is the significance of non-specific pleuritis? A trick question.
</td>
<td style="text-align:left;">
Clin Respir J
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Biomarkers for Predicting Malignant Pleural Mesothelioma in a Mexican Population.
</td>
<td style="text-align:left;">
Int J Med Sci
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Matrix Metalloproteinases Polymorphisms as Baseline Risk Predictors in Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
Radiol Oncol
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
A Clinical Trial of TumorGlow to Identify Residual Disease During Pleurectomy and Decortication.
</td>
<td style="text-align:left;">
Ann. Thorac. Surg.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Combined hyaluronate-based films loaded with pemetrexed and cisplatin for the treatment of malignant pleural mesothelioma: Preliminary evaluation in an orthotopic tumor recurrence model.
</td>
<td style="text-align:left;">
Eur J Pharm Sci
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Aggressive versus symptom-guided drainage of malignant pleural effusion via indwelling pleural catheters (AMPLE-2): an open-label randomised trial.
</td>
<td style="text-align:left;">
Lancet Respir Med
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
The Diagnosis of Pleural Tumors Other Than Mesothelioma.
</td>
<td style="text-align:left;">
Arch. Pathol. Lab. Med.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Cytopathologic Diagnosis of Epithelioid and Mixed-Type Malignant Mesothelioma: Ten Years of Clinical Experience in Relation to International Guidelines.
</td>
<td style="text-align:left;">
Arch. Pathol. Lab. Med.
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
A systematic review and meta-analysis of second-line therapies for treatment of mesothelioma.
</td>
<td style="text-align:left;">
Respir Med
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
ERS/EACTS statement on the management of malignant pleural effusions.
</td>
<td style="text-align:left;">
Eur. Respir. J.
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Mismatch Repair Protein Defects and Microsatellite Instability in Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
ERS/EACTS statement on the management of malignant pleural effusions.
</td>
<td style="text-align:left;">
Eur J Cardiothorac Surg
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Genomics and Epigenetics of Malignant Mesothelioma.
</td>
<td style="text-align:left;">
High Throughput
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleural tumours and tumour-like lesions.
</td>
<td style="text-align:left;">
Clin Radiol
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Upcoming epidemic of asbestos-related malignant pleural mesothelioma in Taiwan: A prediction of incidence in the next 30 years.
</td>
<td style="text-align:left;">
J. Formos. Med. Assoc.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
The Economic Impact of Clinical Research in an Italian Public Hospital: The Malignant Pleural Mesothelioma Case Study.
</td>
<td style="text-align:left;">
Int J Health Policy Manag
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Measurement of telomere length in cells from pleural effusion: Asbestos exposure causes telomere shortening in pleural mesothelial cells.
</td>
<td style="text-align:left;">
Pathol. Int.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Double cancer comprising malignant pleural mesothelioma and squamous cell carcinoma of the lung treated with radiotherapy: A case report.
</td>
<td style="text-align:left;">
Mol Clin Oncol
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant Pleural Mesothelioma, Biphasic Type: An Unusual and Insidious Case of Rapidly Progressive Small Blue Cell Tumor.
</td>
<td style="text-align:left;">
Cureus
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Benign and malignant pleural effusions in former Wittenoom crocidolite millers and miners.
</td>
<td style="text-align:left;">
Aust N Z J Med
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Inhibition of MDM2 via Nutlin-3A: A Potential Therapeutic Approach for Pleural Mesotheliomas with MDM2-Induced Inactivation of Wild-Type P53.
</td>
<td style="text-align:left;">
J Oncol
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Frequency of Germline Mutations in Cancer Susceptibility Genes in Malignant Mesothelioma.
</td>
<td style="text-align:left;">
J. Clin. Oncol.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Surgery in Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
5-hydroxymethylcytosine but not MTAP methylation status can stratify malignant pleural mesothelioma based on the lineage of origin.
</td>
<td style="text-align:left;">
Multidiscip Respir Med
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Current treatments and trials in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Clin Respir J
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Pseudomesotheliomatous Primary Squamous Cell Lung Carcinoma: The First Case Reported in Turkey and a Review of the Literature.
</td>
<td style="text-align:left;">
Open Med (Wars)
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Pembrolizumab as Palliative Immunotherapy in Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Pemetrexed, Vitamin B12, and Thoracic Tumors: The Times, They Are A-Changin’.
</td>
<td style="text-align:left;">
Clin Lung Cancer
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
ADP sensitizes ZL55 cells to the activity of cisplatin.
</td>
<td style="text-align:left;">
J. Cell. Physiol.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Nuclear grading, BAP1, mesothelin and PD-L1 expression in malignant pleural mesothelioma: prognostic implications.
</td>
<td style="text-align:left;">
Pathology
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Early-stage Clinical Characterization of Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
In Vivo
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Ancillary studies in pleural, pericardial, and peritoneal effusion cytology.
</td>
<td style="text-align:left;">
Cancer Cytopathol
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
BAMLET kills chemotherapy-resistant mesothelioma cells, holding oleic acid in an activated cytotoxic state.
</td>
<td style="text-align:left;">
PLoS ONE
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Zoledronic acid in the management of mesothelioma - a feasibility study (Zol-A Trial): study protocol for a randomised controlled trial.
</td>
<td style="text-align:left;">
Trials
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Anesthetic Management of Pleurectomy/Decortication Under Differential Lung Ventilation.
</td>
<td style="text-align:left;">
Kurume Med J
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[PLEURECTOMY/DECORTICATION].
</td>
<td style="text-align:left;">
Nihon Geka Gakkai Zasshi
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant pleural mesothelioma. Value of 67Ga scintigraphy compared to computerized tomography].
</td>
<td style="text-align:left;">
Rofo
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleural malignant mesothelioma versus pleuropulmonary synovial sarcoma: a clinicopathological study of 22 cases with molecular analysis and survival data.
</td>
<td style="text-align:left;">
Pathology
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleural malignant mesothelioma following Wilms’ tumor.
</td>
<td style="text-align:left;">
Am. J. Clin. Pathol.
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma caused by childhood exposure to long-fiber low aspect ratio tremolite.
</td>
<td style="text-align:left;">
Am. J. Ind. Med.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Modification of existing patient-reported outcome measures: qualitative development of the MD Anderson Symptom Inventory for malignant pleural mesothelioma (MDASI-MPM).
</td>
<td style="text-align:left;">
Qual Life Res
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Updates in Effusion Cytology.
</td>
<td style="text-align:left;">
Surg Pathol Clin
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Thrombocytosis in patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Cancer
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Familial risk of pleural mesothelioma increased drastically in certain occupations: A nationwide prospective cohort study.
</td>
<td style="text-align:left;">
Eur. J. Cancer
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Targeting CD26 suppresses proliferation of malignant mesothelioma cell via downmodulation of ubiquitin-specific protease 22.
</td>
<td style="text-align:left;">
Biochem. Biophys. Res. Commun.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Expression of Numb and Gli1 in malignant pleural mesothelioma and their clinical significance.
</td>
<td style="text-align:left;">
J Cancer Res Ther
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Evaluation of the photon dose calculation accuracy in radiation therapy of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J Cancer Res Ther
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Adjuvant, neoadjuvant, and definitive radiation therapy for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Dis
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Diagnostic value of the combined determination of carcinoembryonic antigen (CEA) in pleural effusion and serum with an enzyme immunoassay (EIA). Sensitivity, specificity and relation to tumor type].
</td>
<td style="text-align:left;">
Wien. Klin. Wochenschr.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Survival by Histologic Subtype of Malignant Pleural Mesothelioma and the Impact of Surgical Resection on Overall Survival.
</td>
<td style="text-align:left;">
Clin Lung Cancer
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Preclinical investigation of folate receptor-targeted nanoparticles for photodynamic therapy of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Int. J. Oncol.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Intensity-modulated radiotherapy is a safe and effective treatment for localized malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Thorac Cancer
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Autologous Dendritic Cell Therapy in Mesothelioma Patients Enhances Frequencies of Peripheral CD4 T Cells Expressing HLA-DR, PD-1, or ICOS.
</td>
<td style="text-align:left;">
Front Immunol
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Novel platinum agents and mesenchymal stromal cells for thoracic malignancies: state of the art and future perspectives.
</td>
<td style="text-align:left;">
Expert Opin Ther Pat
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Pathologic Grading of Malignant Pleural Mesothelioma: An Evidence-Based Proposal.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Epidemiological and environmental evidence of the health effects of exposure to erionite fibres: a four-year study in the Cappadocian region of Turkey.
</td>
<td style="text-align:left;">
Int. J. Cancer
</td>
<td style="text-align:left;">
epidemiology
</td>
</tr>
<tr>
<td style="text-align:left;">
Moderately Hypofractionated Helical IMRT, FDG-PET/CT-guided, for Progressive Malignant Pleural Mesothelioma in Patients With Intact Lungs.
</td>
<td style="text-align:left;">
Clin Lung Cancer
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
An Occupational Legacy: Malignant Mesothelioma Incidence and Mortality in Wisconsin.
</td>
<td style="text-align:left;">
J. Occup. Environ. Med.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Four-miRNA Signature to Identify Asbestos-Related Lung Malignancies.
</td>
<td style="text-align:left;">
Cancer Epidemiol. Biomarkers Prev.
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
What’s new in mesothelioma.
</td>
<td style="text-align:left;">
Pathologica
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Investigating unilateral pleural effusions: the role of cytology.
</td>
<td style="text-align:left;">
Eur. Respir. J.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Current and Future Management of Malignant Mesothelioma: A Consensus Report from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Current efforts in research of pleural mesothelioma-An analysis of the ClinicalTrials.gov registry.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Tumor-specific genetic variants can be detected in circulating cell-free DNA of malignant pleural mesothelioma patients.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Antibody drug conjugates in thoracic malignancies.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Highlights of the 14th international mesothelioma interest group meeting: Pathologic separation of benign from malignant mesothelial proliferations and histologic/molecular analysis of malignant mesothelioma subtypes.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Curcumin induces apoptosis and inhibits angiogenesis in murine malignant mesothelioma.
</td>
<td style="text-align:left;">
Int. J. Oncol.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Berberine induces mitochondrial‑mediated apoptosis and protective autophagy in human malignant pleural mesothelioma NCI‑H2452 cells.
</td>
<td style="text-align:left;">
Oncol. Rep.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Is There a Role for Cancer-Directed Surgery in Early-Stage Sarcomatoid or Biphasic Mesothelioma?
</td>
<td style="text-align:left;">
Ann. Thorac. Surg.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Short-term outcomes of pleurectomy decortication and extrapleural pneumonectomy in mesothelioma.
</td>
<td style="text-align:left;">
J Surg Oncol
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
[Clinical and pathological profile of the pleural malignant mesothelioma: A retrospective study about 30 cases].
</td>
<td style="text-align:left;">
Rev Pneumol Clin
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant Pleural Mesothelioma presenting with Cardiac Tamponade- A Rare Case report and Review of the literature.
</td>
<td style="text-align:left;">
Clin Case Rep Rev
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Quantitative mass spectrometry to identify protein markers for diagnosis of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J Proteomics
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Genomic Deletion of <i>BAP1</i> and <i>CDKN2A</i> Are Useful Markers for Quality Control of Malignant Pleural Mesothelioma (MPM) Primary Cultures.
</td>
<td style="text-align:left;">
Int J Mol Sci
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Prophylactic procedure tract radiotherapy for malignant pleural mesothelioma: A systematic review and meta-analysis.
</td>
<td style="text-align:left;">
Clin Transl Radiat Oncol
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Brain-derived neurotrophic factor, a new soluble biomarker for malignant pleural mesothelioma involved in angiogenesis.
</td>
<td style="text-align:left;">
Mol. Cancer
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Inhibiting crosstalk between MET signaling and mitochondrial dynamics and morphology: a novel therapeutic approach for lung cancer and mesothelioma.
</td>
<td style="text-align:left;">
Cancer Biol. Ther.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Iron addiction with ferroptosis-resistance in asbestos-induced mesothelial carcinogenesis: Toward the era of mesothelioma prevention.
</td>
<td style="text-align:left;">
Free Radic. Biol. Med.
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Immunohistochemical evaluation of nuclear 5-hydroxymethylcytosine (5-hmC) accurately distinguishes malignant pleural mesothelioma from benign mesothelial proliferations.
</td>
<td style="text-align:left;">
Mod. Pathol.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Neoantigenic Potential of Complex Chromosomal Rearrangements in Mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
p53 modeling as a route to mesothelioma patients stratification and novel therapeutic identification.
</td>
<td style="text-align:left;">
J Transl Med
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant pleural mesothelioma: The role of surgery].
</td>
<td style="text-align:left;">
Rev Pneumol Clin
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Diagnosis of malignant pleural mesothelioma from pleural fluid by Fourier transform-infrared spectroscopy coupled with chemometrics.
</td>
<td style="text-align:left;">
J Biomed Opt
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Incidence of cutaneous reactions with pemetrexed: Comparison of patients who received three days of oral dexamethasone twice daily to patients who did not.
</td>
<td style="text-align:left;">
J Oncol Pharm Pract
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Integrative Molecular Characterization of Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
Cancer Discov
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Mesothelin as a target for cervical cancer therapy.
</td>
<td style="text-align:left;">
Arch. Gynecol. Obstet.
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Sensitivity to asbestos is increased in patients with mesothelioma and pathogenic germline variants in BAP1 or other DNA repair genes.
</td>
<td style="text-align:left;">
Genes Chromosomes Cancer
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Management of recurrent pleural mesothelioma: Successful rechallenge with nintedanib in combination with chemotherapy.
</td>
<td style="text-align:left;">
Clin Case Rep
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Meet the researchers: an alternative method of engaging patients with research in mesothelioma.
</td>
<td style="text-align:left;">
Res Involv Engagem
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Biomarkers in the diagnosis of pleural diseases: a 2018 update.
</td>
<td style="text-align:left;">
Ther Adv Respir Dis
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Diagnosis of malignant pleural mesothelioma from pleural fluid by Fourier transform-infrared spectroscopy coupled with chemometrics (Erratum).
</td>
<td style="text-align:left;">
J Biomed Opt
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Clinical significance of serum DRAM1 mRNA, ARSA mRNA, hsa-miR-2053 and lncRNA-RP1-86D1.3 axis expression in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J. Cell. Biochem.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Thoracic aortic endografts used to resect the left subclavian artery infiltrated by malignant tumours.
</td>
<td style="text-align:left;">
Eur J Cardiothorac Surg
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Prediction modelling using routine clinical parameters to stratify survival in Malignant Pleural Mesothelioma patients undergoing cytoreductive surgery.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Experimental study of the inhibition effect of CXCL12/CXCR4 in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J. Investig. Med.
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Safety of Same-Day Vitamin B12 Supplementation in Patients Receiving Pemetrexed for the Treatment of Non-Small-Cell Lung Cancer or Pleural Mesothelioma: A Retrospective Analysis.
</td>
<td style="text-align:left;">
Clin Lung Cancer
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Metabolic Characterization of Antifolate Responsiveness and Non-responsiveness in Malignant Pleural Mesothelioma Cells.
</td>
<td style="text-align:left;">
Front Pharmacol
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
18F-FDG PET/CT Revealing Constrictive Pericarditis as the Only Manifestation of Malignant Mesothelioma.
</td>
<td style="text-align:left;">
Clin Nucl Med
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Updated meta-analysis of survival after extrapleural pneumonectomy versus pleurectomy/decortication in mesothelioma.
</td>
<td style="text-align:left;">
Gen Thorac Cardiovasc Surg
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma in Finland: regional and gender variation.
</td>
<td style="text-align:left;">
Acta Oncol
</td>
<td style="text-align:left;">
diagnosis | treatment | epidemiology | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Differential Survival Characteristics of Sarcomatoid Subtype in Biphasic Pleural Mesothelioma.
</td>
<td style="text-align:left;">
Ann. Thorac. Surg.
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Peritoneal Deciduoid Malignant Mesothelioma on 67Ga SPECT/CT.
</td>
<td style="text-align:left;">
Clin Nucl Med
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
An unusual case of chylothorax.
</td>
<td style="text-align:left;">
Respir Med Case Rep
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Apatinib for salvage treatment of advanced malignant pleural mesothelioma: A case report.
</td>
<td style="text-align:left;">
Medicine (Baltimore)
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Peripheral Blood DNA Methylation as Potential Biomarker of Malignant Pleural Mesothelioma in Asbestos-Exposed Subjects.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Multimodality treatment of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
F1000Res
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Factors influencing malignant mesothelioma survival: a retrospective review of the National Mesothelioma Virtual Bank cohort.
</td>
<td style="text-align:left;">
F1000Res
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
<sup>18</sup>F-FDG PET/CT in therapy response and in predicting responders or non-responders in malignant pleural mesothelioma patients, by using semi-quantitative mRECIST and EORTC criteria.
</td>
<td style="text-align:left;">
Hell J Nucl Med
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Reactivity of tumor cells in malignant effusions with a panel of monoclonal and polyclonal antibodies.
</td>
<td style="text-align:left;">
Tumour Biol.
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Primary malignant pleural tumors (mesotheliomas) presenting as localized masses. Fine needle aspiration cytologic findings, clinical and radiologic features and review of the literature.
</td>
<td style="text-align:left;">
Acta Cytol.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Establishment and characterization of CRISPR/Cas9-mediated NF2<sup>-/-</sup> human mesothelial cell line: Molecular insight into fibroblast growth factor receptor 2 in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Cancer Sci.
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Pyruvate Treatment Restores the Effectiveness of Chemotherapeutic Agents in Human Colon Adenocarcinoma and Pleural Mesothelioma Cells.
</td>
<td style="text-align:left;">
Int J Mol Sci
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
A combination of MTAP and BAP1 immunohistochemistry is effective for distinguishing sarcomatoid mesothelioma from fibrous pleuritis.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Real-life treatment practice for malignant pleural mesothelioma in Belgium.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Surgical treatment of pleural mesothelioma].
</td>
<td style="text-align:left;">
Rev Pneumol Clin
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
[The German Mesothelioma Register : Current pathological diagnostics and services].
</td>
<td style="text-align:left;">
Pathologe
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Soluble AXL is ubiquitously present in malignant serous effusions.
</td>
<td style="text-align:left;">
Gynecol. Oncol.
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Extended pleurectomy decortication for thymoma with pleural dissemination.
</td>
<td style="text-align:left;">
Gen Thorac Cardiovasc Surg
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Amelanotic Malignant Melanoma with Dense Pleural Thickening Mimicking Malignant Mesothelioma.
</td>
<td style="text-align:left;">
Intern. Med.
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
The use of patient-reported outcome measures (PROMs) in the management of malignant pleural mesothelioma: a descriptive literature survey.
</td>
<td style="text-align:left;">
Transl Lung Cancer Res
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Hotspots of malignant pleural mesothelioma in Western Europe.
</td>
<td style="text-align:left;">
Transl Lung Cancer Res
</td>
<td style="text-align:left;">
epidemiology
</td>
</tr>
<tr>
<td style="text-align:left;">
Breath analysis as a diagnostic and screening tool for malignant pleural mesothelioma: a systematic review.
</td>
<td style="text-align:left;">
Transl Lung Cancer Res
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant peritoneal mesothelioma: a review.
</td>
<td style="text-align:left;">
Transl Lung Cancer Res
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
The eighth TNM classification for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Transl Lung Cancer Res
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Extrapleural pneumonectomy: still indicated?
</td>
<td style="text-align:left;">
Transl Lung Cancer Res
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Combined modality treatment in mesothelioma: a systemic literature review with treatment recommendations.
</td>
<td style="text-align:left;">
Transl Lung Cancer Res
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Current chemotherapy strategies in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Transl Lung Cancer Res
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Is there a role for prophylactic radiotherapy to intervention tract sites in patients with malignant pleural mesothelioma?
</td>
<td style="text-align:left;">
Transl Lung Cancer Res
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
A randomized phase II study of pleurectomy/decortication preceded or followed by (neo-)adjuvant chemotherapy in patients with early stage malignant pleural mesothelioma (EORTC 1205).
</td>
<td style="text-align:left;">
Transl Lung Cancer Res
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleural mesothelioma in Poland: Spatial analysis of malignant mesothelioma prevalence in the period 1999-2013.
</td>
<td style="text-align:left;">
Geospat Health
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Treatment of malignant pleural mesothelioma with chemotherapy preceding versus after surgical resection.
</td>
<td style="text-align:left;">
J. Thorac. Cardiovasc. Surg.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Phase-II study with the combination of cisplatin and doxorubicin in advanced malignant mesothelioma of the pleura.
</td>
<td style="text-align:left;">
Onkologie
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Systemic Therapy Use and Outcomes After Relapse from Preoperative Radiation and Extrapleural Pneumonectomy for Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
Oncologist
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
The significance of non-occupational asbestos exposure in women with mesothelioma.
</td>
<td style="text-align:left;">
Respirol Case Rep
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
3D Culture Models of Malignant Mesothelioma Reveal a Powerful Interplay Between Photodynamic Therapy and Kinase Suppression Offering Hope to Reduce Tumor Recurrence.
</td>
<td style="text-align:left;">
Photochem. Photobiol.
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
A Novel Prospective Study Assessing the Combination of Photodynamic Therapy and Proton Radiation Therapy: Safety and Outcomes When Treating Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
Photochem. Photobiol.
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Systematic review of quality of life following pleurectomy decortication and extrapleural pneumonectomy for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
BMC Cancer
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Modeling Epidermal Growth Factor Inhibitor-mediated Enhancement of Photodynamic Therapy Efficacy Using 3D Mesothelioma Cell Culture.
</td>
<td style="text-align:left;">
Photochem. Photobiol.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Detection of circulating tumor cells with a novel microfluidic system in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Cancer Sci.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Biodistribution and Tumor Uptake of <sup>67</sup>Ga-Nimotuzumab in a Malignant Pleural Mesothelioma Xenograft.
</td>
<td style="text-align:left;">
Molecules
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Deciduoid type malignant pleural mesothelioma: a case report.
</td>
<td style="text-align:left;">
AME Case Rep
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Molecular Characterization of Malignant Mesothelioma: Time for New Targets?
</td>
<td style="text-align:left;">
Cancer Discov
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Management of database: European Society of Thoracic Surgeons mesothelioma database-difficulties in improving quality data for rare tumour.
</td>
<td style="text-align:left;">
J Thorac Dis
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant pleural mesothelioma: rare and aggressive but with new therapeutic perspectives].
</td>
<td style="text-align:left;">
Rev Prat
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Whole-Body MRI: Comparison of Its Capability for TNM Staging of Malignant Pleural Mesothelioma With That of Coregistered PET/MRI, Integrated FDG PET/CT, and Conventional Imaging.
</td>
<td style="text-align:left;">
AJR Am J Roentgenol
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Tumour associated lymphocytes in the pleural effusions of patients with mesothelioma express high levels of inhibitory receptors.
</td>
<td style="text-align:left;">
BMC Res Notes
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
The role of BRCA1-associated protein 1 in the diagnosis of malignant mesothelioma in effusion and fine-needle aspiration cytology.
</td>
<td style="text-align:left;">
Diagn. Cytopathol.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
A single centre phase II trial to assess the immunological activity of TroVax® plus pemetrexed/cisplatin in patients with malignant pleural mesothelioma - the SKOPOS trial.
</td>
<td style="text-align:left;">
Oncoimmunology
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Low-dose cyclophosphamide depletes circulating naïve and activated regulatory T cells in malignant pleural mesothelioma patients synergistically treated with dendritic cell-based immunotherapy.
</td>
<td style="text-align:left;">
Oncoimmunology
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Assessment of signaling pathway inhibitors and identification of predictive biomarkers in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Clustering of malignant pleural mesothelioma in asbestos factories: a subgroup analysis in a 29-year follow-up study to identify high-risk industries in Taiwan.
</td>
<td style="text-align:left;">
BMJ Open
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Simultaneous presence of lung adenocarcinoma and malignant pleural mesothelioma: A case report.
</td>
<td style="text-align:left;">
Respir Med Case Rep
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Combined modality treatment for malignant pleural mesothelioma: a single-centre long-term survival analysis using extrapleural pneumonectomy.
</td>
<td style="text-align:left;">
Eur J Cardiothorac Surg
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
The FAK inhibitor BI 853520 inhibits spheroid formation and orthotopic tumor growth in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J. Mol. Med.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Induction of thoracic malignancy in inorganic dust pneumoconiosis.
</td>
<td style="text-align:left;">
J Thorac Imaging
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Catheter Tract Metastasis in Mesothelioma Patients with Indwelling Pleural Catheters: A Retrospective Cohort Study.
</td>
<td style="text-align:left;">
Respiration
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
The Role of Yes-Associated Protein (YAP) in Regulating Programmed Death-Ligand 1 (PD-L1) in Thoracic Cancer.
</td>
<td style="text-align:left;">
Biomedicines
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
BAP1 gene mutations in Egyptian patients with advanced sporadic malignant pleural mesothelioma (MPM): relation with clinical outcomes and survival.
</td>
<td style="text-align:left;">
Cancer Genet
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Nodules and masses are associated with malignant pleural effusion in dogs and cats but many other intrathoracic CT features are poor predictors of the effusion type.
</td>
<td style="text-align:left;">
Vet Radiol Ultrasound
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleural thickness after neoadjuvant chemotherapy is a prognostic factor in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J. Thorac. Cardiovasc. Surg.
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Metachronous Lung Cancer After Pleurectomy/Decortication.
</td>
<td style="text-align:left;">
Ann. Thorac. Surg.
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma of the pleura.
</td>
<td style="text-align:left;">
Mayo Clin. Proc.
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
Bull Cancer
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Case report: Steroid responsive mesothelioma-related pleural effusion.
</td>
<td style="text-align:left;">
Respir Med Case Rep
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma: A histomorphological and immunohistochemical study of 24 cases from a tertiary care hospital in Southern India.
</td>
<td style="text-align:left;">
Indian J Cancer
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Efficacy and Safety of Avelumab Treatment in Patients With Advanced Unresectable Mesothelioma: Phase 1b Results From the JAVELIN Solid Tumor Trial.
</td>
<td style="text-align:left;">
JAMA Oncol
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Correlation of patient survival with clinical tumor measurements in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Eur Radiol
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Population-based cohort study on health effects of asbestos exposure in Japan.
</td>
<td style="text-align:left;">
Cancer Sci.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
MicroRNAs for the Diagnosis and Management of Malignant Pleural Mesothelioma: A Literature Review.
</td>
<td style="text-align:left;">
Front Oncol
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Heparanase inhibitors restrain mesothelioma.
</td>
<td style="text-align:left;">
Oncotarget
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Diagnostic Accuracy of a Limited Immuno-panel of Calretinin and Ber-EP4 for Diagnosis of Malignant Effusions.
</td>
<td style="text-align:left;">
J Coll Physicians Surg Pak
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Return to work after surgical treatment for malignant pleural mesothelioma: report of a case.
</td>
<td style="text-align:left;">
Gen Thorac Cardiovasc Surg
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Surgical Risk and Survival Associated With Less Invasive Surgery for Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
Semin. Thorac. Cardiovasc. Surg.
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
BAP1 Loss is a Useful Adjunct to Distinguish Malignant Mesothelioma Including the Adenomatoid-like Variant From Benign Adenomatoid Tumors.
</td>
<td style="text-align:left;">
Appl. Immunohistochem. Mol. Morphol.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Progress of malignant mesothelioma research in basic science: A review of the 14th international conference of the international mesothelioma interest group (iMig2018).
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Molecular pathways and diagnosis in malignant mesothelioma: A review of the 14th International Conference of the International Mesothelioma Interest Group.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Prognostic factors of survival in patients with malignant pleural mesothelioma: an analysis of the National Cancer Database.
</td>
<td style="text-align:left;">
Carcinogenesis
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
ADAM10 mediates malignant pleural mesothelioma invasiveness.
</td>
<td style="text-align:left;">
Oncogene
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Dosimetric Correlates of Pulmonary Toxicity in Patients with Malignant Pleural Mesothelioma Receiving Radiation Therapy to the Intact Lungs.
</td>
<td style="text-align:left;">
Pract Radiat Oncol
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Antagonists of growth hormone-releasing hormone (GHRH) inhibit the growth of human malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Proc. Natl. Acad. Sci. U.S.A.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): results of a prospective, single-arm, phase 2 trial.
</td>
<td style="text-align:left;">
Lancet Respir Med
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial.
</td>
<td style="text-align:left;">
Lancet Oncol.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Early specialist palliative care on quality of life for malignant pleural mesothelioma: a randomised controlled trial.
</td>
<td style="text-align:left;">
Thorax
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Useful Application of Immunostaining to Malignant Pleural Effusion among Lao People in Vientiane Capital, Lao PDR
</td>
<td style="text-align:left;">
Asian Pac. J. Cancer Prev.
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Learning from the past to design better trials in second-line treatment for mesothelioma patients.
</td>
<td style="text-align:left;">
Ecancermedicalscience
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Managing malignant pleural mesothelioma: experience and perceptions of health care professionals caring for people with mesothelioma.
</td>
<td style="text-align:left;">
Support Care Cancer
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Inhibition of collagen production delays malignant mesothelioma tumor growth in a murine model.
</td>
<td style="text-align:left;">
Biochem. Biophys. Res. Commun.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
MesoTRAP: a feasibility study that includes a pilot clinical trial comparing video-assisted thoracoscopic partial pleurectomy decortication with indwelling pleural catheter in patients with trapped lung due to malignant pleural mesothelioma designed to address recruitment and randomisation uncertainties and sample size requirements for a phase III trial.
</td>
<td style="text-align:left;">
BMJ Open Respir Res
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Computed tomography features of local pleural recurrence in patients with malignant pleural mesothelioma treated with intensity-modulated pleural radiation therapy.
</td>
<td style="text-align:left;">
Eur Radiol
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Asbestos-induced malignant tumors].
</td>
<td style="text-align:left;">
Zentralbl Allg Pathol
</td>
<td style="text-align:left;">
epidemiology | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Histomorphological and Immunohistochemical Analysis of Pleural Neoplasms.
</td>
<td style="text-align:left;">
Iran J Pathol
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Gene expression profiling of homologous recombination repair pathway indicates susceptibility for olaparib treatment in malignant pleural mesothelioma in vitro.
</td>
<td style="text-align:left;">
BMC Cancer
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
First report of probe based confocal laser endomicroscopy during medical thoracoscopy.
</td>
<td style="text-align:left;">
Respir Med
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Characteristics and long-term outcomes of advanced pleural mesothelioma in Latin America (MeSO-CLICaP).
</td>
<td style="text-align:left;">
Thorac Cancer
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Robust Cell Detection and Segmentation for Image Cytometry Reveal Th17 Cell Heterogeneity.
</td>
<td style="text-align:left;">
Cytometry A
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Localized malignant pleural mesothelioma arising in the interlobar fissure: a unique surgical case masquerading clinicopathologically as primary lung adenocarcinoma.
</td>
<td style="text-align:left;">
SAGE Open Med Case Rep
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Fluorodeoxyglucose versus Choline Positron Emission Tomography/Computed Tomography Response Evaluation in Two Malignant Pleural Mesothelioma Patients Treated with Talc Pleurodesis and Neoadjuvant Chemotherapy.
</td>
<td style="text-align:left;">
Cureus
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
MST1/Hippo promoter gene methylation predicts poor survival in patients with malignant pleural mesothelioma in the IFCT-GFPC-0701 MAPS Phase 3 trial.
</td>
<td style="text-align:left;">
Br. J. Cancer
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Localized malignant pleural mesothelioma mimicking an anterior mediastinal tumor.
</td>
<td style="text-align:left;">
Eur J Radiol Open
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Use of Immune Checkpoint Inhibitors in Mesothelioma.
</td>
<td style="text-align:left;">
Curr Treat Options Oncol
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Pemetrexed-loaded nanoparticles targeted to malignant pleural mesothelioma cells: an in vitro study.
</td>
<td style="text-align:left;">
Int J Nanomedicine
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Vascular-targeted low dose photodynamic therapy stabilizes tumor vessels by modulating pericyte contractility.
</td>
<td style="text-align:left;">
Lasers Surg Med
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
[Possibilities of cytological diagnosis of the nature of the exudate at the stage of emergency.]
</td>
<td style="text-align:left;">
Klin. Lab. Diagn.
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Maintenance Defactinib Versus Placebo After First-Line Chemotherapy in Patients With Merlin-Stratified Pleural Mesothelioma: COMMAND-A Double-Blind, Randomized, Phase II Study.
</td>
<td style="text-align:left;">
J. Clin. Oncol.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Physical function and health-related quality of life in the convalescent phase in surgically treated patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Support Care Cancer
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Multiple sclerosis outcomes after cancer immunotherapy.
</td>
<td style="text-align:left;">
Clin Transl Oncol
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant Pleural Mesothelioma: Is Tailoring the Second-Line Therapy Really “Raising the Bar?”
</td>
<td style="text-align:left;">
Curr Treat Options Oncol
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Tumor PD-L1 expression in malignant pleural and peritoneal mesothelioma by Dako PD-L1 22C3 pharmDx and Dako PD-L1 28-8 pharmDx assays.
</td>
<td style="text-align:left;">
Hum. Pathol.
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Revisiting localized malignant mesothelioma.
</td>
<td style="text-align:left;">
Ann Diagn Pathol
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
The Role of Adjuvant Radiotherapy in the Treatment of Pleural Mesothelioma.
</td>
<td style="text-align:left;">
Ann. Surg. Oncol.
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Relations between approved platinum drugs and non-coding RNAs in mesothelioma.
</td>
<td style="text-align:left;">
Noncoding RNA Res
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Interplay of non-coding RNAs and approved antimetabolites such as gemcitabine and pemetrexed in mesothelioma.
</td>
<td style="text-align:left;">
Noncoding RNA Res
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Intrapleural immunotherapy: An update on emerging treatment strategies for pleural malignancy.
</td>
<td style="text-align:left;">
Clin Respir J
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
About the diagnostic value of BAP-1 antibody in malignant pleural mesothelioma: a meta-analysis.
</td>
<td style="text-align:left;">
J Immunoassay Immunochem
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Dynamic contrast-enhanced MRI of malignant pleural mesothelioma: a comparative study of pharmacokinetic models and correlation with mRECIST criteria.
</td>
<td style="text-align:left;">
Cancer Imaging
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Development and Validation of a Prognostic Signature for Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
Front Oncol
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Tumour infiltrating lymphocytes and PD-L1 expression as potential predictors of outcome in patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Mol. Biol. Rep.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Deep convolutional neural networks for the automated segmentation of malignant pleural mesothelioma on computed tomography scans.
</td>
<td style="text-align:left;">
J Med Imaging (Bellingham)
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma: Is reconstruction of the diaphragm necessary in left pleurectomy/decortication? A case report.
</td>
<td style="text-align:left;">
Clin Case Rep
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Presence of innate lymphoid cells in pleural effusions of primary and metastatic tumors: Functional analysis and expression of PD-1 receptor.
</td>
<td style="text-align:left;">
Int. J. Cancer
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
A 75 year old male with recurrent unilateral pleural effusion and positive ANA.
</td>
<td style="text-align:left;">
Respir Med Case Rep
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
When RON MET TAM in Mesothelioma: All Druggable for One, and One Drug for All?
</td>
<td style="text-align:left;">
Front Endocrinol (Lausanne)
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Prolonged post-recurrence survival following pleurectomy/decortication for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Oncol Lett
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Solid-liquid Interface Screening SystemーApplication to the Screening of Antibiotic and Cytotoxic Substance-producing Fungi.
</td>
<td style="text-align:left;">
Biocontrol Sci
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Cryobiopsy during flex-rigid pleuroscopy: an emerging alternative biopsy method in malignant pleural mesothelioma. A comparative study of pathology.
</td>
<td style="text-align:left;">
Jpn. J. Clin. Oncol.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Highly expressed EZH2 in combination with BAP1 and MTAP loss, as detected by immunohistochemistry, is useful for differentiating malignant pleural mesothelioma from reactive mesothelial hyperplasia.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
High BIN1 expression has a favorable prognosis in malignant pleural mesothelioma and is associated with tumor infiltrating lymphocytes.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
The importance of FISH signal cut-off values for 9p21 deletion in malignant pleural mesothelioma: Is it underestimated?
</td>
<td style="text-align:left;">
Pathol. Res. Pract.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Body composition and nutritional status in malignant pleural mesothelioma: implications for activity levels and quality of life.
</td>
<td style="text-align:left;">
Eur J Clin Nutr
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
In commemoration of the 2018 Mataro Nagayo Prize: A road to early diagnosis and monitoring of asbestos-related mesothelioma.
</td>
<td style="text-align:left;">
Cancer Sci.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Dissecting heterogeneity in malignant pleural mesothelioma through histo-molecular gradients for clinical applications.
</td>
<td style="text-align:left;">
Nat Commun
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
The “missing cases” of pleural malignant mesothelioma in Minnesota, 1979-81: preliminary report.
</td>
<td style="text-align:left;">
Public Health Rep
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Making cold malignant pleural effusions hot: driving novel immunotherapies.
</td>
<td style="text-align:left;">
Oncoimmunology
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Comparative genetics of diffuse malignant mesothelioma tumors of the peritoneumand pleura, with focus on BAP1 expression.
</td>
<td style="text-align:left;">
Pleura Peritoneum
</td>
<td style="text-align:left;">
epidemiology | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Chemosensitivity and resistance testing in malignant effusions with focus on primary malignant mesothelioma and metastatic adenocarcinoma.
</td>
<td style="text-align:left;">
Pleura Peritoneum
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Normothermic intraperitoneal chemotherapy long term (NIPEC-LT) in the management of peritoneal surface malignancy, an overview.
</td>
<td style="text-align:left;">
Pleura Peritoneum
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Tomotherapy in malignant mesothelioma: a planning study to establish dose constraints.
</td>
<td style="text-align:left;">
Strahlenther Onkol
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Epidermal growth factor receptor (EGFR)-targeted therapies in mesothelioma.
</td>
<td style="text-align:left;">
Expert Opin Drug Deliv
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Patterns of care and survival of older patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J Geriatr Oncol
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Prophylactic Irradiation of Tracts in Patients With Malignant Pleural Mesothelioma: An Open-Label, Multicenter, Phase III Randomized Trial.
</td>
<td style="text-align:left;">
J. Clin. Oncol.
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
A novel diagnostic method for distinguishing parapneumonic effusion and empyema from other diseases by using the pleural lactate dehydrogenase to adenosine deaminase ratio and carcinoembryonic antigen levels.
</td>
<td style="text-align:left;">
Medicine (Baltimore)
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
The forensic significance of pseudomesotheliomatous adenocarcinoma of the lung.
</td>
<td style="text-align:left;">
Forensic Sci Med Pathol
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Unexpected longevity of a patient with malignant pleural mesothelioma: report of a case.
</td>
<td style="text-align:left;">
Cancer
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
New marker for mesothelioma: an immunoperoxidase study.
</td>
<td style="text-align:left;">
J. Clin. Pathol.
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
A case from India of pleural malignant mesothelioma probably due to domestic and environmental asbestos exposure: a posthumous report.
</td>
<td style="text-align:left;">
BMJ Case Rep
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Bilateral diffuse pulmonary infiltrates secondary to malignant peritoneal mesothelioma - A rare clinical presentation.
</td>
<td style="text-align:left;">
Respir Med Case Rep
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Thoracic Hyper-IgG4-Related Disease Mimicking Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
Lung
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
The Investigation of Lipoxygenases as Therapeutic Targets in Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
Pathol. Oncol. Res.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Droplet digital PCR as a novel system for the detection of microRNA‑34b/c methylation in circulating DNA in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Int. J. Oncol.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Pseudomesotheliomatous Carcinoma with a High Pleural Hyaluronic Acid Concentration Arising from a Primary Esophageal Squamous Cell Carcinoma.
</td>
<td style="text-align:left;">
Am J Case Rep
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
A survey of patient and caregiver experience with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Support Care Cancer
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Diagnostic value of soluble mesothelin-related peptides in pleural effusion for malignant pleural mesothelioma: An updated meta-analysis.
</td>
<td style="text-align:left;">
Medicine (Baltimore)
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Survival analysis via nomogram of surgical patients with malignant pleural mesothelioma in the Surveillance, Epidemiology, and End Results database.
</td>
<td style="text-align:left;">
Thorac Cancer
</td>
<td style="text-align:left;">
treatment | epidemiology
</td>
</tr>
<tr>
<td style="text-align:left;">
Benign Pleural Mesothelial Cells Have Higher Osmotic Water Permeability than Malignant Pleural Mesothelioma Cells and Differentially Respond to Hyperosmolality.
</td>
<td style="text-align:left;">
Cell. Physiol. Biochem.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Endobronchial ultrasound-guided transbronchial needle aspiration mediastinal lymph node staging in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Dis
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Extra-pleural pneumonectomy in the era of image-guided intensity-modulated radiotherapy.
</td>
<td style="text-align:left;">
Radiol Med
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Mesothelium and Malignant Mesothelioma.
</td>
<td style="text-align:left;">
J Dev Biol
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Inherited predisposition to malignant mesothelioma and overall survival following platinum chemotherapy.
</td>
<td style="text-align:left;">
Proc. Natl. Acad. Sci. U.S.A.
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
The timing of chemotherapy in the management plan for medically operable early-stage malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Expert Rev Respir Med
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Primary malignant mesothelioma of the diaphragm with liver invasion: A case report and review of literature.
</td>
<td style="text-align:left;">
Medicine (Baltimore)
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Chemotherapy Versus Supportive Care for Unresected Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
Clin Lung Cancer
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesotheliomas with osseous and cartilaginous differentiation.
</td>
<td style="text-align:left;">
Arch. Pathol. Lab. Med.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Disparities in Compliance With National Guidelines for the Treatment of Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
Ann. Thorac. Surg.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Management of Malignant Pleural Mesothelioma in the Elderly Population.
</td>
<td style="text-align:left;">
Ann. Surg. Oncol.
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Role of Ancillary Techniques in Fluid Cytology.
</td>
<td style="text-align:left;">
Acta Cytol.
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Pathological evaluation of the visceral pleura in the radical pleurectomy/decortication for malignant pleural mesothelioma patients.
</td>
<td style="text-align:left;">
J Thorac Dis
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Extra-pleural pneumonectomy.
</td>
<td style="text-align:left;">
J Thorac Dis
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Physician requests by patients with malignant pleural mesothelioma in Japan.
</td>
<td style="text-align:left;">
BMC Cancer
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
A Rare Case of Malignant Mesothelioma Presenting with Systemic Lupus Erythematosus Seropositivity: A Case Report and Review of Literature.
</td>
<td style="text-align:left;">
Cureus
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma in Lynch syndrome: A report of two cases and a review of the literature.
</td>
<td style="text-align:left;">
Am. J. Ind. Med.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Pain management in patients with malignant mesothelioma: challenges and solutions.
</td>
<td style="text-align:left;">
Lung Cancer (Auckl)
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Whole-genome sequencing of human malignant mesothelioma tumours and cell lines.
</td>
<td style="text-align:left;">
Carcinogenesis
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Impact on survival of nuclear atypia in epithelioid malignant mesothelioma.
</td>
<td style="text-align:left;">
Adv Respir Med
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Metadherin Is a Prognostic Apoptosis Modulator in Mesothelioma Induced via NF-κB-Mediated Signaling.
</td>
<td style="text-align:left;">
Transl Oncol
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Unusual thoracic manifestations of epithelioid hemangioendothelioma.
</td>
<td style="text-align:left;">
Arch. Pathol. Lab. Med.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
First-ever Abscopal Effect after Palliative Radiotherapy and Immuno-gene Therapy for Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
Cureus
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Metastatic Clear Cell Renal Carcinoma Without Evidence of a Primary Renal Tumour Mimicking Advanced Stage of Malignant Lung Tumour.
</td>
<td style="text-align:left;">
Klin Onkol
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
A phase Ib study of GSK3052230, an FGF ligand trap in combination with pemetrexed and cisplatin in patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Invest New Drugs
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
50 Patients with Malignant Mesothelioma of Both the Pleura and Peritoneum: A Single-Institution Experience.
</td>
<td style="text-align:left;">
Ann. Surg. Oncol.
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Confocal Laser Endomicroscopy as a Guidance Tool for Pleural Biopsies in Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
Chest
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Potential Diagnostic and Prognostic Role of Microenvironment in Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Diagnosis and characterization of malignant effusions through pleural fluid cytological examination.
</td>
<td style="text-align:left;">
Curr Opin Pulm Med
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Loco-regional staging of malignant pleural mesothelioma by integrated <sup>18</sup>F-FDG PET/MRI.
</td>
<td style="text-align:left;">
Eur J Radiol
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Advances in pulmonary and pleural malignant disorders.
</td>
<td style="text-align:left;">
Clin Med (Lond)
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Adjuvant dendritic cell based immunotherapy (DCBI) after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal mesothelioma, a phase II single centre open-label clinical trial: rationale and design of the MESOPEC trial.
</td>
<td style="text-align:left;">
BMJ Open
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Lymphangitic carcinomatosis: A common radiographic manifestation of local failure following extended pleurectomy/decortication in patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Role of Immunotherapy in Small Cell Lung Cancer, Thymic Epithelial Tumors, and Mesothelioma.
</td>
<td style="text-align:left;">
Am Soc Clin Oncol Educ Book
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Fast, Low-Dose Megavoltage-Topogram Localization on TomoTherapy: Initial Clinical Experience With Mesothelioma Patients.
</td>
<td style="text-align:left;">
Pract Radiat Oncol
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): a double-blind, randomised, placebo-controlled phase 3 trial.
</td>
<td style="text-align:left;">
Lancet Respir Med
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Wnt/IL-1β/IL-8 autocrine circuitries control chemoresistance in mesothelioma initiating cells by inducing ABCB5.
</td>
<td style="text-align:left;">
Int. J. Cancer
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Paraneoplastic phenomenon in mesothelioma.
</td>
<td style="text-align:left;">
Thorax
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
High systemic immune-inflammation index represents an unfavorable prognosis of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Cancer Manag Res
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
The Use of Radiation Therapy for the Treatment of Malignant Pleural Mesothelioma: Expert Opinion from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
A Proposed System Toward Standardizing Surgical-Based Treatments for Malignant Pleural Mesothelioma, From the Joint National Cancer Institute-International Association for the Study of Lung Cancer-Mesothelioma Applied Research Foundation Taskforce.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
CDKN2A copy number and p16 expression in malignant pleural mesothelioma in relation to asbestos exposure.
</td>
<td style="text-align:left;">
BMC Cancer
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Signet ring cell mesothelioma; A diagnostic challenge.
</td>
<td style="text-align:left;">
Pathol. Res. Pract.
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Inactivation of <i>Bap1</i> Cooperates with Losses of <i>Nf2</i> and <i>Cdkn2a</i> to Drive the Development of Pleural Malignant Mesothelioma in Conditional Mouse Models.
</td>
<td style="text-align:left;">
Cancer Res.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
MicroRNA profiling in serous cavity specimens: Diagnostic challenges and new opportunities.
</td>
<td style="text-align:left;">
Cancer Cytopathol
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Clinical Efficacy and Safety of Nivolumab: Results of a <u>M</u>ulticenter, Op<u>e</u>n-label, Single-a<u>r</u>m, Japanese Phase II study in Mal<u>i</u>gnant Pleural Meso<u>t</u>helioma (MERIT).
</td>
<td style="text-align:left;">
Clin. Cancer Res.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Diagnostic value of BRCA1-associated protein-1, glucose transporter-1 and desmin expression in the discrimination between reactive mesothelial proliferation and malignant mesothelioma in tissues and effusions.
</td>
<td style="text-align:left;">
Cytopathology
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
An unexpected cause of dysphagia: pleural mesothelioma.
</td>
<td style="text-align:left;">
Rev Esp Enferm Dig
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Recent Developments in the Regional Treatment of Peritoneal and Pleural Tumours (incl. HIPEC and HITOC)].
</td>
<td style="text-align:left;">
Zentralbl Chir
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Advances in pathological diagnosis of mesothelioma: what pulmonologists should know.
</td>
<td style="text-align:left;">
Curr Opin Pulm Med
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Biomarkers for malignant pleural mesothelioma: a meta-analysis.
</td>
<td style="text-align:left;">
Carcinogenesis
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Health-Related Quality of Life Impact from Adding Bevacizumab to Cisplatin-Pemetrexed in Malignant Pleural Mesothelioma in the MAPS IFCT-GFPC-0701 Phase III Trial.
</td>
<td style="text-align:left;">
Clin. Cancer Res.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Communication of a mesothelioma diagnosis: developing recommendations to improve the patient experience.
</td>
<td style="text-align:left;">
BMJ Open Respir Res
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Defining the role of adjuvant radiotherapy for malignant pleural mesothelioma: a propensity-matched landmark analysis of the National Cancer Database.
</td>
<td style="text-align:left;">
J Thorac Dis
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Expression of estrogen receptor beta (ERβ) and its prognostic value in pleural mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Dis
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
The Prevalence and Clinical Relevance of Nonexpandable Lung in Malignant Pleural Mesothelioma. A Prospective, Single-Center Cohort Study of 229 Patients.
</td>
<td style="text-align:left;">
Ann Am Thorac Soc
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Evaluation of Matrix Metalloproteinase 9 Serum Concentration as a Biomarker in Malignant Mesothelioma.
</td>
<td style="text-align:left;">
Dis. Markers
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Biomarkers for detecting malignant pleural mesothelioma: Protocol for a reanalysis of published data based on systematic reviews of diagnostic test accuracy.
</td>
<td style="text-align:left;">
Medicine (Baltimore)
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Development of novel monoclonal antibodies with specific binding affinity for denatured human CD26 in formalin-fixed paraffin-embedded and decalcified specimens.
</td>
<td style="text-align:left;">
PLoS ONE
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Baseline predictors of negative and incomplete pleural cytology in patients with suspected pleural malignancy - Data supporting ‘Direct to LAT’ in selected groups.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Does Simian Virus 40 (SV40) Have a Role in UK Malignant Pleural Mesothelioma? No Role is Identified in a Sensitive RNA In Situ Hybridization Study on Potentially Affected Birth Cohorts.
</td>
<td style="text-align:left;">
Appl. Immunohistochem. Mol. Morphol.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Breath Analysis: A Systematic Review of Volatile Organic Compounds (VOCs) in Diagnostic and Therapeutic Management of Pleural Mesothelioma.
</td>
<td style="text-align:left;">
Cancers (Basel)
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Evaluation of the psychometric properties and minimally important difference of the MD Anderson Symptom Inventory for malignant pleural mesothelioma (MDASI-MPM).
</td>
<td style="text-align:left;">
J Patient Rep Outcomes
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Unraveling the cellular heterogeneity of malignant pleural mesothelioma through a deconvolution approach.
</td>
<td style="text-align:left;">
Mol Cell Oncol
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Prospective Study of the Utility of Computed Tomography Triage of Pleural Biopsy Strategies in Patients With Pleural Diseases.
</td>
<td style="text-align:left;">
J Bronchology Interv Pulmonol
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Diffusion-Weighted Imaging Can Differentiate between Malignant and Benign Pleural Diseases.
</td>
<td style="text-align:left;">
Cancers (Basel)
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
In Silico Transcriptomic Analysis of Wound-Healing-Associated Genes in Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
Medicina (Kaunas)
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
miR-625-3p and lncRNA GAS5 in Liquid Biopsies for Predicting the Outcome of Malignant Pleural Mesothelioma Patients Treated with Neo-Adjuvant Chemotherapy and Surgery.
</td>
<td style="text-align:left;">
Noncoding RNA
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Prolonged retention of liposomes in the pleural cavity of normal mice and high tumor distribution in mice with malignant pleural effusion, after intrapleural injection.
</td>
<td style="text-align:left;">
Int J Nanomedicine
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Hyperthermic intrathoracic chemotherapy in thoracic surgery].
</td>
<td style="text-align:left;">
Chirurg
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Environmental Health Education for Asbestos-Contaminated Communities in Italy: The Casale Monferrato Case Study.
</td>
<td style="text-align:left;">
Ann Glob Health
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Management of Clinically Lymph Node-Positive Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
Semin. Thorac. Cardiovasc. Surg.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
MicroRNA-215-5p Treatment Suppresses Mesothelioma Progression via the MDM2-p53-Signaling Axis.
</td>
<td style="text-align:left;">
Mol. Ther.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Synergistic Enhancement of Cellular Uptake With CD44-Expressing Malignant Pleural Mesothelioma by Combining Cationic Liposome and Hyaluronic Acid-Lipid Conjugate.
</td>
<td style="text-align:left;">
J Pharm Sci
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
An asbestos contaminated town in the vicinity of an asbestos-cement facility: The case study of Sibaté, Colombia.
</td>
<td style="text-align:left;">
Environ. Res.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
MTAP immunohistochemistry is an accurate and reproducible surrogate for CDKN2A fluorescence in situ hybridization in diagnosis of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Mod. Pathol.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Hemizygous loss of NF2 detected by fluorescence in situ hybridization is useful for the diagnosis of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Mod. Pathol.
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Fibulin-3 as biomarker of malignant mesothelioma.
</td>
<td style="text-align:left;">
Biomark Med
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Antiproliferative Activity of Pt(IV) Conjugates Containing the Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Ketoprofen and Naproxen <sup>†</sup>.
</td>
<td style="text-align:left;">
Int J Mol Sci
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant Pleural Mesothelioma: A Multi-Disciplinary Approach.
</td>
<td style="text-align:left;">
Gulf J Oncolog
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Pattern of failure after adjuvant radiotherapy following extrapleural pneumonectomy of pleural mesothelioma in the SAKK 17/04 trial.
</td>
<td style="text-align:left;">
Radiother Oncol
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Long term survival and perioperative propensity score matched outcomes of diaphragmatic resections compared to stripping in cytoreductive surgery + intra-peritoneal chemotherapy.
</td>
<td style="text-align:left;">
Am. J. Surg.
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
What can independent research for mesothelioma achieve to treat this orphan disease?
</td>
<td style="text-align:left;">
Expert Opin Investig Drugs
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
2-Deoxy-glucose Enhances the Effect of Cisplatin and Pemetrexed in Reducing Malignant Pleural Mesothelioma Cell Proliferation But Not Spheroid Growth.
</td>
<td style="text-align:left;">
Anticancer Res.
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Clinical Response of Live-Attenuated, <i>Listeria monocytogenes</i> Expressing Mesothelin (CRS-207) with Chemotherapy in Patients with Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
Clin. Cancer Res.
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
MWCNT-7 administered to the lung by intratracheal instillation induces development of pleural mesothelioma in F344 rats.
</td>
<td style="text-align:left;">
Cancer Sci.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Preliminary results of entire pleural intensity-modulated radiotherapy in a neoadjuvant setting for resectable malignant mesothelioma.
</td>
<td style="text-align:left;">
Radiat Oncol J
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Mesothelin, Calretinin, and Megakaryocyte Potentiating Factor as Biomarkers of Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
Lung
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Interobserver variation in the assessment of the sarcomatoid and transitional components in biphasic mesotheliomas.
</td>
<td style="text-align:left;">
Mod. Pathol.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Shorter Survival in Malignant Pleural Mesothelioma Patients With High PD-L1 Expression Associated With Sarcomatoid or Biphasic Histology Subtype: A Series of 214 Cases From the Bio-MAPS Cohort.
</td>
<td style="text-align:left;">
Clin Lung Cancer
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Targeting angiogenesis for patients with unresectable malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Semin. Oncol.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Peritoneal mesothelioma and asbestos exposure: a population-based case-control study in Lombardy, Italy.
</td>
<td style="text-align:left;">
Occup Environ Med
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleurectomy/decortication and hyperthermic intrathoracic chemoperfusion using cisplatin and doxorubicin for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Dis
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Efficacy and safety of pemetrexed plus cisplatin as first-line chemotherapy in advanced malignant peritoneal mesothelioma.
</td>
<td style="text-align:left;">
Jpn. J. Clin. Oncol.
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant deciduoid mesothelioma: a rare variant of epithelioid mesothelioma.
</td>
<td style="text-align:left;">
BMJ Case Rep
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Transcriptional suppression of the miR-15/16 family by c-Myc in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Oncotarget
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Pemetrexed-conjugated hyaluronan for the treatment of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Eur J Pharm Sci
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Metastatic Pleural Effusion: An Unusual Presentation of Urothelial Bladder Carcinoma.
</td>
<td style="text-align:left;">
Cureus
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Nivo-lution in Mesothelioma.
</td>
<td style="text-align:left;">
Clin. Cancer Res.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Prostate Carcinoma and Pleural Mesothelioma: An Extremely Rare Co-occurrence.
</td>
<td style="text-align:left;">
Cureus
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Simple and Rapid Quantification of the Multi-Enzyme Targeting Antifolate Pemetrexed in Human Plasma.
</td>
<td style="text-align:left;">
Ther Drug Monit
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Perioperative anesthetic management of patients with malignant pleural mesothelioma undergoing cytoreductive surgery and intraoperative chemotherapy.
</td>
<td style="text-align:left;">
Rev Esp Anestesiol Reanim
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
The Oncolytic Virus <i>dl</i>922-947 Triggers Immunogenic Cell Death in Mesothelioma and Reduces Xenograft Growth.
</td>
<td style="text-align:left;">
Front Oncol
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Association of two BRM promoter polymorphisms and smoking status with malignant pleural mesothelioma risk and prognosis.
</td>
<td style="text-align:left;">
Mol. Carcinog.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
A multicenter, randomized, phase II/III study of dendritic cells loaded with allogeneic tumor cell lysate (MesoPher) in subjects with mesothelioma as maintenance therapy after chemotherapy: DENdritic cell Immunotherapy for Mesothelioma (DENIM) trial.
</td>
<td style="text-align:left;">
Transl Lung Cancer Res
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Molecular characterization of localized pleural mesothelioma.
</td>
<td style="text-align:left;">
Mod. Pathol.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Heterologous sarcomatoid pleural mesothelioma with osteosarcomatous differentiation: a report of autopsy case that accomplished trimodality therapy and review of the literature.
</td>
<td style="text-align:left;">
Gen Thorac Cardiovasc Surg
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma in situ: morphologic features and clinical outcome.
</td>
<td style="text-align:left;">
Mod. Pathol.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Mesothelioma of the tunica vaginalis testis.
</td>
<td style="text-align:left;">
Hum. Pathol.
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
The Prognostic Role of TNM Staging Compared With Tumor Volume and Number of Pleural Sites in Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
Clin Lung Cancer
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Phase II Trial of Cediranib in Combination With Cisplatin and Pemetrexed in Chemotherapy-Naïve Patients With Unresectable Malignant Pleural Mesothelioma (SWOG S0905).
</td>
<td style="text-align:left;">
J. Clin. Oncol.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Induction of gamma-glutamyltransferase activity and consequent prooxidant reactions in human macrophages exposed to crocidolite asbestos.
</td>
<td style="text-align:left;">
Toxicol. Sci.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Differential Diagnosis of Epithelioid Malignant Mesothelioma With Lung and Breast Pleural Metastasis: A Systematic Review Compared With a Standardized Panel of Antibodies-A New Proposal That May Influence Pathologic Practice.
</td>
<td style="text-align:left;">
Arch. Pathol. Lab. Med.
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Diagnostic value of biopsy sampling in predicting histology in patients with diffuse malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Cancer
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Cumulative asbestos exposure and mortality from asbestos related diseases in a pooled analysis of 21 asbestos cement cohorts in Italy.
</td>
<td style="text-align:left;">
Environ Health
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Immune Signature of Malignant Pleural Mesothelioma as Assessed by Transcriptome Analysis.
</td>
<td style="text-align:left;">
Cancer Genomics Proteomics
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Dropwort-induced metabolic reprogramming restrains YAP/TAZ/TEAD oncogenic axis in mesothelioma.
</td>
<td style="text-align:left;">
J. Exp. Clin. Cancer Res.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Association Between Simian Virus 40 and Human Tumors.
</td>
<td style="text-align:left;">
Front Oncol
</td>
<td style="text-align:left;">
epidemiology | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Role of asbestos clearance in explaining long-term risk of pleural and peritoneal cancer: a pooled analysis of cohort studies.
</td>
<td style="text-align:left;">
Occup Environ Med
</td>
<td style="text-align:left;">
epidemiology | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Targeting the C-terminus of galectin-9 induces mesothelioma apoptosis and M2 macrophage depletion.
</td>
<td style="text-align:left;">
Oncoimmunology
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Genetic predisposition for malignant mesothelioma: A concise review.
</td>
<td style="text-align:left;">
Mutat. Res.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
MESOTIP: Phase II multicenter randomized trial evaluating the association of PIPAC and systemic chemotherapy vs. systemic chemotherapy alone as 1st-line treatment of malignant peritoneal mesothelioma.
</td>
<td style="text-align:left;">
Pleura Peritoneum
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Bidirectional chemotherapy allowing surgery and HIPEC for malignant peritoneal mesothelioma.
</td>
<td style="text-align:left;">
Pleura Peritoneum
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Phase I Study of Lentiviral-Transduced Chimeric Antigen Receptor-Modified T Cells Recognizing Mesothelin in Advanced Solid Cancers.
</td>
<td style="text-align:left;">
Mol. Ther.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Multidisciplinary palliative treatment including isolated thoracic perfusion for progressive malignant pleural mesothelioma: a retrospective observational study.
</td>
<td style="text-align:left;">
J BUON
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Phenotypic and functional analysis of malignant mesothelioma tumor-infiltrating lymphocytes.
</td>
<td style="text-align:left;">
Oncoimmunology
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Multi-antigen Vaccination With Simultaneous Engagement of the OX40 Receptor Delays Malignant Mesothelioma Growth and Increases Survival in Animal Models.
</td>
<td style="text-align:left;">
Front Oncol
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Largely Unchanged Annual Incidence and Overall Survival of Pleural Mesothelioma in the USA.
</td>
<td style="text-align:left;">
World J Surg
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Return to intended oncologic treatment after surgery for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J. Thorac. Cardiovasc. Surg.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant Pleural Effusion and Its Current Management: A Review.
</td>
<td style="text-align:left;">
Medicina (Kaunas)
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Integration of Tumor-Treating Fields into the Multidisciplinary Management of Patients with Solid Malignancies.
</td>
<td style="text-align:left;">
Oncologist
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Analysis of CCDC6 as a novel biomarker for the clinical use of PARP1 inhibitors in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Building a Bridge between Chemotherapy and Immunotherapy in Malignant Pleural Mesothelioma: Investigating the Effect of Chemotherapy on Immune Checkpoint Expression.
</td>
<td style="text-align:left;">
Int J Mol Sci
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleuroscopy or video-assisted thoracoscopic surgery for exudative pleural effusion: a comparative overview.
</td>
<td style="text-align:left;">
J Thorac Dis
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Radiologic Considerations and Standardization of Malignant Pleural Mesothelioma Imaging Within Clinical Trials: Consensus Statement from the NCI Thoracic Malignancy Steering Committee - International Association for the Study of Lung Cancer - Mesothelioma Applied Research Foundation Clinical Trials Planning Meeting.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Liquid Biopsy in Malignant Pleural Mesothelioma: State of the Art, Pitfalls, and Perspectives.
</td>
<td style="text-align:left;">
Front Oncol
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Carcinogenic effect of potassium octatitanate (POT) fibers in the lung and pleura of male Fischer 344 rats after intrapulmonary administration.
</td>
<td style="text-align:left;">
Part Fibre Toxicol
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
MicroRNA Signatures in Malignant Pleural Mesothelioma Effusions.
</td>
<td style="text-align:left;">
Dis. Markers
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
EPHA2 mutations with oncogenic characteristics in squamous cell lung cancer and malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Oncogenesis
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Proceedings of the American Society of Cytopathology companion session at the 2019 United States and Canadian Academy of Pathology Annual meeting, part 2: effusion cytology with focus on theranostics and diagnosis of malignant mesothelioma.
</td>
<td style="text-align:left;">
J Am Soc Cytopathol
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Monoclonal Caveolin 1 Expression in the Differential Diagnosis of Malignant Pleural Mesothelioma and Pulmonary Adenocarcinoma: Is it Useful?
</td>
<td style="text-align:left;">
Pathol. Oncol. Res.
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Determination of Mesothelin Levels in Pleural Effusion Does Not Help Predict Survival of Patients With Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
Anticancer Res.
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Survival in patients with malignant pleural effusion undergoing talc pleurodesis.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Molecular Testing on Pleural Fluid Samples.
</td>
<td style="text-align:left;">
Semin Respir Crit Care Med
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant Mesothelioma: Has Anything Changed?
</td>
<td style="text-align:left;">
Semin Respir Crit Care Med
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Expression of FGFR1-4 in Malignant Pleural Mesothelioma Tissue and Corresponding Cell Lines and its Relationship to Patient Survival and FGFR Inhibitor Sensitivity.
</td>
<td style="text-align:left;">
Cells
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
The Role of Immunohistochemistry Studies in Distinguishing Malignant Mesothelioma from Metastatic Lung Carcinoma in Malignant Pleural Effusion.
</td>
<td style="text-align:left;">
Iran J Pathol
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Anaplastic thyroid carcinoma mimicking a malignant pleural mesothelioma: Clues for diagnosis.
</td>
<td style="text-align:left;">
Thorac Cancer
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Inhibition of EZH2 methyltransferase decreases immunoediting of mesothelioma cells by autologous macrophages through a PD-1-dependent mechanism.
</td>
<td style="text-align:left;">
JCI Insight
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
V-domain Ig-containing suppressor of T-cell activation (VISTA), a potentially targetable immune checkpoint molecule, is highly expressed in epithelioid malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Mod. Pathol.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Translating mesothelioma molecular genomics and dependencies into precision oncology-based therapies.
</td>
<td style="text-align:left;">
Semin. Cancer Biol.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
EURACAN/IASLC Proposals for Updating the Histologic Classification of Pleural Mesothelioma: Towards a More Multidisciplinary Approach.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Development of a Novel Prognostic Risk Classification System for Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
Clin Lung Cancer
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Modified Liquid-Based Cytology Technique for Immunocytochemistry in Effusion Specimen.
</td>
<td style="text-align:left;">
Asian Pac. J. Cancer Prev.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Phase I study of YS110, a recombinant humanized monoclonal antibody to CD26, in Japanese patients with advanced malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
PFKFB3 inhibition reprograms malignant pleural mesothelioma to nutrient stress-induced macropinocytosis and ER stress as independent binary adaptive responses.
</td>
<td style="text-align:left;">
Cell Death Dis
</td>
<td style="text-align:left;">
treatment | transmission
</td>
</tr>
<tr>
<td style="text-align:left;">
Volumetric Modulated Arc Therapy After Lung Sparing Surgery for Malignant Pleural Mesothelioma: A Single Institution Experience.
</td>
<td style="text-align:left;">
Clin Lung Cancer
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma in construction workers: the Apulia regional mesothelioma register, Southern Italy.
</td>
<td style="text-align:left;">
BMC Res Notes
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Molecular Analysis of a Patient With Neurofibromatosis 2 (NF2) and Peritoneal Malignant Mesothelioma.
</td>
<td style="text-align:left;">
Am. J. Surg. Pathol.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
In-vivo imaging of methionine metabolism in patients with suspected malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Nucl Med Commun
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
In Vitro Characterization of Cisplatin and Pemetrexed Effects in Malignant Pleural Mesothelioma 3D Culture Phenotypes.
</td>
<td style="text-align:left;">
Cancers (Basel)
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Bortezomib sensitivity is tissue dependent and high expression of the 20S proteasome precludes good response in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Cancer Manag Res
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Morphological difference between pleural mesothelioma cells in effusion smears with either BAP1 loss or 9p21 homozygous deletion and reactive mesothelial cells without the gene alterations.
</td>
<td style="text-align:left;">
Pathol. Int.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Establishment and characterization of human malignant pleural mesothelioma cell line SMC-1.
</td>
<td style="text-align:left;">
Sci. Sin., Ser. B, Chem. Biol. Agric. Med. Earth Sci.
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Intracavitary cisplatin-fibrin chemotherapy after surgery for malignant pleural mesothelioma: A phase I trial.
</td>
<td style="text-align:left;">
J. Thorac. Cardiovasc. Surg.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Survival results in biphasic malignant pleural mesothelioma patients: A multicentric analysis.
</td>
<td style="text-align:left;">
J. Thorac. Cardiovasc. Surg.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Approved and emerging treatments of malignant pleural mesothelioma in elderly patients.
</td>
<td style="text-align:left;">
Expert Rev Respir Med
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Types of surgery post-neoadjuvant chemotherapy for pleural mesothelioma.
</td>
<td style="text-align:left;">
Expert Rev Respir Med
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Effects of the Storage Solution Type and Prolonged Storage on the Immunoreactivity of Cells.
</td>
<td style="text-align:left;">
Acta Cytol.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Endoplasmic Reticulum Stress Signaling as a Therapeutic Target in Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
Cancers (Basel)
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Adequate nephroprotection reduces renal complications after hyperthermic intrathoracic chemotherapy.
</td>
<td style="text-align:left;">
J Surg Oncol
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Dual-input tracer kinetic modeling of dynamic contrast-enhanced MRI in thoracic malignancies.
</td>
<td style="text-align:left;">
J Appl Clin Med Phys
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Treatment of Malignant Peritoneal Mesothelioma.
</td>
<td style="text-align:left;">
Klin Onkol
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Stereotactic Body Radiation Therapy (SBRT) as Salvage Therapy for Oligorecurrent Pleural Mesothelioma After Multi-Modality Therapy.
</td>
<td style="text-align:left;">
Front Oncol
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Functional Genomic Screen in Mesothelioma Reveals that Loss of Function of BRCA1-Associated Protein 1 Induces Chemoresistance to Ribonucleotide Reductase Inhibition.
</td>
<td style="text-align:left;">
Mol. Cancer Ther.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant Mesothelioma - Report of Two Cases with Different Presentations.
</td>
<td style="text-align:left;">
Indian J Occup Environ Med
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant Peritoneal Mesothelioma: Patterns of Care and Survival in the Netherlands: A Population-Based Study.
</td>
<td style="text-align:left;">
Ann. Surg. Oncol.
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Elevated Adenosine Dehydrogenase (ADH) and Positive Tuberculin Test Firstly Misdiagnosed as Tuberculous Pleural Effusion Finally Proved as Pleural Mesothelial Sarcoma by Thoracoscopic Biopsy Pathology: a Case Report and Literature Review.
</td>
<td style="text-align:left;">
Clin. Lab.
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Tumour Treating Fields in combination with pemetrexed and cisplatin or carboplatin as first-line treatment for unresectable malignant pleural mesothelioma (STELLAR): a multicentre, single-arm phase 2 trial.
</td>
<td style="text-align:left;">
Lancet Oncol.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Why Be One Protein When You Can Affect Many? The Multiple Roles of YB-1 in Lung Cancer and Mesothelioma.
</td>
<td style="text-align:left;">
Front Cell Dev Biol
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Posterior Intercostal Lymph Nodes Double Recurrence and Death Risk in Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
Ann. Thorac. Surg.
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
CD70 expression correlates with a worse prognosis in malignant pleural mesothelioma patients via immune evasion and enhanced invasiveness.
</td>
<td style="text-align:left;">
J. Pathol.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Nonrandom chromosomal abnormalities in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Cancer Genet. Cytogenet.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Role of the contrast-enhanced spectral mammography for the diagnosis of breast metastases from extramammary neoplasms.
</td>
<td style="text-align:left;">
J BUON
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Redefining malignant pleural mesothelioma types as a continuum uncovers immune-vascular interactions.
</td>
<td style="text-align:left;">
EBioMedicine
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Diagnostic Value of Computed Tomography Imaging Features in Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
Respiration
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Detection of Anaplastic Lymphoma Kinase-Rearranged Mesothelioma Cells in Ascites by Companion Diagnostics.
</td>
<td style="text-align:left;">
Acta Cytol.
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Multicystic peritoneal mesothelioma: a systematic review of the literature.
</td>
<td style="text-align:left;">
Pleura Peritoneum
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma in situ diagnosed by methylthioadenosine phosphorylase loss and homozygous deletion of CDKN2A: a case report.
</td>
<td style="text-align:left;">
Virchows Arch.
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
24-hour cyclophosphamide infusion therapy for malignant mesothelioma of the pleura.
</td>
<td style="text-align:left;">
Br J Dis Chest
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Emerging therapies in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Crit. Rev. Oncol. Hematol.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Extrapleural pneumonectomies for pleural mesothelioma.
</td>
<td style="text-align:left;">
Expert Rev Respir Med
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Current treatment strategies in malignant pleural mesothelioma with a treatment algorithm.
</td>
<td style="text-align:left;">
Adv Respir Med
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Globular C1q Receptor (gC1qR/p32/HABP1) Is Overexpressed in Malignant Pleural Mesothelioma and Is Associated With Increased Survival in Surgical Patients Treated With Chemotherapy.
</td>
<td style="text-align:left;">
Front Oncol
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[The occurrence of asbestos-related diseases among former employees of asbestos processing plants in Poland].
</td>
<td style="text-align:left;">
Med Pr
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
CRISPR Screening Identifies WEE1 as a Combination Target for Standard Chemotherapy in Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
Mol. Cancer Ther.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
The mTOR Signaling Pathway Is Associated With the Prognosis of Malignant Pleural Mesothelioma After Multimodality Therapy.
</td>
<td style="text-align:left;">
Anticancer Res.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
The prognostic analysis of the some clinicopathological parameters and gene protein expressions in malignant mesothelioma.
</td>
<td style="text-align:left;">
Tuberk Toraks
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Intrapleural urokinase directly under medical thoracoscopy for the diagnosis of tuberculous pleurisy.
</td>
<td style="text-align:left;">
Respirol Case Rep
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Elevated Circulating Activin A Levels in Patients With Malignant Pleural Mesothelioma Are Related to Cancer Cachexia and Reduced Response to Platinum-based Chemotherapy.
</td>
<td style="text-align:left;">
Clin Lung Cancer
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Secretome of pleural effusions associated with non-small cell lung cancer (NSCLC) and malignant mesothelioma: therapeutic implications.
</td>
<td style="text-align:left;">
Oncotarget
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Extended pleurectomy decortication for the treatment of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Multimed Man Cardiothorac Surg
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Inhibition of cyclin-dependent kinase 7 down-regulates yes-associated protein expression in mesothelioma cells.
</td>
<td style="text-align:left;">
J. Cell. Mol. Med.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleural mesothelioma and lung cancer: the role of asbestos exposure and genetic variants in selected iron metabolism and inflammation genes.
</td>
<td style="text-align:left;">
J. Toxicol. Environ. Health Part A
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma among Swiss furniture workers. A new high-risk group.
</td>
<td style="text-align:left;">
Scand J Work Environ Health
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleural small cell carcinoma with massive pleural effusion: A case report.
</td>
<td style="text-align:left;">
Medicine (Baltimore)
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Fibrolipoma of the left ventricle: an uncommon incidental autopsy finding.
</td>
<td style="text-align:left;">
Forensic Sci Med Pathol
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Detection of TGF-β in pleural effusions for diagnosis and prognostic stratification of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Anaplastic Lymphoma Kinase Gene Rearrangement in Children and Young Adults With Mesothelioma.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Long-term benefit from immune modulation and anti-inflammatory treatment in metastatic mesothelioma.
</td>
<td style="text-align:left;">
Respir Med Case Rep
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Correlation of prechemotherapy urinary megalin ectodomain (A-megalin) levels with the development of cisplatin-induced nephrotoxicity: a prospective observational study.
</td>
<td style="text-align:left;">
BMC Cancer
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
MiR-4766-5p Inhibits The Development And Progression Of Gastric Cancer By Targeting NKAP.
</td>
<td style="text-align:left;">
Onco Targets Ther
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Concentration of hyaluronic acid in pleural fluid as a diagnostic aid for malignant mesothelioma.
</td>
<td style="text-align:left;">
Chest
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
A Man in His 20s With Cough, Unilateral Pleural Effusion, and Nodular Pleural Thickening.
</td>
<td style="text-align:left;">
Chest
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Impact of an asbestos cement factory on mesothelioma incidence in a community in Italy.
</td>
<td style="text-align:left;">
Environ. Res.
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1-2 trial.
</td>
<td style="text-align:left;">
Lancet Oncol.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Prognostic Immune Cell Profiling of Malignant Pleural Effusion Patients by Computerized Immunohistochemical and Transcriptional Analysis.
</td>
<td style="text-align:left;">
Cancers (Basel)
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Metabolic rewiring and redox alterations in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Br. J. Cancer
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Mortality and mesothelioma incidence among chrysotile asbestos miners in Balangero, Italy: A cohort study.
</td>
<td style="text-align:left;">
Am. J. Ind. Med.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Serum levels of the chemokine CCL2 are elevated in malignant pleural mesothelioma patients.
</td>
<td style="text-align:left;">
BMC Cancer
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Nivolumab for the treatment of unresectable pleural mesothelioma.
</td>
<td style="text-align:left;">
Expert Opin Biol Ther
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Clinical utility of FDG-PET/CT for post-surgery surveillance of malignant pleural mesothelioma - Comparison with contrast-enhanced CT.
</td>
<td style="text-align:left;">
Oncotarget
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
<i>In-vitro</i> proliferation assay with recycled ascitic cancer cells in malignant pleural mesothelioma: A case report.
</td>
<td style="text-align:left;">
World J Clin Cases
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[How I manage… Malignant pleural mesothelioma in 2019].
</td>
<td style="text-align:left;">
Rev Med Liege
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Cisplatin unleashes Toll-like receptor 3-mediated apoptosis through the downregulation of c-FLIP in malignant mesothelioma.
</td>
<td style="text-align:left;">
Cancer Lett.
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Clinically important associations of pleurodesis success in malignant pleural effusion: Analysis of the TIME1 data set.
</td>
<td style="text-align:left;">
Respirology
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Prognostic influence of tumor microenvironment after hypofractionated radiation and surgery for mesothelioma.
</td>
<td style="text-align:left;">
J. Thorac. Cardiovasc. Surg.
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
A Phase II Study of Pazopanib in Patients with Malignant Pleural Mesothelioma: NCCTG N0623 (Alliance).
</td>
<td style="text-align:left;">
Oncologist
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant Diffuse Mesothelioma in Women: A Study of 354 Cases.
</td>
<td style="text-align:left;">
Am. J. Surg. Pathol.
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Novel Germline Mutations in DNA Damage Repair in Patients with Malignant Pleural Mesotheliomas.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
The Lived Experience of Persons With Malignant Pleural Mesothelioma in the United States.
</td>
<td style="text-align:left;">
Cancer Nurs
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
A gene-expression-based test can outperform bap1 and <i>p16</i> analyses in the differential diagnosis of pleural mesothelial proliferations.
</td>
<td style="text-align:left;">
Oncol Lett
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Diffuse epithelioid malignant mesothelioma of the pleura presenting as a hydropneumothorax and vertebral body invasion.
</td>
<td style="text-align:left;">
BMJ Case Rep
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
A phase II trial of single oral FGF inhibitor, AZD4547, as second or third line therapy in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Implantation and Monitoring by PET/CT of an Orthotopic Model of Human Pleural Mesothelioma in Athymic Mice.
</td>
<td style="text-align:left;">
J Vis Exp
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Combined MEK and PI3K/p110β Inhibition as a Novel Targeted Therapy for Malignant Mesothelioma Displaying Sarcomatoid Features.
</td>
<td style="text-align:left;">
Cancer Res.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Analysis of mismatch repair (MMR) proteins expression in a series of malignant pleural mesothelioma (MPM) patients.
</td>
<td style="text-align:left;">
Clin Transl Oncol
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Mixed clinicopathologic behavior of a solitary mesothelioma.
</td>
<td style="text-align:left;">
Chest
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LOX family and ZFPM2 as novel diagnostic biomarkers for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Biomark Res
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Screening of Pleural Mesothelioma Cell Lines for Kinase Activity May Identify New Mechanisms of Therapy Resistance in Patients Receiving Platin-Based Chemotherapy.
</td>
<td style="text-align:left;">
J Oncol
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Dosimetric Comparison of Lung-Sparing Radiation Therapy between Volumetric Arc Therapy and Helical Tomotherapy for Unresectable Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
Biomed Res Int
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Frequent Homozygous Deletions of Type I Interferon Genes in Pleural Mesothelioma Confer Sensitivity to Oncolytic Measles Virus.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Clinical Outcomes With Recurrence After Pleurectomy/Decortication for Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
Ann. Thorac. Surg.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Predictions of Mortality from Pleural Mesothelioma in Italy After the Ban of Asbestos Use.
</td>
<td style="text-align:left;">
Int J Environ Res Public Health
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Not everything is what it seems: malignant pleural mesothelioma mimicking lung cancer.
</td>
<td style="text-align:left;">
Adv Respir Med
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
99mTc-HDP Bone Scintigraphy, SPECT/CT, and 18F-FDG PET/CT Diagnosis Imaging of Incidental Pleural Mesothelioma in a Patient With Biochemical Recurrences of Prostate Cancer: Is it Really a Coincidence?
</td>
<td style="text-align:left;">
Clin Nucl Med
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Clinical feature of diagnostic challenging cases for pleural biopsy in patient with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Gen Thorac Cardiovasc Surg
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Identification of a CD8+ T-cell response to a predicted neoantigen in malignant mesothelioma.
</td>
<td style="text-align:left;">
Oncoimmunology
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Correction to: Monoclonal Caveolin 1 Expression in the Differential Diagnosis of Malignant Pleural Mesothelioma and Pulmonary Adenocarcinoma: Is it Useful?
</td>
<td style="text-align:left;">
Pathol. Oncol. Res.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
18F-fluorodeoxyglucose positron emission tomography in malignant pleural mesothelioma: diagnostic and prognostic performance and its correlation to pathological results.
</td>
<td style="text-align:left;">
Interact Cardiovasc Thorac Surg
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Diagnosis of Mesothelioma.
</td>
<td style="text-align:left;">
Surg Pathol Clin
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Non-incisional pleurectomy/decortication.
</td>
<td style="text-align:left;">
Eur J Cardiothorac Surg
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
The Role of Neoadjuvant Chemotherapy in Patients with Resectable Malignant Pleural Mesothelioma - An Institutional and National Analysis.
</td>
<td style="text-align:left;">
J. Natl. Cancer Inst.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Deep learning-based segmentation of malignant pleural mesothelioma tumor on computed tomography scans: application to scans demonstrating pleural effusion.
</td>
<td style="text-align:left;">
J Med Imaging (Bellingham)
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
An Emerging Model for Cancer Development from a Tumor Microenvironment Perspective in Mice and Humans.
</td>
<td style="text-align:left;">
Adv. Exp. Med. Biol.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Biocompatibility and Carcinogenicity of Carbon Nanotubes as Biomaterials.
</td>
<td style="text-align:left;">
Nanomaterials (Basel)
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
[Diffuse Intraparenchymal Mesothelioma: An Atypical Presentation].
</td>
<td style="text-align:left;">
Acta Med Port
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Differential Diagnosis of Malignant Pleural Mesothelioma on Cytology: A Gene Expression Panel versus BRCA1-Associated Protein 1 and p16 Tests.
</td>
<td style="text-align:left;">
J Mol Diagn
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Cytologic presentation of malignant mesothelioma in pleural effusions.
</td>
<td style="text-align:left;">
Exp. Cell Biol.
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant Pleural Mesothelioma: State-of-the-Art on Current Therapies and Promises for the Future.
</td>
<td style="text-align:left;">
Front Oncol
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Primary squamous cell carcinoma of the pleura treated with nivolumab.
</td>
<td style="text-align:left;">
Respirol Case Rep
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Endoscopic ultrasound-guided pleural biopsy in the hands of the pulmonologist.
</td>
<td style="text-align:left;">
Respirol Case Rep
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Paclitaxel-loaded expansile nanoparticles improve survival following cytoreductive surgery in pleural mesothelioma xenografts.
</td>
<td style="text-align:left;">
J. Thorac. Cardiovasc. Surg.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Utility of Nuclear Grading System in Epithelioid Malignant Pleural Mesothelioma in Biopsy-heavy Setting: An External Validation Study of 563 Cases.
</td>
<td style="text-align:left;">
Am. J. Surg. Pathol.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Light Fluence Rate and Tissue Oxygenation (S<sub>t</sub> O<sub>2</sub> ) Distributions Within the Thoracic Cavity of Patients Receiving Intraoperative Photodynamic Therapy for Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
Photochem. Photobiol.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Effusion cytology of malignant mesothelioma enables earlier diagnosis and recognizes patients with better prognosis.
</td>
<td style="text-align:left;">
Diagn. Cytopathol.
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Exhaled Breath Analysis in Diagnosis of Malignant Pleural Mesothelioma: Systematic Review.
</td>
<td style="text-align:left;">
Int J Environ Res Public Health
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Infrared navigation system for light dosimetry during pleural photodynamic therapy.
</td>
<td style="text-align:left;">
Phys Med Biol
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Impact of Detecting Occult Pathologic Nodal Disease During Resection for Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
Clin Lung Cancer
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Lung Asbestos Fibre Burden and Pleural Mesothelioma in Women with Non-occupational Exposure.
</td>
<td style="text-align:left;">
Ann Work Expo Health
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Prognostic value of SUVmax on 18F-fluorodeoxyglucose PET/CT scan in patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
PLoS ONE
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Establishment and characterization of patient derived xenograft model of malignant peritoneal mesothelioma in nude mice].
</td>
<td style="text-align:left;">
Zhonghua Bing Li Xue Za Zhi
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
The role of imaging in malignant pleural mesothelioma: an update after the 2018 BTS guidelines.
</td>
<td style="text-align:left;">
Clin Radiol
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
A case of surgically treated bilateral metachronous malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Turk Gogus Kalp Damar Cerrahisi Derg
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Comparison of serum biochemical markers in patients with mesothelioma and pleural plaques versus healthy individuals exposed to environmental asbestos.
</td>
<td style="text-align:left;">
Turk Gogus Kalp Damar Cerrahisi Derg
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Genetic alterations of malignant pleural mesothelioma: association with tumor heterogeneity and overall survival.
</td>
<td style="text-align:left;">
Mol Oncol
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Lurbinectedin as second- or third-line palliative therapy in malignant pleural mesothelioma: an international, multi-centre, single-arm, phase II trial (SAKK 17/16).
</td>
<td style="text-align:left;">
Ann. Oncol.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Preoperative prediction of unresectability in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J. Thorac. Cardiovasc. Surg.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Disease-Related Outcomes and Toxicities of Intensity Modulated Radiation Therapy After Lung-Sparing Pleurectomy for Malignant Pleural Mesothelioma: A Systematic Review.
</td>
<td style="text-align:left;">
Pract Radiat Oncol
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Impressive clinical response to anti-PD-1 therapy in epithelioid mesothelioma with high clonal PD-L1 expression and EML4-ALK rearrangement.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Prolonged Progression-Free Survival in a Patient With Malignant Pleural Mesothelioma Following Korean Herbal Medicine Treatment Alone: A Case Report.
</td>
<td style="text-align:left;">
Integr Cancer Ther
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
A phase II study of the combination of gemcitabine and imatinib mesylate in pemetrexed-pretreated patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Cardiac herniation after extrapleural pneumonectomy.
</td>
<td style="text-align:left;">
J Surg Case Rep
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma of the pleura. A prospective therapeutic study of 132 patients from 1981-1985.
</td>
<td style="text-align:left;">
Klin. Wochenschr.
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Routine surveillance for diagnosis of venous thromboembolism after pleurectomy for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J. Thorac. Cardiovasc. Surg.
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
MicroRNA-98 is a prognostic factor for asbestos-induced mesothelioma.
</td>
<td style="text-align:left;">
J. Toxicol. Environ. Health Part A
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Manipulating microRNAs for the Treatment of Malignant Pleural Mesothelioma: Past, Present and Future.
</td>
<td style="text-align:left;">
Front Oncol
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma cells secrete natriuretic peptides: Data and diagnostic clinical implications.
</td>
<td style="text-align:left;">
Respirology
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
ADAR2 Regulates Malignant Behaviour of Mesothelioma Cells Independent of RNA-editing Activity.
</td>
<td style="text-align:left;">
Anticancer Res.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Histopathological features of epithelioid malignant pleural mesotheliomas in patients with extended survival.
</td>
<td style="text-align:left;">
Hum. Pathol.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Remarkable response to nivolumab in sarcomatoid malignant pleural mesothelioma with high PD-L1.
</td>
<td style="text-align:left;">
Respirol Case Rep
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Immunotherapy in Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
Front Oncol
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Curcumin as an Anticancer Agent in Malignant Mesothelioma: A Review.
</td>
<td style="text-align:left;">
Int J Mol Sci
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
How I treat malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
ESMO Open
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Comprehensive Molecular and Pathologic Evaluation of Transitional Mesothelioma Assisted by Deep Learning Approach: A Multi-Institutional Study of the International Mesothelioma Panel from the MESOPATH Reference Center.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Conversion surgery for locally advanced malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Gen Thorac Cardiovasc Surg
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Molecular and immunological features of a prolonged exceptional responder with malignant pleural mesothelioma treated initially and rechallenged with pembrolizumab.
</td>
<td style="text-align:left;">
J Immunother Cancer
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Comparative analysis of prognostic histopathologic parameters in subtypes of epithelioid pleural mesothelioma.
</td>
<td style="text-align:left;">
Histopathology
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Evaluation of gene expression levels in the diagnosis of lung adenocarcinoma and malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Turk Gogus Kalp Damar Cerrahisi Derg
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma following repeated exposures to cosmetic talc: A case series of 75 patients.
</td>
<td style="text-align:left;">
Am. J. Ind. Med.
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Immune Checkpoint Inhibitors in Thoracic Malignancies: Review of the Existing Evidence by an IASLC Expert Panel and Recommendations.
</td>
<td style="text-align:left;">
J Thorac Oncol
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Intramedullary Metastasis to the Cervical Spinal Cord from Malignant Pleural Mesothelioma: Review of the Literature and Case Reports.
</td>
<td style="text-align:left;">
Asian J Neurosurg
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Single-center study to determine the safety and efficacy of CT-707 in Chinese patients with advanced anaplastic lymphoma kinase-rearranged non-small-cell lung cancer.
</td>
<td style="text-align:left;">
Thorac Cancer
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Talc and mesothelioma: mineral fiber analysis of 65 cases with clinicopathological correlation.
</td>
<td style="text-align:left;">
Ultrastruct Pathol
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Utility of Claudin-4 versus BerEP4 and B72.3 in pleural fluids with metastatic lung adenocarcinoma.
</td>
<td style="text-align:left;">
J Am Soc Cytopathol
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Progressive growth of a human pleural mesothelioma xenografted to athymic rats and mice.
</td>
<td style="text-align:left;">
Br. J. Cancer
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Diffuse mesothelin expression leads to worse prognosis through enhanced cellular proliferation in colorectal cancer.
</td>
<td style="text-align:left;">
Oncol Lett
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Short and long term behaviour of pleural effusion cultures. (Report of 200 cases) (author’s transl)].
</td>
<td style="text-align:left;">
Pathol. Biol.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Application of immunohistochemistry in diagnosis and management of malignant mesothelioma.
</td>
<td style="text-align:left;">
Transl Lung Cancer Res
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Chemotherapy options versus “novel” therapies: how should we treat patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Transl Lung Cancer Res
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Surgery for pleural mesothelioma, when it is indicated and why: arguments against surgery for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Transl Lung Cancer Res
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
IgG4-related pleural disease with aortitis and submandibular glands involvement successfully treated with corticosteroid: case-based review.
</td>
<td style="text-align:left;">
Rheumatol. Int.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Predictors of outcome of pleurodesis in patients with malignant pleural effusion: a systematic review and meta-analysis.
</td>
<td style="text-align:left;">
Expert Rev Respir Med
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Randomised placebo-controlled cross-over study examining the role of anamorelin in mesothelioma (The ANTHEM study): rationale and protocol.
</td>
<td style="text-align:left;">
BMJ Open Respir Res
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Not gene therapy, but genetic surgery-the right strategy to attack cancer.
</td>
<td style="text-align:left;">
Mol. Gen. Microbiol. Virol.
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Emerging Treatments for Malignant Pleural Mesothelioma: Where Are We Heading?
</td>
<td style="text-align:left;">
Front Oncol
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
T cell receptor repertoire characteristics both before and following immunotherapy correlate with clinical response in mesothelioma.
</td>
<td style="text-align:left;">
J Immunother Cancer
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Hypoxia Inducible Factor-1α Inhibition in Von Hippel Lindau-mutant Malignant Pleural Mesothelioma Cells.
</td>
<td style="text-align:left;">
Anticancer Res.
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Tumour cell PD-L1 expression is prognostic in patients with malignant pleural effusion: the impact of C-reactive protein and immune-checkpoint inhibition.
</td>
<td style="text-align:left;">
Sci Rep
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Clinical Trials Eligibility of Patients With Malignant Pleural Mesothelioma: Use of Novel Therapies and Outcomes.
</td>
<td style="text-align:left;">
Clin Lung Cancer
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Detection of Circulating Tumor Cells (CTCs) in Malignant Pleural Mesothelioma (MPM) with the “Universal” CTC-Chip and An Anti-Podoplanin Antibody NZ-1.2.
</td>
<td style="text-align:left;">
Cells
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Surgery for Mesothelioma After Radiation Therapy (SMART); A Single Institution Experience.
</td>
<td style="text-align:left;">
Front Oncol
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
The Biology of Malignant Mesothelioma and the Relevance of Preclinical Models.
</td>
<td style="text-align:left;">
Front Oncol
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Fully Human Antibodies for Malignant Pleural Mesothelioma Targeting.
</td>
<td style="text-align:left;">
Cancers (Basel)
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Treatment of bronchial fistula after extraplural pneumonectomy using flexible bronchoscopy with the administration of OK432, fibroblast growth factor basic and fibrin glue sealant.
</td>
<td style="text-align:left;">
Gen Thorac Cardiovasc Surg
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Potential years of life and productivity loss due to malignant mesothelioma in Turkey.
</td>
<td style="text-align:left;">
Arch Environ Occup Health
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
A Unique Gene-Silencing Approach, Using an Intelligent RNA Expression Device (iRed), Results in Minimal Immune Stimulation When Given by Local Intrapleural Injection in Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
Molecules
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
FDG-PET assessment of malignant pleural mesothelioma: Total Lesion volume and Total Lesion Glycolysis; the central role of volume.
</td>
<td style="text-align:left;">
J. Nucl. Med.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
A phase II study of VP-16 and cisplatin in patients with unresectable malignant mesothelioma. An NCI Canada Clinical Trials Group Study.
</td>
<td style="text-align:left;">
Invest New Drugs
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Defense and protection mechanisms in lung exposed to asbestiform fiber: the role of macrophage migration inhibitory factor and heme oxygenase-1.
</td>
<td style="text-align:left;">
Eur J Histochem
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Differentiating Between Malignant Mesothelioma and Other Pleural Lesions Using Fourier Transform Infrared Spectroscopy.
</td>
<td style="text-align:left;">
Appl Spectrosc
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Telomerase Reverse Transcriptase Promoter Mutations Identify a Genomically Defined and Highly Aggressive Human Pleural Mesothelioma Subgroup.
</td>
<td style="text-align:left;">
Clin. Cancer Res.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Circulating Epigenetic Biomarkers in Malignant Pleural Mesothelioma: State of the Art and critical Evaluation.
</td>
<td style="text-align:left;">
Front Oncol
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Targeted Phototherapy for Malignant Pleural Mesothelioma: Near-Infrared Photoimmunotherapy Targeting Podoplanin.
</td>
<td style="text-align:left;">
Cells
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Modulation of microRNA expression levels after naturally occurring asbestiform fibers exposure as a diagnostic biomarker of mesothelial neoplastic transformation.
</td>
<td style="text-align:left;">
Ecotoxicol. Environ. Saf.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Extracellular vesicles as biomarkers in malignant pleural mesothelioma: A review.
</td>
<td style="text-align:left;">
Crit. Rev. Oncol. Hematol.
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Presence of pleomorphic features but not growth patterns improves prognostic stratification of epithelioid malignant pleural mesothelioma by 2-tier nuclear grade.
</td>
<td style="text-align:left;">
Histopathology
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Genomic analysis in short- and long-term patients with malignant pleura mesothelioma treated with palliative chemotherapy.
</td>
<td style="text-align:left;">
Eur. J. Cancer
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Prognostic and clinicopathological utility of programmed death-ligand 1 in malignant pleural mesothelioma: A meta-analysis.
</td>
<td style="text-align:left;">
Int. Immunopharmacol.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Putative Biomarkers for Malignant Pleural Mesothelioma Suggested by Proteomic Analysis of Cell Secretome.
</td>
<td style="text-align:left;">
Cancer Genomics Proteomics
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
Med Lav
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Treatment patterns among patients with malignant pleural mesothelioma: An Italian, population-based nationwide study.
</td>
<td style="text-align:left;">
Thorac Cancer
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Mutational Profiling of Driver Tumor Suppressor and Oncogenic Genes in Brazilian Malignant Pleural Mesotheliomas.
</td>
<td style="text-align:left;">
Pathobiology
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Low-dose photodynamic therapy promotes a cytotoxic immunological response in a murine model of pleural mesothelioma.
</td>
<td style="text-align:left;">
Eur J Cardiothorac Surg
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Inhibition of miR-18a-3p reduces proliferation of mesothelioma cells and sensitizes them to cisplatin.
</td>
<td style="text-align:left;">
Oncol Lett
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant Pleural Mesothelioma: Genetic and Microenviromental Heterogeneity as an Unexpected Reading Frame and Therapeutic Challenge.
</td>
<td style="text-align:left;">
Cancers (Basel)
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Nivolumab resulting in persistently elevated troponin levels despite clinical remission of myocarditis and myositis in a patient with malignant pleural mesothelioma: case report.
</td>
<td style="text-align:left;">
Transl Lung Cancer Res
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Breath Analysis for Early Detection of Malignant Pleural Mesothelioma: Volatile Organic Compounds (VOCs) Determination and Possible Biochemical Pathways.
</td>
<td style="text-align:left;">
Cancers (Basel)
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Metformin-loaded chitosomes for treatment of malignant pleural mesothelioma - A rare thoracic cancer.
</td>
<td style="text-align:left;">
Int. J. Biol. Macromol.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Eur J Cardiothorac Surg
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Eur. Respir. J.
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Analysis of survival of patients with metastatic malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Tumori
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Amrubicin in previously treated patients with malignant pleural mesothelioma: A phase II study.
</td>
<td style="text-align:left;">
Thorac Cancer
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Initial evaluation of nivolumab in patients with post-operative recurrence of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Jpn. J. Clin. Oncol.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
The Role of Micronucleus Assay to Detect Genetic Instability in Respiratory Cancer Patients.
</td>
<td style="text-align:left;">
J. Environ. Pathol. Toxicol. Oncol.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Adenosine Deaminase in Pleural Effusion and Its Relationship with Clinical Parameters in Patients with Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
Cancer Invest.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Breast metastasis as the initial presentation of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Breast J
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Irinotecan inducing sinus pause bradycardia in a patient with small round cell cancer.
</td>
<td style="text-align:left;">
BMJ Case Rep
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Cisplatin plus pemetrexed therapy and subsequent immune checkpoint inhibitor administration for malignant peritoneal mesothelioma without pleural lesions: Case report.
</td>
<td style="text-align:left;">
Medicine (Baltimore)
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Impact of hypoxia on chemoresistance of mesothelioma mediated by the proton-coupled folate transporter, and preclinical activity of new anti-LDH-A compounds.
</td>
<td style="text-align:left;">
Br. J. Cancer
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant asbestos-related disease in a population exposed to asbestos.
</td>
<td style="text-align:left;">
Am. J. Ind. Med.
</td>
<td style="text-align:left;">
diagnosis | epidemiology | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Comparison of modified Response Evaluation Criteria in Solid Tumors, European Organization for Research and Treatment of Cancer criteria, and PET Response Criteria in Solid Tumors for evaluation of tumor response to chemotherapy and prognosis prediction in patients with unresectable malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Nucl Med Commun
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
TGFα Promotes Chemoresistance of Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
Cancers (Basel)
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Indwelling pleural catheter versus talc pleurodesis for malignant pleural effusion: a meta-analysis.
</td>
<td style="text-align:left;">
Clin. Exp. Metastasis
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Estimate of environmental and occupational components in the spatial distribution of malignant mesothelioma incidence in Lombardy (Italy).
</td>
<td style="text-align:left;">
Environ. Res.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Anti-PD-1 antibody combined with chemotherapy suppresses the growth of mesothelioma by reducing myeloid-derived suppressor cells.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Prognostic Value of Ki67 Percentage, WT-1 Expression and p16/CDKN2A Deletion in Diffuse Malignant Peritoneal Mesothelioma: A Single-Centre Cohort Study.
</td>
<td style="text-align:left;">
Diagnostics (Basel)
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Racial Disparities in Treatment Patterns and Survival Among Surgically Treated Malignant Pleural Mesothelioma Patients.
</td>
<td style="text-align:left;">
J Immigr Minor Health
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Tumor-associated macrophage-derived inflammatory cytokine enhances malignant potential of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Cancer Sci.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Addition of radiotherapy to surgery and chemotherapy improves survival in localized malignant pleural mesothelioma: A Surveillance, Epidemiology, and End Results (SEER) study.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Volumetric PET response assessment outperforms conventional criteria in patients receiving high-dose pembrolizumab for malignant mesothelioma.
</td>
<td style="text-align:left;">
J. Nucl. Med.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Secondary renal amyloidosis associated with asbestos-related pleuropulmonary diseases.
</td>
<td style="text-align:left;">
CEN Case Rep
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
NTRK and ALK rearrangements in malignant pleural mesothelioma, pulmonary neuroendocrine tumours and non-small cell lung cancer.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Genomic-based ancillary assays offer improved diagnostic yield of effusion cytology with potential challenges in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Pathol. Int.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
NLRP3 and CARD8 polymorphisms influence risk for asbestos-related diseases.
</td>
<td style="text-align:left;">
J Med Biochem
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Asbestos-related diseases.
</td>
<td style="text-align:left;">
Int. J. Tuberc. Lung Dis.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
RapidPlan for Knowledge-Based Planning of Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
Pract Radiat Oncol
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Predicting cancer using supervised machine learning: Mesothelioma.
</td>
<td style="text-align:left;">
Technol Health Care
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Role of inflammation in the malignant transformation of pleural mesothelial cells induced by multi-walled carbon nanotubes.
</td>
<td style="text-align:left;">
Nanotoxicology
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Involvement of the M-CSF/IL-34/CSF-1R pathway in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J Immunother Cancer
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Cellular Immunotherapy and Locoregional Administration of CAR T-Cells in Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
Front Oncol
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Genomic profiling of multiple primary cancers including synchronous lung adenocarcinoma and bilateral malignant mesotheliomas: Identification of a novel BAP1 germline variant.
</td>
<td style="text-align:left;">
Pathol. Int.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Acquired multiple mutations ALK I1171N, L1196M and G1202R mediate lorlatinib resistance in EML4-ALK-rearranged malignant pleural mesothelioma: a case report.
</td>
<td style="text-align:left;">
Ther Adv Respir Dis
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
TLD1433-Mediated Photodynamic Therapy with an Optical Surface Applicator in the Treatment of Lung Cancer Cells In Vitro.
</td>
<td style="text-align:left;">
Pharmaceuticals (Basel)
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
A Phase II Trial of Alisertib (MLN8237) in Salvage Malignant Mesothelioma.
</td>
<td style="text-align:left;">
Oncologist
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Gender-based Disparities in Receipt of Care and Survival in Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
Clin Lung Cancer
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleural effusions and pneumothorax: Beyond simple plumbing: Expert opinions on knowledge gaps and essential next steps.
</td>
<td style="text-align:left;">
Respirology
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Questioning the prognostic role of BAP-1 immunohistochemistry in malignant pleural mesothelioma: A single center experience with systematic review and meta-analysis.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Clinical Features in Patients With Malignant Pleural Mesothelioma With 5-Year Survival and Evaluation of Original Diagnoses.
</td>
<td style="text-align:left;">
Clin Lung Cancer
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Comments on a recent case-control study of malignant mesothelioma of the pericardium and the tunica vaginalis testis.
</td>
<td style="text-align:left;">
Scand J Work Environ Health
</td>
<td style="text-align:left;">
epidemiology | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Five Years PLEURATUMOR Register of the German Society of Thoracic Surgery].
</td>
<td style="text-align:left;">
Zentralbl Chir
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Acute kidney injury after cytoreductive surgery and hyperthermic intraoperative cisplatin chemotherapy for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J. Thorac. Cardiovasc. Surg.
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Video-assisted biopsy and talc pleurodesis for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Multimed Man Cardiothorac Surg
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Development of a Pemetrexed/Folic Acid Nanoformulation: Synthesis, Characterization, and Efficacy in a Murine Colorectal Cancer Model.
</td>
<td style="text-align:left;">
ACS Omega
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Clinical long-term outcome of non-specific pleuritis (NSP) after surgical or medical thoracoscopy.
</td>
<td style="text-align:left;">
J Thorac Dis
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Should Lung-Sparing Surgery Be the Standard Procedure for Malignant Pleural Mesothelioma?
</td>
<td style="text-align:left;">
J Clin Med
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
<i>EIF4G1</i> and <i>RAN</i> as Possible Drivers for Malignant Pleural Mesothelioma.
</td>
<td style="text-align:left;">
Int J Mol Sci
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
FDG PET versus CT radiomics to predict outcome in malignant pleural mesothelioma patients.
</td>
<td style="text-align:left;">
EJNMMI Res
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Ganetespib in Combination with Pemetrexed-Platinum Chemotherapy in Patients with Pleural Mesothelioma (MESO-02): A Phase Ib Trial.
</td>
<td style="text-align:left;">
Clin. Cancer Res.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Nucleolin and nucleophosmin expression patterns in pulmonary adenocarcinoma invading the pleura and in pleural malignant mesothelioma.
</td>
<td style="text-align:left;">
Thorac Cancer
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Comparison between closed pleural biopsy and medical thoracoscopy for the diagnosis of undiagnosed exudative pleural effusions: a systematic review and meta-analysis.
</td>
<td style="text-align:left;">
Transl Lung Cancer Res
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Preliminary study highlights the potential of immune checkpoint inhibitors in sarcomatoid mesothelioma.
</td>
<td style="text-align:left;">
Transl Lung Cancer Res
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Clinical significance of histologic subtyping of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Transl Lung Cancer Res
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Integrative approach to cytologic and molecular diagnosis of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Transl Lung Cancer Res
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Testing for BAP1 loss and CDKN2A/p16 homozygous deletion improves the accurate diagnosis of mesothelial proliferations in effusion cytology.
</td>
<td style="text-align:left;">
Cancer Cytopathol
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma: Treatment patterns and outcomes from the Spanish Lung Cancer Group.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
diagnosis | treatment | epidemiology | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Progress in the understanding of the immune microenvironment and immunotherapy in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Curr Drug Targets
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Ovarian metastasis from malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Tumori
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Interobserver Agreement in Histopathological Subtyping of Malignant Pleural Mesotheliomas.
</td>
<td style="text-align:left;">
Turk Patoloji Derg
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Delayed-Phase Enhancement for Evaluation of Malignant Pleural Mesothelioma on Computed Tomography: A Prospective Cohort Study.
</td>
<td style="text-align:left;">
Clin Lung Cancer
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Mesothelioma Biomarkers: A Review Highlighting Contributions from the Early Detection Research Network.
</td>
<td style="text-align:left;">
Cancer Epidemiol. Biomarkers Prev.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Laser ablation inductively coupled plasma mass spectrometry as a Novel Clinical Imaging Tool to Detect Asbestos Fibres in Malignant Mesothelioma.
</td>
<td style="text-align:left;">
Rapid Commun. Mass Spectrom.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Connective tissue growth factor produced by cancer‑associated fibroblasts correlates with poor prognosis in epithelioid malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Oncol. Rep.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Dual Inhibition of CDK4/6 and PI3K/AKT/mTOR Signaling Impairs Energy Metabolism in MPM Cancer Cells.
</td>
<td style="text-align:left;">
Int J Mol Sci
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
New vistas in malignant mesothelioma: MicroRNA architecture and NRF2/MAPK signal transduction.
</td>
<td style="text-align:left;">
Life Sci.
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Nivolumab-induced immune thrombocytopenia in a patient with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Respir Med Case Rep
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Normal Mesothelial Cell Lines Newly Derived from Human Pleural Biopsy Explants.
</td>
<td style="text-align:left;">
Am. J. Physiol. Lung Cell Mol. Physiol.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Determinants of plasma calretinin in patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
BMC Res Notes
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Randomized Study of Maintenance Pemetrexed Versus Observation for Treatment of Malignant Pleural Mesothelioma: CALGB 30901.
</td>
<td style="text-align:left;">
Clin Lung Cancer
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Multiplex Soluble Biomarker Analysis from Pleural Effusion.
</td>
<td style="text-align:left;">
Biomolecules
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Trabectedin in Malignant Pleural Mesothelioma: Results From the Multicentre, Single Arm, Phase II ATREUS Study.
</td>
<td style="text-align:left;">
Clin Lung Cancer
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Verification of a blood based targeted proteomics signature for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Cancer Epidemiol. Biomarkers Prev.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Cytology, immunopathology and flow cytometry in the diagnosis of pleural and peritoneal effusions.
</td>
<td style="text-align:left;">
Lab. Invest.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Mesothelioma of childhood.
</td>
<td style="text-align:left;">
Cancer
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
The pleural manifestations of asbestos exposure.
</td>
<td style="text-align:left;">
Occup Med
</td>
<td style="text-align:left;">
epidemiology | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Value of immunocytochemistry in the study of malignant effusions.
</td>
<td style="text-align:left;">
Diagn. Cytopathol.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
[Toxicity of the CYVADIC modification in patients with soft tissue sarcomas or malignant mesotheliomas].
</td>
<td style="text-align:left;">
Onkologie
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
[Histologic aspects of pleural mesothelioma].
</td>
<td style="text-align:left;">
Arch Inst Pasteur Tunis
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Prognostic factors in diffuse malignant pleural mesothelioma. A study of 167 patients.
</td>
<td style="text-align:left;">
Chest
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma: prognostic variables in a registry of 180 patients, the Dana-Farber Cancer Institute and Brigham and Women’s Hospital experience over two decades, 1965-1985.
</td>
<td style="text-align:left;">
J. Clin. Oncol.
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Diffuse contralateral pulmonary metastases in malignant mesothelioma. An unusual radiographic presentation.
</td>
<td style="text-align:left;">
Chest
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
[Local administration of recombinant interferon-beta to patients with cancer-associated body cavity fluids].
</td>
<td style="text-align:left;">
Gan To Kagaku Ryoho
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Expression of epithelial membrane antigen on malignant mesothelioma cells. An immunocytochemical and immunoelectron microscopic study.
</td>
<td style="text-align:left;">
Acta Cytol.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma in a cohort of asbestos insulation workers: clinical presentation, diagnosis, and causes of death.
</td>
<td style="text-align:left;">
Br J Ind Med
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma: a disease unaffected by current therapeutic maneuvers.
</td>
<td style="text-align:left;">
J. Clin. Oncol.
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Case-control study of diet and mesothelioma in Louisiana.
</td>
<td style="text-align:left;">
Cancer Res.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Freeze-fracture study of intercellular junctions in benign and malignant mesothelial cells in effusions and a comparison with those seen in pleural mesotheliomas (solid tumour).
</td>
<td style="text-align:left;">
J. Submicrosc. Cytol. Pathol.
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Surgical treatment of asbestos-related disease of the chest.
</td>
<td style="text-align:left;">
Surg. Clin. North Am.
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Asbestos-induced pleural diseases–thoracoscopic aspects.
</td>
<td style="text-align:left;">
Endoscopy
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
The role of computed tomography scanning in the initial assessment and the follow-up of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J. Thorac. Cardiovasc. Surg.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Clinicopathologic studies on mesothelioma of the pleura. Differentiated approach to treatment.
</td>
<td style="text-align:left;">
Scand J Thorac Cardiovasc Surg
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Cytophotometric determination of DNA in mesotheliomas and reactive mesothelial cells.
</td>
<td style="text-align:left;">
Anal. Quant. Cytol. Histol.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Thrombocytosis in patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Cancer
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Flow cytometric analysis of ploidy in immunohistochemically confirmed examples of malignant epithelial mesothelioma.
</td>
<td style="text-align:left;">
Am. J. Clin. Pathol.
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Three types of spindle cell tumors of the pleura. Fibroma, sarcoma, and sarcomatoid mesothelioma.
</td>
<td style="text-align:left;">
Am. J. Surg. Pathol.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
[Pleural and mediastinal metastases from a malignant mesothelioma of testicular vaginalis membrane].
</td>
<td style="text-align:left;">
Rev Mal Respir
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Quantitative ultrastructural study of nuclei from exfoliated benign and malignant mesothelial cells and metastatic adenocarcinoma cells.
</td>
<td style="text-align:left;">
Acta Cytol.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Computerized interactive morphometry as an aid in the diagnosis of pleural effusions.
</td>
<td style="text-align:left;">
Acta Cytol.
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Fine needle aspiration cytology of malignant mesothelioma.
</td>
<td style="text-align:left;">
Acta Cytol.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Non-malignant asbestos diseases in workers in an electrochemical plant.
</td>
<td style="text-align:left;">
Br J Ind Med
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleural mesothelioma.
</td>
<td style="text-align:left;">
Ann. Thorac. Surg.
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Asbestos-related malignancy.
</td>
<td style="text-align:left;">
Crit. Rev. Oncol. Hematol.
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Phase II trial of carboplatin (JM8) in treatment of patients with malignant mesothelioma.
</td>
<td style="text-align:left;">
Cancer Chemother. Pharmacol.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
A phase II study of the platinum analogues JM8 and JM9 in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Cancer Chemother. Pharmacol.
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Randomized comparison of cyclophosphamide, imidazole carboxamide, and adriamycin versus cyclophosphamide and adriamycin in patients with advanced stage malignant mesothelioma: a Sarcoma Intergroup Study.
</td>
<td style="text-align:left;">
J. Clin. Oncol.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Tumors of serosal tissue origin.
</td>
<td style="text-align:left;">
Clin. Lab. Med.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Characterization of a human malignant mesothelioma cell line (H-MESO-1): a biphasic solid and ascitic tumor model.
</td>
<td style="text-align:left;">
Cancer Res.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Serum hyaluronate in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Cancer
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Benign and malignant mesothelial lesions of the pleura: quantitative study.
</td>
<td style="text-align:left;">
Appl Pathol
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Monoclonal antibodies to human malignant mesothelioma.
</td>
<td style="text-align:left;">
J. Clin. Immunol.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Accuracy of diagnostic procedures in the initial evaluation and follow-up of mesothelioma patients.
</td>
<td style="text-align:left;">
Respiration
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Notifiable malignant lesions in the RSA, 1979-1983–trends and mortality. II. Primary malignant neoplasms of the pleura.
</td>
<td style="text-align:left;">
S. Afr. Med. J.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Asbestos and cancer: a cohort followed up to death.
</td>
<td style="text-align:left;">
Br J Ind Med
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Non-malignant chest x ray changes in patients with mesothelioma in a large cohort of asbestos insulation workers.
</td>
<td style="text-align:left;">
Br J Ind Med
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
The cytologic diagnosis of mesothelioma.
</td>
<td style="text-align:left;">
Semin Diagn Pathol
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Diffuse malignant mesothelioma of the pleura–intrapleural treatment with doxorubicin.
</td>
<td style="text-align:left;">
Arch. Geschwulstforsch.
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
High incidence of malignant pleural mesothelioma in neighbouring villages of Northwestern Greece.
</td>
<td style="text-align:left;">
Respiration
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma with occupational and environmental asbestos exposure in an Illinois community hospital.
</td>
<td style="text-align:left;">
Arch. Intern. Med.
</td>
<td style="text-align:left;">
diagnosis | epidemiology | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant diffuse peritoneal mesothelioma: clinical and therapeutic aspects. Apropos of a case with gelatinous ascites].
</td>
<td style="text-align:left;">
Rev Med Interne
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Cisplatin administered by the intracavitary route as treatment for malignant mesothelioma.
</td>
<td style="text-align:left;">
Cancer
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Applications of computerized interactive morphometry in pathology. II. A model for computer generated diagnosis.
</td>
<td style="text-align:left;">
Lab. Invest.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Gallium scanning in differentiating malignant from benign asbestos-related pleural disease.
</td>
<td style="text-align:left;">
Am. J. Ind. Med.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesotheliomas. Improved differential diagnosis from lung adenocarcinomas using monoclonal antibodies 44-3A6 and 624A12.
</td>
<td style="text-align:left;">
Am. J. Pathol.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma cells in sputum.
</td>
<td style="text-align:left;">
Diagn. Cytopathol.
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
[Primary malignant tumors of the pleura].
</td>
<td style="text-align:left;">
Rontgenblatter
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Diffuse malignant mesothelioma of pleura. Diagnosis and survival in 92 cases.
</td>
<td style="text-align:left;">
Cancer
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Diagnostic value of ferritin analysis in pleural effusions.
</td>
<td style="text-align:left;">
Scand. J. Clin. Lab. Invest.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Minimal-change nephrotic syndrome associated with malignant mesothelioma.
</td>
<td style="text-align:left;">
Arch. Intern. Med.
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
[pH measurement in the diagnosis of pleural exudates].
</td>
<td style="text-align:left;">
Minerva Med.
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Cardiac abnormalities in patients with diffuse malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Cancer
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Immunodiagnosis of mesothelioma: use of antimesothelial cell serum in an indirect immunofluorescence assay.
</td>
<td style="text-align:left;">
Cancer
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleural fluid CEA levels in the diagnosis of malignant mesothelioma.
</td>
<td style="text-align:left;">
Pathology
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant peritoneal mesothelioma in a child.
</td>
<td style="text-align:left;">
Pediatr Pathol
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Computed tomography of pleural lesions with special reference to the mediastinal pleura.
</td>
<td style="text-align:left;">
Acta Radiol Diagn (Stockh)
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Diagnosis of malignant pleural mesothelioma by axillary lymph node biopsy.
</td>
<td style="text-align:left;">
Chest
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Secretory component in pulmonary adenocarcinoma and mesothelioma.
</td>
<td style="text-align:left;">
Histopathology
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Cytopathology of asbestos-associated pulmonary disease.
</td>
<td style="text-align:left;">
Diagn. Cytopathol.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Computerized interactive morphometry. A study of malignant mesothelioma and mesothelial hyperplasia in pleural biopsy specimens.
</td>
<td style="text-align:left;">
Arch. Pathol. Lab. Med.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
The distinction of mesothelioma from adenocarcinoma in malignant effusions by electron microscopy.
</td>
<td style="text-align:left;">
Acta Cytol.
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Ultrastructural studies of cells in body cavity effusions.
</td>
<td style="text-align:left;">
Acta Cytol.
</td>
<td style="text-align:left;">
transmission
</td>
</tr>
<tr>
<td style="text-align:left;">
Benign and malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Clin. Chest Med.
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
A prospective study of detorubicin in malignant mesothelioma.
</td>
<td style="text-align:left;">
Cancer
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
The role of concurrent determinations of pleural fluid and tissue carcinoembryonic antigen in the distinction of malignant mesothelioma from metastatic pleural malignancies.
</td>
<td style="text-align:left;">
Eur J Cancer Clin Oncol
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Randomized trial of doxorubicin versus cyclophosphamide in diffuse malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Cancer Treat Rep
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
[Monoclonal gammopathies in the aged].
</td>
<td style="text-align:left;">
Minerva Med.
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
The use of vimentin antibodies in the diagnosis of malignant mesothelioma.
</td>
<td style="text-align:left;">
Virchows Arch A Pathol Anat Histopathol
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Glycosaminoglycan in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Cancer
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma with brain metastases.
</td>
<td style="text-align:left;">
Am. J. Med.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Asbestos content of lung tissue in asbestos associated diseases: a study of 110 cases.
</td>
<td style="text-align:left;">
Br J Ind Med
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Asbestos exposure and Alzheimer disease.
</td>
<td style="text-align:left;">
Ital J Neurol Sci
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma in British Columbia in 1982.
</td>
<td style="text-align:left;">
Cancer
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Familial mesothelioma: review and family study.
</td>
<td style="text-align:left;">
Cancer Genet. Cytogenet.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Comparison of needle biopsy with cytologic analysis for the evaluation of pleural effusion: analysis of 414 cases.
</td>
<td style="text-align:left;">
Mayo Clin. Proc.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma secondary to chronic inflammation and old scars. Two new cases and review of the literature.
</td>
<td style="text-align:left;">
Cancer
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Hyaluronic acid content of effusions as a diagnostic aid for malignant mesothelioma.
</td>
<td style="text-align:left;">
Cancer Res.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant diffuse pleural mesothelioma: a comparison between computed tomography and the conventional chest x-ray].
</td>
<td style="text-align:left;">
Digitale Bilddiagn
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant diffuse pleural mesothelioma–does it produce mediastinal shift?
</td>
<td style="text-align:left;">
Radiologe
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Trend and distribution of mesothelioma in Denmark.
</td>
<td style="text-align:left;">
Br. J. Cancer
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Glycosaminoglycans in malignant diffuse mesothelioma.
</td>
<td style="text-align:left;">
Cancer
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Tumours and pseudotumours of the chest wall.
</td>
<td style="text-align:left;">
Scand J Thorac Cardiovasc Surg
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Modified nucleosides in asbestos workers at high risk of malignant disease: results of a preliminary study applying discriminant analysis.
</td>
<td style="text-align:left;">
Br J Ind Med
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Fiber concentration in lung tissue of patients with malignant mesothelioma. A case-control study.
</td>
<td style="text-align:left;">
Cancer
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Trends in mortality from malignant mesothelioma of the pleura, and production and use of asbestos in Australia.
</td>
<td style="text-align:left;">
Med. J. Aust.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Biochemical and cytological features of diffuse mesotheliomas of the pleura.
</td>
<td style="text-align:left;">
Arch. Geschwulstforsch.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Phase II trial of high-dose cisplatin in patients with malignant mesothelioma.
</td>
<td style="text-align:left;">
Cancer Treat Rep
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
[A case of remission in diffuse pleural mesothelioma induced by anticancer chemotherapy with cisplatin and adriamycin].
</td>
<td style="text-align:left;">
Gan To Kagaku Ryoho
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
[Bromocriptine in Parkinson’s disease: pleuropulmonary toxicity].
</td>
<td style="text-align:left;">
Ann Med Interne (Paris)
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Tetracycline sclerosis in the management of malignant pericardial effusion.
</td>
<td style="text-align:left;">
J. Clin. Oncol.
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Metastatic tumours in the testis.
</td>
<td style="text-align:left;">
Histopathology
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
[Pleural and peritoneal cytology].
</td>
<td style="text-align:left;">
Cesk Patol
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant fibrosarcomatous mesothelioma and benign pleural fibroma (localized fibrous mesothelioma) in tissue culture: a comparison of the in vitro pattern of growth in relation to the cell of origin.
</td>
<td style="text-align:left;">
Cancer
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma presenting in the pleura and peritoneum.
</td>
<td style="text-align:left;">
J Surg Oncol
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Differential diagnosis of pleural diseases].
</td>
<td style="text-align:left;">
Z Gesamte Inn Med
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Epidemiologic surveillance of mesothelioma in Canada.
</td>
<td style="text-align:left;">
Can Med Assoc J
</td>
<td style="text-align:left;">
diagnosis | epidemiology
</td>
</tr>
<tr>
<td style="text-align:left;">
Epidemiological and quantitative relationships between mesothelioma and asbestos on Tyneside.
</td>
<td style="text-align:left;">
J. Clin. Pathol.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Two malignant pleural mesotheliomas with unusual histological features.
</td>
<td style="text-align:left;">
Thorax
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Localized primary tumors of the pleura: an analysis of 40 cases.
</td>
<td style="text-align:left;">
Cancer
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Exfoliative cytology of diffuse mesothelioma.
</td>
<td style="text-align:left;">
J. Clin. Pathol.
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
[Diffuse malignant mesothelioma of the pleura and peritoneum].
</td>
<td style="text-align:left;">
Cesk Patol
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Mesothelioma in Scotland.
</td>
<td style="text-align:left;">
Br Med J
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
[Ultrastructural diagnostic problems of pleural tumors. A study of 125 cases (author’s transl)].
</td>
<td style="text-align:left;">
Rev Fr Mal Respir
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
[The computed tomography of the malignant thoracic space-occupying process under special consideration of radiotherapeutic points of view (author’s transl)].
</td>
<td style="text-align:left;">
Strahlentherapie
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
[Rare malignant tumors of the lungs (44 cases)].
</td>
<td style="text-align:left;">
Vopr Onkol
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Asbestosis. Apropos of one case].
</td>
<td style="text-align:left;">
Poumon Coeur
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Immunohistological study of malignant diffuse mesotheliomas of the pleura.
</td>
<td style="text-align:left;">
Histopathology
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma and radiological chest abnormalities in two villages in Central Turkey. An epidemiological and environmental investigation.
</td>
<td style="text-align:left;">
Lancet
</td>
<td style="text-align:left;">
epidemiology
</td>
</tr>
<tr>
<td style="text-align:left;">
Mesothelioma: profile of keratin proteins and carcinoembryonic antigen: an immunoperoxidase study of 20 cases and comparison with pulmonary adenocarcinomas.
</td>
<td style="text-align:left;">
Am. J. Pathol.
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Immunohistochemical localization of prekeratin filaments in benign and malignant cells in effusions. Comparison with intermediate filament distribution by electron microscopy.
</td>
<td style="text-align:left;">
Am. J. Pathol.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Histologic distinction between malignant mesothelioma, benign pleural lesion and carcinoma metastasis. Evaluation of the application of morphometry combined with histochemistry and immunostaining.
</td>
<td style="text-align:left;">
Virchows Arch A Pathol Anat Histol
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma of the pleura with extensive cardiac invasion and tricuspid orifice occlusion.
</td>
<td style="text-align:left;">
Cancer
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Oncofetal antigens as tumor markers in the cytologic diagnosis of effusions.
</td>
<td style="text-align:left;">
Acta Cytol.
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma. Cytopathology of 75 cases seen in a New Jersey community hospital.
</td>
<td style="text-align:left;">
Acta Cytol.
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Typing of intermediate filaments in malignant fibrous pleural tumors.
</td>
<td style="text-align:left;">
J. Cancer Res. Clin. Oncol.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Thymostimulin in malignant pleural effusions.
</td>
<td style="text-align:left;">
Int J Tissue React
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Coexpression of simple epithelial keratins and vimentin by human mesothelium and mesothelioma in vivo and in culture.
</td>
<td style="text-align:left;">
Cancer Res.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma of the pleura: clinical aspects and symptomatic treatment.
</td>
<td style="text-align:left;">
Eur J Respir Dis
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Localized fibrous mesothelioma: an immunohistochemical and electron microscopic study.
</td>
<td style="text-align:left;">
Hum. Pathol.
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
The ultrastructural localization of keratin proteins and carcinoembryonic antigen in malignant mesotheliomas.
</td>
<td style="text-align:left;">
Am. J. Pathol.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Keratins in malignant mesotheliomas and pleural adenocarcinomas: comparative immunohistochemical analysis with polyclonal and monoclonal antibodies.
</td>
<td style="text-align:left;">
Pathol. Res. Pract.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleural granulocytes with cytoplasmic inclusions from patients with malignant lung tumours and mesothelioma.
</td>
<td style="text-align:left;">
Eur J Respir Dis
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Zeolite bodies in human lungs from Turkey.
</td>
<td style="text-align:left;">
Lab. Invest.
</td>
<td style="text-align:left;">
transmission | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Scanning electron microscopy of alcohol-fixed cytopathology specimens.
</td>
<td style="text-align:left;">
Acta Cytol.
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Fiber counting and analysis in the diagnosis of asbestos-related disease.
</td>
<td style="text-align:left;">
Hum. Pathol.
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Environmental fiber-induced pleuro-pulmonary diseases in an Anatolian village: an epidemiologic study.
</td>
<td style="text-align:left;">
Arch. Environ. Health
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma: ultrastructural distinction from adenocarcinoma.
</td>
<td style="text-align:left;">
Am. J. Surg. Pathol.
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Conventional treatment and its effect on survival of malignant pleural mesothelioma in Western Australia.
</td>
<td style="text-align:left;">
Aust N Z J Med
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Detection of tissue CEA-like substance as an aid in the differential diagnosis of malignant mesothelioma.
</td>
<td style="text-align:left;">
Pathology
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma in Turkish immigrants residing in Sweden.
</td>
<td style="text-align:left;">
Scand J Work Environ Health
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
[Pleural mesothelioma: 3 developmental forms].
</td>
<td style="text-align:left;">
Sem Hop
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Incidence of various types of thoracic malignancy induced in rats by intrapleural injection of 2 mg of various mineral dusts after inhalation of 222Ra.
</td>
<td style="text-align:left;">
Carcinogenesis
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Fibre type and concentration in the lungs of workers in an asbestos cement factory.
</td>
<td style="text-align:left;">
Br J Ind Med
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
First report of asbestos-related diseases in Hong Kong.
</td>
<td style="text-align:left;">
Trop Geogr Med
</td>
<td style="text-align:left;">
epidemiology
</td>
</tr>
<tr>
<td style="text-align:left;">
Mesothelioma following Wilms’ tumor in childhood.
</td>
<td style="text-align:left;">
Cancer
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Fiber size and number in amphibole asbestos-induced mesothelioma.
</td>
<td style="text-align:left;">
Am. J. Pathol.
</td>
<td style="text-align:left;">
epidemiology | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Epidemiology of malignant mesothelioma in Western Australia.
</td>
<td style="text-align:left;">
Med. J. Aust.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Non-asbestos-related malignant mesothelioma. A review.
</td>
<td style="text-align:left;">
Cancer
</td>
<td style="text-align:left;">
epidemiology | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Localized mesothelioma of the pleura: benign and malignant variants.
</td>
<td style="text-align:left;">
J. Thorac. Cardiovasc. Surg.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Pseudomesotheliomatous carcinoma of the lung with histochemical and immunohistochemical study.
</td>
<td style="text-align:left;">
Acta Pathol. Jpn.
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Carcinoembryonic antigen in pleural effusions. Diagnostic value in malignant mesothelioma.
</td>
<td style="text-align:left;">
Cancer
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Diagnosis of pleural malignant mesothelioma in life–a practical approach.
</td>
<td style="text-align:left;">
J. Pathol.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Thoracoscopic and computer tomographic findings in pleural mesotheliomas].
</td>
<td style="text-align:left;">
Rofo
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Fibronectin concentrations in pleural effusions of patients with malignant and non-malignant diseases.
</td>
<td style="text-align:left;">
Cancer Lett.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma of the pleura: a study of 52 treated and 64 untreated patients.
</td>
<td style="text-align:left;">
Thorax
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant pleural mesotheliomas. Comparison of roentgenologic and autopsy findings].
</td>
<td style="text-align:left;">
Rofo
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma of the pleura in Barrow-in-Furness.
</td>
<td style="text-align:left;">
Thorax
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Mesothelioma associated with the syndrome of inappropriate secretion of antidiuretic hormone.
</td>
<td style="text-align:left;">
Am. Rev. Respir. Dis.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Chemotherapy of diffuse malignant mesothelioma. Phase II trials of single-agent 5-fluorouracil and adriamycin.
</td>
<td style="text-align:left;">
Cancer
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Postoperative malignant seroma: CT demonstration of its formation mechanism.
</td>
<td style="text-align:left;">
J Comput Assist Tomogr
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Rarity of mineral fibre pleurisy among persons exposed to Finnish anthophyllite and with low risk of mesothelioma.
</td>
<td style="text-align:left;">
Thorax
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Benign mesothelial proliferation with effusion. Clinicopathologic entity that may mimic malignancy.
</td>
<td style="text-align:left;">
Am. J. Med.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Histological types of malignant mesothelioma and asbestos exposure.
</td>
<td style="text-align:left;">
Br J Ind Med
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Thoracoscopy with pleural brushing. A new diagnostic method for pleural diseases].
</td>
<td style="text-align:left;">
Rev Pneumol Clin
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Asbestos-related diseases of lung and pleura: clinical picture and illustrative cases.
</td>
<td style="text-align:left;">
Postgrad Med
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Analysis of number, size and distribution patterns of lipid vacuoles in benign and malignant mesothelial cells.
</td>
<td style="text-align:left;">
Anal Quant Cytol
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Radiologic diagnosis in malignant pleural mesothelioma].
</td>
<td style="text-align:left;">
Radiol Med
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
An unusual cytologic presentation of mesothelioma in serous effusions.
</td>
<td style="text-align:left;">
Acta Cytol.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Cytologic and tissue culture characteristics of asbestos-induced mesothelioma in rats.
</td>
<td style="text-align:left;">
Acta Cytol.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Diffuse malignant mesothelioma of pleura: diagnostic criteria based on an autopsy study.
</td>
<td style="text-align:left;">
Am. J. Clin. Pathol.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Qualitative distinctive differences between the vacuoles of mesothelioma cells and of cells from metastatic carcinoma exfoliated in pleural fluid.
</td>
<td style="text-align:left;">
Acta Cytol.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
CT of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
AJR Am J Roentgenol
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Brain metastases in malignant fibrous mesothelioma. Case report and review of the literature.
</td>
<td style="text-align:left;">
Acta Neuropathol.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
67Ga-transferrin and 67Ga-lactoferrin binding to tumor cells: specific versus nonspecific glycoprotein-cell interaction.
</td>
<td style="text-align:left;">
Eur J Nucl Med
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Asbestos exposure. An update on pleuropulmonary hazards.
</td>
<td style="text-align:left;">
Postgrad Med
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
A consideration on histopathologic variability of diffuse pleural mesothelioma based on DNA cytophotometry.
</td>
<td style="text-align:left;">
Acta Pathol. Jpn.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Mesothelioma in Connecticut, 1955-1977. Occupational and geographic associations.
</td>
<td style="text-align:left;">
J Occup Med
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma in urban dogs.
</td>
<td style="text-align:left;">
Vet. Pathol.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma at St Mary’s Hospital, Portsmouth–a review of 29 fatal cases.
</td>
<td style="text-align:left;">
Postgrad Med J
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Scope of scanning electron microscopy, transmission electron microscopy and freeze fracture technique in diagnostic cytology of effusions.
</td>
<td style="text-align:left;">
Scan Electron Microsc
</td>
<td style="text-align:left;">
diagnosis | transmission
</td>
</tr>
<tr>
<td style="text-align:left;">
Evidence for longer survival of patients with pleural mesothelioma without asbestos exposure.
</td>
<td style="text-align:left;">
Thorax
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Sarcomatous type of malignant mesothelioma.
</td>
<td style="text-align:left;">
Ultrastruct Pathol
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Propagation of a poorly differentiated human pulmonary adenocarcinoma in nude athymic rats.
</td>
<td style="text-align:left;">
Int. J. Cancer
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Calcification in a pleural mesothelioma.
</td>
<td style="text-align:left;">
J Can Assoc Radiol
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma following radiation exposure.
</td>
<td style="text-align:left;">
J. Clin. Oncol.
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Indications of an increase of occupational pleural mesothelioma in Japan.
</td>
<td style="text-align:left;">
J. UOEH
</td>
<td style="text-align:left;">
epidemiology
</td>
</tr>
<tr>
<td style="text-align:left;">
Treatment of six cases of mesothelioma with doxorubicin and cisplatin.
</td>
<td style="text-align:left;">
Cancer
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
A phase II study of m-AMSA in patients with malignant mesothelioma.
</td>
<td style="text-align:left;">
Cancer Chemother. Pharmacol.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma: incidence, asbestos exposure, and reclassification of histopathology.
</td>
<td style="text-align:left;">
Br J Ind Med
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma. The University of Minnesota experience.
</td>
<td style="text-align:left;">
Cancer
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma: the role of computed tomography.
</td>
<td style="text-align:left;">
J Comput Tomogr
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Mesothelioma as an index tumor of the occupational hazard of asbestos dust].
</td>
<td style="text-align:left;">
Dtsch. Med. Wochenschr.
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleurectomy and intraoperative brachytherapy and postoperative radiation in the treatment of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Int. J. Radiat. Oncol. Biol. Phys.
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma. A clinical review of 19 patients.
</td>
<td style="text-align:left;">
Scand J Thorac Cardiovasc Surg
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
The radiology of thoracic malignant mesothelioma.
</td>
<td style="text-align:left;">
Crit Rev Diagn Imaging
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Diagnosis and prognosis in malignant pleural mesothelioma: a prospective study.
</td>
<td style="text-align:left;">
Eur J Respir Dis
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma in two pairs of siblings: is there a hereditary predisposing factor?
</td>
<td style="text-align:left;">
Eur J Respir Dis
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Sarcomatous pleural mesothelioma and cerebral metastases: case report and a review of eight cases.
</td>
<td style="text-align:left;">
Eur J Respir Dis
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Lactic dehydrogenase isoenzyme electrophoretic patterns in the diagnosis of pleural effusion.
</td>
<td style="text-align:left;">
Cancer
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Interpretation of pleural biopsy specimens and aspirates with the immunoperoxidase technique.
</td>
<td style="text-align:left;">
Thorax
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Diffuse malignant mesothelioma: a review.
</td>
<td style="text-align:left;">
West. J. Med.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Glycosaminoglycans of pleural mesothelioma: a possible biochemical variant containing chondroitin sulfate.
</td>
<td style="text-align:left;">
Cancer
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
CT of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
AJR Am J Roentgenol
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma in children: report of seven cases and review of the literature.
</td>
<td style="text-align:left;">
Med. Pediatr. Oncol.
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant mesothelioma and asbestos].
</td>
<td style="text-align:left;">
Schweiz Med Wochenschr
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Intrapleural Corynebacterium parvum for malignant pleural effusions.
</td>
<td style="text-align:left;">
Thorax
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
DNA flow cytometry of pleural effusions. Comparison with pathology for the diagnosis of malignancy.
</td>
<td style="text-align:left;">
Anal Quant Cytol
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Diffuse epithelial pleural mesothelioma presenting as a solitary lung mass.
</td>
<td style="text-align:left;">
Chest
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Computed tomography of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J Comput Assist Tomogr
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Clinical aspects and course of 38 cases of malignant pleural mesothelioma observed in the Marseilles region].
</td>
<td style="text-align:left;">
Poumon Coeur
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Localized benign mesothelioma of the pleura associated with a hypoglycemic episode.
</td>
<td style="text-align:left;">
Arch. Intern. Med.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant thymoma with diffuse extensive growth on the pleura].
</td>
<td style="text-align:left;">
Gan No Rinsho
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Radiological study of pleural changes in relation to mesothelioma in Turkey.
</td>
<td style="text-align:left;">
Thorax
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Vindesine in the treatment of malignant mesothelioma: a phase II study.
</td>
<td style="text-align:left;">
Cancer Treat Rep
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Trephine drill biopsy in the diagnosis of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Eur J Respir Dis
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
[Pleural mesothelioma. Problems, therapy and results].
</td>
<td style="text-align:left;">
Fortschr. Med.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Ultrastructural diagnosis of pleural tumors.
</td>
<td style="text-align:left;">
Pathol. Res. Pract.
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Discrimination between primary pleural and primary peritoneal mesotheliomas by morphometry and analysis of the vacuolization pattern of the exfoliated mesothelial cells.
</td>
<td style="text-align:left;">
Acta Cytol.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Quantitative and qualitative differences between benign and malignant mesothelial cells in pleural fluid.
</td>
<td style="text-align:left;">
Acta Cytol.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma arising after direct application of asbestos and fiber glass to the pericardium.
</td>
<td style="text-align:left;">
Am. Rev. Respir. Dis.
</td>
<td style="text-align:left;">
epidemiology | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
High-dose methotrexate with citrovorum factor and vincristine in the treatment of malignant mesothelioma.
</td>
<td style="text-align:left;">
Cancer
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleural effusions.
</td>
<td style="text-align:left;">
Br J Hosp Med
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Mesothelioma in man and experimental animals.
</td>
<td style="text-align:left;">
Environ. Health Perspect.
</td>
<td style="text-align:left;">
diagnosis | epidemiology | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Use of antisera to epithelial membrane antigen for the cytodiagnosis of malignancy in serous effusions.
</td>
<td style="text-align:left;">
J. Clin. Pathol.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Chemotherapy for malignant mesothelioma; CAMEO.
</td>
<td style="text-align:left;">
Am. J. Clin. Oncol.
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Prevalence and incidence of benign asbestos pleural effusion in a working population.
</td>
<td style="text-align:left;">
JAMA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Immunotherapy with BCG vaccine in 30 cases of mesothelioma.
</td>
<td style="text-align:left;">
S. Afr. Med. J.
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Development of radiological and clinical evidence of parenchymal fibrosis in men with non-malignant asbestos-related pleural lesions.
</td>
<td style="text-align:left;">
Br J Ind Med
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Rib destruction: a neglected finding in malignant mesothelioma.
</td>
<td style="text-align:left;">
Clin Radiol
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Computed tomography in the assessment of malignant mesothelioma of the pleura.
</td>
<td style="text-align:left;">
Clin Radiol
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma of the pleura: review of 123 patients.
</td>
<td style="text-align:left;">
Cancer
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Computerized tomography of malignant pleural mesothelioma with spinal canal invasion.
</td>
<td style="text-align:left;">
Comput Radiol
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Lymphocytic infiltration of pleural mesothelioma and its significance for survival.
</td>
<td style="text-align:left;">
S. Afr. Med. J.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Diffuse malignant mesothelioma. Prospective evaluation of 69 patients.
</td>
<td style="text-align:left;">
Ann. Intern. Med.
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Clinical staging and the tendency of malignant pleural mesotheliomas to remain localized.
</td>
<td style="text-align:left;">
Ann. Thorac. Surg.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
The value of adriamycin in the treatment of diffuse malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Cancer
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Pulmonary asbestos and dust content in East Anglia.
</td>
<td style="text-align:left;">
Thorax
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
[On the aetiology of malignant pericardial mesothelioma (author’s transl)].
</td>
<td style="text-align:left;">
Dtsch. Med. Wochenschr.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Desmoplastic diffuse mesothelioma.
</td>
<td style="text-align:left;">
Am. J. Surg. Pathol.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Combined doxorubicin and radiation therapy in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Cancer Treat Rep
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant mesothelioma of the peritoneum].
</td>
<td style="text-align:left;">
Arkh. Patol.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Metastatic mesothelioma of the pericardium].
</td>
<td style="text-align:left;">
Z Kardiol
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pericardial mesotheliomas and asbestos exposure: a case report.
</td>
<td style="text-align:left;">
Am. J. Ind. Med.
</td>
<td style="text-align:left;">
epidemiology
</td>
</tr>
<tr>
<td style="text-align:left;">
Pulmonary asbestos body counts and electron probe analysis of asbestos body cores in patients with mesothelioma: a study of 25 cases.
</td>
<td style="text-align:left;">
Cancer
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Surgical treatment of pleural mesothelioma.
</td>
<td style="text-align:left;">
J. Thorac. Cardiovasc. Surg.
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma of the pleura: relation between histological type and clinical behaviour.
</td>
<td style="text-align:left;">
Thorax
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleural biopsy in the diagnosis of malignant mesothelioma.
</td>
<td style="text-align:left;">
Thorax
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Asbestos bodies in bronchoalveolar lavage.
</td>
<td style="text-align:left;">
Am. Rev. Respir. Dis.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Morphometric study on the nucleoli of mesothelial and tumour cells being in pleural cavity effusions.
</td>
<td style="text-align:left;">
Arch. Geschwulstforsch.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Human malignant diffuse mesothelioma: submicroscopic study on the epithelial component.
</td>
<td style="text-align:left;">
J. Submicrosc. Cytol.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
The outcome of patients with pleural effusion of indeterminate cause at thoracotomy.
</td>
<td style="text-align:left;">
Mayo Clin. Proc.
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
[Claude Bernard-Horner’s syndrome due to malignant pleural mesothelioma (author’s transl)].
</td>
<td style="text-align:left;">
Rev Fr Mal Respir
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant mesothelioma. Retrospective study of 16 cases].
</td>
<td style="text-align:left;">
Schweiz Med Wochenschr
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Monophasic mesenchymal synovial sarcoma: its identification by tissue culture.
</td>
<td style="text-align:left;">
Cancer
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
The production of malignant tumors of the lung and pleura in dogs from intratracheal asbestos instillation and cigarette smoking.
</td>
<td style="text-align:left;">
Cancer
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
A review of the treatment of diffuse malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
IARC Sci. Publ.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
The consequences of exposure to asbestos dust in a wartime gas-mask factory.
</td>
<td style="text-align:left;">
IARC Sci. Publ.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
The influence of occupational and environmental asbestos exposure on the incidence of malignant mesothelioma in Connecticut.
</td>
<td style="text-align:left;">
IARC Sci. Publ.
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma in Quebec.
</td>
<td style="text-align:left;">
IARC Sci. Publ.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
The clinical and radiological aspects of 185 cases of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
IARC Sci. Publ.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Papillary peritoneal tumors in women.
</td>
<td style="text-align:left;">
Am. J. Surg. Pathol.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Pretumorous lesions and lung and pleural tumours induced by asbestos in rats, Syrian golden hamsters and Macaca mulatta (rhesus) monkeys.
</td>
<td style="text-align:left;">
IARC Sci. Publ.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
The comparative effects of three chrysotiles by injection and inhalation in rats.
</td>
<td style="text-align:left;">
IARC Sci. Publ.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
The use of electron microscopy in the diagnosis of diffuse mesotheliomas using human pleural effusions.
</td>
<td style="text-align:left;">
IARC Sci. Publ.
</td>
<td style="text-align:left;">
diagnosis | transmission
</td>
</tr>
<tr>
<td style="text-align:left;">
Prevalence of asbestos related lung disease among employees in non-asbestos industries.
</td>
<td style="text-align:left;">
Med. J. Aust.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant mesothelioma of the pericardium].
</td>
<td style="text-align:left;">
Arkh. Patol.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Secreting peritoneal mesothelioma. Report of a case with cytological, ultrastructural, morphometric and histological studies.
</td>
<td style="text-align:left;">
Virchows Arch A Pathol Anat Histol
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Diagnostic value of total and differential leukocyte counts in pleural effusions.
</td>
<td style="text-align:left;">
Acta Med Scand
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Learning from quantitation.
</td>
<td style="text-align:left;">
Anal Quant Cytol
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Current indications for thoracoscopy].
</td>
<td style="text-align:left;">
Rev Fr Mal Respir
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Diffuse malignant pleural mesothelioma in Glasgow.
</td>
<td style="text-align:left;">
Br J Dis Chest
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleural mesothelioma presenting as apparent recurrent pulmonary embolism.
</td>
<td style="text-align:left;">
Br J Dis Chest
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Thoracoscopy in the diagnosis of malignant mesothelioma.
</td>
<td style="text-align:left;">
Poumon Coeur
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
[Intrapleural talc in malignant pleural effusions (author’s transl)].
</td>
<td style="text-align:left;">
Poumon Coeur
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Inorganic fibers in lung tissue from patients with pleural plaques or malignant mesothelioma.
</td>
<td style="text-align:left;">
Scand J Work Environ Health
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Diagnostic thoracoscopy.
</td>
<td style="text-align:left;">
Eur J Respir Dis
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Transplantation of human malignant mesothelioma into nude mice.
</td>
<td style="text-align:left;">
Cancer Res.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleural mesothelioma.
</td>
<td style="text-align:left;">
Scand J Thorac Cardiovasc Surg
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Clinical observations following asbestos exposure.
</td>
<td style="text-align:left;">
Environ. Health Perspect.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma: a metastasis to the face.
</td>
<td style="text-align:left;">
J Surg Oncol
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Demonstration of pleural mesothelioma by gallium scan.
</td>
<td style="text-align:left;">
Clin Nucl Med
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Mesothelioma with lung cancer complicating asbestosis.
</td>
<td style="text-align:left;">
Acta Pathol. Jpn.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesotheliomas and chemotherapy.
</td>
<td style="text-align:left;">
J Surg Oncol
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Diffuse, mixed malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Ann. Thorac. Surg.
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleural mesothelioma with calcified liver metastases.
</td>
<td style="text-align:left;">
Chest
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma: a review of 35 cases with diagnosis and prognosis.
</td>
<td style="text-align:left;">
Pathology
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Tumori
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
[A case of localized fibrous mesothelioma arising from visceral pleura of the right lower lobe].
</td>
<td style="text-align:left;">
Kyobu Geka
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Multiple skeletal muscle metastases from malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Pathol. Res. Pract.
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
High frequency of inactivating mutations in the neurofibromatosis type 2 gene (NF2) in primary malignant mesotheliomas.
</td>
<td style="text-align:left;">
Proc. Natl. Acad. Sci. U.S.A.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
[Epidemiology of malignant pleural mesothelioma in the Nantes-Saint Nazaire region. Course in 1956-1992].
</td>
<td style="text-align:left;">
Rev Mal Respir
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Regulation of fibrin deposition by malignant mesothelioma.
</td>
<td style="text-align:left;">
Am. J. Pathol.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Diagnostic video-assisted thoracoscopic procedures.
</td>
<td style="text-align:left;">
Ann. Surg.
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma of the pleura: interobserver variability.
</td>
<td style="text-align:left;">
J. Clin. Pathol.
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Immunohistochemical analysis of the p16INK4 cyclin-dependent kinase inhibitor in malignant mesothelioma.
</td>
<td style="text-align:left;">
J. Natl. Cancer Inst.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Pericardial malignant mesothelioma: case report and discussion of immunohistochemical and histochemical findings.
</td>
<td style="text-align:left;">
Pathol. Int.
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
The diagnostic value of thrombomodulin immunolocalization in serous effusions.
</td>
<td style="text-align:left;">
Arch. Pathol. Lab. Med.
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Localized malignant mesothelioma. A clinicopathologic and flow cytometric study.
</td>
<td style="text-align:left;">
Am. J. Surg. Pathol.
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Aggressive multimodality therapy for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Ann. Thorac. Surg.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Immunocytochemical typification of mesothelial cells in effusions: in vivo and in vitro models.
</td>
<td style="text-align:left;">
Diagn. Cytopathol.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Desmin and neural marker expression in mesothelial cells and mesotheliomas.
</td>
<td style="text-align:left;">
Hum. Pathol.
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Radiotherapy in the treatment of malignant mesothelioma of the pleura, with special reference to its use in palliation.
</td>
<td style="text-align:left;">
Australas Radiol
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[The clinical picture and therapy of malignant pleural mesothelioma].
</td>
<td style="text-align:left;">
Strahlenther Onkol
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Surgical management of malignant mesothelioma.
</td>
<td style="text-align:left;">
Ann. Thorac. Surg.
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Markers for metastatic adenocarcinoma in serous effusion specimens.
</td>
<td style="text-align:left;">
Diagn. Cytopathol.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Molecular cloning of a cell-surface glycoprotein that can potentially discriminate mesothelium from epithelium: its identification as vascular cell adhesion molecule 1.
</td>
<td style="text-align:left;">
Br. J. Cancer
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Immunocytochemical characterization of malignant mesothelioma and carcinoma metastatic to the pleura: IOB3–a new tumor marker.
</td>
<td style="text-align:left;">
Lung
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Production of granulocyte colony-stimulating factor by malignant mesothelioma.
</td>
<td style="text-align:left;">
Eur. Respir. J.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Clinical evaluation of seven tumour markers in lung cancer diagnosis: can any combination improve the results?
</td>
<td style="text-align:left;">
Br. J. Cancer
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant peritoneal mesothelioma after Thorotrast exposure.
</td>
<td style="text-align:left;">
Am. J. Clin. Oncol.
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Platelet-derived growth factor receptor immunoreactivity in mesothelioma and nonneoplastic mesothelial cells in serous effusions.
</td>
<td style="text-align:left;">
Acta Cytol.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Clinical features and current treatment of diffuse malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
A proposed new international TNM staging system for malignant pleural mesothelioma. From the International Mesothelioma Interest Group.
</td>
<td style="text-align:left;">
Chest
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Pseudomesotheliomatous carcinoma in HIV infection].
</td>
<td style="text-align:left;">
Dtsch. Med. Wochenschr.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Lack of apparent excess of malignant mesothelioma but increased overall malignancies of peritoneal cavity in Japanese autopsies with Thorotrast injection into blood vessels.
</td>
<td style="text-align:left;">
J. Cancer Res. Clin. Oncol.
</td>
<td style="text-align:left;">
epidemiology | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
OV 632 and MOC 31 in the diagnosis of mesothelioma and adenocarcinoma: an assessment of their use in formalin fixed and paraffin wax embedded material.
</td>
<td style="text-align:left;">
J. Clin. Pathol.
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Optimal management of malignant mesothelioma after subtotal pleurectomy: revisiting the role of intrapleural chemotherapy and postoperative radiation.
</td>
<td style="text-align:left;">
J Surg Oncol
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Use of photodynamic therapy for the management of pleural malignancies.
</td>
<td style="text-align:left;">
Semin Surg Oncol
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Intracavitary photodynamic therapy for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Semin Surg Oncol
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Novel fluorescence in situ hybridization approaches in solid tumors. Characterization of frozen specimens, touch preparations, and cytological preparations.
</td>
<td style="text-align:left;">
Am. J. Pathol.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Immunoreactivity for c-fos and c-myc protein with the monoclonal antibodies 14E10 and 6E10 in malignant mesothelioma and non-neoplastic mesothelium of the pleura.
</td>
<td style="text-align:left;">
Histol. Histopathol.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Epithelioid hemangioendothelioma of the lung: pleural effusion cytology, ultrastructure, and brief literature review.
</td>
<td style="text-align:left;">
Diagn. Cytopathol.
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Evaluation of the clinical TNM staging system for malignant pleural mesothelioma: an assessment in 88 patients.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Relationship between asbestos exposure and malignant pleural mesothelioma: occurrence near the old Japanese naval shipyard].
</td>
<td style="text-align:left;">
Nihon Kyobu Shikkan Gakkai Zasshi
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Comparison of silver-staining nucleolar organizer region (AgNOR) counts and proliferating cell nuclear antigen (PCNA) expression in reactive mesothelial hyperplasia and malignant mesothelioma.
</td>
<td style="text-align:left;">
Pathology
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
[A case of diffuse malignant mesothelioma diagnosed by thoracoscopic biopsy].
</td>
<td style="text-align:left;">
Nihon Kyobu Geka Gakkai Zasshi
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
[A case of localized fibrous tumor of the pleura with bloody pleural effusion].
</td>
<td style="text-align:left;">
Nihon Kyobu Geka Gakkai Zasshi
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Treatment of experimental human mesothelioma using adenovirus transfer of the herpes simplex thymidine kinase gene.
</td>
<td style="text-align:left;">
Ann. Surg.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleural malignant mesothelioma and non-occupational exposure to asbestos in Casale Monferrato, Italy.
</td>
<td style="text-align:left;">
Occup Environ Med
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Early experience with videothoracoscopic hydrodissection pleurectomy in the treatment of malignant pleural effusion.
</td>
<td style="text-align:left;">
J Surg Oncol
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Parathyroid hormone-related protein antigen localization distinguishes between mesothelioma and adenocarcinoma of the lung.
</td>
<td style="text-align:left;">
J. Pathol.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
A phase II trial investigating primary immunochemotherapy for malignant pleural mesothelioma and the feasibility of adjuvant immunochemotherapy after maximal cytoreduction.
</td>
<td style="text-align:left;">
Ann. Surg. Oncol.
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Prevention of malignant seeding after invasive diagnostic procedures in patients with pleural mesothelioma. A randomized trial of local radiotherapy.
</td>
<td style="text-align:left;">
Chest
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
[Imaging diagnosis of localized pleural mesothelioma].
</td>
<td style="text-align:left;">
Zhonghua Zhong Liu Za Zhi
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Glycosaminoglycans from two human malignant mesothelioma cell lines: determination, distribution, and effect of platelet-derived growth factor on their synthesis.
</td>
<td style="text-align:left;">
Biochem. Cell Biol.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Biological and immunological aspects of malignant mesothelioma.
</td>
<td style="text-align:left;">
Eur. Respir. J.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleural-based mesothelioma in immune competent rats: a model to study adenoviral gene transfer.
</td>
<td style="text-align:left;">
Ann. Thorac. Surg.
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Multiple-marker immunohistochemical phenotypes distinguishing malignant pleural mesothelioma from pulmonary adenocarcinoma.
</td>
<td style="text-align:left;">
Hum. Pathol.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Normal human mesothelial cells and mesothelioma cell lines express insulin-like growth factor I and associated molecules.
</td>
<td style="text-align:left;">
Cancer Res.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleural mesotheliomas–an analysis of 18 cases and review of the literature.
</td>
<td style="text-align:left;">
Medicine (Baltimore)
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Molecular deletion of 9p sequences in non-small cell lung cancer and malignant mesothelioma.
</td>
<td style="text-align:left;">
Genes Chromosomes Cancer
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Karyotypic changes in the preclinical and subsequent stages of malignant mesothelioma: a case report.
</td>
<td style="text-align:left;">
Cancer Genet. Cytogenet.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Characteristics of nine newly derived mesothelioma cell lines.
</td>
<td style="text-align:left;">
Ann. Thorac. Surg.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Intracavitary therapy of neoplastic effusions with cytokines: comparison among interferon alpha, beta and interleukin-2.
</td>
<td style="text-align:left;">
Support Care Cancer
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Diagnostic value of tissue polypeptide antigen in pleural effusions with malignant pleural mesothelioma].
</td>
<td style="text-align:left;">
Nihon Kyobu Shikkan Gakkai Zasshi
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Prognostic significance of DNA aneuploidy in diffuse malignant mesothelioma.
</td>
<td style="text-align:left;">
Cytometry
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Treatment of malignant pleural effusion by percutaneous catheter drainage and chemical pleurodesis].
</td>
<td style="text-align:left;">
Minerva Chir
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant tumors in an area with an asbestos processing plant.
</td>
<td style="text-align:left;">
Public Health Rev
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Fatal pleural mesothelioma diseases caused by familial household contacts with asbestos fiber dust].
</td>
<td style="text-align:left;">
Pneumologie
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Parietal pleurectomy for malignant pleural effusion.
</td>
<td style="text-align:left;">
Ann. Surg. Oncol.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Non-occupational exposure to asbestos and malignant mesothelioma in females.
</td>
<td style="text-align:left;">
Lancet
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Detection of numerical chromosomal aberrations in paraffin-embedded malignant pleural mesothelioma by non-isotopic in situ hybridization.
</td>
<td style="text-align:left;">
J. Pathol.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
The role of growth factors and cytokines in the tumorigenesis and immunobiology of malignant mesothelioma.
</td>
<td style="text-align:left;">
Am. J. Respir. Cell Mol. Biol.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
The value of immunohistochemistry of pleural biopsy specimens in the differential diagnosis between malignant mesothelioma and metastatic carcinoma.
</td>
<td style="text-align:left;">
Pathol. Res. Pract.
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
[High-resolution magnetic resonance tomography (HR-MRT) of the pleura and thoracic wall: normal findings and pathological changes].
</td>
<td style="text-align:left;">
Rofo
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Video-assisted thoracoscopic pleurectomy in the management of malignant pleural effusion.
</td>
<td style="text-align:left;">
Chest
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Video-assisted thoracic surgery: preliminary results of 25 cases].
</td>
<td style="text-align:left;">
Zhonghua Wai Ke Za Zhi
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Interferon (IFN)-alpha and IFN-gamma in combination with methotrexate: in vitro sensitivity studies in four human mesothelioma cell lines.
</td>
<td style="text-align:left;">
Anticancer Drugs
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Brain metastasis from malignant mesothelioma–case report.
</td>
<td style="text-align:left;">
Neurol. Med. Chir. (Tokyo)
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignancies in the lung and pleura mimicking benign processes.
</td>
<td style="text-align:left;">
Semin Diagn Pathol
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Cardiac tamponade disclosing neoplasm: apropos of 23 cases].
</td>
<td style="text-align:left;">
Arch Mal Coeur Vaiss
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Miliary mesothelioma.
</td>
<td style="text-align:left;">
Chest
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Current approach to malignant mesothelioma of the pleura.
</td>
<td style="text-align:left;">
Chest
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Mesothelioma and radical multimodality therapy: who benefits?
</td>
<td style="text-align:left;">
Chest
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Lung surfactant protein-A and carcinoembryonic antigen in pleural effusions due to lung adenocarcinoma and malignant mesothelioma.
</td>
<td style="text-align:left;">
Eur. Respir. J.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
CT-guided pleural needle biopsy in the diagnosis of malignant mesothelioma.
</td>
<td style="text-align:left;">
J Comput Assist Tomogr
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleural mesotheliomas are underreported as occupational cancer in Sweden.
</td>
<td style="text-align:left;">
Am. J. Ind. Med.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma and duration of asbestos exposure: correlation with tissue mineral fibre content.
</td>
<td style="text-align:left;">
Ann Occup Hyg
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant mesothelioma of the pericardium. An anatomo-clinical study of 10 cases].
</td>
<td style="text-align:left;">
Arch Mal Coeur Vaiss
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Fluoroscopically guided percutaneous fine-needle biopsy of the lung using the ROTEX needle: results in 890 patients with focal lung lesions].
</td>
<td style="text-align:left;">
Rofo
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Combination chemotherapy with cisplatin-vinblastine in malignant mesothelioma.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Mesotheliomas].
</td>
<td style="text-align:left;">
Rozhl Chir
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Chromosome analysis in pleural effusions. Efficiency of this method in the differential diagnosis of pleural effusions.
</td>
<td style="text-align:left;">
Respiration
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma presenting as achalasia.
</td>
<td style="text-align:left;">
Intern. Med.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Implantable access system for prolonged intrapleural immunotherapy.
</td>
<td style="text-align:left;">
Eur. Respir. J.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
An autopsy case of malignant mesothelioma associated with asbestosis.
</td>
<td style="text-align:left;">
Pathol. Int.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Diagnostic flexible fiberoptic pleuroscopy in suspected malignant pleural effusions.
</td>
<td style="text-align:left;">
Chest
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma: attributable risk of asbestos exposure.
</td>
<td style="text-align:left;">
Occup Environ Med
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Wilms’ tumor 1 susceptibility (WT1) gene products are selectively expressed in malignant mesothelioma.
</td>
<td style="text-align:left;">
Am. J. Pathol.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Diffuse pleural thickening: percutaneous CT-guided cutting needle biopsy.
</td>
<td style="text-align:left;">
Radiology
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Asbestos-related disease associated with exposure to asbestiform tremolite.
</td>
<td style="text-align:left;">
Am. J. Ind. Med.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant pleural mesothelioma in Norway 1960-1992].
</td>
<td style="text-align:left;">
Tidsskr. Nor. Laegeforen.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Doxorubicin retention and chemoresistance in human mesothelioma cell lines.
</td>
<td style="text-align:left;">
Int. J. Cancer
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Proliferation in malignant mesothelioma as determined by mitosis counts and immunoreactivity for proliferating cell nuclear antigen (PCNA).
</td>
<td style="text-align:left;">
J. Pathol.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Intrapleural treatment with recombinant gamma-interferon in early stage malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Cancer
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Prognostic factors and survival in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Eur. Respir. J.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant mesothelioma in families of asbestos workers].
</td>
<td style="text-align:left;">
Harefuah
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Mortality study of asbestos cement workers.
</td>
<td style="text-align:left;">
Int Arch Occup Environ Health
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma following radiation therapy.
</td>
<td style="text-align:left;">
Am. J. Med.
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Operation and intracavitary photodynamic therapy for malignant pleural mesothelioma: a phase II study.
</td>
<td style="text-align:left;">
Ann. Thorac. Surg.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Spectrum of peritoneal mesothelioma in childhood: clinical and histopathologic features, including DNA cytometry.
</td>
<td style="text-align:left;">
Pediatr Hematol Oncol
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
The pathology of benign and malignant pleural disease.
</td>
<td style="text-align:left;">
Chest Surg. Clin. N. Am.
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
CT and MR imaging in the evaluation of pleural masses.
</td>
<td style="text-align:left;">
Chest Surg. Clin. N. Am.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Thoracoscopy for the evaluation and treatment of pleural space disease.
</td>
<td style="text-align:left;">
Chest Surg. Clin. N. Am.
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Contemporary approaches in the investigation and treatment of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Chest Surg. Clin. N. Am.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleural and pericardial mesothelioma in a general teaching hospital during the last fourteen years.
</td>
<td style="text-align:left;">
Zhonghua Yi Xue Za Zhi (Taipei)
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Transforming growth factor-beta 1 (TGF-beta 1)- and beta 2-like activities in malignant pleural effusions caused by malignant mesothelioma or primary lung cancer.
</td>
<td style="text-align:left;">
Clin. Exp. Immunol.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Localized pleural mesothelioma. The clinical spectrum.
</td>
<td style="text-align:left;">
Chest
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Metastatic epithelioid hemangioendothelioma in a pleural effusion: diagnosis by cytology.
</td>
<td style="text-align:left;">
Diagn. Cytopathol.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[A case of the localized fibrous mesothelioma which size decreased temporarily].
</td>
<td style="text-align:left;">
Kyobu Geka
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Thoracic mesothelioma associated with abdominal mesenteric panniculitis.
</td>
<td style="text-align:left;">
Am. J. Gastroenterol.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Lung cancer mortality among asbestos textile workers: a review and update.
</td>
<td style="text-align:left;">
Ann Occup Hyg
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Other diseases in animals.
</td>
<td style="text-align:left;">
Ann Occup Hyg
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Diagnostic value of lactoferrin analysis in pleural effusions.
</td>
<td style="text-align:left;">
Eur J Clin Chem Clin Biochem
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Trials in malignant mesothelioma. LCSG 851 and 882.
</td>
<td style="text-align:left;">
Chest
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Intrapleural chemotherapy without pleurodesis for malignant pleural effusions. LCSG Trial 861.
</td>
<td style="text-align:left;">
Chest
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Localized benign pleural mesothelioma].
</td>
<td style="text-align:left;">
Langenbecks Arch Chir
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant mesothelioma of the pericardium].
</td>
<td style="text-align:left;">
Medicina (B Aires)
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
A phase II trial of dose-escalated doxorubicin and ifosfamide/mesna in patients with malignant mesothelioma.
</td>
<td style="text-align:left;">
Ann. Oncol.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Successful adenovirus-mediated gene transfer in an in vivo model of human malignant mesothelioma.
</td>
<td style="text-align:left;">
Ann. Thorac. Surg.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Immunohistochemical reactivity in mesothelioma and adenocarcinoma: a stepwise logistic regression analysis.
</td>
<td style="text-align:left;">
APMIS
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Neoplasms of the mediastinum, chest wall, and pleura.
</td>
<td style="text-align:left;">
Curr Opin Oncol
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Localized pleural mesothelioma].
</td>
<td style="text-align:left;">
Helv Chir Acta
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Computed tomography findings of malignant pleural mesothelioma].
</td>
<td style="text-align:left;">
Nihon Kyobu Shikkan Gakkai Zasshi
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Treatment of a patient with malignant mesothelioma with interferon-alpha 2 based on in vitro sensitivity tests.
</td>
<td style="text-align:left;">
Clin Investig
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Intrapleural production of interleukin 6 during mesothelioma and its modulation by gamma-interferon treatment.
</td>
<td style="text-align:left;">
Cancer Res.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Effect of fibrous glass on rat pleural mesothelium. Histopathologic observations.
</td>
<td style="text-align:left;">
Am. J. Respir. Crit. Care Med.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma. Extrapleural pneumonectomy and pleurectomy.
</td>
<td style="text-align:left;">
Chest Surg. Clin. N. Am.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Adjuvant therapy for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Chest Surg. Clin. N. Am.
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
The role of laparoscopy in the evaluation of ascites of unknown origin.
</td>
<td style="text-align:left;">
Gastrointest. Endosc.
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
The histopathological diagnosis of malignant mesothelioma v. pulmonary adenocarcinoma: reproducibility of the histopathological diagnosis.
</td>
<td style="text-align:left;">
Histopathology
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
[Pleural mesotheliomas in the Po River valley near Pavia; mortality, incidence and the correlations with an asbestos cement plant].
</td>
<td style="text-align:left;">
Med Lav
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Weekly high-dose cisplatin in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Ann. Oncol.
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Cytogenetic analysis of effusions from malignant mesothelioma. A diagnostic adjunct to cytology.
</td>
<td style="text-align:left;">
Acta Cytol.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
C-erbB-2 oncoprotein immunostaining in serous effusions.
</td>
<td style="text-align:left;">
Cytopathology
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural tumor in a child mimicking a mesothelioma.
</td>
<td style="text-align:left;">
Eur J Pediatr Surg
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
The sensitivity of hyaluronan analysis of pleural fluid from patients with malignant mesothelioma and a comparison of different methods.
</td>
<td style="text-align:left;">
Cancer
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Pleural mesothelioma: a clinicopathologic study of 42 cases].
</td>
<td style="text-align:left;">
Zhonghua Nei Ke Za Zhi
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Cerebral metastases in pleural mesothelioma: case report and review of the literature.
</td>
<td style="text-align:left;">
J. Neurooncol.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[The kinetics of IL-2 after pleural administration in the treatment of neoplastic pleurisy].
</td>
<td style="text-align:left;">
Rev Mal Respir
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
AIDS and malignant mesothelioma–is there a connection?
</td>
<td style="text-align:left;">
Chest
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[A case of acute subdural hematoma due to dural metastasis from malignant pleural mesothelioma].
</td>
<td style="text-align:left;">
No Shinkei Geka
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant mesothelioma: study of prognostic factors in a series of 188 cases].
</td>
<td style="text-align:left;">
Arch. Anat. Cytol. Pathol.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Immunohistochemistry of mesotheliomas. Technique and current diagnostic contribution of immunohistochemical markers. General review].
</td>
<td style="text-align:left;">
Arch. Anat. Cytol. Pathol.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Mesothelial cell. Cytology. Cytochemistry. Immunocytochemistry. Contribution of immunolabelling to the cytodiagnosis of serous effusions with cells of mesothelial aspect].
</td>
<td style="text-align:left;">
Arch. Anat. Cytol. Pathol.
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
[Flow cytometry and malignant pleural mesotheliomas. Value in the histologic and cytologic diagnosis].
</td>
<td style="text-align:left;">
Arch. Anat. Cytol. Pathol.
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Immunocytology of body cavity fluids. MOC-31, a monoclonal antibody discriminating between mesothelial and epithelial cells.
</td>
<td style="text-align:left;">
Arch. Pathol. Lab. Med.
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Asbestos and nonasbestos fiber content in lung tissue of Japanese patients with malignant mesothelioma.
</td>
<td style="text-align:left;">
Cancer
</td>
<td style="text-align:left;">
transmission | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Interferon alpha and doxorubicin in malignant mesothelioma: a phase II study.
</td>
<td style="text-align:left;">
Aust N Z J Med
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Cohort mortality study of rock salt workers in Italy.
</td>
<td style="text-align:left;">
Am. J. Ind. Med.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Pleural malignant mesothelioma complicated with disseminated intravascular coagulation].
</td>
<td style="text-align:left;">
Hua Xi Yi Ke Da Xue Xue Bao
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Diffuse pulmonary malignant mesothelioma: response to doxorubicin and 5-azacytidine.
</td>
<td style="text-align:left;">
Cancer
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Clinical utility of liquid-chromatographic analysis of effusions for hyaluronate content.
</td>
<td style="text-align:left;">
Clin. Chem.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Extended extrapleural pneumonectomy by median approach for advanced malignant mesothelioma with right supraclavicular lymph node metastasis–a case report].
</td>
<td style="text-align:left;">
Nihon Kyobu Geka Gakkai Zasshi
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Monoclonal antibody Ber-EP4: its use in the differential diagnosis of malignant mesothelioma and carcinoma in cell blocks of malignant effusions and FNA specimens.
</td>
<td style="text-align:left;">
Diagn. Cytopathol.
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleural mesothelioma presenting as an axillary lymph node metastasis with anemone cell appearance.
</td>
<td style="text-align:left;">
Ultrastruct Pathol
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleural changes in malignant pleural effusions: appearance on computed tomography.
</td>
<td style="text-align:left;">
Cleve Clin J Med
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleural mesothelioma and exposure to asbestos: evaluation from work histories and analysis of asbestos bodies in bronchoalveolar lavage fluid or lung tissue in 131 patients.
</td>
<td style="text-align:left;">
Occup Environ Med
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
A phase II trial of pleurectomy/decortication followed by intrapleural and systemic chemotherapy for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J. Clin. Oncol.
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Treatment of primary or metastatic pleural effusion with intracavitary cytosine arabinoside and cisplatin. A phase II study.
</td>
<td style="text-align:left;">
Acta Oncol
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Treatment of malignant pleural mesothelioma with cisplatin, mitomycin C and alpha interferon.
</td>
<td style="text-align:left;">
Oncology
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Asbestos-related mesothelioma in Monfalcone, Italy.
</td>
<td style="text-align:left;">
Am. J. Ind. Med.
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Effect of smoking on pleural thickening in asbestos workers.
</td>
<td style="text-align:left;">
Br J Ind Med
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Radiographic abnormalities and mortality in subjects with exposure to crocidolite.
</td>
<td style="text-align:left;">
Br J Ind Med
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Oral metastasis in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Br J Oral Maxillofac Surg
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant pleural mesothelioma. A diagnostic and therapeutic challenge].
</td>
<td style="text-align:left;">
An Med Interna
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Diagnostic and therapeutic thoracoscopy: techniques and indications in pulmonary medicine.
</td>
<td style="text-align:left;">
Tuber. Lung Dis.
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Survey for primary tumor site in patients with initial clinical presentation of bone metastasis].
</td>
<td style="text-align:left;">
Kaku Igaku
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Needle biopsy of the pleura].
</td>
<td style="text-align:left;">
Orv Hetil
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
[Pericardial mesothelioma. Evolution and update in the last decade].
</td>
<td style="text-align:left;">
Pathologica
</td>
<td style="text-align:left;">
diagnosis | epidemiology | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant mesothelioma of the pleura with an unusual course].
</td>
<td style="text-align:left;">
Ugeskr. Laeg.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Thoracoscopy in pleural mesothelioma].
</td>
<td style="text-align:left;">
Zhonghua Jie He He Hu Xi Za Zhi
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
[Pathologic observation of 298 rat mesotheliomas induced by asbestos].
</td>
<td style="text-align:left;">
Hua Xi Yi Ke Da Xue Xue Bao
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Pulmonary complications of asbestos exposure.
</td>
<td style="text-align:left;">
Am Fam Physician
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Differential expression of platelet derived growth factor-beta in malignant mesothelioma: a clue to future therapies?
</td>
<td style="text-align:left;">
Surg Oncol
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Localized pleural mesothelioma.
</td>
<td style="text-align:left;">
J Belge Radiol
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleural mesothelioma.
</td>
<td style="text-align:left;">
Cancer
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
High doses of intrapleural cisplatin in a case of malignant pleural mesothelioma. Clinical observations and pharmacokinetic analyses.
</td>
<td style="text-align:left;">
Cancer
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Metastatic mesothelioma of the oral cavity. Report of two cases.
</td>
<td style="text-align:left;">
Oral Surg. Oral Med. Oral Pathol.
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Pharmacokinetics of intrapleural recombinant interleukin-2 in immunotherapy for malignant pleural effusion.
</td>
<td style="text-align:left;">
Cancer
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Carcinoembryonic antigen-like reactivity in malignant mesothelioma. A comparison between different commercially available antibodies.
</td>
<td style="text-align:left;">
Cancer
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Recombinant interferon alpha-2b in the treatment of diffuse malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Am. J. Clin. Oncol.
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma induced in baboons by inhalation of amosite asbestos.
</td>
<td style="text-align:left;">
Am. J. Ind. Med.
</td>
<td style="text-align:left;">
epidemiology
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma. Multivariate analysis of prognostic factors on 113 patients.
</td>
<td style="text-align:left;">
Anticancer Res.
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Thoracoscopy in pleural malignant mesothelioma: a prospective study of 188 consecutive patients. Part 1: Diagnosis.
</td>
<td style="text-align:left;">
Cancer
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Thoracoscopy in pleural malignant mesothelioma: a prospective study of 188 consecutive patients. Part 2: Prognosis and staging.
</td>
<td style="text-align:left;">
Cancer
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Prognostic factors of malignant mesothelioma of the pleura.
</td>
<td style="text-align:left;">
Cancer
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
The positive peritoneal effusion. A retrospective study of cytopathologic diagnoses with autopsy confirmation.
</td>
<td style="text-align:left;">
Acta Cytol.
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Diffuse malignant mesothelioma of the pleura: a clinicopathological study of six patients with a prolonged symptom-free interval or extended survival after biopsy and a review of the literature of long-term survival.
</td>
<td style="text-align:left;">
Virchows Arch A Pathol Anat Histopathol
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Randomized phase II trial of cisplatin with mitomycin or doxorubicin for malignant mesothelioma by the Cancer and Leukemia Group B.
</td>
<td style="text-align:left;">
J. Clin. Oncol.
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Three unusual presentations of interscapular back pain.
</td>
<td style="text-align:left;">
Aust Fam Physician
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Male cancer mortality by occupation: 1973-86.
</td>
<td style="text-align:left;">
N. Z. Med. J.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant peritoneal mesothelioma].
</td>
<td style="text-align:left;">
Harefuah
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Could development of malignant mesothelioma be induced by Yersinia enterocolitica infection?
</td>
<td style="text-align:left;">
Med. Hypotheses
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Recurrent deletions of specific chromosomal sites in 1p, 3p, 6q, and 9p in human malignant mesothelioma.
</td>
<td style="text-align:left;">
Cancer Res.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Chemotaxis and haptotaxis of human malignant mesothelioma cells: effects of fibronectin, laminin, type IV collagen, and an autocrine motility factor-like substance.
</td>
<td style="text-align:left;">
Cancer Res.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Ultrastructure of diffuse malignant mesothelioma of the pleura. An analysis of ten cases.
</td>
<td style="text-align:left;">
Patol Pol
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
[Pleural mesothelioma. Review of 3 cases and role of thoracoscopy].
</td>
<td style="text-align:left;">
Rev Med Suisse Romande
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
In vitro effects of recombinant human interferon gamma on human mesothelioma cell lines.
</td>
<td style="text-align:left;">
Int. J. Cancer
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Nose and paranasal sinus malignancies with reference to occupational medicine aspects. A case study].
</td>
<td style="text-align:left;">
HNO
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma: a clinicopathological study.
</td>
<td style="text-align:left;">
J Surg Oncol
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
A new device for the treatment of pleural malignancies: intrapleural chemohyperthermia preliminary report.
</td>
<td style="text-align:left;">
Oncology
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma caused by environmental exposure to asbestos or erionite in rural Turkey: CT findings in 84 patients.
</td>
<td style="text-align:left;">
AJR Am J Roentgenol
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Gap junctional intercellular communication of primary and asbestos-associated malignant human mesothelial cells.
</td>
<td style="text-align:left;">
Carcinogenesis
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma in the Rotterdam area, 1987-1989.
</td>
<td style="text-align:left;">
Eur. J. Cancer
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Round atelectasis and Metsovo lung.
</td>
<td style="text-align:left;">
Chest
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Hypertrophic osteoarthropathy in childhood malignancy.
</td>
<td style="text-align:left;">
Med. Pediatr. Oncol.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Intrapleural recombinant IL-2 in passive immunotherapy for malignant pleural effusion.
</td>
<td style="text-align:left;">
Chest
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
The role of ultrasound assisted thoracoscopy in the diagnosis of pleural disease. Clinical experience in 687 cases.
</td>
<td style="text-align:left;">
Eur J Cardiothorac Surg
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Pleural mesothelioma and renal adenocarcinoma simultaneously discovered in a subject exposed to asbestos].
</td>
<td style="text-align:left;">
Rev Mal Respir
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Cytopathology of malignant mesothelioma: a study of its patterns and histological bases.
</td>
<td style="text-align:left;">
Diagn. Cytopathol.
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Clinical aspects of malignant mesothelioma in Australia.
</td>
<td style="text-align:left;">
Aust N Z J Med
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Natural history and epidemiology of malignant mesothelioma.
</td>
<td style="text-align:left;">
Chest
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Extrapleural pneumonectomy in the setting of a multimodality approach to malignant mesothelioma.
</td>
<td style="text-align:left;">
Chest
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleurectomy/decortication and adjuvant therapy for malignant mesothelioma.
</td>
<td style="text-align:left;">
Chest
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant mesothelioma located in the pleura: its radical surgical treatment].
</td>
<td style="text-align:left;">
G Chir
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
[Cardiac block caused by metastasis of lung adenocarcinoma to the bundle of His].
</td>
<td style="text-align:left;">
Minerva Med.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma in women.
</td>
<td style="text-align:left;">
Thorax
</td>
<td style="text-align:left;">
epidemiology | transmission
</td>
</tr>
<tr>
<td style="text-align:left;">
Node status has prognostic significance in the multimodality therapy of diffuse, malignant mesothelioma.
</td>
<td style="text-align:left;">
J. Clin. Oncol.
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Clinical and pathological features of thoracic neoplasia in the horse.
</td>
<td style="text-align:left;">
Equine Vet. J.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[A case of slowly-growing localized malignant mesothelioma].
</td>
<td style="text-align:left;">
Nihon Kyobu Shikkan Gakkai Zasshi
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant pleural mesothelioma: clinical characteristics, prognostic factors and treatment].
</td>
<td style="text-align:left;">
Arch. Bronconeumol.
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Thoracoscopic management of malignant pleural effusions.
</td>
<td style="text-align:left;">
Clin. Chest Med.
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Smooth muscle tumours presenting as pleural neoplasms.
</td>
<td style="text-align:left;">
Histopathology
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
The differential expression of N-cadherin and E-cadherin distinguishes pleural mesotheliomas from lung adenocarcinomas.
</td>
<td style="text-align:left;">
Hum. Pathol.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma: newer aspects of carcinogenesis, molecular genetics, and prospects for future therapies.
</td>
<td style="text-align:left;">
Surg Oncol
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Tumor-associated lymphocytes (TAL) are competent to produce higher levels of cytokines in neoplastic pleural and peritoneal effusions than those found in sera and are able to release into culture higher levels of IL-2 and IL-6 than those released by PBMC.
</td>
<td style="text-align:left;">
J. Mol. Med.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Multiparameter flow cytometric DNA analysis of effusions: a prospective study of 36 cases compared with routine cytology and immunohistochemistry.
</td>
<td style="text-align:left;">
Mod. Pathol.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
FISH in the evaluation of pleural and ascitic fluids.
</td>
<td style="text-align:left;">
Cancer Genet. Cytogenet.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Biphasic synovial sarcomas arising in the pleural cavity. A clinicopathologic study of five cases.
</td>
<td style="text-align:left;">
Am. J. Surg. Pathol.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Black spots concentrate oncogenic asbestos fibers in the parietal pleura. Thoracoscopic and mineralogic study.
</td>
<td style="text-align:left;">
Am. J. Respir. Crit. Care Med.
</td>
<td style="text-align:left;">
epidemiology | transmission
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma of 17 years’ duration with high pleural fluid concentration of hyaluronate.
</td>
<td style="text-align:left;">
Scand J Respir Dis
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Intrapleural chemotherapy for patients with incompletely resected malignant mesothelioma: the UCLA experience.
</td>
<td style="text-align:left;">
J Surg Oncol
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
The proposed new international TNM staging system for malignant pleural mesothelioma: application to imaging.
</td>
<td style="text-align:left;">
AJR Am J Roentgenol
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Calcification as a sign of sarcomatous degeneration of malignant pleural mesotheliomas: a new CT finding.
</td>
<td style="text-align:left;">
J Comput Assist Tomogr
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
[A case of desmoplastic malignant mesothelioma].
</td>
<td style="text-align:left;">
Nihon Kyobu Shikkan Gakkai Zasshi
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Parental cancer and genetic predisposition in malignant pleural mesothelioma: a case-control study.
</td>
<td style="text-align:left;">
Cancer Lett.
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Post-irradiation malignant mesothelioma.
</td>
<td style="text-align:left;">
Cancer
</td>
<td style="text-align:left;">
diagnosis | treatment | epidemiology
</td>
</tr>
<tr>
<td style="text-align:left;">
Cancer in electrical workers: an analysis of cancer registrations in England, 1981-87.
</td>
<td style="text-align:left;">
Br. J. Cancer
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
The importance of surgical staging in the treatment of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J. Thorac. Cardiovasc. Surg.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Prospective analysis of pneumonectomy: risk factors for major morbidity and cardiac dysrhythmias.
</td>
<td style="text-align:left;">
Ann. Thorac. Surg.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Chemotherapy in malignant pleural mesothelioma. A review.
</td>
<td style="text-align:left;">
J. Clin. Oncol.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Combined systemic chemoimmunotherapy in advanced diffuse malignant mesothelioma. Report of a phase I-II study of weekly cisplatin/interferon alfa-2a.
</td>
<td style="text-align:left;">
J. Clin. Oncol.
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant peritoneal mesothelioma: its relation to asbestos].
</td>
<td style="text-align:left;">
Minerva Med.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Surgery followed by intracavitary plus systemic chemotherapy in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Tumori
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma after radiation therapy for breast cancer. A report of two additional patients.
</td>
<td style="text-align:left;">
Cancer
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Treatment of malignant mesothelioma with methotrexate and vinblastine, with or without platinum chemotherapy.
</td>
<td style="text-align:left;">
Chest
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Mesothelioma, asbestos, and reported history of cancer in first-degree relatives.
</td>
<td style="text-align:left;">
Cancer
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Prospective study of combination chemotherapy with cyclophosphamide, doxorubicin, and cisplatin for unresectable or metastatic malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Cancer
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Intracranial metastases from malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Scand J Thorac Cardiovasc Surg
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
[Dysphagia as an unusual form of presentation of malignant pleural mesothelioma].
</td>
<td style="text-align:left;">
Rev Esp Enferm Dig
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Transsternal transpericardial operations in the treatment of bronchopleural fistulas after pneumonectomy.
</td>
<td style="text-align:left;">
Eur J Cardiothorac Surg
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Bronchoesophagopleural fistula after photodynamic therapy for malignant mesothelioma.
</td>
<td style="text-align:left;">
Ann. Thorac. Surg.
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Imaging of pleural diseases.
</td>
<td style="text-align:left;">
Monaldi Arch Chest Dis
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Extensive pulmonary metastases in malignant pleural mesothelioma. A rare clinical and radiographic presentation.
</td>
<td style="text-align:left;">
Chest
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma following treatment for Hodgkin’s disease.
</td>
<td style="text-align:left;">
J. Clin. Oncol.
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Expression of platelet-derived growth factor (PDGF) and PDGF receptors in human malignant mesothelioma in vitro and in vivo.
</td>
<td style="text-align:left;">
J. Pathol.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Mesothelioma as a risk indicator of asbestos exposure: the role of the pathologist.
</td>
<td style="text-align:left;">
Med Lav
</td>
<td style="text-align:left;">
diagnosis | epidemiology
</td>
</tr>
<tr>
<td style="text-align:left;">
European multicentric case control study on risk for mesothelioma after non-occupational (domestic and environmental) exposure to asbestos.
</td>
<td style="text-align:left;">
Med Lav
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Stereological evaluation of malignant mesothelioma versus benign pleural hyperplasia.
</td>
<td style="text-align:left;">
Pathol. Res. Pract.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Clinical course of human epithelial-type malignant pleural mesothelioma replicated in an orthotopic-transplant nude mouse model.
</td>
<td style="text-align:left;">
Anticancer Res.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Epidemiologic survey of pleural plaques among inhabitants of Matsubase exposed to asbestos].
</td>
<td style="text-align:left;">
Nihon Kyobu Shikkan Gakkai Zasshi
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
The calcium binding protein calretinin is a selective marker for malignant pleural mesotheliomas of the epithelial type.
</td>
<td style="text-align:left;">
Pathol. Res. Pract.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Radiosensitivity of mesothelioma cell lines.
</td>
<td style="text-align:left;">
Acta Oncol
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
A proposed new international TNM staging system for malignant pleural mesothelioma from the International Mesothelioma Interest Group.
</td>
<td style="text-align:left;">
Lung Cancer
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant fibrous mesothelioma of the tunica vaginalis: a histologic and ultrastructural study.
</td>
<td style="text-align:left;">
Cancer
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Treatment and survival in diffuse malignant pleural mesothelioma; a study of 83 cases from the Massachusetts General Hospital.
</td>
<td style="text-align:left;">
Anticancer Res.
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Acid glycosaminoglycans (mucopolysaccharides) in the differential diagnosis of pleural effusion.
</td>
<td style="text-align:left;">
Clin. Chim. Acta
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Stimulatory effects of pleural fluids from mesothelioma patients on CD44 expression, hyaluronan production and cell proliferation in primary cultures of normal mesothelial and transformed cells.
</td>
<td style="text-align:left;">
Int. J. Cancer
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Combined chemotherapy in pleurectomized malignant pleural mesothelioma patients.
</td>
<td style="text-align:left;">
J Chemother
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Cytologic effects of photodynamic therapy in body fluids.
</td>
<td style="text-align:left;">
Diagn. Cytopathol.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Fibrinogen promotes adhesion of monocytic to human mesothelioma cells.
</td>
<td style="text-align:left;">
Thromb. Haemost.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
[Spontaneous hydro-pneumothorax disclosing malignant mesothelioma. Apropos of 2 cases].
</td>
<td style="text-align:left;">
Rev Pneumol Clin
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
[Diagnosis and treatment of pleural mesothelioma: a report of 40 cases].
</td>
<td style="text-align:left;">
Zhonghua Zhong Liu Za Zhi
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Concomitant malignant mesothelioma of the pleura, peritoneum, and tunica vaginalis testis.
</td>
<td style="text-align:left;">
Diagn. Cytopathol.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Diagnostic value of CA 72-4, carcinoembryonic antigen, CA 15-3, and CA 19-9 assay in pleural fluid. A study of 207 patients.
</td>
<td style="text-align:left;">
Cancer
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Peritoneal mesothelioma. Contribution of MRI. Apropos of a case].
</td>
<td style="text-align:left;">
J Radiol
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
[Sarcomatous malignant mesothelioma diagnosed after death].
</td>
<td style="text-align:left;">
Nihon Kyobu Shikkan Gakkai Zasshi
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Treatment of pleural mesothelioma in an immunocompetent rat model utilizing adenoviral transfer of the herpes simplex virus thymidine kinase gene.
</td>
<td style="text-align:left;">
Hum. Gene Ther.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma from nonoccupational asbestos exposure in Metsovo (north-west Greece): slow end of an epidemic?
</td>
<td style="text-align:left;">
Eur. Respir. J.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Extrapleural pneumonectomy in the multimodality therapy of malignant pleural mesothelioma. Results in 120 consecutive patients.
</td>
<td style="text-align:left;">
Ann. Surg.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Lepidic intrapulmonary growth of malignant mesothelioma presenting as recurrent hydropneumothorax.
</td>
<td style="text-align:left;">
Hum. Pathol.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Health effects of working in pulp and paper mills: malignant diseases.
</td>
<td style="text-align:left;">
Am. J. Ind. Med.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Small cell carcinoma of lung simulating pleural mesothelioma. Report of 4 cases with autopsy confirmation.
</td>
<td style="text-align:left;">
Pathol. Res. Pract.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Asbestosic pleural calcifications and the associated pathology (study of 32 cases)].
</td>
<td style="text-align:left;">
Poumon Coeur
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Paclitaxel for malignant pleural mesothelioma: a phase II study of the EORTC Lung Cancer Cooperative Group.
</td>
<td style="text-align:left;">
Br. J. Cancer
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Adenomatoid tumors of the pleura.
</td>
<td style="text-align:left;">
Am. J. Surg. Pathol.
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Analysis of pleural effusions using flow cytometry.
</td>
<td style="text-align:left;">
Respiration
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Occupational and geographical factors in the epidemiology of malignant mesothelioma.
</td>
<td style="text-align:left;">
Monaldi Arch Chest Dis
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Adenocarcinoma simulating mesothelioma.
</td>
<td style="text-align:left;">
Ultrastruct Pathol
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
p53 gene product in pleural effusions. Practical use in distinguishing benign from malignant cells.
</td>
<td style="text-align:left;">
Acta Cytol.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
A comparative immunohistochemical study of malignant mesothelioma and renal cell carcinoma: the diagnostic utility of Leu-M1, Ber EP4, Tamm-Horsfall protein and thrombomodulin.
</td>
<td style="text-align:left;">
Histopathology
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Endobronchial inflammatory pseudotumour in a patient with B-cell chronic lymphocytic leukemia and malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Acta Clin Belg
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleural mesothelioma and household asbestos exposure.
</td>
<td style="text-align:left;">
Rev Environ Health
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Chrysotile asbestos is the main cause of pleural mesothelioma.
</td>
<td style="text-align:left;">
Am. J. Ind. Med.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Laparoscopy: an important tool in the staging of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Ann. Surg. Oncol.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant mesothelioma of the pleura].
</td>
<td style="text-align:left;">
Orv Hetil
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Mesothelioma-binding antibodies: thrombomodulin, OV 632 and HBME-1 and their use in the diagnosis of malignant mesothelioma.
</td>
<td style="text-align:left;">
Histopathology
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Manganese superoxide dismutase in human pleural mesothelioma cell lines.
</td>
<td style="text-align:left;">
Free Radic. Biol. Med.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Accuracy of death certification of pleural mesothelioma in Italy.
</td>
<td style="text-align:left;">
Eur. J. Epidemiol.
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
From the archives of the AFIP. Malignant pleural mesothelioma: radiologic-pathologic correlation.
</td>
<td style="text-align:left;">
Radiographics
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Fibrinolytic system in plasma and pleural fluid in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Thromb. Res.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Inorganic particles in the lungs of five aluminum smelter workers with pleuro-pulmonary cancer.
</td>
<td style="text-align:left;">
Am Ind Hyg Assoc J
</td>
<td style="text-align:left;">
transmission
</td>
</tr>
<tr>
<td style="text-align:left;">
[A case report of surgical resection of renal cell carcinoma with intrathoracic metastasis].
</td>
<td style="text-align:left;">
Nihon Kyobu Geka Gakkai Zasshi
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
[Two cases of recurrent hydropneumothorax caused by malignant pleural mesothelioma].
</td>
<td style="text-align:left;">
Nihon Kyobu Geka Gakkai Zasshi
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant vascular tumors of the serous membranes mimicking mesothelioma. A report of 14 cases.
</td>
<td style="text-align:left;">
Am. J. Surg. Pathol.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Imaging of peritoneal mesotheliomas].
</td>
<td style="text-align:left;">
J Radiol
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Fibronectin expression and organization in mesothelial and mesothelioma cells.
</td>
<td style="text-align:left;">
Am. J. Physiol.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Safety of intrapleurally administered recombinant adenovirus carrying herpes simplex thymidine kinase DNA followed by ganciclovir therapy in nonhuman primates.
</td>
<td style="text-align:left;">
Hum. Gene Ther.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Immunopathology of malignant mesothelioma.
</td>
<td style="text-align:left;">
Pathology (Phila)
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Ber-EP4 for differentiating adenocarcinoma from reactive and neoplastic mesothelial cells in serous effusions. Comparison with carcinoembryonic antigen, B72.3 and Leu-M1.
</td>
<td style="text-align:left;">
Acta Cytol.
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Glutathione S-transferase and N-acetyltransferase genotypes and asbestos-associated pulmonary disorders.
</td>
<td style="text-align:left;">
J. Natl. Cancer Inst.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant mesothelioma of the pleura: correlations between thoracoscopy and radiology].
</td>
<td style="text-align:left;">
Radiol Med
</td>
<td style="text-align:left;">
diagnosis | treatment | epidemiology | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Retroperitoneal malignant mesothelioma. A case report].
</td>
<td style="text-align:left;">
Nippon Hinyokika Gakkai Zasshi
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
[Pulmonary embolism in malignancy of the lung: a retrospective clinical evaluation and pathomorphologic personal material].
</td>
<td style="text-align:left;">
Pneumonol Alergol Pol
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Evaluation of the usefulness of palpation and Daniel’s biopsy for detection of metastasis to supraclavicular and scalene lymph nodes in patients with lung neoplasms].
</td>
<td style="text-align:left;">
Pneumonol Alergol Pol
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Differential diagnosis of malignant and reactive cells from serous effusions: image and texture analysis study.
</td>
<td style="text-align:left;">
Anal Cell Pathol
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Thoracoscopic talc poudrage pleurodesis for malignant effusions. A review of 360 cases.
</td>
<td style="text-align:left;">
Chest
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
[Solitary fibrous tumor of the pleura. Clinical case].
</td>
<td style="text-align:left;">
Minerva Chir
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
The role of cytologic evaluation of pleural fluid in the diagnosis of malignant mesothelioma.
</td>
<td style="text-align:left;">
Chest
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
A case of malignant pleural mesothelioma with metastasis to the orbit.
</td>
<td style="text-align:left;">
Jpn. J. Clin. Oncol.
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Fibrous tumors localized in the pleura].
</td>
<td style="text-align:left;">
G Chir
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleural mesotheliomas have an integrin profile distinct from visceral carcinomas.
</td>
<td style="text-align:left;">
Hum. Pathol.
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Immunoreactivity for hepatocyte growth factor/scatter factor and its receptor, met, in human lung carcinomas and malignant mesotheliomas.
</td>
<td style="text-align:left;">
J. Pathol.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
[Diffuse malignant mesothelioma associated with asbestos pleurisy].
</td>
<td style="text-align:left;">
Nihon Kyobu Shikkan Gakkai Zasshi
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Immunohistochemical phenotype of malignant mesothelioma: predictive value of CA125 and HBME-1 expression.
</td>
<td style="text-align:left;">
Histopathology
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Effusion cytology after extrapleural pneumonectomy for treatment of malignant mesothelioma.
</td>
<td style="text-align:left;">
Am. J. Clin. Pathol.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[A case of localized pleural mesothelioma].
</td>
<td style="text-align:left;">
Kyobu Geka
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Proportionate mortality among unionized construction ironworkers.
</td>
<td style="text-align:left;">
Am. J. Ind. Med.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Patterns of failure after trimodality therapy for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Ann. Thorac. Surg.
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant mesothelioma of the pleura following radiotherapy of Hodgkin disease].
</td>
<td style="text-align:left;">
Bull Cancer
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Immunohistochemical differences between hyaluronan- and non-hyaluronan-producing malignant mesothelioma.
</td>
<td style="text-align:left;">
Eur. Respir. J.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Recurrent DNA copy number changes in 1q, 4q, 6q, 9p, 13q, 14q and 22q detected by comparative genomic hybridization in malignant mesothelioma.
</td>
<td style="text-align:left;">
Br. J. Cancer
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma in Rome, Italy 1980-1995. A retrospective study of 79 patients.
</td>
<td style="text-align:left;">
Tumori
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Response to chemotherapy of brain metastases from malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Tumori
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
p53 immunostaining in differential diagnosis of pleural mesothelial proliferations.
</td>
<td style="text-align:left;">
Anticancer Res.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
p53 immunostaining is a highly specific and moderately sensitive marker of malignancy in serous fluid cytology.
</td>
<td style="text-align:left;">
Cytopathology
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
WT1 mutation in malignant mesothelioma and WT1 immunoreactivity in relation to p53 and growth factor receptor expression, cell-type transition, and prognosis.
</td>
<td style="text-align:left;">
J. Pathol.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleurectomy/decortication for palliation in malignant pleural mesothelioma: results of surgery.
</td>
<td style="text-align:left;">
Eur J Cardiothorac Surg
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
CD44H expression in reactive mesothelium, pleural mesothelioma and pulmonary adenocarcinoma.
</td>
<td style="text-align:left;">
Histopathology
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Videothoracoscopy in the diagnosis and treatment of malignant pleural mesothelioma with associated pleural effusions.
</td>
<td style="text-align:left;">
Thorac Cardiovasc Surg
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Distinction between pleural mesothelioma and pulmonary adenocarcinoma using MOC31 in an asbestos sprayer.
</td>
<td style="text-align:left;">
Respir Med
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleural effusion cytology of embryonal rhabdomyosarcoma.
</td>
<td style="text-align:left;">
Diagn. Cytopathol.
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
[Venous endoprosthesis. Palliative treatment of superior caval syndrome of neoplastic origin].
</td>
<td style="text-align:left;">
J Radiol
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Retroviral gene transfer is inhibited by chondroitin sulfate proteoglycans/glycosaminoglycans in malignant pleural effusions.
</td>
<td style="text-align:left;">
J. Biol. Chem.
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
A mortality study among workers in an English asbestos factory.
</td>
<td style="text-align:left;">
Br J Ind Med
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
[Prevalence of pleural malignant mesothelioma in Poland in 1980-1993].
</td>
<td style="text-align:left;">
Przegl Epidemiol
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
[Problems in diagnosis and therapy of malignant pleural mesothelioma].
</td>
<td style="text-align:left;">
Med. Klin. (Munich)
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Surgically debulked malignant pleural mesothelioma: results and prognostic factors.
</td>
<td style="text-align:left;">
Ann. Surg. Oncol.
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Combined cisplatin, doxorubicin, and mitomycin for the treatment of advanced pleural mesothelioma: a phase II FONICAP trial. Italian Lung Cancer Task Force.
</td>
<td style="text-align:left;">
Cancer
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Localized benign pleural mesothelioma arising in a radiation field.
</td>
<td style="text-align:left;">
Clin Imaging
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
High CD44 expression on human mesotheliomas mediates association with hyaluronan.
</td>
<td style="text-align:left;">
Cancer J Sci Am
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
[A mesenchymal malignant mesothelioma that changed from mixed type to purely sarcomatous type].
</td>
<td style="text-align:left;">
Nihon Kyobu Shikkan Gakkai Zasshi
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Gene therapy of experimental malignant mesothelioma using adenovirus vectors encoding the HSVtk gene.
</td>
<td style="text-align:left;">
Gene Ther.
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Dihydro-5-azacytidine in malignant mesothelioma. A phase II trial demonstrating activity accompanied by cardiac toxicity. Cancer and Leukemia Group B.
</td>
<td style="text-align:left;">
Cancer
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Pathology of malignant mesothelioma.
</td>
<td style="text-align:left;">
Histopathology
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Pseudomesotheliomatous angiosarcoma: a pleuropulmonary lesion simulating malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Histopathology
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma metastatic to the skin, presenting as inflammatory carcinoma.
</td>
<td style="text-align:left;">
Am J Dermatopathol
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
bcl-2 expression in pleural and extrapleural solitary fibrous tumours.
</td>
<td style="text-align:left;">
J. Pathol.
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Diffuse malignant pleural mesotheslioma at CAMC: a retrospective study of 50 patients.
</td>
<td style="text-align:left;">
W V Med J
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Occupational neoplasms in Poland in the years 1971-1994].
</td>
<td style="text-align:left;">
Med Pr
</td>
<td style="text-align:left;">
diagnosis | epidemiology | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Thoracoscopy in malignant pleural effusions].
</td>
<td style="text-align:left;">
Zhonghua Zhong Liu Za Zhi
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleural mesothelioma mimics the integrin profile of activated, sessile rather than detached mesothelial cells.
</td>
<td style="text-align:left;">
Int. J. Cancer
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
[Large-cell carcinoma presenting as diffuse thickening of the pleura and resembling malignant mesothelioma].
</td>
<td style="text-align:left;">
Nihon Kyobu Shikkan Gakkai Zasshi
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
[Use of a bronchoscope for thoracoscopic observation and diagnosis of pleural plaques].
</td>
<td style="text-align:left;">
Nihon Kyobu Shikkan Gakkai Zasshi
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant epithelial neoplasm consistent with primitive cystic hepatic neoplasm with mesothelial differentiation: a case report.
</td>
<td style="text-align:left;">
Zhonghua Yi Xue Za Zhi (Taipei)
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Thoracoscopic surgery for diagnosis and treatment of pleural and mediastinal disease].
</td>
<td style="text-align:left;">
Nihon Kyobu Shikkan Gakkai Zasshi
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
[Utility of thoracoscopy for diagnosis of pulmonary diseases in clinical pulmonary medicine].
</td>
<td style="text-align:left;">
Nihon Kyobu Shikkan Gakkai Zasshi
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
An epidemiological study in an Anatolian village in Turkey environmentally exposed to tremolite asbestos.
</td>
<td style="text-align:left;">
J. Environ. Pathol. Toxicol. Oncol.
</td>
<td style="text-align:left;">
epidemiology
</td>
</tr>
<tr>
<td style="text-align:left;">
Environmental fibrous zeolite (erionite) exposure and malignant tumors other than mesothelioma.
</td>
<td style="text-align:left;">
J. Environ. Pathol. Toxicol. Oncol.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma in south east England: clinicopathological experience of 272 cases.
</td>
<td style="text-align:left;">
Thorax
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Latency periods in asbestos-related mesothelioma of the pleura.
</td>
<td style="text-align:left;">
Eur. J. Cancer Prev.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Altered fractionation of hemithorax irradiation for pleural mesothelioma and failure patterns after treatment.
</td>
<td style="text-align:left;">
Acta Oncol
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
[Imaging of the pleura].
</td>
<td style="text-align:left;">
Rev Prat
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant mesothelioma. Diagnosis and treatment].
</td>
<td style="text-align:left;">
Rev Prat
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Complementary value of five carcinoma markers for the diagnosis of malignant mesothelioma, adenocarcinoma metastasis, and reactive mesothelium in serous effusions.
</td>
<td style="text-align:left;">
Diagn. Cytopathol.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Brain metastasis in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Intern. Med.
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant mesothelioma: incidence, survival and relative risks in selected municipalities 1943-1992].
</td>
<td style="text-align:left;">
Ugeskr. Laeg.
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Newly marketed tissue markers for malignant mesothelioma: immunoreactivity of rabbit AMAD-2 antiserum compared with monoclonal antibody HBME-1 and a review of the literature on so-called antimesothelioma antibodies.
</td>
<td style="text-align:left;">
Hum. Pathol.
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Metastatic malignant mesothelioma presenting as colonic polyps.
</td>
<td style="text-align:left;">
Hum. Pathol.
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Evaluation of tumour angiogenesis as a prognostic marker in malignant mesothelioma.
</td>
<td style="text-align:left;">
J. Pathol.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Clear cell tumors of unknown nature and origin: a systematic approach to diagnosis.
</td>
<td style="text-align:left;">
Semin Diagn Pathol
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Thoracic complications in patients undergoing intraperitoneal heated chemotherapy with mitomycin following cytoreductive surgery.
</td>
<td style="text-align:left;">
J Surg Oncol
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Identification of human complement factor H as a chemotactic protein for monocytes.
</td>
<td style="text-align:left;">
Biochem. J.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Long survival after extrapleural pneumonectomy for pleural malignant mesothelioma with metastasis to infradiaphragmatic lymph node.
</td>
<td style="text-align:left;">
Scand. Cardiovasc. J.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
[Tissue polypeptide antigen as a biological marker of malignant pleural mesothelioma].
</td>
<td style="text-align:left;">
Nihon Kyobu Shikkan Gakkai Zasshi
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
[Photomicrographs of a pleural biopsy specimen, showing malignant mesothelioma and necrosis–malignant pleural mesothelioma in a patient with sarcoidosis].
</td>
<td style="text-align:left;">
Nihon Kyobu Shikkan Gakkai Zasshi
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Squamous-cell carcinoma of the pleura.
</td>
<td style="text-align:left;">
Thorax
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Pericardiectomy in dogs: 22 cases (1978-1994).
</td>
<td style="text-align:left;">
J. Am. Vet. Med. Assoc.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Incidence of malignant pleural mesothelioma after thoracic radiotherapy.
</td>
<td style="text-align:left;">
Cancer
</td>
<td style="text-align:left;">
treatment | epidemiology
</td>
</tr>
<tr>
<td style="text-align:left;">
Proteoglycan synthesis induced by transforming and basic fibroblast growth factors in human malignant mesothelioma is mediated through specific receptors and the tyrosine kinase intracellular pathway.
</td>
<td style="text-align:left;">
Biochimie
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Photodynamic therapy as adjuvant therapy in surgically treated pleural malignancies.
</td>
<td style="text-align:left;">
Br. J. Cancer
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleural plaques as risk indicators for malignant pleural mesothelioma: a necropsy-based study.
</td>
<td style="text-align:left;">
Am. J. Ind. Med.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Innovative therapies for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Chest
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Multimodality therapy for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Chest
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Brachytherapy for non-small cell lung cancer and selected neoplasms of the chest.
</td>
<td style="text-align:left;">
Chest
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Soft tissue sarcomas as a rare cause of pleural effusion].
</td>
<td style="text-align:left;">
Pneumonol Alergol Pol
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
[A resected case of diffuse malignant pleural mesothelioma diagnosed by thoracoscopic biopsy].
</td>
<td style="text-align:left;">
Nihon Kyobu Geka Gakkai Zasshi
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
High-performance capillary electrophoretic analysis of hyaluronan in effusions from human malignant mesothelioma.
</td>
<td style="text-align:left;">
J. Chromatogr. B Biomed. Sci. Appl.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Pathology of diffuse malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Semin. Thorac. Cardiovasc. Surg.
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Surgical staging and work-up of patients with diffuse malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Semin. Thorac. Cardiovasc. Surg.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Chemotherapy for malignant mesothelioma.
</td>
<td style="text-align:left;">
Semin. Thorac. Cardiovasc. Surg.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleurectomy/decortication in the setting of multimodality treatment for diffuse malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Semin. Thorac. Cardiovasc. Surg.
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Extrapleural pneumonectomy in the setting of multimodality therapy for diffuse malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Semin. Thorac. Cardiovasc. Surg.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
New therapies in the treatment of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Semin. Thorac. Cardiovasc. Surg.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma diagnosed after chest trauma.
</td>
<td style="text-align:left;">
Am Surg
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleural malignancies including mesothelioma.
</td>
<td style="text-align:left;">
Curr Opin Pulm Med
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Silica-induced pleural disease: an unusual case mimicking malignant mesothelioma.
</td>
<td style="text-align:left;">
Chest
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Experimental assessment of photodynamic therapy with chlorins for malignant mesothelioma.
</td>
<td style="text-align:left;">
Eur J Cardiothorac Surg
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant lymphoma involving the penis following malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Intern. Med.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant pleural mesothelioma in general practice; complex pain problems].
</td>
<td style="text-align:left;">
Ned Tijdschr Geneeskd
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Calretinin. A selective marker of normal and neoplastic mesothelial cells in serous effusions.
</td>
<td style="text-align:left;">
Acta Cytol.
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Utility of hyaluronic acid in pleural fluid for differential diagnosis of pleural effusions: likelihood ratios for malignant mesothelioma.
</td>
<td style="text-align:left;">
Jpn. J. Clin. Oncol.
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Optimization of a battery using nine immunocytochemical variables for distinguishing between epithelial mesothelioma and adenocarcinoma.
</td>
<td style="text-align:left;">
APMIS
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Pleural malignant mesothelioma and environmental asbestos exposure in Casale Monferrato, Piedmont. Preliminary analysis of a case-control study.
</td>
<td style="text-align:left;">
Med Lav
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
The experience of the Mesothelioma Registry of Tuscany in assessing health hazard associated with asbestos exposure.
</td>
<td style="text-align:left;">
Med Lav
</td>
<td style="text-align:left;">
epidemiology | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma of the pleura in the Trieste-Monfalcone area, with particular regard to shipyard workers.
</td>
<td style="text-align:left;">
Med Lav
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
[A case of malignant mesothelioma of the pleura and the peritoneum detected by sudden onset of back pain and pleural effusion and ascites].
</td>
<td style="text-align:left;">
Nihon Kyobu Shikkan Gakkai Zasshi
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
A case of malignant pleural mesothelioma following exposure to atomic radiation in Nagasaki.
</td>
<td style="text-align:left;">
Respirology
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Immunohistochemical localization of transforming growth factor beta isoforms in asbestos-related diseases.
</td>
<td style="text-align:left;">
Environ. Health Perspect.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Assessment of the value of fibronectin as a tumour marker in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Monaldi Arch Chest Dis
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
[GC12, marker of cells of mesodermal origin. Value and application to cytodiagnosis of serous effusions].
</td>
<td style="text-align:left;">
Arch. Anat. Cytol. Pathol.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Environmental and indoor air exposure to asbestos fiber dust as a risk and causal factor of diffuse malignant pleural mesothelioma].
</td>
<td style="text-align:left;">
Zentralbl Hyg Umweltmed
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant mesothelioma of the pleura. Morphometric study].
</td>
<td style="text-align:left;">
Pathologica
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Evidence that DNA methylation imbalance is not involved in the development of malignant mesothelioma.
</td>
<td style="text-align:left;">
Anticancer Res.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant peripheral nerve sheath tumor of the pleura with epithelial and rhabdomyoblastic differentiation: report of a case clinically simulating mesothelioma.
</td>
<td style="text-align:left;">
Am. J. Surg. Pathol.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Phase III randomized trial of surgery with or without intraoperative photodynamic therapy and postoperative immunochemotherapy for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Ann. Surg. Oncol.
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Combination chemotherapy with cisplatin and/or doxorubicin in malignant mesothelioma. A retrospective study [corrected from prospective].
</td>
<td style="text-align:left;">
Anticancer Res.
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Growth factor responses and protooncogene expression of murine mesothelial cell lines derived from asbestos-induced mesotheliomas.
</td>
<td style="text-align:left;">
Toxicol Pathol
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Multimodality management of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Chest
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
A review of chemotherapy trials for malignant mesothelioma.
</td>
<td style="text-align:left;">
Chest
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience.
</td>
<td style="text-align:left;">
J. Clin. Oncol.
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant pleural mesothelioma in 1997].
</td>
<td style="text-align:left;">
Schweiz Med Wochenschr
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Asbestos increases mammalian AP-endonuclease gene expression, protein levels, and enzyme activity in mesothelial cells.
</td>
<td style="text-align:left;">
Cancer Res.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
The use of epithelial membrane antigen and silver-stained nucleolar organizer regions testing in the differential diagnosis of mesothelioma from benign reactive mesothelioses.
</td>
<td style="text-align:left;">
Cancer
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Comparison of DNA copy number changes in malignant mesothelioma, adenocarcinoma and large-cell anaplastic carcinoma of the lung.
</td>
<td style="text-align:left;">
Br. J. Cancer
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
HBME-1 and antithrombomodulin in the differential diagnosis of malignant mesothelioma of pleura.
</td>
<td style="text-align:left;">
J. Clin. Pathol.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Effects of interleukin-2 for the treatment of malignant mesothelioma.
</td>
<td style="text-align:left;">
Oncol. Rep.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Phase I study of paclitaxel as a radiation sensitizer in the treatment of mesothelioma and non-small-cell lung cancer.
</td>
<td style="text-align:left;">
J. Clin. Oncol.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Etoposide in malignant pleural mesothelioma: two phase II trials of the EORTC Lung Cancer Cooperative Group.
</td>
<td style="text-align:left;">
Eur. J. Cancer
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Higher doses of alpha-interferon do not increase the activity of the weekly cisplatin-interferon combination in advanced malignant mesothelioma.
</td>
<td style="text-align:left;">
Eur. J. Cancer
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Preoperative tumor volume is associated with outcome in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J. Thorac. Cardiovasc. Surg.
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Effectiveness of cisplatin, paclitaxel, and suramin against human malignant mesothelioma xenografts in athymic nude mice.
</td>
<td style="text-align:left;">
J Surg Oncol
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Transduction of non-small cell lung cancer cells by adenoviral and retroviral vectors.
</td>
<td style="text-align:left;">
Am. J. Respir. Cell Mol. Biol.
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
[The clinical utility of asbestos body counts in bronchoalveolar lavage fluid].
</td>
<td style="text-align:left;">
Nihon Kyobu Shikkan Gakkai Zasshi
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Prognosis in malignant mesothelioma related to MIB 1 proliferation index and histological subtype.
</td>
<td style="text-align:left;">
Hum. Pathol.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant mesothelioma of the pleura with etiological association to asbestos: report of 3 clinical cases].
</td>
<td style="text-align:left;">
Rev Assoc Med Bras (1992)
</td>
<td style="text-align:left;">
diagnosis | epidemiology | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
TTF-1 protein expression in pleural malignant mesotheliomas and adenocarcinomas of the lung.
</td>
<td style="text-align:left;">
Cancer Lett.
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
[Cancer risk in asbestos-cement industry workers in Poland].
</td>
<td style="text-align:left;">
Med Pr
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Clinical features and epidemiology of malignant pleural mesothelioma in west Glasgow 1987-1992.
</td>
<td style="text-align:left;">
Scott Med J
</td>
<td style="text-align:left;">
treatment | epidemiology | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B.
</td>
<td style="text-align:left;">
Chest
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Effect of simian virus large T antigen expression on cell cycle control and apoptosis in rat pleural mesothelial cells exposed to DNA damaging agents.
</td>
<td style="text-align:left;">
Oncogene
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma of the pleura. The reproducibility of the immunohistological diagnosis.
</td>
<td style="text-align:left;">
Pathol. Res. Pract.
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Interleukin 6 and its relationship to clinical parameters in patients with malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Br. J. Cancer
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Manganese superoxide dismutase in healthy human pleural mesothelium and in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Am. J. Respir. Cell Mol. Biol.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Hepatocyte growth factor/scatter factor stimulates chemotaxis and growth of malignant mesothelioma cells through c-met receptor.
</td>
<td style="text-align:left;">
Int. J. Cancer
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Glycohistochemical properties of malignancies of lung and pleura.
</td>
<td style="text-align:left;">
Int. J. Oncol.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Thoracoscopy–state of the art.
</td>
<td style="text-align:left;">
Eur. Respir. J.
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
A case of malignant peritoneal mesothelioma showed complete remission with chemotherapy.
</td>
<td style="text-align:left;">
Jpn. J. Clin. Oncol.
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
[Value of thoracoscopy and talc pleurodesis in diagnosis and palliative treatment of malignant pleural mesothelioma].
</td>
<td style="text-align:left;">
Praxis (Bern 1994)
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Dihydro-5-azacytidine and cisplatin in the treatment of malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B.
</td>
<td style="text-align:left;">
Cancer
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Hyperplastic mesothelial cells in lymph nodes: report of six cases of a benign process that can stimulate metastatic involvement by mesothelioma or carcinoma.
</td>
<td style="text-align:left;">
Hum. Pathol.
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
E-cadherin and calretinin: a useful combination of immunochemical markers for differentiation between mesothelioma and metastatic adenocarcinoma.
</td>
<td style="text-align:left;">
Histopathology
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Expression of HGF/SF in mesothelioma cell lines and its effects on cell motility, proliferation and morphology.
</td>
<td style="text-align:left;">
Br. J. Cancer
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Utility of the antibodies CA 19-9, HBME-1, and thrombomodulin in the diagnosis of malignant mesothelioma and adenocarcinoma in cytology.
</td>
<td style="text-align:left;">
Cancer
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma in women.
</td>
<td style="text-align:left;">
Anat Pathol
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Lesions described as nodular mesothelial hyperplasia are primarily composed of histiocytes.
</td>
<td style="text-align:left;">
Am. J. Surg. Pathol.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
The usefulness of CYFRA 21-1 in diagnosing and monitoring malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Acta Med. Okayama
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Translocation (3;3)(p14;q29) as the primary chromosome abnormality in a peritoneal mesothelioma.
</td>
<td style="text-align:left;">
Cancer Genet. Cytogenet.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Central lung embolism in chronic interstitial pneumopathy].
</td>
<td style="text-align:left;">
Praxis (Bern 1994)
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Adenovirus-mediated herpes simplex virus thymidine kinase/ganciclovir gene therapy in patients with localized malignancy: results of a phase I clinical trial in malignant mesothelioma.
</td>
<td style="text-align:left;">
Hum. Gene Ther.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Rounded atelectasis and mesothelioma.
</td>
<td style="text-align:left;">
AJR Am J Roentgenol
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
A urokinase receptor mRNA binding protein from rabbit lung fibroblasts and mesothelial cells.
</td>
<td style="text-align:left;">
Am. J. Physiol.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Gene therapy for malignant mesothelioma: a novel approach for an incurable cancer with increased incidence in Louisiana.
</td>
<td style="text-align:left;">
J La State Med Soc
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Diffuse primary malignant mesothelioma in abdominal cavity].
</td>
<td style="text-align:left;">
Arq Gastroenterol
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
[Clinical evaluation of benign asbestos pleurisy].
</td>
<td style="text-align:left;">
Nihon Kokyuki Gakkai Zasshi
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
SV40-like DNA sequences in pleural mesothelioma, bronchopulmonary carcinoma, and non-malignant pulmonary diseases.
</td>
<td style="text-align:left;">
J. Pathol.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Two familial mesothelioma cases with high concentrations of soluble cytokeratin 19 fragment in pleural fluid.
</td>
<td style="text-align:left;">
Intern. Med.
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Immunoreactivity of pleural malignant mesotheliomas to glutathione S-transferases.
</td>
<td style="text-align:left;">
APMIS
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Metastatic malignant mesothelioma in a tiger (Panthera tigris).
</td>
<td style="text-align:left;">
J. Zoo Wildl. Med.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
A comparative evaluation of immunohistochemical markers for the differential diagnosis of malignant pleural tumours.
</td>
<td style="text-align:left;">
Histopathology
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Static DNA cytometry as a diagnostic aid in effusion cytology: I. DNA aneuploidy for identification and differentiation of primary and secondary tumors of the serous membranes.
</td>
<td style="text-align:left;">
Anal. Quant. Cytol. Histol.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Static DNA cytometry as a diagnostic aid in effusion cytology: II. DNA aneuploidy for identification of neoplastic cells in equivocal effusions.
</td>
<td style="text-align:left;">
Anal. Quant. Cytol. Histol.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
CT and MR in pleural disease.
</td>
<td style="text-align:left;">
Clin. Chest Med.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Asbestos-induced pleural disease.
</td>
<td style="text-align:left;">
Clin. Chest Med.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
[Therapeutic strategy for pleural mesothelioma].
</td>
<td style="text-align:left;">
Nihon Geka Gakkai Zasshi
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Computed tomographic findings of environmental asbestos-related malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Respirology
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Evaluation of membranous staining of mesothelioma.
</td>
<td style="text-align:left;">
Cell Vis
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Gene therapy for malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Hematol. Oncol. Clin. North Am.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Thoracoscopy in undiagnosed pleural effusions.
</td>
<td style="text-align:left;">
S. Afr. Med. J.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
The role of immunohistochemistry in the diagnosis of malignant mesothelioma.
</td>
<td style="text-align:left;">
Monaldi Arch Chest Dis
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Establishment and preliminary characterization of human malignant mesothelioma cell lines.
</td>
<td style="text-align:left;">
Monaldi Arch Chest Dis
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Immunobiology and immune defense mechanisms of mesothelioma cells.
</td>
<td style="text-align:left;">
Monaldi Arch Chest Dis
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Recurrent chromosome 6 abnormalities in malignant mesothelioma.
</td>
<td style="text-align:left;">
Monaldi Arch Chest Dis
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Systemic drug therapy of malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Monaldi Arch Chest Dis
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Human malignant mesothelioma of the pleura: new perspectives for diagnosis and therapy.
</td>
<td style="text-align:left;">
Monaldi Arch Chest Dis
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
[Renal cell carcinoma with many transvenous pleural metastases].
</td>
<td style="text-align:left;">
Nihon Kokyuki Gakkai Zasshi
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Medical thoracoscopy in the diagnosis of unexplained pleural effusion.
</td>
<td style="text-align:left;">
Respirology
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Hepatocyte growth factor/scatter factor and its receptor c-Met are overexpressed and associated with an increased microvessel density in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
J. Cancer Res. Clin. Oncol.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
The diagnosis of desmoplastic malignant mesothelioma and its distinction from fibrous pleurisy: a histologic and immunohistochemical analysis of 31 cases including p53 immunostaining.
</td>
<td style="text-align:left;">
Am. J. Clin. Pathol.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
A urokinase receptor mRNA binding protein-mRNA interaction regulates receptor expression and function in human pleural mesothelioma cells.
</td>
<td style="text-align:left;">
Arch. Biochem. Biophys.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Tumours in experimental animals following exposure to asbestos dust.
</td>
<td style="text-align:left;">
Ann Anat Pathol (Paris)
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
[Anatomopathologic study of 54 cases of diffuse pleural mesothelioma found in the harbor regions of Nantes, Saint-Nazaire and Lorient].
</td>
<td style="text-align:left;">
Ann Anat Pathol (Paris)
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant mesothelioma of the pleura with a large tumor embolus in the left atrium: an autopsy case.
</td>
<td style="text-align:left;">
Intern. Med.
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Cytokeratin markers in malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Cancer Detect. Prev.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Localized malignant mesothelioma: a case report.
</td>
<td style="text-align:left;">
Am Surg
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Unusual metastasis of a malignant pleural mesothelioma].
</td>
<td style="text-align:left;">
Pneumologie
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Metabolic imaging of malignant pleural mesothelioma with fluorodeoxyglucose positron emission tomography.
</td>
<td style="text-align:left;">
Chest
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
Familial pleural malignant mesothelioma: clustering in three sisters and one cousin.
</td>
<td style="text-align:left;">
Cancer Lett.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
[Standards, Options, and Recommendations for the management of patients with malignant mesothelioma of the pleura. Fédération Nationale des Centres de Lutte Contre le Cancer].
</td>
<td style="text-align:left;">
Bull Cancer
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Benign fibrous mesothelioma: report of 8 cases].
</td>
<td style="text-align:left;">
Arch. Bronconeumol.
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Detection of SV40-like DNA sequences in pleural mesothelioma, bronchopulmonary carcinoma and other pulmonary diseases.
</td>
<td style="text-align:left;">
Dev. Biol. Stand.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
SV40 expression in human neoplastic and non-neoplastic tissues: perspectives on diagnosis, prognosis and therapy of human malignant mesothelioma.
</td>
<td style="text-align:left;">
Dev. Biol. Stand.
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
[Asbestos-related diseases].
</td>
<td style="text-align:left;">
Rev Prat
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Changes in expression and microheterogeneity of the genetic variants of human alpha1-acid glycoprotein in malignant mesothelioma.
</td>
<td style="text-align:left;">
J. Chromatogr. B Biomed. Sci. Appl.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Operation and photodynamic therapy for pleural mesothelioma: 6-year follow-up.
</td>
<td style="text-align:left;">
Ann. Thorac. Surg.
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Phase I clinical and pharmacological study of liposome-entrapped NDDP administered intrapleurally in patients with malignant pleural effusions.
</td>
<td style="text-align:left;">
Clin. Cancer Res.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Malignant pleural mesothelioma.
</td>
<td style="text-align:left;">
Eur. Respir. J.
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Intrapleural administration of interleukin-2 for the treatment of patients with malignant pleural mesothelioma: a Phase II study.
</td>
<td style="text-align:left;">
Cancer
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Treatment results of 17 patients with diffuse pleural mesothelioma.
</td>
<td style="text-align:left;">
Ann Thorac Cardiovasc Surg
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
The value of anti-calretinin antibody in the differential diagnosis of normal and reactive mesothelia versus metastatic tumors in effusion cytology.
</td>
<td style="text-align:left;">
Pathol. Res. Pract.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Pleural malignant mesothelioma with osseous cartilaginous and rhabdomyogenic differentiation].
</td>
<td style="text-align:left;">
Nihon Kokyuki Gakkai Zasshi
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant diffuse mesothelioma: contribution of 23 cases].
</td>
<td style="text-align:left;">
Rev Clin Esp
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Adenocarcinoma simulating mesothelioma: a clinicopathologic and immunohistochemical study of 29 cases.
</td>
<td style="text-align:left;">
Ann Diagn Pathol
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
The treatment of malignant mesothelioma with a gene modified cancer cell line: a phase I study.
</td>
<td style="text-align:left;">
Hum. Gene Ther.
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Phase II trial of topotecan for the treatment of mesothelioma.
</td>
<td style="text-align:left;">
Am. J. Clin. Oncol.
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Localized fibrous tumours of the pleura: 15 new cases and review of the literature.
</td>
<td style="text-align:left;">
Eur J Cardiothorac Surg
</td>
<td style="text-align:left;">
diagnosis | treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Modern approach to malignant pleural mesothelioma. 1) Pretherapeutic evaluation].
</td>
<td style="text-align:left;">
Srp Arh Celok Lek
</td>
<td style="text-align:left;">
diagnosis | treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Fibrous pleural tumour producing 171 litres of transudate.
</td>
<td style="text-align:left;">
Eur. Respir. J.
</td>
<td style="text-align:left;">
diagnosis
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant pleural effusions: recourse to early use of talc].
</td>
<td style="text-align:left;">
Rev Med Interne
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Environmentally-induced malignant pleural mesothelioma and HLA distribution in Turkey.
</td>
<td style="text-align:left;">
Int. J. Tuberc. Lung Dis.
</td>
<td style="text-align:left;">
treatment
</td>
</tr>
<tr>
<td style="text-align:left;">
Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients.
</td>
<td style="text-align:left;">
J. Thorac. Cardiovasc. Surg.
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Synovial sarcoma of the pleura and its differentiation from other primary pleural tumours: a clinicopathological and immunohistochemical review of three cases.
</td>
<td style="text-align:left;">
Histopathology
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Cancer in ex-asbestos cement workers in Israel, 1953-1992.
</td>
<td style="text-align:left;">
Am. J. Ind. Med.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Basal lamina reduplication in malignant epithelioid pleural mesothelioma.
</td>
<td style="text-align:left;">
Ultrastruct Pathol
</td>
<td style="text-align:left;">
diagnosis | transmission
</td>
</tr>
<tr>
<td style="text-align:left;">
Primary pleural mesothelioma.
</td>
<td style="text-align:left;">
Cancer
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Malignant pleural mesothelioma. II. Modern therapeutic concepts].
</td>
<td style="text-align:left;">
Srp Arh Celok Lek
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Interleukin 8: an autocrine growth factor for malignant mesothelioma.
</td>
<td style="text-align:left;">
Cancer Res.
</td>
<td style="text-align:left;">
signs
</td>
</tr>
<tr>
<td style="text-align:left;">
[Treatment strategy in pleural mesothelioma].
</td>
<td style="text-align:left;">
Langenbecks Arch Chir Suppl Kongressbd
</td>
<td style="text-align:left;">
treatment | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Cytologic diagnosis of malignant mesothelioma, with particular emphasis on the epithelial noncohesive cell type.
</td>
<td style="text-align:left;">
Diagn. Cytopathol.
</td>
<td style="text-align:left;">
diagnosis | signs
</td>
</tr>
<tr>
<td style="text-align:left;">
Ultrastructure of human malignant diffuse mesothelioma.
</td>
<td style="text-align:left;">
Am. J. Pathol.
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
Environmental exposure to tremolite asbestos: pleural mesothelioma in two Turkish workers in Germany.
</td>
<td style="text-align:left;">
Rev Environ Health
</td>
<td style="text-align:left;">
transmission
</td>
</tr>
</tbody>
</table></li>
</ol>
<p><br></p>
</div>
  
  <ul class="list-unstyled">
    
    
    <li><h5><a href="/mesothelioma/tables/abstract/">Table List</a></h5> </li>
    
    
  </ul>
</div>

      

    
    
    
      <script src="https://cdnjs.cloudflare.com/ajax/libs/jquery/3.4.1/jquery.min.js" integrity="sha256-CSXorXvZcTkaix6Yvo6HppcZGetbYMGWSFlBw8HfCJo=" crossorigin="anonymous"></script>
      <script src="https://cdnjs.cloudflare.com/ajax/libs/jquery.imagesloaded/4.1.4/imagesloaded.pkgd.min.js" integrity="sha256-lqvxZrPLtfffUl2G/e7szqSvPBILGbwmsGE1MKlOi0Q=" crossorigin="anonymous"></script>
      <script src="https://cdnjs.cloudflare.com/ajax/libs/jquery.isotope/3.0.6/isotope.pkgd.min.js" integrity="sha256-CBrpuqrMhXwcLLUd5tvQ4euBHCdh7wGlDfNz8vbu/iI=" crossorigin="anonymous"></script>
      <script src="https://cdnjs.cloudflare.com/ajax/libs/fancybox/3.5.7/jquery.fancybox.min.js" integrity="sha256-yt2kYMy0w8AbtF89WXb2P1rfjcP/HTHLT7097U8Y5b8=" crossorigin="anonymous"></script>

      

      
        
        <script src="https://cdnjs.cloudflare.com/ajax/libs/highlight.js/9.18.1/highlight.min.js" integrity="sha256-eOgo0OtLL4cdq7RdwRUiGKLX9XsIJ7nGhWEKbohmVAQ=" crossorigin="anonymous"></script>
        
        <script src="https://cdnjs.cloudflare.com/ajax/libs/highlight.js/9.18.1/languages/r.min.js"></script>
        
      

    

    
    

    
    
    <script>const code_highlighting = true;</script>
    

    
    
    <script>const isSiteThemeDark = false;</script>
    

    
    
    
    
    
    
    <script>
      const search_config = {"indexURI":"/mesothelioma/index.json","minLength":1,"threshold":0.3};
      const i18n = {"no_results":"No results found","placeholder":"Search...","results":"results found"};
      const content_type = {
        'post': "Posts",
        'project': "Projects",
        'publication' : "Publications",
        'talk' : "Talks"
        };
    </script>
    

    
    

    
    
    <script id="search-hit-fuse-template" type="text/x-template">
      <div class="search-hit" id="summary-{{key}}">
      <div class="search-hit-content">
        <div class="search-hit-name">
          <a href="{{relpermalink}}">{{title}}</a>
          <div class="article-metadata search-hit-type">{{type}}</div>
          <p class="search-hit-description">{{snippet}}</p>
        </div>
      </div>
      </div>
    </script>
    

    
    
    <script src="https://cdnjs.cloudflare.com/ajax/libs/fuse.js/3.2.1/fuse.min.js" integrity="sha256-VzgmKYmhsGNNN4Ph1kMW+BjoYJM2jV5i4IlFoeZA9XI=" crossorigin="anonymous"></script>
    <script src="https://cdnjs.cloudflare.com/ajax/libs/mark.js/8.11.1/jquery.mark.min.js" integrity="sha256-4HLtjeVgH0eIB3aZ9mLYF6E8oU5chNdjU6p6rrXpl9U=" crossorigin="anonymous"></script>
    

    
    

    
    

    
    
    <script id="dsq-count-scr" src="https://procovid19.disqus.com/count.js" async></script>
    

    
    
    
    
    
    
    
    
    
      
    
    
    
    
    <script src="/mesothelioma/js/academic.min.37431be2d92d7fb0160054761ab79602.js"></script>

    






  
  
  <div class="container">
    <footer class="site-footer">
  
  <p class="powered-by">
    
      <a href="/mesothelioma/privacy/">Privacy Policy</a>
    
    
        &middot; 
      <a href="/mesothelioma/terms/">Terms</a>
    
    
        &middot; 
      <a href="/mesothelioma/supp/faq/">FAQ</a>
    
  </p>
  

  <p class="powered-by">
    BioHub - UFPE &middot; 

    Powered by the
    <a href="https://sourcethemes.com/academic/" target="_blank" rel="noopener">Academic theme</a> for
    <a href="https://gohugo.io" target="_blank" rel="noopener">Hugo</a>.

    
    <span class="float-right" aria-hidden="true">
      <a href="#" class="back-to-top">
        <span class="button_icon">
          <i class="fas fa-chevron-up fa-2x"></i>
        </span>
      </a>
    </span>
    
  </p>
</footer>

  </div>
  

  
<div id="modal" class="modal fade" role="dialog">
  <div class="modal-dialog">
    <div class="modal-content">
      <div class="modal-header">
        <h5 class="modal-title">Cite</h5>
        <button type="button" class="close" data-dismiss="modal" aria-label="Close">
          <span aria-hidden="true">&times;</span>
        </button>
      </div>
      <div class="modal-body">
        <pre><code class="tex hljs"></code></pre>
      </div>
      <div class="modal-footer">
        <a class="btn btn-outline-primary my-1 js-copy-cite" href="#" target="_blank">
          <i class="fas fa-copy"></i> Copy
        </a>
        <a class="btn btn-outline-primary my-1 js-download-cite" href="#" target="_blank">
          <i class="fas fa-download"></i> Download
        </a>
        <div id="modal-error"></div>
      </div>
    </div>
  </div>
</div>

</body>
</html>
